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Preface 
Loretta Ford, RN and Henry Silver, MD, founders of the fi rst 
nurse practitioner (NP) program in 1965 at the University of 
Colorado, could have never envisioned the complex and inde-
pendent role evolution of NP practice that has subsequently 
taken place. The nurse practitioner role was developed in re-
sponse to a need for primary care providers in rural areas, 
with a focus on family health. The success of nurse practitio-
ners in providing safe and effective health care in the United 
States is well documented in multiple objective studies. By 
far, the greatest testament to the value of nurse practitioners 
is the tremendous growth in our numbers and the continued 
diversifi cation and advancement of NP practice during the 
past 40 years. As the health care system has become more 
complex and specialized the nurse practitioners’ role has 
kept pace with or has surpassed that level of growth and has 
changed to meet the needs of patients within the system. The 
role continues to expand, with continually higher and more 
complex levels of education, certifi cation, and specialization 
being expected or required for entry into practice. 
The editors of this text provide firsthand testimony to the 
rapid evolution of the nurse practitioner role. Initially edu-
cated as family nurse practitioners in the early 90s, two of 
the editors work exclusively within the critical care environ-
ment in a relatively independent manner and have subse-
quently advanced their degrees to attain certification. Both 
provide care for extremely ill patients and perform complex 
invasive procedures on a regular basis. The role of nurse 
intensivist has become the de facto reality of their practice, 
and this unique and challenging role for the acute care nurse 
practitioner (ACNP) has become increasingly found in many 
health care settings in the United States, and to a lesser 
degree, abroad. 
The educational preparation for entry into advanced 
practice positions continues to evolve and the Doctorate 
of Nursing Practice (DNP) degree has developed and pro-
gressed into a preferred entry level of practice. Disagreement 
exists within both the nursing and medical communities with 
regard to “appropriate” medical supervision and remains a 
highly debated political battle, with significant variations in 
legal statutes from state to state. Not surprisingly, there is 
sparse reference literature available to guide new NPs in this 
rapidly evolving intensivist role. 
This text has been planned and developed with world-
renowned authors to address this growing need and to pro-
vide such a reference. Nurse practitioners in the critical care 
environment deserve an authoritative resource for the care 
of critically ill patients, written by experts with diverse edu-
cational backgrounds and perspectives predominantly from 
within the discipline of nursing. The ACNP programs address 
the care of patients with urgent problems and those who may 
require hospitalization or other specialized care. However, 
critical care content within ACNP programs remains mini-
mal. The expertise contained within this text will contribute 
to increasing and improving the critical care content, knowl-
edge, and complexity within graduate education programs 
for ACNPs and for the practicing ACNP. 
This text contains the insights and first-hand experience 
of clinicians actively working in critical care, many of whom 
are considered experts on a national and international level. 
The topics covered are not exhaustive; however, the editors 
believe that the subject matter chosen within these chapters 
will provide the basis for sound evidence-based care of most 
common health problems faced by individuals requiring crit-
ical care. The editors and authors anticipate that critical care 
nurse practitioners (both novice and expert) and ACNP stu-
dents will find this text invaluable in guiding and improving 
their care of persons requiring critical care of all types. We 
are proud to present the reader with this first edition of a ref-
erence that we hope will become the standard for advanced 
practice nursing care and education within the critical care 
environment. 
x Preface
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1 Introduction 
Nurse practitioners (NPs) are registered nurses with a 
master’s and or Doctoral degrees, advanced licensure, cer-
tification, and function as independent practitioners who 
practice in various health care settings, including ambula-
tory, acute, critical, and long-term care (American Academy 
of Nurse Practitioners [AANP], 2006). Although the origi-
nal focus of advanced practice nursing care was to provide 
health promotion and disease prevention services in primary 
care, an increasing number of NPs are working in acute care 
settings. This is related to the increased acuity levels of hos-
pitalized patients and the need for expert practitioners to 
assist in managing patients with complex health conditions. 
1The Acute Care Nurse 
Practitioner: 
An Established 
Role in Acute 
and Critical 
Care
Ruth M. Kleinpell
2 Critical Care
The acute care nurse practitioner (ACNP) role represents a 
unique opportunity for advanced practice in acute and criti-
cal care. According to the 2004 National Nurse Practitioner 
Sample Survey, approximately 4.5% of the NP population or 
more than 4,500 NPs are ACNPs (Goolsby, 2005). Since the 
formulation of the ACNP role, it has evolved into an estab-
lished specialty area of NP practice. 
 Origins of the Acute Care Nurse 
Practitioner Role 
The ACNP role evolved from the need to have an expert 
practitioner to provide care to patients with critical, acute ill-
ness as well as patients with critical, chronic illness. Driving 
forces in the evolution of the ACNP role included an increase 
in the severity of illness of hospitalized patients, reduction 
in hospital lengths of stay, increase in the aging population 
with chronic conditions, increase in demands for care, access 
to care issues, and changes in medical residency coverage in 
the hospital setting (Steel, 1997). 
Similar to the evolution of the neonatal NP role in the 
late 1970s, the ACNP role developed in response to resi-
dency shortages in the intensive care unit (ICU) (Keeling & 
Bigbee, 2005). As medical education became more sensitive 
to the long hours required by interns and residents, the acute 
care facilities sought alternatives to promote ongoing effec-
tive care for their patients. The nurses who had expertise as 
primary providers were ideally suited to attain the additional 
knowledge and skills to meet the complex needs of these 
patients. Keane and Richmond (1993) were among the first 
to document the role of the inpatient NP in acute care, a role 
that was predominantly focused on patient care in the ICU 
and hospital setting. 
There were several significant milestones in the develop-
ment of the ACNP role. The formulation of annual conferences 
addressing the educational preparation of ACNPs was a cru-
cial element to organize and unify the essential elements for 
this advanced practice specialty. In 1993, the transition began 
and existing bodies of nursing, including the American Nurs-
es Association, American Association of Colleges of Nursing, 
American Association of Critical Care Nurses, and the state’s 
Boards of Nursing, sought to address specific clinical practice 
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issues. The first national certification and the publication of 
the ACNP scope and standards followed in 1995. The devel-
opment of ACNP specialty competencies occurred in 2004, 
including research expectations and publications, highlight-
ing the expansion and growth of the role. These developments 
substantiated the ACNP as a distinct specialty of advanced 
nursing practice. Exhibit 1.1 outlines some of the historical 
developments related to the ACNP role. 
Exhibit
 Year Event 
 1980s–1990  Literature reports and publications on inpatient nurse
 practitioner roles 
 1992–1993 Development of fi rst ACNP educational programs 
 1993  First ACNP Consensus Conference held in Boston, with 40 attendees 
 to discuss issues related to ACNP education and training 
 1993 Published reports on ACNP educational programs and curriculum 
 1994  Second ACNP Consensus Conference held in Cleveland, with 
 80 attendees to discuss issues related to ACNP education and 
 training 
 1995  Scope of practice for the ACNP, published by the American 
 Nurses and the American Association of Critical Care Nurses 
 1995  First National Certifi cation for ACNP, offered by the American 
  Nurses Credentialing Center 
 1995  Third Annual ACNP Consensus Conference held in Rochester 
  New York, with more than 100 attendees 
 1996  Fourth Annual ACNP Consensus Conference held in Hartford, 
  Connecticut 
 1997  Book published pertaining to ACNP role (The Acute Care Nurse 
  Practitioner. Springer Publishing, 1997) 
 1997  Fifth Annual ACNP Consensus Conference held in Myrtle Beach, 
  South Carolina 
1.1 Historical Developments of the Acute Care Nurse Practitioner (ACNP) Role
(continued)
4 Critical Care
 Year Event 
 1998  Publication of fi rst national survey on ACNP practice (Kleinpell, 
  R. M., AACN Clinical Issues)
 1998  Book published on ACNP practice issues (Practice Issues for 
  the Acute Care Nurse Practitioner. Kleinpell, R. M., & 
  Piano, M. R. Springer Publishing, 1998) 
 1998  Sixth Annual ACNP Consensus Conference held in Pittsburgh, 
  Pennsylvania 
 1999  Publication of ACNP Certifi cation Review Book (Acute Care Nurse
  Practitioner Clinical Curriculum and Certifi cation Review.
Gawlinski A, Hamwi, & D. Philadelphia: WB Saunders) 
 1999  Publication of ACNP practice book (Principles of Practice for the Acute
  Care Nurse Practitioner. Logan, P. Stamford: Appleton & Lange) 
 1999  Publication of ACNP Certifi cation Review Questions Book 
  (Miller, S. Health Leadership Associates) 
 1999  Seventh Annual ACNP Consensus Conference held in Portland, Oregon 
 1999  Publication of National Longitudinal Survey on ACNP practice: 
  Year 1 (Kleinpell, R. AACN Clinical Issues) 
 2000  Eighth Annual ACNP Consensus Conference held in Chicago, 
  Illinois 
 2001  Book published on ACNP practice guidelines (Practice Guidelines 
  for Acute Care Nurse Practitioners. Barkley, T. W. & Myers 
  C. M. Philadelphia: Saunders) 
 2001  Ninth Annual ACNP Consensus Conference held in Huntsville, 
  Alabama 
 2001  Publication of National Longitudinal Survey on ACNP practice: 
  Year 2 (Kleinpell, R. AACN Clinical Issues)
 2002  Publication of certifi cation review book (Acute Care Nurse 
  Practitioner Certifi cation Examination Review Questions and 
  Strategies. Todd, B. Philadelphia: FA Davis) 
 2002  Tenth Annual Acute Care Nurse Practitioner Consensus Conference 
  held in Charlottesville, Virginia (last educator conference) 
 2002  Acute Care Interest Group Forum established at the American 
  Academy of Nurse Practitioners Conference 
Exhibit
1.1 Historical Developments of the Acute Care Nurse Practitioner (ACNP) Role (continued)
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 Year Event 
 2003  Acute Care Track established at the annual American Academy 
  of Nurse Practitioners Conference (transitioning of annual 
  ACNP Conference to National Nurse Practitioner Association) 
 2004  Publication of the Acute Care Nurse Practitioner Competencies, 
  National Panel for Acute Care Nurse Practitioner Competencies 
 2005  Publication of Acute care nurse practitioner practice: results of 
  a 5-year longitudinal study. (Kleinpell, R. American Journal of 
  Critical Care)
 2005  Publication of nursing secrets series book on ACNP practice 
  (Acute Care Nurse Practitioner Secrets. Todd BA. St Louis: 
  Elsevier Mosby) 
 2005  Acute Care Column initiated in the Journal of the American 
  Academy of Nurse Practitioners 
 2005 Acute Care Column initiated in the Journal Nurse Practitioner 
 2006  Publication of the revised ACNP Scope and Standards (Scope 
  and Standards of Practice for the Acute Care Nurse Practitioner,
  American Association of Critical Care Nurses 
 2006  Publication on results of national survey of skills taught in 
  ACNP programs (Kleinpell et al. Nurse Practitioner)
 2007  Second National Certifi cation Exam becomes available from the 
  American Association of Critical Care Nurses 
 2008  Development and expansion of doctoral level (doctorate of 
  nursing practice) ACNP programs 
 Acute Care Nurse Practitioner Role 
ACNPs have evolved and refined the role. Practice is not lim-
ited to the confines of the ICU and acute inpatient settings. 
ACNPs care for patients who are critically ill, regardless of the 
practice setting (Howie-Esquivel & Fontaine, 2006). ACNPs 
are currently working in a wide variety of settings including 
hospitals, subacute care facilities, emergency departments, 
urgent care facilities, clinic settings, and various specialty 
practices. The ACNP’s role has also evolved and now includes 
specialty tertiary care areas (e.g., interventional cardiology, 
interventional radiology, oncology, bone marrow transplant) 
and a growing number of specialty settings (e.g., the inten-
sivist and hospitalist roles) (Kleinpell, et al., 2005). 
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Although the ACNP role is recognized as a specialty area 
of NP practice, specific competencies were developed to 
reflect the knowledge base and scope of practice of ACNPs 
(National Panel for Acute Care Nurse Practitioner Compe-
tencies, 2004). The competencies outline essential role com-
ponents, including assessment and diagnosis of complex 
acute, critical, and chronic health conditions and implemen-
tation of interventions to support patients with deteriorat-
ing physiologic conditions, including the application of basic 
and advanced life support and other invasive interventions 
or procedures to promote physiologic stability (National 
Panel for Acute Care Nurse Practitioner Competencies, 2004) 
(Exhibit 1.2). 
The scope of practice for ACNPs identifies that the per-
formance of noninvasive and invasive diagnostic and thera-
peutic interventional measures such as, but not limited to, 
EKG interpretation, radiographic interpretation, respira-
tory support, hemodynamic monitoring, central line and tube 
insertion, and lumbar puncture are within the scope of ACNP 
practice (National Panel for Acute Care Nurse Practitioner 
Competencies, 2004). The acute care practice setting involves 
the care of patients with acute and critical care conditions 
with high acuity levels. The ACNP may perform diagnostic 
and therapeutic measures to manage these significant health 
issues (National Panel for Acute Care Nurse Practitioner Com-
petencies, 2004; Becker et al., 2006). This is a unique aspect of 
ACNP practice that is based on education, training, and spe-
cialty certification. A national survey of ACNP educational 
programs validated that the majority (>55%) teach skills such 
as hemodynamic monitoring, suturing, central line insertion, 
and arterial puncture, which highlights the advanced skill set 
and training of ACNPs (Kleinpell et al., 2006). 
The scope and standards of practice for the ACNP define 
the educational requirements needed for an ACNP. This 
enables advanced practice regulatory bodies to promote 
a universally comparable level of education. Graduates of 
ACNP programs should be able to comprehend and demon-
strate advanced skills necessary to perform comprehensive 
health assessment, order and interpret diagnostic tests and 
procedures, use differential diagnosis, provide and evaluate 
outcomes of interventions for patients who are physiologi-
cally unstable, technologically dependent, and highly vulner-
able for complications (American Association of Critical Care 
Nurses, 2006) (Table 1.1). 
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Exhibit
1.2 ACNP Specialty Competencies for Direct Clinical Practice
 A. Assessment of Health Status 
 1.  Assesses the patients with complex acute, critical, and chronic illness for 
urgent and emergent conditions, using both physiologically and techno-
logically derived data, to evaluate for physiologic instability and potentially 
life-threatening conditions 
 2.  Obtains and documents a health history for patients with complex acute, 
critical, and chronic illness 
 3.  Performs and documents complete, system-focused, or symptom-
specifi c physical examinations on patients with complex acute, critical, 
and chronic illness 
 4.  Assess the need for and performs additional screening, based on initial 
assessment fi ndings 
 5.  Performs evaluations for substance use, violence, neglect and abuse,
barriers to learning, and pain 
 6.  Distinguishes between normal and abnormal developmental and age-
related physiologic and behavioral changes in patients with complex 
acute, critical, and chronic illness 
 7.  Assess for multiple interactive and synergistic effects of pharmacological 
agents, including over the counter preparations and alternative and comple-
mentary therapies, in patients with complex acute, critical, and chronic illness. 
 8.  Assess the impact of an acute, critical and/or chronic illness or injury 
on the individual’s: (a) health status (physical and mental), (b) functional 
status, including activity and mobility, (c) growth and development, 
(d) nutritional status, (e) sleep and rest patterns, (f) quality of life, 
(g) family, social, and educational relationships 
 9.  Provides for the promotion of health and protection form disease by assess-
ing for risks associated with the care of complex acute, critical, and chronic 
illness, such as physiologic risk, including but not limited to immobility, 
impaired nutrition and immunocompetence, fl uid and  electrolyte imbalance, 
invasive interventions, therapeutic modalities, and diagnostic tests 
 10.  Prioritizes data collection, according to the patient’s immediate condition 
or needs, as a continuous proves n acknowledgement of the dynamic 
nature of complex acute, critical, and chronic illness. 
 11.  Assesses the needs of families and caregivers of patients with complex 
acute, critical, and chronic illness 
(continued)
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Exhibit
1.2 ACNP Specialty Competencies for Direct Clinical Practice (continued)
 B. Diagnosis of Health Status 
 1.  Diagnoses acute and chronic conditions that may result in rapid physiologic 
deterioration or life-threatening instability 
 2.  Manages diagnostic tests through ordering, interpretation, performance, 
and supervision in the assessment of patients with complex acute, critical, 
and chronic illness 
 3.  Utilizes specialty-based technical skills in the performance of diagnostic 
procedures to confi rm or rule out health problems 
 4.  Synthesizes data from various sources to make clinical judgments and 
decisions about appropriate recommendations and treatments 
 5.  Prioritizes health problems during complex acute, critical, and chronic 
 illness 
 6.  Formulates differential diagnoses by priority considering multiple potential 
mechanisms causing complex acute, critical, and chronic illness states 
 7.  Distinguishes complications of complex acute, critical, and chronic illness 
considering multisystem health problems 
 8.  Distinguishes common mental health and substance use or addictive 
disorder/disease, such as anxiety, depression, and alcohol and drug use, 
in the presence of complex acute, critical, and chronic illness 
 9.  Reformulates diagnoses by priority based on new or additional assessment 
data and the dynamic nature of complex acute, critical, and chronic illness 
 C.  Plan of Care and Implementation of Treatment 
 1.  Formulates a plan of care to address complex acute, critical, and chronic 
health care needs that (a) integrates knowledge of rapidly changing 
pathophysiology of acute and critical illness in the planning of care and 
implementation of treatment, (b) prescribes appropriate pharmacologic and 
nonpharmacologic treatment modalities, and (c) utilizes evidence-based 
practice in planning and implementing care. 
 2.  Implements interventions to support the patient with a rapidly  deteriorating 
physiologic condition, including the application of basic and advanced 
life support and other invasive interventions or procedures to regain 
 physiologic stability. 
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 Adapted from: National Panel for Acute Care Nurse Practitioner Competencies. (2004). Acute
Care Nurse Practitioner Competencies. Washington, DC: National Organization of Nurse 
Practitioner Faculties .
 3.  Manages, through ordering, performance, interpretation, or supervision, (a) 
interventions that utilize technological devices to monitor and  sustain physi-
ologic function, (b) diagnostic strategies to monitor and sustain  physiologic 
function and ensure patient safety, including but not limited to ECG interpre-
tation, X-ray interpretation, respiratory support, hemodynamic monitoring, 
and nutritional support. 
 4.  Performs therapeutic interventions to stabilize acute and critical health 
problems, such as suturing, wound debridement, tube and line insertion, 
and lumbar puncture. 
 5.  Analyses the indications, contraindications, risk of complications, and 
cost–benefi ts of therapeutic interventions. 
 6.  Manages the plan of care through evaluation, modifi cation, and documenta-
tion according to the patient’s response to therapy, changes in condition, 
and to therapeutic interventions to optimize patient’s outcomes. 
 7. Manages the patient’s response to life support strategies. 
 8.   Manages pain and sedation for patients with complex acute, critical, and 
chronic illness. (a) Prescribes pharmacologic and nonpharmacologic 
interventions. (b) Monitor patient’s response to sedation. (c) Evaluates 
patient’s response to therapy and changes the plan of care accordingly. 
 9.  Implements palliative and end-of-life care in collaboration with the family, 
patient (when possible), and other members of the multidisciplinary health 
care team. 
 10. Initiates appropriate referrals and performs consultations. 
 11.  Assures that the plan of care is individualized, recognizing the dynamic 
nature of the patient’s condition, refl ecting the patient’s and family’s needs, 
and considering cost and quality benefi ts. 
 12.  Coordinates interdisciplinary and intradisciplinary teams to develop or 
revise plans of care focused on patient and/or family concerns. 
 13.  Incorporates health promotion, health protection and injury prevention 
measures into the plan of care within the context of the complex acute, 
critical, and chronic illness. 
 14.  Facilitates the patient’s transition between and within health care settings, 
such as admitting, transferring, and discharging patients. 
 Standards of ACNP Clinical 
Practice 
Standard I: Assessment
The ACNP generates, collects, and 
integrates data from a wide variety of 
sources to make clinical judgments 
and decisions about indicated orders, 
procedures, and treatments.
Standard II: Diagnosis
The ACNP diagnoses and prioritizes 
actual or potential health care 
problems as the basis for designing 
interventions for the restoration of 
health or to meet a patient’s goals.
Standard III: Outcome Identifi cation
The ACNP assumes a leadership 
role in assuring that the patient and 
health care team identify expected 
outcomes of care as the basis for 
developing the interdisciplinary plan 
of care.
Standard IV: Planning
The ACNP develops a plan of care that 
prescribes interventions to attain ex-
pected outcomes for the patient with 
acute, critical, and complex needs.
Standard V: Implementation
The ACNP implements interventions 
identifi ed in the interdisciplinary plan 
of care for the patient with acute, 
critical, and complex chronic illness
Standard VI: Evaluation
The ACNP evaluates the patient’s 
progress toward attainment of 
expected outcomes.
 Standards of ACNP 
Professional Performance 
Standard I: Professional Practice
The ACNP evaluates his or her clinical 
practice in relation to institutional 
guidelines, professional practice 
standards, and relevant statutes and 
regulations.
Standard II: Education
The ACNP acquires and maintains 
current knowledge in advanced 
nursing practice.
Standard III: Collaboration
The ACNP collaborates with the 
patient, family, and other health care 
providers in patient care.
Standard IV: Ethics
The ACNP integrates ethical consider-
ations into all areas of practice.
Standard V: Systems Management
The ACNP develops and participates in 
organizational systems and processes 
promoting optimal patient outcomes.
Standard VI: Resource Utilization
The ACNP considers factors related to 
safety, effectiveness, and cost in 
planning and delivering care.
Standard VII: Leadership
The ACNP provides leadership in the 
practice setting and the profession.
Standard VIII: Collegiality
The ACNP contributes to the professional 
development of peers, colleagues, 
and others.
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1.1 Standards of Clinical Practice for the Acute Care Nurse Practitioner
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Standard VII: Research
The ACNP continually explores scientifi c 
knowledge, identifi es specifi c research 
priorities in practice, and strives to 
enhance knowledge and skills through 
participation in research studies and 
provision of evidence-based practice.
Standard IX: Quality of Practice
The ACNP systematically evaluates 
and enhances the quality and 
 effectiveness of advanced nursing 
practice and care delivery across the 
continuum of acute care services.
Adapted from American Association of Critical Care Nurses (2006). Scope and standards of 
practice for the acute care nurse practitioner. Aliso Viejo, CA: Author.
 Considerations for Acute Care 
Practice: Regulation 
ACNP practice is regulated by individual state practice 
acts and ACNP scope and standards of practice. Regulatory 
authority over advanced practice is predominantly gov-
erned by the Board of Nursing within each state. The major-
ity of states afford title protection for NP practice through 
the Board of Nursing with sole authority over NP practice 
and no statutory or regulatory requirements for physician 
collaboration, direction, or supervision (Phillips, 2007). 
Currently, in all but 6 of the 50 states, regulatory control of 
NP practice falls under the control of the Board of Nursing 
(American Academy of Nurse Practitioners, 2006). In five 
states (Florida, South Dakota, North Carolina, Virginia, and 
Massachusetts), NP practice is collaborative, regulated by 
both the Board of Nursing and Board of Medicine. Nurses 
in these states must enter into an agreement with a phy-
sician to fully engage in advanced practice. In two states 
(Illinois and Nebraska), NP practice is regulated by a sepa-
rate advanced practice board (American Academy of Nurse 
Practitioners, 2006). Awareness of state practice regulations 
provides information regarding credentialing and privi-
leging requirements and the need for specific physician 
“supervision.” ACNP practice can include performance of 
invasive skills and implementation of life-sustaining thera-
pies such as, but not limited to, chest tube insertion, arterial 
line placement, central line placement, intubation, percuta-
neous tracheostomy, percutaneous endoscopic gastric (PEG) 
tube placement, initiation and adjustment of mechanical 
ventilation, and interpretation of hemodynamic monitoring. 
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Collaborative practice agreements outlining the ACNP 
scope of practice are important for defining, enacting, and 
review of specific aspects of advanced nursing practice. 
 Considerations for ACNP Practice: 
Opportunities for Role Expansion 
Originally, the major focus of the ACNP role was unit-based, 
collaborative physician practice based or specialty prac-
tice based. Although this offered initial opportunities for 
ACNP practice, research depicts that there are now more 
ACNPs employed in collaborative and specialty-based prac-
tice (Kleinpell, et al., 2005). ACNPs are often employed by a 
hospital or health care system or hired in collaborative prac-
tice arrangements. Currently, hospitals remain the largest 
employer of ACNPs (Kleinpell & Goolsby, 2006). Specialty-
based practice in traditional inpatient hospital areas, such as 
cardiac surgery, neurology, pulmonary medicine, orthopedics, 
oncology, infectious disease, endocrinology, transplantation, 
general surgery, and trauma, remain a large practice base for 
ACNPs. Additional practice settings include ambulatory clinics, 
collaborative practices, and nontraditional practice areas such 
as holistic clinics, sports medicine, and correctional facilities. 
Collaborative practice models for ACNPs include the estab-
lishment of advanced practice roles as hospitalist, intensivist, 
and surgical first assistant positions. Opportunities for ACNP 
practice have tremendously expanded since the creation of 
national board specialty certification in acute care. ACNP cer-
tification validates the professional nursing expertise of the 
role and will be pivotal in the future expansion of this role. 
 Considerations for ACNP Practice: 
Challenges to Practice 
Along with increasing opportunities for ACNP practice come 
challenges for practice including credentialing and privileg-
ing, ensuring clinical competency, promoting awareness of 
the role, ensuring practice based on existing scope of prac-
tice, education, and reimbursement issues. Petitioning for full 
credentials and privileges based on education and training 
and scope of practice, providing education regarding the 
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Exhibit
Several strategies can be used to ensure clinical competency for NPs 
working in acute care. These include the following:
■ Education and training for acute care skills set
■ Credentialing and privileging for acute care skills
■  Preceptorship and mentorship with a collaborating physician to verify 
skill competency
■ Formal post-master’s education for acute care
■  Certifi cation through advanced courses such as the Society of Critical 
Care Medicine’s Fundamentals of Critical Care Support Course
■  Attendance at conference sessions focusing on skills, such as the
American Academy of Nurse Practitioner’s annual conference
offering arterial and central line insertion workshops, and work
shops on chest tube insertion
■ Use of a formal log to verify clinical skills and procedures
■ Use of simulation laboratory
■  Incorporation of clinical and procedural skill sets within the acute care
programs
1.3 Strategies for Ensuring Clinical Competency in the ACNP Role
Adapted from Melander S. et al., (2008). Journal of the American Academy of Nurse
Practitioners, 20, 63–68.
role of the ACNP, and awareness of worth in terms of bill-
able revenue will lead to continued role recognition and role 
acceptance (Hravnak, et al., 2008; Magdic, et al., 2005). Sev-
eral mechanisms exist to ensure clinical competency for NPs 
working in acute care including continued education and 
training for acute care skill sets, specialty certification, cre-
dentialing, and privileging for acute care skills (Exhibit 1.3). 
In addition to the strategies outlined by Melander et al. 
(2007), the importance of mentorship cannot be underesti-
mated in the refinement and evolution of the ACNP role. The 
ACNPs, who adopted the initial roles and established the need 
for ongoing education and training, scrutiny of policy and legis-
lative changes enabling additional scope of practice, were trail-
blazers. They serve as role models and provide mentorship and 
preceptorship opportunities for future generations of ACNPs. 
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ACNPs are positively impacting outcomes for patient 
care in many clinical settings. An ongoing challenge for 
ACNPs is to demonstrate their direct contributions to patient 
care, patient and family education, nursing staff education 
and competence, as well as on traditional outcome mea-
sures such as costs of care. The value of the ACNP role has 
been demonstrated in several studies assessing outcomes 
of ACNP practice (Burns & Earven, 2002; Hoffman, et al., 
2005; Gawlinski, et al., 2001; Russell, et al., 2002; Rudy, et al., 
1998; Sole, et al., 2001; Cooper, et al., 2002; Meyer and Miers, 
2005, Garcias et al., 2003). ACNPs are noted to contribute to 
excellence in collaborative care, promote evidence-based 
practice, and impact patient care outcomes. Acute care nurs-
ing experts directly impact patient care through the provision 
of high quality, cost-effective care, improved patient satisfac-
tion, reduced length of stay in acute care units, lower mor-
tality rates, decreased nosocomial infection rates, decreased 
rates of skin breakdown, and reduced readmission rates. 
 Summary 
The ACNP role is an ideal extension for the advanced practice 
nurse expert in acute and critical care specializations. Cur-
rently, nurses who have completed a master’s level of edu-
cation and specific advanced knowledge and skills, outlined 
by the ACNP scope of practice, serve complex patients in 
health care settings. In the future, it is anticipated that ACNP 
programs will adapt to doctoral levels for entry into prac-
tice. The Doctorate of Nursing Practice (DNP) concept was 
developed in response to the American Association of Col-
leges of Nursing’s ([AACN], 2005) vision of advanced practice 
nursing entry-level practice at the doctorate level. Practice 
opportunities for the growing specialty area of ACNP prac-
tice will continue to increase because of the complex health 
care needs for patients with acute and chronic disease states. 
The ACNP role represents an exciting career trajectory to 
advance nursing practice in acute and critical care. 
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 Introduction 
The decision to become an acute/critical care nurse practi-
tioner (ACNP) is associated with several values including the 
significant responsibility that comes with the certification and 
the potential interesting cases, invasive procedures, compas-
sionate care, and their cumulative effect on the patient and his 
or her family. There is also a legal and ethical side of advanced 
practice in critical care nursing, and it is our responsibility 
as practitioners to stay abreast of, and knowledgeable about, 
such laws and ethical considerations. As such, this chapter 
will review basic legal issues related to nursing and ACNP 
practice. Because the specifics may vary from state to state, 
a nurse practitioner may need to research the regulations 
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within the state of intended practice to become knowledge-
able about ACNP regulations. State boards of nursing and 
state nursing associations are essential resources for initiat-
ing such research; their Web sites often have extensive infor-
mation regarding the issues at hand. 
 The Nurse Practice Act 
Every state has a Nurse Practice Act (NPA). The NPA is part 
of the laws or statutes of the state and provides an outline of 
nurses’ legal rights and responsibilities. The NPA typically 
outlines the way in which nurses are licensed and regulated 
by the specific state, defines various terms related to nursing, 
and establishes the state’s Board of Nursing (BON). NPAs 
further outline the scope of practice and licensure require-
ments for the nurses at all levels of practice. The NPA identi-
fies standard actions for licensed nurses, describes violations, 
states disciplinary actions and penalties, and sets standards 
for educational programs. Many states include additional 
regulatory issues in the NPA. 
Although NPAs are often written in dry legal prose, it is 
essential that ACNPs are aware of NPA regulations. Without 
astute awareness, unintentional violations of the law can 
occur. Because ignorance of the law is no excuse, accountabil-
ity for violations of the law will be enforced even if the ACNP 
acted in good faith. Upon acceptance of an ACNP license in a 
state, the ACNP agrees to abide by the NPA in that state and 
is accountable to the law, and is required to know of the law. 
NPAs as part of the laws of the states are included in the code 
or the statutes of the state and are available online, generally 
from a link on the state’s BON Web site. Most BONs have staff 
available to answer questions regarding the legal require-
ments of their individual states. 
The National Council of State Boards of Nursing has 
developed a Model Nursing Practice Act and Rules. Although 
these have not been universally accepted in every state, por-
tions of these models are recognizable in each state’s NPA. 
The NPA is the law of the state, but the state legislatures 
would be overwhelmed with work if they had to enact laws 
on every issue concerning nursing. To address these issues, 
the legislature delegates rule-making authority to the exec-
utive branch agencies, typically the Department of Health. 
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Usually through the BON, the Department of Health pro-
mulgates rules that are relevant to the practice of nursing. 
In seven states, the rules that govern practice of nurses are 
promulgated with input from both the Board of Medicine 
and the BON (American Academy of Nurse Practitioners 
[AANP], 2008). These rules reflect the same topics covered 
by the NPA but fill in some of the details missing in the actu-
al laws. The BON may not exceed its legislative authority by 
promulgating rules that exceed the scope of the law or the 
grant of authority from the legislature. 
An example of the rule-making process is when the leg-
islature enacts a law that requires nurses to have 25 hours 
of continuing education credit every 2-year licensure period. 
The legislature will then delegate the task to the BON to 
define the details regarding which topics are most signifi-
cant to nurses. The BON might then promulgate rules that 
would require that nurses take 2 hours of education on rec-
ognizing domestic violence and 2 hours on prevention of 
medical errors with the remaining hours on a topic of the 
nurse’s choice. The legislature would specify in the law that 
the BON is to establish rules that specify the continuing edu-
cation requirements for nurses, which includes education in 
domestic violence and prevention of medical errors as the 
BON deems appropriate. 
 Licensure Issues 
All nurses are regulated and licensed by their states. Typi-
cally, each state has a Department of Health, which licenses 
nurses. Generally, there is a BON that acts under the  auspices
of the Department of Health. The BON licenses licensed 
practice nurses, registered nurses, advanced practice nurses, 
and sometimes nursing assistants. 
The BON staff work for the state agency that houses it. 
It is important to note that BON employees may or may not 
be nurses but are responsible for the daily running of the 
BON including the processing of applications for licensure. 
Because the BON is responsible for licensing different types 
of nurses, it develops and accepts applications for licensure 
and is responsible for verifying the information on a nurse’s 
application and attaining required background checks. BON 
employees also may be responsible for certifying continuing 
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education providers and for auditing nurses to verify that 
they are keeping up with their continuing education require-
ments. In this respect, the BON may have some authority to 
establish fees for license types and then is responsible for 
collecting such fees at the time of application. Requirements 
for licensure and the specific guidelines on the NPA and 
BON are found on each state’s Web site. Completing license 
renewal in a timely manner is essential. Practicing nursing 
without a license can subject the health care provider to dis-
ciplinary actions by the BON as well as to possible criminal 
actions. Compliance with continuing education requirements 
and maintenance of the proof of completion are responsi-
bilities of each nurse and must be met in accordance to the 
BON requirements. One of the most common disciplinary 
issues is failure on the part of the licensee to maintain his or 
her continuing education requirements. 
 Case Study 
 Jane Doe, an acute care nurse practitioner, works hard at a 
hospital by managing the care for multiple patients. When she 
gets her renewal notice from the state’s Board of Nursing, she 
puts it in her to-do pile on her desk. Unfortunately, Jane is very 
busy and forgets to renew her license on time. About 2 weeks 
after her date of renewal, her hospital asks her for a copy of 
her new license. Jane suddenly remembers that she forgot all 
about renewing her license! She rushes to the BON Web site 
and renews online. However, for the past 2 weeks, she has been 
seeing patients without a current license. Her employer is upset 
and tells Jane that she is going to be reported to the BON for 
disciplinary action for practicing without a current license. The 
employer wants Jane to pay back all the money it would have 
billed Medicare for her services during the past 2 weeks. The 
employer states it has consulted its attorney and it cannot bill 
for her services unless she is in compliance with all state laws. 
Because she was out of compliance with her renewal, she was 
out of compliance with state law. Jane is faced with bills from 
her employer for over $10,000, possible loss of her employment, 
and possible disciplinary action from the state’s BON. 
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 Scope of Practice 
As an ACNP, it is critical to understand the nurse practitio-
ner’s scope of practice. There are two definitions of scope 
of practice that should be similar, if not  exactly the same. 
There is the legal scope of practice and the scope of practice 
based on education, training, and experience. Remember 
as well that the scope of practice may vary  tremendously 
from state to state. For example, some advanced practice 
nurses attain what is deemed  “independent” practice. This 
is more common in the western states where advanced 
practice nurses (APN) have played an important role in 
large geographical regions that house an inadequate num-
ber of physician providers (Christian, Catherine, & O’ Neil, 
2007). Arizona and Alaska are two prime examples here. 
Other states have more restricted practices. Florida APN 
must sustain a relationship with a supervising physician 
and file a protocol every 2 years with the BON, which 
reviews the protocol and publishes it online (The Florida 
Senate, 2004). At the time of this publication, Florida is one 
of three remaining states that do not permit APN to pre-
scribe controlled substances. 
The scope of practice for an advanced practice nurse 
encompasses the scope of the registered nurse and is gener-
ally defined in the state’s NPA. The Model Nursing Practice 
Act of 2004 defines the scope of practice of the registered 
nurse as follows: 
Practice as a registered nurse means the full scope of nurs-
ing, with or without compensation or personal profit, that 
incorporates caring for all clients in all settings; is guided 
by the scope of practice authorized in this section, through 
nursing standards established or recognized by the board 
and includes, but is not limited to: 
A.  Providing comprehensive nursing assessment of the 
health status of clients. 
B.  Collaborating with health care team to develop an inte-
grated client-centered health care plan. 
C.  Developing a strategy of nursing care to be integrated 
within the client-centered health care plan that estab-
lishes nursing diagnoses; setting goals to meet identified 
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health care needs; determining nursing interventions; 
and implementing nursing care through the execu-
tion of independent nursing strategies and regimens 
requested, ordered or prescribed by authorized health 
care providers. 
D.  Delegating and assigning nursing interventions to 
implement the plan of care. 
E.  Providing for the maintenance of safe and effective 
nursing care rendered directly or indirectly. 
F.  Promoting a safe and therapeutic environment. 
G.  Advocating for clients by attaining and maintaining 
what is in the best interest of clients. 
H.  Evaluating responses to interventions and the effective-
ness of the plan of care. 
I.  Communicating and collaborating with other health 
care providers in the management of health care and the 
implementation of the total health care regimen within 
and across care settings. 
J.  Acquiring and applying critical new knowledge and 
technologies to the practice domain. 
K.  Managing, supervising and evaluating the practice of 
nursing. 
L.  Teaching the theory and practice of nursing. 
M.  Participating in development of policies, procedures 
and systems to support the client. 
N.  Other acts that require education and training as delin-
eated by the board commensurate with the registered 
nurse’s continuing education, demonstrated compe-
tencies and experience. Each nurse is accountable for 
complying with the requirements of this act and for the 
quality of nursing care rendered; and for recognizing 
limits of knowledge, experience and planning of situa-
tions beyond the nurse’s expertise (National Council of 
State Boards of Nursing [NCSBN], 2008).  
While the Model Nursing Practice Act’s definition is 
quite lengthy and detailed, many of the individual states have 
more abbreviated definitions. For example, Florida defines 
the practice of professional nursing as follows: 
“Practice of professional nursing” means the performance 
of those acts requiring substantial specialized knowledge, 
judgment, and nursing skill based upon applied principles 
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of psychological, biological, physical, and social sciences, 
which shall include, but not be limited to: 
1.  The observation, assessment, nursing diagnosis, 
planning, intervention, and evaluation of care; health 
teaching and counseling of the ill, injured, or infirm; 
and the promotion of wellness, maintenance of health, 
and prevention of illness of others. 
2.  The administration of medications and treatments as 
prescribed or authorized by a duly licensed practitioner 
authorized by the laws of this state to prescribe such 
medications and treatments. 
3.  The supervision and teaching of other personnel in the 
theory and performance of any of the above acts (Florida 
Statutes s. 464.003(2008)).  
There are advantages and disadvantages to having a more 
abbreviated definition. With Florida’s definition, there might 
be different interpretations for a nurse who has practiced on 
the borders of accepted practice and faces disciplinary action. 
Consequently, if a nurse is informed of the definition, like the 
one in the Model Nursing Practice Act, then the nurse has a 
strong reference guide to know whether he or she is about to 
cross the line of the defined scope of practice. 
For its part, Alaska’s more abbreviated definition defines 
the practice of professional nursing as follows: 
“Practice of professional nursing” means the performance 
for compensation or personal profit of acts of professional 
service that requires substantial specialized knowledge, 
judgment, and skill based on the principles of biological, 
physiological, behavioral, and sociological sciences in 
assessing and responding to the health needs of individuals, 
families, or communities through services that include: 
A. Assessment of problems, counseling, and teaching 
B.  Clients to maintain health or prevent illness; and in the 
care of the ill, injured, or infirm; 
C.  Administration, supervision, delegation, and evaluation 
of nursing practice; 
D. Teaching others the skills of nursing; 
E.  Execution of a medical regimen as prescribed by a 
person authorized by the state to practice medicine; 
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F.  Performance of other acts that require education and 
training that are recognized by the nursing profession 
as properly performed by registered nurses; 
G.  Performance of acts of medical diagnosis and the 
prescription of medical therapeutic or corrective mea-
sures under regulations adopted by the board; (AS 
08.68.410(9)).  
Alaska’s abbreviated definition also has the potential 
for different interpretations, whereas, the Model Nursing 
Practice Act provides more detail and clearly defines the 
scope of practice. 
An ACNP’s scope of practice is significantly broader and is 
complicated with additional duties, rights, and responsibilities. 
Confusing matters further, there are different types of ACNPs 
and the legal definition of their scope of practice can vary 
greatly from state to state. In some states, all ACNPs are regu-
lated by the same section of the Nurse Practice Act and have 
similar rights and responsibilities. In other states, certified 
nurse midwives, certified registered nurse anesthetists, and 
clinical nurse specialists may have a legal definition and scope 
that is unique to their practice. In the Model Nursing Practice 
Act , all four types of ACNPs are defined together as follows: 
Advanced practice registered nursing by nurse practitio-
ners, nurse anesthetists, nurse midwives, or clinical nurse 
specialists is based on knowledge and skills acquired in 
basic nursing education; licensure as a registered nurse; 
graduation from or completion of a graduate level advanced 
practice registered nurse (APRN) program accredited by 
a national accrediting body and current certification by 
a national certifying body acceptable to the board in the 
specified APRN role and specialty. 
Practice as an APRN means a scope of nursing in a 
category approved by the board, with or without compen-
sation or personal profit, and includes the registered nurse 
scope of practice. The scope of an APRN includes, but is 
not limited to, performing acts of advanced assessment, 
diagnosing, prescribing, selecting, administering and dis-
pensing therapeutic measures, including over-the- counter
drugs, legend drugs and controlled substances, within the 
APRN’s role and specialty appropriate education and 
certification. 
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The APRN scope of practice supersedes the registered 
nurse scope of practice. 
APRN are expected to practice within standards estab-
lished or recognized by the board. Each APRN is account-
able to clients, the nursing profession and the board for 
complying with the requirements of this Act and the quality 
of advanced nursing care rendered; for recognizing limits of 
knowledge and experience, planning for the management of 
situations beyond the APRN’s expertise; and for consulting 
with or referring clients to other health care providers as 
appropriate (NCSBN, 2008). 
According to the definition, the Model Nursing Practice 
Act delegates authority to the BON to define more specific 
guidelines with the words, “Advanced practice registered 
nurses are expected to practice within standards established 
or recognized by the board.” The Model Nursing Administra-
tive Rules provided within the Model Nursing Practice Act do 
not provide more specific guidelines, but some of the individ-
ual states do provide specific guidelines in statute or rule and 
it is the responsibility of the ACNP to know these specifics. 
 Collaborative Practice Agreements 
In many states ACNPs must have collaborative practice 
agreements (CPA). These agreements are public records 
and document a collaborative or supervisory relationship 
with a physician. These documents may also be called pro-
tocols, standardized procedures, patient care guidelines, and 
standing orders (Likis, 2003). Although CPAs can service an 
important purpose in clinical practice, the legal requirement 
of CPAs in Nurse Practice Acts has also been seen by critics 
as restricting ACNPs. 
Ideally, a collaborative practice agreement can define who 
nurses treat, who they see, and under what circumstances 
they can provide care (McCabe & Burman, 2006). However, 
in today’s world of high technology and decreasing access 
to care, the lines between specialties become blurred. The 
question then becomes an ethical one: “Should we take care 
of something not traditionally within our scope of practice 
because there is no other way for the client to get the care 
they need?”(McCabe & Burman). 
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In addition to its ethical character, this situation also 
raises legal issues particularly in the area of medical mal-
practice and licensure discipline. Data from Nursing Service 
Organization (NSO) in 2004 indicated that 6% of their claims 
were related to scope of practice issues in the advanced 
practice setting (McCabe & Burman, 2006). Plaintiff lawyers 
seek collaborative practice agreements to determine ulti-
mate responsibility when things go wrong (Atkinson, 2007). 
Because of the supervisory nature relationships involved in 
a “collaborative” practice agreement, plaintiffs’ attorneys will 
investigate to determine the liability of the ACNP, the “super-
vising” or “sponsoring” physician, and the nurse’s employer 
(NCSBN, 2008). 
When the scope of practice is rigidly defined in the NPA, 
deviations are more likely to occur. Any deviation from the 
existing definition could have serious ramifications for con-
tinued licensure. Practicing outside the scope of practice may 
result in a citation, licensure suspension, or even revocation. 
Before a CPA is written, however, it is critical that the NPA 
is examined in detail. The legally required elements should 
be clearly identified in the document. There are many sam-
ples or form protocols available from the BON, prospective 
employer, or professional organizations. 
The CPA generally must contain information  regarding 
contact information, practice address, the contract infor-
mation for the collaborating physician, the nature of the 
practice including the conditions that may be treated, 
the medication and treatments prescribed or performed the 
duties of the physician, and the occasions during which 
the physician must directly supervise the ACNP. All parties 
to the protocol must sign the agreement. ACNPs who are 
employed by physicians or physician groups will typically 
have their protocol agreements signed by their employers. 
ACNPs who seek independent practice will hire a phy sician 
to enter into a collaborative practice agreement. Physi-
cians’ compensation will vary dependently on time, need 
for coverage, and consultation. In addition, most physicians 
feel that they may be accepting additional liability for the 
ACNP’s actions when they enter into a collaborative agree-
ment and may expect additional compensation for assuming 
this potential liability. The following exhibits are important 
in this regard (Exhibits 2.1 through 2.4).  
2.1
 I. Requiring Authority: 
 A. Nurse Practice Act, cite your state here 
 B. Your State’s Administrative Code, applicable provisions 
 II. Parties to Protocol: 
 A. Nancy R. Nurse, APRN Lic. # 123456 
 123 Main Street 
 Somewhere, USA 99999 
 B. Ian M. Doctor, MD, MX 999999, DEA 999999 
 Practice Name 
 456 Center Street 
 Somewhere, USA 99999 
 III. Nature of Practice: 
  This collaborative agreement is to establish and maintain a practice model 
in which the nurse practitioner will provide health care services  under the 
general supervision (collaboration) of Dr. Ian M. Doctor. This practice shall 
encompass family practice and shall focus on health  screening and supervi-
sion, wellness and health education and counseling, and the treatment of 
common health problems. (Use appropriate description for your specialty 
and activities) Practice Location(s): 
 List all practice locations here. 
 IV.  Description of the duties and management areas for which the APRN is 
responsible. 
 A. Duties of the APRN :
  The nurse practitioner is responsible for providing health services to 
clients of the (name of clinic or agency). The nurse practitioners will 
provide health promotion, screening, safety instructions, and manage-
ment of acute episodic illness and stable chronic diseases. Referrals will 
be made, as needed, to other health care providers. 
 B.  The conditions for which the APRN may initiate treatment include, but 
are not limited to: 
  Otitis media and externa 
  Conjunctivitis 
  Upper respiratory tract infections 
  Sinusitis 
 Sample Collaborative Agreement I 
(continued )
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 C.  Treatments that may be initiated by the ARNP, depending on the  patient 
condition and judgment of the ARNP: 
  1.  Suture of simple and complex lacerations not requiring ligament or 
tendon repair. 
  2. Incision and drainage of abscesses. 
  3. Removal of ingrown toenail. 
 D.  Drug therapies that the ARNP may prescribe, initiate, monitor, alter, 
or order: 
   Any prescription medication which is within the scope of training and 
knowledge base of the nurse practitioner. 
  -or- 
  Antibiotics 
  Antihypertensives 
  etc. 
 V. Duties of the Physician: 
  The physician shall provide general supervision for routine health care and 
management of common health problems, and provide consultation and/or 
accept referrals for complex health problems. The physician shall be avail-
able by telephone or by other communication device when not physically 
available on the premises. If the physician is not available, his associate, 
John R. Doctor, MD, MX 999999 (or other description of designated doctor(s) 
or groups), will serve as backup for consultation, collaboration and/or 
 referral purposes. 
 VI. Specifi c Conditions and Requirements for Direct Evaluation:
With respect to specifi c conditions and procedures that require direct evalu-
ation, collaboration, and/or consultation by the physician, the following will 
serve as a reference guide: 
  Clinical Guidelines in Family Practice, X Edition, by Constance R. Uphold, 
ARNP, PhD, and Mary Virginia Graham, ARNP, PhD (or other reference 
text or practitioner created reference guide) 
 -or- 
 Consultation will occur: 
 ■  Whenever situations arise that go beyond the intent of the protocols 
or the competence, scope of practice, or experience of the nurse 
practitioner. 
2.1  Sample Collaborative Agreement I(continued)
Exhibit
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 ■  Whenever the patient’s condition fails to respond to the management 
plan within an appropriate time frame, based on the provider’s clinical 
judgment.
■ For any uncommon, unfamiliar, or unstable patient condition. 
■  For any patient condition which does not fi t the commonly accepted 
diagnostic pattern for a disease/condition. 
■  For any unexplained physical examination or historical fi nding or 
abnormal diagnostic fi nding. 
■ Whenever a patient requests. 
 ■  For all emergency situations after initial stabilizing care has been 
initiated.
 VII.  All parties to this agreement share equally in the responsibility for review-
ing treatment protocols as needed and no less than annually. 
 /  License # RN9999999 
 Nancy R. Nurse, APRN/ Date 
 /  License #ME 999999 
 Ian M. Doctor, MD/ Date DEA # 999999 
 (Longworth, 2008; Florida Board of Nursing, 2008) 
Interestingly, the Model Nursing Practice Act only refers 
to a CPA in the context of controlled substance  prescribing. 
However, comprehensive, written, collaborative practice 
agreements are required in 21 states (Christian et al., 2007). 
 Disciplinary Process 
Many ACNPs find that some aspects of practice are regulated 
by the state’s Board of Medicine. However, the state’s BON 
is charged in all states with regulating the practice of nurs-
ing. The BON will investigate complaints against licensees 
and will contact the licensee to seek the licensee’s version 
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 TO: Agency for Health Care Administration 
 Board of Nursing/Compliance Department 
 4052 Bald Cypress Way Bin CO2 
 Tallahassee, Florida 32399-3252 
 FROM: Jane Brown, PhD, ACNP, BC, CCNS 
 DATE: March 10, 2009 
 SUBJECT: Annual Update of Protocols 
 Enclosed is a copy of the protocol / joint practice agreement as Pursuant to 
Florida Board of Nursing Rules Chapter 59S-4. 
 TO: Board of Medicine 
 Agency for Health Care Administration 
 1940 North Monroe Street 
 Suite 60 
 Tallahassee, Florida 32399-0770 
    ATTN: MARM HARRIS 
 FROM: Dr. F. Franks, M.D., FACS 
 Chief of Trauma / Surgical Critical Care 
 University of Miami / Jackson Health System 
 Dr. J. Johns, MD 
 Medical Director Anesthesia Critical Care Medicine 
 University of Miami / Jackson Health System 
 DATE: March 10, 2009 
 SUBJECT:  UPDATE of Joint Practice Agreement with an Advanced Practice 
Registered Nurse (Mary Wyckoff, PhD, MSN, ACNP, BC, FNP-BC, 
CCNS, CCRN, NNP) 
 As pursuant F.S. 458.348, this is to notify the Board of Medicine that a formal joint 
agreement has been established between the physicians and the above named 
nurse practitioner (APRN) of the Department of Trauma/Surgical/Anesthesia 
Critical Care Services at the University of Miami/Jackson Health System. 
An updated copy of the agreement is enclosed. 
2.2
 Sample Collaborative Agreement II 
(Acute Care Surgical Intensive Care Unit 
[SICU] Protocols) 
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  JOINT PRACTICE AGREEMENT 
 I. REQUIRING AUTHORITY 
  Nurse Practice Act, Florida Statute, Chapter 464 
  Florida Board of Nursing Rules, Chapter 59S-4, 
  Administrative Policies 
   Pertaining to Advanced Practice Registered Nurse, 
Florida Administrative Code. 
 II. ADVANCED PRACTICE REGISTERED NURSE CERTIFICATION 
  Jane Brown, PhD, ACNP, BC, CCNS,
  NNP is Board Certifi ed in Acute Care and Family Practice 
  and License # , as issued by the Florida Board 
  of Nursing (copy attached). 
 III. GENERAL AREA OF PRACTICE 
  Jane Brown, PhD, ACNP, BC, CCNS 
  NNP may manage the health care for those clients for 
  which he/she has been educated. 
 IV. SPECIFIC MANAGEMENT AREAS 
  A.  The APRN may prescribe, initiate, or alter medication 
regimens of any FDA approved drugs or OTC 
prepa rations, oral, topical, intravenous, intramuscular, 
 subcutaneous and as a continuous drip. 
  B.  Controlled substances may be initiated by the APRN 
within the practicing facility under the appropriate  federal 
and state guidelines. 
  C.  Other measures may be initiated or performed within the 
boundaries of the APRN’s education, depending upon the 
client’s condition and judgement of the APRN. 
 V. SUPERVISION 
   General supervision will be provided through consultation with 
the physicians as needed via on site and/or telephone 
communication.
 (continued )
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 VI. PARTIES INVOLVED 
   A joint practice agreement has been established between the 
 following APRN, Jane Brown, PhD, ACNP, BC, CCNS and the 
physicians of the  Trauma / Surgical / Anesthesia Critical Care 
Services Departments at the University of Miami / Jackson Health 
System.
 All of the above functions stated in sections III and IV may be performed under 
general supervision 
 Mary Wyckoff, PhD, MSN, ACNP, BC, 
FNP-BC,CCNS,CCRN
 Chief of Trauma/Surgical 
 Critical Care Services 
 License # 
 March 10, 2009 
 Francis Franks, FACS, MDACNP, BC, 
 Trauma/Surgical/Anesthesia 
 Critical Care Services 
 License # 
 March 10, 2009 
 Jonathan Johns, MD 
 Medical Director/Anesthesia Critical 
Care Medicine 
 License # ME 
 March 10, 2009 
2.2
 Sample Collaborative Agreement II 
(Acute Care Surgical Intensive Care Unit 
[SICU] Protocols) (continued)
of events. At this point in time, the ACNP should seek advice 
from an attorney. The attorney will be able to focus on the 
legal arguments in the disciplinary case from a legally direct-
ed perspective. A nurse who faces disciplinary action may 
have acted in a manner unbecoming to a professional nurse, 
or acted in a manner that exceeded the scope of practice. 
Disciplinary action may be the result of something as simple 
as failing to update contact information with BON or failing 
to participate to the required continuing education. 
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 PRIVILEGES AND ACTIVITIES LIST 
 Name: Jane Brown, PhD, ACNP, BC, CCNS
 Acute Care Nurse Practitioner 
 Advanced Practice Registered Nurse 
 Division of Trauma/Surgical/Anesthesia Critical Care Services 
 Category of practice: Board Certifi ed Acute Care Nurse Practitioner 
 Certifi ed Critical Care Nurse Specialist 
 Privileges & Activities: 
  1. Obtain health histories. 
  2. Perform physical examinations. 
  3. Order and interpret laboratory and diagnostic studies. 
  4. Order restraints as indicated. 
  5. Monitor and manage patients with chronic diseases. 
6. Monitor and manage patients with acute injury and illness. 
7. Monitor and manage patients preoperatively and postoperatively. 
8. Monitor and manage patients pretransplant and posttransplant. 
9. Make referrals to consult services as indicated. 
 10. Prescribe, initiate, monitor, and alter medications and treatments. 
 11. Provide counseling and teaching. 
 12.  Under the general supervision and at the discretion of a Florida 
licensed physician (the Chief of Service or his/her designee), 
the APRN may perform select procedures for which he/she has 
been educated. 
 13.  Under the general supervision of the Chief of Service and his/her 
designee, the APRN may perform medical acts of diagnosis and 
develop a treatment plan for such diagnosis, based upon the 
 history, physical examination, and diagnostic fi ndings. 
2.3  Privileges and Activities List 
Exhibit
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 14.  The APRN must practice under the general supervision of the 
Chief of Service or his/her designee. 
 15.  General supervision will be provided through consultation with 
the physicians of the Division of Trauma / Surgical / Anesthesia 
Critical Care Services as needed via on-site and/or telephone 
communication.
 ACNP, BC
Jane Brown, PhD, ACNP, BC, CCNS 
 Acute Care Nurse Practitioner 
 Trauma/Surgical/Anesthesia Critical 
 Care Svcs 
 License # RN / APRN 
 March 10, 2009 
 MD 
 Francis Franks, MD, FACS 
 Chief of Trauma/Surgical 
 Critical Care Svcs 
 University of Miami/Jackson 
Memorial Hospital 
 License # ME 
 March 10, 2009 
, MD 
 Jonathan Johns, MD 
 Medical Director/Anesthesia 
Critical Care Medicine 
 ME 
 March 10, 2009 
 Trauma/Surgical/Anesthesia 
Critical Care Services 
2.3  Privileges and Activities List (continued)
Nurses who are confronted with state disciplinary action 
must comprehend the serious legal and regulatory nature 
of the Board of Nursing. The BON is made up primarily of 
nurses, and it would be a logical, but misguided, assumption 
on the part of a nurse to believe that the BON will be overly 
sympathetic to an admission of guilt. The nurses who com-
prise the BON are fallible; however, they are charged with 
maintaining the standard of the profession and do not lightly 
dismiss conduct unbecoming to the profession. 
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 NURSE PRACTITIONER JOB DESCRIPTION 
 Jane Brown, PhD, ACNP, BC, CCNS 
 The Advanced Practice Registered Nurse (APRN) for the Trauma/Surgical/
Anesthesia Critical Care Services at the University of Miami/Jackson Health 
System will assume the following responsibilities: 
 1. Admission history and physical exams, admission orders for in-house. 
 2.  Discharge orders and dictation of discharge summaries for those patients 
discharged by the APRN. 
 3.  Monitor and management of preoperative and postoperative patients in 
the critical care setting, including, patients with acute injury, illness, and 
transplant. 
 4. Obtain referrals to consulting services as indicated. 
 5. Prescribe, initiate, monitor, and alter medications and treatments. 
 6. Provide ongoing ventilator management. 
 7. Provide counseling and teaching. 
 8. Monitor and provide appropriate nutrition. 
 9. Order and interpret radiographic studies. 
 10.  Privileges and activities as outlined in the Privileges and Activities List and 
Joint Practice Agreement and nurse practitioner protocols. 
 11.  Perform procedures as designated by the Chief of the Department of Trauma 
Surgical Critical Care and Medical Director Anesthesia Critical Care or his/her 
designee. These include but are not limited to advanced cardiac life support, 
electrical cardioversion, open chest intracardiac  defi brillation, placement of 
central line, pulmonary catheter, arterial line,  peripherally inserted central 
catheter, chest tube, dialysis catheter, feeding tubes  placement, intubation, 
tracheostomy and bronchoscopy, insertion of  percutaneous drains, and 
removal of drainage tubes, facilitate extracorporeal membrane oxygenation, 
insertion, removal, and management of intraortic balloon pumps, removal 
epicardial wires, management of ventricular assist devices. 
2.4 Nurse Practitioner Job Description
(continued )
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 12. Participate in writing orders as recognized during rounds. 
 NOTE: The above responsibilities are shared with the interns / residents of 
Trauma / Surgical / Anesthesia Critical Care Services Team and are not solely 
the responsibility of the nurse Practitioner. 
 Approved by: 
, MD 
 Francis Frank, M.D., FACS 
 Chief of Trauma/Surgical Critical Care Svcs 
 University of Miami/Jackson 
 Memorial Hosp. 
 License # ME 
 March 10, 2009 
, MSN, RN 
 Rachel Ray, MSN, RN 
 Director of Nursing 
 Critical Care Nursing Director 
 Jackson Memorial Hospital 
 March 10, 2009 
, MD 
 Jonathan Johns, MD 
 Medical Director/Anesthesia Medicine 
 Trauma /Surgical/Anesthesia 
 Critical Care Svcs 
 March 10, 2009 
, PhD, ACNP, BC 
 Jane Brown, PhD, ACNP, BC, 
 CCNS 
 Advanced Registered Nurse 
Critical Care 
 Practitioner ME 
 License # RN/APRN 
 March 10, 2009 
2.4  Nurse Practitioner Job Description (continued)
When the BON completes the investigation and decides 
that further action should be taken, judicial action will be 
pursed against the licensee. The BON has the power to seek 
revocation or suspension of a nurse’s license. Less significant 
penalties can include citations, fines, extra continuing educa-
tion hours, and public admonishments. 
Some states have laws that require certain events be report-
ed to the BON. Nurses may end up facing possible disciplinary 
action when they are involved with an adverse incident at work 
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or when they are involved in a medical malpractice case. Addi-
tionally, some institutions will have policies regarding when to 
report an employee or medical staff to the BON. 
When faced with possible disciplinary action, the ACNP 
should consider consulting an attorney. Many types of profes-
sional liability insurances cover licensure defense and disci-
plinary matters, therefore consulting an attorney does not have 
to be a significant out-of-pocket expense. However, even if one 
neglects to obtain insurance coverage for disciplinary matters, 
it is almost certainly worth the expense to consult a lawyer. Do 
not panic or react rashly when faced with the prospect of disci-
plinary action, but follow the advice of legal counsel. There are 
several nurses who are also attorneys and these nurse–attor-
neys can address your legal issues while having the additional 
knowledge and insight of the nursing perspective. Additional 
information regarding nurse attorneys can be obtained through 
the Web site of The American Association of Nurse Attorneys. 
 Medical Malpractice 
There is significant angst among health care providers regard-
ing medical malpractice claims. There are many examples of 
physicians and ACNPs who are practicing defensive medicine 
 Case Study 
 Nancy Klein is an acute care nurse practitioner who practic-
es in a state that requires her to have a collaborative practice 
agreement with a supervising physician. In accordance with 
her  protocol, she administers conscious sedation to intensive 
care unit (ICU) patients who are undergoing procedures by her 
 supervising physician. One day, Nancy is in the ICU and is asked 
by a consulting podiatrist to administer conscious sedation for a 
procedure. Nancy has never worked with the podiatrist before 
and feels some hesitance. She calls a lawyer she has consulted 
before and asks if she may administer the sedation for the po-
diatrist. The lawyer tells her that she may only administer the 
sedation if the administration of conscious sedation for podia-
trists is in her protocol. As it is not, Nancy declines to administer 
the sedation in this case. 
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in order to avoid lawsuits but it is unclear if this has had any 
effect on reducing claims. In addition, there is considerable 
concern regarding the cost of medical malpractice insurance 
or professional liability insurance. Although ACNP insurance 
is generally less expensive than physician counterparts, it is 
still quite expensive and may be difficult to obtain. Investigat-
ing through professional organizations may be helpful. 
In a claim for medical malpractice, a plaintiff must show 
(a) the existence of the duty of the health care provider 
to the plaintiff, (b) a breach of that duty, and (c) resultant 
damages. Many states have instituted tort reform, which 
has made it more difficult for plaintiffs to file medical mal-
practice lawsuits. In addition, there are short periods dur-
ing which a case may be filed, limits or caps on damages 
amounts, and presuit screening requirements. In order to 
understand the liability situation for medical malpractice, 
the ACNP must comprehend the duty of a plaintiff to have 
to prove the case against a nurse. This is highlighted in the 
following case study. 
 Case Study 
 Mr. J is admitted to the ICU after having a fall at home resulting 
in a fractured hip. He is a 92-year-old white man with a history of 
hypertension and non–insulin-dependent diabetes. Mr. J receives 
surgery prior to his admission to your unit. He is receiving pain 
medication and is reluctant to get out of bed. Over the course of 
the next few days, Mr. J’s pain level is diffi cult to control and he 
declines to eat full meals or participate in physical therapy. Mr. J 
develops some skin breakdown in his sacral area and a wound 
care consult is ordered, including a specialty air mattress and a 
speech therapist consult. Mr. J continues to improve and is ready 
for discharge to rehabilitation on postoperative day 10. Eighteen 
months later, as the ACNP who provided care for Mr. J, you are 
served with a notice to initiate litigation against you for failing to 
meet the standard of care for Mr. J because his wound has wors-
ened in rehab and has progressed to a stage IV pressure ulcer. 
Mr. J ultimately developed  Escherichia coli sepsis and died before 
his 93rd birthday. The family alleges that the ACNP has failed to 
diagnose Mr. J’s malnutrition. 
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The family will have to prove that the ACNP had a duty 
of care to Mr. J and it was the responsibility of the ACNP to 
diagnose his problems, including malnutrition. If the ACNP 
named was his care provider, proving duty is not difficult. 
As an ACNP and a health care provider, you have a duty to 
provide care to your patients in a nonnegligent manner. 
The family would be responsible to show that the ACNP 
has breached this duty (Florida Statutes s. 766.102 (2008) 
“Medical Malpractice Act”). In a medical malpractice case, 
this is shown by proving that the health care provider has 
breached the standard of care. The standard of care is defined 
as “that level of care, skill, and treatment which, in light of all 
relevant surrounding circumstances, is recognized as accept-
able and appropriate by reasonably prudent similar health 
care providers” (Florida Statutes s. 766.102 (2008) “Medical 
Malpractice Act”). In this case, the family would have to show 
that this is the standard of care to conduct testing for mal-
nutrition (i.e., an albumin, prealbumin levels [monitoring] 
completed and a dietician consult completed). 
The third element of a medical malpractice case is to 
show that Mr. J was damaged by the breach of the standard of 
care (Florida Statutes s. 766.102 (2008) “Medical Malpractice 
Act”). When Mr. J died, he was damaged, but the family will 
have to prove causation. In other words, the family will have 
to prove that his death was secondary to damages caused to 
Mr. J by the breach in the standard of care. 
Without proof of the three elements of a medical malprac-
tice claim, there is no case against the ACNP. At the very first 
hint of a medical malpractice claim, the ACNP should notify 
their insurance carrier. The carrier will identify an attorney 
as appropriate. Competent and careful health care providers 
should not live in fear of a malpractice suit but should acknowl-
edge the existence of the litigious climate in contemporary 
health care. The prudent ACNP should be prepared and seek 
advice from professional legal council when appropriate. 
 End-of-Life Issues 
ACNPs are confronted daily with patients and families coping 
with end-of-life issues. Regardless of how people reach the 
final stages of their lives, emotions run high and families are 
forced to make decisions that they would prefer not to make. 
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There are ethical and legal issues surrounding end-of-
life care. Increasing medical technologies provide treatments 
and interventions for diseases and conditions that were once 
considered fatal. Bioethicists describe the sense of entitle-
ment Americans have toward health care and their typical 
expectation for curative measures. Despite a limited expec-
tation for recovery, futile care is expected and many times 
mandated as a “right.” The role of the ACNP includes guiding 
patients and families through difficult decisions that occur 
with end-of-life care. There are many cases cited in the liter-
ature regarding dignity in death, hope of miracles and cures, 
and care that has become futile. 
 Case Study 
 Karen Ann Quinlan was an unfortunate young woman who 
 inadvertently became a major fi gure in the right to die movement. 
She was a 22-year-old woman who stopped breathing after an 
evening out with friends. The report indicated that alcohol and 
prescription narcotics led to irreparable brain damage caused 
by prolonged anoxia and left her in a persistent vegetative state 
that requires ongoing ventilatory support. After some months 
of waiting for improvement, Karen Ann’s parents recognized 
the futility of the care and requested that the hospital remove 
their daughter from the ventilator. The hospital declined and the 
 parents sought judicial intervention (In re Quinlan, 1976). 
The Quinlans sought the court’s permission to terminate 
life support for their daughter (In re Quinlan, 1976). Prior to 
the Quinlan case, the general philosophy was that physicians 
should make end-of-life decisions for their patients and spare 
the families these difficult decisions. Although the philosophy 
could be argued to be part of that traditional “doctor-knows-
best” theory, it was also meant to spare families the mental 
and emotional agony that end-of-life decisions can cause. 
In addition to Karen’s doctors and the hospital, the Attor-
ney General of New Jersey intervened in the case arguing 
that the state has a compelling interest in the preservation 
of life (In re Quinlan, 1976). The Quinlans argued that Karen 
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Ann would not have wanted to continue life in a persistent 
vegetative state when there was no hope for a cure or even 
improvement (Wijdicks, 2002). However, the court chose not 
to consider this argument because it was felt there was no 
credible evidence that Karen Ann had ever expressed such 
an opinion. The court instead examined the Quinlans’ right 
to privacy and their right to make their own personal, ethical, 
moral, and religious decision about treatment for Karen Ann 
(In re Quinlan, 1976). Although there is no explicit right to 
privacy in the United States Constitution, courts have con-
sistently described a personal right of privacy and have held 
that certain areas of life are too private to justify state inter-
vention (Eisenstadt v. Baird, 1972). 
The New Jersey Supreme Court ultimately upheld that 
decisions made with regard to end-of-life care, at least in 
Karen Ann’s case, are private ones that families may make with-
out state interference. Karen Ann Quinlan’s respiratory support 
was removed after the court’s decision. She continued to live 
for another decade until she died of pneumonia in 1985 (Karen 
Ann Quinlan, Wikipedia, 2008). Karen Ann’s family’s tragedy 
has been attributed with the development of ethics committees 
in hospitals and with the proliferation of advanced directives. 
 Case Study 
 Nancy Cruzan was another young woman who made national 
headlines when she was left in a persistent vegetative state af-
ter an automobile accident (Ashley, 2005). Nancy’s family sought 
the right to discontinue artifi cial hydration and nutrition in order 
to allow their daughter to die. Like Karen Ann’s family, Nancy’s 
family argued that Nancy would not have wanted to live in her 
present condition (Cruzan, by her parents and co-guardians v. 
Missouri Department of Health, 1990). 
The Missouri Supreme Court and then the United States 
Supreme Court upheld that there was insufficient evidence 
that Nancy had expressed such an opinion prior to her acci-
dent and declined to allow the family to remove artificial 
nutrition and hydration. However, the court did recognize the 
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 Case Study 
 Terri Schiavo repeatedly made national headlines during an 
 intense family battle regarding whether to withhold nutrition and 
hydration in order to allow Terri to die in 1990. Terri collapsed 
one  evening in her home and suffered permanent brain dam-
age caused by severe anoxia. Terri’s husband, Michael, and her 
parents, the Schindlers, were initially highly motivated to seek 
treatment for Terri. But by 1998, a disagreement arose  regarding 
the use or futility of treatment for Terri. Michael Schiavo and the 
Schindlers parted ways and Michael fi led a petition in Pinel-
las County Circuit Court to remove Terri’s feeding tube so as to 
 allow her to die. The Schindlers maintained that Terri would not 
have wanted to die and a lengthy and acrimonious 7-year court 
battled ensued. 
right of a competent person to decline treatment including 
artificial nutrition and hydration if done in advance ( Cruzan, 
by her parents and co-guardians v. Missouri Department of 
Health, 1990). 
Following the decision by the court, congress enacted 
the Patient Self-Determination Act of 1990 (Ashley, 1990). 
The act requires hospitals to give inpatients information on 
advanced directives at the time of admission and to inform 
patients of their rights to refuse treatment. 
The Schiavo case resulted in national and international 
headlines and resulted in over 14 reported court opinions. 
Ultimately, the Schindlers’ appeals were unsuccessful and 
the laws enacted by congress and the Florida legislature 
were held unconstitutional. Terri Schiavo died on March 31, 
2005 after having hydration and nutrition withheld for 13 
days (Terri Schiavo, Wikipedia, 2008). 
During the Schiavo–Schindler legal battle, Terri Schiavo 
became a household name and an exemplar for the neces-
sity of advanced directives. Emotions ran high and numerous 
religious, right-to-life, right-to-die, dignity in death, elders 
rights, disabilities rights, and other public interest groups 
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intervened and spoke out on their feeling and beliefs con-
cerning what was right for Terri. Florida Governor Jeb Bush, 
the Florida Legislature, and the United State Congress inter-
vened as well. Ultimately, one must wonder how Terri would 
have felt about her life in the public eye for the last 7 years 
of her life. As ACNPs, probably the most important lesson 
learned from Terri Schiavo is the importance of advanced 
directives. 
Each type of advanced directive serves a distinct purpose, 
and as an ACNP, basic understanding of advanced documen-
tation is critical especially the living will and health care 
proxy. Ideally, these documents are thoughtfully considered 
by patients, discussed with family or significant others and 
will be prepared by an attorney well in advance of the time 
they are needed. 
A living will is a type of advanced directive. This docu-
ment describes when the treatments should be given or in 
what circumstances it should be withheld. This document 
may be as specific or as broad as the author intends. A person 
may specify his or her desire to enact, withhold, or withdraw 
treatment, not to initiate heroic measures, or even nutrition 
and hydration. Although each state may have separate legal 
requirements regarding the specific language that must be 
in a living will, what follows is a good example and complies 
with the law of Illinois (Living Will, n.d.) (Exhibit 2.5). How-
ever, each individual must be sure to comply with the legal 
requirements in their state, or the living will could be declared 
void by a court of law. 
A legally correct living will must be signed and witnessed 
in some manner. The specific manner will be in accordance 
with appropriate state law: generally a correctly executed liv-
ing will requires two witnesses. A health care proxy or health 
care power of attorney is another legal document that gives 
decision-making power to someone other than the patient. 
A person who is of sound mind may appoint a health care 
proxy to make health care decisions in the event that they 
become unable to do so. Presumably, the individual will have 
had some type of conversation with the health care proxy 
and the proxy will have an understanding of their desires and 
wishes. A legal document appointing a health care proxy can 
be similar to a living will, as in Exhibit 2.6, which complies 
with New York state law (New York State, n.d.). The signifi-
cant difference is that a health care proxy is enacted when 
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 LIVING WILL OF JANE DOE 
T his declaration is made this  day of (month, year). 
 I, , being of sound 
mind, willfully and voluntarily make known my desires that my moment of 
death shall not be artifi cially postponed. 
 If at any time I should have an incurable and irreversible injury, disease, or 
illness judged to be a terminal condition by my attending physician who has 
personally examined me and has determined that my death is imminent except 
for death-delaying procedures, I direct that such procedures which would only 
prolong the dying process be withheld or withdrawn, and that I be permitted 
to die naturally with only the administration of medication, sustenance, or the 
performance of any medical procedure deemed necessary by my attending 
physician to provide me with comfort care. 
 In the absence of my ability to give directions regarding the use of such death 
delaying procedures, it is my intention that this declaration shall be honored 
by my family and physician as the fi nal expression of my legal right to refuse 
medical or surgical treatment and accept the consequences from such refusal. 
 Signed 
 City, County and State of Residence 
 The declarant is personally known to me and I believe him or her to be of sound 
mind. I saw the declarant sign the declaration in my presence (or the declarant 
acknowledged in my presence that he or she had signed the declaration) and I 
signed the declaration as a witness in the presence of the declarant. I did not sign 
the declarant’s signature above for or at the direction of the declarant. At the date 
of this instrument, I am not entitled to any portion of the estate of the declarant 
according to the laws of intestate succession or, to the best of my knowledge and 
belief, under any will of declarant or other instrument taking effect at declarant’s 
death, or directly fi nancially responsible for declarant’s medical care. 
 Witness Date  Witness Date
2.5  Living Will Sample 
Exhibit
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the patient can not make their own decisions and appoints a 
specific person to make health care decisions. 
A document appointing a health care proxy must also 
comply with the requirements of the law of the state in which 
it is meant to be effective. Similar to a living will, this docu-
ment will likely need to be witnessed by two witnesses. Gen-
erally, witnesses do not sign in any attempt to attest to the 
contents of the document but only to the authenticity of the 
signature of the patient. 
 New York State Health Care Proxy Form 
 1.  I,  hereby appoint 
 (name, home address and telephone number) 
  as my health care agent to make any and all health care decisions for me, 
except to the extent that I state otherwise. This proxy shall take effect when 
and if I become unable to make my own health care decisions. 
 2.  Optional instructions: I direct my agent to make health care decisions in 
accord with my wishes and limitations as stated below, or as he or she other-
wise knows. (Attach additional pages if necessary.) 
 (Unless your agent knows your wishes about artifi cial nutrition and hydra-
tion (feeding tubes), your agent will not be allowed to make decisions about 
artifi cial nutrition and hydration. 
 See instructions on reverse for samples of language you could use.) 
2.6  Health Care Proxy Form 
(continued )
Exhibit
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 3.  Name of substitute or fi ll-in agent if the person I appoint above is unable, 
unwilling, or unavailable to act as my health care agent. 
 (name, home address, and telephone number) 
 4.  Unless I revoke it, this proxy shall remain in effect indefi nitely, or until the 
date or conditions stated below. This proxy shall expire (specifi c date or 
conditions, if desired):
 5. Signature 
 Address 
 Date 
 Statement by Witnesses (must be 18 or older) 
 I declare that the person who signed this document is personally known to 
me and appears to be of sound mind and acting of his or her own free will. 
He or she signed (or asked another to sign for him or her) this document in 
my presence. 
 Witness 1 
 Address 
 Witness 2 
 Address 
2.6  Health Care Proxy Form (continued)
Most states’ Department of Health Web sites will contain 
the information needed to make sure that the living wills and 
health care proxy forms that are in use are legally sound. 
Hospitals have these forms available and it is likely that hos-
pital attorneys have assisted in the development of the forms. 
Exhibit
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 Case Study 
 A young woman, Amy, is involved in an automobile accident and 
has devastating injuries. She is hospitalized on life support and 
cared for by a team including an acute care nurse practitioner, 
Lisa Smith. Lisa asks the family if the young woman has a living 
will or a health care proxy and the family tells her she does not. 
Amy’s parents feel that she would not have wanted to live on life 
support and wonder if there is hope for meaningful recovery. 
Amy’s brother feels that everything should be done for her that 
is medically possible. The family, already experiencing a high 
level of stress, begins to argue. Lisa watches in dismay as the 
family’s interactions deteriorate. She knows that had Amy had a 
living will or had appointed a health care proxy, many of the deci-
sions involving Amy’s care would be in line with Amy’s wishes. 
As it stands now, the family will have to negotiate these diffi cult 
decisions amongst themselves or their family’s tragedy may end 
up in the court system. 
 Conclusion 
The role of the ACNP is complex and multidimensional. 
There are primary legal elements required to attain and 
maintain licensure, guide practice, and direct clinical practice 
agreements. In an effort to provide optimal care to patients, 
families, and society, ACNPs must comprehend and demon-
strate a working knowledge of contemporary legal and ethi-
cal issues. Consultation with legal professionals should be 
viewed as a proactive strategy in establishing and maintain 
advanced clinical practice. 
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 Introduction 
An essential component of critical care is the management of 
acute respiratory failure. Respiratory failure can result from 
a pulmonary or nonpulmonary insult and often requires the 
application of mechanical ventilation. This chapter focuses on 
the ventilatory management of patients with critical illness 
from intubation to weaning. To ensure that the application of 
mechanical ventilation is appropriately applied, a discussion 
of the pathophysiology of selected restrictive and obstructive 
conditions is included. 
Critical Care 
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 Restrictive and Obstructive Conditions 
 Restrictive Pathology 
Restrictive conditions are those that result in decreased lung 
expansion. The conditions may be caused by thoracic chest 
wall abnormalities, such as a fibrothorax, or lung and/or pleu-
ral conditions. Restrictive conditions common to critical care 
are acute respiratory distress syndrome (ARDS), pneumonia, 
atelectasis, pulmonary edema, pleural effusions, and pneu-
mothorax. Other less common conditions include bronchi-
olitis obliterans organizing pneumonia (BOOP) and neuro-
muscular conditions, such as myasthenia gravis, that result in 
a relative decrease in lung expansion secondary to weakness. 
Regardless of the condition, the pathology is often similar 
and is helpful to understand so that application of mechani-
cal ventilation is appropriate. Table 3.1 (pages 52 through 55) 
lists selected obstructive and restrictive conditions. 
When restrictive conditions exist, the result is a 
decrease in lung expansion and, subsequently, lung volume. 
Functional residual capacity (FRC) is reduced and compli-
ance is decreased. Laplace’s law describes how spherical 
air-filled objects, such as the alveoli, behave under these 
conditions. With a reduction in volume, the pressures acting 
on the sphere are increased and directed inward with the 
result being closure or collapse of the sphere. In contrast, 
with restoration of volume, the work associated with dis-
tending the sphere decreases. With restrictive diseases like 
ARDS, FRC is greatly reduced and the pressure, and subse-
quently the work of breathing required to open the alveoli, 
is high. Alveolar collapse results in the shunting of blood; 
oxygenation suffers and is refractory to provision of applied 
oxygen. Thus recruitment of the alveoli is necessary, and 
prevention of derecruitment is required. Whereas recruit-
ment is an inspiratory maneuver (and will be described 
in detail later in this chapter), derecruitment is generally 
managed with the provision of applied positive end-expira-
tory pressure (PEEP). 
 Obstructive Pathology 
Obstructive conditions are those in which there is limitation 
to airflow. Airway resistance results in a decrease in the flow 
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of gases down the airways. To maintain flow, the pressure 
must be increased, which results in an increase in the work 
of breathing. Emphysema/chronic bronchitis and asthma 
are examples. For the purposes of this chapter, emphysema 
and chronic bronchitis are considered together and will be 
referred to as chronic obstructive pulmonary disease (COPD). 
Asthma will be discussed separately. 
In COPD, the loss of alveolar surface area results in a 
decrease in the elastic properties of the lung and a resultant 
increase in FRC. The patient works at a mechanical disadvan-
tage because the diaphragm is displaced downward and the 
chest is distended, requiring additional effort during exhala-
tion to assure emptying. Exhalation is active, and early air-
way closure is common and contributes to airflow limitation 
and further hyperinflation. The net result is the increased 
work of breathing. Mucous plugging and bronchospasm may 
also exist and exacerbate airflow limitation. 
With asthma, the major determinant of airflow limitation 
is airway resistance secondary to bronchospasm and, to some 
degree, mucous plugging. Bronchospasm makes exhalation 
difficult and results in hyperinflation of the lungs, especially 
with mechanical ventilation. This dynamic hyperinflation, or 
auto-PEEP (when on the ventilator), may result in pneumo-
thorax and subsequent hypotension, and should be avoided. 
 Mechanical Ventilation: Modes and Methods 
Criteria for intubation and initiation of mechanical ventila-
tion generally fall into the following categories: apnea (and/
or need for anesthesia with surgery), severe hypoxemia (PaO 2
≤ 50 mmHg on room air), progressive or impending respira-
tory failure (serial arterial blood gases indicating worsening 
status with clinical signs and symptoms of fatigue), and acute 
respiratory failure (uncompensated respiratory acidosis 
and hypoxemia on room air). Once the patient is intubated, 
it is necessary to select a mechanical ventilator mode and 
associated parameters. Understanding the pathology of the 
condition necessitating mechanical ventilation is essential if 
the lung is to be protected while meeting hemodynamic and 
acid–base management goals. 
Microprocessor technology has increased the versatility of 
traditional modes and has resulted in a wide variety of new 
 Condition Category Pathophysiology Management Comments 
 Acute Respiratory 
Distress Syndrome 
(ARDS)
 Restrictive  Noncardiogenic pulmonary edema, pulmonary 
capillary leak, bilateral diffuse infi ltrates, PaO 2 /
FiO2 ratio < 200.
Etiology is indirect or direct injury. High 
mortality. 
Treat etiology: infection, 
trauma, hypotension, etc.
 Supportive: oxygenation, 
ventilation, cardiac output.
 Optimize lung recovery 
and prevent lung injury: 
avoid O 2 toxicity (FiO 2 <
.5–.6), tidal volumes: 
6 ml/kg, (plateau pres-
sures < 30). Maintain 
lung recruitment with 
PEEP, consider prone 
positioning.
 Hypercarbia and asso-
ciated acidosis may 
be the outcome of 
using lung protec-
tive strategies such 
as low lung volume 
ventilation and is re-
ferred to as permis-
sive hypercarbia. 
 PEEP at higher levels 
(14–16 cm H 2O
range) may be 
necessary to recruit 
the lung. 
 Pneumonia  Restrictive  Community Acquired: Common organisms include 
Streptococcus pneumoniae, Haemophilus 
Infl uenzae, Moraxella catarrhalis, viruses, and 
atypicals (Legionella, Mycoplasma etc.) 
 Treatment of all pneumo-
nias is dependent on 
diagnostic category: 
start with empiric cover-
age fi rst and adjust with 
recovery of organism or 
treatment failure. 
If the patient is 
immune compro-
mised, bronchosco-
py is done early to 
recover organism.
 Examples of Selected Restrictive and Obstructive Pulmonary Conditions 
That Require Mechanical Ventilation 3.1
 Hospital Acquired: (within 3–5 days of being in 
the hospital, recent hospitalization, nursing 
home, etc.). These pneumonias are often the 
result of an aspiration and resistant bacteria 
such as methicillin-resistant  Staphylococcus 
aureus (MRSA) , Pseudomonas, Enterobacter, 
and Serratia are often responsible.
 Ventilator Associated Pneumonia (VAP) ; after 
3–5 days of mechanical ventilation. 
VAP is preventable and 
measures should be put 
in place upon intubation 
(elevate head of bed 
>30 degrees, etc.)
 Bronchiolitis 
Obliterans 
Organizing 
Pneumonia or 
Cryptogenic 
Organizing 
Pneumonitis 
(BOOP/COP) 
Restrictive BOOP is seen with connective tissue disorders, 
solid organ transplantation, and infections such 
as  Legionella .
It is called idiopathic BOOP or cryptogenic orga-
nizing pneumonia (COP) when its etiology is 
undetermined.
 Commonly, the patient presents with a 
community acquired pneumonia that fails to 
respond to antibiotics. 
 The course is usually subacute, developing over 2 
weeks to 6 months of the initial event. 
 Biopsy fi ndings may show a widespread infl am-
matory response with terminal and respiratory 
bronchiole involvement as well as the alveolar 
ducts. 
 The majority of patients 
respond to corticoste-
roids. Treatment is usu-
ally required for at least 
6 months. 
Cytotoxic therapy is con-
sidered early if failure 
to respond to steroids 
is seen.
(continued)
 Condition Category Pathophysiology Management Comments 
 Examples of Selected Restrictive and Obstructive Pulmonary Conditions 
That Require Mechanical Ventilation  (continued)3.1
Idiopathic 
Pulmonary Fibrosis 
(IPF)
Restrictive It is an uncommon infl ammatory/fi brotic inter-
stitial lung disorder of unknown etiology.
Corticosteroids are the 
mainstay of treatment, 
although their role is 
now being questioned. 
Cyclophosphamide can 
be used as a second im-
munosuppressive agent. 
Single-lung transplant is 
the defi nitive therapy 
 The disease was origi-
nally described by 
Hamman and Rich 
as a fulminant form 
of pneumonitis. 
 COPD (emphysema 
/bronchitis) 
Obstructive  Chronic Bronchitis: Chronic or recurrent excess 
mucus production in bronchial tree.
Occurs 3 months in a year for 2 consecutive years.
Common to have repeated respiratory infec-
tions (RSV: respiratory syncytial virus, strep 
pneumonia, H-fl u)
Emphysema: Abnormal permanent enlarge-
ment of airspaces distal to terminal bronchiole, 
accompanied by destruction of the walls. Centri-
lobular proximal, most common.
Panlobular (panacinar), entire acinus involved. 
Lower lobes more involved with alpha 
1-antitrypsin defi ciency
Relieve reversible airway 
obstruction, cough 
control, and sputum 
production.
Eliminate/prevent airway 
infections.
Increase exercise tolerance 
and control complica-
tions (cardiovascular 
and hypoxemia)
Generally, emphysema 
and bronchitis are 
considered to-
gether because they 
often have similar 
pathology.
 Acute Severe 
Asthma (ASA) 
Obstructive Severe acute bronchoconstriction that is 
intense, unrelenting, and unresponsive to 
usual therapy.
Pathology includes airway infl ammation, 
bronchoconstriction, and mucus
production.
Bronchodilators: beta 
2-agonists (1st line), 
anticholinergics (2nd 
but often given in com-
bination with beta ago-
nists), steroids (always 
a fi rst line drug).
Oxygen.
Hydration.
Antibiotics if infection 
suspected.
Methylxanthine and 
magnesium have 
been used but rarely.
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sophisticated mode options. However, despite many available 
mode options, there is little scientific evidence supporting 
the selection of any one mode over another. Instead, the cli-
nician must carefully apply the options to selected conditions 
to assure good outcomes. To that end, a discussion of volume 
and pressure modes follows. Table 3.2 (pages 56 through 58) 
describes traditional and common mode parameters found on 
most ventilators. Table 3.3 (pages 58 through 61) describes the 
parameters required for selected volume and pressure modes.
 Parameter Settings Comments 
 Fraction of Variable from .21–1.00 High levels of FiO 2 (>50%)
Inspired   are considered toxic. Positive
Oxygen (FiO 2)   end-expiratory pressure 
(PEEP) is added to recruit 
lung and decrease shunt and 
ventilation/perfusion 
mismatch.
 Tidal Volume 8–12 ml/kg. With acute lung Remember the combination of
(Vt) injury or ARDS use   Vt, f, and Ti contribute to
  6 ml/kg   hyperinfl ation in obstructive 
   conditions. 
 Respiratory Rate is initially set between “Normal” PaCO 2 is not a goal
Rate/ 10–20. Once the Vt is   for all mechanical ventilation.
frequency ( f ) determined, the rate is  In ARDS, lung protection
adjusted to attain   using small  Vts will result in
  desired PaCO 2 level.  anticipated hypercarbia and 
 acidosis. This is referred to 
 as “permissive hypercarbia”. 
Inspiratory Average adult  Ti is determined by the fl ow 
time ( Ti )    Ti = .7–1.0 seconds  rate of the gas. The higher
   the fl ow, the shorter the  Ti (for 
 any given Vt). Increasing fl ow 
 increases pressure. Very high 
f s result in very short Ti s; the 
 fl ow pattern becomes very 
 turbulent, and gas distribution 
 is poor.
3.2  Traditional Ventilator Parameters
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 Parameter Settings Comments 
 I /E ratio is usually 1:2 or 1:3  Generally, obstructive  conditions 
 require longer expiratory 
 times to prevent auto-PEEP. 
 In contrast, restrictive condi-
 tions do not require long 
 expiratory times. 
 Sensitivity  Pressure sensing:  Flow triggering (if set correctly)
(Pressure   generally set between −1  results in less patient work
and/or fl ow  to −2 cm H 2 O  than does pressure sensing.
triggering) The greater the negative   
  pressure, the harder the
  patient work to get a 
  breath.
 The smaller the fl ow sensi- Generally, fl ow sensing will
  tivity number (e.g., 500 ml/  default to pressure sensing if
  min), the more sensitive  not set correctly (i.e., the fl ow
  the ventilator. The higher  trigger is too large)
  the setting (e.g., 1–2L/min),
  the less sensitive. Set at
  the minimal level above
  auto-triggering. 
 Positive  PEEP of 5 cm H 2 O is Maintains positive pressure 
End- considered “physiologic.”  at end exhalation. “Recruits”
Expiratory   Weaning below this level  alveoli & holds them open. 
Pressure   is rarely necessary.   Restores functional residual 
(PEEP)  Higher levels are required  capacity (FRC).
  to  “recruit the lung”. 
 When exhalation is Factors that contribute to auto-
  inadequate, auto-PEEP  PEEP include expiratory 
  (occult or hidden PEEP)  resistance, low elastic recoil, 
  is the result. Auto-PEEP  high MV, short expiratory
  may be an anticipated  time, mucus hypersecretion, 
  result of some ventilator  increased wall thickness and
  modes such as PC/IRV,  airway closure or collapse.
  or an undesirable result  Mechanical factors like water
  of inadequate ventilator  in the circuit may also result
  settings.   in auto-PEEP.
(continued)
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 Parameter Settings Comments 
Continuous Pressure is maintained
Positive  continuously above baseline
Airway  (i.e., “0”). CPAP is a spon-
Pressure  taneous breathing mode.
(CPAP)   As with PEEP, it is used to
  restore FRC. Other uses
  are as a spontaneous
  breathing method for
  weaning and for noninva-
  sive ventilation as in
  obstructive sleep apnea
  (serves as a pneumatic
  splint to keep the upper
  airway open during sleep). 
 Mode Name Main Parameters Comments 
 Assist Control Vt Generally considered a support
(A/C) fx  mode. Must switch to another
Ti  mode or method for weaning.
 Sensitivity
 FiO 2
 PEEP 
Synchronized Vt Originally used as a “weaning mode”;
Intermittent RR  however, work of breathing is
Mandatory Ti  high at low IMV rates.
Ventilation Sensitivity Often used in conjunction with PSV.
(SIMV) FiO 2  
 PEEP
3.3  Volume and Pressure Modes and Corresponding Ventilator Parameters 
3.2 Traditional Ventilator Parameters (continued)
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 Mode Name Main Parameters Comments 
 Pressure PS level Pressure is often arbitrarily
Support Sensitivity  selected (e.g., 10–20 cm H 20) then
Ventilation FiO 2  adjusted up or down to attain the
(PSV) PEEP   desired tidal volume. Some use 
the plateau pressure if transi-
tioning from volume ventilation 
as a starting point. 
 Pressure IPL Varients of PCV include Volume 
Control  fx   Assured Pressure  Options and 
Ventilation  Ti  some other modes such as
(PCV) Sensitivity   Airway  Pressure Release 
 FiO 2 Ventilation and BiLevel Ventilation. 
 PEEP  They are listed below. 
 Pressure As for PCV, an inverse  Some ventilators allow for the I/E
Controlled-  I/E ratio is attained  ratio to be selected.
Inverse   by lengthening the 
Ratio   Ti . Inverse ratios
Ventilation  include 1:1, 2:1, 3:1,
  and 4:1. 
 Airway  Pressure high (PHIGH) Generally, the CPAP level is adjusted
Pressure  - the high CPAP   to assure adequate oxygenation,
Release level   whereas the  fx of the releases are
Ventilation Pressure low (PLOW )  increased or decreased to meet
  which is generally   ventilation goals. Vt is variable
  0–5 cm H 2O   dependent on the CPAP level,
 Time high (THIGH)  compliance and resistance of the
 Time low (TLOW )  patient, and patient spontaneous
 FiO 2  effort. 
 Volume These modes provide These modes are ventilator specifi c. 
Assured  pressure breaths   Although the simi larities are
Pressure  with a volume   greater than the differences, they
Modes guarantee. are called different names. Often, 
(1–5 below)   the names suggest that the mode
   is a volume mode yet a decelarating
   fl ow pattern (associated with pres-
   sure ventilation) is always provided. 
 1. Volume  Vt , The pressure level is automatically
 Support  Sensitivity  adjusted to attain the desired  Vt . 
 (VS) FiO 2  If control of pressure is desired, it
 PEEP  must be carefully monitored. 
(continued)
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 Mode Name Main Parameters Comments 
 2. Pressure-  fx and  Ti set in  As with VS, the difference is that
 Regulated  addition to those   this is a control mode. Spontaneous
 Control  set for VS breaths however may also occur.
 (PRVC)
 3. Volume  Vt This mode is one option in a
 Support Sensitivity  category called “Volume Ventila-
 (VS) FiO2  tion Plus.” This is the spontaneous
 PEEP  breathing option in this category
   and is similar to VS above. 
 4. Volume  fx and  Ti are set in  This mode is also a mode option
 Control  addition to those   listed in the category called
 Plus   set for VS  “Volume Ventilation Plus”.
 (VC+)   To access this mode, the user 
 selects the SIMV or assist control 
 (both control modes) then selects 
 VC+. For some clinicians, this 
 is confusing as it appears that the
  patient is on two different modes 
 versus VC+.
Bilevel PEEPH If additional support is desired for
Positive PEEPL  patient-initiated breathing, Psupp
Airway  fx and  Ti  may be selected as well. Atten-
Pressure   tion to Vt is important, because
(Bilevel or   the patient can augment Vt
BiPAP)   signifi cantly with supported
   spontaneous breaths.
Adaptive Body weight Once basic settings are selected, ASV 
Support %MinVol  is started and %MinVol is adjusted
Ventilation  (minute volume)  if indicated. Spontaneous breathing
(ASV) High pressure limit  is automatically encouraged, and 
   when the inspiratory pressure
 (Pinsp) is consistently = 0 and fx
    control (rate) = 0, extubation may 
be considered.
3.3 Volume and Pressure Modes and Corresponding Ventilator (continued)
Chapter 3: Critical Care Pulmonary Management 61
 Mode Name Main Parameters Comments 
 Proportional Proportional Pressure Depending on the ventilator, the
Assist Support- PPS™   amount of “assist” that is provided
Ventilation  (Drager Medical,   is determined by the clinician, and
(PAV)  Canada): PEEP, FiO 2,   different parameters are selected
  % volume assist,   to do so. Default % support
  and fl ow assist  numbers are recommended, but
 Proportional Assist   the clinician must determine the
  Plus ([PAV+] Puritan  timing of reductions of the same.
  Bennett, now
  Covidien) PEEP, 
  FiO 2, % Support 
 Automatic Endotracheal tube This is not a mode but rather a
Tube   internal diameter  pressure option to offset the work
Compen- % compensation associated with tube resistance.
sation (ATC)   It can be combined with other
   modes or can be used alone as 
   in a CPAP weaning trial. 
 Adapted with permission from Burns SM. Pressure Modes of Mechanical Ventilation: The good, 
bad and the ugly. Advanced Critical Care. 2008; 19: 399–411. 
Key: Vt : tidal volume; PS: pressure support; FiO 2: fraction of inspired oxygen; PEEP:  positive end-expi-
ratory pressure; IPL: inspiratory pressure level;  fx : respiratory frequency;  Ti :  inspiratory time; PEEPH:
high PEEP; PEEPL: low PEEP; Psup: pressure support in bilevel mode; MinVol: minute volume.         
 Volume Versus Pressure Modes 
Volume ventilators are still in use but are increasingly being 
supplanted by pressure modes. One reason for the current 
popularity of pressure modes is the characteristic decelerat-
ing flow pattern of pressure breath delivery that is associated 
with improved gas distribution (Figure 3.1). 
With volume ventilation, a predetermined volume is deliv-
ered with each breath regardless of changes in compliance 
or resistance (Figure 3.2). Pressure increases or decreases 
accordingly on a breath to breath basis. In contrast, when 
pressure modes were first introduced, pressure was select-
ed by the clinician and it remained stable, whereas volume 
varied with changing compliance and resistance. Unlike the 
earlier pressure mode options, newer pressure modes no lon-
ger sacrifice volume for pressure. Current ventilators allow 
for guaranteed volumes while delivering the pressure breath 
with the characteristic decelerating flow pattern.  
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Although it is not within the scope of this chapter to describe 
every mode available on ventilators manufactured today, 
categories of ventilator modes are described for the reader’s ref-
erence. The Acute Care Nurse Practitioner (ACNP) is encour-
aged to access specific manufacturer ventilator  operating user 
3.2
Square Flow Pattern With Volume Ventilation (A-B)
Reprinted by permission from Nellcor Puritan Bennett LLC, Boulder, Colorado, part of Covidien.
3.1
Decelerating Flow Pattern With Pressure Ventilation 
Reprinted by permission from Nellcor Puritan Bennett LLC, Boulder, Colorado, part of Covidien.
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manuals for specific details related to the modes and how to 
adjust ventilators to assure proper mode operation. 
 Volume Modes 
Control Mandatory Ventilation (CMV). CMV is the term used 
when the goal is to prevent patient–ventilator interaction. 
This is usually accomplished with the aid of sedation and 
sometimes neuromuscular blockade. (Figure 3.3). 
Assist/Control Ventilation (A/C) A/C delivers volume breaths 
at a predetermined rate and inspiratory time. Between the 
control breaths, the patient can initiate a respiration and 
upon doing so receives a volume breath as configured for 
3.3
Pressure Waveform: Control Mandatory Ventilation 
(A: No spontaneous effort noted, all breaths are control breaths.)
Reprinted by permission from Nellcor Puritan Bennett LLC, Boulder, Colorado, part of Covidien.
3.4
Pressure Waveform: Assist Control Ventilation
The arrow points to a negative defl ection representing a patient-initiated breath. Once 
the patient initiates the breath, a volume as set for the control breaths is delivered.  
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the control breaths (Figure 3.4).This mode is useful when the 
goal is to provide full ventilatory support. The patient must 
be transitioned to another mode when able to be weaned 
from mechanical ventilation. 
Synchronized Intermittent Mandatory Ventilation (SIMV). With 
SIMV, the ventilator synchronizes the delivery of volume breaths 
at a predetermined rate and inspiratory time. The patient may 
breathe spontaneously between mandatory breaths at his/her 
own respiratory rate and tidal volume. (Figure 3.5). 
Early studies on the use of SIMV suggest that the work 
of breathing associated with spontaneous breathing at low 
SIMV rates is excessive. Thus, pressure support ventilation 
(PSV) is often used to support the patient-initiated breaths. 
Although this combination of pressure-supported and vol-
ume-supported breaths is common, weaning times may be 
prolonged with the combination mode. This will be discussed 
later in the section on weaning. 
The manner in which the traditional volume modes 
operate related to patient–ventilator interaction is impor-
tant to remember. Some of the new ventilator pressure mode 
options require the user to select a mode setting that is called 
SIMV or A/C, so that pressure breath delivery is configured 
similarly. For example, a pressure mode may be selected, but 
how the breaths are delivered may depend on the selection of 
either an A/C or SIMV setting. If A/C is selected, the control 
pressure breaths will be delivered at the predetermined rate 
and inspiratory time, and when the patient initiates a breath, 
3.5
Pressure Waveform: Synchronized Mandatory Ventilation
Note: The fi rst arrow is pointing to a mandatory volume breath. The second arrow 
is pointing to one of the patient-initiated breaths.
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a control pressure breath is delivered. With the selection of 
SIMV, the spontaneous breaths will be patient controlled 
(e.g., inspiratory time, volume, and rate). 
 Pressure Modes 
Pressure Support Ventilation (PSV). PSV is a spontaneous 
breathing mode. With PSV, the clinician selects the pressure 
level, but the patient determines the rate (  f ), tidal volume 
(Vt ), and inspiratory time ( Ti  ). Spontaneous inspiration is 
augmented with the PSV level. (Figure 3.6). High levels of 
PSV provide almost full ventilatory support, whereas the 
gradual reduction in the pressure level allows for a progres-
sive increase in workload (MacIntyre, 1997). 
Pressure Control Ventilation (PCV) and Pressure Control 
Inverse Ratio Ventilation (PC/IRV). PCV was first introduced as 
a mode used in patients with ARDS. The idea was to control 
airway pressure while providing a decelerating flow pattern. At 
the time, it was not known if peak airway pressure or plateau 
pressure was responsible for lung injury. Inverse ratio ventila-
tion (IRV) was used to lengthen inspiration in an attempt to 
keep the lung open for longer periods of time (Tharrat, Allen, & 
Albertson, 1988). Given the restrictive nature of ARDS, the pro-
longed inspiratory to expiratory (I/E) ratio could be adjusted 
from 1:1 to 4:1 to assure improved oxygenation. (Figure 3.7). 
These modes require that the clinician designate a pressure 
level, rate, and inspiratory time. 
A common problem encountered with the use of traditional 
PC/IRV is the inability of the patient to receive adequate gas flow 
3.6
Pressure Waveform: Pressure Support (square pressure waveform)
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3.7
Pressure Waveform: Pressure Controlled/Inverse Ratio Ventilation
with spontaneous effort. Thus, sedatives and paralytic agents 
have been required to assure patient–ventilator synchrony. 
Although traditional PC/IRV is rarely used today (newer tech-
nology allows for improved flow to the patient upon demand), 
the concept of preventing derecruitment of alveoli with a pro-
longed inspiratory time is incorporated into more sophisticated 
modes such as airway pressure release ventilation. 
Airway Pressure Release Ventilation (APRV) and Biphasic 
Ventilation. APRV is a spontaneous breathing mode that 
requires the selection of a relatively high level (15–20 cm 
H2O) of continuous positive airway pressure (CPAP) and 
short timed-frequency releases (1–1.5 sec) to a baseline 
pressure. This mode is designed for use in patients with 
ARDS who require a high level of pressure to recruit 
alveoli (Cane, Peruzzi, & Shapiro, 1991). The short releases 
prevent derecruitment and aide in the elimination of CO 2.
The extremely short airway pressure releases are the hall-
mark of APRV and set it apart from PCV and biphasic ven-
tilation (Putensen et al., 2001). (Figure 3.8) 
Biphasic ventilation may be considered a form of PCV 
and/or PC/IRV, depending on the inspiratory to expiratory 
ratio. Similar to the two modes, an inspiratory pressure level 
and PEEP level are selected in addition to  Ti and   f. In con-
trast to traditional PC or PC/IRV, biphasic ventilation allows 
for patient breathing during all portions of the respiratory 
cycle. Spontaneous breathing may be assisted with PS if 
additional support is desired. Parameters for the inspiratory 
pressure and PEEP levels are referred to as  high PEEP and 
low PEEP or high pressure and low pressure . (Figure 3.9) 
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Both APRV and biphasic modes appear to be safe and 
effective and may have the additional advantage of not 
requiring the use of muscle relaxants or heavy sedatives to 
assure patient–ventilator synchrony (Rathgeber et al., 1997). 
The microprocessor technology in these modes allows for 
rapid delivery of flow throughout the cycles for the support 
of spontaneous patient breathing. 
Volume-Assured Pressure Modes. This category includes 
several ventilator mode options that provide a pressure breath 
3.8
Airway Pressure Release Ventilation
Reprinted by permission from Nellcor Puritan Bennett LLC, Boulder, Colorado, part of Covidien.
3.9
Biphasic or Bilevel Ventilation    
Reprinted by permission from Nellcor Puritan Bennett LLC, Boulder, Colorado, part of Covidien.
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3.10
Volume Support Ventilation
Note that the pressure level is increased on a breath-to-breath basis to maintain 
the volume, and that all breaths are patient initiated.  Pressure-regulated volume 
control is similar, but the rate is set. 
(with a decelerating pressure waveform) combined with a 
volume guarantee. Despite the mode names, which often have 
volume in the title, these modes are designed to deliver pressure 
breaths. Some examples of volume assured pressure modes 
are volume support (VS), pressure- regulated volume con-
trol (PRVC), and volume control plus (VC+) (Puritan Bennett 
product information, 2008; Maquet product information, 2008). 
VS is a spontaneous breathing mode, whereas PRVC is 
not. With each mode, the ventilator automatically adjusts the 
pressure level (in 3 cm H 2O increments) on a breath-to-breath 
basis to attain the clinician-desired volume (Figure 3.10). Sim-
ilar to PRVC, VC+ is the mandatory option of a volume guar-
anteed pressure mode. Both PRVC and VC+ are considered 
control modes and require that respiratory frequency (   fx) and 
inspiratory time ( Ti ) are selected for the control breaths. 
Adaptive Support Ventilation (ASV) (Hamilton medical product 
information 2008). This mode is referred to by the manufac-
turer as intelligent ventilation . The mode is designed to assess 
lung mechanics on a breath-to-breath basis (controlled loop 
ventilation) for spontaneous and control settings. It automat-
ically adjusts mandatory fx and  Ti to attain the optimal  Vt 
(as determined by the ventilator calculations). The ventilator 
is designed to adapt workload so that elastic and resistive 
loads are minimized. It automatically promotes spontane-
ous breathing in all modes, and parameter adjustments are 
few. Settings include body weight, % min volume, and a high 
Chapter 3: Critical Care Pulmonary Management 69
pressure limit. The ventilator has built-in lung protective 
algorithms that activate automatically. They include strat-
egies to minimize auto-PEEP, prevent apnea, tachypnea, 
excessive dead space, and excessively large breaths. 
Proportional Assist Ventilation (PAV) (Draeger product 
information, 2008; Puritan Bennett product information, 2008). 
PAV was designed to assist breath-to-breath ventilation in 
proportion to the resistance and elasticity of the system. To 
that end, current PAV modes take measurements throughout 
the inspiratory cycle and then automatically adjust the pres-
sure, flow, and volume proportionally. Different names for the 
modes are provided by specific manufacturers and param-
eters that require varying adjustments. Essential parameters 
in which to apply this mode include the percent of volume 
assist and flow assist. 
Automatic Tube Compensation (ATC). ATC is available in 
many of the microprocessor ventilators and is designed to 
overcome the work of breathing induced by artificial air-
ways. Although it is not a mode of ventilation per se, it does 
adjust pressure (proportional to tube resistance) required to 
provide a variable fast inspiratory flow during spontaneous 
breathing. The clinician must enter the internal diameter of 
the artificial airway and the proportion of compensation for 
the ventilator to accurately compensate for tube resistance. 
 What Modes are Best? 
Although the new modes of ventilation are attractive because 
of their sophistication, versatility, and potential applications, 
little data exists that demonstrates their superiority. Instead, 
application, understanding, and familiarity with the modes 
are the key to good outcomes. Variation in practice breeds 
mistakes and should be decreased when possible. When clini-
cians do not understand the modes, the potential for inaccu-
rate and inefficient management exists. This is true through-
out the continuum of ventilation (from the acute stage to the 
weaning stage). Thus, it is essential that the ACNP understand 
the modes, so that they are appropriately applied. 
Perhaps the greatest challenge with regard to mechanical 
ventilation is the management of the most complex patients. 
ARDS and acute severe asthma (ASA) are two extreme exam-
ples of restrictive and obstructive pathology. A discussion of 
the ventilatory management of these conditions follows. 
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 Ventilatory Management of ARDS and ASA 
 Background 
As noted in Table 3.1, ARDS is often referred to as non-
cardiac pulmonary edema. The precipitating event may be 
nonpulmonary, as in the case of sepsis, or pulmonary, as in 
the case of aspiration pneumonia. Regardless of the etiology, 
the result is a pulmonary capillary leak. Pathologic changes 
include ventilation abnormalities, decreased lung compliance 
(and atelectasis), shunting, and refractory hypoxemia. Work 
of breathing is very high, and high pressures are required 
to open the lung (Dreyfuss & Saumon,1993). Most patients 
with ARDS require mechanical ventilation as a supportive 
measure, while treatment of the underlying condition that 
precipitated the ARDS is accomplished. Mortality continues 
to be as high as 50% (TenHoor, Mannino, & Moss, 2001). 
Over 20 years ago, investigators studying the ARDS lung 
in animal models began to recognize the relationship of high 
distending pressures to lung injury. They noted that with the 
use of large traditional volumes (at that time between 12 and 
20 ml/kg) and pressures >35 cm H 2O, animals that were ven-
tilated for >72 hours suffered alveolar fractures and edema. 
The lung injury was referred to as  volutrauma (Dreyfuss, 
Bassset, Soler & Saumon, 1985; Dreyfuss, Soler, Bassett, & 
Saumon, 1988; Dreyfuss & Saumon, 1998, Fu, Z. et al., 1992). 
Subsequent studies clarified other potential mechanisms 
of injury in the noncompliant ARDS lung. Computed tomog-
raphy (CT) scans taken of the ARDS lung demonstrated that 
the disease distribution was not homogeneous, meaning that 
the pressure delivered to the lung was preferentially being 
delivered to “open” areas (Gattinoni et al., 1986). This syn-
drome was referred to as  baby lung , and it was noted that 
these areas were especially prone to injury from the distend-
ing forces of a big breath. 
An additional study noted that when the lung is not fully 
recruited, the forces needed to open the stiff alveoli are large 
and with repetitive tidal opening; the associated stress result-
ed in injury. It was suggested that recruitment with PEEP was 
necessary to keep the lung open and prevent this “repetitive 
opening injury.” 
Amato et al., (1995) subsequently noted in a random-
ized controlled trial that higher PEEP levels were associated 
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with improved mortality and other outcomes in patients with 
ARDS. Using inflection pressures to determine the optimal 
PEEP level to recruit the lung, they noted that levels of 14–16 
cm H 2O were often necessary to achieve lung recruitment 
(Amato et al., 1995; Amato et al., 1998). 
Tidal volume ( Vt) and the related pressures to attain Vt 
were also the focus of randomized controlled trials (RCT). 
Hickling, Henderson, and Jackson (1990) noted that patients 
ventilated with low volume ventilation had lower mortal-
ity than those ventilated with traditional lung volumes. In a 
multisite study sponsored by the National Heart, Blood, and 
Lung Institute of the National Institutes of Health, 800 patients 
meeting the criteria for ARDS (i.e., PaO 2 /FiO 2 < 300, noncardiac, 
bilateral infiltrates) were assigned to low-volume ventilation 
or traditional volume ventilation (6 vs. 12 ml/kg, respectively). 
FiO 2 and PEEP were assigned in an algorithmic approach (The 
ARDS Clinical Trials Network, 2000). The results of the study 
noted 25% lower mortality in those ventilated at the lower lung 
volumes. Although the results were dramatic, it was difficult to 
determine what part PEEP (and/or auto-PEEP) contributed to 
the improved outcomes. In a subanalysis of the data, it was also 
noted that the plateau pressure associated with the low and 
traditional tidal volume  ventilation strategies were ∼26 and 35, 
respectively (The ARDS Clinical Trials Network, 2000). These 
plateau pressures were substantially less than those noted to 
be injurious in animal models. See Exhibit 3.1 for the definition 
and measurement of plateau pressure. 
The evidence related to mechanical ventilation of patients 
with ARDS suggests that application of selected protective 
lung strategies is essential. They include the use of low tidal 
volume ventilation (6 ml/kg), lung recruitment with PEEP, 
and the prevention of derecruitment (The Acute Respiratory 
Distress Syndrome Network, 2003)
Application of Protective Lung Strategies in ARDS. 
 ■ Low lung volume ventilation. Volume modes of ventila-
tion are useful to assure that tidal volumes of 6 ml/kg 
(lean body weight) are consistently delivered. To main-
tain a pH that is within an acceptable range,  fx is gen-
erally high (20–30). If this protective strategy results in 
hypercarbia and acidosis, it may be necessary to sedate 
and paralyze the patient to depress respiratory drive. 
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Permissive hypercarbia is relatively well tolerated in 
many patients, but it is contraindicated in those with 
elevated intracranial pressure and in some with car-
diac conditions (Hickling et al., 1990). When pressure 
modes are used, constant attention to the delivered 
volumes is necessary. Furthermore, it is important 
to remember that the plateau pressure necessary to 
Exhibit
 Compliance (or how easy it is to distend the lungs and chest wall) is  measured 
with a plateau pressure. 
Resistance (how easy it is to move gases down the airways) is measured 
by noting the difference between peak airway pressure and plateau pressure.
Plateau pressure (also known as distending pressure, static pressure, and 
 alveolar pressure) is the pressure required to hold the lungs and chest wall open. 
It is referred to as a “static” measurement because it is measured at the end 
of a full inspiration during a breath hold (no air fl ow). The resultant  pressure is 
generally 10–15 cm H2O less than the peak airway pressure. This occurs because 
the pressure required to assure the fl ow of gas down the airways contributes 
to the peak airway pressure (which is the result of both airways resistance and 
lung/chest wall compliance). During the end-inspiratory hold maneuver, this fl ow 
is eliminated. With decreased compliance, the plateau pressure will increase.
In obstructive conditions such as asthma, resistance to airfl ow is high and pres-
sure must increase to maintain fl ow. Resistance is measured by performing a pla-
teau pressure maneuver and is the difference between peak airway pressure and 
plateau pressure. Increased resistance will result in an increase in peak airway 
pressure and, with severe hyperinfl ation, an increased plateau pressure as well .
Measurement of plateau pressure:
1.  Switch to volume mode of ventilation for measurement.
2.  At the end of inspiration, activate the end-inspiratory hold button.
3.  Hold briefl y while observing the peak airway pressure.
4.  The peak pressure will drop, and the resulting pressure is the plateau 
 pressure.
5.  This maneuver is diffi cult to do in a spontaneous breathing patient and may 
require sedation (and sometimes neuromuscular blockade) to accomplish 
accurately.
3.1 Measurements of Compliance and Resistance
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prevent lung injury is unknown. Based on the ARDS 
network study, the required plateau pressure may be 
within a 26–30 cm H 2O range; however, plateau pres-
sure is reflective of chest wall as well as lung, thus 
making it difficult to determine what the pressure goal 
should be. 
 ■  Lung recruitment is generally accomplished with PEEP. 
Unfortunately, it is clinically very difficult to determine 
what critical opening pressure is required to uniformly 
recruit the ARDS lung. Some have used maneuvers such 
as the “40/40 or 60/60 maneuvers” for lung recruitment 
(Foti et al., 2000; Fujino et al., 2001). These consist of 
using critical opening pressures (PEEP) of 40 or 60 cm 
H2O for 40–60 seconds. The techniques are difficult to 
accomplish and carry the additional risk of barotrauma. 
Instead, many use high levels of PEEP (e.g., 14–16 cm 
H2O) and monitor the effect on PaO 2. Unfortunately, 
improved oxygenation may result from recruitment or 
may be the result of redistribution of blood flow to aer-
ated areas of the lung. Definitive methods of assessing 
lung recruitment are few and include serial CT scans 
with changes in PEEP (very unrealistic cost and labor 
intensive). Another method is to monitor plateau pres-
sure with increases in PEEP. With this technique, pla-
teau pressure should remain stable or decrease with 
increases in PEEP. In contrast, an increase in plateau 
pressure with the addition of PEEP may be reflective of 
overdistention. Prone positioning may also be used to 
“recruit lung” (Tobin & Kelly, 1999, Albert, Lesa, Sand-
erson, Robertson, & Hlastala, 1987) although definitive 
data demonstrating positive effects on mortality sec-
ondary to prone positioning are lacking (Gattinoni et 
al., 2001; Mancebo et al., 2006). However, subanalyses 
in the existing studies do suggest that the technique 
may result in improved outcomes in those with the 
most severe ARDS (PaO 2/FiO 2 ratios of <100) (Gattinoni 
et al., 2001; Mancebo et al., 2006). Further studies are 
necessary to clarify the use of prone positioning, espe-
cially as related to duration, frequency, and timing of 
the technique. Regardless of the method used to assure 
recruitment, it is important to remember that derecruit-
ment occurs quickly, such as when the ventilator circuit 
is broken, and is to be avoided. 
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 Acute Severe Asthma (ASA) 
Background. The hallmark pathologies in asthma include 
airway inflammation, bronchospasm, and mucus production. 
With ASA, therapy consists of aggressive pharmacologic 
management and mechanical ventilation when necessary. 
Pharmacologic management includes treatment of inflam-
mation with steroids, bronchodilators (specifically β-2 ago-
nists and anticholinergics), and fluid resuscitation. Despite 
definitive pharmacologic therapies, many of these patients 
require admission to a critical care unit and support with 
mechanical ventilation. Unfortunately, ventilating patients 
with ASA is difficult and must be carefully achieved if lung 
injury and death are to be avoided. Mortality associated with 
ventilation of the ASA patient is generally low but is noted to 
be as high as 22% in some patients (Mansel, Stogner, Petrini, 
& Norman, 1990). Morbidity associated with the mechanical 
ventilation of patients with asthma includes dynamic hyper-
inflation and auto-PEEP, hypotension (the effect of intratho-
racic pressure on venous return), and barotrauma (Pepe & 
Marini, 1982; Mansel et al., 1990). 
Dynamic hyperinflation refers to the overdistension of 
the lung related to bronchospasm and is common with ASA. 
Exhalation is incomplete as a result of airway narrowing and 
noncommunicating airways (from bronchospasm or mucus 
plugging). The diaphragm is displaced into a disadvantageous 
downward position in the chest. This mechanical disadvantage 
results in a substantial increase in the work of breathing. With 
mechanical ventilation, inadequate exhalation time results in 
hyperinflation and is called auto-PEEP. Factors contributing 
to auto-PEEP include expiratory resistance, low elastic recoil, 
high minute ventilation, high rates, short expiratory times, 
mucus hypersecretion, increased wall thickness, and airway 
closure or collapse. Mechanical factors, such as water in cir-
cuits, also can result in auto-PEEP. Thus, interventions are 
aimed at preventing and/or reducing auto-PEEP. 
 Application of Protective Lung Strategies 
for ASA 
 ■  Prevent hyperinflation and auto-PEEP by decreasing 
the rate, shortening the inspiratory time, and decreasing 
the volume. In severe cases, sedation and even neuro-
muscular blockade will be necessary to accomplish these 
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interventions because they will result in hypercarbia and 
acidosis (and increased respiratory drive). The goal is to 
prevent morbidity and mortality associated with auto-
PEEP. Measurement of resistance and plateau pressure 
may be done to track progress and assess adequacy of 
interventions. Refer to Exhibit 3.1 on page 72. 
 ■  Assume hyperinflation and auto-PEEP in patients with 
ASA. Measure auto-PEEP. The absence of auto-PEEP 
does not necessarily mean it is not present. Instead, 
it simply may not be measurable. Noncommunicating 
airways secondary to early airway closure during exha-
lation, mucus, and/or severe bronchoconstriction may 
prevent measurement (Leatherman & Ravenscraft, 
1996). Occasionally, applied PEEP will help by pre-
venting closure of the airways during exhalation and 
will allow for better emptying (refer to Exhibit 3.2). 
Exhibit
Auto-PEEP or occult PEEP is a result of inadequate exhalation time from any 
cause.
Measurement:
1.  At the end of a full expiration (right before inspiration), activate the 
end-expiratory hold button.
2.  Observe the baseline pressure (set PEEP level or zero). As gases in the 
system equilibrate, the baseline pressure will rise to a higher pressure if 
auto-PEEP is present.
3.  Auto-PEEP is the difference between the higher pressure and the baseline 
pressure.
4.  In some cases, noncommunicating airways secondary to early airway 
closure during exhalation, mucus plugging and bronchospasm preclude 
accurate measurement of auto-PEEP. Applied PEEP may help by prevent-
ing premature airway closure. To assess, a plateau pressure is checked 
 following application of PEEP. If no increase in plateau pressure occurs
(or if it decreases), the addition of PEEP is resulting in more complete 
 exhalation. If, however, the plateau pressure increases with the addi-
tion of PEEP, it is contributing to alveolar overdistension and should be 
decreased.
3.2 Measurements of Auto-PEEP
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 ■  If hypotension is noted with mechanical ventilation 
of the patient with ASA, consider a brief cessation of 
mechanical ventilation. This may be lifesaving as the 
hypotension may be the result of extreme levels of 
auto-PEEP. This is often noted with vigorous or over-
zealous mechanical ventilation of these patients. 
 Summary: Ventilatory Management of ARDS 
and Asthma 
Ventilating the sickest patients requires an understanding 
of the pathophysiology of the conditions and knowledge of 
existing evidence related to the appropriate application of 
management strategies. In the case of ARDS (a restrictive 
disorder) and ASA (an obstructive disorder), lung protection 
is essential to assure good outcomes, yet the methods to do so 
differ greatly. Although many other obstructive and restric-
tive conditions may require mechanical ventilation, different 
concepts related to ventilation of these individual conditions, 
exemplified with the discussions of ARDS and ASA, may be 
applied. 
 Weaning From Mechanical Ventilation 
The process of weaning from mechanical ventilation has 
evolved greatly over the last 10 years. Prior to studies that 
employed protocols for weaning trials, weaning was accom-
plished with a wide variety of modes and methods; variability 
in practice was the norm. We know that protocols for wean-
ing trials work because they decrease practice variability. 
Randomized controlled trials indicated that the combination 
of weaning trial screens (to determine when to start a trial); 
protocols for how to accomplish the weaning trial (mode, 
method, and when to stop); and multidisciplinary approach-
es to weaning resulted in improved outcomes (Esteban et al., 
for the Spanish Lung Failure Collaborative Group, 1995; Ely 
et al., 1996; Marelich et al., 2000; Kollef et al., 1997; Burns et 
al., 1998; Burns et al., 2003; Smyrnios et al., 2002). 
Weaning is not just about ventilator management. As noted 
in two systematic reviews, prior to weaning, attention to the 
myriad of pulmonary and nonpulmonary factors that affect 
weaning should be corrected (Cook, Meade, Guyatt, Griffith, & 
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Booker, 1999; MacIntyre, Cook et al., 2001). In addition, research 
in the area of sedation management and other care elements, 
such as glucose control, suggest that ventilator duration, ICU 
and hospital length of stay, including mortality data, may also be 
positively affected with the use of standardized management 
algorithms and protocols (Brook et al., 1999; Kress, Pohlman, 
O’Connor, & Hall, 2000; Van den Berghe, et al., 2001). 
A discussion of sedation management, assessment 
of readiness to wean, and the design and use of weaning 
protocols follows. In addition, a brief discussion related to the 
timing of tracheostomy is included. 
 Weaning Assessments
Although it is understood that the underlying condition or 
disease resulting in the need for mechanical ventilation 
must be improved prior to weaning, rarely is that enough 
to assure weaning success, especially in those requiring 
mechanical ventilation for longer than 3 days. These patients 
suffer from iatrogenic insults that further compromise their 
recovery. Ventilator-associated pneumonia (VAP), gastro-
intestinal bleeding, urinary tract infection (UTI), pneumo-
thorax, immobility, and venous thromboembolism (VTE) are 
just a few subsequent sequelae that can emerge over time 
(Cook. et al., 1996; Geerts et al., 2001; Chastre & Fagon, 2002). 
Thus, management of the ventilator patient actually begins 
with intubation and must include interventions to eliminate 
impediments to weaning and prevent complications with 
appropriate prophylaxis and treatments.
One very important factor to assess is the need for seda-
tion in the ventilated patient with critical illness. Sedation, 
especially infusions of sedatives, although necessary in some 
cases, may adversely affect the ventilated patient. Brook, et 
al., (1999) and Kress, et al., (2000) found that standardized 
sedation management methods, such as daily sedative inter-
ruptions, sedation vacation, and algorithmic approaches, 
respectively resulted in better outcomes, such as ventilator 
duration and length of stay (LOS) (Brook et al., 1999; Kress 
et al., 2000). Additional work by Kress et al., demonstrated 
that daily sedation infusion interruptions decreased long-
term psychological stress and resulted in fewer iatrogenic 
complications in patients compared with the outcomes of 
those who did not experience daily sedative interruptions 
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(Kress et al., 2003; Schweickert, Gehlbach, Pohlman, Hall, 
& Kress, 2004).
Perhaps most intriguing, is the link between sedation 
and delirium (Dubois, Bergeron, Dumont, Dial, & Skrobik, 
2001). Benzodiazepines are an independent risk factor for 
delirium (Pandharipande et al., 2006) And some individuals
who experienced delirium developed an unanticipated long-
term cognitive dysfunction (Ely et al., 2001; Ely et al., 2004). 
Thus, the ACNP should consider stopping sedatives as ear-
ly as feasible in the course of a patient’s stay. As noted in 
Table 3.4 below, sedation protocols and methods to systemat-
ically decrease sedation are linked with improved outcomes.
Although head–to-toe assessments are part of routine 
ACNP care management, there are many key elements, such 
as sedation, that represent impediments to weaning, and 
these should be addressed systematically. “Checklists” pre-
vent omissions and errors that may delay care or even result 
in untoward events (Gawande, 2008). Thus, the use of a check-
list to assure “weaning readiness” is helpful to the team and 
keeps care planning on target. One such checklist is the  Burns
Wean Assessment Program (BWAP) (Exhibit 3.3). The use of 
this checklist, in combination with a systematic comprehen-
sive care management model, is associated with improved 
weaning times, ICU and hospital LOS, and subsequent 
mortality (Burns, S., Burns J., & Truwit, 1994; Burns et al., 
1998; Burns et al., 2003).
Author
(type of protocol) Vent Duration ICU-LOS Hosp-LOS Mortality
Kress et al(10) Yes* Yes* No No
(sedation
 protocol)
Brook et al(9) Yes* Yes* Yes* No
 (sedation protocol)  
3.4
Effect of Sedation Management 
Protocols on Selected Outcomes 
by Author
*Statistically signifi cant.
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Exhibit
 GENERAL ASSESSMENT 
  NOT 
 YES NO ASSESSED 
 ___ ___ ___  1. Hemodynamically stable? (Pulse rate, cardiac output) 
 ___ ___ ___  2.  Free from factors that increase or decrease 
 metabolic rate (seizures, temperature, sepsis, 
bacteremia, hypo/hyper thyroid)? 
 ___ ___ ___  3. Hematocrit >25% (or baseline)? 
 ___ ___ ___  4.  Systemically hydrated? (weight at or near 
 baseline, balanced intake and output)? 
 ___ ___ ___  5.  Nourished? (albumin >2.5, parenteral/enteral 
feedings maximized) 
If albumin is low and anasarca or third spacing is 
present, score for hydration should be “no.” 
 ___ ___ ___  6.  Electrolytes within normal limits? (including 
Ca++ , Mg + , PO 4 ).
*Correct Ca ++ for albumin level. 
 ___ ___ ___  7. Pain controlled? (subjective determination) 
 ___ ___ ___  8. Adequate sleep/rest? (subjective determination) 
 ___ ___ ___  9.  Appropriate level of anxiety and nervousness? 
(subjective determination) 
 ___ ___ ___ 10.  Absence of bowel problems (diarrhea, 
 constipation, ileus)? 
 ___ ___ ___ 11.  Improved general body strength/endurance? 
(i.e., out of bed in chair,  progressive activity 
 program)? 
 ___ ___ ___ 12. Chest x-ray improving or returned to baseline? 
3.3  Burns Wean Assessment Program(BWAP) (©1990) 
   (continued )
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 RESPIRATORY ASSESSMENT 
  NOT 
 YES NO ASSESSED 
 Gas Flow and Work of Breathing 
 ___ ___ ___ 13.  Eupneic respiratory rate and pattern (spontaneous 
RR <25, without dyspnea, absence of accessory 
muscle use). 
     *This is assessed  off the ventilator while measuring 
#20–23. RR =
 ___ ___ ___ 14.  Absence of adventitious breath sounds? (rhonchi, 
rales, wheezing) 
 ___ ___ ___ 15. Secretions thin and minimal? 
 ___ ___ ___ 16. Absence of neuromuscular disease/deformity? 
 ___ ___ ___ 17. Absence of abdominal distention/obesity/ascites? 
 ___ ___ ___ 18. Oral ETT > #7.5 or trach > #6.0 (I.D.) 
 Airway Clearance 
 ___ ___ ___ 19. Cough and swallow refl exes adequate? 
 Strength 
 ___ ___ ___ 20. NIP <−20 (negative inspiratory pressure) 
     NIP =
 ___ ___ ___ 21. PEP >+30 (positive expiratory pressure) 
     PEP =
 Endurance 
 ___ ___ ___ 22. STV >5 ml/kg (spontaneous tidal volume)? 
     Spont VT  =    STV/BW in kg =
 ___ ___ ___ 23. VC > 10–15 ml/kg (vital capacity)? 
     VC =
 ABGs 
 ___ ___ ___ 24. pH 7.30–7.45 
 ___ ___ ___ 25. PaCO2∼40 mm/hg (or baseline) with M.V. <10 L/min 
    *This is evaluated while on ventilator. 
     PaCO 2 =   MV =
 ___ ___ ___ 26. PaO2 >60 on FiO2 <40%
Exhibit
3.3  Burns Wean Assessment Program(BWAP) (©1990) (continued)
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 Weaning Screens
Weaning screens were first introduced by Esteban et al., (1995) 
in a research protocol seeking to determine the best weaning 
method (Esteban et al., Spanish Lung Failure Collaborative 
Group, 1995). This RCT first “screened” ventilated patients 
using a short list of criteria that represented stability using such 
clinical measures such as FiO 2 and PEEP levels and the need 
for vasopressors and other clinical criteria. Patients meeting 
the screening criteria were assigned to a 2-hour spontaneous 
breathing trial (SBT). If signs of intolerance emerged during 
the trial interval, mechanical ventilation was resumed, and the 
patient was randomized to one of three protocol-driven wean-
ing methods. Those that tolerated the 2-hour trial were extu-
bated. Of the extubated cohort, 20% required reintubation.
Intrigued with this study, Ely et al., (1996) sought to 
determine the safety and efficacy of SBTs in coronary and 
medical intensive care patients. Using a weaning screen 
similar to that used by Esteban et al., (1995), patients who 
passed the screen were randomly assigned to a SBT or tradi-
tional weaning (as determined by the team on a daily basis). 
The study results demonstrated that ventilator duration was 
significantly improved in those assigned to the intervention 
and that the reintubation rate was only 4%. The conclusion 
indicated that use of a protocol-driven SBT in patients who 
passed a simple weaning screen was both safe and effective.
The weaning screen, in contrast to a full assessment of 
potential impediments to weaning, is a tool used to provide a 
rapid snapshot of the patient’s stability. The screen is not com-
prehensive, but rather is designed to assure that an aggressive 
weaning trial may be safely attempted while preventing delays. 
With the implementation of the weaning screen, the next step 
is to attempt a spontaneous breathing trial. The choice of ven-
tilator mode is somewhat arbitrary and, to some degree, deter-
mined by clinician preference. Regardless, the most common 
methods for SBTs include CPAP at a low level (e.g., 5 cm H 2O) 
or T-piece trials. Many also use PSV at a low level. Decisions 
related to protocol development and selection of mode follow.
 Protocol Development: Modes, Methods, etc.
Studies suggest that a weaning trial method using SBTs of CPAP 
or T-piece for 2 hours or less are effective and safe (Esteban, et 
al., Spanish Lung Failure Collaborative Group, 1995; Ely et al., 
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1996). Some prefer to use PSV for trials in those who are weak 
or who have cardiac problems that preclude the more stress-
ful CPAP or T-piece trials. It is likely that any of these meth-
ods will work well provided that they do not result in delayed 
progression of weaning trials and assure prompt return to the 
ventilator when the patient demonstrates intolerance.
One exception to selection of modes for weaning may be 
the combined use of SIMV and PSV. In a survey seeking to 
determine methods of weaning and subsequent ventilator 
duration, the combination of SIMV plus PSV was associated 
with significantly longer ventilator times than other  methods
(Esteban, Alia, Ibanez, Benito, & Tobin, 1994). Although it con-
tinues to be unclear why such a result occurred, it is possible 
that the main problem with using these modes in combina-
tion is that doing so increases the complexity of the plan. The 
process of weaning SIMV and/or PSV is more complicated 
than if simply placed on an SBT of CPAP for example. In 
busy critical care units, multiple changes in mode parameters 
are difficult to accomplish in a timely fashion and lead to varia-
tion in practice. The less complicated the better.
The most effective protocols are easy to apply and clearly 
understood by caregivers. Essential elements of the protocol 
include mode, method, signs of intolerance (and what to do if 
they emerge), and duration of the trial. Finally, how to rest the 
patient between trials and at night are important to delineate. 
Exhibit 3.4 is an example of a weaning trial protocol that incor-
porates all these elements.
 Timing of Tracheostomy
Clinicians and scientists have long debated the merits of 
early versus delayed tracheostomy placement. Retrospective 
and observational studies suggest that early tracheostomy is 
associated with lower costs, shorter duration of ventilation, 
ICU LOS, and hospital LOS (Brook, Sherman, Malen, & Kollef, 
2000; Freeman, Borecki, Coopersmith & Buchman, 2005). In 
addition, one study noted that patients with tracheostomies 
required less sedation, spend less time heavily sedated, and 
achieve more autonomy earlier in the course of the hospital-
ization (Nieszkowska et al., 2005).
Recently in a prospective, randomized study of patients 
who were projected to require mechanical ventilation for 
>14 days, medical patients with critical illness were assigned 
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Exhibit
 Weaning Trial Screen: 
 1.  Hemodynamic stability (no dysrhythmias, HR ≤120, absence of pressors—
low dose dopamine and dobutamine are exceptions) 
 2. Fi0 2 ≤50%
 3. PEEP ≤8 cm H 2 0 
 4. Patient comfortable and able to interact 
 CPAP Protocol: 
 1. One trial for 1 hour on CPAP of no more than 8 cm H 2 0. 
 2.  With any signs of intolerance, the trial is discontinued and the patient is 
returned to a resting mode until the next trial. 
 3.  When trial is completed without signs of intolerance, the team is approached 
and extubation potential is discussed. 
 4. Full respiratory muscle rest is provided between trials and at night. 
 Intolerance is defi ned as any of the following: 
 1. RR ≥35 for 5 mins. 
 2. 0 2 sat ≤90% or a decrease of 4% 
 3. HR ≥140 and/or a 20% sustained change of HR in either direction 
 4. Systolic BP ≥180, ≤90 mm Hg 
 5. Excessive anxiety or agitation 
 6. Diaphoresis 
 Rest: 
 1.  PSV max: PSV max is that pressure level required to attain a RR of 20 or 
less and a Vt of 8–12 ml/kg. Respiratory pattern should be synchronous and 
there should be no accessory muscle use. 
 2.  Other modes: With volume modes of ventilation (i.e. A /C or IMV), respiratory 
muscle rest is not assured unless there is cessation of respiratory muscle 
activity. Therefore, rest is considered that level of support required to prevent 
patient initiated breaths. When IMV is used, PSV may be added for protection 
(i.e. as a “safety” ). Regardless, the goal is cessation of spontaneous effort 
3.4  Example of Weaning Trial Protocol: CPAP 
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to early percutaneous dilatational tracheotomy (within 48 
hours of intubation) or to delayed tracheotomy (Rumbak et 
al., 2004). Mortality, incidence of pneumonia, and acciden-
tal extubations were all statistically significant and showed 
improvement in the early tracheostomy group compared 
with the controls. Although the reason why early tracheos-
tomy resulted in better outcomes is not known, it is possible 
that the lower requirement for sedation was responsible. 
In addition, the presence of tracheostomy provides an ele-
ment of safety that is not possible with an endotracheal tube; 
reintubation following an unsuccessful trial is not necessary, 
Thus, earlier and potentially more aggressive trials with a 
tracheostomy are possible.
In patients with tracheostomies who require excessively 
prolonged stays on the ventilator (i.e., weeks or months), spon-
taneous breathing trials can be progressed gradually. A plan 
incorporating daytime trials, with nighttime rest on the ventila-
tor works well until they can tolerate a full 12 hours. At that point, 
extension of the trial into the nighttime hours is reasonable.
 Summary
Managing complex patients with respiratory failure requires 
attention to a myriad of factors that affect outcomes from the 
acute to the weaning stages of mechanical ventilation. An 
understanding of the pathophysiology of conditions result-
ing in respiratory failure, modes of ventilation and their 
appropriate applications, and how best to wean patients is 
essential. The application of evidence-based methods and 
systematic, comprehensive approaches goes a long way in 
assuring good outcomes. Continuity and consistency clearly 
showed decreasing variations, which is an important step in 
the weaning process.
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 Introduction 
In 1999, the American Heart Association (AHA) set a strategic 
goal of reducing the death rates from coronary heart disease 
and stroke and reducing 25% of the risk factors for these dis-
eases by 2010 (AHA, 2008). The most current data reflects that 
in 2005, the United States had achieved this initial goal (CDC, 
2008). The reduction equates to approximately 160,000 lives 
saved in 2005 compared to the 1999 baseline data. The AHA 
cites this progress in the reduction of death rates as a landmark 
achievement. 
These accomplishments have been achieved as a result of 
tremendous efforts from many partners in practice, research, 
health care, government, business, and communities. Despite 
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this encouraging data, heart disease remains number one and 
stroke remains number three as the leading causes of death in 
the United States (CDC, 2008). There are goals that have not 
been achieved, such as reductions in the risk factors that lead to 
heart disease and stroke, as well as eliminating the striking dis-
parities in care for women and minority populations. Continu-
ous attention by health care providers is essential to address 
both acute and primary care issues required to reduce death 
and disability among the population in the United States. 
The AHA regularly publishes scientific statements, guide-
lines, performance measures, and clinical data standards. Their 
purpose is to increase knowledge and awareness of health 
care professionals regarding effective, state-of-the art science 
related to the causes, prevention, detection, and management 
of cardiovascular diseases (AHA, 2008). AHA scientific state-
ments represent the consensus of the leading experts in car-
diovascular disease and stroke and are subjected to blind peer 
review prior to approval by the highest scientific body of the 
AHA (AHA, 2008). 
In 2000, the AHA launched the “Get with the Guidelines” 
program to help hospitals treat patients with evidence-based 
strategies to optimize patient outcomes for heart disease and 
stroke. These guidelines have affected more than one million 
people to date. Consistent with the national focus on health 
care quality, the American College of Cardiology (ACC) and 
the AHA have developed a multifaceted strategy to facili-
tate the process of improving clinical care. One aspect of this 
effort is the creation of clinical practice guidelines that care-
fully synthesize available evidence to guide better patient 
care. Such guidelines are written to suggest diagnostic or 
therapeutic interventions that apply to patients in most cir-
cumstances, but clinical judgment is required to adapt these 
guidelines to the care of individual patients. The guidelines 
are based on available evidence, providing varying degrees of 
recommendation. 
Clinical guidelines, as defined by the Institute of Med-
icine’s definition, are “systematically developed statements 
to assist practitioner and patient decisions about appropri-
ate health care for specific clinical circumstances.” The AHA 
often develops practice guidelines in conjunction with the 
ACC, but may also independently institute practice guide-
lines or develop a partnership with other organizations as 
appropriate. All current guidelines adhere to the levels of 
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evidence and classes of recommendation as established by 
the ACC/AHA Guidelines Task Force (AHA, 2008). 
Another element of the ACC/AHA effort is to improve the 
quality of cardiovascular care by the development of perfor-
mance measures. Multidisciplinary committees address both 
retrospective and prospective data with explicit documented 
clinical criteria (AHA, 2008). Furthermore, the data elements 
required for the performance measures are linked to exist-
ing ACC/AHA clinical data standards to encourage uniform 
measurements of cardiovascular care. By facilitating mea-
surements of cardiovascular health care quality, ACC/AHA 
performance measurement sets may serve as vehicles to 
accelerate appropriate translation of scientific evidence into 
clinical practice. These documents are intended to provide 
practitioners with tools to measure the quality of care and 
identify opportunities for improvement. 
Ongoing scientific research has led to improvements in 
medications and technology. The development of evidence-
based practice guidelines has helped health care providers 
know what is effective both for the treatment and prevention 
of cardiovascular disease. Some of the advances are complex 
and others are quite simple, though important. More than 94% 
of heart attack patients are now receiving aspirin on admis-
sion, compared to 76.4% at baseline (AHA, 2007). Patients with 
cerebral vascular accidents (CVA) arriving at a facility within 
2 hours of onset of symptoms now receive thrombolysis >63% 
of the time versus 23.5% at baseline (AHA, 2007). 
Evidence-based data has shifted the paradigm of cardiac 
care in United States. “Time is muscle” was a common man-
tra among health care teams in the 1990s. The importance 
of access to care and timely presentation to the hospital are 
central to saving lives. Rapid response of emergency teams 
and interventions, such as angioplasty, which facilitates blood 
flow through blocked coronary arteries, or thrombolysis may 
be performed when primary angioplasty is not available or 
appropriate. These prompt interventions are making a critical 
difference in morbidity and mortality. 
Community commitment to establish primary stroke cen-
ters and competent acute care specialists who provide rapid 
and improved care for stroke victims has all made positive 
impacts. Improving the quality of care through the dissemina-
tion of evidence-based clinical guidelines can help patients 
benefit from research, facilitating longer lives, and reducing 
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their risk of a second heart attack, stroke, or long-term sec-
ondary sequelae (AHA, 2008). 
Acute care nurse practitioners (ACNPs) are confronted 
with many challenges in caring for the cardiovascular needs 
of patients with primary and secondary cardiovascular dis-
ease processes. Common cardiovascular diagnoses include 
acute coronary syndromes or coronary artery disease, hyper-
tension, heart failure, valvular disease, peripheral vascular 
disease, pulmonary hypertension, cardiac rhythm distur-
bances, pericarditis, tamponade, cardiomyopathy, aneurysms, 
and endocarditis. Although it is beyond the scope of this 
chapter to provide expert cardiology knowledge, the chapter 
will review aspects of care that promote optimal outcomes of 
these areas for the ACNP. 
 Key Concepts in Cardiology 
 Electrophysiology 
The potential resting membrane of the myocardium is about 
−90 mV with the inside being negatively charged comparative 
to the outside, which is relatively positive. The diffusion of 
ions across the membrane, their concentration gradients, and 
cyclic permeability are the basis for depolarization, action 
potential, and return to a resting state. The concentration 
gradient is produced by the work of the sodium–potassium 
adenosine 5′-triphosphate (ATP) pump by which sodium is 
pumped out of the cell and potassium into the cell. 
By producing concentration equilibrium, this creates an 
electrical potential and as ions flux, this causes the interior 
to be less negative and thus there is a cycle of depolarization. 
There are two basic cardiac action potentials,  fast and slow .
 Electrical Conduction System 
The cardiac electrical impulses arise in the sinus node, which 
is approximately 10 –20 mm long near the junction of the supe-
rior vena cava (SVC) and the right atrium (RA). The specialized 
muscle tract conducts the impulses to the atrioventricular (AV) 
node, which is located under the right atrial endocardium at the 
level of the septal leaf of the tricuspid. This is the only normal 
conduction pathway between the atria and the ventricles. After 
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stimulation of the AV node and a brief delay, the impulse is 
carried down the bundle of His posterior along the interven-
tricular septum, giving rise to the right and left bundle branches. 
The left side divides again into the anterior and posterior fas-
cicles. Both bundle branches continue to divide into Purkinje 
fibers and finally conduct to the ventricular myocardium. 
 Understanding the ECG 
The electrocardiogram (ECG) is essential for interpretation 
and monitoring of the cardiac patient. The standard 12-lead 
pattern involves 10 electrodes placed in a specific pattern; one 
on each limb and six across the chest known as the  V leads .
Together, these leads record the electrical difference of two 
leads at a time. The standard leads I, II, III and the augmented 
leads aVR, aVL, and aVF predominately record the potentials 
from the frontal plane, whereas the V leads (1–6) record across 
the horizontal plane. Together they reflect the magnitude and 
direction of the electrical signals. The augmented leads are 
unipolar in that they record the potential difference between 
one limb and an indifferent composite electrode. 
In general, the standard lead II is best for seeing the P wave 
and thus looking for arrhythmia. The V5 chest lead is the most 
sensitive for diagnosing myocardial ischemia. Together, these 
two leads should be monitored continuously in the acute care 
setting. Although complete interpretation of ECG is beyond the 
scope of this chapter, there are some myocardial abnormalities 
that can have serious consequences if not detected and may 
negatively affect overall patient outcomes. As a result, the 
ACNP must be confident in advanced ECG interpretation and 
integrate essentials with patient’s clinical symptoms and car-
diac risk factors. 
Once establishing the overall heart rate, the clinician pro-
ceeds in evaluating cardiac conduction. The P wave must be 
identified, the presence or absence of the wave, and if present, 
whether it is positive or negative in deflection (except in V1 
where they are usually biphasic). The duration of the P wave 
should be <0.12 seconds and the height <0.25 mV.  Large P waves 
may be present in right atrial hypertrophy. The absence of a 
discernable P wave will point to an atrial arrhythmia. 
The PR interval is a reflection of intracardiac con-
duction and should be 0.10–0.22 seconds. A prolonged PR 
interval is seen in first- and second-degree heart block. The 
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QRS morphology begins with the small Q wave deflection. 
These can be seen normally in all the leads except for the 
chest leads. When Q waves appear in the chest leads, they 
are indicative of a transmural myocardial infarction. The 
next component of the QRS is the R wave, which typically 
increases incrementally in size from V1–V4. The absence 
of this phenomenon is referred to as poor R-wave progres-
sion and may indicate prior infarction. The QRS complex 
should have duration of 0.07–0.10 seconds. Abnormally 
long QRS could indicate abnormal intracardiac conduction. 
The amplitude of the QRS ranges considerably; the larger 
amplitude may reflect physical fitness or conversely ven-
tricular hypertrophy. A small QRS is suggestive of emphy-
sema, pericardial effusion, or obesity. 
The QRS axis is the net direction of electrical flow of the 
heart. The normal vector is −30° to +90°. When the leads’ vec-
tor is −30° to −90°, this is left axis deviation and may be caused 
by left anterior hemiblock, inferior myocardial infarction, 
chronic obstructive pulmonary disease (COPD), and left ven-
tricular (LV) hypertrophy. When the vectors are in the range 
of +90° to 180°, it is referred to as right axis deviation and the 
causes include left posterior hemiblock, right ventricular 
(RV) hypertrophy, and myocardial infarction. 
The T wave representing ventricular repolarization is 
normally positive in leads aVR and V1. If these T waves are 
inverted, this is a sign of ischemia and perhaps infarction. A 
flattened T wave is indicative of hypokalemia and a peaked 
T wave would indicate hyperkalemia. 
The next and perhaps most important component of the 
ECG is the ST segment. While there may be slight upslope or 
downslope, the truly elevated ST segment may indicate myo-
cardial infarction or pericarditis. Depending on the pattern 
of the ST segments and their elevation, this information may 
be used to help diagnose which part of the heart is infarcting. 
The ST-segment elevation across a range of leads is com-
mon in postoperative patients and ST-segment depression is 
usually associated with myocardial ischemia, but may also be 
secondary to strain, digoxin, or hypokalemia. 
The positive deflection following the T wave is an abnormal 
entity known as the U wave, which may represent hypokalemia, 
but may also be present in hypercalcemia, thyrotoxicosis, and 
exposure to digoxin, epinephrine, and class 1A and III antiar-
rhythmics, as noted in Exhibit 4.1. 
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Exhibit
Class I — Sodium-channel blockers
Disopyramide (Norpace)
Flecainide (Tambocor)
Lidocaine (Xylocaine)
Mexiletine (Mexitel)
Moricizine (Ethmozine)
Procainamide (Procan, Procanabid, Pronestyl)
Propafenone (Rythmol)
Quinidine (Cardioquin, Quinaglute Dura-Tabs, Quinidex Extentabs, Quinora)
Tocainide (Tonocard)
Class II — Beta-blockers
Acebutolol (Sectral)
Atenolol (Tenormin)
Betaxolol (Kerlone)
Bisoprolol (Zebeta)
Carvedilol (Coreg)
Esmolol (Brevibloc)
Metoprolol (Toprol-XL, Lopressor)
Nadolol (Corgard)
Propranolol (Inderal)
Sotalol (Betapace, Betapace AF, Sorine)
Timolol (Blocadren)
Class III — Potassium-channel blockers
Amiodarone (Cordarone, Pacerone)
Azimilide (Stedicor)
Bepridil (Vascor)
Dofetilide (Tikosyn)
Ibutilide (Corvert)
Tedisamil (Pulsium)
Class IV — Calcium-channel blockers
Diltiazem (Cardizem, Tiazac, Cartia XT, Dilacor XR, Diltia XT)
Verapamil (Calan, Covera-HS, Isoptin SR, Verelan)
Miscellaneous
Adenosine (Adenocard, Adenoscan)
Digoxin (Lanoxin, Digitek)
4.1 Antiarrhythmic Drugs (AHA, 2007)
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An inverted U wave may further represent myocardial isch-
emia or LV volume overload. The U wave represents the repo-
larization of the papillary muscles or Purkinje fibers. Lastly, the 
QT interval can vary significantly with heart rate and should 
be corrected for this variation (QTc). Although most ECG pro-
grams will calculate this information, the manual formula is 
the division of the QT by the square root of the RR interval. The 
upper measure of normal is 0.44 seconds, if longer; this reflects 
a potential prolongation, delay, or repolarization. This can be 
congenital or acquired secondary to some medications and 
can predispose the patient to a potentially deadly dysrhythmia 
known as torsades de pointes ventricular tachycardia. 
 General Treatment of Arrhythmias 
The approach to the patient with arrhythmias is individual, 
but should be centered on history, physical examination, ECG, 
vital signs, and stability. In general, the patient who presents 
with severe symptoms requires aggressive evaluation and 
treatment. Syncope adds a level of confusion and mandates 
a comprehensive evaluation to rule out cardiac versus neu-
rological origins. Family history, especially consistent with 
sudden death or arrhythmias, warrants a higher degree of 
concern. The physical examination should be focused on 
presentation of cardiac disease, but the absence does not 
ensure that an arrhythmia is benign. In contrast, the identi-
fication of cardiac or respiratory findings in the presence of 
palpitations or syncope is a worrisome sign. 
In approaching arrhythmias, the initial consideration must 
be rate. In the presence of fast arrhythmias, the next step is 
to determine if it is narrow or wide, regular or irregular, and 
most importantly, the hemodynamic stability of the patient. A 
slower arrhythmia may be physiologic or pathologic, the latter 
needing consideration of a permanent pacemaker. Medication 
history is paramount to determine if the rate is iatrogenic. See 
Exhibit 4.2 for common etiologies. 
 Ventricular Arrhythmias 
A premature ventricular complex is noted by the early occur-
rence of a QRS complex that is distinctively different and lasts 
greater than 120 ms. A large T wave results from opposition 
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polarity to the QRS complex. A compensatory pause typically 
follows the premature beat. Ventricular bigeminy is used to 
denote alternating normal sinus beats and premature ven-
tricular complexes (PVC). Three or more successive PVCs 
are defined as ventricular tachycardia. Premature ectopic 
beats, arising from the ventricle, increase with age and may 
be aggravated by exposure to precipitating stimuli. Studies 
have demonstrated an increased risk for life-threatening 
arrhythmias in individuals with 10 or more ectopic beats per 
hour or the presence of three to five consecutive impulses 
on Holter monitoring (Hebbar & Hueston, 2002). Evidence 
supports structural heart disease, and diminished LV func-
tions are the key factors in determining treatment options 
and prognosis. 
Ventricular tachycardia is defined by chaotic ventricu-
lar ectopy at a rate >100 beats per minute (bpm). The ECG 
reveals wide-complex tachycardia in the absence of conducted 
P waves (Table 4.1). Wolff–Parkinson–White (WPW), bundle 
branch block (BBB), aberrant conduction, and supraventricular 
tachycardia (SVT) can appear similar to ventricular tachycar-
dia. Because of the potentially catastrophic outcomes associ-
ated with untreated ventricular tachycardia, all wide-complex 
Exhibit
■ Ischemia
■ Metabolic abnormalities
■ Acidosis
■ Hypoxia
■ Hyperkalemia
■ Hypokalemia
■ Hypomagnesium
■ Cardiomyopathy
■ Valvular disorders
■ Stimulants: cocaine, alcohol, caffeine
■  Medications: digoxin, theophylline, antipsychotics, antidepressants, 
antiarrhythmics with proarrhythmic potential (i.e., fl ecainade, quinidine) 
4.2 Common Etiologies of Ventricular Arrhythmias
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tachycardia should be assumed to be ventricular tachycardia 
until proved otherwise. Practitioners must note that patients 
with ventricular tachycardia may be asymptomatic. 
The AHA guidelines for the treatment of ventricular 
tachycardia in mildly symptomatic patients, advise the initial 
use of amiodarone. Patients with stable ventricular tachycar-
dia may also benefit from amiodarone until there is a con-
version to sinus rhythm or a less harmful rhythm is evident. 
Lidocaine is a less suitable alternative. Hemodynamically 
unstable patients require electrical cardioversion according 
to current ACLS guidelines. 
The implantable cardioverter-defibrillator (ICD) is con-
sidered the golden standard for patients with life-threatening 
ventricular tachycardia or fibrillation (Gregoratos, Abrams, 
Epstein et al., 2002). Multiple studies have shown the ICD to be 
superior to antiarrhythmic drug therapy in patients with a his-
tory of life-threatening ventricular tachyarrhythmias (VT) and 
ventricular fibrillation (VF) (Kuck, Cappato, Siebels, & Rüppel, 
2000, Moss et al., 2002). ICDs are typically prescribed as initial 
therapy, poststabilization, for sustained VT in association with 
structural heart disease or for those who present secondary to a 
resuscitated cardiac arrest (Strickberger et al., 2003; Moss et al., 
2002). Exceptions include patients with idiopathic VT because 
the prognosis is excellent, VF caused by rapid rates during 
preexcited atrial fibrillation (AF), and in patients with specific 
dysrhythmias such as WPW. The initial therapy should be cath-
eter ablation, once the patient is stabilized, for VT or VF, when 
this occurs early in an acute transmural infarction. Patients 
in whom a transient or reversible cause for the arrhythmia is 
detected are excluded from ICD implantation. 
The treatment options for those with polymorphic VT or 
VF, secondary to acute ischemia, in the absence of an acute 
transmural infarction are more vague. Although in the past, 
these patients were frequently treated with revasculariza-
tion only, the current trend appears to be ICD implanta-
tion following revascularization (Goldenberg, Moss, et al., 
2005). In addition to ICD use as secondary prophylaxis 
after ventricular arrhythmia, multiple studies support ICD 
use as primary prophylaxis in ischemic and nonischemic 
cardiomyopathy. 
The impact of the Multicenter Automatic Defibrillator 
Implantation Trial II (MADIT) and Multicenter Unsustained 
Tachycardia Trial (MUSTT) studies support patients with a 
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prior infarct, ejection fraction <40%, and spontaneous nonsus-
tained VT should receive ICD implantation if the arrhythmia 
is inducible (Moss et al., 2002; Klein, & Reek, 2000). Heart fail-
ure patients with ischemic or nonischemic cardiomyopathy, 
ejection fraction <35% or less, and New York Heart Association 
(NYHA) functional class II or III are also considered appro-
priate candidates for ICD (Goldenberg, Moss, et al., 2005). 
Patients who experience syncope of undetermined origin with 
hemodynamically significant inducible VT or VF during elec-
trophysiology studies (EPS) or when drug therapy is ineffec-
tive or not an option should also be considered for ICD. 
Given the poor sensitivity and specificity of EPS in patients 
with nonischemic cardiomyopathy, patients with unexplained 
syncope in the setting of nonischemic cardiomyopathy are 
frequently treated empirically with ICD implantation. High-
risk patients with prolonged QT syndrome, hypertrophic car-
diomyopathy, arrhythmogenic RV cardiomyopathy, Brugada 
syndrome, which is a genetic disease with high risk of sudden 
death, and short QT syndrome are candidates for prophylac-
tic ICD implantation, although what constitutes high risk in 
these patient populations remains controversial. Currently, 
high-risk features include syncope and a family history of 
unexplained sudden cardiac death. 
 Atrial Arrhythmias 
Atrial fibrillation is perhaps the most common ECG arrhyth-
mia found in the intensive care unit (ICU) and postopera-
tive setting. Although considered a disease of aging with 
fibrosis of the atrium, the irritated heart from surgery or 
electrolyte imbalance lends itself to frequent bouts postop-
eratively. Atrial fibrillation is a result of multiple reentrant 
circuits randomly colliding, dissipating, and reactivating in 
the absence of a clear-cut P wave on the ECG. These multiple 
depolarizations cause rapid atrial contractions with a highly 
variable and irregular ventricular response. Although gen-
erally not life threatening once controlled, the disorganized 
atrial to ventricular contractions and “loss of atrial kick” or 
complete emptying of the atrium and thus reduced ventricu-
lar filling results in modest to severe hypotension dependant 
on the interventions.
The AHA 2008 refined atrial fibrillation and atrial flut-
ter guidelines to establish simplicity and clinical relevance. 
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Nonsustained Ventricular Three or more beats in duration, terminating spontaneously in <30 seconds
 Tachycardia (VT)
  VT is a cardiac arrhythmia of three or more consecutive complexes in duration emanating from the
   ventricles at a rate of >100 bpm (cycle length <600 ms).
Monomorphic - nonsustained VT with a single morphology
Polymorphic - nonsustained VT with a changing morphology at cycle length between 600 and 180 ms
Sustained VT VT >30 seconds and/or requiring termination due to hemodynamic compromise in <30 seconds
Monomorphic - sustained VT with a single QRS morphology
Polymorphic - sustained VT with a changing morphology at cycle length between 600 and 180 ms
Bundle branch reentrant VT due to reentry involving the His–Purkinje system, usually with LBBB morphology; usually occurs in
 tachycardia  the presence of cardiomyopathy
Bidirectional VT VT with a beat to beat alternans in the QRS frontal plane axis, often in the presence of digoxin toxicity
Torsades de pointes VT associated with a long QT or QTc and ECG changes refl ective of twisting of QRS peak complexes 
   around the isoelectric line during the arrhythmia:
  “Typical” initiated following short-long-short coupling intervals
  Short coupled variant initiated by normal-short coupling
Ventricular Flutter A regular (cycle length variability 30 ms or less) ventricular arrhythmia approximately 300 bpm (cycle length
   200 ms) with a monomorphic appearance; no isoelectric interval between successive QRS complexes
Ventricular Fibrillation Rapid usually >300 bpm/200 ms (cycle length <180 ms), grossly irregular ventricular rhythm with 
   marked variability in QRS cycle length, morphology and amplitude
ECG Classifi cation of Ventricular Arrhythmias4.1
Adapted from AHA Guidelines (2006).
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Initially, the provider must identify whether the episode of 
AF is a first episode and whether or not it is symptomatic, 
and be aware that there may be ambiguity regarding the 
duration of the episode and the possibility of previously 
undetected episodes. Recurrent AF is defined as two or 
more episodes. When AF resolves spontaneously, it is iden-
tified as paroxysmal; once sustained, AF is classified as 
persistent. Persistent AF may be either the initial presenta-
tion of the arrhythmia or resultant of recurrent episodes of 
paroxysmal AF.
The classic description of AF is that the rhythm is irregu-
larly irregular. On the ECG, it is generally impossible to make 
out a discernable P wave. One caveat when looking for AF 
is the possibility of AF with complete heart block. The ven-
tricular rhythm may appear equal, but there would still be no 
preceding P wave.
Reversible AF may be a consequence of acute myo-
cardial infarction, acute pulmonary disease, cardiac sur-
gery, pericarditis, hyperthyroidism, pulmonary embolism, 
pneumonia, pulmonary edema, or other acute illness. This 
form of transient AF is considered separately because AF 
is less likely to recur once the precipitating condition has 
resolved (ACC/AHA, 2008). In these settings, AF is not the 
primary problem, and treatment of the underlying disor-
der concurrently with management of the episode of AF 
usually results in termination of the arrhythmia without 
recurrence.
AF may appear as atrial flutter or atrial tachycardia. 
Atrial flutter is characterized by a sawtooth pattern of regu-
lar atrial activation called flutter (  f) waves on the ECG, more 
typically noted in leads II, III, aVF, and V1. The rate ranges 
from 240–320 beats/min, with  f waves inverted in leads II, 
III, and aVF and upright in lead V1. Upright  f waves in II, 
III, and aVF represent the reversed direction of activation 
in the right atrium. Atrial flutter may degenerate into AF, 
and AF may convert to atrial flutter. Although atrial flutter 
is more commonly identified, misdiagnosis may occur when 
coarse fibrillatory atrial activity is evident in more than one 
ECG lead.
Atrial flutter is actually a microreentrant pattern con-
fined to the atrium as there is an anatomic physiologic 
block to conduction. Usually, there is a ventricular response 
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rate of 1:2 or 1:3. The  f waves of atrial depolarization are 
sent to continually disrupt the ECG and thus produce the 
classic sawtooth pattern. The morphology of the atrial  f
waves tends to appear similar or consistent. Usually, these 
patients are hemodynamically stable. Terminating the 
atrial flutter is directed at the rate and rhythm with rate 
being the prime consideration; antiarrhythmic therapy is 
often ineffective because it only serves to slow conduction. 
Examining electrolytes and correcting any abnormalities 
may be of assistance but, if the atrial flutter is persistent 
and symptomatic, then anticoagulation, defibrillation, or 
EP ablation may be needed.
Risk stratification for embolic events is as critical for 
patients with atrial flutter using the same criteria as for AF. 
The AHA included atrial flutter as an arrhythmia appro-
priate for performance measures on the basis of several 
considerations. Most significant is the potential for patients 
with atrial flutter to be at higher risk for thromboembolism. 
The current guidelines indicate as a Class I recommenda-
tion that it is prudent to stratify patients on the basis of 
thromboembolic risk and to consider anticoagulation for 
atrial flutter in a fashion similar to that for patients with AF 
(ACC/AHA, 2008).
Anticoagulation is essential in patients who have known 
risk factors for CVA associated with AF (see Exhibit 4.3). 
Initial treatment with IV heparin is suggested for high-risk 
patients if the duration of AF is >12 hours and hemodynamic 
stability is evident. Chronic anticoagulation with warfarin to 
target the INR between 2 and 3 is recommended in patients 
with persistent or paroxysmal AF, age consideration should 
be evaluated based on the potential of secondary injury 
from anticoagulation. Termination of atrial fibrillation may 
be necessary because of hemodynamic instability or clini-
cal presentation. Confirmation of anticoagulation status 
should be documented prior to electrical conversion except 
in emergent scenarios. After 48 hours of atrial fibrillation, all 
patients should be anticoagulated because of the increased 
risk of atrial clot formation. Once the patient is anticoagulat-
ed, another attempt at cardioversion may be attempted after 
approximately 3 weeks. Should the patient require cardio-
version prior to this time, an echocardiogram is mandatory 
to rule out a preformed atrial clot, which could be dislodged 
by cardioversion.
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 Supraventricular Arrhythmias 
Premature atrial beats may be normal, abnormal, or noncon-
ducted and typically are followed by a noncompensatory pause. 
The important factor is to differentiate aberrantly conducted 
premature atrial complexes (PAC) from premature ventricu-
lar complexes (PVC). PACs may be unifocal or multifocal. The 
apical rate is typically slower, the P wave morphology varies, 
and PR interval is slightly shorter than in sinus rhythm.
A multifocal atrial rhythm is an irregularly irregular rhythm 
caused by the arbitrary release of multiple ectopic stimuli. This 
is defined as a heart rate ≤ 100 beats/min. This arrhythmia most 
typically occurs in patients with existing pulmonary disease or 
in situations when the patient is hypoxic, acidotic, or experienc-
ing theophylline toxicity. P-wave morphology is distinctive in 
each beat and there are three or more dissimilar P waves. The 
presence of P waves distinguishes wandering atrial pacemaker 
from atrial fibrillation. Multifocal atrial tachycardia is a chaotic 
rhythm. By definition, the heart rate is >100 beats/min. The 
characteristics are the same as those of wandering atrial pace-
maker except for rate. Treatment is focused at improvement of 
the underlying respiratory diagnosis.
 Atrial Tachycardia 
Atrial tachycardia is a result of rapid response from a single 
focus. The resultant heart rate is >150 beats/min. The under-
lying mechanisms include increased atrial automaticity and 
Exhibit
History of prior Cerebralvascular Attack or Diabetes Mellitus
 Transient Ischemic Attack 
>75 years of age Mitral stenosis
Hypertension Congestive Heart Failure
4.3 Risk Factors for CVA in the Presence of Atrial Fibrillation
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intra-atrial reentry. Atrial tachycardia may be caused by 
atrial irritation such as pericarditis, drugs, alcohol, and toxic 
gas inhalation. Symptoms include palpitations, shortness 
of breath, and chest discomfort. The P waves are distinc-
tive from normal sinus P waves because they precede QRS 
complexes but may be hidden within the preceding T wave. 
Treatment may include pharmacologic agents or may be 
terminated by direct-current cardioversion. Drugs used in 
the treatment of atrial tachycardia include antiarrhythmic 
drugs in class Ia, Ic, and III (See Exhibit 4.1). Patients who 
fail to respond to noninvasive measures may require radio-
frequency ablation. 
Junctional tachycardia is caused by abnormal conduction 
in the AV node or adjacent tissue and is common after heart 
surgery, acute inferior MI, myocarditis, or digitalis toxicity. 
The cardiac monitor reveals regular QRS complexes without 
P waves or with retrograde P waves (inverted in the inferior 
leads) that occur preceding or following the QRS complex. 
The rhythm is differentiated from paroxysmal SVT by the 
reduced heart rate.
Acute onset of SVT typically requires targeted interven-
tion. The underlying pathology should be quickly identified 
and, if possible, be addressed (increased atrial pressures, 
irritating central lines, or electrolyte disturbances). When 
patients are hemodynamically unstable, then synchro-
nous electrical cardioversion is indicated. The patient that 
is hemodynamically stable has other options such as vagal 
maneuvers and medical interventions. There remains some 
disagreement between those that feel sinus rhythm should be 
the ultimate goal and those that feel that simple ventricular 
rate control will suffice.
Adenosine may be an option for SVT of unknown  etiology. 
This short-acting medication causes transient heart block in 
the AV node, which breaks the SVT and is administered by 
rapid IV bolus, then by a large saline bolus to ensure prompt 
administration. Should the initial dosage be ineffective, two 
subsequent doses are given at 5-minute intervals. Temporary 
(2–3 second) moments of cardiac standstill are to be antici-
pated and adequate patient support is necessary to avoid 
distress. Other methods of restoring sinus rhythm include 
antiarrhythmics, particularly the class II and III drugs (see 
Exhibit 4.1). Beta-blockers decrease the conduction through 
the AV node and may be used as long-term maintenance. 
Chapter 4: Cardiac Concepts in Acute Care 105
Calcium channel blockers are negative inotropes that 
decrease the force of contraction and slow down the conduc-
tion of electrical activity by blocking the calcium channel 
during the plateau phase of the action potential of the heart, 
causing a negative chronotropic effect.
Accessory pathway reentrant tachycardia involves spe-
cific areas that bypass normal cardiac conduction. This may 
be the result of either premature atrial or ventricular ectopy. 
The most frequent manifestation is WPW syndrome charac-
terized by both accessory pathway and normal conducting 
path utilization noted in sinus rhythm. This results in early 
ventricular depolarization. Subsequently, there is a short PR 
interval and a notable upstroke to the QRS complex referred 
to as a delta wave . This delta wave prolongs the QRS and may 
depict a normal appearing complex except for the delta wave 
and in some instances, a Q wave may be noted.
When persistent narrow complex tachycardia persists, 
AV node blockers are indicated to prevent the firing of the 
AV node during the reentry cycle. Adenosine is the first 
choice and other options include verapamil or diltiazem. 
AV nodal blockers may also be effective in the presence 
of wide QRS complex tachycardia. The essential goal is to 
determine the source of the arrhythmia and to specifically 
exclude ventricular tachycardia as AV nodal blockers may 
intensify ventricular tachycardias at which point IV pro-
cainamide may be initiated. Synchronized cardioversion 
with 50 joules may be a more acceptable approach to phar-
macologic therapy.
For critical or unrelenting nodal reentrant tachycardia, 
long-term antiarrhythmics or transvenous catheter radiofre-
quency ablation is typically prescribed. Ablation is prefer-
able since long-term efficacy is rapidly achieved. In unstable 
patients or those electing to avoid interventional options, drug 
prophylaxis may be initiated with digoxin, beta-blockers, non-
dihydropyridine calcium channel blockers, or other appropri-
ate antiarrhythmics.
 Atrioventricular Block 
AV block is a temporary or complete disruption of conduc-
tion from the atria to the ventricles. Idiopathic fibrosis or 
sclerosis of the conduction system is cited as the most com-
mon underlying pathology. Interventions are dependent on 
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the degree of block and symptomatology with the treatment 
choice typically including pacing. AV block may be second-
ary to medications such as beta-blockers, calcium channel 
blockers, digoxin; increased vagal tone, valvular disease, con-
genital heart disease, or other disorders.
First-degree AV block is noted when normal P waves are 
followed by QRS complexes, but the PR interval takes longer 
than 0.2 seconds. This is typically asymptomatic and does not 
necessitate intervention. Proactive investigation may deter-
mine if the block is secondary to another heart disorder or 
is drug induced. Second-degree AV block indicates the pres-
ence of typical P wave followed by QRS complexes, but in 
some instances, the P wave is not followed by a QRS. When 
this occurs, there are two specific types of known blocks: 
Mobitz I and Mobitz II.
Mobitz I is a lengthening of the PR interval until the atrial 
stimuli are not conducted and the QRS complex is missing 
(Wenckebach phenomenon); AV nodal conduction normal-
izes then the cycle repeats. Mobitz I arises from the junction 
of the AV node in most patients with a distinctly narrow QRS 
complex. When an entire block occurs, a junctional escape 
rhythm may ensue in an attempt to restore function. Inter-
vention is unnecessary unless the block results in symp-
tomatic bradycardia. The recommendation for treatment is 
pacemaker insertion.
Mobitz II has a regular PR interval. Beats are randomly 
dropped with a notable absence of QRS, in a repetitive cycle. 
Frequent patterns may ensue with every 3rd (3:1 block) or 4th 
(4:1 block) P wave. Mobitz II is indicative of underlying dis-
ease along the bundle branches. Symptoms may range from 
dizziness, weakness, and syncope, depending on the propor-
tion of nonconducted beats. Treatment of 2nd-degree AV 
block and structural disease includes permanent pacemaker 
insertion except in the presence of a reversible cause.
Third-degree or complete heart block is resultant of an 
absence of electrical communication between the atria and 
ventricles. The ECG depicts no connection between P waves 
and QRS complexes. The heart attempts to preserve function 
through junctional escape or ventricular pacemaker beats. 
Beats originating above the bifurcation of the bundle of His 
display narrow QRS complexes and the patient exhibits a heart 
rate >40 beats/min with minimal symptoms. Escape rhythms 
arising beneath the bifurcation produce wider QRS complexes, 
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lower and more erratic heart rates, and worsening symptom-
atology, including loss of consciousness or heart failure.
When the heart block is secondary to drugs, discontinu-
ation of the specific medication may restore normal rhythm, 
but temporary pacing might be necessary. Complete heart 
block may be produced by acute inferior MI and the dis-
turbance typically denotes significant myocardial necrosis. 
Immediate transvenous pacemaker insertion is indicated 
with interim external pacing as necessary. Spontaneous 
resolution may occur, but further diagnostic evaluation of 
conduction is indicated.
 Cardiac Arrest 
In adults, acute cardiac arrest or sudden death results pri-
marily from underlying cardiac disease. However, it may 
be the initial manifestation of the disease. Some additional 
causes include trauma, pulmonary embolism, hemorrhage, or 
drug overdose. Global ischemia is the consequence of cardiac 
standstill with cellular damage and edema ensuing quickly. 
Rapid response and resuscitation decreases the likelihood 
of death and disability, but even patients with full supportive 
measures may experience long-term cerebral dysfunction.
Decreased ATP production following arrest creates a loss 
of cellular membrane integrity with an efflux of potassium 
and calcium. Elevations of nitrous oxide cause free radical 
formation and may activate cellular destruction. Abnormal 
depolarization sets off neurotransmitters including gluta-
mate, which triggers an overload of calcium. Inflammatory 
mediators surge result in increased thrombosis and worsen-
ing of edema. Apoptosis as a result of overwhelming isch-
emia causes cell death.
Initial evaluation for potential treatable causes including 
hypoxia, hypovolemia, pneumothorax, or cardiac tamponade 
is paramount in acute care. Rapid intervention that utilizes 
current advanced cardiac life support (ACLS) guidelines is 
essential. A primary survey of airway, breathing, circulation, 
and defibrillation is always the primary intervention even in 
the acute care setting. Precordial thump is not indicated except 
in the absence of a defibrillator. Prompt direct current cardio-
version is the most effective intervention for conversion of VF 
or VT. The success of defibrillation is correlated to time with a 
10% decline in success with each minute of pulselessness.
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There is little definitive evidence to support the effec-
tiveness of ACLS drugs in survival of cardiac arrest to hospi-
tal discharge. Some may enhance circulatory responses such 
as the first line drugs, which include epinephrine, vasopres-
sin, atropine, and amiodarone. Other agents may be utilized 
to address individual patient scenarios including metabolic 
disturbances or drug overdose. Cessation of resuscitation 
events is determined by patient stability, pronunciation of 
death, or failure to establish spontaneous circulation within 
30–45 minutes. Patients with hypothermia must be rewarmed 
to 34°C to make an accurate assessment of death.
 Heart Failure 
Intrinsically, the LV function is tied to cardiac output. Under-
standing the LV function and thus dysfunction it is best to 
review the basics; energy supply and demand of the heart. 
The primary energy demands are heart rate, wall tension, 
and contractility. The ventricle is largest during diastole, 
whereas the greatest pressure occurs during systole. Rate 
will increase contractility and thus use greater energy. With 
an increase in any of these factors, oxygen demand must be 
increased to match demand.
With just a resting heart rate, the myocardium already 
uses 6–8cc O 2·min·100g while skeletal muscle only uses 
0.15 cc O 2·min·100g. Furthermore, the myocardium must 
extract nearly 80% of the oxygen, whereas skeletal muscle 
needs only 25%. There is not a large reserve for the heart 
when it needs to increase energy expenditure. The deter-
minants of myocardial oxygen delivery are coronary artery 
blood flow, hemoglobin concentration, and arterial oxygen 
saturation. Coronary blood flow can increase from a resting 
level of 70–80 cc·min·100g to 400–600 cc·min·100g when at 
maximal demand. With inadequate supply, when supply out 
strips demand, ventricular dysfunction is common. As an 
extreme example, when the oxygen supply for the heart is 
interrupted and unable to meet demand, dyskinesia results 
and can result in pulseless electrical activity.
Cardiac contractility, ventricular function, and myocardial 
oxygen demand are determined by (a) preload, (b) afterload, 
(c) heart rate, (d) rhythm, and (e) the presence of substrates 
including fatty acids, oxygen, glucose, and viable myocardium. 
Cardiac output is defined as stroke volume × heart rate and 
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is dependent on venous return, peripheral vascular tone, and 
neurohumoral factors.
Preload is the pressure stretching, which expands the 
ventricle after passive filling and contraction of the atrium. 
Preload corresponds to the amount of end-diastolic stretch 
of cardiac fiber cells and end-diastolic volume. These are 
products of ventricular diastolic pressure and myocardial 
structure. LV end-diastolic pressure is synonymously iden-
tified as the amount of preload. The factors that create an 
increased ventricular filling pressure causing a high preload 
include elevations in central venous pressure, increased ven-
tricular compliance, underlying conditions such as valvular 
disease and heart failure, increased atrial contractile force, 
decreased heart rate, and increased aortic pressure. Preload 
is decreased by factors including low blood volume, atrial 
arrhythmias, elevated heart rate, ventricular diastolic failure, 
and mitral and tricuspid stenosis.
Afterload is the force that resists cardiac contraction 
upon systole and is also defined as the pressure necessary 
to eject blood from the chamber and is a consequence of 
systemic arterial pressure. Under normal circumstance as 
afterload increases, there is a resultant decrease in cardiac 
output. The Frank-Starling principle illustrates the effects 
of preload and cardiac performance. Contractility typically 
requires interventional methods to be measured, but can be 
reasonably deduced by the ejection fraction estimation on an 
echocardiogram.
Cardiac reserve reflects the heart’s capacity to per-
form above resting levels secondary to stressors including 
emotional or physical conditions. Factors affecting cardiac 
reserve include tachycardia, systolic and diastolic volume, 
stroke volume, and the difference between oxygen content in 
arterial blood and mixed venous or pulmonary artery blood. 
At rest the arterial blood is estimated at 18 ml O 2/dl of blood, 
or pulmonary artery blood estimates equate to 14 ml/dl. The 
oxygen extraction is therefore calculated at 4.0 ml/dl, but as 
demand rises, it may be increased to 12–14 ml/dl. This effect 
provides some adaptation for blood flow in the presence of 
heart failure.
There are several causes of primary ventricular failure. 
Valvular disease is a prominent cause of ventricular dys-
function. Chronic states like endocarditis or acute ischemia 
may cause failure. The patient with chronic hypertension will 
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generally have increased left ventricle hypertrophy, which 
results in mitral insufficiency because of the dilation of the 
ventricle and mitral ring as well as inadequate alignment 
of the papillary muscle. This increases demand with pri-
mary forward and backward dysfunction causing pulmonary 
edema. The demand is increased at a time when supply is 
decreased particularly in the subendocardial areas.
Individuals with heart failure experience inadequate 
blood flow to meet metabolic needs and subsequent elevation 
of pressure may result in organ congestion. This state cre-
ates dysfunction of systolic or diastolic activity or both. Dur-
ing systolic dysfunction, there is poor ventricular inotropy 
and ineffective emptying, which results in elevated diastolic 
volume and lowered ejection fraction. Systolic dysfunction 
can also result from the loss of contractile muscle cells in 
the heart following acute myocardial infarction. Intracellular 
calcium modulation and cAMP production prevent effective 
utilization and storage of energy with resultant electrophysi-
ological and functional abnormalities.
During diastolic disturbances that affect the function, 
there is a weakened relaxation of the ventricle with impaired 
filling and a decreased ventricular end-diastolic volume, 
increased end-diastolic pressure, or both. Primary features of 
diastolic dysfunction include, but are not limited to, valvular 
disease, stiffness, and constrictive pericarditis. The ejection 
fraction may be within normal limits despite the inadequate 
LV filling. The effects of poor LV filling are evident in lowered 
cardiac output measurements and the manifestation of sys-
temic symptoms. As right atrial pressures increase, there is 
pulmonary congestion. Resistance to filling may be secondary 
to reduction of myocytes and the deposit of collagen. Diastolic 
dysfunction may be present in hypertrophic cardiomyopathy, 
hypertrophic ventricular states, and cardiac disease second-
ary to amyloidal permeation.
LV dysfunction may produce LV failure. This is manifested 
by decreased cardiac output and elevations in pulmonary 
venous pressure. The rapid rise in pulmonary capillary pres-
sure surpasses colloidal osmotic pressure resulting in shunt-
ing of fluid from the capillaries to interstitial and alveolar 
areas with poor pulmonary compliance causing respiratory 
insufficiency. Marked volume pulmonary edema changes 
ventilation–perfusion reactions. Pulmonary arterial blood 
passes through alveoli with negligible ventilator capacity 
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thus limiting systemic arterial oxygenation and producing 
shortness of breath. Dyspnea may occur before ventilation–
perfusion mismatch because of rising pulmonary venous 
pressure and the heightened burden of breathing. Pleural 
effusions are evident in persistent or severe or chronic dys-
function of the left ventricle and can exacerbate dyspnea. 
Small increases in ventilation induce lower PaCO 2 and pro-
duce respiratory alkalosis. Elevations of PaCO 2 are ominous 
signs of respiratory failure representative of interstitial 
edema of the alveoli.
RV dysfunction and elevation of systemic venous pres-
sure with resultant edema are the manifestations of right 
heart failure. The liver is affected and gastrointestinal organs 
exhibit congestion as evident by the presence of ascites. The 
severe dysfunction of the right ventricle creates hepatic con-
gestion and impairment, specifically high bilirubin levels, ele-
vated PT, and hepatic enzymes. The overloaded liver is unable 
to meet the demands of circulating aldosterone, thus increas-
ing and adding to increased volume. Patients may develop 
anorexia, malabsorption, hypoalbuminemia, chronic blood loss, 
and in rare cases, ischemia of the mesenteric vessels.
Atrial natriuretic peptide is an amino acid that is pro-
duced by cardiac cells in response to atrial distension, angio-
tensin II, and sympathetic stimulation typically in response 
to hypervolemic states. Brain-type natriuretic peptide (BNP) 
is peptide produced in the brain and ventricles. BNP is also 
produced by excessive volume and mimics physiological 
actions. BNP and NT-pro-BNP are specific diagnostic indi-
cations for heart failure. Neutral endopeptidase (NEP) is a 
complex chemical that degrades the natriuretic peptides. 
Therefore, it may block natriuretic peptide and intensifies 
their effects. Natriuretic peptides serve as counterregula-
tory processes for the renin–angiotensin–aldosterone sys-
tem. A recombinant human BNP is approved for use in the 
acute treatment of decompensated heart failure caused by 
systolic dysfunction. New classes of drugs that are NEP 
inhibitors prevent enzymatic response in combination with 
ACE inhibitors.
Ventricular remodeling is a consequence of prolonged 
elevations of preload and subsequent cardiac output. There 
is notable change in ventricular shape, width, and weight 
over time, and then hypertrophy ensues. Compensatory 
mechanisms result in markedly decreased diastolic capacity 
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thereby compromising cardiac workload especially during 
stress. Elevated ventricular stiffness raises oxygen demand 
and stimulates apoptosis of the myocardium. Valvular regur-
gitation increases in the presence of chronic elevated end-
diastolic volumes.
Sepsis may result in ventricular failure because of by-
products of inflammation. The circulation of inflammatory 
products, IL-1, IL-9, tumor necrosis factor, and cytokines, 
causes a decrease in cardiac function. As sepsis ensues, the 
patient experiences a decline in SVR and profound hypoten-
sion. In an effort to maintain an acceptable blood pressure, 
the heart must increase demand, thus outstripping the myo-
cardial reserves.
The renin–angiotensin–aldosterone system is stimulated 
by decreased perfusion to the kidneys. Increases in sodium, 
water retention, renal, and peripheral vascular tone are evi-
dent. The end result is intense sympathetic activation that 
is seen in heart failure. Heightened sympathetic activity 
with increased circulating angiotensin II and vasopressin, 
contribute to an intensified systemic vascular resistance. 
Drugs that may reduce these mechanisms include angioten-
sin-converting enzyme inhibitors. The angiotensin receptor 
blockade agents may improve stroke volume by decreasing 
afterload. Arterial and venous dilators, such as hydralazine 
and sodium nitroprusside are indicated for the acute reduc-
tion of afterload in patients with critical illness.
Angiotensin II aggravates failure by stimulating vaso-
constriction, including efferent renal vasoconstriction, and 
by raising circulatory aldosterone. This enhances retention of 
sodium in the distal kidney and is responsible for myocardial 
and vascular collagen deposition and fibrosis. Norepineph-
rine, a by-product of Angiotensin II, increases antidiuretic 
hormone (ADH) and can trigger apoptosis. Angiotensin II is 
credited with vascular and myocardial hypertrophy and ulti-
mately attributed to the cycle of failure by remodeling the 
heart and peripheral vasculature.
There is also evidence that other factors such as nitric oxide 
and endothelin may play a role in the pathogenesis of heart fail-
ure. Some drug treatments for heart failure involve attenuating 
the neurohumoral changes. Beta-blockers have been shown 
to provide significant long-term benefit, because they block 
the excessive sympathetic activation in cardiac muscle. Angio-
tensin-converting enzyme inhibitors, angiotensin receptor
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blockers (ARBs), and aldosterone receptor antagonists are 
commonly used to treat heart failure by inhibiting the actions of 
the renin–angiotensin–aldosterone system.
Ischemia and necrosis of the primary organs produce 
cytokine, also known as tumor necrosis factor (TNF)-α, is 
produced. This catabolic entity causes cachexia, which is 
common in severe failure. Metabolic changes occurring in 
end-stage heart failure include elevated free fatty acid con-
sumption and decreased glucose utilization. Systemic and 
cardiac specific factors can impair cardiac performance and 
cause failure. Biventricular failure results from disorders that 
affect the entire heart including viral or congenital states.
The term  high-output heart failure refers to conditions in 
which the heart requires elevated cardiac output to maintain 
functionality. Ultimately, the cardiac muscle cannot meet the 
demand and failure ensues. Some of the underlying causes of 
high-output failure include, but are not limited to, severe ane-
mia, hyperthyroidism, Paget disease, and persistent tachycar-
dia. Failure may be noted in forms of cirrhosis, but the edema 
is typically attributed to underlying hepatic mechanisms.
 Treatment 
Critical intervention is essential for acute or worsening fail-
ure in the presence of acute myocardial infarction, atrial 
fibrillation, severe hypertension, acute valvular regurgitation, 
as well as for patients with pulmonary edema, new-onset 
failure, or individuals who are refractory to outpatient treat-
ment. The primary goal is to diagnose and treat the under-
lying cause (Exhibit 4.4). Initially, therapy is centered on 
improving hemodynamic stability, avoiding electrolyte imbal-
ance, improving renal insufficiency, lessening symptoms, and 
correcting neurohumoral activation. Long-term needs must 
address hypertension, the progression of coronary heart dis-
ease, reduction of MI risk, improving cardiac function, reduc-
ing acute care days, and improving quality of life.
 Pharmacotherapy in Heart Failure 
Drug treatment for heart failure includes diuretics, nitrates, 
ACE inhibitors, ARBs, and beta-blockers for diastolic 
HF. Severe diastolic dysfunction predisposes patients to 
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hypotension and reduction of plasma volume; therefore, 
diuretics and nitrates are prescribed in lower doses. Current 
research supports data on plasma biomarkers that may pre-
dict which patients might respond best to which drug or drug 
combination.
Diuretics are a staple in the management of symptomatic 
systolic dysfunction and current or previous volume over-
load. Loop diuretics including furosemide and bumetanide 
are commonly prescribed and, in refractory cases, increased 
dosage of furosemide, ethacrynic acid, bumetanide, or meto-
lazone may have an additive effect. Intravenous infusion of 
Exhibit
Identify and treat arrhythmias
Aggressive attempts to convert atrial fi brillation
Treat underlying conditions
Hyperthyroidism, pulmonary emboli, fever, anemia
Correct electrolyte abnormalities
Consider ICD therapy for appropriate patients
Ultrafi ltration (venovenous fi ltration)
Patients who fail diuretic therapy with worsening cardiorenal syndrome
Intra-aortic counterpulsation balloon pump
Surgery
Closure of congenital or acquired intracardiac shunts
Coronary artery bypass graft
Valve repair or replacement
Heart transplantation
Patients younger than the age of 60 who have severe, refractory HF and no 
 other life-threatening conditions.
LVAD
Bridge to transplantation or recovery
4.4 Treatment Considerations forHeart Failure
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furosemide is effective in the presence of severe edema. Side 
effects include the following: hypovolemia with hypoten-
sion, hyponatremia, hypomagnesemia, and severe hypoka-
lemia. Acute doses of diuretic should be targeted to resolve 
failure and decreased or discontinued as heart function 
improves. High doses of diuretics lower CO, impair renal 
function, and increase mortality. These medications should 
be used judiciously. Serum electrolytes must be monitored 
closely especially after increasing dose.
Spironolactone or eplerenone may limit the hypokalemia-
associated side effects related to higher-dose loop diuretics. 
Hyperkalemia may result in combination of ACE inhibitors 
or ARBs and may aggravate renal dysfunction. These drugs 
have been noted to benefit patients with chronic RV failure 
as hepatic congestion increases aldosterone levels.
Patients with systolic dysfunction should be maintained 
on oral ACE inhibitors unless contraindicated (i.e., by plasma 
creatinine >2.8 mg/dl, bilateral renal artery stenosis, renal 
artery stenosis, or past medical history of ACE induced angio-
edema). ACE inhibitors facilitate vasodilation, lower LV filling 
pressures, decrease systemic vascular resistance, and resist 
ventricular remodeling. ACE inhibitors have been credited 
with prolonged survival and reduced subsequent admissions 
for failure especially in individuals with diabetic nephropa-
thy (Strippoli, Craig, Schena, et al., 2006). ACE inhibitors may 
reduce MI and stroke risk in individuals with coronary heart 
disease and delay the onset of nephropathy in patients with 
diabetes. Thus, ACE inhibitors may be used in patients with 
diastolic dysfunction and any of these disorders.
ACE inhibitors may be responsible for temporary eleva-
tions in serum creatinine secondary to vasodilation of the 
efferent glomerular vessels. Subtle increases in creatinine 
should not be the rationale for termination of therapy but 
should alert the provider to titrate the dose carefully, reduce 
diuretics, and avoid use of NSAIDs. Regular evaluation of 
renal function and electrolytes should be initiated prior to 
onset of ACE inhibitors, repeated at least 1 month, and follow-
ing any deviations in clinical condition or dose adjustment. 
Dehydration or poor renal function may develop because of 
acute illness and then, the ACE inhibitor dose may need to be 
reduced or the drug may need to be temporarily withheld.
ARBs are less likely to cause cough and angioedema 
than the ACE inhibitor and may be indicated if adverse 
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effects prohibit ACE inhibitor use. MI studies revealed that 
ACE inhibitors and ARBs are equally effective although their 
equivalence is less clear in chronic failure. Ongoing studies 
are underway to explore long-term dosing standards. Simi-
lar to ACE inhibitors, ARBs may aggravate renal dysfunction, 
and the dose may need to be reduced or discontinued in acute 
scenarios. In the presence of severe or repetitive episodes 
of heart failure, the provider may add an ARB to the ACE 
inhibitor, beta-blocker, and diuretic regimen. Combination 
therapy necessitates ongoing evaluation of blood pressure, 
plasma electrolytes, and renal function.
Aldosterone production is independent of the renin–
angiotensin system and the effects cannot be removed despite 
maximal dosing of ACE inhibitors and ARBs. Spironolactone 
and eplerenone decrease mortality, including from sudden 
death, in patients with low ejection fraction severe or acute 
episodes, or following acute MI. Potassium supplementation 
should be terminated and monitored frequently.
Beta-blockers are an important addition to ACE inhib-
itors for chronic systolic dysfunction in most patients. 
These agents are most effective if initiated in the absence 
of pulmonary congestion. Research supports the role of 
beta-blockers for improved ejection fraction and decreased 
morbidity and mortality in patients with chronic systolic dys-
function (AHQR, 2003). Beta-blockers are efficacious for dia-
stolic dysfunction because of heart rate reduction, prolonging 
diastolic filling time, and may possibly improve ventricular 
relaxation. During acute decompensation, beta-blockers should 
not be initiated until hemodynamic stability is achieved. Dos-
age titration is required for those on beta-blocker therapy 
at the time of decompensation. Once treatment is initiated, 
cardiac oxygen consumption decreases whereas stroke vol-
ume and filling pressure remain unchanged.
Hydralazine and isosorbide dinitrate can offer relief for 
patients intolerant of ACE inhibitors or ARBs. Ethnopharma-
cologic data indicates that African American patients, may 
experience additional benefits when supplemented with 
standard treatment options. Vasodilators improve blood flow, 
reduce regurgitation, and increase exercise capability with-
out compromising renal function.
Nitrates alone can relieve the symptoms related to failure 
and patients may be taught to initiate sublingual nitroglycerin 
as needed for acute dyspnea or utilize transdermal modalities 
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for nocturnal symptoms. Nitrates are easily prescribed, cost 
effective and generally tolerated in individuals. Common side 
effects include hypotension, flushing, and headache.
Calcium channel blockers are excluded in the manage-
ment of systolic dysfunction. Short-acting dihydropyridines 
and nondihydropyridines in fact may be lethal. Amlodipine 
and felodipine may be suitable alternatives in patients pre-
senting with angina and hypertension.
Digoxin inhibits the Na-K pump, thus, lessening the pos-
itive inotropic effect reduces sympathetic activity, slows ven-
tricular response specifically in atrial fibrillation, and limits 
vasoconstriction while improving renal circulation. There is 
no data to support effects on mortality, but when used with 
diuretics and an ACE inhibitor, it may produce resolution of 
symptoms. Providers must recognize the potential for toxic-
ity especially in patients with renal dysfunction.
Positive inotropic drugs have been evaluated in heart 
failure, but except for digoxin, have a limited role because of 
increased mortality. Researchers are studying the effects of 
calcium sensitizers, cytokine blockers, endothelin blockers, 
matrix metalloproteinase inhibitors, and immune modula-
tors as potential future treatment modalities in the manage-
ment of heart failure.
 Chest Pain 
Chest tightness, pressure, discomfort, or any pain arising 
along the anterior aspect of the thorax may be described as 
chest pain. Many people with chest pain fear a heart attack. 
However, there are many possible causes of chest pain 
including cardiac diseases resulting from blockages in coro-
nary arteries, other cardiac problems (such as pericarditis), 
musculoskeletal diseases of the chest wall, gastrointestinal 
diseases, arthritis, and neurological disease. Any organ or 
tissue in your chest can be the source of pain, including your 
heart, lungs, esophagus, muscles, ribs, tendons, or nerves. 
The pain may range from mildly bothersome to serious and 
could even be life threatening.
Angina is a type of heart-related chest pain resultant from 
ischemia and may present in the same manner as the pain of a 
heart attack. Angina is referred to as stable angina when chest 
pain begins at a predictable level of activity. Unstable angina 
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is chest pain that occurs unexpectedly after light activity or 
occurs at rest and necessitates immediate attention. Other 
causes of chest pain include respiratory infection, pulmonary 
embolism, pneumothorax, asthma, or pleurisy. In these cases, 
the chest pain often worsens on deep inspiration or cough and 
is described as sharp and pulling or may be expressed in terms 
of tension between the ribs. Unstable angina results from an 
imbalance between oxygen supply and demand. Angina pain 
is a clinical manifestation of this imbalance. Because the left 
ventricle comprises the majority of the cardiac mass and faces 
the greatest pressures, it is at the highest risk for ischemia. 
The ischemia may be precipitated by coronary atheroscle-
rosis, plaque rupture, coronary artery spasm, anemia, and 
hypoxemia, with subsequent and limited diastolic filling time 
secondarily produced by tachycardia and hypertension.
The term  unstable angina denotes new pain or a depar-
ture from previous anginal pattern. Unstable angina occurs 
at rest or more commonly with light activity. Pain lasting for 
more than 15 minutes also suggests an unstable pattern after 
activity is discontinued. The pain of unstable angina may 
awaken a patient from sleep. The correlation between severe 
ischemia and death has heightened the need for definitive 
diagnostic and therapeutic intervention in individuals with 
chest pain. Braunwald (2000) identified 5 critical factors that 
lead to the diagnosis of unstable angina and increase the 
likelihood of survival if indeed there is an ischemic event. 
Careful history is essential to identify these elements. They 
include: (1) the nature of the symptoms, (2) a prior history of 
CAD, (3) age, (4) sex, and (5) the number of traditional risk 
factors that are present for CAD. Patients with UA should 
be identified quickly and access to appropriate reperfusion 
modalities expedited to improve outcomes.
 Myocardial Infarction 
The spectrum referred to as acute coronary syndrome 
includes ST-elevation MI (STEMI), non–ST-elevation MI 
(NSTEMI), and unstable angina. This categorization is valu-
able because patients with ischemic discomfort may or may 
not have ST-segment elevations on electrocardiogram. Those 
without ST elevations may ultimately be diagnosed with 
NSTEMI or with unstable angina based on the presence or 
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absence of cardiac enzymes. In addition, therapeutic deci-
sions, such as administering an intravenous thrombolytic or 
performing percutaneous coronary intervention (PCI), are 
often made based on these criteria.
Diagnostic testing, specifically the measurement of car-
diac markers, helps to categorize myocardial infarction. Tro-
ponin is the ideal biomarker for diagnosis as it provides the 
greatest sensitivity and specificity. The test may be utilized 
in both diagnostic and prognostic aspects of care. Troponin 
is not found in serum except in the presence of myocardial 
necrosis. Troponin I is detectable in serum 3–6 hours after an 
AMI and its level remains elevated for 10–14 days.
CK-MB may also be utilized in diagnosing MI. Serum 
levels rise approximately 4 hours following injury, peak at 
18–24 hours, and normalize in 3–4 days. Therefore, it is essen-
tial to note that normal findings do not exclude myocardial 
necrosis. Infarcts can be missed by CK-MB and should be 
used in addition to serial troponin levels in patients with 
suspected MI and negative serial CK-MBs.
Chest radiography, CT scan, or transesophageal echo-
cardiography (TEE) may assist in the detection of MI from 
aortic dissection in high-risk patients. Echocardiography is 
helpful in evaluating wall motion abnormalities and overall 
ventricular function. Perfusion imaging has been used in risk 
stratification after MI and for measurement of infarct size 
to evaluate reperfusion therapies. CT scanning reveals fine 
details of the patient’s coronary arteries. This noninvasive 
technology enables early diagnosis and potentially earlier 
treatment before coronary ischemia ensues. Improved visu-
alization can depict the status of coronary arteries, potential 
plaque within the artery, or the patency of a graft.
TEE has become the single most important tool during 
the intraoperative course with it multifaceted indications. 
Commonly, it is used to determine ejection fraction, ventricu-
lar and atrial wall movement, abnormalities of flow, integrity 
and function of valves, determination of intravascular vol-
ume, presence of abnormal anatomy, evaluation of post valve 
repair/replacement, and pericardial effusion just to name a 
few. This tool is geared to the intraoperative arena, requiring 
intubation and currently only used for an examination rath-
er than sustained monitoring. During the ICU monitoring, a 
TEE can be used for assessment of hemodynamic instability, 
assessment of unexplained respiratory failure, suspected 
120 Critical Care
endocarditis, suspected pulmonary embolus, diagnosis of 
aortic dissection, and evaluation of clot formation before car-
dioversion in patients with AF.
Both transthoracic echocardiography (TTE) and TEE 
require significant training to obtain and accurately interpret 
findings. The TEE determines the ventricular contraction, 
volume status and presence of pericardial fluid/tampon-
ade. The echocardiogram functions by using a transducer to 
transmit and receive ultrasound waves into cardiac and vas-
cular structures. Two-dimensional (2D) and M-mode imaging 
provide details of structure and motion based on the intensity 
and time delay of ultrasound waves that are reflected at the 
tissue interfaces. Doppler imaging provides velocity informa-
tion based on the change in frequency of backscattered ultra-
sound waves produced by moving structures, usually blood. 
The classic example is that of standing still and listening to 
a passing train. As the train approaches and then passes, the 
pitch changes.
Real-time imaging or 2D imaging involves rapidly sweep-
ing an ultrasound beam back and forth across a plane. The 
reflected ultrasound signals are used to generate a 2D thin 
slice through the structure of interest with motion displayed 
in real time.  M-mode imaging display reflects ultrasound 
waves along a single scan line over time known as  motion 
over time. M-mode imaging has a very high depth of resolu-
tion and therefore is ideal for measuring distances along the 
scan line and for observing rapidly moving structures. 
There are currently 4 Doppler imaging modes in use, 
which include the following: (a) color flow, (b) pulsed wave 
(PW), (c) continuous wave (CW), and (d) tissue. The flow 
Doppler displays blood velocity as a color map over the 2D 
image. By convention, red represents flow toward the trans-
ducer whereas blue is blood flowing away. The importance is 
to recognize that depending on the angle of the transducer 
or what structure you are examining,  blue can be arterial 
flow whereas  red can be venous flow. When the velocity of 
the flow exceeds a certain speed, the color flows can reverse. 
The classic example of this, known as aliasing or exceeding 
the Nyquist limit, is the optical illusion of watching a wheel 
that goes so fast that it looks like it is going backward. The 
spectral Doppler, the pulse wave, continuous wave, and tis-
sue Doppler also record velocities along a single scan line. 
The TTE will more reliably visualize the LV apex and the 
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ventricular apex of a prosthetic mitral valve because of ori-
entation. The TEE provides excellent view of the mitral and 
aortic views.
Interventional technologies have become essential in 
the reperfusion of coronary arteries. PCI are performed as a 
primary intervention when available or may be indicated in 
the individual who experiences failure of thrombolysis. PCI 
is more effective than thrombolysis when readily available 
and is indicated for confirmed STEMI in the presence of a 
new left bundle branch block, severe congestive heart fail-
ure. Success is correlated to early intervention specifically 
within hours of symptom onset.
Complications caused by hemorrhage following PCI are 
minimal when compared with thrombolysis. There is resto-
ration of patency of cardiac vessels in most patients. The lim-
iting factor is the requirement of an angioplasty suite with 
the required staff round the clock. On call cardiothoracic 
capabilities can also prohibit universal availability of PCI. 
Primary PCI for STEMI should be performed at hospitals 
with readily available cardiothoracic surgery. This is open to 
interpretation and may be defined as the ability to transport 
patients to a facility with cardiothoracic capabilities.
Patients with persistent ST elevation require evaluation 
for reperfusion modalities. In the presence of ST elevation, 
diagnosis may be driven by troponin levels. Unstable angina 
may be noted in the absence of cardiac marker elevation. 
Patients presenting with no ST-segment elevation are not 
candidates for emergent thrombolytics, but rather, elective 
angiography and PCI may be of value. For unstable angina, 
diagnosis may be delayed to enable diagnostic studies such 
as coronary angiography or imaging studies to rule out non-
coronary causes of chest pain. The primary goal is identifying 
and intervening quickly in patients with STEMI. Treatment 
should be multifaceted and aimed at restoring oxygen-
ation, minimizing ischemia, relieving pain, and preventing 
complications.
Patients presenting with STEMI have a different  pathology 
and therefore a different treatment protocol. These patients 
generally have a thrombotic occlusion of a coronary artery. 
The goal is early reperfusion therapy. Studies have shown 
(Thrombolysis in Myocardial Infarction[TIMI]) that mortal-
ity decreases with early treatment. Initial and immediate
treatment includes the aforementioned aspirin, clopidogrel, 
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heparin, beta-blockers, nitrates, oxygen, and morphine. The 
next and most important step is the administration of throm-
bolysis therapy. Currently, alteplase, streptokinase, tenecteplase, 
and reteplase are available. Although potentially myocardial 
sparring, the reperfusion patency is only 60% of patients with 
the potential complication of bleeding.
Aspirin should be administered immediately to decrease 
mortality and reinfarction rates after MI. Aspirin inhibits 
cyclooxygenase-1, which prevents the formation of throm-
boxane A2 and thus inhibiting the ability of platelet aggre-
gation. Clopidogrel may be an alternative in case of aspirin 
allergy but may also be recommended as adjunctive therapy. 
Clopidogrel irreversibly binds to adenosine diphosphate 
receptor and inhibits ADP-dependent platelet activation. 
Understandably, the combination of clopidogrel and aspirin 
increases the risks of bleeding and should be discontinued 
at least 5 days prior to a planned coronary artery bypass 
grafting (CABG). Additional treatment to inhibit platelet for-
mation is the glycoprotein IIb/IIIa-receptor antiagonist. Cur-
rently, three agents are available, abciximab (ReoPro)<PE>, 
eptifibatide (Integrilin), and tirofiban (Aggrastat). Heparin, 
both unfractionated and low molecular weight, is also ben-
eficial when combined with aspirin and clopidogrel for the 
acute treatment phase.
Traditionally, the nonischemia therapy has been nitrates 
with their ability to vasodilate veins, arteries, and arterioles. 
They augment collateral coronary blood flow, decrease pre-
load and demand, reduce coronary artery vasospasm, and 
may inhibit platelet aggregation. Intravenous nitroglycerin 
will also cause hypotension, flushing, headaches, and has a 
tendency to cause tachyphylaxis after 24 hours.
Beta-blocker therapy to control rate and reduce myocar-
dial oxygen demand are mandated unless contraindicated. 
Metoprolol, the most common selective beta1-adrenergic 
receptor blocker, decreases automaticity of contractions. 
Beta-blockers have been determined to reduce reinfarction 
rate, prevent ischemia, and ultimately reduce mortality.
Nitrates reduce preload and enhance relief of acute symp-
toms but do not demonstrate an impact on overall mortality in 
MI. These potent vasodilators are contraindicated if systolic 
BP <90, HR <60 or >100, and in the presence of RV infarction. 
Parenteral nitroglycerin may reduce ischemic discomfort, con-
trol blood pressure elevations, or assist in relieving pulmonary 
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congestion. Men who have taken phosphodiesterase inhibitor 
for erectile dysfunction should be given a 24-hour time frame 
prior to the administration of nitrates (Kloner, 2005). Men 
who have been prescribed tadalafil require a 48-hour window 
before nitrates may be administered (Kloner, 2005).
Optimal outcomes in thrombolytic therapy are clear when 
administered within the initial 2 hours after MI.  Thrombolysis 
is generally preferred when the PCI door-to-balloon time 
exceeds 3 hours. Administration of a platelet glycoprotein (GP) 
IIb/IIIa-receptor antagonist is suggested, in addition to aspirin 
and heparin, for patients with persistent ischemia or other high-
risk features in whom PCI is anticipated is recommended. The 
addition of intravenous platelet GP IIb/IIIa-receptor antagonists 
to aspirin and heparin improves both early and late outcomes, 
including mortality, Q-wave MI, need for revascularization pro-
cedures, and length of hospital stay.
Consistent with AHA guidelines and clinical guidelines 
patients with suspected ischemia require prompt identifi-
cation, intervention and possibly transfer to interventional 
facilities. Thrombolytics should be considered immediately 
upon diagnosis. Administration may serve as a bridge for 
those who do not have immediate access to interventional 
facilities. Gershlick et al., (2005) cited improved outcomes for 
patients undergoing rescue angioplasty to prevent death in 
patients who fail thrombolysis during an MI. Heparin serves 
as adjunctive agent in patients receiving alteplase, reteplase, 
or tenecteplase, but should not be used with nonselective 
fibrinolytic agents. Heparin is also indicated in patients 
undergoing primary PCI. Low–molecular-weight heparins 
(LMWH) may be preferred because of convenient dosing 
and reliable therapeutic levels. No definitive trials of LMWH 
in patients with STEMI are available to provide an evidence-
based approach.
An ACE inhibitor is indicated in the first 24 hours of 
STEMI in the presence of anterior infarction, pulmonary 
congestion, or LV ejection fraction <40% in the absence of 
hypotension. An angiotensin receptor blocker (valsartan or 
candesartan) should be administered to patients with STEMI 
who are intolerant of ACE inhibitors and have either clinical 
or radiological signs of heart failure or LVEF <40%.
Overall community management of MI and the avail-
ability of resources for reperfusion are critical to survival 
after MI. Resources and protocols must proactively address a 
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collaborative effort between emergency team,  interventional 
providers, and cardiothoracic surgeons. The decision to 
administer a thrombolytic agent may be made by the emer-
gency providers, with or without the input of a cardiologist, 
depending on institutional protocol. In a center with the full 
range of treatment options, an expeditious phone consulta-
tion with a cardiologist would be prudent to determine the 
most appropriate option for the patient.
 Aortic Surgery 
The four major diseases that present for surgical correction 
in the aorta are dissection, aneurysm, rupture, and coarcta-
tion. The aneurysm and dissection tend to go together as one 
syndrome; both of which can be progressive. There are many 
causes of aneurysms; however, the most common are hyper-
tension, atherosclerosis, infections, and genetic or congenital 
causes, which would include Marfan syndrome. The aneuris-
mal sac can take on several forms. Thoracoabdominal aortic 
aneurysms are classified based on where it is initiated and 
ends using the Crawford classification (see Exhibit 4.5). 
Aortic aneurysms are slow to expand but have great 
potential to dissect or rupture. Aneurysms do not grow lin-
early and tend to get increase in smokers and the chronically 
hypertensive. Current recommendation suggests a deferral of 
Exhibit
TYPE I  arises distal to the left subclavian and extends to the level of the superior
mesenteric artery but above the renals.
TYPE II arises distal to the left subclavian and extends to below the renal arteries.
TYPE III  arises from below the level of the sixth intercostals and extends to below
the renal arteries.
TYPE IV  arises from the level of the twelfth intercostal space and extends to below
the renal artery.
4.5 Crawford Classifi cation
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intervention until the aneurysm is over 5.5 cm in the ascend-
ing aorta and over 6 cm in the descending aorta.
Generally, aortic aneurysms are found as incidental find-
ings from a chest x-ray or CT scan. Some aneurysms can cause 
vague symptoms from pressure or hoarseness with stretching of 
the recurrent laryngeal nerve. Accurate diagnosis is best accom-
plished with a CT scan with contrast and axial reconstruction.
Treatment of the aneurysm is dependent on several fac-
tors including size, location, and rapidity of growth. Conven-
tional medical treatment is diet, blood pressure control, and 
smoking cessation. The advent of advanced endovascular 
options enables the treatment of descending aneurysms by 
stenting. Current options enable some ascending aneurysms 
to be stented, which is a remarkable shift in therapy and 
reduces risk of morbidity and mortality.
Aortic dissections, although still part of the continuum 
of disease of the aortic aneurysm, are far more abrupt, pain-
ful, and if left untreated, will result in death. The patient may 
describe the pain as a sharp or tearing in nature in their chest. 
During the dissection, the intima of the aorta is sheared off the 
aorta, creating a false lumen, which can spread in either direc-
tion. Most of the aortic dissections begin at the ascending aorta, 
5%–10% being at the arch and 30%–35% being in the first part 
of the descending aorta. There are two main classifications: the 
DeBakey and Stanford classification. For the DeBakey type I 
and II (Stanford A), surgery is usually indicated to prevent 
aortic rupture and aortic insufficiency. DeBakey III (Stanford 
B) is usually managed medically (see Table 4.2).
A functional aortic regurgitation can result from the 
dilation of the annulus or root. A pericardial effusion may 
accompany the dissection. As the intima shears off and cre-
ates a false luminal passage vital organs may be compro-
mised by ischemia. Although ECG and chest x-ray may be 
abnormal, they may also appear normal and may be difficult 
to interpret. CT scan, in contrast, has 90% sensitivity and 
85% specificity. MRI provides high-quality images, but may 
be time prohibitive in the patient who is hemodynamically 
unstable. TEE offers rapid visualization of the ascending 
and descending aorta but requires a skilled operator and the 
descending aorta cannot be easily visualized. Angiography is 
invasive and may fail to show entry and reentry sites.
The key for the ICU practitioner is to control the blood 
pressure and thereby reduce shear forces against the wall 
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and further dissection. Blood pressure targets should be 
adjusted based on evidence of perfusion to other vital organs 
(i.e., renal, cerebral). The treatment of choice is to use a com-
bination therapy of beta-blocker and vasodilator, such as 
labetalol and sodium nitroprusside, respectively. The use of 
invasive blood pressure monitoring is essential for appropri-
ate management.
 Coronary Artery Bypass 
CABG is very effective in reducing or eliminating symptoms 
in patients with angina pectoris and in certain subgroups, 
CABG improves prognosis. For stable patients with pre-
served LV function, the operative mortality risk is <1% and 
even for patients with impaired LV dysfunction, there is still 
a survival advantage of CABG over medical therapy in select 
populations. LV dysfunction increases the operative risk 
and the risk of difficulty of separating the patient from the 
bypass machine. Since PTCA has become more prevalent, 
the patients assigned for open CABG procedures are usually 
older, sicker, and have more extensive disease. Other factors 
that can influence the decision regarding CABG include the 
size of the coronary vessels and the nature of diffuse or distal 
coronary artery disease, which may reduce the effectiveness
of grafts. Some short-term risk factors that influence mortal-
ity following a CABG include age, COPD, peripheral vascular 
disease, elevated creatinine, prior heart surgery, prior MI, 
urgency, NYHA class III or IV, and low ejection fraction. Con-
duits used for the bypass include the saphenous veins, the 
internal mammary arteries, and the radial artery from the 
nondominant hand. The left internal mammary artery is com-
Site of Ascending &  Confi ned to Ascending
Involvement Descending the Ascending Aorta not 
 Aorta Involved Aorta Involved
DeBakey I II III
Stanford A A B
Classifi cation of Aortic Dissections4.2
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monly used for a direct bypass to the left anterior descending 
artery. The arterial grafts, particularly the left and right inter-
nal mammary arteries have the longest patency rates.
CABG surgery is often considered for patients with unac-
ceptable angina pectori despite medical therapy, patients with 
left main coronary artery disease, and triple vessel disease. 
CABG does not however stop coronary artery disease pro-
gression. Obstruction can occur in native vessels that were not 
bypassed and in the bypassed grafts themselves. Most arterial 
grafts have a patency of 10 years, whereas the venous grafts tend 
to stay patent for only 7 years, with angina reoccurring in 50% 
of these patients. Universal interventions in maintaining graft 
patency are aspirin therapy, changes in diet, smoking cessation, 
blood pressure control, and change in sedentary life style.
Patients with obstructive coronary artery disease are 
considered for percutaneous transluminal coronary angio-
plasty. As angioplasty and stenting with drug eluding stents 
becomes more advanced, the patient population that would 
be served well increases. Drug-eluting stents are coated with 
antiproliferative drugs such as sirolimus. PTCA involves 
threading a balloon catheter into a coronary artery, position-
ing the balloon across the stenotic lesion and then inflating 
the balloon to dilate the stenosis. The procedure disrupts the 
intima, splits the atherosclerotic plaque, and often results in 
a small local dissection. Acute coronary occlusion can com-
plicate the PTCA and lead to acute myocardial infarction and 
or the need for emergency coronary bypass. The mortality 
rate associated with PTCA is about 1%. Restenosis rates vary 
dramatically and the deployment of a stent will improve the 
patency rate. The introduction of drug-eluting stents com-
pared to the initial bare metal stents have shown improved 
long-term success rates. Patients though with a left main 
lesion are not typically candidates for PTCA or stenting.
 Heart Transplant 
United Network of Organ Sharing (UNOS) is the national U.S. 
organization that is responsible for control and fair distribu-
tion of donated organs. UNOS will offer organs on the basis of 
geography, donor–recipient compatibility, and medical urgency. 
UNOS is a nonprofit, scientific, and educational organization that 
administers the nation’s only Organ Procurement and Transplan-
tation Network (OPTN). UNOS is required to collect and manage 
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data about every transplant event occurring in the United States. 
The organization facilitates the organ matching and placement 
process using specific data technology. Collectively, UNOS brings 
together medical professionals, transplant recipients, and donor 
families to develop organ transplantation policy.
The criteria for selection for heart recipients have evolved 
as the success of this procedure has improved, but the avail-
ability of donors remains limited. Candidates must have end-
stage cardiac disease with limited life expectancy and have 
exhausted conventional therapies, including pharmacologic 
and bypass surgery. The primary diagnoses that are consid-
ered criteria include ischemic and nonischemic cardiomyopa-
thy, valvular disease, congenital heart disease, and  primary
heart transplant failure. The exclusion criteria include older 
than 65 years of age, irreversible hepatic or renal failure, 
active infection, poor medication compliance,  psychological
instability, malignancy, alcohol, recreational drug abuse, obe-
sity, cerebrovascular disease, crossmatch incompatibility, and 
a pulmonary vascular resistance over 5 Woods units. The 
placement of a healthy donor heart into a patient with pulmo-
nary hypertension will rapidly fail, whereas the native heart 
with its longstanding compensation has greater ability to 
overcome pulmonary hypertension. The ACNP should restrict 
exposure to unnecessary blood transfusions that will create a 
higher percentage of panel reactive antibodies with the cross-
matched potential donor and create a greater likelihood of a 
rejection. The uncomplicated heart transplant patient with 
short ischemic time, minimal blood loss, and good function, 
with or without low-dose inotropic support, should be extu-
bated in <24 hours with a usual postoperative recovery. Chest 
tubes can be removed if the output is approximately <100 ml 
in a 24-hour period.
The new transplanted heart will have some degree of 
dysfunction, with the right ventricle usually being affected 
more than the left. This may require slightly higher filling 
pressures. Generally, a modest tachycardia is advisable as the 
ventricles tend to be stiff. This is generally achieved in several 
methods including dopamine and milrinone, and/or pacing. 
Most transplant patients need a small degree of vasopressors 
for a few days following surgery, secondary to the naturally 
occurring vasodilation. Pulmonary hypertension should be 
avoided and it is not uncommon to induce a moderate diure-
sis after the second day as these patients tend to retain fluid.
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Vigilance in the use of masks, gloves, and gowns must be 
maintained when in contact with transplant patients as the 
need for scrupulous infection control measures outweighs 
almost any other priority. Immunosuppression protocols 
vary among institutions and ongoing evaluation of regimens 
prevails at centers of excellence.
The major cause of early mortality is primary graft failure. 
Ventricular failure, predominantly left sided, may be the first 
sign. Myocardial stunning from prolonged ischemia time and 
recipient pulmonary hypertension as a result of heart failure 
may cause the donor heart to fail. Considering temporary 
extracorporeal membrane oxygenation (ECMO) may supply 
time for the donor heart to adapt.
Despite all acceptable therapy, the possibility of rejection 
must always remain a consideration with any change in sta-
tus. Hyperacute rejection is an uncommon cause of primary 
graft failure. Human leukocyte antigen (HLA) antibodies are 
increased with higher amounts of transfusion exposure, in 
particular platelets. Leukocyte depleted transfusions are 
recommended for the recipient if blood is needed. Further-
more, with a high percentage of panel reactive antibodies, 
preoperative plasmapharesis should be a consideration to 
prevent postoperative complications.
Other early complications for the heart transplant patient 
include tricuspid regurgitation (TR), respiratory failure and 
bleeding, renal failure with fluid overload, and gastrointesti-
nal problems. Complications that occur after the first 5 days 
include acute rejection, infection, systemic embolism, and 
coronary artery disease, secondary to the new-onset rejec-
tion. The insidious path of acute rejections is marked by 
arrhythmias, hypotension, and ventricular dysfunction best 
seen with an echocardiogram. Planned biopsy at or near the 
10th day should be a routine. Coronary artery disease may be 
caused by rejection and this is manifested by chronic rejec-
tion, wherein a perfectly healthy donated heart will develop 
rapid coronary occlusion.
Use of Devices/Ventricular Assist Device
Pharmacologic management described earlier in this chap-
ter have improved quality of life for patients with failing 
hearts. However, even with the most aggressive treatments, 
130 Critical Care
some still require surgical intervention. Currently, there are 
several options, which include reduction ventriculoplasty, 
transmyocardial laser revascularization, and the insertion of 
partial or total heart assist devices.
Consideration of an assist device should not be taken light-
ly; one must first consider the limitations of a device and the 
anticipated benefit. The HeartMate left ventricular assist device 
(LVAD) is the only device labeled as destination therapy because 
it is designed to be implanted in the patient with external drive 
lines. What is important for the practitioner to understand is 
the general types of devices available, the anatomic placement, 
and recognition of problems in the acute care setting.
The physiology of these devices is to facilitate the patient’s 
ability to augment or, if need be, totally rely on these devices 
for left, right, or biventricular output. These devices were 
first developed as an outcome of the initial cardiopulmonary 
bypass (CPB) machines when it was recognized that some 
patients were not able to be separated. The initial thought 
was that these devices would be used for short-term rest and 
recovery to eventually wean and separate a patient from the 
CPB. Initial attempts throughout the 1960s were less than 
successful. Eventually in 1980, the National Institute for 
Health (NIH) funded research that supported a long-term 
LV assist device.
The basic mechanisms of all the devices are similar. The 
devices remove blood proximal to the diseased ventricle 
bypass the ventricular system and return the blood distally. 
The two main mechanisms are pulsatile flow devices and 
continuous flow devices. The later includes the axial flow 
pumps and the centrifugal flow pumps.
 Indications 
The indications for the insertion of the ventricular assist 
device are increasing and evolving. However, the three major 
categories are a bridge to destination therapy, a bridge to 
transplant, or in rare occasion, a bridge to recovery. With 
experience, timing, device selection, and most importantly, 
appropriate patient selection, there have been improved 
outcomes. The indication may include cardiogenic shock or 
decompensated chronic heart failure as a bridge to recovery. 
There are also a few well-studied protocols for use of the 
LVAD in pulmonary transplant failure and ARDS.
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The use of the LVAD as a bridge to recovery is most prom-
ising in the patient with fulminate acute myocarditis, which 
can cause heart failure; unfortunately, this patient population 
is very limited. Acute cardiogenic shock is more common and 
the data reflects that those requiring LVAD in cardiogenic 
shock as intraoperative rescue procedure, postoperative, or in 
the case of acute myocardial infarction have poor outcomes. 
The bridge to transplant population have more positive data, 
although the lack of available suitable donors severely restricts 
this indication. The insertion of a VAD in a patient already on 
the transplant list offers more hope. These patients represent 
a more robust recipient and improved outcomes. The bridge to 
recovery population comprises the following three subgroups: 
postoperative patients, individuals with shock following myo-
cardial infarction, and those with acute myocarditis; the last 
group having the best prognosis.
 Complications 
Although positive results have been seen with the institution 
of the VAD, there are many complications associated with 
their placement. Early complications include hypoxemia, air 
embolism, hemorrhage, and RV heart failure. The hypoxemia 
occurs secondary to missed atrial defects that can cause a 
right to left shunt. Air embolism, like hypoxemia, can be the 
result of a patent foramen ovale (PFO). Hemorrhage may 
obviously occur with the simple placement of the device as 
extensive surgery may be required for proper orientation. 
Compounding this is the fact that most transplant surgeons 
are reluctant to transfuse potential recipients for fear of 
inducing HLA alloimmunization. Furthermore, most patients 
are already debilitated and recovery from such a procedure 
may prove an insurmountable hurdle. While most devices are 
placed for left heart failure, one must be cognizant that the 
right heart may be in failure and not sufficient to fill the left 
side and a subsequent biventricular device may be inserted.
Late complications include infection, thromboembolism, 
and primary device failure. Infection may be the primary 
cause. Once a device is infected, there are few options. Predis-
posing factors include multiple central lines, the drive lines, 
the surgically created pockets for devices, poor nutrition, and 
the need for an ICU environment despite the exposure to 
many pathogens. The incidence of thromboembolism may 
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have improved with the advent of better materials, surfaces, 
and protocols. Lastly, there is the possibility of the devastat-
ing primary device failure.
 Device Selection 
Device selection tends to be based on several factors, includ-
ing the need for single or biventricular assistance, size of 
the patient, and duration of the expected support. Generally, 
however, the comfort of the surgeon with a particular device 
seems to be the most pressing factor, particularly in the acute 
need as in postoperative failure.
The devices currently available can be divided by sev-
eral characteristics including implantability, size, pulsatil-
ity, and need for anticoagulation. Ideally, a device should 
be small enough to be totally implanted, allowing mobility. 
The device should not need any anticoagulation, as most 
devices only require antiplatelet therapy, be resistant to 
infection, be failure free, and should have enough energy 
to be mobile for a prolonged period. No device meets all 
these criteria at this time.
The ABIOMED® AB5000 Ventricle is a short-term, exter-
nal device that is used to support the heart. This device can 
be used as a bridge to a longer term support device, or as 
a cardiac assist device to allow time for the heart to rest 
after surgery or other reversible heart dysfunction. The 
ABIOMED® AB5000 Ventricle is approved by the FDA for use 
as a bridge to recovery for patients with potentially revers-
ible heart failure. Patients on this device must remain in the 
hospital during the support phase. This device can provide 
right, left, or biventricular cardiac support.
The Thoratec HeartMate® XVE is an implantable LVAD 
that can be used as a bridge to heart transplantation or as des-
tination therapy. The pump is implanted in the upper abdomen 
and is attached to the heart. This pulsatile pump assists the left 
ventricle. The pump is monitored and controlled by an external
controller that is approximately the size of an adult’s hand. 
The patient carries the controller in a fanny pack. Patients 
on this device are discharged from the hospital and can go 
back to work or school and resume most daily life activi-
ties. The device is powered by an AC unit or by batteries. 
The device is approved by the FDA as a bridge to heart 
transplantation.
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The HeartMate® II is a new technology that utilizes rotor 
flow to propel blood from the left ventricle to the aorta. This 
device is used primarily as a LVAD and is a bridge to heart 
transplantation. The pump is approximately the size of a large 
candy bar and can be placed in smaller patients because of 
its smaller size. This device is an internal pump and is moni-
tored by an external controller that is approximately the size 
of an adult’s hand. Like the Heartmate XVE, the patient 
carries the controller in a fanny pack. The patient on this 
device is discharged from the hospital and can go back to 
work or school and resume most daily life activities. The 
device is powered by an AC unit or by batteries.
The Thoratec® IVAD can be used for left, right, or biventric-
ular support. This device is primarily used as a bridge to heart 
transplantation. The pump can be used internally (IVAD) or 
externally (PVAD). Patients can be discharged on both devices 
and may resume most normal daily activities. While at home, 
the pumps are operated using a portable compressor system 
that is about the size of a piece of carry-on luggage.
The patient with a VAD should be monitored closely with 
regard to progress, including improved homeostasis, enhanced 
renal function, liver function, and, weight gain. Long-term 
complications may include clot formation, thrombi, infection, 
and to some degree, psychological disturbances.
When considering the use of a VAD in a patient, a thor-
ough evaluation of comorbidities must be undertaken. Those 
with chronic irreversible end-organ disease states are poor 
candidates for assist devices. Other situations that would be 
a poor choice would include the use of a VAD for a bridge to 
transplant with little or no hope of succeeding on the trans-
plant list, destination therapy with a poor prognosis, and 
certainly those who would be bridge to recovery, but have 
little hope in that regard. In addition, there are several addi-
tional relative contraindications for a VAD such as severe 
pulmonary dysfunction, excessive weight, and malignancy. 
Irreversible neurologic injury and overwhelming infection 
are absolute contraindications.
Outcomes of these devices have improved over the years 
with good results for destination therapy, bridge to recovery, 
and bridge to transplant. There are more devices and modi-
fications in future development to make these options more 
readily available. The ultimate goal might still be considered 
the totally implantable, artificial heart. Cardio West does have 
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one approved by the FDA as a bridge to transplant; therefore, 
it is probably only a matter of time and engineering that one 
is given approval as destination therapy.
 Use of Devices/Intraortic Balloon Pump 
Intraaortic balloon counterpulsation (IABP) is a short-term 
support for patients with severe myocardial ischemia or LV 
systolic failure. The IABP device itself is a long catheter with 
two lumens. One lumen is used for the flow of the helium, 
whereas the second lumen is used for the transducing intra-
aortic pressure. The catheter is connected to an external 
console that controls the timing of the balloon inflation and 
deflation, including a display for the ECG, arterial blood pres-
sure, and balloon pressures. The balloon is fashioned as a sau-
sage shape. The underlying purpose of the device is to inflate 
at the start of diastole and to deflate at the start of systole. The 
net effect is afterload reduction via reduction of aortic end-
diastolic pressure resulting in a reduction in LV systolic wall 
tension. Secondarily, and perhaps most importantly, the infla-
tion in the diastolic phase will increase coronary perfusion.
 Extracorporeal Membrane
Oxygenation (ECMO) 
The critical element of inserting a device in the bridge to recov-
ery population is timing and perhaps more importantly the 
timing of when to discontinue therapy. With all extracorporeal 
devices, the risk benefit needs to be addressed continually and 
the risk of infection, bleeding, clotting, and costs increase with 
each hour and day. For the patient in acute shock due to the 
above categories, daily evaluation of ejection function should 
be assessed with echocardiography. Capabilities of bridging 
with these devices are for a limited time frame.
 Postcardiac Surgery Monitoring 
The key to monitoring a postoperative cardiac patient or one 
with risk factors undergoing thoracic or noncardiac surgery is 
the measurement of cardiac performance. The cardiac output 
is a reflection of preload, afterload, contractility, and heart rate. 
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Many ICUs use the preferred method of pulmonary artery 
catheter (PAC) with continuous cardiac output capabilities 
and SVO2 measurement. There has been great discussion on 
the impact of survivability and possible increased risk asso-
ciated with a PAC, although these catheters have not been 
specifically studied in postcardiac patients. New less invasive 
technologies are now emerging to estimate the cardiac output 
usually based on the Fick principle. The Fick method relates 
cardiac output to oxygen consumption and the arteriovenous 
content. The direct Fick method with the requirement of mea-
sured oxygen consumption is generally impractical. So the 
indirect Fick methods of using a normogram for consumption 
(125ml/m2) is based on body surface area. When the arterial 
oxygen is being consumed by the body and replenished by the 
lungs at an equal rate, the VO2 is the product of cardiac output 
and the O 2 concentration difference. The oxygen content from 
the systemic arterial and mixed venous (pulmonary arterial) 
is measured and the sample allows calculation of the flow rate 
(cardiac output). Under nonsteady states of oxygen consump-
tion, these calculations could be less accurate.
Other conventional invasive methods of cardiac output 
measurement include the PAC with manual cold thermodi-
lution technique (rarely used), PAC with continuous cardiac 
output and a warming coil, and TEE. There are several semi-
invasive methods available including, transpulmonary thermo-
dilution with arterial pulse contour analysis (PiCCO), lithium 
dilution curve with arterial waveform analysis (LiDCO),and
the doppler method. Noninvasive techniques include pulse 
contour analysis (FloTrac) and bioimpedance cardiography. 
Dye-dilution techniques were the first methods to be used for 
estimation of cardiac output. The Stewart–Hamilton equation 
assumes that the injection of a certain quantity indicator will 
appear and disappear and is reflective of the cardiac output. 
The dye dilution technique has been supplanted by the eas-
ier thermodilution technique. The thermodilution technique 
was developed following the introduction of the flow directed 
PAC (Swan & Ganz, 1970). While initially devised to measure 
right-sided pressures and PAD, with the addition of thermal 
indicators, it became more useful for continuous and nearly 
continuous measurement of CO. There is great debate about 
the utility and safety about PAC, however in studies that 
sought to correlate the values from the Fick equation, there 
is evidence that when the cardiac output is above 5 L/min, 
the precision of the Swan declines.
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Thermodilution technique requires a bolus of liquid into 
the proximal port of the catheter. The change in temperature 
registered at the distal thermometer is then calculates the 
area under the curve as the cardiac output and it is similar 
to dye-dilution method. Patients with shunts or TR or pulmo-
nary regurgitation (PR) early recirculation will cause inac-
curate recordings. Furthermore, rapid infusion of fluids will 
alter the effectiveness of this device. Continuous thermodilu-
tion cardiac output measurement is similar to the above cold 
bolus techniques except the catheter releases a small amount 
of heat to the distal thermostat then calculates the cardiac 
output. The correlation to the bolus method is more precise.
Lithium dilution technique has a core indictor of the dilu-
tion technique. The advantage is that it can be given through 
a peripheral catheter and measurement of the waves from 
an ion-selective electrode attached to the peripheral arte-
rial catheter. The technique is considered safe and accurate. 
The only contraindication is if the patient is already taking 
lithium. The primary utility of this technology at this time is 
to calibrate the Pulse CO monitor (LiDCO) that calculates the 
continuous cardiac output by arterial pulse wave analysis.
Doppler-based method can be used to determine cardiac 
output by measuring the blood flow velocities. Placement of 
the probe in parallel to the flow is vital as it can lead to errors. 
Several technologies take advantage of this method including 
an endotracheal tube with an ultrasound probe mounted on 
the tip as this method has inherent problems, including the 
need for the patient to be sedated and intubated. Further-
more, there are frequent discrepancies due to positioning.
 Conclusion 
The entire spectrum of diagnosis and treatment of car-
diovascular disease has undergone a dramatic shift and 
embraces an evidence-based approach. Aggressive treatment
options have proven able to mitigate damage and preemp-
tive care has decreased morbidity. The responsibility of the 
practitioner caring for these patients is to keep abreast of the 
most current therapies.
However, when we look specifically in the cardiovascular 
ICU and care of the cardiovascular patient, it is important to 
remain keenly attentive to the basics. The care of the cardiotho-
racic patient employs, above all, the tenets of excellent ICU care: 
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attention to cardiac function, EKG and rhythm identification and 
intervention hemodynamics, fluid and electrolyte balance, and 
thoughtful therapies. Vigilance, attention to detail, and judicious 
critical care are essential to the cardiac patient in critical care.
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 Introduction: Initial Evaluation 
of the Neurologically Impaired Patient 
The most critical portion of neuroscience care is the neuro-
logic examination. When the practitioner fully understands 
the physiology behind the examination, a lesion can be local-
ized by clinical findings. This chapter is designed to assist the 
acute care nurse practitioner to obtain a detailed, yet effi-
cient examination. In addition, this chapter will review the 
main tests used to diagnose neurologic emergencies in the 
neurocritical care setting. 
Neurological 
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 Physical Examination 
Anatomy Review. When performing neurological assessment, 
it is important to understand basic anatomy and then use that 
anatomy to correlate the examination. The lobes of the brain 
are referred to as the cerebral cortex and include the frontal, 
parietal, temporal, and occipital lobes (Hickey, 2002). The key 
functions of the frontal lobes are the awareness portion of 
the level of consciousness, intelligence, judgment, attention 
span, memory, voluntary motor, and motor/ expressive speech 
(Broca area). The parietal lobes are primarily responsible for 
sensory functions including the ability to identify objects by 
touch, distinguish right from left, and have awareness of one’s 
body position in space (proprioception). Sensory/ receptive 
speech is a function of both the parietal and temporal lobes 
(Wernicke area). The primary auditory receptive areas are 
located in the temporal lobes, as is smell interpretation and 
long-term memory. Occipital lobes contain the primary visual 
cortex and interpret visual cues. The cerebellum is responsi-
ble for coordination (Gelb, 2000). Cranial nerves III through 
XII have their origins in the brainstem. The III and IV cranial 
nerves originate in the midbrain, V through VII in the pons, 
and the medulla contains the origins of cranial IX through 
XII. Cranial nerves I and II are located in the cerebral cortex 
(Seidel, Ball, Dains, & Benedict, 2006). The reticular forma-
tion, which is responsible for wakefulness and arousability 
portion of the level of consciousness, also has its origins in 
the brainstem (Hickey). By performing the examination from 
cortex to brainstem in an orderly fashion, the examiner will 
obtain the main components of the neurological assessment 
in a concise and organized fashion. This reduces the chances 
of missing any key component of the examination (Gelb). 
Any neurological examination should include assessment 
of level of consciousness, memory, language, motor strength, 
sensory, coordination, cranial nerves, and reflexes. 
Level of Consciousness/Memory/Language. When assessing 
the level of consciousness, the examiner gathers informa-
tion regarding memory and language. Initially, level of con-
sciousness assessment begins with three basic orientation 
questions of person, place, and time (Seidel, Ball, Dains, & 
Benedict, 2006). The examiner can then ask the patient if 
they know why they are in the hospital and if they know their 
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providers name, thereby assessing short-term memory. A 
long-term memory question that the examiner can validate 
easily is asking the patient for his date of birth. While the 
patient is providing the answers to the examiner’s questions, 
the examiner should be listening to the patient’s speech, noting 
the clarity, appropriateness, and presence of any word find-
ing difficulties. To further evaluate language, the examiner 
should ask the patient to repeat phrases such as “No ifs, ands, 
or buts” and “It’s a bright and sunny day in (insert city).” It 
is also critical to ask the patient to identify objects and is 
also critical to note his or her difficulty or inability to name 
them. Comprehension can be assessed by asking the patient 
to perform a task such as “Take your left hand and touch your 
right ear,” ensuring that no visual cues are used (Gelb, 2000). 
A helpful tool that is utilized in addition to the earlier 
mentioned tests to assess consciousness is the Glasgow Coma 
Scale (GCS) (Table 5.1). This scale is divided into three parts 
and assesses best motor, verbal, and eye opening responses. 
The highest score a patient can obtain is a 15 and the lowest 
is a 3. It is an excellent way to trend the neurologic examina-
tion (Hickey, 2002). 
Motor. The motor examination is simply performed by 
assessing the individual muscle groups and rating them 
with the motor scale as noted in Table 5.2. The strength of 
each muscle group should be documented with the result 
being expressed as a fraction, using 5 for the denominator 
(Seidel, Ball, Dains & Benedict, 2002). For example, a person 
with active movement against gravity in a particular extrem-
ity should have their strength documented as 3/5 for that 
extremity. 
Sensory. There are various examinations that can be performed 
to assess gross sensory function; however, the simplest are right 
and left discrimination and proprioception or position sense 
(Goetz, 2007). Ask patients to close their eyes and to identify 
where in their body they are being touched. As the examiner, 
first touch one arm, then the other, and then both. Repeat the 
same for the lower extremities. The reason for the simultane-
ous stimulation of upper and lower extremities is to assess for 
tactile extinction, which is an indication of a hemineglect. Tac-
tile extinction is noted when the patient can feel touch in each 
individual extremity, but when touched on both, sides he or she 
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Glasgow Coma Scale
Eye Opening
Spontaneous 4
To loud voice 3
To pain 2
None 1
Verbal Response
Oriented 5
Confused, disoriented 4
Inappropriate words 3
Incomprehensible 2
Sounds 2
None
Best Motor Response
Obeys commands 6
Localizes 5
Withdraws (fl exion) 4
Abnormal fl exion 3
Abnormal extension 2
None 1
5.1 The Glasgow Coma Scale
Muscle Strength Rating
No contraction 0
Flicker or trace of contraction 1
Active movement, with gravity eliminated 2
Active movement against gravity 3
Active movement against gravity and resistance 4
Normal power 5
5.2 Rating of Muscle Strength
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can only feel only unilateral stimulation. The presence of this 
finding indicates a possible lesion in the contralateral sensory 
cortex. A more detailed sensory examination to include super-
ficial pain is warranted on any patient with spinal pathology. 
Assessing for superficial pain is done by testing the patient’s 
ability to distinguish sharp from dull throughout the various 
dermatomes from C4 through S1 (Figure 5.1). In this way, a 
deficit can be directly correlated to an anatomical location on 
the spine (Devereaux, 2007). Proprioception of both the upper 
and lower extremities can be assessed by testing joint position 
sense. This is done by holding the lateral aspects of the thumb 
5.1
Dermatomes
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or toe in a raised or lowered position and asking the patient to 
state in which direction his or her toe or thumb is pointed. 
Coordination. Coordination in the critical care arena is tested 
via assessment of rapid alternating finger-to-nose and heel- 
to-shin movements (Hickey, 2002). Assess rapid alternating 
movements by asking the patient to touch the thumb of one 
hand to each finger on the same hand, starting with the index 
finger and ending with the little finger and back. Assess this 
on both hands. Next, ask the patient to alternately touch his 
or her own nose and then touch the examiner’s finger with 
the index finger of one hand. Have him or her repeat this 
with the other hand. Finally, have the patient run the heel of 
one foot down the shin of the other leg (Seidel, Ball, Dains, 
& Benedict, 2006). Again, this should be performed on both 
lower extremities. 
Cranial Nerves. The assessment of the cranial nerves does 
not need to be an arduous task. In an inpatient setting,  cranial
nerve I (olfactory nerve) is not tested. Table 5.3 lists the basic 
examination for remaining cranial nerves II to XII. 
Reflexes. Deep tendon reflexes (DTRs) should be a part of 
any initial neurological assessment and include the biceps, 
triceps, brachioradial, patellar, and Achilles (Seidel, Ball, 
Dains, & Benedict, 2006). See Table 5.4 for a rating scale of 
DTRs. Assess for ankle clonus by briskly dorsiflexing the 
patient’s foot with the hand and noting any rhythmic, oscil-
lating movements of the foot against the examiner’s hand. 
The plantar reflex is assessed by stroking the lateral aspect 
of the foot from the heel to the ball then curving across the 
ball of the foot to the medial side (Goldberg, 2007). A normal 
plantar reflex is plantar flexion of all toes. An “up going” or 
dorsiflexion of the great toe with or without fanning of the 
other toes is an abnormal response, which is indicative of 
motor tract dysfunction. 
Unconscious Patient. The assessment of a patient who is not 
following commands and unable to participate in a full neu-
rological assessment is obtained by utilizing the GCS and 
assessing a core of cranial nerves. Assessing the pupils (CN 
II and CN III), corneas, (CN V and CN VII) and cough and gag 
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Nerve Name Test
II Optic  Visual acuity—have patient read some-
 thing (id badge) and ask if it is clear
   Visual fi elds—assess via confrontation
 of both eyes with examiner  covering
 his eye and patient covering the
 opposite eye
   Pupils—sensory portion of pupillary
 response
III Oculomotor  Pupils—motor portion of pupillary
 response
  Eyelid—assess if keeps eyelid open
   Extraocular movements—up, medially,
 and down and out
III, IV, VI  Extraocular movements
 (EOMs)
III Oculomotor EOMs—up, medially, and down and out
IV Trochlear EOMs—down and in
VI Abducens EOMs—lateral gaze
V Trigeminal  Facial sensation: ophthalmic,
 maxillary, and mandibular branches
  Facial motor: clenching teeth
   Corneal refl ex on non-awake patient:
 sensory portion
VII Facial  Facial motor: assess symmetry 
 of smile
  Eyelid- ability to close eye tight
   Corneal refl ex on non-awake patient:
 motor portion
VIII Acoustic Hearing
IX Glossopharyngeal  Cough, gag, swallow and palate
 symmetry
X Vagus  Cough, gag, swallow and palate
 symmetry
XI Spinal Accessory  Strength of shoulder shrug and turning
 face against examiner’s hand
XII Hypoglossal Tongue—ability to stick out straight
5.3 The Cranial Nerves and Their Functions
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(CN IX and CN X) will give the examiner a critical snapshot 
of brainstem function (Lower, 2002). 
 Imaging 
The main imaging studies that are utilized in the neurocritical 
care population are magnetic resonance imaging (MRI) with 
and without gadolinium and computerized axial tomography 
(CT) with and without contrast. Table 5.5 lists the available 
modalities and the indications for each. In general, for an 
acute process such as trauma, stroke, severe headache, and 
mental status change, a noncontrast head CT is the first choice. 
If the findings suggest tumor or abscess, a contrast head CT 
should be considered. (Gunderman, 2006). Any question of 
acute spinal cord compression should be evaluated with an 
MRI of the spine. MRI of the brain is usually obtained for a 
process whose onset is >48 hours (Gunderman). 
Other diagnostic tests that are utilized in the neurocriti-
cal care environment are the electroencephalogram (EEG) 
and electromyography (EMG). An EEG is used primarily to 
diagnose seizures and to assist with the differential diagnosis 
of acute encephalopathy (Praline et al., 2007). EMG is simply 
the electrophysiologic assessment of the neuromuscular sys-
tem. It includes a needle electromyographic study and nerve 
conduction studies (NCS) (Warrell, Cox, Firth, & Benz, 2003). 
EMG and NCS both aid in the differential diagnosis of disor-
ders of the peripheral neuromuscular system such as Guil-
lain-Barré syndrome (GBS) and myasthenia gravis (MG). 
Grade DTR response
 0  No response
 1+ Present but sluggish or diminished
 2+ Normal amplitude
 3+ Increased in amplitude with spread to an adjacent site
 4+  Increased in amplitude with spread to an adjacent site with
  intermittent clonus
5.4 Rating of Deep Tendon Refl exes (DTRs)
Modality Indications/Conditions
BRAIN
CT: No Acute change in mental status: Hemorrhage/Edema/
 contrast Mass effect/Herniation/Hydrocephalus
  Acute trauma: Skull fractures/Hemorrhage/Contusions/
 Mass effect/Herniation
 Acute stroke: Ischemia/Hemorrhage/Hydrocephalus
  Acute severe headache: Hemorrhage 
 (Subarachnoid/Intracerebral/Intraventricular)
CT: Contrast Mass: tumor/abscess
 Staging of cancers known to have brain metastasis
MRI: No Infl ammatory conditions; meningitis, encephalitis
 Contrast Posterior fossa lesions of all types
 Subacute stroke
  Subacute trauma: Diffuse axonal injury, subdural hematoma
 at skull base
 Anoxic brain injury
 Epilepsy
MRI: Contrast Mass: tumor/abscess
MR angiogram Ischemic stroke: assess vessels
 (MRA)  Hemorrhagic stroke: vascular abnormalities (arteriovenous
 malformations, aneurysms)
CT angiogram Ischemic stroke: carotid arteries (neck CT) for occlusion
 (CTA)  or dissection/intracranial vascular occlusions
  Hemorrhagic stroke: vascular abnormalities
 (arteriovenous malformations, aneurysms)
SPINE
Non-contrast Acute Trauma: fractures/ligamentous injury (MRI superior)
 CT Lumbar disc disease
 Hemorrhage
 Postoperative for suspected hardware displacement
Contrast CT Spinal abscess
CT Myelogram When MRI contraindicated or will cause hardware artifact
 Vascular malformations of the spinal cord
MRI: No Acute trauma; fi rst choice to assess ligamentous injury and
 contrast   cord compression
  Rapidly progressive paraparesis/paraplegia: cord compression;
 edema; tumor
 Cervical and thoracic disc disease
5.5 Neuroimaging for Acute Neurologic Conditions
Adapted from Grainger, Allison & Dixon, 2008; Castillo, 2006; Gunderman, 2006.
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 Change in Mental Status 
 Introduction 
Changes in mental status are daily occurrences in the acute 
care setting. It is important that providers are aware of the 
multitude of conditions that lead to altered mental status 
and the proper workup to rule out those conditions. Primary 
neurologic causes of mental status changes such as seizures, 
hemorrhages, ischemia, trauma, and central nervous system 
infections are discussed in other sections of this chapter. This 
segment is devoted to reviewing the non-neurologic causes of 
the acute confusional states of delirium and encephalopathy. 
 Clinical Manifestations/Symptoms 
The terminology used to describe changes in mental status can 
be quite confusing. Table 5.6 lists the various types and defini-
tions of altered behavior that patients in the acute care setting 
may exhibit. It should be noted that dementia is not an acute con-
fusional state but rather a progressive disorder that, if present, is 
likely a part of the patient’s medical history (Caselli, 2003). 
Term Defi nition
Acute confusional Presents with impaired attention, logical thinking,
 state  and memory with incoherent conversation
Delirium  Type of acute confusional state characterized by agitation,
 autonomic disturbances (tachycardia, hypertension,
 diaphoresis), hallucinations, and restlessness.
Encephalopathy  Type of acute confusional state that is accompanied by a
 change in level of consciousness from drowsiness to
 stupor or coma
Dementia  An acquired and often progressive impairment of memory
 and at least one other cognitive function without alterations
 in level of consciousness or underlying psychiatric illness
5.6 Altered Mental Status Terminology
Adapted from Roper & Brown, 2005.
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 Pathophysiology 
The causes of non-neurologic changes in mental status as 
well as the proper diagnostic tests to rule out the individual 
causes are listed in Table 5.7. The etiologies are divided into 
toxic, metabolic, and systemic. 
Possible Cause Findings/Diagnostic Tests
  TOXIC
Prescription Medications  Review medication list for interactions or CNS
 depressant side effects
Alcohol intoxication Toxicology screen of blood and urine
 or withdrawal
Illicit drugs  Toxicology screen of blood and urine
Poisons
■ Ethylene glycol —  Fluorescent urine under UV lamp, osmolar gap
 >10, metabolic acidosis
■  Methanol —  Hyperemic optic disc, osmolar gap >10,
 metabolic acidosis
■  Insecticides —  Cholinergic symptoms: DUMBBELS
 (Diarrhea, Urination, Miosis, Bradycardia, 
 Bronchospasm, Emesis, Lacrimation, Salivation)
■  Carbon monoxide —  Carboxyhemoglobin levels (Stone, 2008)
Systemic infections/Sepsis —  Complete blood count with differential
 —  Culture and sensitivity blood, urine and sputum
 —  Urinalysis
 —  Chest x-ray
  METABOLIC
Electrolytes: high or low Electrolyte studies
■  Sodium
■  Calcium
■  Magnesium
■  Phosphate
Hypercapnia Arterial blood gas
Hypoxemia Arterial blood gas
5.7 Common Causes of Mental Status Changes in the Acute Care Setting
(continued )
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 Diagnostic Criteria 
When a patient presents with a change in mental status, it is key 
to remember the ABCs. If there is any question of oxygenation 
or ventilation status, an arterial blood gas should be performed 
(Stone & Humphries, 2008). If a noninfectious neurologic cause 
has been ruled out via a noncontrast head CT and EEG, the 
Possible Cause Findings/Diagnostic Tests
Hyperglycemia Blood glucose
 or Hypoglycemia
Hyperthyroid Thyroid function tests
 or Hypothyroid
Hyperadrenalism —  Dexamethasone suppression test, 24-hour
 urine “free” cortisol level
Hypoadrenalism —  ACTH stimulation test
 Nutritional
■ Wernicke’s — Classic triad of clinical fi ndings: opthalmoplegia
 encephalopathy   (usually horizontal gaze paralysis), ataxia and
 (thiamine   confusion, thiamine (B1) level, macrocytic
 defi ciency)    anemia on peripheral blood smear
■  Vitamin B12 — B12 level
defi ciency
■  Folate defi ciency —  Folate level (Aminoff, 2005)
  SYSTEMIC
Hypertensive Vital signs
 encephalopathy
Cardiac failure —  Cardiac enzymes
 —  Pro-Brain Naturetic Peptide
 —  Transthoracic echocardiogram
Liver failure —  Liver function tests
 —  Serum ammonia levels
Renal Failure —  Serum Creatinine
 —  Creatinine clearance
 —  Fractional excretion of sodium (FENa)
5.7 Common Causes of Mental Status Changes in the Acute Care Setting (continued)
Adapted from Stone & Humphries, 2008; Roper & Brown, 2005; Tintanelli et al., 2004.
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following tests should be performed: lumbar puncture, chemis-
try panel to include liver function studies, complete blood count 
with differential, and ammonia (Aminoff, Greenburg, & Simon, 
2005). If the results of those preliminary tests are inconclusive, 
then further studies as listed in Table 5.7 should be obtained. 
 Treatment 
Treatment depends on the underlying cause of the mental 
status alteration. Because many of the causes of the change 
in mental status are life-threatening, prompt recognition and 
appropriate diagnostic workup are critical in order for the 
proper treatment to be initiated. 
 Prognosis and Outcomes 
Patients with delirium have a 1-month mortality rate of 14% 
and a 6-month mortality rate of 22% (McAvay et al., 2006). This 
is partially related to patients having concomitant dementia 
as well as significant comorbid diseases. The prognosis and 
outcome for patients with encephalopathy are highly depen-
dent on the underlying cause, the expeditious nature of iden-
tifying, and treating the cause as well as comorbidities. 
 Cerebral Edema and Intracranial 
Hypertension
 Definition and Types of Cerebral Edema 
Cerebral edema, simply defined, is an increase in the nor-
mal brain water content of approximately 80%. It is usually a 
response to a primary brain insult, which includes traumatic 
brain injury (TBI), subarachnoid hemorrhage (SAH), central 
nervous system (CNS) infection, and ischemic and hemor-
rhagic strokes (Raslan & Bhardwaj, 2007). Cerebral edema 
has traditionally been classified into two major subtypes: 
cytotoxic and vasogenic. Cytotoxic brain edema is character-
ized by sustained intracellular water accumulation involving 
both astrocytes and neurons, which occurs independently 
from the blood–brain barrier (BBB) integrity (Unterberg, 
Stover, Kress, & Kiening, 2004). The most common cytotoxic 
edema occurs as the result of cerebral ischemia/infarction. 
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This edema type is conventionally thought to be resistant to 
any known medical treatment. Vasogenic edema is defined as 
fluid originating from blood vessels that accumulates around 
cells (Marmarou, 2007). Vasogenic edema that results from 
the breakdown of the BBB because of increased vascular per-
meability, as commonly encountered in TBI, neoplasms, and 
inflammatory conditions, predominately affects the white 
matter. This edema subtype is responsive to steroid adminis-
tration (in the setting of neoplasm) and osmotherapy (Raslan 
& Bhardwaj). Most brain insults involve a combination of 
these fundamental subtypes of edema, although one can 
predominate depending on the type and duration of injury. 
Cytotoxic and vasogenic edema are greatest between 24 and 
72 hours after the initial insult. (Marmarou, 2007). Most cases 
of brain injury that results in elevated intracranial pressure 
begin as focal cerebral edema (Raslan & Bhardwaj). 
 Cerebral Dynamics 
The Monro-Kellie doctrine provides the framework for 
reviewing physiology and treatments for elevation in intra-
cranial pressure (ICP). It states that the intracranial compart-
ment is a rigid container and consists of three components: 
brain tissue (80%), blood (10%), and cerebrospinal fluid (CSF) 
(10%). Under normal physiologic conditions, these compo-
nents are balanced in a state of dynamic equilibrium. When 
an increase occurs in the relative volume of one component, 
such as brain tissue, the volume of one or more of the other 
components decreases to maintain a normal ICP (Arbour, 
2004). Once the compensatory mechanisms are exhausted, 
even a subtle increase in one component may result in large 
increases in ICP. This phenomenon is referred to as a loss of 
intracranial compliance. 
In adults, normal ICP range is 5–15 mmHg. Intracranial 
hypertension (HTN) is defined as ICP >20 mmHg (Rangel-
Castillo & Robertson, 2007). Sustained increases in ICP are 
of great importance to the practitioner because intracranial 
hypertension decreases cerebral perfusion, which leads to 
ischemia, infarction, and ultimately, death. The brain requires 
50–55 ml of blood per 100 g of brain tissue to maintain a nor-
mal metabolic state. Cerebral perfusion pressure (CPP) is an 
approximation of global cerebral blood flow (Arbour, 2004). 
CPP is equal to the mean arterial pressure (MAP) minus 
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5.2
Cerebral Autoregulation
The solid line represents normal cerebral autoregulation between a CPP of 50 and 
150 mmHg. The dotted line represents how in an injured brain, how CPP can be 
passively pressure dependent.
the ICP. As a result, CPP (and thus cerebral perfusion) can 
be reduced from an increase in ICP, a decrease in blood 
pressure or a combination of both factors. Through a regula-
tory process called cerebral autoregulation, the brain is able 
to maintain a normal cerebral blood flow (CBF) with CPP 
ranging from 50–150 mmHg. If CPP falls below 50 mmHg, 
the brain may not be able to compensate adequately and 
CBF will passively follow changes in CPP. In addition, after 
a brain insult, cerebral autoregulation may be absent or 
impaired. As a result, even with a normal CPP, CBF will pas-
sively follow changes in CPP (Figure 5.2) (Rangel-Castillo 
& Robertson). 
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 Increased ICP 
Elevation in ICP beyond 20 mmHg for an extended period 
of time can rapidly lead to brain damage or death through 
the following two principal mechanisms: (a) global  hypoxic–
ischemic injury caused by a reduction in CPP and (b) 
mechanical compression, distortion, and herniation of brain 
tissue (Mayer, Coplin, & Raps, 1999). Each of these mecha-
nisms represents a means of secondary brain injury. The pri-
mary injury represents the initial damage to the brain such 
as brain tumor, intracranial hemorrhage (ICH), ischemic 
stroke, and TBI. The detrimental sequelae that follows, any-
where from hours to days post injury, is known as secondary 
brain injury. There are intracranial as well as extracranial 
processes, which lead to secondary brain injury. Intracranial 
processes include cerebral edema, hydrocephalus, increased 
ICP, and cerebral herniation. Extracranial processes that 
promote secondary brain injury include airway obstruction, 
hypoxia, hypercapnia, hypertension or hypotension, hyper-
pyrexia, and seizures. 
Neurologic Examination. An accurate assessment of a patient 
with a neurologic injury is challenging from the onset and 
with the additional complications of cerebral edema and 
subsequent intracranial HTN, it becomes a challenging 
endeavor. In terms of physical examination, the neurologic 
indicators for intracranial HTN are varied, not necessarily 
found in all patients, and defined as early and late signs. 
Early signs of increased ICP include decreased level of con-
sciousness (LOC), confusion, lethargy, agitation, changes 
in mental status, headache, seizures, unequal or sluggish 
pupillary responses, hippus, and cranial nerve defects—CN 
III paresis (difficulty with upward gaze) and CN VI pare-
sis (difficulty with looking outward, seizures, and sensory 
changes).  Late signs of increased ICP include continued 
decrease in LOC, flexor/extensor posturing, headache, vital 
sign variation (Cushing triad—widening pulse pressure, bra-
dycardia, respiratory variation), dilated fixed pupil(s), vomit-
ing (without nausea), coma, and loss of protective reflexes—
cough, gag, and corneal reflexes. Because of the inconsistency 
at which these signs present themselves, the only real way to 
accurately assess ICP is to insert an ICP monitor. 
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Herniation Syndromes. When elevations of ICP are severe 
and sustained, there is risk for herniation, which is defined 
as abnormal protrusion of an organ or other body structure 
through a defect or natural opening in a covering membrane, 
muscle, or bone (Hickey, 2002). In general, cerebral hernia-
tion syndromes are classified into two major types: supra-
tentorial and infratentorial. Supratentorial herniations occur 
above the meningeal layer of the tentorium cerebelli and 
include central, uncal, and subfalcine herniation. Infraten-
torial herniation occurs below the tentorium and includes 
tonsillar herniation (Hickey). See Table 5.8 and Figure 5.3 on 
page 157 for a review of the herniation syndromes. 
ICP Monitoring Techniques. ICP cannot be reliably estimated 
from any specific clinical feature or CT finding; it must be 
directly measured. The decision as to when to utilize an ICP 
monitor has only been specifically outlined in the TBI litera-
ture; however, it is used for various brain injuries. In general, 
a patient is suspected to be at risk for increased ICP if a CT 
shows cerebral edema or intracranial mass effect (midline 
shift or effacement of basal cisterns) as well as having rat-
ing of <8 on the Glasgow Coma scale (Arbour, 2004). Several 
methods, which include intraventricular catheter (external 
ventricular drain [EVD] and ventriculostomy), subarach-
noid bolt, subdural/epidural catheter, and intraparenchymal 
insertion of a fiber-optic transducer-tipped catheter, are used 
to monitor ICP (Figure 5.4). 
The intraventricular catheter is currently the standard 
for ICP measurement (Arbour, 2004). It is usually inserted 
into the nondominant ventricle and is attached to an external 
fluid-filled drainage system where pressure is transduced 
using the foramen of Munroe (external auditory meatus) as 
the reference point. This system allows accurate, continuous 
ICP monitoring as well as the ability to drain and sample CSF 
and to evaluate cerebral compliance. The main disadvantage 
to the intraventricular catheter is infection, but it may also 
become obstructed by a clot or brain matter and needs to be 
recalibrated often. The subarachnoid bolt (SAB) is another 
fluid-filled system. It is inserted through a burr hole, which 
perforates the dura and comes in contact with the subarach-
noid space. The bolt, which is primed with preservative free 
saline, transduces pressure through the external system. The 
main advantage of the SAB is that it is easily placed and has 
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 Anatomical Changes Signs of Herniation
Supratentorial
Cingulate/ —Cingulate gyrus is forced Contralateral lower
Subfalcine  under the falx cerebri,  extremity weakness
  displacing it toward the
  opposite side
Central —Downward displacement of —Stupor to coma
  one or both cerebral —Gradual loss of vertical
  hemispheres  gaze
  —Contralateral hemiplegia
  —Bilateral small reactive
   pupils progressing to
   dilated & fi xed
  —Rigidity developing into
   fl exor/extensor posturing
  —Elevated ICP
  —Cushing’s triad
Uncal —Herniation of mesial —Decreased LOC
  temporal lobe, uncus —Ipsilateral papillary dilation
  and hippocampal gyrus —Contralateral hemiparesis
  through the tentorial —Decerebrate posturing
  incisura —Central neurogenic
 —Compression of  hyperventilation
  oculomotor nerve,  —Elevated ICP
  midbrain, and posterior
  cerebral artery
Infratentorial
Tonsillar —Herniation of cerebellar —Precipitous changes in
  tonsils through the  blood pressure & HR
  foramen magnum, —Small pupils
  medullary compression —Ataxic breathing
  —Disturbance of conjugate
   gaze
  —Quadraparesis
5.8 Herniation Syndromes
Adapted from Hickey (2002), Raslan & Bhardwaj (2007).
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5.3
Types of Herniation
This diagram shows four types of herniation. 1) The brain squeezes under the falx 
cerebri in cingulate herniation 2) The brainstem herniates caudally 3) The uncus 
and the hyppocampal gyrus herniate into the tentorial notch 4) The cerebellar 
tonsils herniate through the foramen magnum in tonsillar herniation
Reprinted with permission from Wikipedia.
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a low risk of infection. The main disadvantages of the SAB 
are that CSF cannot be drained, it tends to be less accurate 
at higher ICPs, frequent recalibration is required and it has 
the potential for dampened waveform because of debris 
(Arbour). The placement of subdural or epidural catheters is 
accomplished via a small-twist drill hole through the skull. 
Advantages to these monitors are that they have a low infec-
tion rate, that they are easily placed, and that they are less 
invasive. However, they are prone to malfunction, displace-
ment, and drift as well as inaccuracy caused by a wedge effect 
from the catheter and the adjacent dura (Arbour). Lastly, the 
intraparenchymal fiber-optic transducer-tipped catheter is 
placed through a bolt into the brain tissue. The benefits of 
the fiber-optic catheters are ease of insertion, maintenance 
of quality waveforms, single calibration upon insertion, mini-
mal drift, and no required transducer adjustment when there 
5.4
ICP Monitoring Devices
This fi gure depicts the anatomical placement of each of the ICP monitoring device 
(Arbour, 2004).
Ventricular
Subarachnoid
Intraparenchymal
Epidural
Subdural
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is a change in patient position. The disadvantages are that 
it provides no access for CSF drainage and that it is easily 
damaged (Arbour). 
 Treatment 
General Measures to Reduce ICP. The overall treatment goals 
for management of cerebral edema and intracranial HTN are 
to optimize CBF and prevent further ischemic injury. These 
are achieved by reducing and controlling increases in ICP 
(<20 mmHg), maintaining an adequate CPP (>60 mmHg), 
and promoting oxygenation and venous drainage as well as 
minimizing cerebral metabolic demands (Raslan & Bhard-
waj, 2007). The following general care measures help achieve 
these goals. 
To optimize venous outflow and promote displace-
ment of CSF from the intracranial compartment, finding 
the optimal neutral head position is essential for avoiding 
jugular compression. The head of bed should be maintained 
at 30 degrees and the neck should remain in neutral posi-
tion (Hickey, 2002). It is also important to avoid devices that 
impede venous outflow, so circumferential devices to secure 
endotracheal tubes should be avoided. 
Hypoxia and hypercapnia are potent cerebral vasodilators 
and should be avoided in patients with cerebral edema. It is 
recommended that any patients with GCS scores less than or 
equal to 8 or those with poor upper airway reflexes be intu-
bated preemptively for airway protection (Raslan & Bhardwaj, 
2007). Levels of PaCO 2 should be maintained in the low normal 
range (35–40 mmHg) in the absence of active increases in ICP. 
Prophylactic hyperventilation should be avoided unless one is 
actively treating increases in ICP, seeing that this may actually 
worsen ischemia, especially in the first 48 hours. Avoidance 
of hypoxemia and maintenance of PaO 2 at about 100 mmHg 
is also recommended (Raslan & Bhardwaj). Positive pressure 
ventilation can also have deleterious effects and delivery of 
positive end expiratory pressure (PEEP) at levels >10 cm H 20
should be monitored closely as it can also increase ICP. 
Systemic dehydration and the use of hypotonic solutions 
(such as dextrose-containing solutions or half-normal saline) 
should be avoided at all costs unless treating a symptomatic 
hypertonic state (Mayer et al., 1999). To maintain adequate 
CPP of >60 mmHg, euvolemia or mild hypervolemia with 
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the use of isotonic fluids (0.9% saline) should be maintained. 
Avoidance of hypotension should also be paramount and 
means should be taken to keep MAP elevated enough to 
maintain adequate CPP (>60 mmHg). In the absence of an 
available ICP monitor and known ICP value, a systolic blood 
pressure (SBP) <100 mmHg or MAP <60 mmHg should be 
actively treated with fluid and vasoactive agents if necessary. 
In terms of controlling cerebral metabolic demands, it is 
important to avoid hyperthermia, treat seizure activity, and 
control agitation. Fever increases metabolic rate by 10% to 
13% per degree Celsius and is a potent vasodilator. Fever 
should be controlled with antipyretic and cooling blankets 
(Rangel-Castillo & Robertson, 2007). Seizures increase cere-
bral metabolic demand and also counterproductively cause 
profound elevation of CBF, blood volume, and ICP even in 
patients who are sedated and paralyzed (Mayer et al., 1999). 
Routine seizure prophylaxis is controversial and is not rec-
ommended for all patients but is recommended for TBI 
patients for the 1st week. It is important to consider seizures 
(nonconvulsive status epilepticus) in comatose patients and 
to treat seizures promptly. Lastly, agitation and pain may 
significantly increase blood pressure and ICP. The goal in 
treatment of agitation is to keep the patient quiet and nearly 
motionless but with ability to be aroused (if possible) for neu-
rologic examination. The choice of agent is important with an 
optimal agent causing minimal hemodynamic changes. If the 
need be vasoactive agents may need to be added to maintain 
CPP. Some common agents used in the intensive care unit 
(ICU) for sedation include fentanyl, remifentanil, propofol, 
midazolam, and lorazepam. 
 Specific Treatment to Reduce Refractory ICP 
Controlled Hyperventilation. For patients with sustained 
elevations in ICP of >20–25 mmHg, additional measures are 
needed to control ICP. Based on the principles of cerebral 
pathophysiology associated with brain injury, controlled 
hyperventilation remains the most efficacious therapeutic 
intervention for cerebral edema (Raslan & Bhardwaj, 2007). 
A decrease in PaCO 2 by 10 mmHg produces a proportional 
decrease in CBF (and decreases cerebral blood volume 
(CBV) in the cranial vault) resulting in rapid and prompt 
ICP reduction. A common clinical practice is to lower and 
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maintain PaCO 2 by 10 mmHg to a target level of approxi-
mately 30–35 mmHg. The vasoconstrictive effects of hyper-
ventilation has been shown to last for 10–20 hours. It should 
be noted that controlled hyperventilation is to be used as a 
rescue or resuscitative measure for a short duration until 
more definitive therapies are instituted. Prolonged hyper-
ventilation has been shown to worsen outcomes in TBI and 
overaggressive hyperventilation may actually result in cere-
bral ischemia (Raslan & Bhardwaj, 2007). 
Steroids. Steroids are commonly used for primary and met-
astatic brain tumors to decrease vasogenic cerebral edema. 
Dexamethasone (Decadron) at a dose of 4 mg intravenously 
(IV) every 6 hours is a common regimen with higher doses 
required in the setting of increased ICP (Gomes, Stevens, 
Lewin, Mirski, & Bhardwaj, 2005). However, this is the only 
setting in which steroids are indicated for increased ICP. The 
corticosteroid randomization after significant head injury 
(CRASH) trial in patients with TBI showed no benefit with 
a significant increase in death (Rangel-Castillo & Robertson, 
2007). Therefore, steroids are  not indicated in TBI. They have 
also shown to be ineffective in treating cytotoxic edema and 
therefore have no role in the treatment of SAH or stroke. 
Osmotherapy. The fundamental goal of osmotherapy is to 
create an osmotic gradient to egress water from the brain 
extracellular (and possibly intracellular) compartment into 
the vasculature, thereby decreasing intracranial volume and 
improving compliance (Raslan & Bardwaj, 2007). An ideal 
osmotic agent is one that produces a favorable osmotic gra-
dient, is inert and nontoxic, is excluded from an intact BBB, 
and has minimal systemic side effects (Raslan & Bhardwaj). 
The two main agents used in osmotherapy are mannitol 
and hypertonic saline. Mannitol is the most commonly used 
hyperosmolar agent for intracranial hypertension. IV bolus 
administration of mannitol lowers the ICP in 1–5 minutes with 
a peak effect at 20–60 minutes. The effect of mannitol on ICP 
lasts 1.5–6 hours depending on the clinical condition. Man-
nitol is usually given as a bolus of 0.25–1 g/kg, with a dose of 
1g/kg given in cases when urgent reduction of ICP is needed 
(Rangel-Castillo & Robertson, 2007). Hypertonic saline (HS) 
is available in various formulations (2%, 3%, 7.5%, 10%, and 
23.4%). It produces increasing osmotic gradients with higher 
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concentrations although there is little clinical evidence for 
choosing one concentration over another in terms of attenu-
ating brain water content (Quereshi & Suarez, 2000). It is 
postulated that HS produces this diuretic effect from stimu-
lation of atrial natriuretic peptide (ANP) release rather than 
direct osmotic diuresis, which accounts for its ability to aug-
ment intravascular volume and cardiac performance, avoid-
ing hypotension and hypovolemia (Ziai, Toung, & Bhardwaj, 
2007). HS in the form of 2% or 3% is administered as a con-
tinuous drip and can also be given in boluses of 250–500 cc in 
a controlled setting. A desired sodium goal of 145–155 mEq/L 
(or higher) is set and the drip is titrated over 24–48 hours 
to meet the desired goal. Larger concentrations of HS (e.g., 
23.4%) are often given as a bolus doses in the emergent set-
ting of cerebral herniation to quickly control ICP (this must 
be given via central line over several minutes to avoid fur-
ther hemodynamic compromise). Overall HS has shown to be 
as efficacious as mannitol in reducing ICP. Although a large 
scale trial that is randomized and controlled, which directly 
compares equiosmolar doses of mannitol and HS has yet to be 
undertaken, several clinical studies suggest that HS solutions 
may be more effective in lowering elevated ICP than mannitol 
(Ziai et al., 2007). 
Pharmacological Coma. Induced pharmacologic coma is 
used in the setting of retractable ICP where other methods 
of ICP reduction have failed. Traditionally, high-dose barbi-
turates (pentobarbital) have been used to induce coma and 
decrease cerebral metabolic activity, resulting in reduction 
in CBF, CBV, and ultimately, ICP. The recommended regimen 
entails a loading IV bolus of pentobarbital (3–10 mg/kg) fol-
lowed by continuous infusion of (0.5–3 mg·kg −1·hr−1). The 
infusion is titrated to a reduction of ICP or burst suppression 
on EEG as well as targeted levels of 30–50 mcg/ml (Raslan 
& Bhardwaj, 2007). The barbiturate coma is maintained for 
48–72 hours during which time, daily pentobarbital levels 
are obtained. After 48–72 hours, the drip is slowly with-
drawn and the ICP is monitored closely to assess for per-
sistent intracranial HTN. Barbiturate therapy is not without 
controversy. Barbiturates carry with them a list of unwanted 
side effects including hypotension (lowering CPP), cardiac 
depression, immunosuppression, and risk of ileus (Raslan 
& Bhardwaj). 
Chapter 5: Neurological Critical Care 163
As a result, propofol has emerged as an appealing alter-
native especially because of its extremely short half-life 
(Bratton et al., 2007). Propofol is loaded at 3–5 mg/kg with 
continuous infusion starting at about 30 mcg·kg −1·min−1 and 
titrated to either ICP control or burst suppression. Hypoten-
sion is the major side effect of propofol, and vasoactive agents 
are often needed to maintain CPP during the coma period. 
Propofol infusion syndrome is also of concern in patient is 
characterized by severe metabolic acidosis, rhabdomyoly-
sis, and cardiovascular collapse frequently leading to death. 
Some data suggests that this disorder is caused by interfer-
ence with mitochondrial respiration (Marik & Varon, 2004). 
It is currently recommended that the dosage not exceed 
100 mcg·kg −1·min−1 and measurements of daily creatinine 
kinase (CPK) a marker of rhabdomyolysis and triglycerides 
to identify failure of free fatty acid metabolism in the form of 
hyperlipidemia be done to monitor for the syndrome. 
Hypothermia. Although it is very clear that hyperthermia 
has deleterious effects on the brain, the role of hypothermia 
is controversial in terms of translation to neurological out-
comes. The setting of out-of-hospital cardiac arrest and the 
induction of hypothermia to 32°C within 8 hours and main-
tained for 12–24 hours has improved mortality and functional 
outcomes (Raslan & Bhardwaj, 2007). A hypothermia trial in 
patients with TBI did not improve long-term outcomes. How-
ever, in the setting of intractable ICP, a trial of adjunctive, 
controlled hypothermia may be considered. The mainstay of 
treatment, as discussed previously, is a focus on normother-
mia via the use of antipyretics and cooling devices. 
Surgical Decompression. The surgical decompression of 
part of the calvaria to create a window in the cranial vault 
is the most radical intervention for intracranial hyperten-
sion. Decompressive craniotomy has been used to treat 
uncontrolled intracranial hypertension of various origins, 
including cerebral infarction, trauma, SAH, and spontaneous 
hemorrhage. Patient selection, timing of operation, type of 
surgery, and severity of clinical and radiologic brain injury 
all are factors that determine the outcome of the procedure 
(Rangel-Castillo & Robertson, 2007). The size of the crani-
otomy is of critical importance. In small craniotomies there is 
risk of brain herniation with venous infarction and increased 
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edema at the bone margins. It is also recognized now that the 
dura must be opened to achieve decompression (Hutchin-
son, Timofeev, & Kirkpatrick, 2007). The role of decompres-
sive craniotomy is accepted in the TBI population, but data 
still remains controversial in the setting of stroke, mainly in 
terms of improvement in functional outcomes. As a result, 
many institutions have established strict criteria on which 
patients receive this life-saving procedure. 
 Prognosis 
Overall prognosis in the setting of cerebral edema and 
increased ICP is dependent on the underlying primary injury 
(stroke, tumor, TBI, infection) and the degree of secondary 
injury endured. 
 Traumatic Brain Injury 
 Definition and Epidemiology 
Traumatic brain injury (TBI) is a nondegenerative, noncon-
genital insult to the brain from an external mechanical force, 
possibly leading to permanent or temporary impairments 
of cognitive, physical, and psychosocial functions with an 
associated diminished or altered state of consciousness (Segun, 
2007). TBI is commonly categorized by means of the GCS, as 
severe (GCS ≤8), moderate (GCS 9–13) and minor (GCS 14–15). 
TBI is usually the consequence of impact to the head, which 
undergoes sudden acceleration, deceleration, or rotation. Inju-
ries are divided into two subcategories: (a) primary injury that 
occurs at the moment of trauma and (b) secondary injury that 
evolves hours or days after injury as a consequence of systemic 
or intracranial complications (Toyama et al., 2005). 
An estimated 1.1 million patients are evaluated each 
year in emergency departments for acute TBI. It occurs most 
often in young people, with peak incidence at 15–24 years of 
age (Heegaard & Biros, 2007). High-risk populations include 
low income individuals, unmarried individuals, members of 
ethnic minority groups, residents of inner cities, men, and 
individuals with history of substance abuse (Segun, 2007). 
Although the most common mechanism for TBI has changed 
from assaults to motor-vehicle–associated injuries, TBI 
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remains the single largest cause of trauma morbidity and 
accounts for nearly one third of all trauma deaths (Heegaard 
& Biros). 
 Pathophysiology and Types of 
Primary Brain Injury 
As previously mentioned, primary brain injury occurs at the 
moment of trauma and is irreversible. The physical mecha-
nisms of brain injury are classified using the following cate-
gories: acceleration/deceleration injury and rotational injury. 
Acceleration–deceleration trauma is the most common result 
of a closed head injury. This occurs when the head is acceler-
ated and then stopped suddenly, as in a motor vehicle colli-
sion, and this causes discrete, focal lesions to two areas of the 
brain. The brain will suffer contusions at the point of direct 
impact (coup) and at the site directly opposite the point of 
impact because of the oscillation of the brain within the skull 
(contra coup). Rotational trauma occurs when impact causes 
the brain to move within the cranium at a different veloc-
ity than the skull. This results in a shearing of axons by the 
bones of the skull. Because this type of injury damages neu-
ral connections rather than gray matter, it can affect a wide 
array of cerebral functions and should therefore be consid-
ered a type of diffuse injury (Hickey, 2002). 
Common types of primary TBI include skull fractures, 
concussion, diffuse axonal injury, epidural hematoma, sub-
dural hematoma, traumatic subarachnoid hemorrhage, cere-
bral contusion, and penetrating head injury. 
Skull Fractures. A skull fracture is a break in one or more of 
the bones in the skull caused by a head injury. Isolated skull 
fractures are not very serious injuries, but the presence of a 
skull fracture may indicate that significant enough impact 
occurred to cause brain trauma (Graham & Gennareli, 2000). 
Linear skull fractures are the most common type of skull 
fracture and occur in 69% of patients with severe head injury. 
They occur when the impact causes the area of the skull that 
was struck to bend inward, making the area around it buckle 
outward (Graham & Gennareli). Linear fractures are highly 
associated with extradural hematomas. Temporal linear skull 
fractures with laceration of the middle meningeal artery are 
commonly seen (Davis & Briones, 1998). 
166 Critical Care
Comminuted skull fractures, those in which a bone is 
shattered into many pieces, can result in bits of bone being 
driven into the brain causing lacerations to the parenchyma 
(Graham & Gennareli, 2000). They can be depressed or non-
depressed as well as open or closed. The depressed skull 
fracture has a characteristic “step off” where the skull frag-
ment is resting on the brain structures below. In a closed-type 
fracture, the dura remains intact, allowing no communication 
between the brain and the environment whereas open frac-
tures permit communication with the outside environment 
(Davis & Briones, 1998). 
Basilar skull fractures are those that involve the ante-
rior, middle, and/or posterior fossas of the skull. Anterior 
fossa skull fractures are easily recognizable by the clas-
sic “raccoon’s eyes” caused by bleeding into the periorbital 
space. Middle fossa skull fractures typically display “Battle 
sign,” which is ecchymosis of the mastoid process and may 
also have associated conductive hearing loss and Bell’s palsy. 
Dural tears often accompany these types of fractures and 
leaking of cerebral spinal fluid either from the nose (rhinor-
rhea) or ear (otorrhea) is common (Hickey, 2002). Posterior 
fossa skull fractures, in the form of an occipital condyle frac-
ture, are rare and are usually accompanied by cervical spine 
injury, lower cranial nerve injury, and limb paresis/plegia 
(Graham & Gennareli, 2000). 
Concussion. A concussion is a transient brief interruption of 
neurologic function after minor head trauma, with or with-
out a loss of consciousness, usually a result of acceleration–
deceleration forces to the head (Heegaard & Biros, 2007). 
Although anyone can sustain a concussion, it is most often a 
consequence of a sports-related minor head injury. The most 
common complaints after concussion are headache, confu-
sion, and amnesia; the neurologic examination is nonfocal. 
Various theories have been proposed to explain the physical 
and functional signs and symptoms following a concussion. 
These include shearing or stretching of white matter fibers, 
temporary neuronal dysfunction, transient alterations in 
levels of neurotransmitters, or temporary changes in cere-
bral blood flow and oxygen use (Heegaard & Biros). Vague 
symptoms, such as headaches, sensory sensitivity, memory 
or concentration difficulties, irritability, sleep disturbances, 
or depression may persist for prolonged periods after a 
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concussion. These constitute the postconcussive syndrome 
(PCS). For years, it was believed that PCS was psychosomat-
ic, but functional imaging and sophisticated neuropsycho-
metrics have documented structural abnormalities, which 
offer an explanation for the symptoms associated with the 
syndrome (Heegaard & Biros). 
Diffuse Axonal Injury. Diffuse axonal injury (DAI) is now 
widely accepted as one of the most common types of primary 
brain lesions in patients with severe head trauma. Patients 
with DAI usually present with severe impairment of con-
sciousness from the moment of impact, presenting with a GCS 
≤ 8. The mechanism is one of widespread tearing of axons 
caused by shearing forces during acceleration, deceleration, 
and rotation of the brain (Toyama et al., 2005). A component 
of DAI is believed to be present in all motor vehicle colli-
sions where the patient has lost consciousness (Meythaler, 
Peduzzi, Eleftheriou, & Novack, 2001). The predominant ana-
tomic sites of injury seen with DAI are the parasagittal white 
matter of the cerebral cortex, basal ganglia, corpus callosum, 
and the pontine–mesencephalic junction adjacent to the 
superior cerebellar peduncles. Injury to the tracts leading in 
and out of the hypothalamus and/or direct injury to the pitu-
itary stalk and gland, results in many of the common medical 
complications noted after TBI including dysautonomia, hor-
monal changes, disorders of salt and water metabolism, and 
altered temperature regulation (Meythaler et al., 2001). 
CT and MRI scans taken initially after injury are often 
normal. Only 10% of DAI patients demonstrate the classic CT 
findings associated with DAI characterized by hemorrhagic 
punctate lesions of the corpus callosum, the gray-white mat-
ter junction of the cerebrum, and the pontine–mesencephalic 
junction adjacent to the cerebellar peduncles (Meythaler 
et al., 2001). The Adams classification is used to categorize the 
degree of DAI as mild, moderate, or severe. Mild (Grade 1) DAI 
is characterized by microscopic changes in the white matter 
of the cerebral cortex, corpus callosum, brainstem, and occa-
sionally, the cerebellum. Moderate DAI (Grade 2) is defined by 
grossly evident focal lesions isolated to the corpus callosum. 
In severe DAI (Grade 3), there are additional focal lesions to 
the dorsolateral quadrants of the rostral brainstem (Meytha-
ler et al.). Overall, DAI is the most common cause of vegetative 
state and severe disability after injury (Toyama et al., 2005). 
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Epidural Hematoma. Epidural hematoma (EDH) is the accu-
mulation of blood between the dura and the inner table of the 
skull. Normally because the periosteal surface of the dura is 
densely adherent to the inner table of the skull, no epidu-
ral space exists. Blunt trauma to the head, with or without 
skull fracture, may cause the dura to separate from the inner 
table. The separation may occur on the side of the trauma 
(coup) or the contralateral side (contra-coup). EDH into the 
traumatically created epidural space may result from lacera-
tion of the middle or posterior meningeal artery, meningeal 
emissary veins, or venous sinus (Harris, 2000). The most 
common locations are the temporal, frontal, and occipital 
regions. On CT, the hematoma has a biconvex or lenticular 
shape with sharp margination as a result of the fact that the 
dura remains adherent at both edges. EDH tends not to cross 
cranial sutures where the dura is tightly adherent. Because 
they lie outside the dura, EDH may cross the falx or displace 
the dural venous sinuses (Toyama et al., 2005). 
Classically, there is an initial period of unconsciousness 
followed by a lucid interval after which rapid neurological 
deterioration develops (Toyama et al., 2005). The lucid inter-
val is a delay between the trauma and the moment the EDH 
enlarges and becomes symptomatic. However, this classic 
lucid interval is seen in only 40% of patients with acute EDH. 
The mass compresses the brain and may cause compression 
or obliteration of the ipsilateral lateral ventricle and uncal 
herniation with midline shift. Surgery to evacuate the clot 
and ligate the ruptured vessel is the mainstay of treatment 
for EDH (Toyama et al., 2005). 
Subdural Hematoma. Subdural hematoma (SDH) represents 
a collection of blood located between the dura and arachnoid 
membrane. The blood comes principally from torn superfi-
cial cortical veins separating the arachnoid from the dura but 
may also arise from the venous sinus or by bleeding cere-
bral contusions. SDH is classified into three categories based 
on the clinical timeline and radiographic findings—acute: 
immediate to 72 hours, subacute: 72 hours–2 weeks, chronic: 
>2 weeks (Toyama et al., 2005). 
Underlying cerebral injuries are more frequent with 
acute SDH than acute EDH. Associated contusions are pres-
ent in 50% of patients with SDH. Swelling of the underlying 
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hemispheres is common, so that mass effect is greater than 
expected based on the size of the clot alone. The classic CT 
appearance of an acute SDH is a crescent-shaped, extra-axi-
al collection that is homogeneously and hyperdense and that 
spreads diffusely over the affected hemisphere. The usual 
management of acute SDH is surgical (Toyama et al., 2005). 
However, the use of early surgery has not always improved 
outcomes. Other factors including age, GCS on presentation, 
amount of blood, and absence/presence of midline shift often 
weigh in on whether surgery is pursued or the patient is to 
be watched clinically. 
Traumatic Subarachnoid Hemorrhage. Traumatic sub-
arachnoid hemorrhage usually arises from hemorrhagic 
contusion with bleeding into the subarachnoid space and 
is a frequent occurrence in severe head injury. The most 
frequent location is over the convexity, followed by the fis-
sures and basal cisterns (Toyama et al., 2005). Despite the 
severity of injury noted to the brain, mortality doubles in 
the presence of traumatic SAH. If there is blood in the basal 
cisterns, there is a 70% positive predictive value of a poor 
outcome. The volume and extent of traumatic SAH is related 
to outcome,  independent of the other injuries noted in TBI 
patients (Chestnut et al., 2007). 
Cerebral Contusion. Contusions are focal injury of the brain 
surface caused by direct impact with the calvarium. Contu-
sions are most common at sites of bony protuberances of the 
skull base and therefore, are seen in the frontal poles, orbital 
surface of the frontal lobes, temporal poles, and inferior sur-
face of the temporal lobes and adjoining the anterior sylvian 
fissure near the lesser sphenoid wing (Toyama et al., 2005). 
On a noncontrast CT, hemorrhagic contusions appear as het-
erogeneous, hyperdense lesions (hemorrhage) surrounded 
by an irregularly marginated hypodense component (edema 
and necrosis). Lesions that are small on initial head CT have 
the potential to “blossom” within 24–48 hours into larger, 
more extensive hemorrhages with increased surrounding 
edema. Given this fact, patients with a TBI associated with a 
loss of consciousness and any evidence of contusion should 
be monitored in the hospital and undergo repeat imaging in 
24–48 hours (Toyama et al., 2007). 
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Penetrating Head Injury. The definition of a penetrating 
head trauma is a wound in which a projectile breaches the 
cranium but does not exit it (Vinas & Pilitsis, 2006). Despite 
the prevalence of these injuries, the morbidity and mortality 
of penetrating head injury remains high. Penetrating head 
injuries can be the result of numerous intentional or unin-
tentional events, including missile wounds, stab wounds, and 
motor vehicle or occupational accidents (nails, screwdriv-
ers). The pathological consequences of penetrating head 
wounds depend on the circumstances of the injury, including 
the properties of the weapon or missile, the energy of the 
impact, and the location and characteristics of the intracrani-
al trajectory. In missile wounds, the amount of damage to the 
brain depends on numerous factors including (a) the kinetic 
energy imparted, (b) the trajectory of the missile and bone 
fragments through the brain, (c) ICP changes at the moment 
of impact, and (d) secondary mechanisms of injury (Vinas & 
Pilitsis).
Stab wounds represent a smaller fraction of penetrating 
head injuries. The causes may be from knives, nails, spikes, 
forks, scissors, and other assorted objects. Penetrations most 
commonly occur in the thin bones of the skull, especially in 
the orbital surfaces and the squamous portion of the tempo-
ral bone. The mechanisms of neuronal and vascular injury 
caused by cranial stab wounds may differ from those caused 
by other types of head trauma. Unlike missile injuries, no 
concentric zone of coagulative necrosis caused by dissipated 
energy is present. Unlike motor vehicle accidents, no dif-
fuse shearing injury to the brain occurs. Unless an associ-
ated hematoma or infarct is present, cerebral damage caused 
by stabbing is largely restricted to the wound tract (Vinas & 
Pilitsis, 2006).
 Pathophysiology and Types of
Secondary Injury
Secondary brain injury may occur in minutes, hours, to 
days after injury as a consequence of systemic or intracra-
nial complications. Examples of systemic secondary brain 
insults include hypotension, hypoxia, anemia, hypercapnia, 
and hypocapnia. Intracranial secondary brain insults include 
intracranial hypertension (increased ICP), seizures, cere-
bral edema, hydrocephalous, and herniation (Hickey, 2002). 
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The degree and type of secondary brain insults are major 
determinants in the final neurologic outcome. For a review 
of cerebral physiology and the impact of cerebral edema and 
intracranial HTN on secondary brain injury, please see the 
increased ICP section of this chapter.
 Diagnosis
The diagnosis and categorization of TBI (mild, moderate, 
severe) is made on the basis of the clinical examination, 
which includes a comprehensive neurologic examination 
with GCS scoring and radiographic findings on CT. It is also 
imperative as the practitioner to get an accurate account 
of the events (mechanism of injury, loss of consciousness, 
any vomiting, seizures, presence of severe headache, or 
any amnesia since the injury) from the patient or a reliable 
bystander (New Zealand Guideline Group [NZGG], 2006). 
Often the patient is unable to give specific details as to the 
manner at which the injury occurred due to a loss of con-
sciousness. The physical examination is also vital and must 
include neurologic examination (including GCS), inspec-
tion for signs of skull fracture (otorrhea/rhinorrhea) or 
other overt injuries. Noncontrast CT is the gold standard for 
diagnosing TBI. CT scans should be immediately requested 
for adults who have sustained a head injury if they have 
any one of the following risk factors: (a) any deterioration 
in condition, (b) a GCS of <13 when assessed (irrespec-
tive of the time elapsed since the injury), (c) a GCS of 13 
or 14 two hours after the injury, (d) a suspected open or 
depressed skull fracture, (e) any sign of basal skull fracture 
(raccoon eyes, cerebrospinal fluid otorrhoea/rhinorrhea, 
Battle sign), (f) posttraumatic seizure, (g) focal neurological 
deficit, (h) more than one episode of vomiting, or (i) amne-
sia for more than 30 minutes for events before the injury 
(NZGG, 2006). In addition, CT scanning should be imme-
diately obtained for adults with any of the following risk 
factors who have experienced an injury to the head with 
some loss of consciousness or amnesia since the injury: 
(a) age 65 years or older, (b) coagulopathy (history of bleeding, 
clotting disorder, current treatment with warfarin), (c) high-
risk mechanism of injury (a pedestrian struck by a motor 
vehicle, (d) an occupant ejected from a motor vehicle, (e) or 
a fall from a height of >1 m or five stairs (NZGG, 2006).
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 Treatment of TBI
The treatment of TBI depends on the type of primary injury 
as well as the presence and extent of any secondary injury. 
For the purposes of this review, we will focus on the treat-
ment of moderate and severe TBI. The Brain Trauma Foun-
dation has released its newest set of guidelines regarding the 
Surgical Management of Traumatic Brain Injury as well as 
Guidelines for the Management of Severe, Traumatic Brain 
Injury, 3rd edition. The recommendations from those guide-
lines are summarized in Tables 5.9 and 5.10.
 Prognosis
Approximately 52,000 U.S. deaths per year has resulted 
from TBI. Local factors in the United States may influence 
this mortality rate; it is lowest in the Midwest and North-
east and is highest in the South. The initial GCS score, and 
therefore, the severity of the TBI help to predict likeli-
hood of death from the injury. The mortality rate is high in 
severe TBI and low for moderate TBI (Segun, 2007). Over-
all, the type of primary injury incurred (concussion, contu-
sion, hemorrhage, DAI) and the development and severity 
of secondary brain injury are the factors in morbidity and 
mortality.
Spinal Cord Injury
 Introduction
Acute spinal cord injury (ASCI) is a devastating diagnosis 
that is encountered in the acute neurosciences arena. There 
are approximately 11,000 new cases of ASCI per year and 
it is estimated that there are about 250,000 people in the 
United States living with spinal cord injury. The average 
age of injured individuals is 38 and men are more likely 
to sustain an ASCI than woman. The number one cause of 
traumatic ASCI is motor vehicle accidents, number two is 
falls followed by violent acts (gunshot wounds), and third 
is sports injuries (National Spinal Cord Injury Statistical 
Center, 2006)
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Type of Is Surgery  
Injury Indicated?/Criteria Timing & Methods
5.9 Surgical Management of TBI
(continued)
Depressed 
Skull
fracture
Patients with open (com-
pound) cranial fractures 
depressed greater than 
the thickness of the 
cranium should undergo 
operative intervention to 
prevent infection
Elevation and débridement is 
recommended as the surgical 
method of choice.
Replacement of bone is a surgical 
option in the absence of wound 
infection at the time of surgery.
All management strategies for open 
(compound) depressed fractures 
should include antibiotics
Basilar skull 
fracture
No Manage ICP and CSF leak
Concussion No Observation
Contusion Patients with contusions 
AND
■  Signs of progressive 
neurological deteriora-
tion referable to the 
lesion
■  Medically refractory 
increased ICP
■  Signs of mass effect on 
computed tomography 
(CT)
■  GCS 6–8 with frontal or 
temporal contusions 
>20 cm3 in volume with 
midline shift of at least 
5 mm and/or cisternal 
compression on CT 
scan,
■ Any lesion >50 cm3
Craniotomy with evacuation of 
mass lesion
■  Is recommended for those 
patients with focal lesions and 
the surgical indications listed
Bifrontal decompressive craniectomy
■ Within 48 hours
■  Treatment option for patients 
with diffuse, medically refractory 
posttraumatic cerebral edema 
and resultant increased ICP.
Decompressive procedures 
(subtemporal decompression/
temporal lobectomy/hemispheric 
decompressive craniectomy)
■  Refractory increased ICP and 
diffuse parenchymal injury
■  Clinical and radiographic 
evidence for impending 
transtentorial herniation
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5.9 Surgical Management of TBI (continued)
Type of Is Surgery  
Injury Indicated?/Criteria Timing & Methods
Diffuse Axo-
nal Injury
No Supportive Care
Subdural 
  Hema-
toma
■  Thickness >10 mm
 OR
■  Midline shift >5 mm on 
CT scan
****Regardless of GCS 
****
IF GCS ↓ between time of 
injury and hospital admis-
sion by 2 or more AND/OR
■  The patient presents 
with asymmetric or 
fi xed and dilated pupils
■ ICP >20 mmHg
Timing:
■  If meet criteria as defi ned
■ ASAP
Methods:
■  Craniotomy with/without bone 
fl ap removal
 AND
■ Duraplasty
Epidural 
  Hema-
toma
INDICATIONS
■ >30 cm3 should be 
evacuated regardless 
of GCS
TIMING
■  If acute EDH in coma 
(GCS score <9)
WITH
■  Anisocoria (unequal pupils)
■ ASAP
METHODS
■ Craniotomy
■  There are insuffi cient data 
to support one surgical 
treatment method, however 
provides a more complete 
evacuation of the hematoma
Traumatic 
 SAH
No Medical management
If hydro- EVD
Penetrating Varies Removal of object
I&D
Adapted from from Bullock et al. (2006).
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 Level of
Intervention Evidence* Recommendation
Blood Pressure & 
Oxygenation
Level II
Level III
■  Goal SBP >90
■  Goal Sats >90%
■  PaO2 >60 mmHg
Hyperosmolar 
Therapy
■ Mannitol
■ Hypertonic
saline
Level II
Level III
Insuffi cient 
evidence
■ 0.25–1 g/kg
■ Avoid hypotension (SBP <90)
■  No evidence to suggest that a 
bolus is better than continuous
■  Only use BEFORE placing ICP 
monitor if patients is actively 
herniating or has progressive 
neurological deterioration
■  Need randomized controlled trial 
to determine benefi ts of mannitol 
versus hypertonic saline
Prophylactic 
Hypothermia
Level III ■  Suggest a decrease in mortality 
risk when hypothermia is main-
tained for >48 hours (32–35° C)
Infection
 Prophylaxis
General Care
Level II ■  Periprocedural antibiotics for intu-
bation should be used to decrease 
the incidence of pneumonia
■  Early tracheostomy will decrease 
number of ventilator days (but not 
mortality or pneumonia).
External 
 Ventricular 
 Device (EVD)
Level III NOT Recommended
■ To do routine EVD exchange
■  To give prophylactic antibiotics 
for EVD placement
5.10 Management for Severe TB
(continued)
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 Level of
Intervention Evidence* Recommendation
Deep Vein 
Thrombosis 
(DVT)
Prophylaxis
Level III ■  SCDs are recommended until 
patient is ambulatory
■  Low molecular weight  heparins 
or low dose unfractionated 
heparin should be used in combo 
with SCDS. However, there is an 
 increase risk of ICH expansion
■  No data for preferred agent or timing
ICP Monitor Level II
Level III
■  Severe TBI (GCS 3–8)
■  Abnormal Head CT
■  Severe TBI (GCS 3–8) with normal 
CT and 2 or more of
- >40 years old
- Posturing
- SBP <90
ICP Monitoring 
Technology
No Level listed ■  EVD is most accurate, lowest cost 
device
■  Fiber-optic/microstrain gauge 
placed in EVD provides greater 
benefi t but costs more.
■  Subarachnoid, subdural, and 
epidural are not as accurate
ICP Threshold Level II
Level III
■  Initiate treatment for ICP >20 mmHg
■  Combo of ICP, clinical picture, and 
head CT fi ndings should be used to 
determine need for treatment
CPP Threshold Level II
Level III
■  AVOID aggressive attempts to get 
CPP >70 with fl uid and pressors 
caused by ↑ risk ARDS
■  AVOID CPP <50 mmHg
■  CPP target 50–70 mmHg
5.10 Management for Severe TB (continued)
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 Pathophysiology
An ASCI is caused when there is direct physical force that 
damages either the ligaments, vertebrae, or disks of the 
spinal column causing bruising, crushing, or tearing of 
the spinal cord (Beers, Porter, Jones, Kaplan, & Berkwits, 
2006). Just as with traumatic brain injury, there is primary 
injury, which occurs at the moment of trauma and then 
secondary injury, which occurs hours to days after the ini-
tial insult. Secondary injury of the spinal cord is the result 
of many pathologic processes including ischemia, hemor-
rhage, and inflammation. The ultimate expression of sec-
ondary injury is spinal cord edema. Cord edema peaks at 
3–5 days postinjury and lasts for weeks after the trauma 
(Stevens, Bhardwaj, Kirsh, & Mirski, 2003). The types of 
ASCI are complete or incomplete. A complete spinal cord 
injury is defined as total loss of motor and sensory below 
the level of the injury caused by a complete transection of 
the cord. Most complete injuries are the result of penetrat-
ing injuries such as a gunshot or knife wound. The damage 
to the cord with both complete and incomplete injuries is 
the result of either flexion, extension rotation, and/or com-
pression of the spine (Sekhon & Fehlings, 2001). The types 
of incomplete spinal cord injuries are Brown–Séquard, 
anterior cord, and central cord syndrome.
■  Using monitors for cerebral blood 
fl ow, oxygenation, or metabolism 
facilitate CPP management
Brain Oxygen 
Monitoring and 
Thresholds
Level III Treatment thresholds
■  Jugular venous saturation <50%
OR
■  Brain tissue oxygen tension 
<15 mmHg
*  Level I: Good quality randomized controlled trial (RCT), Level II: Moderate quality RCT, Good 
 quality cohort, Good quality case control, Level III: Poor quality RCT, moderate or poor quality 
cohort, moderate or poor quality case control, case series, databases or registries.
Adapted from Bratton et al. (2007).
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 Clinical Manifestations/Symptoms
A complete ACSI causes immediate, complete, flaccid 
paralysis with loss of all sensory function and reflexes 
and causes autonomic dysfunction below the level of the 
injury (Beers et al., 2006). Within hours to days, the flaccid 
paralysis becomes spastic paralysis and if the injury has 
spared the lumbosacral region, DTRs will return and will 
be hyperreflexic. With incomplete ASCI, there are various 
degrees of motor and sensory dysfunction. Brown–Séquard 
syndrome is hemisection of the cord usually caused by a 
penetrating injury, which results in results in loss of motor 
(spastic paralysis), vibration, and proprioception below 
the level and on the same side as the injury and contralat-
eral loss of pain and temperature. On the same side of the 
lesion, the pain and temperature are spared and contralat-
eral to the lesion, motor, vibration, and proprioception are 
spared (Tintanelli, Kelen, Stapczynski, Ma, & Cline, 2004) 
Anterior cord syndrome occurs as the result of injury to 
the anterior spinal artery causing ischemia to the anterior 
two thirds of the spinal cord. As a result, only vibration, 
light touch, and proprioception remain intact and motor 
and sensory below the level of the injury are lost. Cen-
tral cord syndrome is a type of incomplete ASCI that is 
seen with cervical trauma usually in patients with preex-
isting cervical spondylosis who sustain a hyperextension 
injury. The classic presentation of central cord syndrome 
is motor weakness more severe in the arm than the legs 
and varying sensory dysfunction depending on which sen-
sory tracts are injured (Tintanelli et al.). Spinal shock, the 
loss of all spinal cord function, including reflexes, occurs 
immediately after the ASCI and can last hours to days 
(Ditunno, Little, Tressler, & Burns, 2004). Most often spi-
nal shock is seen with injuries occurring at T6 and above. 
Bradycardia and hypotension are seen during this stage 
because of the loss of sympathetic outflow, vasodilatation, 
and vagal stimulation to the heart (Hall, Schmidt, & Wood, 
2005). Autonomic dysreflexia, a syndrome characterized 
by paroxysmal hypertension, headache, and bradycardia, 
is rarely seen in the acute care setting. It is usually seen in 
patients with injury above T6 and occurs weeks to months 
after the initial injury (Branco, Cardenas, & Svircev, 2007).
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 Diagnostic Criteria
The imaging guidelines for the cervical spine (c-spine) are 
outlined in Table 5.11. “Clearing” the cervical spine is the 
priority in ASCI to avoid a potentially devastating injury if 
the c-spine is unstable and not properly immobilized. The 
initial imaging for suspected thoracic and lumbar ACSI is a 
noncontrast CT to assess bony involvement. MRI is superior 
in assessing the spinal cord itself (Castillo, 2006).
 Treatment
In May 2000, the Section on Disorders of the Spine and Periph-
eral Nerves of the American Association of Neurological Sur-
geons and the Congress of Neurological Surgeons began the 
painstaking process of developing guidelines for the man-
agement of acute spinal cord injuries. After an exhaustive 
review of the published scientific evidence, this group pub-
lished the Guidelines for the Management of Acute Cervical 
Spine and Spinal Cord Injuries in 2002 (Hadley, et al.). The 
recommendations are identified as a Practice Standard, Prac-
tice Guideline, or a  Practice Option . Practice Standards have 
the highest degree of clinical certainty as they are backed by 
the strongest scientific evidence. Practice Guidelines have a 
moderate degree of clinical certainty because the data to sup-
port them were extracted from less stringent clinical studies. 
Finally, Practice Option reflects unclear clinical certainty as 
these recommendations were taken either from case series, 
case reports, flawed randomized controlled trials, or expert 
opinion (Hadley et al.). Table 5.12 summarizes the guidelines 
as they relate to the management of the cervical spine immo-
bilization, radiographic assessment and surgical intervention, 
the need for intensive respiratory and cardiovascular moni-
toring, blood pressure management, pharmacologic interven-
tions, DVT prophylaxis, and nutritional support.
An area that may be underrecognized in this population is 
pain. Patients with ASCI may experience pain, due to postsur-
gical manipulation, as well as muscle spasm and neuropathic 
pain. Nonsteroidal anti-inflammatory drugs (NSAID), opiates, 
antispasmodic medications, antidepressants, and anticonvul-
sant are all possible options for pain control depending on the 
type of pain the patient is experiencing (Ullrich, 2007).
5.11
Recommendation Details
Intervention Level
Imaging Guidelines for the Management of Acute Cervical Spine and 
Spinal Cord Injuries Summary
Recommended Not Recommended
C-spine* immobilization 
before admission to 
hospital on all trauma 
patients with an actual or 
suspected c-spine injury
Option ■ Immobilize at the scene and
 during transport
■ Use a combination of a rigid
 cervical collar with supportive 
 blocks on a rigid backboard with 
 straps
■ Use of sand bags and tape 
 alone
Radiographic assessment of 
c-spine in asymptomatic, 
awake, alert and not 
intoxicated trauma 
patients with no other 
signifi cant injury** to 
distract from the physical 
examination
Standard ■ Clinical examination to include 
 assessment of neck pain or
 mid line tenderness on palpation
■ Radiographic assessment
Radiographic assessment 
of c-spine in symptomatic 
***, trauma patients
Standard ■ Anteroposterior, lateral and 
 odontoid “3-view” c-spine fi lms
■ C-spine CT to further defi ne
  suspicious or poorly visualized 
areas
Discontinuing C-spine 
 immobilization:
Awake, symptomatic patient
Option ■ Normal “3-view” c-spine series
■ Normal c-spine CT if needed
    AND
 ONE of the following
■  Normal adequate dynamic 
 fl exion/extension radiographs
    OR
■ Normal MRI within 48 hours of 
 injury
Discontinuing C-spine 
immobilization: Uncon-
scious or uncooperative
Option ■ Normal “3-view” c-spine series
■ Normal c-spine CT if needed
    AND
 ONE of the following
■  Normal adequate dynamic 
flexion/extension radiographs
    OR
■ Normal MRI within 48 hours of 
 injury
    OR
■ At the discretion of the treating 
 physician
Closed-reduction of c-spine 
fracture-dislocation 
injuries
Option ■ Early closed-reduction with 
 craniocervical traction in AWAKE 
 patients (to continually assess 
 neurologic function)
■ Obtain a c-spine MRI prereduc-
 tion on non-awake patients to 
 assess for disc herniation
■ Obtain a c-spine MRI for patients 
 who fail closed reduction
■ For patients with additional 
 rostral injury
5.12
Recommendation Details
Intervention Level 
Guidelines for the Management of Acute Cervical Spine and Spinal Cord 
Injuries Summary
 Recommended Not Recommended
Management in an intensive 
care unit or other 
monitored setting
Option ■ Patients with ASCI are best managed 
 in the ICU setting for 7–14 days post
 injury due to increased susceptibility to 
 cardiac and respiratory instability
Blood Pressure Option ■ Avoid and correct systolic blood 
 pressure <90 mmHg
■ Maintain mean arterial blood pressure   
>85–90 mmHg for 7 days postinjury
Pharmacological Therapy:
 Corticosteroids
Option: only undertaken 
with the knowledge that 
evidence suggests more 
harmful side effects 
than benefit
■  Methylprednisolone (30 mg/kg IV for 
 1 hour and then 5.4 mg/kg × 23 hours) 
 given within 8 hours of injury for either 
 24 or 48 hours
Pharmacological Therapy: 
GM-1 ganglioside
Option without clinical 
benefi t
■ GM-1 ganglioside (300 mg loading dose 
 and then 100 mg/day for 56 days) after
 administration of methylprednisolone
(continued)
VTE**** Prophylaxis Standard ■ Prophylactic treatment VTE with either:
 - LMWH*****
 - Rotating beds
 -  Adjusted dose heparin to maintain 
APTTr 1.5 × control
 - Combination of modalities
 -  Low dose heparin (5000 units sq BID 
or TID) in combination with PCS***** 
or electrical stimulation)
Guidelines ■  Low-dose 
 heparin 
 alone
Options ■  Diagnostic tests with lower extremity 
Doppler ultrasound, impedence 
plethysmography and venography
5.12
Recommendation
 Details
Intervention Level 
The Guidelines for the Management of Acute Cervical Spine and Spinal 
Cord Injuries Summary (continued)
Recommended Not Recommended
■  3 month duration of prohylaixs
■  Vena cava fi lters if
  — patient does not respond to anticoagulation
    OR
  —  patient is not a candidate for anticoagulation 
and/or other mechanical devices including
Nutritional Support Option ■  Nutritional support to meet caloric and nitrogen 
needs via enteral route if functional gut and 
parenteral route for nonfunctional gut
■  Energy expenditure assessment via indirect 
calorimetry rather than the less accurate 
equation estimates
*C-spine: cervical spine
**Signifi cant injury is defi ned as long bone fractures, visceral injuries requiring surgical evaluation, large lacerations, deglovings, crush injuries, large burns
***Symptomatic patient is defi ned as either an awake patient complaining of neck pain and/or c-spine tenderness, a patient with a neurologic defi cit associated 
with the c-spine, an unconscious, uncooperative, intoxicated patient, or a patient with other signifi cant injuries
****VTE: venous thromboembolism
*****LMWH: low molecular weight heparins
******PCS: pneumatic compression stockings
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Treatment of spinal shock is primarily aimed at manag-
ing the dysautonomia. Treatment of hypotension should start 
with ensuring adequate volume status with IV crystalloids. If 
IV fluids alone does not assist with meeting the blood pres-
sure goals, vasoactive drugs should be used. The choice of 
vasoactive drip depends on the patient’s heart rate and car-
diac function. (Stevens et al., 2003) Bradycardia should be 
treated per advanced cardiac life support guidelines (Ameri-
can Heart Association, 2005).
 Prognosis and Outcomes
The predictor of survival of ACSI is age, level of injury, and 
neurologic grade per rating scales like American Spinal Inju-
ry Association Scale (American Spinal Injury Association, 
2002). Early death rates vary between 4% and 20% (Sekhon 
& Fehlings, 2001). Within the cervical cord injury population, 
there is anywhere from a 1.5- to 6.6-fold increased risk of 
death depending on level of injury.
 Postoperative Elective
Neurosurgical Patients
 Introduction
Elective neurosurgical surgery comprises approximately 
60% of the patients admitted to the neurocritical care set-
ting. Although these cases are not emergent, they require 
an ICU stay given the high risk of neurologic devastation 
if a postoperative complication occurs and is not identified 
quickly. Most patients require less than a 24-hour ICU stay 
for close monitoring and can transfer to a nonmonitored 
setting on postoperative day 1 (Nitahara, Valencia, & Bron-
stein, 1998). The predominent elective surgical procedures 
admitted in this setting are craniotomy and major spinal 
surgery (Bhardwaj, Mirski, & Ulatowski, 2004). Craniotomy 
is most often done for tumor resection, unruptured intracra-
nial aneurysm clipping, arteriovenous malformation resec-
tion, seizure focus resection, and repair of an Arnold–Chiari 
malformation. Major spinal surgeries include multilevel, 
complicated spinal fusions, and tumor resection (Bhardwaj 
et al.). In many hospital settings, these patients are admit-
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ted directly to the neurosciences ICU with no recovery room 
stay (Nitahara, et al.).
 Pathophysiology
The major neurologic complications postcraniotomy, regard-
less of the anatomical location of the surgery, are intracranial 
hemorrhage, edema, and infection (Brell, Ibanez, Caral, & 
Ferrer, 2000). Other possible postcraniotomy complications 
vary, depending on the anatomical location of the surgery 
as well as the type of surgical procedure. Patients under-
going resection of a pituitary adenoma via a craniotomy or 
transphenoidal approach carry the risk of diabetes insipidus 
as well as visual field deficits (Loh & Verbalis, 2008). After 
the resection of a vestibular schwannoma, there is the risk 
of facial nerve damage as well as hearing loss (Bennett, & 
Haynes, 2007). The risks of postspinal surgery are bleed-
ing, infection (Boakye et al., 2007; Zak, 2003), and hardware 
failure (Brantigan, Steffee, Lewis, Quinn, & Persenaire, 2000; 
Brkaric et al., 2007). A summary of the neurologic complica-
tions that the clinician must anticipate when caring for the 
neurological patient postoperatively are listed in Table 5.13.
 Diagnostic Criteria
The best diagnostic tool the clinician has in the neurosci-
ence population is the neurologic examination (Lower, 2002). 
Therefore, it is key for the clinician to know the preprocedure 
baseline examination to be able to identify subtle changes 
in the postoperative course. Communication with the neu-
rosurgical team during the immediate postoperative period 
regarding any anticipated neurologic deficits based on the 
surgical procedure is crucial. To ensure the best chance of 
identifying a significant neurologic change, the initial post-
procedure examination should be done with all providers 
and nurses of the neurocritical care team present (Bhardwaj 
et al., 2004). Thereafter, the nursing staff should perform the 
neurologic assessment every 1–2 hours. If there is a change 
in the examination, an emergent noncontrast head CT is 
warranted for the craniotomy patients (Castillo, 2006). If the 
head CT findings do not explain the neurologic deterioration, 
an EEG should be considered to rule out subclinical seizures 
(Praline et al., 2007). Unanticipated motor or sensory changes 
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Procedure Potential Complications
Supratentorial Craniotomy Cerebral edema
 (cerebral cortex) Ischemic stroke
 Intracranial hemorrhage
 Meningitis
 Seizures
Infratentorial Craniotomy Cerebral edema
 (cerebellum and brainstem) Ischemic stroke
 Intracranial hemorrhage
 Meningitis
 Brainstem injury
 Cranial nerve injury
 Hydrocephalus
Pituitary Adenoma Cerebral edema
Resection Ischemic stroke
 Intracranial hemorrhage
 Meningitis
 Cerebrospinal fl uid (CSF) leak
 Visual fi eld defi cit
 Diabetes Insipidus (DI)
Vestibular Schwannoma Cerebral edema
Resection Ischemic stroke
 Intracranial hemorrhage
 Meningitis
 Cerebrospinal fl uid (CSF) leak
 Brainstem injury
 Cranial nerve injury (especially VII, VIII)
Spine Surgery Epidural hematoma/Epidural abscess
 Meningitis
 Myelopathy
 Cranial nerve defi cits (high cervical)
5.13 Potential Neurologic Complicationsafter Elective Neurosurgery
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in the postoperative spine patient warrants emergent imag-
ing, such as an MRI, CT, or CT myelogram, depending on the 
procedure (Gunderman, 2006).
 Clinical Manifestations/Symptoms
As previously mentioned, it is key to have strong neurologi-
cal assessment skills to be able to detect subtle changes in 
the neurological examination. Often, the earliest indication 
that a patient may be experiencing a complication after cra-
niotomy is a change in level of consciousness (Hickey, 2002). 
Other signs include a subtle motor weakness such as a pro-
nator drift, new speech difficulties, or a cranial nerve deficit 
(Lower, 2002). Transient increases in blood pressure with 
concomitant bradycardia (Cushing reflex) are a later finding 
indicative of increased intracranial pressure and impending 
herniation (Morgan, Mikhail, & Murray 2006).
 Treatment
The interventions in this patient population are aimed at 
preventing postoperative complications. Common medica-
tions patients given in the postoperative period are summa-
rized in Table 5.14.
All patients with brain tumors are prescribed cortico-
steroids during the preoperative and postoperative period. 
The exact mechanism by which steroids work is not clearly 
understood; however, there are multiple studies describing 
their benefit for the reduction of peritumoral edema (Gomes 
et al., 2005). Dexamethasone is the steroid of choice because 
of its nominal mineralocorticoid activity and long half-life 
(Drappatz, Schiff, Kesari, Norden, & Wen, 2007). Low doses 
of 4–8 mg daily are effective at decreasing edema and mass 
effect, although higher doses (80–100 mg daily) are utilized 
(Gomes et al.). Patients with tumors of the spinal cord may 
also benefit from the use of dexamethasone to decrease 
swelling (Koehler, 1995). A patient with a brain tumor who 
has experienced a seizure will be placed on an antiepileptic 
drug (AED). Although there is no data to support the effi-
cacy of seizure prophylaxis in individuals with brain tumor, 
most providers prescribe AEDs for patients who have nev-
er had a seizure after resection of a cortically based brain 
lesion (Glantz et al., 2000). A loading dose of the AED is often 
administered intraoperatively. 
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Procedure Recommended Post-op Meds
Supratentorial craniotomy Dexamethasone
 for tumor AED
 Proton pump inhibitor or H2 blocker
 Sliding scale regular Insulin
 Antiemetic: nondrowsy
   Metoclopromide
   Ondansetron
   Dolasetron
 Narcotics
   Fentanyl IV while NPO
   Oxycodone once taking po
 Antibiotic × 24 hours
Infratentorial Craniotomy Dexamethasone
 Proton pump inhibitor or H2 blocker
 Sliding scale regular Insulin
 Anti-emetic: nondrowsy
   Metoclopromide
   Ondansetron
   Dolasetron
 Narcotics
   Fentanyl IV while NPO
   Oxycodone once taking po
 Antibiotic × 24 hours
Transphenoidal hypophysectomy Proton pump inhibitor or H2 blocker
 Sliding scale regular Insulin
 Anti-emetic: nondrowsy
   Metoclopromide
   Ondansetron
   Dolasetron
 Narcotics
   Fentanyl IV while NPO
   Oxycodone once taking po
 Antibiotic × 24 hours
Spine Surgery Dexamethasone for tumor only
 Proton pump inhibitor or H2 blocker
 Sliding scale regular Insulin
5.14 Suggested Medications to Prescribe Postoperatively by Procedure
(continued)
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Blood Pressure Control. Acute postoperative hypertension 
(APH) is common in the neurosurgical patient and is often 
caused by pain, anxiety, or a prior history of hypertension. 
The sequela of APH can lead to bleeding at the surgical site 
and cardiovascular stress There is no consensus concern-
ing the treatment threshold for the management of non-
cardiac surgery patients with APH. Treatment is frequently 
a bedside decision by the anesthesiologist or surgeon that 
takes into consideration the baseline BP, concomitant dis-
ease, and the perceived risk of complications (Marik & 
Varon, 2007). Medications used to manage postoperative 
hypertension that can be safely given as an intravenous 
bolus, include hydralazine and labetalol (Aggarwal & Khan, 
2006). Restarting preadmission blood pressure medica-
tions is prudent once the patient is able to take medications 
by mouth. 
Pain Control. Practitioners must be mindful of the narrow 
index between effective analgesia and the consequences of 
oversedation. Masking neurological deficits due to excessive 
medication prevents timely intervention and can result in 
death or disability. Both the spinal surgery and craniotomy 
patient populations have significant pain postoperatively and 
it is key to initiate pain management as soon as reasonable. 
This is usually after the initial neurological assessment has 
been performed by the team. For the patients undergoing a 
Procedure Recommended Post-op Meds
 Anti-emetic: nondrowsy
   Metoclopromide
   Ondansetron
   Dolasetron
 Narcotics
   Fentanyl IV while NPO
   Oxycodone once taking po
 Antibiotic × 24 hours
5.14 Suggested Medications to Prescribe Postoperatively by Procedure (continued)
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craniotomy, small (25–50 mcg) intermittent (every 25 min-
utes) IV boluses of the short-acting opioid fentanyl provides 
excellent pain control without oversedation (Frakes, Lord, 
Kociszewski, & Wedel, 2006). Once the gastrointestinal tract 
is functioning and bowel sounds have returned, transitioning 
to an enteral opioid such as oxycodone 5–10 mg by mouth 
should be initiated in preparation for transfer to a nonmoni-
tored setting. There is limited data available assessing the 
safety of intravenous patient-controlled analgesia (IV PCA) 
for postoperative craniotomy pain. This is an area that war-
rants further investigation because the steady narcotic dose 
provided with IV PCA provides optimal pain control (Ortiz-
Cardona & Bendo, 2007). However, the risk of oversedation 
masking a neurologic complication is a major concern.
Pain from spinal procedures in the neurointensive care 
arena is best managed with IV PCA. Using longer-acting 
opioids such as morphine or hydromorphone tend to offer 
better pain control than fentanyl, due to fentanyl’s short 
duration of action (Ornstein & Berko, 2006). Because many 
patients who undergo spine surgery have chronic pain, the 
provider should be familiar with the patient’s prior narcotic 
use because this is key to ensuring adequate opiate dosing 
postoperatively (Ortiz-Cardona & Bendo, 2007). There have 
been studies demonstrating the benefit of ketorolac in pain 
control after spinal surgery, however, NSAID have been 
associated with a decrease in spinal fusion rates (Ornstein 
& Berko, 2006).
Nausea/Vomiting. Postoperative nausea and vomiting 
(PONV) is common after both craniotomy and spine surgery. 
Choosing an antiemetic with minimal central nervous system 
depression is optimal for patients postcraniotomy. Ondan-
setron 4 mg IV intraoperative has been proven to decrease 
PONV in patients undergoing craniotomy for supratentorial 
tumors (Wig, Chandrashekharappa, Yaddanapudi, Nakra, & 
Mukherjee, 2007). Metoproclamide 10 mg IV q 6 is also effec-
tive in relieving PONV without causing sedation.
Antibiotic Prophylaxis. The consensus of the National Sur-
gical Infection Prevention Project on antibiotic prophylaxis 
is that antibiotics should be given within 60 minutes before 
surgical incision and that prophylactic antimicrobial agents 
should be discontinued within 24 hours of the end of surgery 
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(Bratzler & Houck, 2005). A meta-analysis of the data on the 
use of prophylactic antibiotics prior to craniotomy by Barker 
(2007) revealed that this practice reduces the rate of postop-
erative meningitis by approximately 50%.
Venous thromboembolism (VTE) Prophylaxis. The recommen-
dations for VTE prophylaxis postcraniotomy are  intermittent
pneumatic compression (IPC) initiated intraoperatively with 
or without graduated compression stockings (Geertz et al., 
2004). Use of either low-dose unfractionated heparin (LDUH) 
or low molecular weight heparin (LMWH) in addition to IPC 
and/or graduated compression stockings is indicated in those 
patients that are high risk for VTE formation (prior VTE, >40
years old, malignancy) (Geertz et al.). Most providers prefer 
to deter pharmacologic prophylaxis until 24 hours postopera-
tively to decrease the risk of bleeding into the operative bed. 
The recommendation for patients undergoing major spine 
surgery as those seen in the neurocritical care arena is to 
institute either postoperative LMWH alone or LDUH alone 
or perioperative IPC alone. Patients with multiple risk factors
should receive a combination of LDUH or LMWH with grad-
uated compression stockings and/or IPC (Geertz et al.).
Stress Ulcer Prophylaxis. Stress ulcer prophylaxis with H2 
receptor agonists or a proton pump inhibitor is appropriate
in the postoperative patient in the neurocritical care arena, 
especially because those patients with tumors will be on 
high-dose steroids (Allen, Kopp, & Ersted, 2004).
Glycemic Control. Studies have demonstrated that tight glu-
cose control can reduce morbidity and mortality in patients 
with critical illness (Van den Berghe et al., 2001). Utilizing 
rapid-acting or short-acting insulin during the postopera-
tive period while patient is NPO is ideal for maintaining 
normoglycemia. Once the patient is eating, prescribing a 
basal dose with an intermediate-acting insulin as well as 
with correctional and prandial insulin is recommended 
(Hassan, 2007). 
 Prognosis and Outcomes
The rate of postoperative complication for craniotomy and major 
spine procedures varies depending on the reason for the surgery, 
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location of the lesion, patient’s age, and  comorbidities (Boakye 
et al., 2008; Brell et al., 2000; Petrozza, 2002; Zak, 2003).
 Stroke
Stroke is the leading cause of disability and loss of produc-
tive years in the United States and is the third leading cause 
of death (Adams, del Zoppo, & von Kummer, 2006). There are 
two main categories of stroke: hemorrhagic and ischemic. 
Distinguishing between the two is important because it influ-
ences the care given. Intracerebral hemorrhage comprises 
9% of all strokes and the majority of hemorrhagic strokes. 
Subarachnoid hemorrhage is less common and comprises 
3% of all strokes. Ischemic strokes account for the remaining 
88% of strokes (American Heart Association Statistics Com-
mittee and Stroke Statistics Subcommittee, 2006).
 Hemorrhagic Stroke
Pathophysiology. Intracerebral hemorrhage is the type of 
hemorrhagic stroke that is typically seen in patients older than 
55 years of age and has a higher incidence of morbidity and 
mortality than ischemic stroke. The patient with an intra-
cerebral hemorrhage is more unstable, has a greater need 
for neurocritical care and possible neurosurgery than the 
patient with an ischemic stroke (Bhardwaj et al., 2004). Risk 
factors for intracerebral hemorrhage include hypertension, 
anticoagulation, underlying vascular abnormalities, alco-
hol use, liver dysfunction, use of aspirin, use of cocaine or 
amphetamines, smoking, diabetes, prior ischemic stroke, and 
hematologic disorders (Adams et al., 2006). SAH accounts 
for a small portion of all total strokes, but it is a devastating 
event that affects a relatively young population (Feigin et al., 
2005). SAH is discussed fully later in this text and is excluded 
from the discussion that follows.
Presenting Symptoms/Diagnosis. Obtaining an accurate histo-
ry is key in determining if a stroke is hemorrhagic or ischemic. 
The patient with an ICH is more likely to have a headache that 
begins while they are active, focal neurological deficits that 
progressively worsen over minutes to hours and an associated 
change in level of consciousness. Increased blood pressure 
and vomiting are common (Broderick et al., 2007). 
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Treatment. Early recognition of ICH and rapid treatment are 
keys to reducing morbidity and mortality associated with this 
disease. Determining the underlying etiology of the hemor-
rhage and preventing further bleeding are essential; radio-
graphic imaging helps to guide further treatment (Broderick 
et al., 2007). If a cerebellar hemorrhage is found on head CT, 
then transferring the patient to a tertiary care center that 
has the ability to provide neurosurgical intervention is rea-
sonable (Jensen & St. Louis, 2005). Other treatment for ICH 
includes reversing any coagulopathy, controlling hyperten-
sion, and providing supportive care (Adams et al., 2006). 
Table 5.15 summarizes the guidelines for management of 
spontaneous ICH in adults.
 Ischemic Stroke 
Pathophysiology. Ischemic stroke, a clinical syndrome of 
rapid onset of focal cerebral deficit, comprises the majority of 
all strokes and can occur for various reasons (Bandera et al., 
2006). There are three main causes: thrombotic, embolic, and 
hypoperfusion strokes. Risk factors associated with all isch-
emic stroke subtypes include current smoking, hypertension, 
diabetes, lower high-density lipoprotein cholesterol, and 
lower education level (Ohira et al., 2006). Thrombotic strokes 
are usually caused by an obstruction of the artery caused by 
artherosclerosis, whereas embolic strokes are more likely to 
occur from a cardiac source and are common in patients with 
atrial fibrillation and valvular heart disease. Patients that 
present with strokes related to hypoperfusion have relative 
systemic hypoperfusion and may have intracranial or extra-
cranial stenosis (Bhardwaj et al., 2004). 
Presenting Symptoms/Diagnosis. The patient with an acute 
stroke usually presents with a change in neurological status. 
The timing and progression of the symptoms are important 
in helping to differentiate between the types of stroke and 
other diseases. It is important to rule out other disease states 
that mimic ischemic stroke including masses, encephalitis, 
seizures or postictal state, metabolic derangement (hypo-
glycemia or hyperglycemia), and migraines (Bhardwaj et al., 
2004). An ischemic stroke can at times be precipitated by a 
transient ischemic attack (TIA). Most TIAs last <30 minutes 
but the definition of TIA is transient loss of neurological 
function that lasts <24 hours (Lerner, 1995). 
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  Recommendation
 Intervention Level*
Recommendations
for Emergency 
Diagnosis and 
Assessment 
of ICH
ICH should be promptly recognized 
and diagnosed with either a head 
CT or MRI
Class I
Recommendations
for Initial 
Medical Therapy
Monitoring and management of 
patients should take place in 
an ICU
Appropriate antiepileptic therapy 
should always be used for treat-
ment of clinical seizures
Class I
Class I
Sources of fever should be treated 
and antipyretic medications ad-
ministered to lower temperatures 
in febrile patients
Class I
Early mobilization and rehabilita-
tion are recommended in patients 
with ICH who are clinically stable
Class I
Treatment of elevated ICP
■  elevate head of bed
■  provide analgesia and  sedation
The following generally require 
monitoring of ICP and BP; CPP 
>70 mmHg must be  maintained.
■  osmotic diuretics (Mannitol and 
hypertonic saline)
■ CSF drainage via EVD
■ Neuromuscular blockade
■ Hyperventilation
Class IIa
Tight glycemic control, treat  glucose 
>185 mg/dL
Class IIa
5.15
Guidelines for the Management 
of Spontaneous Intracerebral 
Hemorrhage in Adults
(continued)
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  Recommendation
 Intervention Level*
Blood pressure control with bolus 
doses or continuous  infusions of 
Labetalol, Nicardipine,  Esmolol, 
Enalapril, Hydralazine, Nipride, or 
Nitroglycerin
■  If SBP >200 mmHg or MAP 
>150 mmHg → aggressive 
reduction of BP
■  If SBP >180 mmHg or MAP >130 
mmHg and evidence of elevated 
ICP → monitor ICP 
and reduce BP to keep CPP 
>60 mmHg to 80 mmHg
■  If SBP >180 mmHg or MAP >130 
mmHg and no elevated ICP →
modest reduction of BP, goal 
MAP 110 mmHg or target BP 
160/90 mmHg
Class IIb
Treatment with recombinant 
activated factor VII within fi rst 
3–4 hours after onset of bleed
Class IIb
Use of prophylactic antiepileptic thera-
py may reduce risk of early seizures 
in patients with lobar hemorrhage
Class IIb
Recommendations 
for Prevention 
of Deep Vein 
Thrombosis 
and Pulmonary 
Embolism
Use of intermittent pneumatic 
 compression devices on 
patients with hemiparesis/
hemiplegia
Long-term treatment of 
 hypertension
Class I
Class I
After cessation of bleeding, low-dose 
subcutaneous low-molecular-
weight heparin or unfractionated 
heparin in patients with hemiplegia 
after 3–4 days from onset
Class IIb
5.15
Guidelines for the Management 
of Spontaneous Intracerebral 
Hemorrhage in Adults (continued)
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Patients who develop acute proximal 
venous thrombosis should be 
considered for placement of vena 
cava fi lter
Class IIb
Adding long-term antithrombotic 
therapy several weeks after 
placement of vena cava filter →
cause of hemorrhage must be 
taken into consideration and 
associated conditions with 
increased arterial throm-
botic risk (atrial fibrillation and 
overall health and mobility of 
patient)
Class IIb
 Recommendations 
for the Man-
agement 
of ICH Related 
to Coagulation 
and Fibrinolysis
Protamine sulfate should be used to 
reverse heparin-associated ICH, 
dose dependent on time from ces-
sation of heparin
Treatment with IV vitamin K to 
reverse warfarin-associated ICH 
and treatment to replace clotting 
factors
Class I
Class I
Prothrombin complex concentrate, 
factor IX complex concentrate and 
rFVIIa normalize elevated INR 
levels rapidly but have greater 
risk of thromboembolism. FFP 
can be used but is associated with 
greater volumes and longer infu-
sion times
Class IIb
Decision to restart antithrombic 
therapy after ICH
Class IIb
■  Antiplatelet therapy may be 
a better choice for patients 
with a lower risk of cerebral 
infarction and a higher risk 
of amyloid angiopathy or with 
very poor overall  neurological 
function
(continued)
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  Recommendation
 Intervention Level*
■  Restart warfarin therapy 
7–10 days after onset of original 
ICH in patients with very high 
risk of  thromboembolism
Treatment of patients with ICH related 
to thrombolytic therapy includes ur-
gent empirical therapies to replace 
clotting factors and platelets
Class IIb
 Recommendations 
for Surgical 
 Approaches
In patients with cerebellar ICH 
>3 cm who are deteriorating 
neurologically or who have 
brainstem compression and/or 
hydrocephalus from ventricular 
obstruction should have surgical 
removal of hemorrhage
Class I
Stereotactic infusion of urokinase 
into clot cavity within 72 hours of 
ictus reduces clot burden and risk 
of death, but rebleeding is more 
common and functional outcome 
is not improved → usefulness 
unknown
Class IIb
Minimally invasive clot evacuation 
using mechanical devices or 
endoscopy→ usefulness unknown
Class IIb
Evacuation of supratentorial ICH by 
standard craniotomy might be 
considered for patients present-
ing with lobar clots within 1 cm of 
surface
Class IIb
Routine evacuation of supratento-
rial ICH by standard craniotomy 
within 96 hours of ictus is NOT 
RECOMMENDED
Class III
5.15
Guidelines for the Management 
of Spontaneous Intracerebral 
Hemorrhage in Adults (continued)
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*Class I Recommendation, Benefi t >>>Risk
Class IIa Recommendation, Benefi t >>Risk
Class IIb Recommendation, Benefi t > or equal to Risk
Class III Recommendation, Risk > or equal to Benefi t
Adapted from Broderick et al., 2007.
Recommendations 
for Timing of 
Surgery
No clear evidence shows that 
ultra-early craniotomy improves 
functional outcome or mortality 
rate; very early craniotomy may 
be associated with increased risk 
of recurrent bleeding.  Operative 
removal within 12 hours, when 
performed by less-invasive 
methods has the most supportive 
evidence
Class IIb
Delayed evacuation by craniotomy 
appears to offer little if any benefi t; 
in patients presenting in coma 
with deep hemorrhages, removal 
of ICH by craniotomy may actu-
ally worsen outcome and is NOT 
RECOMMENDED
Class III
Recommendations 
for Decompres-
sive Craniectomy
Too few data exist to comment on 
the potential of decompressive 
craniectomy to improve outcome 
in ICH
Class IIb
Recommendation 
for Withdrawal 
of Technological 
Support
Careful consideration of aggres-
sive full care during the 24 hours 
after ICH onset and postpone-
ment of new DNR orders during 
that time
Class IIb
Recommendations 
for Prevention of 
Recurrent ICH
Treating hypertension in the non-
acute setting
Discontinuation of smoking, heavy 
alcohol use, and cocaine use
Class I
Class I
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Treatment. There are many different modalities that are 
available for stroke treatment. Intravenous tissue plasmin-
ogen activator (tPA), intra-arterial thrombolysis, and clot 
extraction by mechanical methods are some of the more 
advanced treatments that are available at tertiary care 
centers that are designated as stroke centers. Rapid brain 
imaging, including noncontrast head CT and MRIs, are tools 
that aid the clinician in rapid assessment and manage-
ment options for stroke patients (Hill, Demchuk, Tomsick, 
Palesch, & Broderick, 2006). Treatment options are time 
sensitive and only a small portion of patients who suffer 
from ischemic stroke actually receive thrombolysis or clot 
extraction (Weintraub, 2006). If any of the aforementioned 
modalities are used to treat an ischemic stroke, the patient 
will need to be admitted to the intensive care unit for sup-
portive care. After the acute phase of the ischemic stroke 
has passed, it is essential to focus on the rehabilitation and 
modification of risk factors for the stroke patient (Bhardwaj 
et al., 2004). Guidelines for the early management of the 
adult with acute ischemic stroke are summarized in Table 
5.16. Class III recommendations guide the provider regard-
ing activities that may place the patient with an acute isch-
emic event at greater risk based on existing data. The Class 
III recommendations for ischemic stroke are summarized 
in Table 5.17. 
Prognosis and Outcomes. Stroke is the leading cause of dis-
ability and the third leading cause of death in the United 
States (Adams et al., 2006). The majority of functional recovery 
after stroke occurs in the first 3 months and prognosis after 
stroke is dependent on the type of stroke suffered and on the 
anatomical location of the lesion. (Aronen, Laakso, Moser, & 
Perkio, 2007). 
 Subarachnoid Hemorrhage 
 Definition and Etiology 
Subarachnoid hemorrhage, defined as bleeding between the 
arachnoid and pia mater layers of the meninges (McQuillan, 
Von Reuden, Hartsock, Flynn, & Whalen, 2002), is a subtype 
of stroke that accounts for 10% of all strokes. The main cause 
of SAH is trauma; nontraumatic SAH is usually caused by 
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  Recommendation
 Intervention Level*
Designation of 
Stroke Centers
Creation of primary stroke  centers 
(PSC)
Class I
Development of a comprehensive 
stroke center (CSC)
Class I
For patients with suspected stroke, 
EMS should bypass hospitals that do 
not have resources available to treat 
acute stroke and go to closest facility 
capable of treating acute stroke
Class I
Emergency
Evaluation
and Diagnosis 
of Acute
Ischemic Stroke
Have an organized protocol for the 
emergency evaluation of patients 
with suspected stroke
■  Goal = complete evaluation 
in 60 minutes
■  Careful clinical  assessment, 
including neurological 
examination
Class I
Use of stroke rating scale, 
 preferably NIHSS
Class I
A limited number of hematologic, 
coagulation, and biochemistry 
tests are recommended during 
initial emergency evaluation
Class I
Patients with clinical evidence of 
acute cardiac or pulmonary dis-
ease may warrant a chest x-ray
Class I
Obtain an ECG because of high inci-
dence of heart disease in patients 
with stroke
Class I
Early Diagnosis: 
Brain and Vas-
cular Imaging
Imaging of brain is recommended 
before initiating any therapy to 
treat ischemic stroke
■  Head CT is usually  suffi cient
■  Imaging should be interpret-
ed by physician with expertise 
in reading CTs or MRIs
Class I
5.16 Guidelines for the Early Management of Adults with Ischemic Stroke
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  Recommendation
 Intervention Level*
Vascular imaging is needed as a 
preliminary step for intra-
arterial administration of phar-
macological agents, surgical 
procedures, or endovascular 
interventions
Class IIa
General Supportive 
Care and 
 Treatment 
of Acute 
 Complications
Airway support and ventilatory as-
sistance if patient has decreased 
level of consciousness or bulbar 
dysfunction
Class I
Hypoxic patients should receive 
supplemental oxygen
Class I
Treat sources of fever and adminis-
ter antipyretic medications
Class I
Use of cardiac monitors to screen 
for atrial fi brillation and other 
serious arrhythmias for fi rst 
24 hours
Class I
Cautious management of arterial 
hypertension
Class I
Treat BP in patients that are 
 otherwise eligible for rtPA
■ SBP <185 mmHg
■  DBP <110 mmHg before 
lytic therapy is started.
Maintain BP below 180/105 mmHg 
for the fi rst 24 hours after rtPA is 
given.
Class I
In patients undergoing acute 
 interventions to reopen  occluded 
 vessels, the rtPA BP guide-
lines should be followed
Class I
5.16
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Treat underlying cause of arterial 
hypotension
Class I
■  Treat hypovolemia with 
normal saline
■  Correct cardiac arrhyth-
mias that may reduce 
cardiac output
Treat hypoglycemia, goal =
 normogylcemia
Class I
Intravenous 
 Thrombolysis
Intravenous rtPA (0.9 mg/kg, maxi-
mum dose 90 mg) recommended 
for select patients who are treated 
within 3 hours of onset of ischemic 
stroke
Class I
Physicians should be aware of po-
tential complications with rtPA
■  Bleeding
■  Angioedema, causing 
 airway obstruction
Class I
Intra-Arterial 
 Thrombolysis
Intra-arterial thrombolysis is a treat-
ment option for selected patients 
who have major stroke symptoms 
<6 hours duration due to occlusions 
of the MCA; these patients are not 
candidates for intravenous rtPA
Class I
Treatment must take place at an 
experienced stroke center that 
has immediate access to cerebral 
angiography and qualifi ed inter-
ventionalists
Class I
Intra-arterial thrombolysis is 
reasonable in patients who have 
contraindications to  intravenous 
thrombolysis such as recent 
surgery
Class IIa
Antiplatelet
Agents
Administration of aspirin 325 mg 
within 24–48 hours after stroke 
onset
Class I
(continued)
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  Recommendation
 Intervention Level* 
Volume 
 Expansion, 
Vasodilators, 
and Induced 
 Hypertension
In exceptional cases vasopressors 
may be used to augment cerebral 
blood fl ow
Class I
Endovascular
 Interventions
Use of MERCI device is a reason-
able intervention for extraction of 
intra-arterial thrombi
Class IIb
Admission to the 
Hospital and 
General Acute 
Treatment
Use of stroke units incorporating 
rehabilitation
Use of standardized stroke care 
order sets
Class I
Class I
Early mobilization and 
measures to prevent subacute 
 complications of stroke
Class I
Swallow assessment before  eating 
or drinking
Class I
Treat patients with suspected 
urinary tract infections or 
pneumonia with antibiotics
Class I
Prevent deep vein thrombosis 
in immobilized patients with 
subcutaneous injections of 
anticoagulants
Class I
Treat concomitant medical  
diseases
Class I
Prevent recurrent stroke by 
promoting early interventions
Class I
Treatment of Acute 
Neurological 
 Complications
Patients with large areas of infarc-
tion are at high risk for brain 
edema and increased ICP.
Class I
■  Close neurological monitor-
ing during fi rst few days
5.16
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■  Take measures to lessen 
cerebral edema
■  Consider  transfer 
to  institution with 
 neurosurgical expertise
Treat patients with acute hydroceph-
alus with placement of ventricular 
drain
Class I
Decompressive surgical evacuation of 
space-occupying cerebellar infarct
Class I
Treat recurrent seizures after 
stroke
Class I
Decompressive surgery for malignant 
edema may be life- saving, but 
impact of morbidity is unknown. 
Family should be  informed about 
potential outcomes including 
severe disability
Class IIa
*Class I Recommendation, Benefi t >>>Risk
Class IIa Recommendation, Benefi t >>Risk
Class IIb Recommendation, Benefi t > or equal to Risk
Class III Recommendation, Risk > or equal to Benefi t
Adapted from Adams et al., 2007.
the rupture of a saccular aneurysm. There are several risk 
factors that contribute to the incidence of aneurysmal sub-
arachnoid hemorrhage, including cigarette smoking, heavy 
alcohol consumption, hypertension, oral contraceptive use, 
cocaine/amphetamine use, and familial history (Feigin et al., 
2005). This section focuses on the diagnosis and management 
of aneurysmal SAH. 
 Diagnosis 
One of the keys to accurately diagnosing SAH is a compre-
hensive clinical history. The patient with aneurysmal SAH 
will typically complain of “the worst headache of life” or 
describe a headache with a sudden, “thunderclap” onset. 
Noncontrast head CT is essential to the diagnosis of SAH 
(Liebenberg, Worth, Firth, Olney, & Norris, 2005). On a non-
contrast head CT, blood is seen in the subarachnoid space 
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Intervention
Recommendation
Level
Early Diagnosis: 
Brain and 
Vascular 
Imaging
Emergency treatment of stroke 
should NOT be delayed to obtain 
multimodal imaging studies
Vascular imaging should NOT delay 
treatment of patients whose symp-
toms started <3 hours ago and 
who have acute ischemic stroke
Class III
Class III
Intra-arterial 
 Thrombolysis
The availability of intra-arterial 
 thrombolysis should NOT preclude 
the intravenous administration 
of rtPA if the patient is eligible 
for rtPA
Class III
Anticoagulants Urgent anticoagulation with the 
goal of preventing early recurrent 
stroke, halting neurological wors-
ening, or improving outcomes is 
NOT recommended in patients with 
acute ischemic stroke
Class III
Antiplatelet
Agents
Aspirin should NOT be considered a 
substitute for other acute interven-
tions for treatment of stroke
Class III
Do NOT administer aspirin as an 
 adjunctive therapy within 24 hours 
of thrombolytic therapy
Class III
Do NOT administer clopidogrel alone 
or in combination with aspirin for 
treatment of stroke
Class III
Do NOT administer antiplatelet 
agnets that inhibit the glycoprotein 
IIb/IIIa receptor
Class III
Volume 
Expansion,
Vasodilators, 
and Induced 
Hypertension
Hemodilution and volume expansion 
is NOT recommended
Do NOT administer medications such 
as pentoxifyline
Class III
Class III
5.17 Ischemic Stroke CLASS III Recommendations
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in 92% of cases if the head CT is performed within the first 
24 hours of presentation. After 24 hours, the sensitivity of 
CT to detect the SAH decreases. Once subarachnoid blood 
is seen on a head CT, then no further workup is needed to 
diagnose the SAH. However, if the clinical history is suspi-
cious for SAH and head CT is negative for blood, then a 
lumbar puncture (LP) must be obtained (Al-Shahi, White, 
Davenport, & Lindsay, 2006). In the setting of SAH, the 
opening pressure on LP will be elevated and there would 
be red blood cells (RBCs) present in all tubes. The LP can 
only be considered a traumatic tap if the last collection tube 
has no RBCs. If both head CT and LP are performed within 
a few days after initial headache and are negative, then 
the diagnosis of SAH can be eliminated. However, if the 
clinical history is still highly suspicious for aneurysmal 
SAH, then a cerebral angiogram should be performed 
(Liebenberg et al.). 
Once the diagnosis of SAH has been established, it is 
necessary to determine the etiology of the SAH. Saccular 
aneurysm rupture is the most common cause of nontraumat-
ic SAH. The golden standard for diagnosing and determining 
the etiology of SAH is the four-vessel cerebral angiogram. 
In about 20% of cases, the initial angiogram may be negative 
because of vasospasm, poor technique, compression of the 
vessel caused by extravascular clot, or thrombus in the aneu-
rysmal pouch. If the initial angiogram is negative, it should 
be repeated in 2 weeks. The aneurysm location, size, and 
Admission to the 
Hospital and 
General Acute 
Treatment
Nutritional supplements are NOT 
needed
AVOID placement of indwelling 
bladder catheters
Class III
Class III
Treatment 
of Acute 
Neurological 
 Complications
Corticosteroids are NOT 
recommended
Prophylactic administration of anticon-
vulsants to patients who have NOT 
had seizures is NOT recommended
Class III
Class III
*Class I Recommendation, Benefi t >>>Risk
Class IIa Recommendation, Benefi t >>Risk
Class IIb Recommendation, Benefi t > or equal to Risk
Class III Recommendation, Risk > or equal to Benefi t
Adapted from Adams et al., 2007.
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presence of neck are factors that can be seen on angiogram 
which help determine the best course of treatment (Bhard-
waj et al., 2004). 
Grading Scales. There are different grading systems for clas-
sifying SAH that aid clinicians in guiding management deci-
sions and providing prognostic data for patients and fam-
ily members, although there is no one accepted standard. 
The most commonly used scale is the Hunt and Hess Scale 
(see Table 5.18) but it has many inherent faults; it is subjec-
tive and it is difficult to assign patients to a grade when they 
have an atypical presentation. The other commonly used 
scale is the Fisher scale (see Table 5.19), which grades the 
severity of SAH on radiographic appearance. The Fisher 
scale provides an excellent prediction of risk of vasospasm 
(Rosen & MacDonald, 2005). 
 Treatment 
Aneurysms can be either clipped surgically or coiled with 
endovascular intervention. Smaller aneurysms (<4 mm) that 
have a narrow neck are favorable for endovascular coiling. 
There is some controversy regarding the timing of the treat-
ment of aneurysms after SAH. Early aneurysm treatment 
after hemorrhage may be more challenging because of edema 
and vasospasm; whereas the risk of later aneurysm repair is 
Grade Neurological Status
 1 Asymptomatic or mild headache and slight nuchal rigidity
 2  Severe headache, stiff neck, no neurologic defi cit except cranial 
 nerve palsy
 3 Drowsy or confused, mild focal neurologic defi cit
 4 Stuporous, moderate, or severe hemiparesis
 5 Coma, decerebrate posturing
5.18 Hunt and Hess Scale
Based on initial neurologic examination; adapted from Hunt, W, Hess, R, (1968). J Neurosurgery
28: 14.
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greater if hypervolemic and hypertensive therapies are initi-
ated in the setting of vasospasm (Bhardwaj et al., 2004). 
Patients with aneurysmal SAH patients should be 
admitted to an intensive care unit for continuous cardiac 
monitoring and frequent neurological assessments. Prior 
to securing the aneurysm; blood pressure should be con-
trolled, lights should remain low, and loud noises avoided 
to reduce the risk of further rupture of the aneurysm. A 
systolic blood pressure of <140 mmHg is suggested prior 
to securing the aneurysm and can be achieved with intra-
venous medications such as labetalol, hydralazine, or a 
nicardipine gtt. Agents that have vasodilatory effects (nitro-
prusside and nitroglycerin) increase intracranial pressure 
by increasing cerebral blood volume and should be avoided 
(Bhardwaj et al., 2004). 
 Complications and Management 
After aneurysm repair, SAH patients continue to be managed 
in the ICU because of the high rate of complications includ-
ing seizures, cerebral edema, hydrocephalus, vasospasm, and 
hyponatremia. 
Seizures. Seizures are more common in SAH patients that 
have aneurysms clipped versus those repaired with endo-
vascular coiling. During the first 7 days after SAH, if seizures 
are not present, then likelihood of developing seizures is low 
and antiepileptic therapy is discontinued. For SAH patients 
Group Appearance of Blood on Head CT Scan
 1 No blood detected
 2 Diffuse deposition or thin layer with all vertical layers <1 mm thick
 3 Localized clot and/or vertical layers 1 mm or more in thickness
 4  Intracerebral or intraventricular clot with diffuse or no subarachnoid blood
5.19 Grading Scale Based on Radiographic Information*
*Used to Determine Vasospasm Risk, not Clinical Outcome
Adapted from Fisher, C. M., Kistler, J. P., Davis, J. M. Relation of cerebral vasospasm to 
subarachnoid hemorrhage visualized by CT scanning. Neurosurgery 1980, 6:1.
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that do have a seizure, antiepileptic therapy is continued for 
at least 6 months after SAH. Prophylactic antiepileptic ther-
apy has not been studied and remains controversial (Naval, 
Stevens, Mirski, & Bharwaj, 2006). 
Cerebral edema. SAH patients are at risk for cerebral edema 
therefore it is important to keep them well-hydrated with 
isotonic or hypertonic fluids. Hypotonic fluids will lead to 
increased cerebral edema (Bhardwaj et al., 2004). 
Hydrocephalus. Hydrocephalus associated with SAH can be 
acute, occurring within the first 24 hours after aneurysmal 
bleed. This obstructive hydrocephalus occurs due to impedance 
of cerebrospinal fluid (CSF) by blood clots in the ventricular 
system. Hydrocephalus seen later in SAH is usually commu-
nicating. Communicating hydrocephalus, also known as non-
obstructive hydrocephalus, is caused by impaired cerebrospi-
nal fluid resorption in the absence of any CSF-flow obstruction. 
Management of acute hydrocephalus may require the place-
ment of an external ventricular drainage (EVD) catheter. Care 
must be used when placing an EVD in the patient with acute 
hydrocephalus as a large change in the transmural pressure 
may cause rerupture of an unsecured aneurysm (Springborg, 
Frederikson, Eskesen, & Olsen, 2004). Patients that develop 
hydrocephalus later in their disease course may need EVDs or 
serial LPs to relieve increased ICP until the ventricular system 
is able to reabsorb CSF normally. Among patients with SAH, 
20% need long-term diversion of CSF with placement of shunts 
(Dehdashti, Rillet, Rufenacht, & de Tribolet, 2004). 
Vasospasm. Vasospasm, the constriction of cerebral blood 
vessels caused by the presence of blood in the subarachnoid 
space occurs in 60% to 75% of patients with SAH. The actual 
incidence of clinical vasospasm (patients with change in men-
tal status or a focal neurological deficit) is somewhat lower. 
Vasospasm can occur up to 21 days after the initial bleed but 
the peak incidence is days 7 through 11 (Kassab et al., 2007). 
Nimodipine has been shown to improve outcomes in SAH, 
although the exact mechanism of action is not fully understood 
(Brown & Carley, 2004). Medical management of vasospasm 
includes nimodipine 60 mg every 4 hours for 21 days after 
SAH. When signs of clinical or symptomatic vasospasm are 
noted, then hypervolemic, hypertensive, hemodilutional ther-
apy (triple-H  therapy) is initiated. Triple-H therapy consists of 
aggressive fluid repletion with the goal of euvolemia to positive 
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fluid balance. Isotonic to hypertonic IV solutions are ordered 
to avoid hyponatremia, which can result in cerebral edema 
(Naval et al., 2006). The target hematocrit for the SAH patient 
is 30 and aggressive fluid repletion with hypervolemic therapy 
helps to achieve this goal. Blood pressure is augmented with 
vasopressors to increase cerebral perfusion pressure. Because 
not all SAH patients have an EVD with the ability to moni-
tor CPP, a mean arterial pressure goal is set based on correla-
tion with patient’s clinical examination (Bhardwaj et al., 2004). 
Severe vasospasm may be refractory to all medical manage-
ment and require further interventions. Transcranial Doppler 
(TCD) studies are obtained daily as one method of monitoring 
for vasospasm (Kassab et al., 2007). When blood flow velocities 
are visualized as increased via TCDs and the patient has an 
associated change in neurological examination, an angiogram 
may be warranted to further assess for vasospasm. With severe 
vasospasm, the patient has a high risk of ischemic stroke due 
to constriction of cerebral blood vessels. Large vasospastic ves-
sels may be opened with balloon angioplasty. When vasospasm 
is seen in smaller, distal vessels then intra-arterial injections 
of vasodilators such as papaverine, verapamil, nicardipine, or 
nimodipine may be used (Feigin & Findlay, 2006). 
Hyponatremia. Many SAH patients develop hyponatremia 
during the course of their illness. There are two main rea-
sons for SAH patients to become hyponatremic—syndrome 
of inappropriate secretion of antidiuretic hormone (SIADH) 
and cerebral salt wasting (CSW). Diagnosing SAH accurately 
is imperative as the treatments for SIADH and CSW are very 
different (see Table 5.20) (Naval et al., 2006). 
 Serum Fluid Urine
Disorder Na Level Balance Output Treatment
SIADH Low Hypervolemic Low Fluid restriction (contra-
   or euvolemic    indicated in SAH)
CSW Low hypovolemic High  Aggressive fl uid resus-
 citation with
 hypertonic saline
5.20 Hyponatremia Treatment
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 Prognosis and Outcomes 
SAH outcomes have not improved significantly over the last 
few years; death or dependence is usually associated with 
complications surrounding SAH and have rates as high as 70% 
(Feigin & Findlay, 2006). This disease process has a relatively 
young age of onset and can dramatically affect quality of life. 
 Seizures 
 Definition 
A seizure is an event of altered brain function as a result of 
abnormal hypersynchronous paroxysmal cortical neuronal 
discharge with either motor (convulsion), sensory, or cogni-
tive dysfunction (Varelas & Mirski, 2001). Clinical manifes-
tations of seizures occur when enough neurons are excited. 
The resultant seizure activity reflects the area of the brain 
involved. Epilepsy is defined as a condition of recurrent (two 
or more) unprovoked seizures (Krumholz et al., 2007). 
 Pathophysiology 
Abnormal neuronal excitability is thought to occur as a result 
of disruption of the depolarization & repolarization mecha-
nisms of the cell (termed “excitability”). Aberrant neural net-
works that develop abnormal synchronization can result in the 
development and propagation of an epileptic seizure (termed 
“synchronization”). Epileptic seizures originate in a setting of 
both altered excitability and synchronization of neurons. The 
excitability of individual neurons is affected by cell membrane 
properties, intracellular processes, structural features of neu-
ronal elements, and interneuronal connection (Nair, 2003). 
 Classification of Seizures 
The International League Against Epilepsy (ILAE) has devel-
oped a generally accepted classification system for seizures 
(Commission on Classification and Terminology of the Inter-
national League Against Epilepsy, 1982). This classification 
of seizures is divided into two specific categories—partial 
and generalized. A  partial seizure involves only a portion of 
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the brain at onset, whereas a  generalized seizure involves the 
entire brain at onset (Holmes, 1997). 
Partial seizures can be divided into simple partial and 
complex partial subtypes. During simple partial seizures, con-
sciousness remains intact. The signs or symptoms of simple 
partial seizures depend on the location of the seizure focus. 
Examples include focal motor (rhythmic activity of arm, leg, 
or face), somatosensory (visual, auditory, olfactory signs), 
autonomic (sweating, pallor, flushing), or psychic symptoms 
(hallucinations, illusions) (Holmes, 1997). 
The complex partial seizure is progression to another area 
of the brain. A person’s level of awareness or consciousness is 
impaired, although they do not lose consciousness. The patient 
either does not respond to commands or responds in an abnor-
mally slow manner. An example of a complex partial seizure 
is an automatism (involuntary motor activity) characterized as 
facial grimacing, chewing, lip smacking, or repeating phrases. 
The patient does not recall this activity after the seizure. Com-
plex partial seizures usually last from 30 seconds to several 
minutes and may be preceded by a simple partial seizure (aura), 
which serves as a warning that more seizures are to come as 
well as aids the practitioner to the seizure’s initial focus. Both 
types of partial seizures can spread to the entire brain; this is 
referred to as secondary generalized seizures (Holmes, 1997).
Primary generalized seizures arise simultaneously in 
both cerebral hemispheres. They generally involve impair-
ment of consciousness and may range from barely notice-
able to tonic–clonic convulsion. Types of generalized seizures 
include absence, myoclonic, tonic, clonic, tonic–clonic, and 
atonic (Holmes, 2007).
Absence seizures are generalized seizures, which usually 
start abruptly without an aura, last from a few seconds to a 
half a minute, end abruptly, and may be associated with motor, 
autonomic, and behavioral phenomena such as automatisms. 
They are often difficult to distinguish from complex partial 
seizures.  Myoclonic seizures are characterized by sudden, 
brief (<350 milliseconds), shock-like contractions. These 
may be generalized, confined to face/trunk/limb or to an 
individual muscle group. Because of the brevity of seizures, 
it is not possible to determine if consciousness is impaired. 
Tonic seizures are brief seizures (usually <60s) consisting of 
the sudden onset of increased tone in the extensor muscles. 
Clonic seizures consist only of rhythmic or semirhythmic 
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contraction of muscle groups (without increase in tone/stiff-
ening).  Generalized tonic–clonic (formerly called grand mal) 
seizures occur with the onset of generalized stiffening (tonic 
phase) followed by generalized jerking of the muscles (clonic 
activity). A loss of consciousness usually occurs simultane-
ously with the onset of the tonic phase and is followed by 
a deep postictal phase.  Atonic seizures, or drop attacks, are 
characterized by a sudden loss of muscle tone, they begin 
suddenly and without warning. Atonic seizures are rare and 
are usually confined to childhood (Holmes, 1997).
 Diagnostic Criteria
Seizures are often a symptom of an underlying disorder, which 
may be genetic, traumatic, metabolic, infectious, malignant, 
or pharmacologic. Table 5.21 summarizes common etiologies 
of seizures. The underlying disorder must be identified and 
treated to control the seizure in most cases (Browne & Holmes, 
2001). Evaluation of seizures begins with a history and physi-
cal exam with focus on the comprehensive neurologic exami-
nation. Metabolic abnormalities may be responsible for up to 
30% to 35% of seizures in patients with critical illness (Varelas 
& Mirski, 2001). Therefore, it is imperative to send laboratory 
work to include complete blood count (CBC), electrolytes, 
liver function tests, glucose, and toxicology. The patient with a 
known seizure disorder, should have serum antiepileptic drug 
levels obtained to determine compliance. Noncontrast CT or 
MRI should be performed immediately in the setting of new 
focal neurologic deficit, trauma, fever, persistent headache, 
history of cancer, or anticoagulant therapy (Browne & Holmes, 
2001). LP should also be considered in the setting of fever, 
nuchal rigidity, and altered mental status to rule out menin-
gitis or encephalitis. The LP should be done after imaging has 
been completed to avoid precipitation of cerebral herniation 
in the setting of increased ICP. EEG can be helpful and should 
be considered especially in those patients who are comatose 
because nonconvulsive status epilepticus is often undiagnosed 
in the ICU (Praline et al., 2007).
 Treatment
Most commonly, seizures manifest as single episodes that 
serve to alert the practitioner that a metabolic or structural 
abnormality exists (Varelas & Mirski, 2001). Often, a patient 
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Metabolic Causes
■ Hypoglycemia, hyponatremia, 
  hypocalcemia, hypophosphatemia
■ Fluid balance: dehydration/water 
  intoxication
■ Hypoxia, ischemia (postcardiac arrest)
Neurovascular
■ Ischemic stroke
■ Intracerebral hemorrhage
■ Subarachnoid hemorrhage
■ Vascular malformations
Toxins (poisons)
■ Carbon monoxide
■ Lead
Tumors/Lesions
Alcohol / Drug Withdrawal
■ Barbiturates, Opioids, Benzodiazepines
Drug Overdose
■ Isoniazid
CNS Infection
■ Meningitis, Encephalitis
Infl ammatory Disease
■ Vasculitis
Medications (Lower Seizure Threshold)
■ Bronchodilators (Theophylline)
■ Antibiotics (Beta Lactams, Flagyl)
■ Antidepressants (Wellbutrin, Tricyclics)
■ Local anesthetics (Lidocaine)
■ Psychostimulants (Cocaine)
Head Trauma
■ Contusion
■ Subdural Hematoma
■ Epidural Hematoma
Abrupt Withdrawal of CNS Depressants Birth Trauma
Sepsis, Infection, Fever Neurofi bromatosis
Renal/ Hepatic Dysfunction Primary Epilepsy
Idiopathic Low-Antiepileptic Levels 
 (noncompliance)
5.21 Common Etiologies of Seizures
who has had a single seizure with no evidence of structural 
lesion or electroencephalographic abnormalities may be 
monitored but not given medication (Browne & Holmes, 2001). 
However, if an underlying etiology, such as mass lesion or 
diagnosis of epilepsy is made, medication is initiated depend-
ing on the type of seizure. Table 5.22 summarizes the usual 
dosages for common antiepileptic drugs used in patients 16 
years of age and older. There are instances in which medi-
cal therapy via antiepileptic drugs fails and a person’s sei-
zures become intractable. For intractable seizures, there are 
surgical options to remove a portion of the patient’s brain 
      Therapeutic
     Range of 
    Maintenance Plasma
Drug Starting Dose Dose Frequency Dose Increase Dose Concentrations
      (mg/day)        (mg/day)   (μg/ml)
 Antiepileptic Drugs in Patients 16 Years and Older*
 Carbamazepine 
(Carbatrol, Tegretol, 
Tegretol-XR)
400  Carbatrol or Tegretol-
XR, twice a day; 
Tegretol or generic, 
three times a day
 200 mg/day at 1-wk 
intervals
600-1200 4–12
Divalproex sodium 
(Depakote)
500–1000 Twice a day 250 mg/day at 1-wk 
intervals
1000–3000 50–150
Ethosuximide
(Zarontin)
500 Twice a day 250 mg/day at 1-wk 
intervals
1000–2000 40–120
Gabapentin (Neu-
rontin)
900 Three times a day 300 mg/day at 24-hr 
intervals
900–3600 Not established
Lamotrigine†
(Lamictal)
50 Twice a day 50 mg/day at 2-wk 
intervals‡
300–500 Not established
Levetiracetam (Kep-
pra)
1000 Twice a day 1000 mg/day at 2-wk 
intervals
1000–3000 Not established
Oxcarbazepine
(Trileptal)
600 Twice a day 600 mg/day at 1-wk 
intervals
600–2400 Not established
5.22
 Phenobarbital 90  Daily  30 mg/day at 4-wk 
intervals
90–120 10–40
Phenytoin (Dilantin) 300 Daily 100 mg/day at 4-wk 
intervals§
300–500 10–20
Primidone (Mysoline, 
Neurosyn)
100–125 Three times a day Days 1-3, 100-150 mg 
daily at bedtime; 
days 4-6, 100-125 
mg twice a day; days 
7–9, 100-125 mg 
three times a day; 
day 10, 250 mg three 
times a day
750–1000 5–12
Tiagabine (Gabitril) 4 Twice a day to four 
times a day
4–8 mg/day at 1-wk 
intervals
32-56 Not established
Topiramate (To-
pamax)
25–50 Twice a day 25–50 mg/day at 1-wk 
intervals
200-400 Not established
Zonisamide (Zone-
gran)
100 Twice a day 100 mg/day at 2-wk 
intervals
400-600 Not established
*Data are from Browne and Holmes.5 Information on dosages for younger patients is also available from this source.
†The information shown is for persons who are taking lamotrigine in combination with an enzyme-inducing antiepileptic drug (carbamazepine, phenobarbital, 
phenytoin, or primidone) and who are not taking valproic acid. For persons who are not taking an enzyme-inducing antiepileptic drug or who are taking valproic acid, the 
dose schedule is different. Consult the package insert.
‡After four weeks, the daily dose can be increased by 100 mg every two weeks.
§The dose should be increase at a rate of 30 to 50 mg per day at four-week intervals when the phenytoin plasma concentration is higher than 10 μg per milliliter.
Reprinted with permissions from Browne & Holmes, 2001.
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(usually a portion of the temporal lobe) where the seizure 
focus originates. This is done after cortical mapping of the 
brain to localize the dominant language centers. Discontinu-
ation of therapy may be considered for epilepsy syndromes 
if the patient is seizure free after 2 years of therapy (Browne 
& Holmes, 2001).
 Prognosis
Overall prognosis for patients with seizure disorders is 
linked to the underlying etiology of the seizure. Many times 
those with primary epilepsy grow out of their seizures or 
may be well controlled by medications. However, a subgroup 
develops intractable epilepsy for which their quality of life is 
severely affected. Others present with seizures as a clinical 
manifestation of severe underlying pathology and prognosis 
is often poor or uncertain (Browne & Holmes, 2007).
 Status Epilepticus
 Definition
Status epilepticus (SE) is usually defined as continuous sei-
zure activity lasting 30 minutes or as two or more discrete 
seizures between which consciousness is not fully regained 
(Dodson, DeLorenzo, & Pedley et al., 1993). In 1999, modifica-
tions to this definition were proposed by Lowenstein, Bleck, 
and Macdonald to consider SE as a continuous, generalized, 
convulsive seizure lasting >5 minutes, or two or more sei-
zures during which the patient does not return to baseline 
consciousness. The rationale behind this revision is that a 
generalized tonic–clonic (GTC) seizure rarely lasts >5 min-
utes, and clinical experience suggests that the likelihood of 
spontaneous termination decreases after this time period.
 Pathophysiology
The emergence of SE requires a pool of neurons capable 
of initiating and sustaining abnormal firing (Noe & Manno, 
2005). This abnormal discharge is facilitated by the loss of 
inhibitory synaptic transmission mediated by -aminobutyric 
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acid (GABA) and sustained excitatory transmission mediated 
by glutamate (Nandhagopal, 2006).
 Classification of SE
In general SE can be classified broadly into generalized con-
vulsive status epilepticus (GCSE) and nonconvulsive status 
epilepticus (NCSE). In GCSE, generalized convulsive activity 
presents as prolonged tonic or clonic activity of the extremi-
ties, and is associated with complete loss of consciousness. 
With prolonged seizure activity, clinical manifestations may 
become less apparent and prolonged seizures may evolve 
into subtle findings such as ocular deviation, fine nystagmus, 
or subtle jaw, lip, finger, or eyelid twitching before progress-
ing to only electrical activity without physical correlation 
(Manno, 2003). NCSE refers to continuous or near con-
tinuous generalized electrical seizure activity for at least 30 
minutes without physical convulsion (Towne et al., 2000). It 
constitutes approximately 20% to 25% of SE cases and some 
suggest that it is a more benign condition (Marik & Varon, 
2004). However, patients may progress to NCSE after ini-
tially presenting in GCSE or may actually present in a coma 
because of the absence of outward signs of NCSE. Both have 
a significant mortality rate and therefore, both types of SE 
should be aggressively treated.
 Diagnosis
Status epilepticus, in particular GCSE, should be considered a 
medical emergency. Treatment is focused on early termination 
of seizures; however the  most important initial assessments 
and interventions should be centered on ensuring an ade-
quate airway and vascular access. Once this is accomplished, a 
full diagnostic evaluation should be initiated including perti-
nent history, physical findings, recent changes in medications, 
alcohol or drug use, trauma, history of previous epilepsy, or 
neurologic insult. A full neurologic examination should be 
performed with the goal of identifying any focal neurologic 
deficits which could reveal underlying pathology. Laboratory 
studies should be sent to include a complete blood count, arte-
rial blood gas, serum electrolytes, liver/kidney function, toxi-
cology, and serum antiepileptic drug levels if applicable. In the 
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absence of a known seizure disorder, a noncontrast head CT 
should be performed once the patient is stabilized and sei-
zures are controlled. Lumbar puncture may yield important 
diagnostic information especially in the setting of fever and 
nuchal rigidity (Manno, 2003). The role of EEG is most help-
ful when a patient presents in a comatose state or does not 
regain consciousness after treatment. EEG can help deter-
mine whether the patient is in nonconvulsive status verses a 
prolonged postictal state (Praline et al., 2007).
The primary causes of SE include stroke, CNS tumor, 
epilepsy, toxic–metabolic encephalopathy (i.e., renal failure, 
alcohol withdrawal, sepsis), CNS infection, hypoxic–ischemic 
injuries, and trauma (Lowenstein, 2006). The identification 
and treatment of the underlying cause for SE is paramount 
and should be promptly pursued and reversed. When the 
practitioner suspects chronic alcoholism or if hypoglycemia 
exists, then the use of 100 mg of thiamine followed by 50 gm 
of 50% dextrose should be administered. The thiamine is 
required as correcting the hypoglycemia in the presence of 
a thiamine deficiency may cause Wernicke encephalopathy 
(Manno, 2003).
 Initial Management of Status Epilepticus
First-Line Treatment. The goals for treatment of SE include 
rapid termination of seizures and preservation of neurologic 
function with minimal systemic complications. Once an ade-
quate airway is secured (endotracheal intubation if  necessary), 
respiratory support provided, and vascular access are obtained 
then medications can be initiated. First line pharmacologic 
treatment for SE includes administration of fast acting ben-
zodiazepines such as lorazepam, diazepam, or midazolam. 
Benzodiazepines are a class of drugs that act at the GABA A
receptor. Stimulation of this subunit leads to inhibition of neu-
ral transmission through hyperpolarization of the resting cell 
membrane (Manno, 2003). Lorazepam, dosed at 0.1 mg/kg, 
given at a rate of 2 mg/min, has been the preferred initial agent 
by many due to longer duration of action and pharmacokinetic 
profile. Many times initial benzodiazepine administration is 
enough to break the seizures, however when resistant to first-
line treatment, a reevaluation of airway protection must be 
completed (because of sedating effects of the benzodiazepines) 
and second-line treatment initiated (see Figure 5.5).
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Second-Line Treatment. Second-line treatment should 
be initiated if treatment of SE fails. Following failure of 
benzodiazepines then loading the patient with phenytoin 
(Dilantin) dosed at 20 mg/kg and infused at a maximum rate 
of 50 mg/min is indicated. Phenytoin is a barbiturate-like 
drug that is effective in controlling seizure activity by limit-
ing the repetitive firing of action potentials and slowing of 
the rate of recovery of voltage-activated sodium channels 
(McNamara, 2001). Phenytoin is highly protein bound, mak-
ing only the free portion metabolically active. Phenytoin has a 
pH of 12, making it very caustic to peripheral veins and must 
be given no faster than 50 mg/min. Phenytoin should be used 
judiciously as it may cause hypotension, QT  prolongation, 
1.
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5.
6.
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Lorazepam
(0.1 mg/kg IV at 2 mg/min)
Seizures continuing
Seizures continuing
Seizures continuing
Proceed immediately to anesthesia with midazolam,
 propofol, or pentobarbital if the patient develops status
 epilepticus while in the intensive care unit, has severe
 systemic disturbances (e.g., extreme hyperthemia), or
 has seizures that have continued for more than 60 to 90 min
Seizures continuing
Additional emergency drug therapy may not be required if seizures
  stop and the cause of status epilepticus is rapidly corrected.
Seizures continuing
Time (minutes)
Phenytoin or fosphenytoin
(additional 5–10 mg/kg or 5–10 mg/kg PE)
Phenobarbital
(20 mg/kg IV at 50–75 mg/min)
Phenobarbital
(additional 5–10 mg/kg)
Anesthesia with
  midazolam, propofol,
  or pentobarbitol
Phenytoin (20 mg/kg IV at 50 mg/min) or
fosphenytoin (20 mg/kg PE IV at 150 mg/min)
5.5
Algorithm for Status Epilepticus
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and other cardiac dysrhythmias, which can be alleviated by 
reducing the infusion rate (McNamara). Given the limita-
tions of phenytoin, fosphenytoin, which is water soluble, is an 
alternative in the setting of SE where rapid administration is 
desired. Fosphenytoin is measured in phenytoin equivalents 
(PE) and similarly loaded at 20 PE/mg at a maximum rate 
of 150 mg/min. The cardiovascular side effects are less with 
fosphenytoin and it can be infused at a much higher rate. 
When seizures do not respond to an initial bolus of either 
phenytoin or fosphenytoin, and additional 5–10mg/kg or 
5–10 PE/kg may be given (Manno, 2003).
Another antiepileptic drug used as a second line agent 
is valproic acid (VPA), with a mechanism that is similar to 
phenytoin. VPA is loaded at a dose of 20 mg/kg in SE at a rate 
of administration of 3–6 mg·kg·min without adverse affects. 
The role of VPA in SE is not clearly defined; however, this 
has been advocated by some as an initial second line therapy 
after benzodiazepines because of its ease of administration 
and safety profile (Manno, 2003).
Phenobarbital has also been used for treatment of SE. 
This barbiturate prevents seizure activity by increas-
ing GABA A mediated cellular inhibition. The use as of this 
medication as a second line therapy has decreased because 
of serious adverse effects including respiratory depression, 
decreased level of consciousness, hypotension, and decreased 
cardiac contractility. Phenobarbital has a half-life of as long 
as 96 hours and is now considered third line treatment for 
SE or deferred in favor of continuous IV administration mid-
azolam, propofol, or pentobarbital (see Figure 5.5).
 Refractory Status Epilepticus
There is no universally accepted definition of refractory 
status epilepticus (RSE). However, in general it is defined 
as SE that fails to respond to first- and second-line therapy. 
RSE occurs in 9% to 31% of patients with SE and is associ-
ated with a high morbidity and mortality (Claassen, Hirsch, 
Emerson, & Mayer, 2002). Continuous intravenous infusions 
with anesthetic doses of midazolam, propofol, or high-dose 
barbiturates for 24–48 hours are common therapies for 
RSE. These patients require ICU monitoring, an advanced 
airway, and continuous EEG monitoring. The goal of titra-
tion of these agents is either seizure suppression or burst 
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suppression on EEG, which remains a matter of debate. 
There is no prospective collected data that shows one more 
efficacious than the other. Many believe that titration to sei-
zure suppression is adequate to break RSE because higher 
doses of drug are needed to achieve electrographic burst 
suppression that may lead to deleterious systemic effects 
for the patient. These agents are administered initially for 
24 hours at which time their dose is reduced and the patient 
is closely monitored for clinical or EEG signs of continued 
SE (Claassen et al., 2002).
Midazolam, a short-acting benzodiazepine, is given at a 
loading dose of 0.2 mg/kg and maintained at a continuous 
infusion of 0.1 to 2 mg·kg·hr titrated to either burst suppres-
sion or seizure suppression. Induction is rapid, effective, and 
well tolerated being a favorable intervention in the setting of 
alcohol withdrawal seizure for example, when one agent can 
serve two functions. The main limitation to midazolam is the 
fairly rapid development of tachyphylaxis that often requires 
persistent escalation of the dose (Manno, 2003).
Propofol, a short-acting nonbarbituate hypnotic, 
has been used extensively for the induction and main-
tenance of anesthesia and for sedation in the ICU. This 
global CNS depressant directly activates the GABA recep-
tor. Propofol has the advantage of rapid induction and 
elimination, making it easy and practical in the treatment 
of RSE. A loading dose of 3–5 mg/kg is recommended, fol-
lowed by an infusion of 30–100 mcg/kg/min titrated to 
EEG seizure suppression (Marik & Varon, 2004). Propofol
does cause hypotension, which may need to be supported 
with vasoactive medications during the infusion. However, 
the most severe complication associated with propofol is the 
“propofol infusion syndrome,” a very rare complication report-
ed primarily in pediatric patients associated with high-dose
propofol infusion. This syndrome is characterized by severe 
metabolic acidosis, rhabdomyolysis, and cardiovascular col-
lapse frequently leading to death. Some data suggests that 
this disorder is caused by interference with mitochondrial 
respiration (Marik & Varon). The current recommended dos-
age should not exceed 100 mcg/kg/min and  measurements of 
daily creatinine kinase (a marker of rhabdomyolysis) and tri-
glycerides (a marker of failure of free fatty acid metabolism 
in the form of hyperlipidemia) need to be done to monitor for 
the syndrome.
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High-dose barbiturate therapy using pentobarbital is 
also used for the treatment of RSE. Pentobarbital has a load-
ing dose of 5–15 mg/kg over 1 hour and is maintained at an 
infusion dosage of 0.5–10 mg·kg·hour. This therapy is usu-
ally used after midazolam or propofol therapies have failed 
because of the profound hemodynamic and immunosup-
pressive effects of pentobarbital (Manno, 2003).
 Prognosis
The overall mortality of SE is about 20% but varies widely 
on the basis of age, etiology, and duration of SE. Mortality is 
higher in elderly patients with some data suggesting mortal-
ity as high 76% for this population (Logroscino, Hesdorffer, 
& Cascino, 2002). Mortality is also higher when SE is sec-
ondary to an acute insult (i.e., acute stroke, anoxia, trauma, 
infections, metabolic disturbances). Most notably, the pres-
ence of myoclonic SE after acute anoxic brain injury carries 
a poor prognosis. SE secondary to previous strokes, alcohol 
or anticonvulsant withdrawal, tumors, or epilepsy has a more 
benign prognosis (Manno, 2003).
 Myasthenia Gravis
 Definition
Myasthenia gravis (MG) is the most common autoimmune 
disorder of the neuromuscular junction. MG is characterized 
by the production of antiacetylcholine receptor antibiotics, 
which impairs neuromuscular transmission. Treatment for 
MG has improved dramatically resulting in a relatively low 
mortality rate (Thanvi & Lo, 2004).
 Diagnosis
Clinical Features. The patient with MG commonly presents 
with visual symptoms, including ptosis and diplopia. Patients 
may also present with dysphagia, difficulty chewing or speak-
ing, and may complain of muscle fatigue and weakness (Kothari, 
2004). Approximately 20% of patients who have MG will pres-
ent with myasthenic crisis at some point during their disease 
course. Many times there is no precipitating factor for the 
crisis but more frequently, infection and medication changes 
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will precipitate a crisis. Patients in myasthenic  crisis may pres-
ent with ptosis, muscular weakness (especially upper extremi-
ties), and respiratory distress. The patient in myasthenic crisis 
may require intubation and supportive care until the myas-
thenic crisis is resolved. The primary factor is to differentiate 
myasthenic crisis from cholinergic crisis, in which the patient 
may present with increased salivation, bradycardia, abdominal 
cramps, and miosis. Cholinergic crisis usually occurs after a 
dosage adjustment of medication (Bhardwaj et al., 2004). 
Tensilon Test. One way of diagnosing MG is with the Tensilon 
test and can be easily performed at the bedside. The patient’s 
blood pressure and heart rate must be closely monitored 
and the test should not be performed on patients in respira-
tory distress. A dose of 10 mg of edrophonium (Tensilon) is 
administered slowly through an intravenous line; atropine 
should be at the bedside during the test. An improvement 
in ptosis or muscular strength should be seen for the test 
to be considered positive; a patient’s subjective report that 
strength or fatigue improves should not be considered a pos-
itive result (Kothari, 2004).
Laboratory Studies. The presence of acetylcholine recep-
tor antibodies (AChR-Ab) aid in confirming the diagnosis of 
MG, but the absence of AChR-Ab does not exclude the diag-
nosis. The presence of antimuscle-specific kinase (MuSK) 
antibodies should be tested if AChR-Ab are not detectable 
then the diagnosis of MG is suspected (Conti-Fine, Milani, & 
Kaminski, 2006)
Electrophysiologic Testing. The two main electrophysiologic 
tests that are used in diagnosing MG are repetitive nerve 
stimulation and single-fiber EMG. Single-fiber EMG is the 
most sensitive test, although it is not specific for MG and is 
not widely available (Meriggioli & Sanders, 2004).
 Treatment
Thymectomy. When patients are initially diagnosed with 
MG, they should be screened for a thymoma and if found, 
a thymectomy is indicated. Symptomatic improvement in 
MG usually occurs 6 months to 1 year after the thymecto-
my. When a thymectomy is performed on medically stable
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patients younger than 60 years old and no thymoma is found, 
approximately 80% of these patients experience improvement 
in their MG symptoms after surgery (Thanvi & Lo, 2004).
Anticholinesterase Agents, Corticosteroids, Immunosuppres-
sants. Anticholinesterase agents provide symptomatic relief 
for MG, but symptoms rarely resolve completely with these 
agents. Corticosteroids are frequently used and are effective at 
reducing the levels of anti-AChR-Ab levels during the first few 
months. Patients are maintained on low-dose steroids for years, 
but they frequently encounter steroid-related complications. 
Other agents that are effective in treating MG include azathio-
prine, cyclophosphamide, cyclosporine, tacrolimus, and myco-
phenolate (Kothari, 2004). Many of these agents have undesir-
able side effects or have a delayed clinical response. In patients 
that do not respond to these treatments, plasma exchange 
or intravenous immunoglobin (IVIG) are additional options 
(Lehmann, Hartung, Hetzel, Stuve, & Kiesier, 2006, Part II).
Plasma Exchange and Intravenous Immunoglobulin. Plasma
exchange, an extracorpeal blood purification technique that 
removes autoantibodies, is a therapy that is used for patients 
in myasthenic crisis with acute severe muscular weakness. 
This procedure is also used prethymectomy and postthymec-
tomy in patients with severe MG. Plasma exchange is per-
formed 3–5 times and 1–1.5 plasma volumes are exchanged 
per procedure per day (Lehmann, Hartung, Hetzel, Stuve, & 
Kiesier, 2006, Part I). IVIG involves administering 0.4 g/kg 
immunoglobulin per day from pooled human plasma for 
3–5 doses. IVIG can be  given in lieu of plasma exchange for 
MG patients in myasthenic crisis (Dalakas, 2004).
 Relevant Monitoring
The most significant risk for a patient in myasthenic crisis is 
respiratory failure. Indicators of impeding respiratory failure 
include worsening negative inspiratory force and forced vital 
capacity. Knowing the patient’s baseline values are helpful 
(Mehta, 2006). Ptosis time can be monitored to aid in deter-
mining if the patient’s condition is improving or deteriorating. 
Ptosis is elicited by asking the patient to sustain an upgaze for 
>1 minute. Proximal muscles will weaken more quickly than 
distal muscles; a change in muscular strength can be deter-
mined by testing arm abduction (Roper & Brown, 2005).
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 Guillain-Barré Syndrome
 Definition
Guillain-Barré syndrome is an eponym for a heteroge-
neous group of immune-mediated peripheral neuropathies. 
A feature common in all GBS variants is a rapidly evolv-
ing polyradiculopathy preceded by a triggering event, most 
often an infection. GBS generally manifests as a symmet-
ric motor paralysis with or without sensory and autonomic 
disturbances (Newswanger & Warren, 2004).
 Subtypes and Pathophysiology
The 4 most commons subtypes of GBS include: 1) Acute 
inflammatory demyelinating polyradiculopathy (AIDP), 
Acute motor axonal neuropathy (AMAN), Acute motor and 
sensory neuropathy (AMSAN) & Miller Fisher Syndrome 
(MFS). They differ in their pathophysiology and immu-
nological profiles. AIDP is the most common type of GBS 
where the macrophages invade the myelin sheath and 
denude the axons mediated by both humoral and cellular 
immunity. Axons can be involved as a “bystander” when the 
inflammation is severe. Characteristic electrophysiologi-
cal features reflect segmental demyelination (Seneviratne, 
2000). In AMAN and AMSAN the pathological process is dif-
ferent: antibodies directed against ganglioside antigen may 
damage the axons at the node of Ranvier or at the nerve 
terminals, thus leaving the myelin sheath intact. Nerve con-
duction is impaired due to the damage induced by either a 
conduction block or an axonal severage and degeneration. 
When the ventral root is damaged a motor dysfunction in 
the form of AMAN is the result. AMAN is characterized by 
rapidly progressive weakness, often with respiratory fail-
ure but usually good recovery. When the dorsal, as well as 
the ventral roots are affected AMSAM results (Hughes & 
Cornblath, 2005). The motor and sensory dysfunction in 
AMSAN is characterized by marked muscle wasting and 
poor recovery, the disease course is typically fulminant, 
generally with slow and incomplete recovery. The pathology 
of Fisher’s syndrome is not as clear. This syndrome consists 
of a triad of symptoms ataxia, areflexia and opthalmoplegia. 
Mild limb weakness, ptosis, facial palsy, and bulbar palsy 
may also occur. This form accounts for only about 5% of 
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patients with GBS (Seneviratne). The primary electrophysi-
ological finding in Fisher’s syndrome is an abnormality of 
sensory conduction.
 Diagnosis
Most patients with GBS will have an acute neuropathy 
reaching a peak in under 4 weeks, symmetric weakness (usu-
ally ascending), hyporeflexia or areflexia, and raised protein 
concentrations in CSF (Hughes & Cornblath, 2005). Other 
common associated symptoms include pain, dysautonomia, 
and cranial nerve involvement.
The acute care nurse practitioner should prioritize a 
thorough history and physical to accurately diagnose GBS. 
About two thirds of GBS patients have an infection within 
a 6-week period prior to the diagnosis, generally either a 
flu-like episode or gastroenteritis. The organisms that are 
most likely to be involved in the infections are Campylo-
bacter jejuni, cytomegalovirus (CMV), Epstein–Barr virus 
(EBV) and Mycoplasma pneumonia (Cosi & Versino, 2006). 
Therefore, it is imperative to ask about any recent illness-
es, how the symptoms presented and progressed. The dif-
ferential diagnosis for GBS includes brainstem disorders, 
spinal cord, and conus lesions as well as basilar artery 
thrombosis, myasthenia gravis, metabolic myopathies, and 
transverse myelitis.
The actual diagnosis of GBS is based on clinical features 
(progressive motor weakness and areflexia), electrodiagnos-
tic examination (Electromyography [EMG]) and examination 
of the cerebrospinal fluid (CSF). EMG findings suggestive of 
GBS include an absent H reflex, low amplitude or absent 
sensory nerve potentials, an abnormal F wave and other less 
frequent abnormalities (Newswanger & Warren, 2004). Char-
acteristic CSF findings consist of elevated protein without 
pleocytosis (abnormal number of cells in the CSF). CSF is 
often normal for <48 hours following initial symptoms, but 
by the end of 1 week CSF protein levels are elevated. The 
evaluating of CSF prior to treatment with IVIG is imperative 
as IVIG may cause aseptic meningitis and skew the results. 
Other laboratory tests that can corroborate the diagnosis and 
may be helpful include stool culture for  C. jejuni , antibodies 
to C. jejuni , CMV, EBV,  M. pneumoniae , CBC, electrolytes and 
liver enzymes to rule out other causes.
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 Treatment
Treatment for GBS is multidisciplinary with a focus on both 
supportive and disease specific therapy. Supportive therapy 
has been the cornerstone of treatment for GBS for many 
years. Respiratory failure occurs in about 25% and is com-
mon in rapidly progressive GBS with upper limb involvement 
and/or bulbar palsy (Cosi & Versino, 2006). Intubation should 
be considered when the FVC falls below 15–20ml/kg. Close 
monitoring for dysautonomia is also essential. Dysautonomic 
symptoms are quite common and potentially harmful; they 
include cardiac arrhythmias, hyper or hypotension, ileus and 
urinary retention. The dysautonomia is largely responsible 
for the mortality associated with GBS. The goal is to provide 
hemodynamic support and prevent sudden cardiac death from 
fatal arrhythmias or wide swings in blood pressure or heart 
rate (Cosi & Versino, 2006). Pain is a frequent symptom associ-
ated with GBS which may be under diagnosed as patients are 
not often able to make their needs known.The team needs to 
be aware of this fact and use various communication tools and 
behavioral pain scoring systems to assess the patients pain 
level. Narcotics should be used with caution due to their risk of 
ileus. Medications such as gabapentin (neurontin) and carba-
mazepine (tegretol) have been used in conjunction with nar-
cotics for treatment of neuropathic pain associated with GBS. 
These medications are targeted to treat neuropathic pain and 
help reduce the amount of narcotic needed for adequate control 
(Cosi & Versino, 2006). Prophylaxis for venous thromboembo-
lism (VTE) should also be initiated according to the guidelines 
for VTE prophylxis in the critically ill patient (Geertz et al., 
2004). These guidelines recommend low dose unfractionated 
heparin (5000 units BID) or low molecular weight heparin 
(<3,400 units/day) as well as graduated compression stockings 
and intermittent pneumatic compression devices.
Disease specific therapy in the form of plasma exchange 
or intravenous immunoglobulin (IVIG) is used to halt progres-
sion and promote recovery. Plasma exchange became accepted 
as the gold standard treatment for GBS almost 20 years ago as 
this process removes or dilutes the circulating immune factors 
implicated in the pathogenesis of GBS. The usual regimen is a 
total exchange of about five plasma volumes during 1–2 weeks. 
Complications include septicemia, hypotension, hypocalcemia 
and abnormal clotting (Seneviratne, 2000).
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IVIG produces a modulation of the immune system through 
multiple mechanisms including anti-idiotypic suppression 
of autoantibodies. In recent years, a randomized control trial 
showed treatment with high dose IVIG was equally as effica-
cious as plasma exchange for the treatment of GBS. Another 
multicenter trial also showed that there was no benefit to com-
bined treatment. As a result IVIG has become utilized in more 
hospitals due to its easier administration, increased comfort 
for the patient and less complications. American Academy of 
Neurology practice parameters recommend either plasma 
exchange or IVIG for the treatment of GBS, but questions 
about best regimen still remain (Hughes & Cornblath, 2005).
 Prognosis
Approximately 85% of patients with GBS achieve a full and 
functional recovery within 6–12 months. However some 
patients have persistent minor weakness, areflexia and par-
esthesia. Approximately 7% to 15% of patients have permanent 
neurologic sequelae including bilateral footdrop, intrinsic hand 
muscle wasting, sensory ataxia, and dyesthesia. In tertiary care 
centers with specialists familiar with GBS the mortality rate 
is <5%; however, this can be as high as 20% in a community 
hospital setting. Several factors during the acute phase of the 
illness predict poor recovery. These factors include age great-
er than 60, severe rapidly progressive disease and low nerve 
conduction amplitudes which suggest axonal loss. In general, 
a poor long-term prognosis is directly related to the severity 
of the acute episode and delay in onset of specific treatment 
(Newswanger & Warren, 2004).
 Neuro-Infections: Meningitis, Encephalitis
Differential diagnoses due to alteration in mental status must 
include an infectious process of the brain. The most common 
infections seen in the neurocritical care environment are 
meningitis and encephalitis.
 Meningitis
Pathophysiology. Meningitis is an infectious process of the 
meningies of the brain, specifically the arachnoid mater, and 
the cerebrospinal fluid in the ventricles and subarachnoid 
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space. Meningitis is categorized as bacterial or aseptic. The 
most common bacterial pathogens are Streptococcus pneu-
moniae and  Neisseria meningitidis . Because of the intro-
duction of childhood vaccinations, infections secondary to 
Haemophilus influenzae have markedly decreased (Goetz, 
2003). Aseptic meningitis refers to any meningitis that is 
associated with clinical and laboratory evidence of menin-
geal inflammation with negative routine bacterial cultures 
(Roper & Brown, 2005). Infections such as mycobacterium 
tuberculosis, mycoplasma, and spirochetes fall into this cat-
egory. Viral causes of meningitis are most commonly the 
enteroviruses coxsackie, echovirus, and herpes simplex virus 
(HSV). The immunocompromised patient, has a risk of fungal 
invasion with  Cryptococcus neoformans, Coccidioide immitis, 
and Histoplasma capsulatum (Fitch, Lord, Kociszewski, & 
Wedel, 2008). Meningitis can develop through either coloni-
zation of the nasopharynx leading to a bloodstream infec-
tion and subsequent CNS invasion or a localized infection 
(urinary tract infection, endocarditis, tooth abscess) causing 
bacteremia that leads to invasion of the CNS. Infections of 
the mastoid or sinuses can cause direct entry into the CNS 
as can infections from neurosurgical procedures, cerebrospi-
nal fluid (CSF) leak, and hardware (shunt, extraventricular 
drain) placement (van de Beek et al., 2004).
Diagnostic Criteria. Diagnosis of meningitis is made via 
analysis of the CSF. There is data that shows that obtaining 
a noncontrast head CT prior to performing the LP is only 
required in the following circumstances: new onset seizures, 
change in mental status, papilledema, or a focal  neurological
deficit (cranial nerve deficit, motor/sensory deficit) (Tunkel 
et al., 2004). However, given the minimally invasive nature 
and the immediacy of findings in noncontrast head CT, the 
risk of missing a critical pathological finding which may 
result in cerebral herniation outweighs the benefit of delay-
ing CT prior to the LP. The noncontrast CT will not show any 
abnormal findings in a patient with meningitis. A noncon-
trast MRI is nondiagnostic as well. On a contrast MRI, there 
may be enhancement of the meninges and ventricular lining, 
however, as it is does not yield significant data this test is not 
routinely obtained (Gunderman, 2006).
At a minimum, CSF should be sent for Gram stain, bac-
terial, acid-fast bacilli, fungal cultures, glucose, protein, cell 
count, and differential (Tunkel et al., 2004). Viral testing, 
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including HSV, although depending on the history, the CSF 
may also be sent for West Nile virus (WNV), varicella–
zoster virus (VZV) or Cytomegalovirus (CMV) (Roper & 
Brown, 2005). The presence of white blood cells, high pro-
tein, and low glucose in the CSF are hallmarks of bacterial 
meningitis (Goetz, 2007). Table 5.23 provides the normal 
CSF profile as well as the findings with bacterial and viral 
meningitis. Additional laboratory tests should include blood 
cultures and a CBC with differential.
Clinical Manifestations/Symptoms.  The classic triad of men-
ingitis symptoms is altered mental status, fever, and neck 
stiffness. Absence of these symptoms does not preclude the 
diagnosis, although one of the three symptoms is usually pres-
ent (Bloch, 2006; van de Beek, et al., 2004). Incidentally, the 
sensitivity of the Brudzinski sign (passive flexion of patient’s 
neck causes hip flexion) and the Kernig sign (passive hip 
flexion followed by knee extension causes pain in back and 
leg) is quite low (Fitch et al., 2008) in diagnosing meningi-
tis. Patients with  N. meningitidis (meningococcal) meningitis
may have skin manifestations of petechiae and palpable 
purpura as part of their presentation. Seizures occur in 30% 
of patients with bacterial meningitis (Bloch, 2006)
Parameter Normal Viral Bacterial
Glucose CSF: Serum Normal <45 mg/dL CSF:
  ratio >50%   Serum ratio <40%
Protein 23–38mg/dL 50–250 mg/dL >250 mg/dL
White Blood  0–5 cells/mm3 100–500 cells/mm3 >1000 mg/dL
Cells*  Lymphocytes PMNs**
  Predominate Predominate
Opening Pressure <20 cm H2O <20 cm H2O 20–50 cm H2O
5.23 CFS Profi le in Bacterial and Viral Meningitis
*For a traumatic tap, subtract 1 white blood cell for every 700 red blood cells (Goetz, 2003)
** PMNs: polymorphonuclear leukocytes
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Treatment. Rapid recognition of meningitis is key to survival 
in meningitis. Rapid intervention minimizes the disease pro-
gression and increases, the chance of a full recovery (van de 
Beek et al., 2004). Common practice is to empirically initiate 
broad spectrum antimicrobials after the LP and then nar-
row coverage once culture and sensitivities are available. 
For adults younger than 50 years old, the recommendation 
is vancomycin plus a third-generation cephalosporin and 
for patients older than 50 years of age, ampicillin is added to 
the regimen of vancomycin and cephalosporin (Tunkel et al., 
2004). The addition of dexamethasone (0.15 mg/kg q 6 hrs for 
2–4 days) prior to or during the first antibiotic dose has been 
shown to decrease morbidity and mortality in patients with 
pneumococcal meningitis. Therefore, dexamethasone is rec-
ommended as an adjunctive treatment for suspected or prov-
en meningitis (de Gans & van de Beek). Once the Gram stain 
and culture results are back, the dexamethasone should be 
continued only in patients with Gram-positive diplococci or 
S. pneumoniae in CSF or blood. The patient who has already 
received the first dose of antibiotic should not have the dexa-
methasone initiated (de Gans & van de Beek, 2002). Once the 
CSF cultures are negative generally after 24–48 hours, and 
the patient’s clinical condition is improving, the most likely 
cause considered is viral and antibiotics should be discontin-
ued without the need to repeat the LP (Ziai & Lewin, 2006). 
The patient whose symptoms are worsening and the diagno-
sis is unclear warrants a repeat LP.
Prognosis and Outcomes. The mortality rate with  bacterial 
meningitis ranges from 13% to 27% depending on the patho-
gen (van de Beek et al., 2004). Viral meningitis is a self- limiting
course that usually resolves within 2 weeks and is associated 
with low morbidity and mortality (Aminoff, Greenberg, & 
Simon, 2005).
 Encephalitis
Pathophysiology. Encephalitis is primarily caused by a viral 
infection, with HSV-1 being the most common pathogen. 
There are many more possible viral pathogens and obtain-
ing a detailed history will offer clues to other viral etiologies 
(Goetz, 2007). Because there are more viruses than there are 
diagnostic tests viruses, often the specific pathogen is never 
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identified (Kupila, Vuorien,Vainionpaa, Hukkanen,  Marttila, 
& Kotilainen, 2006). The routes of transmission are virus 
specific. Herpes simplex encephalitis (HSE) is thought to 
be caused by the reactivation of the HSV lying dormant in 
the trigeminal ganglia. Mosquitoes or ticks are responsible 
for the transmission of the arbovirus and the rabies virus 
is transferred via animal bite. The immunocompromised 
patient is at risk for VZV and CMV encephalitis (Roper & 
Brown, 2005). The virus replicates outside the CNS and then 
gains entry into the CNS either via the olfactory nerve path-
ways or neural pathways.
Diagnostic Criteria. Encephalitis is diagnosed via examina-
tion of the CSF as well as imaging. CSF characteristics are 
the same as viral meningitis (Table 5.23). As noted before, 
often a virus is not isolated given the many viruses that have 
no diagnostic test. HSV, the most common form of encepha-
litis, has very distinguishing characteristics on CT and MRI. 
CT will be normal until 3–5 days after onset and in 50% of 
cases, hypodensity of involved cortex will develop. MRI is 
the imaging of choice with any form of encephalitis and with 
HSV there will be signal changes with surrounding edema 
and possible scattered hemorrhage in inferior parts of the 
frontal and temporal lobes (Roper & Brown, 2005). EEG is 
indicated to rule out seizures.
Clinical Manifestations/Symptoms. The main difference in 
clinical presentation between meningitis and encephalitis is 
related to consciousness. Patients with encephalitis will pres-
ent with a change in level of consciousness ranging from sleep-
iness to unresponsiveness as well as a focal neurologic deficit 
such as sensory, motor, or speech dysfunction (Peters, 2008). 
Seizures are common with both encephalitis and meningitis.
Treatment. Although there are many viruses that can cause 
encephalitis, the only current available antiviral treatment 
is for HSV-1 encephalitis. Therefore, if viral etiology is sus-
pected, empiric treatment for HSV-1 infection with acyclovir
(10 mg/kg IV Q8h) should be initiated as soon as possible 
because early therapy is associated with a significant decrease 
in mortality and morbidity. Acyclovir is also an option if VZV 
encephalitis is likely (Whitley, 1990). However, if the HSV 
or VZV results are negative, the acyclovir should be dis-
continued. As previously described, seizures are possible 
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with encephalitis and control of seizures is necessary with 
anticonvulsant therapy. The anticonvulsants should be con-
tinued for at least a year and then discontinued as long as 
there is no clinical or EEG evidence of continued seizures 
(Roper & Brown, 2005). When a large volume of brain tissue 
is affected by the encephalitis, there may be cerebral edema 
and increased ICP. Treatment should include the measures 
describe in the ICP management section of this chapter. 
Cardiovascular support may be required due to the presence 
of dysautonomia (Kleiter, Steinbrecher, Bogdahn, & Schulte-
Mattler, 2006). Depending on the degree of decreased level of 
consciousness, airway protection initially with endotracheal 
intubation and eventually a tracheostomy may be necessary 
as well as ventilatory support (Aminoff et al., 2005). Pulmo-
nary toileting that includes suctioning and chest physiother-
apy may be required for patients with increased secretions 
and or atelectasis. Venous thromboembolism (VTE) is a sig-
nificant concern for this population since most patients will 
initially be immobile and the guidelines for VTE prophylaxis 
in the patient with critical illness (Geertz et al., 2004)
Prognosis and Outcomes. Death occurs in 5% to 20% of these 
patients and residual signs such as mental deterioration, amne-
sic defects, personality change, recurrent seizures, and hemipa-
resis are seen in about another 20% (Roper & Brown, 2005).
 Brain Death 
 Definition
Brain death is the irreversible cessation of all functions of the 
entire brain including the brainstem. There are strict, well-
defined criteria that must be present for the diagnosis of brain 
death to be made. These include irreversible coma, absence 
of cortical activity, absence of motor response to pain, loss of 
brainstem reflexes, and apnea (Hickey, 2002). In 1968, an ad hoc 
committee at Harvard Medical School developed the criteria 
that are currently used to determine brain death. In 1980, the 
Uniform Determination of Death Act (UDDA) was passed and 
adapted into legislation in each state. Specific policies on brain 
death testing may differ from institution to institution. How-
ever, the UDDA defines that ”for legal and medical purposes, 
an individual who has sustained irreversible cessation of 
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all functioning of the brain, including the brain stem, is 
dead.” (http://www.nccusl.org/nccusl/uniformact_factsheets/
uniformacts-fs-udda.asp, assessed April 12, 2008)
 Brain Death Criteria
The diagnosis of brain death is a clinical diagnosis that con-
sists of three cardinal findings: coma, absence of brainstem 
reflexes, and apnea. Two clinical evaluations are performed 
6 hours apart. Patients who meet brain death criteria should 
have no motor response to painful stimuli. The patient may 
have reflexic responses, such as triple-flexion, and spontane-
ous movement of the limbs should not be misinterpreted for 
motor responses (Young, Shemie, Doig & Teitelbaum, 2006). 
Central pain should be given by performing a trapezius 
squeeze or sternal rub, or by applying supraorbital pressure; 
if no motor response is elicited, then cranial nerve function 
should be assessed. Pupillary response is examined by dark-
ening the room and checking for pupillary reaction with a 
bright light. The oculocephalic reflex, more commonly known 
as doll’s eyes, assesses cranial nerves III and VI. The patient’s 
eyes are held open and the head is turned side to side while 
a change in position of eyes is noted, if there is no change 
in position, then the reflex is absent. This test should not be 
performed when a cervical spine injury is suspected. The ves-
tibuloocular reflex, known as cold calorics, assesses cranial 
nerves III, VI, and VIII. This test is completed by instilling 50 
ml of cold water in each ear while the eyes are held open to 
determine any deviation to one side or the other. Tympanic 
membranes must intact for this test to be performed. Eye 
deviation is assessed for one full minute after the instillation 
of the cold water; if no movement is seen then the reflex is 
absent. Corneal reflexes, cranial nerves V and VII, are assessed 
by drawing a wisp of cotton across the eye. The facial grimace, 
which also assesses cranial nerves V and VII, is tested for by 
applying supraorbital pressure or deep pressure to the nail 
bed and evaluating for a grimace. Cough and gag reflexes, cra-
nial nerves IX and X, are tested by bronchial suctioning with 
a suction catheter and stimulating the posterior pharynx with 
a tongue blade. When all cranial nerve reflexes are absent 
then an apnea test is performed to establish the clinical diag-
nosis of brain death (Hickey, 2002). During the apnea test, the 
patient is removed from the ventilator to assess respiratory 
drive. The patient is preoxygenated with 100% oxygen and a 
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baseline arterial blood gas (ABG) is drawn. After removing 
the patient from the ventilator, oxygen is supplied by insert-
ing a tube into the endotracheal tube that will deliver oxygen 
at the level of the carina. The endpoint of the apnea test is 
an arterial blood gas with a carbon dioxide (CO 2) level of 60 
mmHg or a delta of 20 points from the patient’s baseline CO 2
level. The patient who is not sedated or receiving analgesics 
and does not initiate a spontaneous breath indicates there is 
no hypoxic respiratory drive; the examination is consistent 
with brain death. This may take as long as 15 minutes to have 
the CO 2 level rise, during this time the patient may become 
hemodynamically unstable or desaturated, indicating a need 
to send the ABG and terminate the apnea test. The CO 2 level 
at this point may not be high enough to complete the apnea 
test, then it may be necessary to perform ancillary testing to 
confirm the diagnosis of brain death (Bhardwaj et al., 2004).
Ancillary Tests. Ancillary tests that measure brain perfusion 
are the only accepted tests for confirmation of the clinical 
diagnosis of brain death. A confirmatory test is not manda-
tory but may be helpful in patients in whom parts of the 
clinical examination cannot be reliably performed. The gold 
standard is the four-vessel cerebral angiogram. This is an 
invasive procedure that requires continuous monitoring of 
the patient’s vital signs, as the patient may be hemodynami-
cally unstable because of loss of the autoregulatory system. 
Presence of blood flow is determined by injecting contrast 
material and looking for intracerebral filling at the level of 
the carotid bifurcation or circle of Willis for at least 1 minute 
after injection (Young, Shemie, Doing, & Teitelbaum, 2006). 
Other confirmatory tests that are recognized by the Ameri-
can Academy of Neurology are EEG, TCDs, technetium-99m 
hexamethylpropleneamineoxime brain scan, and somato-
sensory evoked potentials (“Practice parameters,” 1995).
 Summary
Brain death is a clinical diagnosis that is made by a physi-
cian, acute care nurse practitioners can participate in the 
care of the patient but are not able to make the diagnosis of 
brain death. The number of physicians required to perform 
the brain death examination and the timing of the two brain 
death examinations differ from state to state (Wijdicks, 2007). 
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The American Academy of Neurology suggests that 6 hours 
be allowed to elapse between the two examinations. Docu-
mentation of the etiology and irreversibility of the patient’s 
condition including imaging consistent with an acute central 
nervous system catastrophe, absence of brainstem reflexes, 
absence of motor response to pain, and absence of respiratory 
effort with an arterial CO 2 level of >60 mmHg is required to 
pronounce the patient brain dead (American Academy of 
Neurology, 1995). Throughout the process of diagnosis of brain 
death, the family should be included in the process and the 
issue of organ donation introduced. Following pronouncement 
of death, there should be a timely discussion regarding the 
opportunity to participate in organ donation. The exact proce-
dure for organ donation differs from state to state (Bhardwaj 
et al., 2004).
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6
 Introduction 
Managing liver, kidney, and pancreas transplants in the inten-
sive care unit (ICU) are now a major concern of caregivers. 
Currently, more than 17,000 individuals in the United States 
are waiting for a liver transplant. From 1988 through January 
2008, over 88,600 liver transplants have occurred through-
out the U.S. (Organ Procurement and Transplant Network 
[OPTN]). The United Network for Organ Sharing (UNOS) 
classifies who meets the criteria to receive a liver transplant 
by utilizing the Model for End-Stage Liver Disease (MELD) 
scoring system, which calculates the severity of the disease 
in each individual. Status 1 is the defined classification for 
patients with acute severe liver disease or recent  development 
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of the disease, or critically ill in an ICU setting with <7 days 
of life without a liver transplant. The MELD score is based 
on the probability of death within 3 months and is calculated 
based on variables of laboratory data including creatinine, 
bilirubin, international normalized ratio, with the score rang-
ing from 6–40 (Kamath et al., 2001). 
Available liver donors are first offered locally to status 
1 patients and then accordingly to patients with the highest 
MELD score. When there are no local recipients available, the 
liver is then offered regionally and nationally as  indicated. 
Individuals who would not qualify for transplant include 
those with active alcohol or substance abuse, metastatic can-
cer, advanced heart and lung disease, severe infections, and 
massive liver failure with associated brain injury. 
Unfortunately, the average waiting time for kidney trans-
plantation is >2 years because of the large waiting list and 
relatively small pool of organ donors (Kaufman, 2007). As of 
April 2008, for example, there were 75,514 patients on the 
UNOS list awaiting cadaver renal transplant, 1,627 awaiting 
pancreas transplants, and 2,273 awaiting combined renal and 
pancreas transplant (UNOS, 2008). 
 Pathophysiology 
The liver, weighing approximately 1500 grams has multiple 
functions within the body and is the largest solid organ. The 
liver is a unique powerhouse organ managing the carbohy-
drates, fats, and proteins as the building blocks for growth 
and vitamins. A functioning liver regulates the blood clotting 
factors within the body and regulates the bile production. 
The liver also has functions such as clearance of toxins and 
host defense. 
 Indications for Transplant 
Cirrhosis accounts for >80% of transplants performed in 
adults, with hepatitis C and alcoholism being the two most 
common diagnoses. Other indications include cholestatic 
liver disease, such as primary biliary cirrhosis (PBC), biliary 
atresia, primary sclerosing colangitis (PSC), chronic  hepatitis
Chapter 6: Managing Liver, Kidney, and Kidney–Pancreas Transplant 249
(autoimmune hepatitis, hepatitis B), metabolic disease such 
as hemochromatosis or Wilson disease, nonalcoholic ste-
atohepatitis (NASH), primary hepatocelluler carcinoma, 
Budd–Chiari syndrome, and fulminant hepatic failure (FHF) 
(Luu, Van Gelder, & Conrad, 2006). Ascites, hepatic encepha-
lopathy, and hepatorenal syndrome are common symptoms 
of decompensated liver disease. Spontaneous bacterial peri-
tonitis (SBP) may also occur secondary to bacteria within 
the ascites. Scarring or fibrosis secondary to liver disease 
may cause portal hypertension and splenomegaly, which will 
subsequently destroy red blood cells and trap thrombocytes, 
which will cause thrombocytopenia. Esophageal varices may 
also occur and may require intervention such as endoscopic 
banding and embolization (Guillen, Black, & Grace, 2005). 
Major pediatric indications for liver transplant include biliary 
atresia and metabolic liver disease. 
Patients who require pre–liver transplant have an 
enhanced risk of bleeding from the gastrointestinal tract 
secondary to portal hypertension that requires beta  blockade
to decrease the portal pressure. Lactulose is also generally 
indicated to facilitate the clearance of toxins when the liver 
is not functioning (Guillen et al., 2005). Metronidazole may 
be considered to decrease the gastrointenstinal bacterial 
load. Liver failure presents as acute, chronic, and fulminant, 
usually encompassing multiorgan failure. Patients may pres-
ent with hepatic encephalopathy (HE) that subsequently 
entails cerebral edema and intracranial hypertension. These 
alterations in cerebral metabolism are of major sequelae, 
because the brain uses glucose as an energy source only 
under normal physiological conditions. Hyperammonemia 
is consistent with liver failure and correlates with altera-
tions in brain metabolism (Strauss, Moller, Larsen, Kondrup, 
& Knudsen, 2003). 
The pretransplant evaluation is a complex workup that 
includes multiple specialists such as a transplant surgeon, 
anesthesiologist, hepatologist, cardiologist, nephrologist, 
and, if necessary, psychiatrist and social worker. The pre-
transplant evaluations include laboratory evaluation of the 
liver function tests, hematological studies, electrolytes and 
kidney function tests, tumor markers, hepatitis serology, viral 
serology, blood type, tuberculosis testing, computerized test-
ing of the liver, and ultrasound. 
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 Contraindications 
Contraindications to liver transplant are center specific. Many 
centers have a multidisciplinary meeting that discusses and 
evaluates whether patients are candidates for transplant. 
Some of the diagnosis that are questioned include cholan-
giocarcinoma, exceedingly large hepatoma, active substance 
abuse, including an inability to stop alcohol abuse, extrahe-
patic malignancy, advanced cardiac or pulmonary disease, 
and absence of ability to maintain care of the organ (Bufton, 
Emmett, & Byerly, 2008). Some examples include psychologi-
cal inability to cope, absence of family or social network, and 
homelessness. These diagnoses and situations are discussed, 
and the ability to rectify the situations is generally evaluated. 
Should the underlying conditions be complicated by need of 
a coronary artery bypass, lung or heart transplant, or kid-
ney failure, these patients may be scheduled prior to, or dur-
ing the liver transplant. Some patients have received heart, 
lung, and kidney transplant (Bufton et al., 2008). The health 
care society is in rapid growth, and it continues to move for-
ward with unique advancements to extend and prolong life 
depending on the underlying well health of the individual. 
 Transplantation 
 Intraoperative Techniques 
There are multiple types of liver transplant including a whole 
liver, reduced liver, or a partial segment. The orthotopic liver 
transplantation generally involves a disruption of portal and 
inferior vena caval blood flow that occasionally might require 
venovenous bypass, which is indicated to divert the blood to 
the superior vena cava during the anhepatic phase of the liver 
transplant. The inferior vena cava, portal vein, hepatic artery, 
and the biliary duct are anastomosed. A Roux-en-Y choledo-
chojejunostomy connects the bile duct to the bowel and may 
be indicated when a duct-to-duct anastomosis is not feasible 
(Bufton et al., 2008). The surgical incision is in the shape of 
a chevron opening both on lower chest and abdomen, which 
may cause patients postoperative difficulties in mobility. Pain 
management is significant in promoting mobility, respiratory 
survivability, extubation, and early ambulation. 
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 Postoperative Management 
Detailed acute postoperative management is key to survival 
and prevention of infections. Operative blood loss, hypoten-
sion, or cardiac problems before, during, or after reperfusion, 
and use of venovenous bypass are the important information 
that needs to be known for early management of patients. 
Fluid management is used to stabilize blood pressure and 
urine output, which is crucial to the resuscitation of patients. 
Patients who had hepatorenal syndrome and significant 
hemodynamic instability during the operation will continue 
to have renal insufficiency postoperatively and might require 
temporary dialysis. Most patients with hepatorenal syndrome 
with a functioning liver graft will recover from renal insuf-
ficiency in the immediate postoperative period. 
Patients who have critical chronic liver disease may be 
hyperdynamic postoperatively, exhibiting a low systemic vas-
cular resistance (SVR), high cardiac output (CO), and cardiac 
index (CI). Considering the chronicity of this patient popula-
tion, it is important to keep in mind that these hyperdynamic 
numbers might reflect sepsis secondary to infection, which 
was not recognized prior to the transplantation. 
Management may incorporate fluid resuscitation but with 
limitations and inotropic support. Maintaining adequate fluid 
balance facilitates the perfusion of the liver and the hepatic 
artery to prevent cellular death, which is vital to the organs 
(Bufton et al., 2008). Patients’ post–liver transplant evaluation 
and follow up must be done systematically. During the first few 
hours and days after the transplant, patients’ general clinical 
condition, even without any laboratory workup, provides sig-
nificant information about the function of the transplanted 
liver graft. Maintaining normotension is specifically imperative 
based on thrombocytopenia. Hypertension with systolic blood 
pressures >140 mmHg may precipitate an intracranial hemor-
rhage, specifically those with thrombocytopenia. Medications 
indicated to maintain normotension include, but are not limited 
to, continuous infusions of labetalol based on heart rate, and 
nicardipine may be another consideration once the pain has 
been managed. An awake patient with good urine output most 
likely has functioning graft including self-correction of lactic 
acidosis and coagulopathy, which reflects good synthetic func-
tion of the liver. Also, the fibrinogen levels >100 are the main 
prognostic indicator of a functioning liver. Daily follow up of 
252 Critical Care
liver function tests and liver duplex  ultrasound to check vascu-
lar anastomotic patency are routine in the postoperative period 
of liver transplant patient. Daily levels for calcineurin inhibitors, 
which facilitate dose adjustment, are significantly important in 
the early post operative period to prevent rejection. Patients 
must be aggressively mobilized and, if possible, be weaned to 
extubation if not extubated in the operating arena. 
Evaluation of medications, pain management, and moni-
toring of antirejection medication levels while preventing hos-
pital-acquired infection facilitates a rapid ICU discharge and 
home environment. Arranging discharge planning, social work 
involvement, and physical and occupational therapy will fur-
ther enhance the recovery period. Family and patient educa-
tion with clear communication facilitates long-term outcomes. 
 Fluid and Electrolyte Management 
Management of fluids and electrolytes is important in the 
initial postoperative period. The primary focus is to maintain 
patients normovolemia. Whether patients are volume over-
loaded or volume under loaded is always the challenging fac-
tor. This may be based on the actual surgical procedure and 
the resuscitative effort indicated to maintain stability. The 
goal is to keep patients slightly hypervolemic in the initial 
postoperative period. Blood pressure, CVP, and pulmonary 
artery (PA) catheter information will assist in determining 
volume status and in determining when fluid boluses are 
required. Monitoring serum chemistries for electrolyte sta-
tus will improve outcomes. Magnesium and potassium are 
generally the electrolytes that need the most replacements. 
 Blood Glucose Management 
A continuous infusion of regular insulin is often required 
post–liver transplant. Steroids such as methylprednisolone 
are administered preoperatively and postoperatively, causing 
the blood glucose to require close attention. Insulin sliding 
scales facilitate the management of blood sugar and enhance 
the healing process. 
 Respiratory Management 
Patients who required transplant are extubated once pain man-
agement is controlled. The chest radiograph, intake and output, 
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breath sounds, oxygen saturation, and patients’ clinical appear-
ance must be monitored based on preoperative conditions and 
urine output. As with all postoperative patients, aggressive pul-
monary therapy and early ambulation are encouraged. 
 Gastrointestinal Prophylaxis 
Prevention of stress- and steroid-induced peptic ulcer dis-
ease is essential postoperatively especially in patients with 
preexisting esophageal varices. Patients are routinely placed 
on proton pump inhibitors, H2 receptor blockers, antacids, 
or sucralfate, with the preference being proton pump inhibi-
tors. Upon return of bowel function, the nasogastric tube is 
removed, and patients are placed on a progressive diet; ulcer 
prophylaxis may be continued, particularly if the immuno-
suppressive regimen includes corticosteroids. 
 Immunosupression 
Graft survival is paramount and is accomplished through 
immunosuppression following the transplant. Immunosup-
pression therapy includes a combination of corticosteroids, 
a calcineurin inhibitor such as cyclosporine or tacrolimus, 
and an antiproliferative agent. During the immediate post-
operative period and at the time of induction, high-dose cor-
ticosteroids and an antithymocyte globulin or a monoclonal 
antibody, such as alemtuzumab (Campath), is administered. 
The monoclonal antibody binds to CD52 surface antigen of 
multiple cell types, which results in lysis. 
Postoperatively, immunosuppression is maintained with 
tacrolimus and weaning doses of corticosteroids.  Tacrolimus 
known as FK–506 is a macrolide antibiotic produced by 
streptomyces tsukubaensis. Tacrolimus inhibits calcineu-
rin recruitment, decreases IL-2 production, and suppresses 
humoral immunity through the inhibition of B-lymphyocyte 
activation. Tacrolimus is metabolized in the liver through the 
cytochrome P450 system. The oral dose in liver transplant 
recipients is 0.1–0.15 mg/kg per dose. Tacrolimus may also 
be given as a continuous intravenous therapy when absorp-
tion is questionable. Daily levels are monitored, and there is 
a lower incidence of hypertension and hyperlipidemia, but 
a higher rate of diabetes and neurotoxicity (Luu et al., 2006; 
Bufton et al., 2008). 
254 Critical Care
Corticosteroids are administered in a high dose with a 
daily weaning scale following transplantation. They inhibit 
cytokine gene transcription and prevent recruitment and 
activation of T cells. The initial dosing is IV methylpredniso-
lone and then changed to oral form. Acute rejection should be 
treated with high dose IV methylprednisolone. The secondary 
effects of steroids include hypertension, cushingoid appear-
ance, personality changes, weight gain, dyslipidemia, osteo-
porosis, hyperglycemia, diabetes, cataracts, and increased risk 
of infection (Luu et al., 2006). 
 Primary Nonfunction 
Once reperfusion occurs graft function is viable, but primary 
nonfunction may occur secondary to preservation injury, 
which leads to multiorgan failure. Some of the causative fac-
tors include donor age, prolonged donor hospitalization, and 
prolonged cold ischemic time. The risk of primary nonfunc-
tion is approximately 2% to 5%, and retransplantation is indi-
cated or patients will die (Bufton et al., 2008). 
Maintaining optimal fluid balance also decreases the 
potential for early hepatic artery thrombosis. The initial 
signs are deterioration including an elevated alanine ami-
notransferase (AST), aspartate aminotransferase (ALT), 
and/or fever. Even though the prothrombin time may be as 
high as 19 or 20 seconds, careful observation and follow up 
will be acceptable, unless there are signs of bleeding. Platelet 
transfusion also might not be necessary, unless the level goes 
below 20,000/L. There is a concern of thrombosis of hepatic 
artery occurring by overcorrecting the coagulopathy. There is 
no clear cause for this occurrence, but it may be secondary 
to a kink or narrowing in the artery and must be ruled out if 
primary nonfunction occurs (Bufton et al., 2008). 
 Acute Rejection 
Acute rejection generally occurs within 7–14 days postopera-
tive in approximately 20% to 70% of patients. Clinically, these 
patients present with hyperbilirubinemia, a rise in alkaline 
phosphatase, and an elevation in ALT and AST. The clinical 
symptomology includes fever, liver tenderness, general mal-
aise, and symptoms of infection. Acute rejection is treated with 
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high-doses steroids, generally methylprednisolone 1 gram 
for 3 days or alternatively with monoclonal therapy such as 
OKT3. These treatment regimines are effective in 65% to 80% 
of patients (Luu et al., 2006). 
 Chronic Rejection 
Liver transplant patients may also present with general malaise, 
jaundice, pruritius, elevated serum alkaline phosphatase, and 
bilirubin. This is generally a chronic graft rejection that occurs 
in approximately 5% of postoperative liver transplant patients. 
This diagnosis is made by liver biopsy, because loss of liver 
synthetic function does not occur until later in the course. 
Infection is another primary problem in postoperative 
liver transplant patients secondary to immunosuppression. 
Patients may present with fever, abdominal pain, and hyper-
thermia or hypothermia. This population is generally so 
immunosuppressed that they usually cannot mount a white 
blood cell count (WBC) or a fever. A complete septic evalua-
tion would include a complete blood count, a full chemistry 
panel, liver function profile, coagulation studies, urinalysis, 
urine culture, and blood culture including viral studies. Other 
tests would generally include a liver duplex ultrasound, com-
puterized tomography with contrast, kidney function test, 
evaluation for abscess, and a liver biopsy. 
Infections are primarily hospital acquired, such as 
Acinetobacter baumanii, Pseudomonas aerigonsa, Enterococci,
Staphylococcus aureus, Klebsiella pneumonae, and  Candida
species, which are 75% of the infections. Patients present-
ing with fevers, malaise, arthralgias, atypical lymphocytes, 
thrombocytopenia, and elevated transaminase levels may 
be harboring a cytomegalovirus (CMV), which infects 25% 
to 85% of patients who require liver transplant during their 
1st and 3rd postoperative months. This viral infection may 
be fatal if it becomes disseminated. CMV pneumonitis is 
demonstrated on a chest radiograph as bilateral infiltrates. 
The treatment regimine for CMV is intravenous ganciclovir 
for 2–4 weeks.  Pneumocystis carinii pneumonia (PCP) can 
be a complicating factor with CMV infection, and transplant 
recipients are placed on PCP prophylaxis with trimethoprim 
sulfamethoxazole 1 gram single strength 3 times per week to 
potentially prevent these sequelae. 
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Liver transplant patients presenting with rejection 
symptoms, who are placed on increased immunosupression 
therapy, are exposed to other opportunistic pathogens such 
as Candida species, herpes zoster, toxoplasmosis, or hepati-
tis C reccurrence, which occurs in 50% to 80% of postopera-
tive patients. Hepatitis B is less common and only reoccurs 
in 10% of patients. The second leading cause of late death 
in liver transplant recipients is lymphomas, squamous cell 
carcinoma, and posttransplant lymphoproliferative disorder 
(PTLD), which is the adverse effect of immunosupression. 
 Outcomes 
The survival rates vary from center to center, but overall, the 
1-year survival rate after liver transplantation is approxi-
mately 90% for those who come to the hospital to receive their 
transplant. Patients in the ICU preoperatively and at the time 
of transplant, are critically ill, generally have a much lower 
rate of survival, approximately 60%. In 5 years, the survival 
rate in compliant patients is 80% (Luu et al., 2006). 
 Kidney Transplantation 
Kidney transplant is the treatment of choice for patients 
with chronic end-stage renal disease, which is defined as 
an irreversible glomerular filtration rate of <20 ml/min 
(Lipshutz & Wilkinson, 2007; Klingensmith, Amos, Green, 
Halpin, & Hunt, 2005). Kidney transplant affords prolonged 
survival rates and improved quality of life compared with 
the alternative therapy, dialysis. Renal transplant recipients 
have a higher success rate of becoming productive, active 
members of the community posttransplantation (Johnston, 
2007; Matas, 2003). 
 Pancreas Transplantation 
Whole vascularized pancreas transplant is the treatment of 
choice for type 1 diabetes mellitus, an autoimmune disease 
that results in destruction of the insulin-producing islets of 
Langerhans within the pancreas (Lipshutz & Wilkinson, 
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2007). In addition, pancreas transplant rates are  increasing for 
patients with complicated type 2 diabetes (Hummel, Langer, 
Wolters, Senninger, & Brockmann, 2008). Diabetes is a chronic 
illness that causes devastation to end organs and leads to com-
plications such as blindness, cardiovascular disease, cerebro-
vascular disease, loss of limbs, and dyslipidemia within 10–20 
years of diagnosis (Lipshutz & Wilkinson, 2007). 
Pancreas transplantation normalizes blood glucose 
levels more effectively than any other treatment currently 
available. A successful graft results in freedom from insulin 
administration, frequent blood sugar measurements, pre-
vention or improvement of secondary complications, a halt 
to the progression of end-organ failure, a lack of dietary 
restrictions, and an improved quality life (Kaufman, 2007; 
Lipshutz & Wilkinson, 2007). Pancreas transplant yields the 
best results in patients whose disease has not yet caused 
severe target-organ  damage (Bindi et al., 2005). Approxi-
mately 34% of patients with diabetes develop renal failure 
within 15 years; therefore, it is not surprising that >90% of 
the pancreas transplants are performed simultaneously with 
kidney transplants (Lipshutz & Wilkinson, Wikipedia, 2008). 
 Indications for Kidney Transplant 
Most kidney transplants are performed secondary to end-
stage renal failure (ESRF) (Johnston, 2007). Most renal 
transplant recipients are surviving because of hemodialysis, 
hemofiltration, or peritoneal dialysis. Those who have a  living
donor available may choose to receive a transplanted kidney 
prior to the initiation of dialysis, because this has been shown 
to have improved outcomes. 
Renal failure, secondary to diabetes mellitus, comprises 
approximately 25% to 31% of the cases in the United States and 
is now the most common disease requiring kidney transplant. 
Other common diseases leading to ESRF are previous graft 
rejection, hypertension, chronic glomerulonephritis, polycys-
tic kidney disease, lupus, scleroderma, chronic pyelonephritis, 
interstitial nephritis, nephrotic syndrome, hypertensive neph-
rosclerosis, obstructive uropathy, amyloidosis, and traumatic 
causes, such as vascular occlusion or parenchymal destruc-
tion (Kaufman, 2007; Organ Procurement and Transplantation 
Network [OPTN], 2006). 
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 Indications for Pancreas Transplant and 
Combined Kidney Pancreas Transplant 
Indications for pancreas transplant include type 1 diabetes 
or type 2 diabetes with significant secondary sequelae. Indi-
viduals with diabetes, in addition to end-stage renal disease, 
which is usually >90% of pancreas transplants, generally 
will receive a simultaneous pancreas and kidney transplant 
(SKP) from a cadaver donor. This is considered the interven-
tion of choice, minimizing patients’ risk by performing one 
surgical intervention and limiting the recipient exposure to 
one donor human leukocyte antigen (HLA). This will further 
minimize the potential for rejection. An individual with severe 
metabolic complications of type 1 diabetes and maintains a 
creatinine clearance of 60–70 ml/min or greater will receive a 
pancreas transplant alone (PTA). Patients with diabetes and 
renal failure may receive a kidney transplant only when the 
pancreas is not available and then receive a  pancreas trans-
plant after the kidney when the organ is available (PAK), 
which is the common surgical intervention (Hummel et al., 
2008; Kaufman, 2007; Lipshutz & Wilkinson, 2007). 
 Contraindications 
Contraindications to kidney and pancreas transplant are  center 
specific and often relative contraindications. Some commonly 
accepted contraindications to kidney and pancreas transplant 
are substance abuse, HIV, and AIDS. Relative contraindications 
include systemic infections, sepsis, multisystem organ failure, 
severe cardiopulmonary insufficiency, recent cancer within the 
past 2–5 years, and history of noncompliance (Johnston, 2007). 
Most centers have variations of age criteria and are based on 
individual functionality. Some centers, such as Jackson Health 
System in Miami, Florida, have performed kidney transplan-
tation on patients older than 85 years, patients who are HIV 
positive, and in some circumstances within 2 days after heart 
transplantation, utilizing the same donor with the kidney 
maintained on a pump in a preservation solution. Therefore, 
end-stage cardiac failure is not an absolute contraindication 
to kidney transplant. Similarly, patients who are HIV positive 
with well-maintained cluster of differentiation 4 (CD4) counts 
may be candidates for transplantation at some centers. 
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 Intraoperative Techniques 
 Kidney Transplant Operative Technique 
Although alternate techniques may be employed, the most 
common operative technique for kidney transplantation is 
retroperitoneal placement in the right iliac fossa as opposed to 
intra-abdominal placement. Patients who may be candidates 
for pancreas transplant at a later time should have the  kidney 
placed in the left iliac fossa, with the right side reserved for the 
pancreas. The donor renal artery is anastomosed to the exter-
nal iliac artery of the recipient, and the renal vein is anasto-
mosed to the external iliac vein (Matas, 2003;  Klingensmith
et al., 2005). The donor ureter is implanted in the recipient’s 
bladder, with the creation of an extravesicular ureteroneo-
cystostomy known as Lich–Gregoir reimplantation to prevent 
obstruction and posttransplant reflux pyelonephritis (John-
ston, 2007; Klingensmith et al., 2005; Matas, 2003). 
Alternatively, intravesical ureterocystostomy may be done 
when necessary. During this technique, the bladder is incised, 
which is known as a Leadbetter–Politano reimplantation, and 
a urethral catheter is placed to drain the bladder. This cathe-
ter is left in place for 3–7 days postoperatively (Klingensmith 
et al., 2005). Prophylactic ureteral stents are commonly used 
to reduce complications such as urine leaks and ureteral ste-
nosis and are retrieved within a few weeks postoperatively 
via cystoscopy (Johnston, 2007; Wilson, Bhatti, Rix, & Manas, 
2005). Sometimes, ureteral stents are tied to a foley catheter 
intraoperatively and are removed with the foley. 
The native kidneys are usually left in place. A native 
nephrectomy may be performed prior to transplantation in 
necessary circumstances, such as in cases of chronic paren-
chymal infection, unmanageable proteinuria, polycystic 
kidney disease, intractable hypertension, infected stones, or 
acquired renal cystic disease (Klingensmith, et al., 2005). 
 Pancreas Transplant Operative Technique 
The donor pancreas may be placed retroperitoneally in the 
right iliac fossa, or may be placed intraperitoneally. Typi-
cally, the arterial anastomosis is achieved by using the donor 
splenic and superior mesenteric artery anastomosed to the 
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Y-graft formed from the donor iliac artery prior to implan-
tation and attaching it to the recipient’s common or exter-
nal iliac artery. Connection of the venous system entails the 
donor’s portal vein being anastomosed to the recipient’s 
common or external iliac vein. The recipient retains the 
native pancreatic exocrine function to aid in digestion, and 
exocrine secretions of the graft must be managed to mini-
mize complications. Management of the pancreatic fluid 
produced by the graft is accomplished by enteric drainage 
or bladder drainage. 
Enteric drainage necessitates an intra-abdominal 
operation and carries the risk of development of an  enteric 
leak. Drainage of the pancreas into the bladder avoids 
these risks and permits measurement of urine amylase and 
lipase as a measure of pancreatic graft function. This is a 
less physiologic process, and it results in higher incidence 
of urinary tract infections, dehydration, and metabolic 
derangements secondary to loss of high amounts of bicar-
bonate (Lipshutz & Wilkinson, 2007; Matas, 2003; Rainer & 
Sutherland, 2004). 
 Early Postoperative Management 
In many centers, patients with uncomplicated renal trans-
plant may recover in the postanesthesia recovery unit 
(PACU) and then be transported to a regular floor or trans-
plant floor that utilizes nurses who are trained in the care 
of postoperative transplant patients. Adequate staffing is 
essential to accommodate the demanding needs of post-
transplant patients specifically in monitoring of intake and 
output to prevent graft failure. Patients with simultaneous 
pancreas and kidney transplants, or those with significant 
comorbidities, may be best served by admission directly from 
the operating room to the surgical intensive care unit (SICU). 
Immediate postoperative care includes management of 
hemodynamic status, acid–base balance, fluid and electrolyte 
status, blood glucose, respiratory management, gastrointes-
tinal prophylaxis, assessment of graft function, monitoring 
of immunosuppression, and patient education. Research by 
Bindi et al., (2005) identified the mean ICU stay as 4.7 days 
for isolated pancreas transplants as well as simultaneous 
kidney– pancreas transplant recipients. 
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 Hemodynamic Status 
Postoperative transplant patients generally arrive in the 
ICU with a central venous catheter and an arterial catheter, 
although blood pressure may be frequently assessed with the 
use of noninvasive monitoring alone. Although not necessary 
for most kidney–pancreas recipients, patients with signifi-
cant cardiac risk factors may be monitored with the use of a 
PA catheter to achieve optimum cardiac function monitoring. 
Kidney and kidney–pancreas transplants experience rapid 
fluid changes and generally are managed on milliliter of 
urine output per milliliter of fluid replacement. The goal of 
intense monitoring is to prevent pulmonary edema, volume 
overload, or dehydration during this initial postoperative 
period of rapid changes in fluid status. 
Hypotension must be avoided because decreased perfu-
sion pressures increase the risk of acute tubular necrosis or 
graft thrombosis; hypertension increases the risk of postop-
erative bleeding and stroke (Matas, 2003). Most of renal and 
pancreas transplant recipients have a past medical history 
of hypertension, while perioperative use of corticosteroids 
further causes sodium and fluid retention that contributes to 
postoperative hypertension. Typical goal parameters in the 
immediate postoperative period for systolic blood pressure 
are 120–150 mmHg or mean arterial pressure of 90–105 mmHg 
(Klingensmith et al., 2005). Central venous pressure (CVP) 
monitoring is useful in guiding the ACNP’s choice of interven-
tions in the face of low urine output, specifically because CVP 
trends are more useful than absolute numbers. A decreasing 
urine output with a decreasing CVP and blood pressure indi-
cate the need for a fluid challenge, whereas low urine output 
with an elevated CVP and elevated blood pressures usually 
indicates the need for a diuretic. Furosemide drips may be ini-
tiated ranging from 5–20 mg/hr. Dopamine administered at a 
dose of 2–5 μg·kg −1·min−1 intravenously is used to elevate a low 
blood pressure and promote urine output once preload (intra-
vascular fluid volume status) has been optimized (Klingen-
smith et al., 2005). Pharmacologic agents, such as intravenous 
beta-blockers (labetalol, lopressor, esmolol), calcium channel 
blockers (nicardipine), or vasodilators (hydralazine) are fre-
quently used to control postoperative hypertension. 
Tachycardia is to be avoided, especially in patients with 
cardiovascular disease or risk factors such as  diabetes, 
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hypertension, or dyslipidemia. Pain as a cause of  tachycardia 
should be assessed, and intravenous morphine or other nar-
cotics are appropriate for postoperative pain  management. 
Tachycardia may be an indication of inadequate perfu-
sion, although blood pressure appears relatively normal. 
Decreasing bicarbonate levels and worsening base deficit 
on the arterial blood gas, as well as elevated lactic acid level 
may provide clues that tachycardia is a result of inadequate 
perfusion and impending cellular death. These laboratory 
values combined with a decreasing CVP indicate the need 
for increasing intravenous fluids. Once pain and hypo-
perfusion has been assessed and managed, if tachycardia 
remains unresolved, administration of beta-blockers may 
be effective in controlling heart rate and minimizing asso-
ciated increased myocardial oxygen demand. During cases 
of suspected myocardial stress, the ACNP should evaluate 
patients for potential myocardial ischemia or infarction by 
electrocardiogram and appropriate laboratory tests such as 
cardiac enzymes and troponin level as adjusted for creati-
nine levels. 
The posttransplant patient must be monitored for signs of 
hemorrhage, including continuous monitoring of the surgical 
drains for sanquinous output, hematuria that progresses to a 
continuous sanguineous urine, falling hematocrit, decrease 
in blood pressure that responds to fluid boluses initially, per-
sistent tachycardia, and worsening metabolic acidosis indi-
cating the possibility of bleeding. Replacement with packed 
red cells and correction of any coagulopathy is the initial 
treatment, and the surgical team is notified to evaluate the 
need for exploration. Frequently, the bleeding tamponades, 
and immediate surgical intervention is not necessary; how-
ever, evacuation of the hematoma may be indicated at a later 
time (Matas, 2003). 
 Acid Base Balance 
Renal Transplant Recipients. Until the transplanted kidney 
is functioning well, the postoperative patient will continue to 
have a renal tubular acidosis (RTA). After ruling out hypoper-
fusion as a cause of metabolic acidosis, bicarbonate adminis-
tration may be necessary to normalize serum pH. Generally, 
a good functioning kidney helps to correct the acidosis, mini-
mizing the need for bicarbonate administration. 
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Pancreas Transplant Recipients. When pancreas grafts are 
surgically placed to drain into the duodenum, bicarbonate 
can be reabsorbed. However, when there is 800–1,000 ml/day 
of exocrine pancreatic fluid drained into the bladder, the loss 
of bicarbonate may result in a metabolic acidosis. Bicarbon-
ate replacement may be necessary (Kaufman, 2007). 
 Fluid and Electrolyte Management 
Management of fluids and electrolytes is challenging in the 
postoperative kidney transplant patient. Initially, the goal 
is to keep patients slightly hypervolemic. Urine output is 
measured hourly and replaced with 0.45 normal saline mil-
liliter for milliliter, and a maintenance intravenous fluid to 
replace insensible losses infuses at 30–60 ml/hr (Klingen-
smith, 2005). Half-normal saline is used as a replacement 
fluid to prevent a high chloride load that could cause acido-
sis secondary to the high volume urine output. Blood pres-
sure and CVP can assist with determining volume status 
and need for fluid boluses. Patients who receive a marginal 
graft may be oliguric or even aneuric and may only require 
maintenance intravenous fluids without replacement. Com-
munication with the surgical transplant team is necessary 
to determine postoperative expectations of the transplanted 
kidney. Information regarding patients’ native renal function 
and preoperative urine production are useful in determining 
the amount of urine production by the transplanted kidney. A 
sudden cessation of urine output may indicate an obstruction 
in the urinary catheter that requires gentle irrigation. 
Monitoring of serum chemistries for electrolyte status 
is imperative. Potassium levels must be monitored, because 
hypokalemia may develop with posttransplant diuresis and 
fluid replacement. Potassium is replaced cautiously and con-
servatively in the absence of dysrhythmias. Hyperkalemic 
patients with poor initial graft function may require aggres-
sive treatment and may ultimately become an indication for 
posttransplant dialysis. 
 Blood Glucose Management 
A continuous infusion of regular insulin is often required 
post–kidney transplant as well as post–pancreas transplan-
tation. When steroids such as methylprednisolone have been 
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administered perioperatively, blood glucose control requires 
close attention. During the immediate postoperative period, 
blood sugars are monitored hourly, and some centers use 
continuous infusions of 50% dextrose and regular insulin 
simultaneously for patients receiving pancreas transplants. 
 Respiratory Management 
The post–renal and post–pancreas transplant patients are 
normally extubated prior to admission to the ICU, or rapidly 
weaned and extubated shortly after arrival. Some indications 
for prolonged mechanical ventilation are hemodynamic insta-
bility and pulmonary edema due to aggressive intraoperative 
fluid resuscitation (Matas, 2003). The transplant team may 
decide to maintain an endotracheal airway until the first dose 
of the muromonab (OKT3), an immunosuppressive, is given, 
as the most concerning drug reaction related to monoclonal 
antibody is pulmonary edema. This is an unusual condition, 
because most immunosuppressive induction and mainte-
nance regimens do not include OKT3 currently. The chest 
radiograph, intake and output, breath sounds, oxygen satu-
ration, and patients’ clinical appearance must be mo nitored
as urine output is rapidly replaced post–renal transplant. As 
with all postoperative patients, aggressive pulmonary toilet 
and early ambulation are encouraged. 
 Gastrointestinal Prophylaxis 
Prevention of stress and steroid-induced peptic ulcer disease 
is essential postoperatively. Patients are routinely placed on 
proton pump inhibitors, Histamine 2-receptor agonists, ant-
acids, sucralfate, or a combination thereof (Matos, 2003). Upon 
return of bowel function, the nasogastric tube is removed, and 
patients are placed on a progressive diet. The ulcer prophy-
laxis may be continued, particularly if the immunosuppres-
sive regimen includes corticosteroids. 
 Assessment of Graft Function 
Renal Graft Assessment. Hourly urine output is assessed 
upon arrival to the SICU, and while urine production may be 
adequate, the function of the kidney is further assessed by 
monitoring blood urea nitrogen (BUN) and creatinine. Serum 
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pH, bicarbonate, and base excess should begin to normalize as 
the kidney reabsorbs bicarbonate. 
Initial renal graft function can be categorized into three 
groups including immediate graft function (IGF), slow graft 
function (SGF), or delayed graft function (DGF). IGF is evident 
in recipients when the creatinine falls rapidly, and diuresis 
occurs immediately postoperative. Most living renal donor and 
half of cadaveric renal donor grafts display immediate function. 
Recipients have fewer episodes of rejection and better long-
term results than those with delayed graft function. SGF recipi-
ents are oliguric with a slowly decreasing creatinine, and do 
not require dialysis. DGF recipients have very poor initial graft 
function, are mostly anuric, and require dialysis. DGF is usually 
attributed to prolonged ischemic time but may occur as a result 
of marginal donor quality or high panel reactive antibodies, and 
usually manifests as acute tubular necrosis (ATN). DGF is not 
a result of other complications that may impact graft function 
such as urine leaks, graft thrombosis, or accelerated acute rejec-
tion. Graft function improves slowly over days to weeks, and is 
linked to a higher risk for acute rejection as wells as decreased 
graft survival (Johnston, 2007; Kaufman, 2007; Matos, 2003). 
When renal graft function suddenly declines, renal 
artery or vein graft thrombosis should be suspected. These 
complications most frequently occur within the first 2–3 days 
after transplantation (Klingensmith, 2005). Some centers 
routinely perform regular renal scans and duplex ultrasound 
of the graft on the first postoperative day to identify graft and 
artery complications. 
Pancreatic Graft Assessment. Postoperative blood glucose 
levels normalized with minimal use of exogenous insulin 
demonstrate good pancreatic graft function. Recipients who 
have bladder drainage of pancreatic enzymes require urine 
measurements of amylase and lipase, which can identify 
intact endocrine function as an indication of a healthy graft, 
and a biopsy, if indicated, may be achieved via cystoscopy. 
Pancreatic graft anastomosis, connecting to the duodenum 
of the recipient as a means of exocrine drainage allows for 
visualization of the graft via gastroscopy (Hummel, 2008). 
Pancreatic graft Doppler ultrasonography is important in 
the postoperative period to follow venous thrombosis and, if 
identified, immediate action including anticoagulation and 
possible surgical intervention should be taken. 
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 Immunosuppression 
Prescribing immunosuppressive therapy prevents the 
recipient’s immune system from destroying the transplanted 
graft(s). The surgical transplant team implements its cen-
ter-specific protocols and actively monitors immunological 
markers and drug levels to adjust drug therapy daily. The 
ACNP needs to have an understanding of the intended action 
of common immunosuppressive medications prescribed and 
the side effects of these agents. The various forms of rejec-
tion are discussed below. 
Rejection. Hyperacute rejection occurs within hours of trans-
plantation, when preformed HLA antibodies attack the 
graft and result in vessel thombosis quickly progressing to 
necrosis of the graft. The graft is unsalvageable and must be 
immediately removed. 
Accelerated acute rejection occurs from 12 hours to 1 week 
after transplantation. Immediate therapy with antilympho-
cyte globulin and pulse corticosteroids results in frequent 
recovery of graft function. 
Acute rejection occurs 1–3 months posttransplant, and is 
T-lymphocyte mediated. Diagnosis is confirmed with biopsy. 
Treatment is with corticosteroids alone or in conjunction 
with anti-T cell antibodies. 
Chronic rejection can occur weeks to years after trans-
plant and involves progressive irreversible destruction to the 
graft and its vessels (Kaufman, 2007; Klingensmith, 2005). 
Induction Therapy. Anti-T cell antibodies that block or 
inhibit T-cell response to the graft(s) are used for induc-
tion therapy immediately after transplant or for treatment 
of episodes of acute rejection. Examples of these agents are 
antithymocyte globulin, muromonab-CD3, daclizumab, and 
alemtuzumab. Use of these powerful agents increases the 
recipient’s risk of infection. Alemtuzumab has been associ-
ated with rash, thrombocytopenia, bronchospasm, and hypo-
tension. Monitoring concerns with muromonab-CD3 include 
cytokine release syndrome, fever, chills, risk of pulmonary 
edema, neurotoxicity, and nephrotoxicity. Attention to fluid 
status prior to administration is essential. Premedication 
with an acetaminophen, an antihistamine, and corticosteroid 
can minimize these adverse events. 
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Corticosteroid therapy can also be used to treat episodes 
of acute rejection. Methylprednisolone is the drug of choice; 
secondary sequelae include complicated blood glucose man-
agement, gastrointestinal ulceration, extreme mood swings, 
psychosis, delayed wound healing, elevated blood pressure 
because of sodium and water retention, and a sudden eleva-
tion in WBC count. 
Maintenance Therapy. A combination of immunosuppressive 
agents is used for prevention of graft rejection. A calcineu-
rin inhibitor such as tacrolimus or cyclosporine is commonly 
prescribed. Patient management involves the careful assess-
ment of drug interactions, because these immunosuppressive 
drug levels may elevate or decrease with concomitant use of 
various pharmacologic agents involving the cytochrome P450 
system, which is routinely used in the ICU. Tacrolimus and 
cyclosporine have dose-related nephrotoxicity, and care is 
taken to monitor levels of these immunosuppressives while 
avoiding coinciding use of other nephrotoxic agents whenev-
er possible. The adverse effects of tacrolimus and cyclospo-
rine are dose dependent and are difficult to compare without 
stating the relative dose used. Renal toxicity may be revers-
ible secondary to renal vasoconstriction, and irreversible 
nephron loss may occur with atrophy and fibrosis secondary 
to the vascular damage. Calcineurin inhibitors, specifically 
tacrolimus, have neurotoxic effects and may cause seizures 
and in addition to a calcineurin inhibitor, mycophenolate or 
azathioprine may be used. Renal function must be monitored 
closely. Mycophenolate inhibits proliferation of B cells and T 
cells selectively; nausea and diarrhea are the primary side 
effect. Azathioprine inhibits lymphocyte cell division and 
can lead to severe leukopenia. Sirolimus is an agent useful 
in limiting the dose of calcineurin inhibitor required, thereby 
minimizing toxic effects of cyclosporine or tacrolimus; how-
ever, marked thrombocytopenia may occur, and therapy may 
be complicated by multiple drug interactions (Johnston, 2007; 
Kaufman, 2007). 
Corticosteroids usually have a role in initial maintenance 
therapy, but with the advances in current immunosuppres-
sion protocols, steroids have been avoided or minimized to 
avoid long-term side effects such as hypertension, ulcer dis-
ease, osteoporosis, infection, obesity, hypercholesterolemia, 
and glucose intolerance (Johnston, 2007). 
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 Outcomes 
Prognosis after transplantation is excellent; the 1-year graft 
survival is 95% for kidney and 80% to 85% for pancreas (John-
ston, 2007). Discharge teaching is a high priority for success 
of the graft and should begin while patients demonstrate 
readiness to learn, and can begin gradually in the immedi-
ate postoperative period. Posttransplant education is focused 
toward understanding early postoperative monitoring and 
treatment, understanding new medications and related 
effects of these medications, lifestyle modifications, and the 
importance of compliance (Kaufman, 2007). 
 Summary 
Although management of patients who have undergone 
liver transplant, kidney transplant, and pancreas transplant 
requires close monitoring, frequent interventions, and an 
elaborate medication regime, the benefits to the recipients 
are well described. Collaboration between the ACNP and 
surgical transplant teams is essential in the immediate post-
operative period to quickly identify and prevent complica-
tions and ensure optimal graft function. 
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 Introduction 
In the United States, trauma is the leading cause of death among 
children, adolescents, and adults under the age of 35 years. In 
2003, the Centers for Disease Control (CDC) estimated that 
more than 400 U.S. residents died each day from injury. Motor 
vehicle and transportation-related injuries accounted for most 
of these deaths (29%), followed by firearm injuries (18%), and 
falls (11%). A recent study that examined the economic impact 
of trauma in the Unites States found that the total lifetime costs 
associated with medically treated injuries was over $400 billion 
annually. The greatest financial and often psychological bur-
den associated with trauma is the extensive disability that may 
result from injuries, often in young persons in the early part 
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of their work career (Corso, Finkelstein, Miller, Fiebelkorn, & 
Zaloshnja, 2006). The epidemic of trauma-related deaths is a 
global health crisis with a staggering 1 in 10 deaths worldwide 
resulting from injury (Mackenzie & Fowler, 2008). 
Governments have responded in part to this public health 
crisis by creating trauma systems to manage and coordinate 
the care of individuals who have been significantly injured. 
These systems are organized using several identified phases 
of trauma care that include prehospital care, acute inpatient 
care, and rehabilitation. The primary goal of these systems 
is to coordinate health care from the initial injury through 
the rehabilitation phase so that outcomes are optimized, and 
patients can regain maximal functionality. The critical care 
nurse practitioner is typically involved in only a part of this 
long sequence of events to recovery. 
In this chapter, we will focus on the acute care manage-
ment of trauma patients. A discussion of the initial assessment 
of the injured patient and the approach to managing shock 
states and resuscitation will be discussed. An overview of com-
monly encountered injuries will be provided with an emphasis 
on thoracic, intra-abdominal, and musculoskeletal injuries. 
 Initial Assessment of the Injured Patient 
The primary survey and subsequent management of criti-
cally injured patients remains a daunting task even for the 
most experienced practitioner. The forces sustained during 
a major trauma are formidable and can result in a diverse 
array of seemingly unrelated injuries that involve multiple 
regions of the body. The most important element of the ini-
tial trauma assessment is to maintain an orderly sequence of 
evaluations regardless of the distracting nature of presenting 
injuries. This orderly sequence of evaluations is referred to 
as the primary survey and can be recalled using a modifica-
tion of the commonly taught mnemonic ABCDE. 
1.  Airway: Confirm and maintain airway patency with cer-
vical spine immobilization. 
2.  Breathing: Establish the presence of spontaneous respi-
rations and exclude life-threatening impairments to nor-
mal ventilation (e.g., tension pneumothorax, neurological 
injury, influence of drugs and/or alcohol). 
Chapter 7: Care of the Critically Injured Patient 273
3.  Circulation: Ensure the presence of effective circula-
tion and exclude exsanguinating hemorrhage. Establish 
intravenous access. 
4.  Disability: Perform a gross neurological assessment to 
rule out significant intracranial injury and determine the 
patient’s level of consciousness using the Glasgow Coma 
Scale (GCS). 
5.  Exposure: Remove all clothing and scan the patient head-
to-toe to rule out significant life-threatening injury. Ensure 
appropriate measures to prevent hypothermia. 
Most critically injured patients have sustained a sufficient 
force of injury to warrant the initial presumption of cervical 
spine injury, so their cervical spine should be immobilized 
before beginning any assessment. This includes the applica-
tion of a hard cervical collar and maintenance of inline spine 
immobilization. In certain situations, the trauma team leader 
may elect to forgo immobilization if the mechanism of injury 
is clearly incompatible with cervical spine injury (e.g., pen-
etrating injury to the extremities). 
The highest priority in any resuscitation is determin-
ing whether the patient’s airway is patent. Injured patients 
often demonstrate diminished levels of consciousness (e.g., 
brain injury, intoxication, shock, etc.) that may prevent them 
from protecting their own airway. Traumatic injuries to the 
face can also result in significant nasopharyngeal bleeding, 
leading to airway obstruction. If the patient is conscious, the 
simple act of responding to questions is often sufficient to 
preclude any obstruction. Signs of airway obstruction include 
stridorous and labored breathing. Any evidence of obstruc-
tion requires immediate intervention via oropharyngeal suc-
tioning, inserting a nasopharyngeal airway, or endotracheal 
intubation. 
After the airway has been deemed patent, the presence 
of spontaneous breathing needs to be established. Patients 
who are not breathing spontaneously require supported 
forms of ventilation. A rapid and focused respiratory exami-
nation should also be conducted to exclude significant tho-
racic injury. Inspection of the chest wall for signs of external 
trauma (contusion, deformity, laceration) often provides the 
first indication that there is an underlying lung injury. The 
presence of subcutaneous emphysema on palpation may also 
signify serious pulmonary trauma. Auscultation is performed 
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to establish that there is normal and equal air entry bilater-
ally. Diminished air entry may signify an underlying hemo-
thorax and/or pneumothorax. Patients with hemodynamic 
instability and clinical evidence of a pneumothorax require 
immediate decompression of their pleural space with needle 
and tube thoracostomy. Supplemental oxygen is adminis-
tered, and oxygen-saturation monitoring is established. 
The patient’s pulse and blood pressure are quickly assessed 
at this point to ensure adequate circulatory function. A rapid 
visual scan of the patient’s body should also be conducted to 
exclude significant external hemorrhage. Intravenous (IV) 
access is critical and is established early with 2 large-bore 
peripheral IVs (14 or 16G) or via central venous catheteriza-
tion. Crystalloid fluids and blood products are administered 
as indicated. 
A cursory neurological examination should be subse-
quently performed to rule out significant intracranial trau-
ma. The patient’s pupils are assessed for size and reactivity. 
A fixed and dilated pupil suggests a significant underlying 
brain injury and necessitates intervention to decrease intra-
cranial pressure. The patient’s level of consciousness should 
be assessed using the GCS (Table 7.1). A GCS score below 9 
indicates severe brain injury requiring immediate neurosur-
gical consultation (see Chapter 5). 
The patient’s clothing should be completely removed. It 
is critical that all bandages applied in the prehospital set-
ting eventually be removed and be carefully inspected by 
the trauma team. It is not uncommon to miss subtle findings 
in the field setting that would dramatically affect manage-
ment. A small laceration, for example, may actually repre-
sent a small tear from an underlying open fracture. “Arterial 
pumpers” observed in the field may represent inconsequen-
tial bleeding from subcutaneous tissues or might indeed be a 
major vascular injury. It is important to rely only on what you 
or your team has personally visualized and not on the assess-
ment of prehospital personnel or transferring physicians. 
Hypothermia is also a serious concern in trauma patients, 
particularly when there is evidence of hemorrhagic shock. 
Strategies employed to minimize lowering of the patient’s 
core body temperature include the use of warmed resuscita-
tion fluids and warming blankets, as well as increasing the 
ambient room temperature when feasible. 
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 Investigations and Monitoring Adjuncts 
to the Primary Survey 
Once the primary survey has been completed, several adjuncts 
are employed to monitor patients’ physiologic status. If the 
primary survey has not already been done, patients should be 
attached to a pulse oximetry device to ensure adequate oxygen-
ation and have electrocardiographic (ECG) monitoring leads 
attached. Catheterization of the bladder is performed early to 
allow for monitoring of volume status and organ perfusion and 
 Score
Eyes
Opens eyes spontaneously 4
Opens eyes in response to voice 3
Opens eyes in response to painful stimuli 2
Does not open eyes 1
Verbal
Oriented, converses normally 5
Confused or disoriented 4
Inapropriate words 3
Incomprehensible sounds 2
Makes no sounds 1
Motor
Obeys commands 6
Localizes painful stimuli 5
Withdraws (normal fl exion) to painful stimuli 4
Abnormal fl exion to painful stimuli (decorticate response) 3
Extension to painful stimuli (decerebrate response) 2
Makes no movements 1
Glasgow Coma Scale (GCS)7.1
GCS ≤ 8 = Severe; GCS 9–12 = Moderate; GCS ≥ 13 = Mild
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to prevent bladder distention. Urethral catheterization is abso-
lutely contraindicated in patients with a suspected urethral 
injury. The presence of blood at the urethral meatus or a “high-
riding” prostate on digital rectal examination should alert the 
clinician to the possibility of such an injury. In this situation, 
catheterization should be deferred until definitive imaging of 
the distal genitourinary tract has been performed. 
An orogastric (OG) or nasogastric (NG) tube is commonly 
inserted to decompress the stomach contents and minimize 
the risk of aspiration. Trauma patients are at increased risk 
for aspiration, because they are physically immobilized on 
spine boards and often have a diminished capacity to protect 
their airway. Insertion of an NG tube is absolutely contra-
indicated in patients with a suspected basal skull fracture, 
because there have been rare case reports of NG tubes inad-
vertently being passed through a fractured cribiform plate 
into the cranial vault. In these cases, gastric decompression 
via oral intubation is preferred. 
Laboratory studies should be drawn from patients during 
this phase of resuscitation. Although protocols vary across 
hospitals, commonly ordered studies include a complete blood 
count (CBC), a chemistry panel, coagulation parameters, and 
arterial blood gases. All patients are screened for blood type 
and crossmatch when blood transfusion is required. 
Radiological imaging is an important component of the 
initial assessment, and arrangements should be made to 
have the appropriate personnel and equipment available. 
A plain anterior–posterior (AP) chest and AP pelvic film are 
mandatory in all polytrauma patients. For patients who are 
not undergoing brain imaging with computed tomography 
(CT), plain films of the cervical spine should be obtained, 
including AP, lateral, and odontoid views. 
 Shock and the Trauma Patient 
Shock plays a central role in the assessment and management 
of critically injured patients. The initial goal of all trauma 
resuscitations is to recognize the possible presence of shock 
and to identify and treat the condition(s) responsible for its 
occurrence.  Shock is an umbrella term used to describe a 
life-threatening physiological state in which there is marked 
impairment in blood flow and oxygen delivery to vital organs. 
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It occurs when the cardiovascular and/or pulmonary system 
malfunction to such an extent that vital organs no longer 
receive sufficient oxygen and nutrient delivery to perform 
their baseline functions. This impaired delivery of blood 
together with the accumulation of cellular waste products 
results in severe cellular derangements, organ dysfunction, 
and eventually death. 
 Approach to the Patient in Traumatic Shock 
One of the most significant obstacles in managing patients in 
shock is recognizing its presence in the first place. Because 
shock exists along a continuum rather than as an all-or-none 
phenomenon, its manifestations can be quite subtle, especially 
in the early phases and among young healthy patients with 
significant physiological reserve. There have been countless 
attempts of researchers to identify a single laboratory test or 
physical examination finding that can reliably establish the 
presence of shock. To date, no such parameter has been found. 
To diagnose shock, clinicians must rely on the integra-
tion of various different clinical findings and biochemical 
tests that, when combined, highly suggest a state of hypo-
perfusion (see Table 7.2). Clinicians cannot depend on any 
single finding to reliably establish or rule out the presence of 
shock. Consequently, a high degree of suspicion is required 
when dealing with all critically injured patients. 
Clinical Findings. Because shock refers to impaired blood 
flow and oxygen delivery to vital organs, the body’s initial 
response is to compensate by increasing its heart rate in an 
attempt to improve tissue perfusion. In adults, a heart rate 
above 100 beats/min should raise the clinical suspicion of 
circulatory shock. It is important to recognize, however, that 
the absence of tachycardia does not exclude the possibility of 
shock. Elderly patients, for example, often have a blunting of 
their cardiac response to adrenergic stimulation and may be 
incapable of mounting a tachycardic response to  hypovolemia, 
or a consideration of baseline beta- blockers may cause inhi-
bition. Patients with neurogenic shock may also be incapa-
ble of compensating with a tachycardic response resulting 
from loss of sympathetic tone. Another early manifestation 
of shock is cutaneous vasoconstriction as the body increases 
vascular tone. Accordingly, trauma patients who are cool and 
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Shock Classifi cation Table
  Differential 
Classifi cation Description Diagnosis Intervention
Hemorrhagic —  An inadequate 
circulating volume 
of blood resulting 
from loss of whole 
blood leading to 
impaired tissue 
perfusion
—  By far, the most 
common form of 
shock in trauma 
patients
Bleeding —  Fluid 
administration 
with crystalloids 
+/− blood
—  Surgical 
 hemostasis as 
indicated
Nonhemorrhagic
Cardiogenic
—  Inadequate 
 tissue perfusion 
 resulting from 
primary cardiac 
dysfunction
Myocardial 
infarction
Arrythmias
Blunt cardiac 
 injury
—  ACLS protocol 
(see Chapter 4)
— Cardiac telemetry
Distributive —  A hemody-
namic state 
caused by loss of 
 sympathetic tone 
 resulting in arte-
riolar and venular 
dilatation
Sepsis —  Infectious source 
control
—  Antibiotics
—  +/− inotropic 
support
Anaphylaxis — Epinephrine
— +/− steroids
Neurogenic 
Shock
—  Fluids
—  Vasoac-
tive medications 
if refractory
Obstructive 
 (extracardiac)
—  Mechanical 
obstruction of the 
great vessels of 
the heart, leading 
to diminished 
blood fl ow through 
the cardiopulmo-
nary circuit
Cardiac 
tamponade
—  Pericardio-
centesis/ 
pericardotomy
—  Surgical repair of 
cardiac injury
Tension 
pneumo-
thorax
—  Decompressive 
needle
 thoracostomy
—  Chest tube 
insertion
7.2
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tachycardic must be presumed to be in a state of shock until 
proven otherwise (American College of Surgeons Committe 
on Trauma, 2004). 
When the degree of organ perfusion worsens, additional 
clinical findings begin to emerge. The kidney is exquisitely 
sensitive to decreases in blood delivery and responds by 
decreasing the amount of urine produced. Clinicians tend to 
rely heavily on the trend of urine output to identify patients 
in shock and monitor the degree of end-organ perfusion. A 
normal urinary output is approximately 0.5–1.0 ml·kg −1·hr−1.
Alterations in mental status should also alert the cli-
nician to the possibility of shock. In the early phases of 
shock, these changes can be quite subtle. Patients initially 
exhibit varying degrees of anxiety that eventually pro-
gresses to confusion, lethargy, and coma while cerebral 
perfusion diminishes. 
The sine qua non of profound circulatory collapse, 
however, is hypotension. When compensatory mechanisms 
become inadequate to maintain perfusion, a significant fall 
in systolic blood pressure ensues (typically <90 mmHg). It is 
important to note that up to 30% blood volume loss is needed 
before hypotension begins to manifest. Given this delay in 
presentation, clinicians cannot rely solely on hypotension as 
an indicator of shock. The presence of any degree of hypo-
tension should be interpreted as representing a profound 
degree of circulatory collapse and requires immediate atten-
tion and intervention. 
 Identify and Correct the Underlying Cause 
Restore Tissue Perfusion. In the acute phase of manage-
ment, the overwhelming majority of trauma patients who 
exhibit signs of shock are bleeding and are consequently 
hypovolemic. These patients require aggressive fluid resus-
citation beginning with warmed  isotonic crystalloids or col-
loid solutions and progressing to blood products as necessary. 
The American College of Surgeons Committee on Trauma 
recommends an initial bolus of 1–2 L to expand the intravas-
cular space and replenish interstitial and intracellular losses 
(American College of Surgeons Committee on Trauma, 2004). 
Patients in hypovolemic shock who fail to respond fully to 
this fluid challenge, or respond only transiently, should have 
blood products transfused to restore the oxygen- carrying 
capacity of their intravascular volume. 
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An interesting paradigm shift is currently emerging in 
the resuscitation of patients with penetrating injuries. There 
is increasing, albeit not yet conclusive, evidence to suggest 
that patients with penetrating injuries may benefit from a 
more limited approach to fluid resuscitation. This strategy, 
known as  permissive hypotension, operates on the assump-
tion that aggressive fluid resuscitation may be detrimental 
to patients with penetrating injuries, because even normal 
systolic blood pressures may be sufficiently high to dislodge 
clots that have formed on bleeding blood vessels. Thus, in 
selected cases, trauma physicians may elect to limit the 
amount of fluid administered and maintain lower systolic 
blood pressures as means for bridging patients to definitive 
operative repair. 
Although the administration of fluids and blood prod-
ucts may temporize the effects of hypovolemic shock, trauma 
patients often have significant underlying bleeding that will 
continue unabated unless surgically corrected. Accordingly, 
the presence of shock in an injured patient demands that 
a surgeon be immediately involved to assess the need for 
operative intervention. 
 Common Injuries in the Critically Injured 
Trauma Patient 
 Rib Fractures, Flail Chest, and Pulmonary 
Contusion
Rib fractures are the most common injury sustained fol-
lowing blunt chest trauma. It has been estimated that 10% 
of all trauma admissions have fractured ribs, although the 
incidence is likely higher, because chest x-rays fail to detect 
up to 50% of such injuries. Although simple rib fractures are 
rarely life-threatening, they can carry significant morbidity 
because of pain, atelectasis, and underlying lung injury. This 
increased morbidity and mortality is particularly apparent 
in the elderly population. Bulger, Alnerson, Mock, and 
Jurkovich (2000) found that elderly patients with blunt chest 
trauma and rib fractures have twice the mortality of younger 
patients. Moreover, each additional rib fracture in the elderly 
results in a 19% increase in mortality. 
Chapter 7: Care of the Critically Injured Patient 281
When three or more consecutive ribs are fractured in two 
or more places, a situation is created where the injured seg-
ment of thoracic wall becomes detached from the remaining 
chest wall. This condition is known as a  flail chest, and results 
in an island of chest wall that moves independently from the 
remaining thoracic cage. That is, the flail segment moves 
inward while the rest of the chest moves out and vice versa. 
Although this instability of the chest wall may  independently
result in significant respiratory impairment, the primary 
clinical concern is the pulmonary contusion that invariably 
accompanies this injury. 
A pulmonary contusion is an injury to lung parenchy-
ma that is characterized by interstitial and alveolar edema, 
hemorrhage, and loss of normal lung structure and function. 
It is a “bruising” of the lung that occurs when a significant 
amount of kinetic energy is transferred to the chest, such as 
when an unrestrained driver strikes the steering column or 
when an overlying rib fracture lacerates the pulmonary paren-
chyma. Hypoxemia and respiratory distress develop over the 
course of 24–48 hours, with some patients progressing to an 
acute respiratory distress syndrome (ARDS). The diagnosis of 
pulmonary contusion is confirmed with radiographic imaging 
on plain chest x-ray or CT that demonstrates nonanatomic, 
infiltrative lesions and associated rib fractures. 
The management of simple rib fractures, flail chests, 
and pulmonary contusions is largely supportive. Pain relief 
is an important component of therapy to minimize restric-
tion of patient’s respiratory effort (splinting), which leads to 
atelectasis and pneumonia. For severe chest wall injuries, con-
tinuous epidural infusion is an excellent form of analgesia and 
should be strongly considered. The addition of nonsteroidal 
anti-inflammatory drugs are also extremely effective but 
should be used with caution in patients with high bleeding 
risks. In patients with pulmonary contusions, excessive fluid 
administration should be avoided to minimize increasing 
the edema within the contused lung. Aggressive pulmonary 
toilet should also be provided. Large pulmonary contusions 
may significantly affect gas exchange, particularly within 
the first 24–48 hours after injury and may require endo-
tracheal intubation. Endotracheal intubation should not be 
performed in an attempt to “treat” the contusion and prevent 
subsequent respiratory decompensation; it should only be 
performed in response to subjective and objective clinical 
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signs of respiratory distress in patients. The use of nonin-
vasive ventilation in this setting is usually quite effective in 
maintaining oxygenation, and clinicians are encouraged to 
consider the use of this respiratory adjunct in the hemody-
namically stable patient who is significantly hypoxemic after 
a pulmonary contusion. 
 Simple Pneumothorax or Hemothorax 
Normal respiratory function is predicated on the ability to 
move air into and out of the lungs. Humans have evolved an 
ingenuous mechanism for enabling this process to occur. The 
pleural sac surrounding each lung acts as a natural adhesive 
that closely approximates each lung to the chest wall.  During
inspiration, humans employ several muscle groups to expand 
their chest wall, causing the adherent lung to expand in 
tandem. This expansion creates a negative pressure gradient 
drawing air into the lung. 
A traumatic pneumothorax (or “collapsed lung”) occurs 
when air is inadvertently allowed to enter the pleural space. 
This could result from blunt trauma (e.g., a fractured rib that 
lacerates the lung causing air to escape into the pleural space) 
or penetrating lung trauma (e.g., stab wound).  Regardless of 
the cause, the accumulation of air in the pleural space inter-
feres with the ability of the lung to remain adherent to the 
chest wall. This causes the lung to collapse away from the 
chest wall, thereby impeding the normal indrawing of air 
when the thoracic cage expands. 
The clinical manifestations of this condition depend 
largely on the degree of collapse. On one end of the spectrum, 
patients with small pneumothoraces often remain entirely 
asymptomatic. Patients with large pneumothoraces, however, 
typically present with shortness of breath or pleuritic chest 
pain. Auscultation classically reveals diminished air entry 
on the affected side. Definitive diagnosis is made with plain 
radiographs that demonstrate a displacement of the pleura 
away from the chest wall and accumulation of intrapleural 
air on the affected side. 
The management of this condition consists of  placing 
a thoracostomy tube into the pleural space. The tube is 
connected to a suction device to allow for removal of the 
misplaced air and permit re-expansion and adherence of the 
lung to the chest wall. The tube is typically left in place for 
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48–72 hours, until there is evidence of lung re-expansion on 
x-ray and an absence of air leakage on the suction device. 
Occasionally, a second tube may need to be inserted for large 
pneumothoraces. 
A hemothorax occurs when blood is allowed to enter the 
pleural space. This blood can originate from injury to the soft 
tissue and muscles of the chest wall, intercostal vessels, or 
laceration of the lung parenchyma. Managing of hemotho-
rax is usually limited to placement of a thoracostomy tube to 
allow for drainage of the blood. In cases of excessive ongoing 
blood loss, surgical exploration to arrest the bleeding may 
be required. Meticulous documentation of the nature and 
amount of output by the nursing staff is critical in managing 
injured trauma patients. It is also important that all of the 
blood be completely evacuated from the pleural space. 
Even small amounts of residual blood can lead to fibro-
thorax, a condition in which a thick fibrin peel forms over the 
pleural surfaces. This peel restricts normal lung movement 
during the respiratory cycle that results in impaired lung 
function. This condition often requires surgical exploration 
to remove the peel, which can carry a significant morbidity 
(Meyer, 2007). 
Tension Pneumothorax. A tension pneumothorax is a life-
threatening condition that occurs when air progressively 
accumulates under pressure in the pleural space. It is an 
extreme form of a simple pneumothorax that is thought to 
occur when the lung and adjacent pleura are injured in such 
a way that a one-way valve is created. This valve opens during 
inspiration, allowing air to accumulate in the pleural space, 
but closes during expiration. This effectively prevents escape 
of the accumulated air. The accumulation of air progresses 
unabated until there is complete lung collapse, impairment 
of venous return to the heart, and mechanical compression 
of the heart. The precise point at which a simple pneumo-
thorax becomes a tension pneumothorax is not always clear. 
Most clinicians, however, consider a pneumothorax to be 
under tension when it results in significant cardiorespiratory 
compromise that reverses on decompression of the pleural 
space (Leigh–Smith & Harris, 2005). 
A tension pneumothorax must be considered in trauma 
patients who experience a sudden deterioration in their 
cardiorespiratory status. Given the importance of timely 
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intervention to prevent complete cardiorespiratory collapse, 
the diagnosis is strictly clinical and should not be based on 
radiological findings. Patients typically present with short-
ness of breath, pleuritic chest pain, and decreased air entry 
on the affected side. The defining features of this  condition, 
however, are hypoxemia, tachycardia, and hypotension. 
Occasionally, these patients present with tracheal deviation 
and distended neck veins; however, the presence of these 
findings is inconsistent. 
A high index of suspicion is required so that definitive 
therapy can be instituted prior to complete cardiovascular col-
lapse. Given the importance of minimizing delay in interven-
tion, needle decompression followed by tube  thoracostomy 
is considered the treatment of choice. It is vital to appreciate 
that a tension pneumothorax is a clinical diagnosis and should
not be made based on radiographic findings. Needle decom-
pression involves insertion of a large bore cannula or needle 
through the pectoralis muscles at the second intercostal 
space in the midclavicular line. A rush of air is often heard 
when air escapes under pressure and is accompanied by 
immediate amelioration of the patient’s clinical status. This 
maneuver is not diagnostic. A tension pneumothorax cannot 
be definitively excluded, simply because no air escapes on 
needle decompression. Placement of a tube thoracostomy is 
mandatory after a therapeutic needle decompression. 
 Cardiac Tamponade 
The heart is enclosed within a fibrous sac, called the  pericar-
dial sac (or pericardium), that permits only a limited amount 
of elasticity. Traumatic cardiac tamponade refers to a life-
threatening condition in which blood accumulates within 
the pericardial sac causing acute compression of the cardiac 
chambers. In the trauma patient, cardiac tamponade occurs 
most commonly as a result of a penetrating injury to the 
heart. With each contraction of the myocardium, more and 
more blood extravasates into the pericardial space leading 
to further compression of the cardiac chambers, decreased 
diastolic compliance, and eventually obstruction of venous 
inflow. It has been estimated that as little as 100 ml of blood is 
sufficient to cause a tamponade effect (Spodick, 2003). 
Cardiac tamponade reflects a spectrum of physiological 
compromise as blood continues to accumulate within the 
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pericardial sac. Although the compromise in cardiac filling 
ultimately leads to profound cardiovascular collapse, the 
initial physical findings can be difficult to detect. The clas-
sical findings are referred to as Beck’s triad and include 
(a) hypotension, (b) jugular venous distention, and (c) muf-
fled heart sounds. Another key diagnostic finding is pulsus 
paradoxus, defined as a cyclical fall in systolic blood pressure 
of 10 mmHg or more with each inspiration. Ultrasonography 
is highly accurate in detecting the presence of hemopericar-
dium and is the diagnostic modality of choice in most trauma 
situations. In stable patients with equivocal findings, echo-
cardiography can be employed for definitive diagnosis. 
The presence of a traumatic cardiac tamponade is a 
surgical emergency requiring immediate pericardial decom-
pression. Because all trauma patients with blood in the peri-
cardial sac are presumed to have a concomitant injury to the 
heart, open surgical decompression with exploration and 
repair of the heart is the decompression technique of choice. 
Although needle decompression (pericardiocentesis) is 
highly effective for nontraumatic causes of cardiac tampon-
ade (e.g., fluid, pus), it tends to be less effective at aspirating 
clotted blood and obviously does not address any underlying 
injury. The use of pericardiocentesis in trauma is increasingly 
limited to situations in which a patient has become unstable 
from cardiac tamponade and there is no surgeon available 
for open decompression. 
 Abdominal Trauma 
Abdominal trauma is a leading cause of morbidity and mor-
tality among trauma patients, and it accounts for a  significant
percentage of allocated critical care resources. Although we 
usually think that the abdomen is comprised only of that part 
of the torso extending from costal margins to the groin, it 
is important to recognize that significant intra-abdominal 
injury can result from injuries to the lower chest, back, and 
flank regions. The abdominal cavity is typically divided into 
four anatomic zones, namely; intraperitoneal, retroperito-
neal, thoracoabdominal, and pelvic. Within these anatomical 
confines, there are solid organs (liver, spleen, pancreas, and 
kidneys), hollow viscous organs (distal esophagus, stomach, 
small intestine, colon, and rectum), and numerous vascular 
structures. 
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The abdominal assessment is a notoriously difficult 
component of the initial evaluation of an injured patient. 
Unlike the chest and musculoskeletal regions of the body, 
injuries within the abdomen are typically not apparent with-
out the aid of advanced imaging technologies (e.g., CT) or 
surgical exploration. Clinicians are often forced to rely only 
on indirect findings of injury (e.g., tenderness, hemodynamic 
 Diagnosis Management Options
Clinical Diagnostic Hemodynam- Hemodynam-
Organ(s) Findings Modality ically stable ically unstable
Spleen —  Left-sided 
rib fractures
—  Left upper 
quadrant 
(LUQ) 
 contusion/
tenderness
—  Referred 
pain to left 
 shoulder
1. FAST
2. CT scan
—  Close 
 observation 
if no other 
indication
for surgery 
and stable 
hematocrit
—  Splenectomy
—  Splenic 
 repair (less 
 common)
Liver —  Right-sided 
rib  fractures
—  RUQ 
 contusion/
tenderness
1. FAST
2. CT scan
—  Close 
 observation 
if no other 
indication 
for surgery 
and stable 
hematocrit
—  Surgical 
exploration 
and repair 
of liver 
injury
—  Angio-
emboliza-
tion (less 
 common)
Stomach/
Duodenum
—  Epigastric 
contusion/
tenderness
—  Diffuse 
 peritonitis
1. Chest 
radiograph 
(CXR): Free 
air (poor 
 sensitivity)
2. CT scan
— Surgical exploration and 
repair of injury mandatory.
7.3 Abdominal Trauma
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instability, free fluid on ultrasound) when formulating their 
treatment plan. Given the “black box” nature of abdominal 
injuries, the key when initially assessing trauma patients is 
often not to accurately diagnose the type of injury, but rather 
to recognize that there is an injury. 
 Assessment of the Abdomen 
Trauma surgeons rely heavily on physical examination 
findings when assessing patients for the possibility of 
intra-abdominal injury. Although the physical examination 
technique is similar to that of noninjured patients, the inter-
pretation of these physical findings is tailored to the detec-
tion of signs suggesting an underlying injury. 
Inspection. Physical examination begins with careful inspec-
tion of the abdomen for external evidence of injury. In blunt 
trauma, contusions of the abdominal wall suggest that a 
significant force was applied to the abdominal cavity and 
that a high degree of suspicion for injury needs to be main-
tained. Bruising in the shape of a seat belt (“seat belt sign”) 
has been shown to be associated with underlying pancreatic 
injury, intestinal perforation, and fracture of the lumbar ver-
tebrae. In patients who present with penetrating injuries, it 
is critical that the patient be completely exposed and that a 
meticulous search for penetrating wounds is conducted. This 
includes hidden areas such as the axilla and gluteal clefts, 
and logrolling the patient to examine the back. Finally, clini-
cians should note the shape of the abdomen, because a dis-
tended abdomen may indicate internal bleeding. 
Percussion. In patients with a protuberant abdomen, dullness 
on percussion suggests a fluid-filled cavity, (i.e., intra- abdominal 
bleeding) and tympany suggests gastric distention or, less com-
monly, pneumoperitoneum from a perforated viscous. However, 
percussion provides a means of identifying patients with perito-
nitis. Patients with peritoneal inflammation often demonstrate 
exquisite tenderness when their abdominal wall is percussed. 
This tenderness is a highly abnormal finding and should alert 
the clinician of the possibility of underlying injury. 
Palpation. The primary purpose of abdominal palpation is 
to elicit signs suggestive of peritoneal irritation. Signs that 
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indicate peritonitis include tenderness to palpation, increased 
abdominal wall rigidity, voluntary and/or involuntary guarding, 
and pain with movement. It is important to determine whether
these findings are present diffusely throughout the entire 
abdominal wall or remain localized to particular quadrants. 
When localized, the point of maximal tenderness will often 
provide a clue to which organ is injured. For example, splenic 
injuries typically present with left upper quadrant tender-
ness, whereas renal injuries may present with flank pain. 
The presence of diffuse peritonitis is an indication for surgi-
cal exploration of the abdomen. 
Digital Rectal Examination. Digital rectal examination (DRE) 
is typically performed when the patient is logrolled to assess 
the posterior torso and spine. The presence of gross blood 
on digital examination suggests the possibility of colorec-
tal injury. The presence of rectal bleeding and palpable 
bony fragments within the rectum indicates the presence of 
an open pelvic fracture. In men, a high-riding or difficult-
to-palpate prostate gland may indicate the presence of an 
underlying urethral injury. Finally, anal sphincter tone and 
sensation should be assessed for possible spinal cord injury. 
 Adjunct Diagnostic Tests and Procedures 
In the past decade, abdominal ultrasound has assumed a 
prominent role in the management of severely injured trauma 
patients. Once the sole domain of radiologists, the ultrasound 
has now become a critical tool in the trauma physician’s arma-
mentarium to identify the presence of internal hemorrhage. 
The technique known as  focused assessment with sonography 
for trauma (FAST) evaluates several discrete regions within 
the peritoneal cavity and pericardium to determine whether 
free fluid (i.e., blood) is present. The use of ultrasound is 
particularly helpful for patients who are hemodynamically 
unstable; because in this context, the finding of free fluid is 
an indication for emergent surgical exploration. Patients who 
are hemodynamically unstable require immediate transport 
to the operating room so that internal bleeding can be surgi-
cally arrested. Although there are certain limitations inherent 
to this diagnostic modality, the FAST examination is inexpen-
sive, readily obtainable, and quite sensitive in the appropriate 
setting for identifying even small quantities of blood. 
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Diagnostic peritoneal lavage (DPL) is another technique 
used to detect intra-abdominal injury. This technique involves 
placing a catheter into the peritoneal cavity and instilling 1L 
of fluid (normal saline or Ringer’s lactate). The fluid is then 
drained under gravity from the peritoneal cavity and sent 
for laboratory analysis. It is analyzed macroscopically and 
microscopically to quantify the amount of red blood cells, 
white blood cells, and amylase present. Numerous studies 
have established that a certain concentration of each of these 
indices can reliably predict the presence of intraperitoneal 
bleeding and/or bowel injury. 
In recent years, this test has been largely overshadowed 
by newer diagnostic modalities (i.e., ultrasound). Currently, 
DPL is primarily employed in situations where a patient is 
hemodynamically unstable, and trauma ultrasonography is 
not readily available or remains indeterminate. It is also occa-
sionally employed when there is a suspicion of bowel injury 
on CT but no evidence of peritonitis on physical examination. 
CT has assumed a central role in the modern manage-
ment of trauma patients. Technological advances have made 
CT scans extremely sensitive and accurate in the detection 
of most types of body injury. CT scans have become readily 
accessible, with dedicated machines located near most resus-
citation bays. Injuries that had previously gone undiagnosed 
are now identified early in the assessment process so that 
appropriate treatment can be provided. Interestingly, however, 
many now argue that CT scans are becoming overutilized in 
trauma patients and should be limited to situations where 
there is a high probability of injury or when a reliable clinical 
examination cannot be obtained (e.g., severe traumatic brain 
injury, intoxication, distracting injuries). 
 Musculoskeletal Injuries 
Musculoskeletal injuries are exceedingly common in patients 
who have sustained blunt trauma. It is estimated that ortho-
pedic surgeries for skeletal trauma outnumber all other 
trauma operations by 5:1 (Harkess, Ramsey, & Harkess, 1991). 
These injuries range in severity from minor to life and limb 
threatening. This section addresses the clinical examination 
of the musculoskeletal system and outlines an approach to 
fracture management. 
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 Assessment 
Although musculoskeletal injuries are sometimes dramatic 
in their appearance, it is critical that the primary survey 
take precedence in the evaluation of all trauma patients. 
With the exception of exsanguinating external hemorrhage 
(e.g., amputation or mangled extremity), the assessment and 
management of all extremity injuries should begin only after 
a properly conducted primary survey. 
Once the primary survey has been completed, a head-
to-toe examination of the patient is performed to exclude 
additional injuries—a process referred to as the secondary 
survey. The musculoskeletal system forms an integral part 
of the secondary survey and involves evaluation of both the 
axial and appendicular structures for possible injury. 
Assessment of musculoskeletal trauma begins by asking 
patients to localize any bone pain. The bone structure is then 
inspected for deformity, swelling, and bruising. It is impor-
tant to inspect the overlying skin for small tears that might 
indicate the possibility of an open fracture. The extremity 
is palpated for tenderness; and a neuromotor examination 
is performed with attention to sensory function, range of 
motion, and muscle strength. A focused evaluation of the 
peripheral vascular system is also mandatory. Distal pulses 
are palpated, and capillary refill of the digits and toes are 
assessed. A Doppler probe is frequently employed to supple-
ment this assessment. All pulse points should be compared 
with the contralateral extremity for symmetry. 
Finally, any abnormal clinical examination findings (e.g., 
pain and deformity) should be followed up with appropriate 
x-ray imaging to confirm and define the nature of the injury. 
 Principles of Fracture Management 
The primary goal of fracture management is to have the 
broken bone segments heal in a position that will produce 
optimal functional recovery and to prevent fracture and soft-
tissue complications. The initial approach to managing skeletal 
fractures consists of realigning the broken segments and 
then immobilizing the limb. 
Once a fracture has been identified, clinicians must deter-
mine whether realignment (i.e., reduction) is necessary. Most 
significantly displaced, shortened, or angulated fractures will 
Chapter 7: Care of the Critically Injured Patient 291
require some form of reduction to reappose the fractured seg-
ments. This can usually be accomplished using a closed tech-
nique by applying manual traction along the long axis of the 
injured limb in a direction opposite the mechanism of injury. 
Operative intervention to reduce the fracture (i.e., open reduc-
tion) may be necessary if closed reduction fails, the fracture is 
unstable, or there is intra-articular displacement. 
Once the injured segments have been successfully 
reduced, it is necessary to immobilize the limb to prevent 
further soft tissue and neurovascular injury. Immobilization 
also provides a degree of symptomatic relief for most patients. 
Immobilization is most commonly accomplished using a splint 
or cast; however, external fixation is occasionally required. 
A neurovascular examination should be performed before 
and after reduction and immobilization to ensure that patient’s 
neurovascular status remains intact. 
Finally, orthopedic consultation should be obtained to 
plan definitive care and to ensure appropriate follow-up and 
rehabilitation. 
 Cervical Spine 
An overwhelming majority of trauma patients undergo spi-
nal immobilization to prevent additional spinal cord injury in 
the event of vertebral fracture. Prior to the removal of spinal 
immobilization precautions, it is necessary to exclude bone 
and ligament injury. For decades, the standard of care for 
excluding body spine fracture was plain radiograph. This has 
included three views of the cervical spine (lateral, anterior–
posterior, and odontoid) and imaging of the thoracolumbar 
spine. Recently, it has been demonstrated that plain x-rays 
may miss more than one third of all clinically significant 
fractures (Barrett, Mower, Zucker, & Hoffman, 2006; Richards, 
2005). This has prompted many traumatologists to move to 
CT imaging, particularly in patients in whom there is a high 
degree of suspicion for injury. Because these patients often 
have head-associated injuries, a CT scan from the skull base 
to the top of the thoracic spine is often obtained concurrently 
with brain imaging. 
However, not all trauma patients require radiologic 
imaging. Clinical clearance of the spine can be carried out 
in the following circumstances (Hoffman, Mower, Wolfson, 
Todd, & Zucker, 2000; Richards, 2005; Stiell et al., 2001): 
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1. the patient is alert and oriented 
2. absence of tenderness on palpation of the cervical spine 
3. absence of focal neurological deficits 
4. no significant distracting injuries 
5. low risk mechanism of injury 
6. age <65 years 
Once bone injury has been excluded radiographically, 
the patient should be reassessed for tenderness of the cervi-
cal spine and pain with active range of motion. If there is no 
pain, the hard cervical collar can be removed. However, if 
pain is elicited with either of these maneuvers, the patient 
should be maintained in a cervical collar and imaged further 
for the possibility of ligament injury (e.g., cervical spine MRI 
or flexion–extension radiographs). 
Because it is not possible to clinically clear the cervical 
spine of patients with diminished levels of consciousness 
(e.g., coma), two general approaches have been adopted. The 
first approach is to maintain the patient in cervical spine 
immobilization until they are sufficiently alert to permit clini-
cal clearance. The second approach is to rule out ligamen-
tous injury using MRI. Published literature is not definitive 
regarding which approach is better, because the sensitivity of 
MRI for ligament injuries is still a matter of debate (Richards, 
2005; Stassen, Williams, Gestring, Cheng, & Bankey, 2006). 
 Pelvic Fractures 
The pelvis is a ring-like bone structure located at the base of the 
spine. In addition to its role as a supportive structure, the pelvis 
also serves to protect the lower abdominal viscera and vessels 
from injury. This protective role can be a double-edged sword 
because pelvic fractures also have the potential to cause signifi-
cant internal injury. Pelvic fractures are most commonly asso-
ciated with urogenital (bladder and urethra), gastrointestinal 
(rectal), and vascular injuries. The latter group poses a signifi-
cant problem for trauma physicians, because they can cause a 
significant amount of bleeding that is difficult to control. Unlike 
vessels in the extremity, bleeding pelvic veins and arteries are 
typically covered by bone and are not amenable to external 
compression. Moreover, even in the operating room, pelvic ves-
sels are extraordinarily difficult to expose and control. 
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The initial assessment of pelvic fractures is similar 
to that of other skeletal structures. The pelvic bones are 
inspected and palpated for tenderness and deformity. The 
perineum and urogenitalia are also examined for possible 
injury. A  digital rectal examination is mandatory to rule out an 
open pelvic fracture and to assess for a high-riding prostate 
in men. A thorough vascular examination is conducted with 
special attention to femoral and lower extremity pulses. The 
diagnosis is confirmed with a standard anterior– posterior 
plain x-ray. 
In the face of hemodynamic instability, treatment begins 
with the primary survey and institution of appropriate resus-
citative measures. Because pelvic fractures are ubiquitous in 
the bluntly injured patient, a search for alternate sources 
of bleeding is critical. Thoracic and abdominal bleeding is 
excluded with careful clinical examination and radiologic 
imaging, including chest x-ray and trauma ultrasound or 
DPL. Long-bone fractures are another source of ongoing 
bleeding that need to be ruled out. As previously discussed, 
patients with hemodynamic instability and intraperitoneal 
fluid on ultrasound generally require an exploratory lapa-
rotomy for definitive surgical hemostasis. 
Certain types of pelvic fractures are amenable to exter-
nal reduction for control of venous bleeding. In particular, 
anterior–posterior compression injuries tend to result in 
disruption of the pubic symphysis and/or sacroiliac joints 
and can cause an opening of the pelvic ring or “open-book” 
fracture. As the pelvic ring opens and the bone volume 
increases, bridging vessels are at significant risk of being 
torn. Fortunately, reclosing the pelvic ring and reducing the 
bony volume can often arrest this form of bleeding. This can 
be accomplished using various commercially available pelvic 
binders or simply tightening a bed sheet around the patient’s 
waist and upper thighs. If blood loss continues despite the 
use of a pelvic binder and there is no evidence of intraperi-
toneal bleeding, patients should undergo angioembolization 
in the interventional suite to stop possible arterial bleeding. 
In select circumstances, surgeons may elect to proceed to the 
operating room to tamponade the bleeding with extraperito-
neal packing. A definitive stabilization procedure, if needed, 
will be conducted after the patient is resuscitated and medi-
cally stable for the procedure. 
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 Summary 
The management of trauma patients who have serious illness 
requires knowledge of current evidence-based standards of 
care, sound practitioner judgment, and a careful and thor-
ough approach to initial patient assessment. Identification 
and subsequent treatment of injuries should follow estab-
lished clinical algorithms, in order of priority, as described 
above. Completeness of the primary and secondary surveys 
are vitally important to fully understand the patient’s injuries 
and to ensure their prompt treatment. Prompt identification 
and early resuscitation of shock states is crucial in achieving 
optimal patient outcomes and in minimizing organ dysfunc-
tion during and after the acute phase of patient care. 
 Online Resources 
http://www.facs.org/trauma/index.html (American College of 
Surgeons-Trauma Programs) 
http://www.amtrauma.org (American Trauma Society) 
http://www.cdc.gov/ncipc (National Center for Injury Control 
and Prevention) 
http://www.trauma.org (non-profit educational organization) 
http://www.aast.org (American Association for the Surgery 
of Trauma) 
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 Introduction 
Approximately 1.25 million people are burned yearly in 
the United States; 50,000 of these require hospitalization, 
and 4,500 die annually. Care of the critically burned patient 
requires a multidisciplinary team approach to provide the 
comprehensive, coordinated, long-term care required for the 
best outcome. Major burn injuries should be cared for in a 
burn center (U.S. Fire Administration [FEMA], 2008; Centers 
for Disease Control [CDC]; Pruit, Wolf, & Madison, 2007). 
The Acute Care Nurse Practitioner (ACNP) is in a prime 
position to orchestrate this care to ensure consistency and 
continuity of care and to facilitate communication among 
all team members. The principles of Advanced Trauma Life 
Support (ATLS) apply to all burn patients. Initial care of the 
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burn patient is similar to that of critically ill patients with 
other diseases or multiple trauma. Burn patients are consid-
ered trauma patients first until proven otherwise. The extent 
or appearance of the burn injury should not distract from 
the ABC’s of the primary survey. Initial attention is focused 
on hemodynamic stability, including fluid and electrolyte 
balance, respiratory support and ventilation, surveillance of 
infections with appropriate culture-directed antibiotic cov-
erage, release of pressure in compartments influenced by 
restrictive eschar, early nutritional support, and monitoring 
for adrenal insufficiency. 
The integumentary system is the largest organ system in 
the body. It is the body’s first line of defense against infection, 
body fluid loss, and thermal regulation. When the integrity of 
the skin is breached because of severe burn injury, the entire 
body is affected. The magnitude of the physiologic response is 
dependent on the depth, extent, and the cause of the burn. 
The outermost layer of the skin is the epidermis. The epi-
dermis has five stratified layers containing diversified cell 
types. These include keratinocytes, which provide strength, 
flexibility, and waterproofing by producing the protein 
keratin. Merkel cells are sensory cells for touch reception. 
Melanocytes produce the melanin that pigments the skin 
and helps to protect against ultraviolet rays. Langerhans 
cells in the epidermis help regulate the immune response 
to external antigens. Burns involving only the epidermis are 
considered first degree. First-degree burns are erythema-
tous and locally painful. There are no blisters, and the skin 
retains its ability to prevent invasion of microorganisms 
and retain the protection from fluid and electrolyte losses. 
For this reason, first-degree burns have little physiologic 
impact on the body and are not included when calculating 
the extent of burn (Patal & Hartman, 2005). 
The second layer of the skin is the dermis. The dermis 
is the living layer that consists of fibroelastic connective 
tissues. The layer just below the epidermis is the papillary 
layer, which contains Meissner corpuscles. These layers are 
sensory touch receptors and are the microcirculation that 
delivers nutrition to the epidermis. 
The deeper reticular layer of the dermis contains most 
of the fibroblasts that produce the protein collagen, reticular 
fibers, and elastin, that combine with nonfibrous substances 
such as glucosaminoglycans to form the extracellular matrix, 
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which provides strength, structure, and elasticity to the skin. 
Also located in the reticular layer of the dermis are the sen-
sory receptors for pain and deep touch called the Pacinian 
corpuscles and lymph vessels. 
Skin appendages, including sebaceous glands, apocrine 
and eccrine sweat glands, and hair follicles originate within 
the dermis or just below the dermal subcutaneous junction. 
The region of the hair follicle known as the  follicular bulge
is the area responsible for regeneration of skin cells and 
sebaceous glands following injury (Bessy, 2007). The smooth 
muscles located in the dermis aid in temperature regulation. 
Burns that destroy the entire epidermis and extend into the 
dermis are considered second-degree or partial-thickness 
burns. Superficial partial-thickness injury extends into the 
superficial papillary layer and is characterized by fluid-filled 
blisters. These wounds are very moist and painful but usually 
heal in 2–4 weeks. 
Deep partial-thickness burns involve the entire dermis, 
both the papillary and reticular layer, but the skin appendages 
are spared. They are characterized by formation of dead and 
devitalized tissue called  eschar. The eschar is dry, inelastic, 
and may be yellow or brown in color. Deep partial-thickness 
wounds take several weeks for the epidermis to regenerate 
depending on the number of surviving hair follicles. Wounds 
that extend into the reticular dermis and heal secondarily 
take 3 or more weeks to heal and have a greater potential for 
hypertrophic scarring (Bessy, 2007). 
The third layer of the skin is the subcutaneous layer. The 
adipose tissue insulates and pads the body and gives the body 
form. The subcutaneous tissue contains blood vessels and 
lymph vessels. Burns into the subcutaneous layer are con-
sidered third-degree or full-thickness burns. The wound will 
have a thick, dry, leathery eschar that is lacking in elasticity 
because the entire extracellular matrix has been destroyed. 
Full-thickness injuries are insensate because of the loss of 
the nerves that are located in the dermal layer (Standring, 
2005; Revis & Seagle, 2006). 
 Pathophysiology 
When the skin comes in contact with a heat source, a burn 
injury occurs. In 1953, Jackson described three zones of tis-
sue injury that results following a thermal injury. The zone 
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of coagulation is the area that has the most contact with the 
heat source. This consists of dead and dying cells as a result 
of coagulation necrosis and is devoid of blood supply. The 
wound may appear white or charred. Adjacent to the zone 
of coagulation is an area characterized by capillary vasocon-
striction and ischemia called the zone of stasis. The tissues 
in this area contain a combination of nonviable, damaged, 
and viable cells. These potentially viable cells could convert 
to a zone of coagulation as a result of edema, decreased per-
fusion, or infection. The cells in the zone of stasis appear 
deep red and may have petechial hemorrhages. The third 
zone, the zone of hyperemia, is more distant from the heat 
source. Inflammatory mediators incite vasodilatation. The 
cells in this area will typically remain viable (Pham, Gibran, 
& Heimbach). 
A major goal of wound management is to protect the 
viability of the zone of stasis to promote wound healing with 
desirable cosmetic and functional outcomes. Several factors 
have been attributed to the progressive demise of cells in the 
zone of stasis. Thromboxane A 2 is produced by platelets in the 
wound, causing vasoconstriction and increasing the ischemia 
beneath the wound. The release of prostaglandin derivatives 
and oxygen free radicals, such as xanthine oxidase, in the 
burn wounds contribute to vasodilatation and the formation 
of burn edema, decreased tissue perfusion, and can increase 
the depth of the burn wound from partial to full thickness. 
Adults with thermal injury extending over 20% of their 
body surface area experience both a local and systemic 
response to the tissue injury that begins immediately post-
burn. The major physiologic effects that occur in the first 
24–48 hours postburn are concentrated around fluid losses 
caused by an increased capillary permeability, an increased 
intravascular hydrostatic pressure, and a negative pressure 
in the interstitial tissues at the site of the injury (Shirani, 
Vaughhan, Mason, & Pruitt, 1996). 
At the time of injury, the thermally injured cells release 
histamine from their mast cells, causing immediate increase 
in capillary permeability. Macrophages and neutrophils infil-
trate the wound, releasing prostaglandins into the general 
circulation. The prostaglandins promote vasodilatation and 
increased capillary permeability. As the capillaries become 
more permeable, plasma proteins are permitted to enter the 
interstitial space, exerting colloid osmotic pressure, causing 
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rapid and sometimes massive edema to form. Because of the 
massive leak of fluids and resultant edema, patients experi-
ence intravascular hypovolemia. 
The resultant decrease in perfusion and oxygen deliv-
ery to the tissues leads to further cellular damage and 
ischemia. Ischemia stimulates a release of catecholamines, 
vasopressin, and angiotensin that cause peripheral and 
splanchnic bed vasoconstriction, affecting all of the major 
organ systems including the heart. Myocardial contractil-
ity may be reduced because of the circulating inflammatory 
cytokines, tumor necrosis factor-, and oxygen free radicals 
(Horton, White, Maass, & Sanders, 2004). The reduced cardiac 
contractility exacerbates the ischemic problem by shunting 
blood away from the liver, kidneys, and gut. Burn injury also 
causes changes at the cellular membrane level. In a major 
burn, this occurs systemically and is not isolated to the ther-
mally injured cells. The cellular transmembrane potential is 
decreased,  resulting in an alteration of the sodium–potassium 
pump, thus  increasing cellular edema (Morris, 2006). 
A cycle is established of inflammatory mediator-induced 
capillary permeability causing increasing edema, hypo-
volemia, and hyperviscosity, which in turn leads to tissue 
ischemia, acidosis, reduced cardiac function, and multiorgan 
dysfunction. The ensuing acidosis and reduced oxygenation 
of the tissues leads to further cellular destruction, releasing 
more vasoactive mediators. Burn shock results from the mas-
sive fluid leak, changes in hydrostatic pressures, and cardiac 
and multiorgan system failure. The cycle will continue in a 
downward spiral without aggressive intervention. The goal of 
fluid resuscitation is to deliver an adequate supply of oxygen 
to the cells by providing adequate tissue perfusion (Cartotto, 
Choi, Gomez, & Cooper, 2003). 
 Compartment Syndrome 
The elastic properties of the skin are lost in deep partial-
thickness or full-thickness wounds. When the burn edema 
develops beneath the nonelastic eschar, the skin is unable 
to expand to accommodate the increased fluid mass. If the 
wound is circumferential, the result is increased pressure in 
the compartments of the extremities. Initially, the increased 
pressure occludes the venous outflow, causing pressure to 
build up rapidly until the pressure increases enough to halt 
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arterial capillary inflow. When the pressure exceeds the 
capillary filling pressure, the blood supply is cut off from 
the extremity, resulting in death of the muscle. Muscular 
infarction produces release of myoglobin, edema, and acido-
sis. If the pressure is not released, death of the extremity will 
ensue (American Burn Association, 2001). 
 Metabolic Response 
As with other forms of major trauma, the stress response is 
triggered in response to burn injury. The stress response in 
patients with burns over 40% of their total body surface area 
(TBSA) causes increased metabolic rates up to twice the nor-
mal increased oxygen consumption, accelerated fat breakdown, 
and erosion of body mass. The hypermetabolic, hypercatabolic 
state peaks within the first 1–2 weeks and progressively returns 
to normal in the months following wound closure. Increased 
protein consumption associated with the hypermetabolic state 
hinders the immune response and slows wound healing (Nor-
bury & Henderson, 2007). 
 Postburn Anemia 
Postburn anemia occurs in patient with thermal injuries over 
10% of their body surface area. Initially, there is a  trapping
of red blood cells in thrombosed capillaries as well as 
destruction of the erythrocytes from the heat. The inflam-
matory mediators that are released following thermal injury 
work to decrease the life span of the erythrocyte from their 
normal 80–120 days. Production of new red blood cells is 
slowed because of bone marrow suppression. These factors, 
added to the loss of blood during dressing changes, excision 
of wounds, and phlebotomy, lead to significant anemia in 
patients with major burns (Kwan, Gomez, & Cartotto, 2006). 
 Inhalation Injury 
Respiratory pathophysiology in a burn patient results directly 
from thermal injury to the upper airway, inhalation of smoke 
and the by-products of combustion, and indirectly from the 
pulmonary response to the inflammatory mediators. Thermal 
injury to the airways is rare. Usually, this occurs secondary 
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to the exposure to superheated steam, inhalation of scalding 
liquids, or flammable gases under pressure. Thermal injury of 
the airway is usually limited to the upper airway, because the 
larynx closes as a reflex to the superheated air. Resultant  edema 
of the structures in the upper airway may cause obstruction 
of the airway. When the fluid resuscitation progresses and the 
edema expands, progressive worsening of the airway obstruc-
tion is to be anticipated (McCall & Cahill, 2005). 
Inhalation injuries that occur below the glottis are usu-
ally chemical in nature as a result of the noxious chemicals 
that are released during a fire. In the course of a fire, organic 
carbon containing substances burn, and carbon monoxide is 
formed as a by-product of incomplete combustion. Carbon 
monoxide combines to the body’s hemoglobin molecules, 
creating carboxyhemoglobin. The carbon monoxide has an 
affinity for hemoglobin that is 200 times greater than that of 
oxygen. Oxygen delivery to the cells is decreased as a result 
of the decreased oxygen-carrying capacity of the hemoglo-
bin, as well as the fact that greater affinity blocks the release 
of the oxygen to the tissues (McCall & Cahill, 2005). Normal 
blood concentration of carboxyhemoglobin is <1%. Smokers 
and people who are exposed to heavy traffic have a carboxy-
hemoglobin around 5% to 10%. Although 15% to 40% of the 
hemoglobin is bound to carbon monoxide, the victim may 
experience various symptoms of cerebral hypoxia,  including
impaired judgment and confusion. Carboxyhemoglobin 
levels of 40% to 60% causes patients to become obtunded and 
may cause subsequent loss of consciousness. Levels above 
60% lead to unconsciousness, respiratory failure, and death 
(American Burn Association, 2001). 
When plastics and synthetic materials are consumed by 
fire, hydrogen cyanide is released. Hydrogen cyanide causes 
inhibition of the cytochrome oxidase system by binding with 
the ferric iron atom, rendering the cells incapable of using 
any available oxygen. The cells convert to anaerobic produc-
tion of ATP, and lactic acid is produced. The result is increased 
hypoxia and metabolic acidosis (Schraga & Pennardt, 2008). 
When both carbon monoxide and hydrogen cyanide is 
present, there is a synergistic effect that increases tissue 
hypoxia and acidosis and further decreases cerebral oxygen 
consumption (Traber, Herndon, Enkhbaatar,  Maybauer, & 
Maybauer, 2007). 
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Noxious chemicals such as aldehydes, sulfur oxides, 
and phosgenes are released and carried on the surface of 
the smoke particles. When they come in contact with the 
epithelium of the airways, the ciliary activity is impaired, 
reducing the body’s ability to clear the noxious agents. The 
inflammatory process is initiated including hypersecretion, 
edema formation, increased blood flow, and ulceration of the 
mucosa. The timing of the onset of symptoms of an inhala-
tion injury is unpredictable and depends in part on the vol-
ume of smoke inhaled. The bronchi and the bronchioles may 
go into severe spasm with higher doses of smoke inhalation. 
Wheezing and respiratory distress will occur immediately in 
patients with prolonged exposure to a smoke-filled environ-
ment. The edema formation and inflammatory response may 
not be evident initially but will increase with fluid resuscita-
tion. Mucosal sloughing may occur as late as 4–5 days postin-
jury, so patients with history that suggests a high suspicion 
of inhalation injury need to be observed closely (American 
Burn Association, 2001). 
 Clinical Manifestations/Symptoms 
Criteria for admission of a burn victim into the intensive care 
unit include the following: 
 ■ Adults with burns >20% TBSA 
 ■ Pediatrics with burns >10%–15% TBSA 
 ■ Inhalation injury 
 ■ High voltage electrical injury 
 ■ Patients with premorbid diseases such as diabetes, 
cardiac, or renal disease 
 ■ Full-thickness injuries 
 ■ Associated trauma 
 ■ Extremes of age 
Neurological. Burn victims are generally awake, alert, and 
oriented on admission, if not, look for associated trauma. 
Changes in level of consciousness occur with hypovolemia, 
medications, and smoke inhalation. Patients may be fear-
ful, distraught, agitated, anxious, and in pain as a result of 
the events surrounding the accident. Suspected hypoxia or 
hypovolemia must be ruled out immediately. Obtaining the 
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patient’s medical and social history, including the details of 
the accident, is a priority if the patient is stabilized. A proxy 
or health care surrogate should be named, and advanced 
directives should be initiated prior to intubation or sedation 
when possible. 
Pulmonary. Pulmonary dysfunction is a major cause of 
death in burn victims. Patients with inhalation injury may 
present with or without cutaneous burns. A history of being 
in an enclosed space during a fire should raise an index of 
suspicion for inhalation injury. Signs and symptoms of inha-
lation injury include singed nasal or facial hair, facial burns, 
hoarseness, agitation, and carbonaceous sputum. Presence 
of symptoms does not necessitate immediate intubation but 
does require 24-hour observation for signs of airway com-
promise. Signs and symptoms of inhalation injury may not 
be present until 18–36 hours post injury. Chest radiograph 
and arterial blood gases may have normal results in the first 
24 hours. Direct laryngoscopy can be used to visualize the 
upper airway if there is a suspicion of injury. Visualization 
of erythema,  edema, ulceration, and soot deposits makes 
bronchoscopy useful in evaluating the extent of injury to 
the tracheobronchial tree (Serebrisky, Nazarian, &  Connolly, 
2008). The presence of carbonaceous material, edema, 
erythema, or lesions below the vocal cords confirms the diag-
nosis of inhalation injury. 
Initial and ongoing assessment includes monitoring for 
the actual or potential loss of the airway. Extensive face or 
neck burns, hoarseness, or stridor may necessitate early 
intubation. Tracheal intubation should be considered early 
before progressive edema, exacerbated by fluid resuscitation, 
begins to compromise the airway in patients with extensive 
burns of the face and neck. The head of the bed should be 
elevated 30–45 degrees to help decrease facial edema. Sup-
plemental humidified oxygen is initiated on all burn patients 
and patients with suspected inhalation injury. 
Serial blood gases will reveal metabolic acidosis and 
abnormal carboxyhemoglobin levels. Carbon monoxide 
decreases the blood oxygen content and hinders the release 
of oxygen from hemoglobin to the tissues. Pulse oximetry 
values may be normal, because it monitors saturation and 
makes no distinction between carbon monoxide and oxygen. 
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Treatment for carbon monoxide poisoning is supplemental 
oxygen at 100%. The supplemental oxygen hastens the dis-
sociation of carbon monoxide from hemoglobin in direct 
relation to the partial pressure of oxygen. Treatment con-
tinues until values are normal. 
Treatment for smoke inhalation injury is supportive. 
 ■ Auscultate breath sounds. 
 ■ Monitor chest excursion and need for escharotomies. 
 ■ Observe depth and rate of respirations. 
 ■ Observe need for suctioning. 
 ■ Note the color, consistency, and amount of the sputum. 
 ■ Continually reassess the patient for the need for intu-
bation and ventilatory support. 
Ongoing fluid resuscitation may compromise the airway 
by edema formation that necessitates continual reassess-
ment for the need of intubation and ventilatory support. Use 
of the high-frequency percussive ventilator has been shown 
to reduce mortality in inhalation injury with further human 
trials ongoing. (Sanford & Herndon, 2001). 
Circumferential full-thickness burns of the torso may 
impede respiratory excursion, making it difficult to ventilate 
the patient because of the inelasticity of burn eschar. Increased 
peak inspiratory pressures (PIPs), decreased tidal volumes, or 
inability to adequately ventilate the patient with a bag valve 
mask may indicate the need for escharotomies of the torso. 
Tracheostomy may be indicated in special situations. Indica-
tions include prolonged intubation, emergent  airway access, 
facial trauma, and deep partial-thickness or full-thickness 
wounds of the face or neck with significant edema. 
Cardiovascular. Major burn injuries cause a dramatic 
increase in catecholamine release, resulting in tachycardia 
and increased myocardial work. Burn shock follows the same 
pathway as other forms of hypovolemic shock including 
decreased venous return, ventricular filling pressures, stroke 
volume and cardiac output with resultant hypotension, 
increased peripheral vascular resistance, and decreased tis-
sue perfusion. Decreased tissue perfusion can increase the 
depth of the burn wound from partial to full thickness. 
Monitor adequate circulation by palpating peripheral 
pulses and checking capillary refill. Monitor for signs of 
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compartment syndrome in circumferentially burned extrem-
ities and torso. Circumferentially burned extremities should 
be elevated continually above heart level to help decrease 
edema formation. Monitor hourly intake and output, vital 
signs, and heart rhythm. Fluid requirements exceeding 
calculated resuscitation amounts after 24 hours suggest an 
inhalation component to the injury. 
Patients with electrical injuries may have sustained ven-
tricular fibrillation at the scene and may have received CPR. 
Sinus tachycardia and nonspecific ST-T segment changes 
remain the most common cardiac findings. Most arrhythmias 
seen on admission spontaneously resolve in a few hours. 
Patients who present in the emergency room without evi-
dence of cardiac arrhythmia rarely develop them later. 
Progressive anemia because of loss of cell mass and 
decrease in the half-life of the red blood cell leads to low 
hematocrit, so monitor trends. Transfuse the patient only if 
the patient is symptomatic, has a cardiac history, or has poor 
oxygenation. Blood transfusion increases the infection and 
mortality rates in critically ill burn patients. The accepted trig-
ger point for transfusion is 7g/dl and 21%. (Palmieri, Caruso, 
Foster, Cairns, Peck, Gamelli et al., 2006). 
Fluid Management. Massive fluid shifts occur in the first 
24 hours after a major burn injury, which leads to hypovolemic 
shock and death if interventions are not initiated. Two large-
bore IVs are inserted for initial fluid resuscitation. Intravenous 
catheters can be placed through burn eschar if access is diffi-
cult. Increased capillary permeability leads to loss of fluid and 
plasma proteins into the interstitial space. Burn edema occurs 
in burned tissue and in unburned tissue, causing sodium to be 
translocated into skeletal muscle and other tissues through 
the leaky capillaries. Large amounts of fluid are required to 
maintain hemodynamic stability, and often patients are under-
resuscitated because of fear of volume overload. 
There are various burn fluid resuscitation formulas. The 
American Burn Association’s consensus formula is com-
monly used to guide the resuscitation. The formula is as 
follows: ringers lactate 2–4 ml/kg of body weight per percent 
of TBSA burned (4 ml × kg × % burn). First-degree burns are 
not included in the TBSA. One half of the calculated volume 
is given in the first 8 hours post burn and the second half is 
given over the next 16 hours. 
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For example, a 70-kg man with a 50% TBSA burn would 
require 4 ml × 70 kg × 50% = 14,000 ml over 24 hr. Therefore, 
7,000 ml would be infused over the first 8 hours at 875 ml/hr 
and 7,000 ml over the next 16 hours at a rate of 438 ml/hr. 
Glucose is not initially used because of glucose intol-
erance and potential for glycosuria that could lead to an 
osmotic diuresis, thereby eliminating the urine output as an 
accurate monitoring tool for fluid management. In addition 
to the calculated fluid resuscitation, a vitamin C drip may be 
administered at a rate of 66 mg·kg −1·hr−1 for the first 24 hours. 
Vitamin C has been shown to decrease the required resus-
citation volume and decrease the number of ventilator days 
(Tanaka et al., 2000). 
The 24-hour timeframe for initiating fluid resuscita-
tion begins at the time of injury, not at the time of arrival to 
the hospital. The formulas are guidelines and are based on 
individual patient response. The rate of resuscitation fluid 
is based on hourly urine output via a Foley catheter. The 
urine is monitored hourly and should be 0.5 ml·kg −1·hr−1 or 
30–50 ml/hr (American Burn Association, 2001). The excep-
tion is electrical injuries, where an increased urine output 
is warranted and should be >100 cc/hr to avoid the accu-
mulation of hemachromagens in the renal tubules. Sodium 
bicarbonate may be given to alkalinize the urine to avoid 
clumping of the hemachromagens, which occurs in an acid 
environment and may block the renal tubules. If the urine 
output requirements are greater or less than the calculated 
resuscitation amounts, increase or decrease the intravenous 
rate by 25%. Fluid boluses result in an increase in intravas-
cular hydrostatic pressure and are therefore lost in the tis-
sues. If the fluid required exceeds the calculated amounts by 
2–3 times at the end of the 24-hour period, this is indicative 
of an inhalation component to the burn injury. The resus-
citation formulas do not take into account fluid loss from 
the leaky pulmonary capillaries. Practitioners who are 
inexperienced in the care of burn patients often underre-
suscitate patients because of the enormous volume of fluids 
that patients require to maintain hemodynamic stability. 
Hematocrits initially can be in the 50–60 g/dl range 
because of hemoconcentration. The hematocrit will begin to 
trend down with adequate fluid replacement. Capillary leak 
begins to resolve in 24 hours, preventing the leak of fluids into 
the interstitium. Colloids are started after the first 24 hours 
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of resuscitation to assist mobilization of fluid into the intra-
vascular space where it is excreted. Loss of plasma proteins 
contributes to the loss of intravascular fluid. Colloids, such as 
salt-poor albumin in drip form, will help replace the proteins 
once the capillary leak has been resolved. 
The use of central lines and pulmonary artery catheters 
has limited use during the initial resuscitation period. The 
central venous pressure (CVP) and the pulmonary artery 
occlusion pressures (PAO) will read below normal because 
of the fluid shifts from the intravascular space. There is a 
risk of overloading patients with fluid during the resuscita-
tion because normal CVP and PAO pressures will be elusive 
until the capillary leak resolves in 18–24 hours. 
 Renal 
Renal failure is rare in appropriately resuscitated patients 
in the early phase of care. Decreased urine output, 
decreased cardiac output, accumulation of hemachroma-
gens in the renal tubules, and underresuscitation can lead 
to acute tubular necrosis. The use of diuretics during the 
primary resuscitation phase is contraindicated except in 
rare instances. 
 Infection Control 
The first line of defense against the invasion of microorgan-
isms is breached with loss of the skin. Infection remains the 
number one cause of death in the burn patients. Central 
lines are guidewired every 3 days and sent for culture until 
the burn wounds close. According to CDC recommenda-
tions, routine guidewire exchange of central venous cath-
eters (CVC) should not be done after burn wounds close, 
and timing of replacement of CVCs is a matter of some 
debate. Positive catheter segment culture (>15 cfu) war-
rant the removal of the line (King, Schulman, Pepe et al., 
2007). Prophylactic antibiotics are not routinely given in 
burn patients. Surveillance for infection is constant, and 
administration of antibiotics is culture driven. Empiric anti-
biotics are initiated when signs of sepsis appear without a 
documented source while awaiting culture results. Broad-
spectrum antibiotics are initiated and should be guided by 
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unit or hospital-specific antibiograms until speciation of 
the bacteria is identified. 
 Temperature Regulation 
Heat loss through an open burn wound can be excessive; 
therefore, keeping the environment warm with radiant heat-
ing devices is imperative. The temperature in the operating 
room is usually 80–90° F. Use of warming catheters has been 
useful in maintaining patients’ core temperature during long 
operative procedures. Warm blankets, warm fluids, and cov-
ering the patient’s head aid in heat conservation. 
Temperature regulation of the hypothalamus is reset 
after a major burn injury. Burn patients are hypermetabolic 
and suffer the effects of the systemic inflammatory response. 
Unless there is a change in mental status or vital signs, 
patients do not need to have cultures ordered secondary to 
fever in the first 4–5 days post injury. 
Drug pharmacokinetics can be altered in patients with 
major burn because of altered capillary permeability, loss 
of plasma proteins from the intravascular space, and edema 
that increase the volume of distribution (Weinbren, 1999). 
For this reason, systemic antibiotics are frequently given at 
higher than normal doses to burn patients. Antibiotic serum 
concentrations are monitored for proper dosing. 
 Burn Wound Management 
Calculation of TBSA is required because fluid resuscitation 
formulas are based on this percentage. The Lund–Browder 
burn sheets are used to accurately estimate the percent of 
the body burned. The percentages take into consideration 
the body parts that change with age such as the head, thighs, 
and lower legs. For example, a burn wound of a 2-year old 
whose entire head is burned would calculate to be 13%, com-
pared with the adult head, which would be 7%. The palm and 
fingers of the patient’s hand equals approximately 1% and 
can be used to calculate the percent of burn. This method 
is useful for wounds that are scattered over the body in a 
splatter-type pattern, which occur when an agent like tar or 
grease spill onto a body part. The burn wound is the source of 
the systemic response seen clinically when the body reacts to 
the dead and dying tissue. 
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In electrical injuries, the appearance of the outer cutaneous 
burn wound is not reflective of the extent of damage below the 
burned or nonburned skin. This type of wound is described as 
the “tip of the iceberg.” Electrical current that enters and exits 
the body produces the most damage where current meets the 
most resistance. Bone creates the most resistance and, there-
fore, the most heat damage. These types of injuries usually 
result in some form of amputation. Technetium-99 pyrophos-
phate scanning of an extremity can aid in deciding whether to 
amputate and/or attempt to save the limb when the degree of 
injury is not obvious by direct observation. 
The goal of wound management is to prevent infec-
tion, expedite wound closure, and prevent conversion of the 
wound to a deeper level. Infection or desiccation of the burn 
can cause conversion of the wound from a partial-thickness 
injury to a full-thickness injury. Burn wounds at the extremes 
of age are deceptive in the first 24–48 hours because of the 
thinness of the skin. In the elderly and young children, 
viewing the wounds initially may provide a false sense of the 
burn wound depth, because it may appear superficial. After 
24 hours, what was thought to be a nonoperative, superfi-
cial wound, often results in a deep wound requiring excision 
and/or grafting for wound closure. 
The depth of the wound is determined by skin struc-
tures and layers that have been damaged or destroyed. When 
describing the burn wounds, it is important not to fixate on 
correctly naming or classifying the wounds according to 
the depth. The best way to document the appearance of the 
wound is to describe what is observed or assessed. For exam-
ple, description of the wound may include, color, absence or 
presence of hair follicles, absence or presence of pain, and 
whether there is blanching of the wound with applied pres-
sure. A wound that is pink, clean, moist, and painful to touch 
with intact hair follicles usually indicates a partial-thickness 
injury. Eschar is a dead devitalized tissue and is often con-
fused with the protein exudates or pseudoeschar that accom-
panies partial-thickness wounds. Eschar that is dry, leathery, 
nonblanching with pressure, and anesthetic to pain is indica-
tive of a full-thickness injury. Deep circumferential burns of 
the extremities or thorax can cause a tourniquet-like effect 
because of the inelasticity of the eschar. This can be exac-
erbated by the edema formation that occurs with the fluid 
resuscitation. 
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In circumferentially burned extremities, it is important to 
perform hourly neurovascular checks to assess the compart-
ments. Checking capillary refill, palpating the compartments 
for tightness and measuring compartment pressures are 
effective tools for evaluating compromise. Patients who are 
responsive may be able to describe tingling and numbness in 
the extremities, which may be the first sign of compromise. 
Removal of eschar can be done through surgical, enzy-
matic, or biomedical debridement (maggots). Wounds are 
cleansed with soap and tap water, and then covered with an 
antimicrobial topical cream such as silver sulfadiazine. Ionic 
silver has antimicrobial properties, and there are various 
commercially available dressings that contain ionic silver 
that can be used to cover the wound. The dressings can be 
left in place and provide antimicrobial coverage for 4–7 days 
depending on the product. This avoids the painful twice-
daily dressings that include removal of the antimicrobial 
topical agent, which have been the mainstay of burn care. 
The occlusive dressings protect the nerve endings, decrease 
evaporative losses, decrease pain, decrease nursing time, 
and decrease the amount of pain medications used for dress-
ing changes.
The natural contraction of wounds that are healing sec-
ondarily puts patients at risk for contractures. The position of 
comfort is the position of deformity for burn patients. Occu-
pational and physical therapists follow their patients on a 
daily basis for passive or active range of motion exercises 
involving joints and foot drop, such as splinting of extremi-
ties to avoid contracture formation. The therapists assist in 
developing a positioning program to counteract the con-
tractile forces of wound healing. Applying the splints and 
adjunctive equipment as ordered by the therapist facilitate 
optimization of function. 
Burn patients requiring wound care may be uncoopera-
tive, restless, and confused. Hypoxia and hypovolemia must 
be assessed and evaluated, before assuming that it is pain 
or anxiety. Once these have been ruled out, patients may be 
medicated with intravenous opioids and anxiolytics in small 
increments after resuscitation fluids are infusing. Medica-
tions are given intravenously; no intramuscular medica-
tions (except for tetanus prophylaxis) are given during the 
resuscitation period. Medications given intramuscularly will 
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become sequestered in the muscle. Once the capillary leak 
subsides, remobilization of fluid back into the general circu-
lation can cause an overdose of the medication. 
Burn wounds are the source of the most unimaginable 
pain one can experience. Burn wound pain increases as the 
wounds progress toward healing because of the exposure of 
nerve endings to the environment once the eschar or protein 
layer is removed and the edema resolved. Pain management 
revolves around three types of pain, namely, background 
pain, procedural pain, and breakthrough pain. Intubated 
burn patients in the intensive care unit may be placed on 
fentanyl- and propofol-continuous infusions. Additional 
medications are given prior to dressing changes and physical 
or occupational therapy. 
 Nutrition 
Major burn injuries cause a dramatic alteration in metabo-
lism, leading to hypermetabolism and hypercatabolism. Met-
abolic rates of burn patients can exceed 2–3 times normal 
and can cause tremendous wasting of lean body mass within 
a few weeks of injury. The hyperdynamic state and hyper-
metabolism require increased nutritional requirements. 
On admission, small silastic feeding tubes are inserted, 
and enteral feeds are started to avoid malnutrition. Various 
formulas are available in calculating individualized caloric 
requirement, which should include 100:1 or 150:1 kilocalo-
ries (kcal) to nitrogen. 
Gastric and duodenal ulceration has long been recognized 
as a complication of burn injury. (McAlhany, Colmic Czaja, & 
Pruitt, 1976) Mucosal ulceration prophylaxis is accomplished 
by early administration of enteral feedings. H2 blocker or pro-
ton pump inhibitors in combination with antacids should be 
added to maintain a gastric pH above 5 (Mozingo & Mason, 
2007). Monitoring of nutrition laboratories and following the 
trends can be useful in guiding caloric intake. When pos-
sible, patients should be weighed weekly. The administration 
of oxandrolone, an anabolic steroid, has been shown to limit 
muscle wasting in patients with large burn injuries, with less 
androgenic effects. Oxandrolone can be given orally. Patients 
on regular diets with poor appetites also benefit from the 
addition of appetite stimulants such as dronabinol. Nutritional 
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requirements in patients with major burn injuries exceed 2–3 
times the normal daily caloric intake and may increase with 
associated injuries. 
Maintaining high ambient temperature and relative 
humidity can reduce caloric requirements by up to 20%. 
Antibiotics and routine early burn wound excision have 
reduced infection and modulated hypermetabolism. In addi-
tion, covering burn wounds with autograft, allograft, or syn-
thetic substitutes shortens the duration of hypermetabolism. 
Mechanical ventilation and chemical sedation or paralysis 
reduce energy requirements. 
Several formulas for calculating nutritional require-
ments are available The major energy source for burn 
patients should be carbohydrates. Glucose is the preferred 
fuel for healing wounds (Saffle & Graves, 2007). Protein 
catabolism can exceed 150 g/day; as burn size increases 
progressively, more protein is required for positive nitrogen 
balance (Matsuda, Kagan, Hanumadass, & Jonasson, 1983). 
Current recommendations require 1.5–2.0 g of protein/kg 
of body weight per day. Enteral nutrition and high protein 
intake are important; expenditure needs fluctuate through-
out hospitalization and need to be reevaluated frequently. 
 Prognosis and Outcome 
The chance of survival from a burn injury has increased 
over the past several decades. Several risk factors identified 
by Ryan et al., (1998) continue to be the strongest predic-
tors of death in the burn patient. These risk factors are age 
>60 years, a burn >40% of the body surface area, and the 
presence of inhalation injury. In the presence of no risk fac-
tors, patients’ chance of mortality is 0.3%; patients with one 
risk factor have a 3% chance of mortality; patients with two 
risk factors have a 33% chance of mortality, and all patients 
with three risk factors have approximately a 90% chance of 
mortality. Other factors have also been identified as deter-
mining factors in the survival of the burn patient. In a study 
conducted on a national sample of over 31,000 burn patients 
the presence of preexisting medical conditions at admission 
increased the risk of mortality and required a longer hos-
pital stay than patients of similar age, sex, and burn injury 
characteristics, but with less comorbidity (Thombs, Singh, & 
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Haloren, 2007). Predicting mortality for a burn patient is not 
the priority issue. The new challenge has become to facilitate 
an improved quality of life for patients who are surviving 
these injuries 
Even after survival, patients will most likely encounter 
extended surgical, medical, psychological, and rehabilitation 
interventions for years. An expert in multidisciplinary burn 
care team to guide and support patients increases the prob-
ability of patients to obtain a desirable quality of life, because 
no longer is survival the sole goal and desired outcome; a 
successful outcome is determined by the ability of the burn 
survivor to be integrated back into the community with an 
acceptable quality of life as determined by the survivor. With 
no predetermined notion of what patients’ definition of qual-
ity of life may be, this presents a challenge. 
Recent studies have demonstrated that most burn survi-
vors appear to have adjusted satisfactory to their limitations 
over time (Sheridan et al., 2000). The first year is usually 
plagued with physical difficulties and discomforts that are 
transient. Psychological adaptation continues over several 
years and should be periodically assessed by experts in the 
field. Massively burned individuals cannot be returned to 
their preinjury appearance and function, but the combination 
of expert acute care with supportive multidisciplinary reha-
bilitative care can produce satisfying long-term outcome. 
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 Introduction 
 The problem of organ failure continues to perplex clini-
cians and scientists, and it contributes to fatal outcomes 
for patients with illnesses, infections, and injuries after 
operations.
—Dr. Roger Bone, 1992 
Multiple organ dysfunction syndrome (MODS/MOF/
MSOF) is a constellation of acute or acute-on-chronic systemic 
disorders that profoundly affect mortality and morbidity. The 
continuum of sepsis, severe sepsis, and septic shock are inti-
mately linked to multiorgan dysfunction and may ultimately 
result in organ failure and death. 
Multisystem
Organ Failure 
Barbara A. McLean 
9
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Technological advances in acute care, such as volume 
resuscitation and blood transfusion, decreased the incidence 
of renal failure; however, the resulting increased survival 
rate gave rise to a post resuscitation lung disorder that later 
became known as acute lung injury and acute respiratory 
distress syndrome. Understanding the malignant, destructive, 
uncontrolled inflammatory and coagulation process became 
the primary focus in the management of patients exhibiting 
signs and symptoms of severe sepsis and MODS (Figure 9.1). 
The American College of Chest Physicians/Society of 
Critical Care Medicine Consensus Conference offered a 
specific approach for identification of high-risk patients in 
1992 (see Exhibit 9.1 on page 321). This method of evaluating 
patients was based on their clinical presentation, risk factors 
and ultimately laboratory diagnosis. The high-risk patient 
9.1
The Continuum of SIRS to Septic Shock
SIRS: BE Aware !!!
•  Temperature core
  <38.3° C or <36° C
•  Heart Rate 
  >90 bpm or >2
SD above nor-
mal for age and 
context
•  Respiratory Rate 
  >20 pm or 
>20 MV
•  White Blood Count
  >than 12,000 
cells mm-3 or 
<4000 cells mm-
3 or greater than 
10% immature 
(band) forms
Control The Source!!!
•  As in SIRS +
Documented
or suspected 
infection
•  Altered Mental 
Status
•  Signifi cant +
fl uid balance
>20mL/Kg in 
24 hours
•  Blood Glucose 
>140 mgm in 
absence of 
diabetes
Stop the Organ 
Dysfunction!!
Support the Organs!!
•  As in SIRS +
SEPSIS
•  simple signs 
of acute organ 
dysfunction
•  simple signs 
of tissue 
hypoperfusion
Maintain the blood 
pressure
•  As in SIRS +
SEPSIS + Severe 
•  loss of vascular 
tone
  refractory to 
volume
  requires vaso-
pressors
ªmaldistribution of 
blood fl ow
•  inappropriate 
shunting of 
 oxygenated 
blood
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must present at least two of the specified indicators. The cri-
teria are very sensitive and require the astute practitioner 
to utilize the identifiers in conjunction with critical intuition 
and a comprehensive analysis of the patient’s history. 
Because the terms for identifying systemic inflamma-
tory response syndrome (SIRS) are simplistic, nonspecific, 
and sensitive, others have suggested additional evaluations 
beyond the initial presentation (Levy et al., 2003; Cunneen, 
& Cartwright, 2004) (Exhibit 9.2). These include evaluation 
of tissue hypoxia and simple organ indicators of dysfunction 
to promote a strategic identification of the patient’s risk and 
may facilitate a more timely and accurate intervention. 
In severe sepsis, the inflammatory response to a nidus of 
infection (or inflammation) is fulminating and out of control. 
Stimulated by-products of antigen ingestion, activated neu-
trophils, and other humoral mediators combine, activate, and 
potentiate an ongoing endothelial injury with a concomitant 
proinflammatory, procoagulating, antifibrinolytic responses. 
Among other mediators, an increased presence of tissue factor 
persistently stimulates thrombin, which ultimately increases 
fibrinogen conversion to fibrin and promotes platelet aggre-
gation. In addition to the increased platelet activity, excessive 
thrombin production and a secondary decrease in endothe-
lial production of plasminogen activator, thrombomodulin, and 
activated protein C, profoundly increases microocoagulation 
while limiting fibrinolysis. The endothelial regulation of appro-
priate blood flow related to a balanced expression of vasodila-
tors (i.e., nitric oxide NO) and vasoconstrictors (e.g., endothelin) 
becomes uncoupled and nonspecific. The corresponding loss of 
Bone, R. C. et al., (1992).
Exhibit
9.1 Systemic Infl ammatory Response Syndrome (SIRS)
1 Temperature >38°C or <36°C
2 Heart rate >90 beats/min
3 Respiratory rate >20 breaths/min or PaCO2 <32 torr
4 WBC >12,000 cells mm-3 or <4,000 cells mm-3 or >10% immature (band) forms
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  Laboratory Measures of
Clinical Infl ammatory Signs Infl ammation
Hyperthermia    Leukocytosis
Hypothermia    Leukopenia
Heart rate >90 bpm or 20 higher  Normal WBC count with 
 than normal (persistent)    bands >10%
Hyperventilation: RR > 20 bpm  ↑ C-reactive protein
Altered mental status   ↑ procalcitonin
     Hyperglycemia >150 mgm
     measured × 2 1 hour apart
Tissue Perfusion/Hemodynamics Organ Dysfunction
SvO2−ScVO2 < 70% or >70%   Failure of arterial oxygenation
 in the presence of clinical   ■ P/F < 200 on ≥0.40 FiO2 or
 compensatory signs   ■ A-a difference >normal
Lactic Acidosius > 4 mMol/dL   20 mmHg (corrected for baro-
Lactate Clearance of <10% / 24 hours   metric pressure and FiO2) or
Anion gao > 20    ■  Oxygenation index >15
Stroke volume variation >15% in a  Plateau pressure (inspiratory
 ventilated patient. Measured with   hold) >30 cm H2O in the
 controlled positive pressure breaths.  absence of chest wall
      compliance disorders or
      space occupying lesions
      (hemothorax, pneumothorax)
      measured on a ventilated
      patient with a controlled
      breath.
Cardiac Index >4.0 L·min·m2 or  Urine output <0.5 ml/kg
<2.5 L·min·m2     following fl uid resuscitation, 
      Cr ↑ >50%
Heart rate >90 bpm or 20 higher than  Coagulation abnormalities:
 normal    ↑ PT, INR, D-Dimers
↓ platelets, fi brinogen
.9.2 Modifi cation of SIRS and MODS
Levy, M. M., Fink, M. P., Marshall, J. C., et al., 2003; Cunneen, J. and Cartwright, M., 2004.
Exhibit
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vascular tone and maldistribution of blood flow occurs at the 
both the macrovascular and microvascular level, resulting in 
a scenario of mixed ischemia and hyperemia at the same sur-
face area Frequently the patient’s blood pressure will begin to 
decrease, signifying a loss of compensatory vasoconstriction. 
In addition, myocardial depressant factor is released and ulti-
mately may contribute to the loss of the compensatory cardiac 
output (CO) (Exhibit 9.3). 
A patient with sepsis presents with at least two of the 
previously mentioned SIRS criteria: an abnormal body tem-
perature, elevated heart and respiratory rates, and an altered 
white blood cell (WBC) count. Sepsis with one or more acute 
organ dysfunctions is considered severe sepsis. Septic shock 
is severe sepsis with cardiovascular dysfunction (primary 
loss of vascular tone) that does not respond to fluid resusci-
tation, requiring the administration of vasopressors. 
 Multiple Organ Dysfunction Syndrome (MODS) 
Patients with severe sepsis or prolonged tissue hypoxia, 
the problem is not as simple as a nidus of infection; it is 
Failure of vascular tone (nitric oxide synthase and induced NO release)
Vasodilatation due to local metabolites
Loss of reactivity of smooth muscle
Consumption of coagulating proteins
Activation of tissue factor, thrombin, fi brinogen
Diminished activation of protein C, tissue plasminogen
Alteration in red blood cell deformability
Hemoconcentration, sludging, intravascular coagulation, occlusion of the
capillaries
AV Shunting
Capillary leak and intestitial edema
Infl ammatory responders such as cortisol, glucagons, epinephrine promoting 
insulin resistance and hyperglycemia
.9.3 An Example of the Expression of Unopposed Infl ammation
Exhibit
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more concisely the inflammatory response that is out of 
control, wreaking havoc on the endothelium. 
The term  MODS is used to identify the early phase of 
organ dysfunction and was coined by Marshall as a relative 
predictor of overt failure (Marshall et al., 1995). The potential 
for organ failure looms large during this period, and currently 
the primary therapy is based on the initial identification and 
suppression of the nidus of inflammation focusing on the 
management and support of each organ that is dysfunctional 
as well as supporting blood flow, cardiac output and ultimately 
vascular tone. Quite simply, rapid diagnosis, constant vigilance, 
and appropriate and timely therapeutic intervention can sig-
nificantly reduce the evolution of sepsis to MODS. Under 
recognized and underresuscitated, severe sepsis (presence 
of MODS with indicators of sepsis) frequently leads to organ 
failure and ultimately death. 
Deconstructing this complex process into a few simple tools, 
guidelines, and protocols is nearly impossible. However, if ther-
apy is initiated in an emergent manner, the progression may be 
arrested, and therefore mortality and morbidity may indeed be 
decreased. The acute care nurse practitioner (ACNP) evaluates 
clinical signs and symptoms of SIRS and correlates the assess-
ment with an index of suspicion, patient’s history, and com-
plaints of illness, then designs an appropriate evaluation, early 
treatment, and reevaluation platform. Early treatment involves 
rapid volume resuscitation of 20 ml/kg over 30–60 minutes or 
an even shorter time frame, depending on the vital signs, his-
tory and age,. Resuscitative fluids will impact tissue perfusion. 
Following the drawing of blood cultures and other appropri-
ate cultures, a broad-spectrum antibiotic must be administered 
intravenous (IV), based on unit antibiogram (chapter 11). 
 Endothelial Dysfunction 
Despite numerous clinical trials aimed at supporting or 
antagonizing humoral mediators and cellular communica-
tors, no single strategic method of control has been identi-
fied. Indeed, controlling one cascade often leads to another 
problem (Figure 9.2). 
There is no predictable model for MODS, a complex, 
nonlinear monolith, affecting inflammation (both pro and 
anti), apoptosis (a process referred to as cellular suicide 
or programmed cell death), coagulation, and fibrinolysis 
referred to as endothelial dysfunction. In the absence of the 
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presentation of a specific nidus, the ACNP should consider 
the patient’s condition and where they sit on the continuum 
of sepsis, making treatment decisions accordingly. Rapidly 
instituting a therapy driven toward increasing and main-
taining blood flow, therefore decreasing the heart rate and 
respiratory rate (as compensatory measures), increasing the 
diastolic blood pressure and pulse pressure, and clearing lac-
tic acid, is an important intervention. All of these therapies 
combined will increase endothelial protection. 
Assuming that the focal point of inflammation is infec-
tious, the ACNP should perform blood and appropriate sys-
tem cultures and should initiate broad-spectrum antibiotics 
(Chapter 11) within 4 hours after patient identification. If 
cultures cannot be obtained, antibiotics should be initiated 
regardless. In the presence of a hypotensive state, rapid diag-
nosis and administration of antibiotic therapy appears to be 
essential to reduce mortality (Kumar et al., 2006) 
The endothelium was historically considered a passive 
barrier between tissues and blood. Over the last 2 decades, cell 
traffic, proinflammation and antiinflammation, coagulation, 
9.2
Infl ammatory Cascade
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fibrinolysis, and vascular tonal control have been uncovered 
as just a few of the many endothelial functions. 
The primary stimulation for this endothelial chaos is 
the systemic and local release of inflammatory mediators 
(Figure 9.3). The cytokine-based communicators activate 
the endothelium and attract WBC, which further generates 
endothelial activation. The heightened activation trips the 
coagulation component, in a prothrombin and antifibrino-
lytic cascade. Unopposed, this process may lead to a pro-
found consumptive coagulopathy, diminished distal blood 
flow as a result of microcoagulation, and activated apoptosis 
(Aird, 2002). The blood flow necessary to maintain tissue 
oxygenation and aerobic metabolism, nutrient transfer, and 
metabolic waste removal is profoundly threatened. 
There are two basic types of endothelial cells: the quiet 
endothelial cells expressing antiadhesive, anticoagulation, 
and vasodilation mediators, and the activated cells, which per-
form the opposite functions. There is an intricacy of function 
and molecular components contributed by the endothelium. 
The presence of continuous flowing blood (and the 
dynamic shear stress generated when blood is ejected), an 
acidotic pH, the increased presence of thrombin, and cell-to-
cell communications of dysfunction significantly impacts the 
complexity of endothelial function. Heightened apoptosis also 
significantly impacts the complexity, and dysfunction, of the 
endothelial properties. Apoptosis is the pogram of cell death. 
Cells can die in two ways: by damaging their cell membrane 
9.3
Endothelial Cascade
cell
adhesion
Inflammatory stimulation
      1.   microbial activation
      2. activation of
 neutrophils
      3. cytokine actovation
Consequences
      1.   Refractory
 hypotension
      2. Consumption
 of coagulation
 products
      3. Capillary leak
free
radical
damage
altered
barrier
microvascular
thrombus
altered
vascular
tone
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and then undergoing necrosis or by shrinking and blebbing 
the intact cell membrane. This process is a normal one: all 
cells have a programmed life and death. There is evidence 
to suggest that an increase in the apoptotic processes may 
play a determining role in the outcome to sepsis syndromes. 
Therapeutic efforts in modulating the apoptotic response, 
particularly by interfering with cell signaling pathways that 
lead to early and increased apoptosis, represent an attractive 
therapeutic target for the patient with sepsis. 
The evolution of sepsis to MODS resulting ultimately in 
organ failure and death initially presents as a form of hypo-
volemia (distributive shock). To the unsuspecting practitio-
ner, the early signs of arterial underperfusion may be masked 
by the patient’s appearance and relative health history. Sep-
sis and severe sepsis are equal opportunistic inflammatory 
states; no age, gender, or requirement of prior health issues 
are necessary for the process to occur or to render a patient 
resilient to the process, although there are multiple issues 
that may place the patient in higher risk category. 
The primary mechanism for initial compensation is an 
acute stress, inflammation, or a hypermetabolic state that 
increases cardiac output. Attention to the details of inflamma-
tion and compensation (Figure 9.1) followed by an immediate 
intervention may significantly improve survival and prevent 
the patient’s imminent decompensation, significantly reduc-
ing the evolution to MODS (see Figure 9.3 on page 326). 
 Cellular Perfusion 
At the bedside, three basic assumptions drive practice. 
Assumption One: If everything looks normal, “it is.”
Patients will frequently appear “normal” because their 
cardio–pulmonary–vascular systems compensate for early 
inflammation and hypermetabolism with hyperventilation 
and/or increased heart rate or vasoconstriction. The color and 
temperature of the peripheral extremities is one of the com-
mon evaluation tools determining blood flow that might lead 
the provider astray. An inherent error may occur in the patient 
who has the microcirculatory deficits of severe sepsis, because 
their blood flow is essentially maldistributed. The hands and 
feet may be warm because the patient is infarcting cells and 
organs that are unseen and unable to be evaluated. 
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Assumption Two: If blood pressure is normal, blood flow 
“must” be adequate.
When patients present in the early stages of shock, 
catecholamines, neuroendocrine responses, and the cor-
responding cardiac response may profoundly impact the 
actual blood pressure, maintaining pressure while masking 
the inadequacy of blood flow. Blood pressure monitoring 
may not be a sensitive indicator for the patient with com-
pensated shock. Profound reductions is blood pressure is a 
sign of end-organ decompensation; the goal is to recognize 
the symptoms prior to this severe decompensation. 
Assumption Three: If the pulse oximeter is acceptable, 
oxygenation “must” also be good
Traditional pulse oximetry, both SpO 2 as well as SaO 2,
are not strong indicators of cellular oxygen, although both 
importantly (indirectly and directly) reflect the alveolar cap-
illary gas exchange. When saturation of hemoglobin (Hgb), 
arterial oxygen content, and PaO 2 appear to be adequate, the 
cells may still be profoundly hypoxic. 
 Contributors to Blood Flow and 
Tissue Oxygenation 
From the time of the early work of Shoemaker et al., (1988) and 
Kreymann et al., (1993), it has been well established that global 
tissue hypoxia accompanies  all forms of shock. Categorically, 
oxygen delivery in shock (cardiac, hypovolemic, and hemor-
rhagic) affect the mechanics of oxygen supply and availability, 
while systemic inflammatory response or severe sepsis with 
the secondary effects of endothelial dysfunction, vasodila-
tion, inflammatory mediation, and unopposed procoagulation, 
interferes with the utilization of oxygen at a microcirculatory 
and cellular level. This persistent hypoxia further exacerbates 
the systemic response, and if unresolved, it will lead to organ 
dysfunction and eventually death (Table 9.1). 
SIRS can rapidly progress from severe sepsis to septic 
shock, with tissue hypoxia undetected by traditional mea-
surements. Tissue oxygenation indicators provide a frame-
work of reference that should direct therapy toward a more 
valid perfusion goal. When the potential for a hypoxic states 
exists, two primary physiological responses occur to maintain 
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Type/indicator Heart Cardiac Filling SVR Pulse SvO2
 rate output pressures  pressure
Cardiogenic ↑ ↓ ↑ ↑ ↓ ↓
Hypovolemic ↑ ↓ ↓ ↑ ↓ ↓
Hemorrhagic ↑ ↑ ↓ ↓↓ ↑ ↓ ↓↓
Neurogenic ↓ ↓ ↓ ↓ ↑ ↓
Anaphylaxis ↑ ↓ ↓ ↓ ↑ ↓
Compensated ↑ ↑ ↓ ↓ ↑ ↓↓
 Severe Sepsis
Decompensated ↑↓ ↓ ↑ ↑ ↓ ↑
 Severe Sepsis
Comparing Shock Types9.1
tissue oxygen consumption: increasing the delivery of oxy-
gen (primarily via increased CO) and increasing the release 
rate of oxygen from Hgb (desaturating Hgb at the capillary 
level) expressed as a shift to the right of the saturation of 
hemoglobin (oxyHgb) dissociation curve (Figure 9.4). 
9.4
Oxyhemoglobin Dissociation 
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9.5
 Maintaining Oxygen Balance 
 Maintaining Oxygen Consumption 
The adequate delivery and consumption of oxygen can 
be assured only in the face of an adequate CO and appro-
priate release of bound oxygen, as well as oxygen content 
(Figure 9.5). CO is the product of heart rate × stroke vol-
ume (see Figure 9.6). Although heart rate is easily mea-
sured and evaluated, the evaluation of stroke volume must 
be performed with echocardiography or tissue oxygenation 
monitors and then leading to increasingly invasive mecha-
nisms including volumetric end tidal CO2, continuous arte-
rial signal processes, Fick calculations based on arterial 
and central venous or mixed venous oxygenation measures, 
and intrapulmonary (thermodilution) or intra arterial tech-
niques. The appropriate release of bound oxygen (tradi-
tionally inferred from the mixed venous saturation of Hgb) 
requires a continuous method of measuring the central or 
mixed venous Hgb saturations as well as correlating the 
aerobic/anerobic environment of the tissues (traditionally 
inferred from the anion gap, lactic acid levels, base deficit, 
serum CO2, and calculated bicarbonate). The methodology 
ultimately depends on the resources available as well as 
the expertise of the providers. The clinician must be aware 
of the limitations of any measurement technique that is 
selected and utilize all measures to create a strong picture 
of the pathologic process. 
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9.6
Maintaining Cardiac Output/Index: Balance of Heart Rate and Stroke Volume 
 Oxygen Content 
Content of arterial oxygen (CaO 2) is defined as the amount of 
bound Hgb (SaO2) plus the amount of dissociated, dissolved 
oxygen (PaO 2) found in the arterial blood. The role of the satu-
rated Hgb is to transport and then release oxygen as the blood 
flows through the capillaries, maintaining a relatively con-
stant partial pressure of oxygen in the dissolved (usable) state. 
Every Hgb cell that is fully saturated with oxygen, transports 
approximately 1.34–1.36 ml of oxygen, and is the only reser-
voir for oxygen that appropriately balances tissue demands 
(Table 9.2 on page 332). As the red cells deform, flow into the 
capillaries, and past the cells, a constant dissociation occurs 
as the partial pressure of dissolved oxygen decreases based 
on cellular uptake of oxygen. The ability of Hgb to release 
oxygen when cellular demand is increased is the second most 
important compensatory mechanism utilized to sustain cel-
lular integrity. In terms of the oxyHgb dissociation curve, this 
reflects a shift to the right or a release of bound oxygen to 
the dissolved or usable state (PaO 2). This process occurs at 
the capillary interface level and therefore cannot be directly 
measured in the arterial blood. When arterial blood volume is 
inadequate, ventricular function is poor and/or Hgb levels do 
not fulfill oxygen-carrying capacity criteria, the second com-
pensatory mechanism, shifting to the right, may save the day. 
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Typically, the oxygen delivery (CO × content of oxygen) is 
in profound excess of the tissue demand (see Table 9.3) rep-
resenting the normal reserve of saturated Hgb. Normally, tis-
sues consume about 20% to 30% of reserve oxygen, desaturat-
ing Hgb to approximately 70%. When oxygen delivery (DaO 2)
decreases, because the CO has gone down or there is an inad-
equate oxygen-carrying capacity, the reserve will be tapped at 
a greater level. However, when tissues cannot use the oxygen 
delivered to them, the initial compensatory mechanism is to 
increase the delivery via an increase in CO. 
 Cardiac Output: Delivering the Oxygen Content 
Heart Rate. The first compensatory mechanism that expresses 
the patient’s attempt to increase oxygen delivery is an increase 
in the intrinsic heart rate. Patients who are unable to manifest 
increase in heart rate (as a result of beta blockade or acute 
cervical spinal cord injury) will have a limited ability to com-
pensate. In the appropriate clinical circumstances, persistent 
tachycardia should be considered as an attempt to increase 
oxygen delivery compensating for low hemoglobin, high tis-
sue demand or inadequate oxygenation at the cellular level 
   PaO2 /
Measures Hgb Saturation PvO2 Formula Normal
Arterial 14 gm 0.95–1.00 80–100 
mmHg
SaO2 (Hgb ×
 1.36) + PaO2
 (0.03)
18–20
ml/dl
Mixed
Venous (PAC) 
Oximetry
14 gm 0.60–0.80 40–45 
mmHg
SvO2 (Hgb ×
 1.36) × PaO2
 (0.03)
11.5–15 
ml/dl
Central 
Venous (CVP) 
Oximetry
14 gm 0.65–0.85 40–45 
mmHg
ScvO2 (Hgb ×
 1.36) + PaO2
 (0.03)
13–16
ml/dl
.9.2 Measurements of Oxygen Content
Values based on Reinhart, K., et al., (2004) and Reinhart, K., et al., (2006).
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until proven otherwise (diagnosis of exclusion). Optimal man-
agement calls for increasing the stroke volume and thereby 
decreasing the heart rate., as well as utilizing sedation and pain 
management strategies to reduce tissue demands. The ability to 
evaluate the stroke volume or CO may significantly impact the 
treatment measures and patient outcome. The variables that 
affect the stroke volume include contractile function, preload, 
and afterload. Invasive and noninvasive methods can be used to 
indirectly or directly to assess these components (Figure 9.7). 
 Stroke Volume 
Contractility. Contractility is the intrinsic ability of cardiac 
muscle to develop force for a given muscle length. The ability 
to develop tension or power is related to the intrinsic myocar-
dial state. The amount of force required (tension or afterload) 
and the filling volume (preload) are essential factors which 
impact contractility. However, the contractile function is ulti-
mately an independent one and is independently affected by 
crossbridges, calcium, mitochondrial function, and oxygen 
  Cardiac 
Measures Content Output Formula Normal
Arterial 18–20 ml/dl 4–8 L/min CaO2 (10)  1000 ml/min
   Cardiac output
Mixed  11.5–15 ml/dl 4–8 L/min CvO2 (10)  830 ml/min
Venous (PAC)    Cardiac output 460–1200
Oximetry    
Central  13–16 ml/dl 4–8 L/min CcvO2 (10)  920 ml/min
Venous (CVP)   Cardiac output 520–1280
Oximetry
9.3 Measurements of Oxygen Delivery
Legend Mixed Venous
Lowest 11.5(4)10 = 460
Highest 15 (8(10 = 1200
mean average = 830
Legend Central Venous
Lowest 13(4)10 = 520
Highest 16(8)10 = 1280
mean average =  920
Values based on Reinhart, K., et al., (2004) and Reinhart, K., et al., (2006).
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delivery. There are no known bedside measures that directly 
monitor the true contractile state of the myocardium. 
Preload. Frank and Starling are credited with the seminal 
observation that peak ventricular ejection increases as the 
end-diastolic volume (EDV) increases in an intact ventricular 
model. The integral distendability of the chamber and the vol-
ume load it can accept are the basis of the Frank–Starling curve: 
the more filling, the greater the stretch; the greater the stretch, 
the better the ejection.Until overdistension is reached the vol-
ume load will no longer equal the ejection volume, this volume 
load is usually estimated from the easily measured pressure in 
the venous column (measured in the vein or the atria) prior to 
the ventricle that is being filled. The right and/or left ventricu-
lar end-diastolic pressures are therefore indirectly reflected in 
the central vein or the pulmonary artery respectively. 
Preload pressure is a measure or estimate of the ventric-
ular volume load in the chamber at the end of diastole. These 
two preload pressures are reflective of the EDV as well as the 
compliance of the ventricular wall (Exhibit 9.4). The implied 
equivalency between the pressure and volume in the ven-
tricular chambers is often not correct and depends on the 
9.7
When Cardiac Output is Inadequate for the Oxygen Consumption/Demand
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compliance or distendability of the ventricle. During acute 
or chronic myocardial ischemia, sepsis, valvular dysfunction 
states, and even in simple tachycardia, the ventricles may 
become less compliant and may not fully relax during dias-
tole. Any changes in intrathoracic pressures (pneumothorax, 
hemothorax, positive pressure ventilation, distending airway 
pressures) will affect the ventricular compliance, as well as 
the pressure required to fill the ventricle and ultimately the 
ventricular volume. This pathologic diastolic dysfunction 
reduces the chamber size and decreases volume load at end-
diastole, and a smaller EDV may continue to be expressed 
in terms of a high filling pressure, therefore misleading the 
provider into assuming adequate volume loading. 
Afterload. Afterload is the resistance or pressure load that 
the ventricle must overcome in order to shorten the myofi-
brils, generate an opening pressure and eject the ventricular 
volumes into the outflow artery (right ventricle to pulmonary 
artery and left ventricle to aorta). This amount of tension 
that is required to eject volume into the arterial bed is not 
measurable and is referred to as afterload. Afterload is tra-
ditionally documented with basic or complex calculations for 
vascular resistance. The tension or power that the ventricle 
must develop directly opposes the valvular–arterial resis-
tance. The higher the afterload, the more tension the ventricle 
must develop, therefore due to the increased workload, the 
less efficient the contraction may become. The integrity of the 
1. Heart Rate
2. Positive Pressure Ventilation
3. Outlet Valve Stenosis/Regurgitation
4. Alteration in Arterial Resistance
5. Tension Development of the Ventricle (Afterload)
6. Ischemia
7. Remodeling
9.4 Factors Affecting Ventricular Compliance
Exhibit
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ventricular wall, the compressing thoracic and pleural pres-
sure, valvular (semilunar) function, and the outflow vascular 
tone affect the tension development required. The preload 
volume-stretch affects the afterload as the filling volumes 
must be moved via tension development. 
 Compensatory Mechanisms 
Three major compensatory mechanisms designed to sustain 
tissues are: increasing the CO, vasoconstriction of the vessels 
supplying organs that do not require a high level of oxygen, 
and releasing more of the bound oxygen. This is critical in 
maintaining and preserving tissue oxygenation (demand or 
consumption known as VO 2) (Figure 9.8). 
A profound neuroendocrine response stimulates both 
the beta and alpha receptors begins with α stimulation which 
in an intact endothelium will promote vasoconstriction and 
ultimately redirects blood flow from high flow, low oxygen 
requiring organs (i.e., skeletal muscles, peripheral nervous 
system) toward oxygen dependent organs (i.e., heart, brain, 
diaphragm). The beta-1 (β-1) stimulation effects will pri-
marily affect heart rate and myocardial contractility. If the 
Oxygen
Consumption
9.8
Increasing Cardiac Output and Compensatory Oxygen Dissociation from HgB 
(Must be measured in venous or capillary circulation.)
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receptor sites are intact and not opposed by circulatory 
mediators, tachycardia, increased contractility and vaso-
constriction will ensue. The correlating clinical measure of 
“cold hands and feet” is associated with this compensatory 
mechanism in shock, although those subjective indicators 
may lose value in the presence of complex disease and vari-
able compensatory mechanisms. The significant increase in 
CO is limited solely by the intrinsic volume status, as well 
as the endogenous and exogenous cardiac dynamics. Other 
processes, such as the release of renin, vasopressin, and 
other hormonal communicators, lead to a decreased excre-
tion of water, preserving the water load in an attempt to 
increase the circulating volume and hopefully the oxygen 
delivery (Figure 9.9). 
The second compensatory component, increasing the 
rate of release of oxygen off-load from the Hgb at the capil-
lary level (shift to the right) requires that indeed the blood 
flows into the capillary, the cell signals its need for oxygen 
(presence of acidosis), and there is adequate releasing prod-
uct to separate the oxygen from the Hgb (2,3-diphospho-
glycerate). The patient will not be able to acutely increase 
oxygen content (CaO 2: Hgb [1.34] saturation in the decimal) 
by increasing his own red cell count, although this is exactly 
what the chronic patient will do, as evidenced by patients 
with disease and polycythemia (Figure 9.10 on page 338). 
9.9
Oxygen
Consumption
Failure of Oxygen Dissociation and Compensatory Increase in Cardiac Output
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When supporting oxygen delivery, the ACNP should con-
sider volume, inotropic enhancement, and administration of 
packed red blood cells. Consideration should be taken for 
the risk of any of these therapies. If the patient has refrac-
tory, unexplained acidosis, and/or continued compensatory 
mechanisms, all three may be necessary. 
Monitoring of mixed, central venous or local oximetry 
as well as indicators of tissue hypoxia (metabolic acidosis) 
may provide insight toward alterations in oxygenation. The 
stimulation of central and peripheral chemoreceptors via the 
presence of metabolic acid drives a shift toward the  easily 
manipulated CO 2. A rapid respiratory rate “blows off” the 
excess acid in an attempt to maintain the required electri-
cally neutral blood pH. 
Confirmation of adequacy of either or both of these com-
pensatory mechanisms can be supported with combinations 
that include compensatory measures such as heart rate, respi-
ratory rate, blood pressure, pulse pressure, stroke  volume, 
stroke volume variation, as well as indicators of appropriate 
tissue oxygenation including SvO2, StO2 anion gap, base defi-
cit, serum CO 2, bicarbonate, and serial lactic acid levels. The 
three major variables that ensure oxygen delivery are CO, 
Hgb (mg/dl), and arterial saturation (SpO 2 or SaO 2). 
9.10
Failure of Cardiac Output and Compensatory Increase in Oxygen Dissociation
Oxygen
Consumption
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 Methodology for Monitoring and Evaluation 
In recent years, there has been significant reduction in the 
utilization of invasive monitoring catheters and a greater 
emphasis on minimally and noninvasive methods of evaluat-
ing the dynamics of oxygenation and blood flow. The utili-
zation of pulmonary artery (PA) catheters was attributed to 
an increased mortality and morbidity in catheterized patient 
groups (Connors et al., 1996). Other studies have challenged 
these results. There continues to be controversy over wheth-
er or not the utilization of PA catheter-based information is 
beneficial in the management of specific disease states. 
 Measuring Cardiac Output 
In most clinical circumstances, tachycardia should be consid-
ered a compensatory attempt to increase oxygen delivery to 
the cellular level. Optimal management calls for  increasing 
the stroke volume and thereby decreasing the heart rate. 
The ability to evaluate the stroke volume or CO may signifi-
cantly impact the treatment measures and patient outcome. 
Contractility is generally assumed by the CO. Contractility 
is highly dependent on preload and afterload and is diffi-
cult to measure as an independent variable. Evidence of low 
contractility may cause an imbalance in the oxygen delivery 
or demand response. Evidence of a higher CO usually indi-
cates a compensatory mechanism for an increased demand 
or the functional inability to utilize oxygen at the cellular 
level. Following are some of the current methods utilized 
for CO measurement. 
Bioimpedence. Noninvasive hemodynamic assessment in 
heart failure has been either unreliable or difficult to obtain. 
Bioimpedance relies on the proportional change in the con-
duction of alternating current applied across the thorax as 
a function of blood volume in the heart and great vessels. 
Stroke volume, CO, thoracic fluid volume and measures of 
diastolic function can be determined with bioimpedance, 
but the presence of extravascular lung fluids significantly 
impacts the validity of the readings. Although not generally 
utilized in critical care, the use of bioimpedence has been 
strongly supported in outpatient clinics and emergency 
departments. 
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Volumetric End-Tidal CO 2. Any gas that diffuses across the 
alveolar capillary membrane can be utilized in the Fick cal-
culation. Continuous monitoring of end-tidal CO 2 (PETCO 2)
reflects the arterial partial pressure of CO 2, and minute venti-
lation is used to calculate the actual estimated CO 2 production. 
The rate of CO 2 clearance is then used to estimate perfusion, 
and correction testing is done to eliminate alterations in venti-
lation as a CO 2 source. This methodology utilized in intubated 
patients, evaluates only the blood flow that is processed and 
does not include shunted blood; therefore, in shunt disease 
states, the accuracy of actual CO may underestimate cardiac 
function and volume indicators. 
Esophageal Doppler Probes. Using a Doppler transducer on 
the tip of a probe, the esophageal Doppler measures aortic 
blood velocity that is then converted into systemic stroke 
volume. Recent studies advocate the use of Doppler technol-
ogy to evaluate fluid resuscitation in high-risk patients and 
have been correlated to improved outcomes. Compared with 
ultrasound transit time measures, the esophageal Doppler 
has accurately evaluated the aortic blood flow and therefore 
the left ventricular (LV) stroke volume. The probe may be 
placed by a qualified ACNP; however, even with experienced 
clinicians, accurate placement and position may be difficult 
to achieve and maintain. 
The Arterial Pressure Wave. Arterial waveform analysis uses 
the complete pressure waveform for analysis and and to pre-
dict stroke volume. The shape of the waveform, the systolic 
component, velocity, ejection time, arterial resistance (age, 
gender, and weight based) and the overall pulse pressure 
are all indicators that should be considered. These measure-
ments rely on an intact arterial catheter, a transducer system, 
and a viable waveform. Different products offer a different 
palate of calculated measures in addition to CO, stroke vol-
ume (standard and indexed), and stroke volume variabil-
ity (see Figure 9.11). Additional measures depend on either 
operator input of fixed values (Hgb, hematocrit [Hct], central 
venous pressure [CVP]) or direct measurements that are 
either required (central line) or independent (central line 
with oximetry or input data). Some of the available  methods
require external calibration using an indicator washout curve 
or thermodilution. 
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Monitoring Pressures and Assuming Volumes. CVP, which 
estimates the right ventricular (RV) EDP, is considered less 
invasive than intrapulmonary artery monitoring and may 
also be utilized to provide direct oxygenation information 
that allows for Fick calculation of CO and other measures 
designed for goal direction in therapy. Normal CVP is tradi-
tionally 4–8 mmHg; however, when treating patients who are 
in a pre-shock or shock state, CVP goals may need to be driv-
en higher (8–12 mmHg or higher when there is evidence of 
compliance loss of the ventricle) (Hofer et al., 2005; Kincaid, 
Meredith, & Chang, 2001; Kramer, Zygun, Hawes, Easton, & 
Ferland, 2004; Michard et al., 2003; Rivers et al., 2001) Normal 
or high CVP measurements must be evaluated cautiously, as 
pressure may not be an accurate predictor of actual preload 
volume. 
An indwelling arterial catheter allows for beat-to-beat 
determination of blood pressure, pulse volume or pressure 
(which trends with cardiac stroke volume), mean arterial 
pressure, arterial blood gases, and arterial based CO monitor-
ing. The catheter is never used for infusion of any medications 
or fluids and must be continuously monitored via a special-
ized pressure monitoring setup. The calculation of the mean 
is based on area under the curve and is most significantly 
effected by diastolic pressure and time (heart rate effect). 
Recently, the effects on variation of systolic pressure 
and/or stroke volume related to pleural and thoracic pres-
sure changes have received significant notice as indicators 
9.11
Pulse Pressure=
Systole-Diastole
Normal: 30-40 mmHg
Arterial Waveform Analysis
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of both tension development and volume responsiveness 
in critical patients on positive pressure ventilatory support. 
There is increasing interest in the evaluation of the inspira-
tory effects on the arterial pulse pressure in order to predict 
the probable hemodynamic response to a fluid challenge. 
This variation reflects the ability of the ventricular system to 
maintain optimum ejection despite changes in pleural, tho-
racic, and myocardial pressure (Figure 9.12). 
The cyclic variations in intrathoracic and pleural pres-
sure during positive pressure breaths produce corresponding 
variations in the central venous and arterial waveforms (De 
Waal, Rex, Kruitwagen, Kalkman, & Buhre, 2008). The intra-
thoracic pressure is transmitted to the vascular space and 
affects the intravascular pressure by altering the compliance 
of the ventricles. The digital reading of the filling pressures 
during inspiration will vary accordingly and may profoundly 
misrepresent volume load. In general, low intravascular 
9.12
Stroke Volume Variation with Positive Pressure Ventilation
ArterialPressure
Time
Inspiration
Controlled Ventilation
Expiration
Controlled Ventilation
VentilatorPressure
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volume will be accompanied by a significant reproducible 
drop in pressure, stroke volume when positive inspiratory 
pressures are applied. The variable of inspiratory pressure 
must be controlled in order for the reduction of pulse volume 
following the positive pressure breath to be meaningful. 
 Monitoring Tissue Oxygenation 
The more recent development of a centrally placed triple 
lumen catheter with an oximeter on the tip is significantly 
less invasive than the PA and allows clinicians to actually 
evaluate tissue oxygenation in both the ICU and non-ICU 
environment. This tool assists in directing goals toward 
tissue perfusion rather than blood pressure. Because tis-
sue oxygenation is so profoundly affected in patients with 
shock, it becomes the most meaningful indicator, even in the 
presence of normal blood pressure (it is important to remem-
ber that central or mixed venous monitoring reflects global 
oxygenation, not regional or local). Some organs may still be 
hypoperfused in the face of a normal ScvO 2 or SvO 2.
The measurement of the (de)saturation of Hgb reflects 
the dissociation of oxygen, a function that uniquely occurs 
in an environment where the cells are using oxygen and 
perfusion is optimized. As the red cells deform and flow into 
the capillaries a constant dissociation occurs when the capil-
lary partial pressure of oxygen decreases as the cells uptake 
oxygen. Measurement of the saturation of Hgb in the cen-
tral vein at right atrial inflow provides a view of the leftover 
oxygen still bound to the hemoglobin. As the Hgb, via blood 
flow, moves into the right atria and mixes with the acutely 
desaturated Hgb from the coronary sinus (the myocardium) 
and the inferior vena cava (IVC), the blood mix mobilizes 
into the right ventricle, mixes again, and is ejected into the 
pulmonary artery. The monitoring and evaluation of central 
venous oximetry (ScvO 2, measured just before the inflow 
vessel of the right atrial via a triple lumen catheter with an 
oximeter on the distal tip) has been significantly popularized 
since the work of Rivers (2001) was published. Two of the 
unique components of this study were the instrumentation 
and measurement of central venous oximetry in the emer-
gency department. The study also hypothesized the promo-
tion of increased oxygen delivery with the end goal of tis-
sue oxygenation prior to (if possible) a mitochondrial failure 
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state, such as occurs in severe sepsis, as a method of pre-
vention rather than intervention. Normal values range from 
65%–85% and should always be evaluated and treated when 
persistently below 70%. Any sustained decrease in the ScvO 2
should be considered as a compensatory mechanism (shift to 
the righ of the oxyhemoglobin dissociation curve) and is evi-
dence that the patient is in a critical state, sustained only by 
their oxygen reservoir. The goal is to maintain the reservoir 
at a normal level, therefore always having an adequate pro-
tective mechanism. However, ACNPs should be aware that 
normal values of ScvO 2 may be misleading in the presence of 
microcirculatory deficits. 
 Concerning Adequacy of Tissue Oxygenation 
To objectively and proactively identify the patient at risk, the 
traditional parameters, heart rate, blood pressure, respira-
tory rate, urine output, the monitoring of the saturation of 
continuous central or mixed venous Hgb, and serum creati-
nine should be correlated to the most available and simple 
method of confirming appropriate tissue oxygenation is the 
serial evaluation of lactic acid and the anion gap. 
Lactic Acidosis. Arterial lactate concentration is dependent 
on the balance between its production and clearance. In the 
critically ill septic population, increased glucose metabolism, 
increased energy expenditures and profound catabolism are 
the norm (Tappy & Chiolero, 2007; Revelly et al., 2005). The cor-
responding lactic acidosis signals physiologic stress, but may 
not necessarily be evidence of tissue hypoxia. The concomi-
tant energy expenditures, along with metabolic dysfunction, 
will increase lactate production. These conditions, in addition 
to an exaggerated inflammatory response and increasing oxy-
genation dysfunction at the tissue level, combine to produce 
a profound tissue acidosis. The lactate production is further 
increased via other abnormal pathways specifically related to 
metabolic dysfunction, even in the absence of tissue hypoxia 
(Type B lactic acidosis). The main cause of the significantly 
increased lactate is unknown (Table 9.4), but one factor that 
contributes to lactic acidosis is the failure of adenosine triphos-
phate (ATP) production that clearly occurs in the presence of a 
profound oxygen supply–demand imbalance (Type A lactic aci-
dosis). The mitochondrial ability to utilize pyruvate, is indicative 
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of a profound metabolic hyperlactatemia, an elevated lactate/
pyruvate ratio, increased glucose, and low-energy production. 
Always be aware dynamic liver clearance of lactate may mask 
this disturbing trend. 
Ultimately, as severe sepsis progresses and evolves, a 
mediator induced cardiac failure, or profound intra-arterial 
hypovolemia occurs. The presence of elevated lactate levels 
should be treated first with volume resuscitation (20 ml/kg of 
isotonic crystalloids, with continued volume resuscitation as 
Lactic Acid Checklist
Nonhypoxic Problem Problem Hypoxic
Lactic Metabolic Regional/local (Ischemic)
Acidosis Dysfunction Hypoperfusion Lactic Acidosis
Liver Dysfunction υ υ Cardiogenic Shock
Renal Dysfunction υ υ Hypovolemic Shock
Malignancies υ υ Hemmorrhagic 
    Shock
Accelerated  υ υ Hyperglycemic 
Aerobic    Hyperosmolar 
Glycosis DKA    Syndrome
Methanol, Ethanol υ υ Severe Pulmonary 
    Dysfunction
Antiretrovirals, INH υ υ Carbon Monoxide 
    Poisoning
Cyanide Poisoning υ υ Cardiac Arrest
Valproic Acid υ υ Any Condition 
    Where Oxygen 
    Delivery is 
    Inadequate
Early Sepsis υ υ Severe Sepsis
Pyruvate   Profound Tissue 
Dehydrogenase    Hypoxia and
Defi ciency    metabolic 
    dysfunction
9.4 Common Causes of Elevated Lactate in Acute and Critical Patients
346 Critical Care
necessary). It may be necessary to support the CO with low-
dose inotropes to prevent the evolution of profound tissue 
hypoxia. Goal: Lactate < 2.0 mEq/L, ScvO 2 ≥ 70%. 
Single lactate measurements are not significantly ben-
eficial in the continued treatment and evaluation of severe 
sepsis (Nguyen et al., 2004). In patients with sepsis, persistent 
hyperlactatemia has been linked to mortality and morbid-
ity (Levraut et al., 1993). Bakker et al., coined the phrase “lac 
time” as the time during which lactate remains >2 mmol/L and 
observed that this duration of lactic acidosis was predictive of 
organ failure and survival. Nguyen et al., proved a  significant 
correlation between normalization of elevated lactate in the 
first 24 hours of therapy and survival (100%), regardless of 
whether or not metabolic deficits or profound hypoxia (or a 
combination thereof) were the primary causes. 
Anion Gap. Metabolic acidosis is a condition that generally 
occurs from an addition of H +, the primary expression of 
tissue respiration and metabolism (normal and abnormal). 
The increased H+ binds to bicarbonate causing a fall in the 
primary serum bicarbonate level, In this simple chemical 
and reversible equation, H + represents tissue acid, bicarbon-
ate (H 2C03) represents the primary buffer, CO 2 represents the 
gaseous carbonic acid, H 2O: water, and HCO 3 (carbonic acid) 
represents the traditional combination of the acid and the 
neutralizing components. The level of carbonic acid inversely 
affects the pH. Initially, in most metabolic acidotic environ-
ments, hydrogen goes up, bicarbonate goes down, carbonic 
acid increases and shifts to the H 20 and CO 2 side. As long 
as the patient can hyperventilate, the increased CO 2 will be 
blown off and the pH should be compensated. 
(H+ + HCO 3−) ↔ H 2CO3 ↔ (H 2O + CO 2)
For every 1 mEq/L drop of HCO 3−  below 25, the p aCO2
should decrease by ∼1 torr in order to compensate for the 
increase in metabolic acid. Therefore a compensatory p aCO2
in the face of HCO 3− of 10 would be around 25 mmHg. If the 
pH is not normalized because of failure of the opposing sys-
tem to adequately regulate the offending product, that is 
known as a mixed disorder. 
The combination of metabolic acidosis with a widening 
of the serum anion gap (AG) is one of the most important 
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confirmation of metabolic acidosis. Extreme elevations of 
the AG is predicated on the concept of physiological elec-
troneutrality: the assumption that the sum of all available 
cations (positively charged ions) is equal to the sum of all 
available anions (negative charged ions). This is quite sim-
ply evaluated as 
(Na)+ − (Cl − + HCO3) = AG = 12−14. 
A wide gap can appear in various clinical settings and 
are usually associated with serious metabolic problems. The 
by-product of tissue respiration is hydrogen ion (+). Hydrogen 
binds to the bicarbonate (or serum CO 2) and chloride causing 
a decrease in the measured anions. This now will produce a 
“gap” in the measured cations and anions (Table 9.5). An AG 
of >20 mEq/L is suggestive of ketoacidosis and/or lactic aci-
dosis. The anion gap is only performed when confirming or 
evaluating metabolic acidosis. 
Serum albumin contributes ∼one half of the total anion 
equivalency of the the unmeasured anion pool.  Assuming 
normal electrolytes, a 1 gm/dl decline in serum albumin 
increases the AG measurement by 3 mEq/L and needs to be 
accounted for and manually corrected when suspicious of 
the patient’s condition (Rocktaeschel et al., 2003; Kaplan & 
Kellum, 2004). 
Therefore an AG of 12 mEq/L is corrected to 17–18 mEq/L 
when the serum albumin is half of normal; this is an important 
correction factor in settings of chronic illness, malnourished 
patients, or in the hypermetabolic stress response of severe 
sepsis. 
Endogenous Acidosis Wide Gap
Uremia (uncleared organic acids) No
Ketoacidosis Yes
Lactic acidosis (increased  Yes
organic acid production)
renal failure Not necessarily
9.5 Gap and Acidosis
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The normal value of lactate identified by Shoemaker (1998) 
is <2.5 ml/dl. However, more recent literature tells us to be vigi-
lant in any individual with a lactate level >1.5 ml/dl (Nguyen, 
2004). In mediator shock, (as in anaphylaxis or severe sepsis) 
the presence of normal to elevated SvO 2 in the face of persis-
tent lactic acidosis is an ominous sign and requires immediate 
resuscitation. 
The value of lactate is obviously limited due to lactate 
concentrations that are affected by both production as well 
as elimination. Individuals who have hepatic dysfunction 
and hypoperfusion may have higher lactate levels than the 
person who does not have liver disease, and both may have 
a significant degree of stress. Therefore, lactate levels by 
themselves will not give as much beneficial information as 
those in the presence of wide anion gap and low or normal 
ScvO2.
Recently, Nguyen et al., (2004) validated that the higher 
the clearance of lactate in the first 6 hours after resuscitation, 
the more significant the reduction in mortality. The statistical 
significance of improved survival for individuals who could 
clear their lactate levels >10% in the first 6 hours of resus-
citation was sustained across all cause mortality at 60 days 
out. In those first hours following resuscitation, achieving 
a normal ScvO 2 along with increasing lactate clearance is a 
desired therapeutic end point and achieving these endpoints 
safely and rapidly may significantly reduce the potential for 
multiple organ dysfunction. 
 Shock and MODS 
The two overarching categories of shock: Oxygen Delivery 
and Oxygen Use failures generally present with tachycardia, 
hypotension, and even lactic acidosis. The limitation of these 
presentations depends on the patient’s history and medica-
tion regimen (for example, beta-blocker therapy). Extreme 
caution must be utilized when evaluating patients presenting 
with shock. As a compensatory mechanism, a surge in cate-
cholamines and neural regulation maintains arterial pressure 
via a regional vasoconstrictive response and tachycardia may 
sustain or increase the cardiac indices, although the actual 
ventricular efficiency may be depressed. This response may 
mask how serious the situation is. 
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The more traditional divisions of cardiogenic, hypovo-
lemic, and hemorrhagic shock can be classified as failure of 
the mechanics of oxygen delivery. This failure includes three 
basic oxygenation delivery parameters including CI, Hgb, 
and Hgb saturation as well as pure vascular tonal deficits 
(such as acute spinal cord injury, anaphylaxis, vasodilator 
overdose, severe sepsis). The therapies involved are rela-
tively traditional and are aimed at restoring oxygen delivery 
to a normal level in respect to oxygen demand. Patients with 
mechanical shock will compensate via sympathetic discharge 
and a catecholamine surge, shifting blood away from nones-
sential organs to essential organs. The nonessential organ 
uses <50% of oxygen delivered to them and are generally 
not profoundly affected by a short period of ischemia. The 
redirected blood flow sustains the oxygen dependent organs, 
including the heart, the brain, and the lung parenchyma as 
well as the diaphragm. 
 Hypovolemic Shock 
Hypovolemic shock occurs when either total body, intravas-
cular or intra-arterial volumes are significantly decreased. 
This depletion may be a result of hemorrhage, which not 
only affects the volume load, but also the oxygen carrying 
capacity associated with the Hgb. Loss of effective arterial 
volume can occur with third-space losses, salt-wasting disor-
ders, diabetic shock syndromes (diabetic ketoacidosis [DKA] 
and hyperosmolar hyperglycemic state [HHS]) vomiting, 
diarrhea, and/or dehydration. The hemodynamic findings in 
hypovolemic shock are typically tachycardia, decreased CO, 
decreased stroke volume, narrow pulse pressures, increased 
calculated SVR, normal to low ventricular filling pressures, 
and a very low SvO 2. When hemorrhage is the culprit, the 
Hgb and Hct may underpredict the severity of bleeding as 
those two measures might be affected by the concurrent 
dehydration. Index of suspicion and serial Hct, as well as 
BUN and creatinine measures, may differentiate bleeding 
from pure hypovolemia, particularly after volume resusci-
tation, as hemorrhagic shock may initially be misconstrued. 
Postural vital signs should be measured in the upright or 
semi-Fowler’s position, with narrowing pulse pressure and 
tachycardia noted as one of the primary signs of decreased 
CO and compensatory vasoconstriction. 
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The primary compensatory mechanism is to conserve 
oxygen for the essential organs and allow the nonessential 
organs to generate some metabolic failure, lactic acidosis, and 
hydrogen ion accumulation. In the inadequate delivery state, 
the essential organs, to escape ischemia and infarction, will 
maintain the level of oxygen consumption necessary for pres-
ervation via dissociation of oxygen. The evaluation of venous 
Hgb saturation via continuous monitoring SvO 2 or ScvO 2 deter-
mines the reservoir level and facilitates the therapeutic goal of 
reducing tissue demands and improving oxygen delivery. 
When the oxygen saturated Hgb in the continuous cen-
tral or mixed venous compartment is less than normal, the 
issues are clear: demand is higher than supply can keep up 
with. There are three common issues with oxygen delivery 
and tissue demand: decreased content, decreased CO/CI, and 
increased demand. The inability of oxygen delivery to match 
oxygen demand (consumption) will result in a desaturation of 
Hgb (Rivers, 2001). As tissue demand exceeds the arterial sup-
ply (supply–demand imbalance), Hgb will more aggressively 
desaturate to maintain tissue consumption, causing a drop in 
the measured venous saturation of Hgb (SvO 2/ScvO2). Along 
with more traditional parameters (MAP, heart rate, respiratory 
rate, CVP, pulse pressure, or stroke volume and the correspond-
ing variation), this shift to the right provides a therapeutic end 
point and a window of opportunity for therapy. 
 Relative Hypovolemic Shock 
Distributive. Relative hypovolemic shock occurs primarily 
when sympathetic tone is lost (as in acute spinal cord injury), 
when there is a profound mediator vasodilation syndrome 
(Anaphylaxis an late Sepsis or septic shock) or as an inci-
dental symptom in acute acidostic environments (pH < 7.25), 
hypokalemia, and hypocalcemia states. As loss of vascular 
tone ensues, there is a substantial inability to maintain capil-
lary perfusion pressures, and the compensatory mechanism 
will be assisted by a neuroendocrine mediated cardio renal 
response designed to preserve volume and increase CO. If 
sympathetic tone is lost or opposed, as in acute spinal cord 
injury, the failure of the cardiac compensatory response (rela-
tive bradycardia in an acute hypotensive state) must alert the 
clinican to the potential for cell death. When there is opposi-
tion at the vascular surface, as in histamine-related anaphy-
laxis or mediator (such as nitric oxide) induced vasodilation, 
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the cardiac compensation is generally inadequate to maintain 
blood pressure, as the volume input from LV ejection cannot 
supplant the vascular tonal requirement for blood pressure 
management. This is frequently known as distributive shock, 
an uncontrolled vascular dilation with inability to shunt 
bloods adequately towards the oxygen dependent organs 
(heart, brain, lung parenchyma, and kidney, in that order). 
 Microcirculatory and Mitochondrial 
Unlike all the other forms of shock, this unique process 
presents with increasing evidence of lactic acidosis and 
organ dysfunction in the face of an initial increase in oxy-
gen delivery. With adequate volume and an initially normal 
cardiac function, primary compensation is to increase the 
CO. As time progress, the inverse relationship between 
measured CO and the increasing SvO 2 (indicating available, 
unutilized oxygen) coupled with the evidence of tissue dys-
function (organ indicators, increasing lactic acidosis) com-
plicates the treatment and resolution of severe sepsis. 
Early stages were previously known as compensated or 
warm shock and the later stage, which is similar to cardio-
genic shock (and in fact may be heart failure), as late, cold, or 
decompensated shock. The critical point is early recognition 
and intervention during the compensatory stage, to limit endo-
thelial and mitochondrial, and therefore organ, dysfunction. 
The development of critical hypotension, unresponsive to fluid 
resuscitation in the face of SIRS and index of  suspicion, may 
actually portend vascular tonal loss. Tonal loss most frequently 
occurs with acidotic environments, hypocalcemia and endo-
thelial production of nitric oxide. In these situations, the patient 
may be refractory to α stimulation type vasopressors. After 
volume resuscitation, vasopressor management, and evalua-
tion and treatment of the first two conditions, consideration of 
continuous intravenous vasopressin or IV bolus dose cortisol, 
which may potentiate vascular tone, should be considered. 
 Summary 
In the severely septic state, circulating mediators, and com-
municators change the capillary integrity and cause capillary 
leak, promoting microcoagulopathies in multiple small ves-
sels, therefore, limiting the ability of the Hgb to move into the 
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capillary and release the oxygen. Proinflammation, procoagu-
lation, endothelial dysfunction, and neutrophil sequestration 
are the hallmarks of septic shock. Despite an adequate Hgb 
level and often times an increased CI, the microcirculatory 
blood flow is limited by nondeformable red blood cells, fibrin 
clots, and platelet plugs. This condition sets up a systemic 
shunt, or a shift to the left of the oxyHgb dissociation curve, 
in the face of significant tissue level hypoxia. That ongoing 
tissue hypoxia perpetuates and sustains more inflammatory 
stimulation. Vasopressors and uncontrolled hyperglycemia 
may also impact the capillary dynamics, therefore, the early 
compensatory mechanism is to increase the CO. 
The tissues signal for sympathoadrenal response as tis-
sue hypoxia and lactic acidosis mounts. Despite available 
oxygen reservoirs (reflected by normal to elevated SvO 2 or 
ScvO2), there is an ongoing state of microcirculatory deficits, 
evidenced by increasingly elevated lactate levels, wide anion 
gap, base deficit, and evolving organ dysfunction. As the 
oxygen delivery increases (via increasing CO) to meet tissue 
demands, the proportional oxygen extraction (S aO2 – ScvO 2/
SaO2) ratio will decrease. In the most basic sense, the patient 
needs and has oxygen, but is not using it proportionately.
At this point, the effect on the oxyHgb curve may be very 
misleading. Despite persistent lactic acidosis, these patients 
may present with a normal to high normal or even high SvO 2.
Along with more traditional measurable parameters, this 
shift to the left in the presence of lactic acidosis provides a 
window for therapy. In severe sepsis and septic shock, the 
primary compensatory mechanism is to increase the deliv-
ery of oxygen primarily via an increase in CO. The cardiac 
response relates to the systemic microcirculatory shunt and 
the compounding tissue hypoxia. However, the more oxygen 
delivery increases, the more profoundly one may see a failure 
of oxygen utilization. Our earliest identification of patients at 
risk may well be related to these global indicators of tissue 
perfusion. A mixed venous or central monitoring technique 
will communicate the availability of reserve oxygen, whether 
or not it has been appropriately utilized, and lactic acid levels 
will differentiate the adequacy of the oxygen dissociation. 
The identification of the early subtle and less subjective 
indicators of hypoperfusion is critical. When delivery of oxy-
gen is poor or inadequate to meet the cellular needs, there will 
be a significant drop in the ScvO 2 or SvO 2. This is generally 
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accompanied by rapid heart rate and/or rapid respiratory rate. 
Coupled with an increasing lactic acidosis and wide anion gap, 
these parameters warn of impending danger and possible 
severe organ dysfunction. This patient requires very focused 
early goal direction aimed at tissue perfusion. 
The patient in mediator shock is even more difficult to 
diagnose in the early stages, presenting initially with delivery 
dependent consumption and then spiraling toward an extrac-
tion deficit. The elevated ScvO 2 with persistent lactic acidosis 
forewarns the possibility of a microcirculatory deficit. 
In summary, individuals with primary delivery deficit will 
traditionally have a low SvO 2 or ScvO 2 and may or may not have 
elevated lactate. Without early aggressive resuscitation, a severe 
lactic acidosis will develop. The mediator shock syndrome, in the 
earliest stage presents with a low ScvO 2, but later presents with 
normal to elevated SvO 2 or ScvO 2. Hgb desaturates to maintain 
cellular oxygenation when demand is high and delivery poor. 
In the inverse, the Hgb does NOT desaturate when demand is 
low, delivery is high, or there are microcirculatory deficits. The 
astute provider evaluates the venous saturations in the pres-
ence of serial lactic acid levels, determining whether or not the 
patient has an adequate reservoir of oxygen. 
Supporting tissue demand and providing stability, prior 
to endothelial damage may prevent end organ death. The 
ability to closely monitor the oxygen delivery, the release 
of oxygen from the Hgb and the adequacy of both forms 
of compensation via serial lactic acid levels and anion gap 
facilitates earlier, more appropriate therapies for the acute 
patient at risk for MODS. 
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 Introduction 
Critically ill patients experience metabolic changes that 
include hypermetabolism, and net protein catabolism that 
can lead to depletion of lean body mass. (American Soci-
ety for Parenteral and Enteral Nutrition [A.S.P.E.N.], 2002). 
The goal of nutrition support in the critical care setting is 
to minimize nitrogen losses. Critically ill patients requiring 
nutritional support must be monitored closely because both 
underfeeding as well as overfeeding can result in adverse 
outcomes. This chapter reviews metabolism, fluid, electrolyte, 
and nutrient needs, and nutrition support therapies for criti-
cally ill patients. 
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 Metabolism 
The metabolic response to conditions leading to critical 
illness is divided into three phases: shock/resuscitation, 
acute catabolic, and anabolic. During the shock/resusci-
tation phase, patients are hypometabolic. The reaction 
to the initial insult or injury leads to low cardiac output, 
hypotension, reduced oxygen consumption, poor tissue 
perfusion, and eventual shock. Lower energy expenditure 
and low insulin levels also occur. After 24–48 hours, the 
acute catabolic phase ensues with a sharp rise in counter-
regulatory hormones (glucagon, cortisol, epinephrine, and 
norepinephrine). 
During the acute catabolic phase, the rise in glucagon 
stimulates glycogenolysis and gluconeogenesis, (Chiolero, 
Revelly, & Tappy, 1997). An increase in production of proin-
flammatory cytokines such as tumor necrosis factor (TNF), 
and interleukins (IL) 1, 2, and 6 also leads to many of the 
changes that occur during this phase (Hill, 2000). Protein 
becomes a preferred energy source resulting in increased 
proteolysis and ureagenesis and protein losses cannot be 
corrected with nutrition support (Cerra, Siegel, & Coleman, 
1980). Oxygen consumption and energy expenditure rise, 
and significant catabolism occurs. 
The metabolic response is a key part of the systemic inflam-
matory response syndrome (SIRS) and about 50% of critically 
ill patients have SIRS (Brun-Buisson, 2000). SIRS is defined as 
having two of the following (Muckart & Bhagwanjee, 1997): 
 ■ Temperature > 38°C or <36°C 
 ■ Heart rate > 90 beats/min 
 ■ Respiratory rate > 20 breaths/min or PaCO2 < 32 torr 
 ■ WBC > 12,000 cells/mm 3 or <4,000 cells/mm 3, or >10% 
immature band cells 
During the anabolic phase, counter regulatory hormones 
and energy expenditure return to normal levels. Additional 
energy may be needed to replenish losses or support the 
increases in activity. Patients often still require nutritional 
support therapy while they begin their transition back to a 
regular diet. 
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 Nutrient Requirements 
Energy. Assessment of energy needs in the critically ill 
patients continue to be challenging to clinicians, especially 
in patients with extremes of age or body size. Failure to meet 
caloric needs can impair wound healing, organ function, 
and immune function (Cresci & Martindale, 2000), whereas 
excess calories can result in azotemia (Gault, Dixon, Doyle, 
& Cohen, 1968), electrolyte abnormalities, hepatic steato-
sis (Kaminski, Adams, & Jellinek, 1980), hyperglycemia 
(Rosmarin, Wardlaw, & Mirtallo, 1996), pulmonary compro-
mise (Askanazi, Elwyn, Silverberg, Rosenbaum, & Kinney, 
1980; Covelli, Black, Olsen, & Beekman, 1982), and failure 
to wean from the mechanical ventilator (Dark, Pingleton, & 
Kerby, 1985) .
The use of indirect calorimetric methods to measure 
energy expenditure are the gold standard for determin-
ing energy needs. However, conducting these tests requires 
time, expensive equipment, and well-trained personnel to 
conduct the study and interpret the results. Because not 
all health care facilities are equipped to conduct indirect 
calorimetry studies, several equations have been developed 
to predict the energy needs of critically ill patients. Over 
100 different predictive equations are available for use, 
but clinicians must find the equation that best meets the 
patient’s needs. 
Based on the current research, the American Dietetic 
Association’s Critical Illness Guidelines recommend 
equations that have the highest predictive accuracy in 
the critically ill patients. Recommended predictive equa-
tions are shown in Table 10.1. Those no longer recom-
mended for use include the Harris–Benedict equation 
(with or without stress factors), the 1997 version of the 
Ireton–Jones equation, and the Fick method. In addition, 
the Mifflin–St. Jeor equation, which is recommended to 
determine energy needs in the healthy population, has 
not been validated for use in the critically ill population 
(Frankenfield, Hise, Malone, Russell, Gradwell, & Com-
pher, 2007). Predictive equations recommended for use to 
predict energy needs of the critically ill obese patient are 
shown in Table 10.1. 
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Critically Ill Patients
Penn State 
Equation (2003a)
EE = HBEE (0.85) + VE (33) + Tmax (175) − 6433
Swinamer EE = 945 (BSA) − 6.4 (A) + 108 (Temp) + 24.2 (f) +
817 (VT) − 4349
Ireton–Jones 
Equation (1992)
EE (v) = 1925 − 10(A) + 5 (W) + 281(S) + 292(T) +
851(B)
EE (s) = 629 − 11(A) + 25(W) − 609(O)
Critically Ill Obese Patients
Ireton–Jones 
(1992)
EE (v) = 1925 − 10(A) + 5 (W) + 281(S) +
292(T) + 851(B)
EE (s) = 629 − 11(A) + 25(W) − 609(O)
Penn State 
(1998)
EE = HBEE(1.1) + VE(32) + Tmax(140) − 5340
 EE = energy expenditure; HBEE = Harris–Benedict energy expenditure; V E = minute ventilation 
(liters per minute); T max  = maximum temperature (degrees Celsius); BSA = body surface area 
(m2 ); Temp = current temperature (degrees Celsius); f = respiratory rate (breath per minute); 
VT = tidal volume (liters per minute); s = spontaneously breathing; A = age (years); W = weight (kg); 
O = obesity (present = 1; not present = 0); v = ventilated; S = sex (male = 1; female = 0); T = 
trauma (present = 1; not present = 0); B = burn (present = 1; not present = 0). 
 Source : Frankenfi eld, D., Hise, M., Malone, A., Russell, M., Gradwell, E., & Compher, C. 
(2007).  Prediction of resting metabolic rate in critically ill adult patients: results of a sys-
tematic review of the evidence.  Journal of the American Diatetic Association , p. 1552 . 
10.1 Predictive Equations Used to Predict Calories Needs
Hypocaloric feeding regimens have gained attention in 
recent years, particularly in the obese population. Studies 
of hypocaloric regimens in obese patients have found that 
patients achieve positive nitrogen balance (Dickerson, 
Rosato, & Mullen, 1986), heal wounds (Dickerson, Rosato, 
& Mullen, 1986), and have better glucose control (Cho-
ban, Burge, Scales, & Flancbaum, 1997), shorter length of 
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stay (LOS) in ICU, and shorter duration of antibiotic days 
(Dickerson, Boschert, Kudsk, & Brown, 2002). There is no 
agreed-upon definition of hypocaloric feeding regimens, but 
the studies have used anywhere from 50% of the patients’ 
measured energy expenditure (MEE) to 14 cal/kg actual 
weight or <20 cal/kg adjusted ideal body weight. All of the 
studies provided approximately 2.0 grams protein/kg ideal 
body weight. Initial studies are promising, and A.S.P.E.N. 
suggests the use of hypocaloric feeding regimens with 
supplemental protein in mild to moderately stressed obese 
patients (A.S.P.E.N., 2002); however, it is not yet known 
whether this can be applied to other patient populations 
including the nonobese. One study in the nonobese popu-
lation did not find benefit to hypocaloric total parenteral 
nutrition (TPN) regimens (McCowen et al., 2000). An addi-
tional observational study linked more infectious complica-
tions to critically ill patients with the greatest cumulative 
energy deficit (Villet et al., 2005). 
Carbohydate. Carbohydrates are the main source of calories 
in most diets and provides energy to all cells in the body, pro-
viding 4 cal/g. Cells in the central nervous system (e.g., brain) 
and those that rely on anaerobic glycolysis (e.g., red blood 
cells) have an absolute carbohydrate requirement (Otten, 
Hellwig, Meyers, 2006a). 
Underfeeding carbohydrates in critically ill patients 
further exacerbates protein breakdown. Without adequate 
carbohydrates, adipose and muscle tissue are broken down 
and are used as fuel source, entering gluconeogenic path-
ways to provide glucose to the body. Protein catabolism 
leads to loss of skeletal muscle mass and loss of body pro-
teins, which may lead to impaired immune response and 
poor wound healing. 
Excessive carbohydrates in critically ill patients affects 
glycemic response, respiratory function, and long term liver 
function. Hyperglycemia causes a rise in insulin levels that 
can shift electrolytes intracellularly (e.g., potassium and phos-
phorus), and this is reflected by a drop in serum levels. Excess 
carbohydrate intake has also been reported to contribute to 
respiratory distress (Askanazi et al., 1980), hypercapnia dur-
ing weaning from mechanical ventilation (Dark et al., 1985), 
and respiratory failure (Covelli et al., 1982). Death has been 
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reported as a complication of overfeeding (75 kcals/kg per day 
as carbohydrate) in malnourished patients (Weinsier & Krum-
dieck, 1981). Potential signs of overfeeding include increased 
carbon dioxide (CO 2) production, increased minute ventila-
tion, difficulty weaning from the ventilator, acute respiratory 
acidosis or metabolic alkalosis, and a respiratory quotient 
(RQ) >1.0 (Klein, Stanek, & Wiles, 1998). When overfeeding 
is suspected, a reduction in carbohydrate and total calories 
may prevent respiratory compromise (Talpers, Romberger, 
Bunce, & Pingleton, 1992). Patients at risk of being overfed are 
the elderly, those with unusual body sizes (malnourished or 
extremely obese), and those on dialysis using a dialysate con-
taining dextrose (Klein et al., 1998). 
The adequate intake established for carbohydrates is 
130 g/day (Otten et al., 2006a). Additional suggestions for 
carbohydrate intake in critically ill patients range from 
30% to 70% of total calories (Cerra et al., 1997). Critically ill 
patients should receive no more than 4 mg·kg −1·min−1 of car-
bohydrates. For burn patients, no more than 5 mg·kg −1·min−1
is acceptable (Jacobs et al., 2004). It has been suggested to 
limit this to 2.5–4.0 mg·kg −1·min−1 in patients with hypergly-
cemia or those receiving steroid therapy (Klein, Stanek, & 
Wiles, 1998). Additional suggestions are to limit dextrose to 
100–150 g/day in malnourished patients who are at risk of 
developing refeeding syndrome (Chan, McCown, & Black-
burn, 1999). The ideal dose of carbohydrates is the amount 
that can allow for maximal protein sparing while minimizing 
hyperglycemia. 
Fat. Fat is a concentrated source of energy providing 9 cal/g. 
It functions in cell signaling and helps with absorption of fat 
soluble vitamins (Otten, Hellwig, & Meyers, 2006b). The only 
essential fatty acids are linoleic acid and alpha-linolenic acid. 
Limiting fat can impair growth in children. When com-
bined with inadequate intake of carbohydrate and protein, 
a negative energy balance develops leading to malnutrition. 
Insufficient fat intake can lead to essential fatty acid defi-
ciency. Three weeks of TPN without added fat was reported 
to result in essential fatty deficiency (EFAD) (Richardson & 
Sgoutas, 1975). Signs and symptoms of EFAD include scaly 
dermatitis, alopecia, thrombocytopenia, anemia, and impaired 
wound healing; the deficiency can be confirmed by checking 
a triene-to-tetraene ratio. 
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Excess fat intake may lead to hypertriglyceridemia. 
Overfeeding parenteral sources of fat may also contribute to 
immunosuppression, because the omega-6 fatty acids desat-
urate and elongate to form arachidonic acid, a precursor to 
proinflammatory eicosanoids (Alexander, 1998). The use of 
sedatives such as propofol are provided in a lipid emulsion 
providing 1.1 cal/ml, which contributes to fat and total calo-
rie intake of critically ill patients. Any long-term use of this 
sedative requires adjustments be made to the nutrition regi-
men to avoid overfeeding fat and total calories. 
The acceptable macronutrient distribution range for total 
fat is 20% to 35% of total calories (Otten et al., 2006b). At least 
2% to 4% of total calories should be provided as essential fatty 
acids (1%–2% linoleic acid and 0.5% from alpha-linolenic acid) 
to prevent development of EFAD (A.S.P.E.N., 2002). Fat intake 
should not exceed 1 g/kg body weight per day (A.S.P.E.N., 
2002). Overfeeding fat calories can easily be prevented by 
aiming for 15%–30% total calories coming from fat. Contrain-
dications in providing a parenteral source of fat include egg 
allergy and hypertriglyceridemia. Parenteral sources of fat 
are generally considered safe to provide as long as triglycer-
ide levels are <400 mg/dl (A.S.P.E.N., 2002). When triglycer-
ides are >400 mg/dl, the minimum amount of fat needed to 
avoid EFAD should be given (250 ml 20% IV lipid emulsion 
1–2 times/week). 
Protein. Protein is a main structural and functional com-
ponent of every cell in the body. Enzymes, membrane car-
riers, blood transport molecules, intracellular matrices, 
hair, fingernails, keratin, collagen, many hormones, and a 
large portion of membranes are actually proteins. All body 
proteins are continuously degraded and resynthesized in 
a process referred to as protein turnover (Otten, Hellwig, 
& Meyers, 2006d). Protein can provide 4 cal/g when used 
for energy. 
Underfeeding protein can result in greater protein losses 
and impaired wound healing. Protein deficiency can affect 
all organs and many systems in the body. Although the risk 
of excessive intake of protein from foods is very low, there 
have been reports of adverse events from overfeeding pro-
tein in patients requiring enteral and parenteral nutrition 
(Otten et al., 2006d). Any excess protein is deaminated, and 
the ammonia is excreted as urea (Frankenfield, 2001). Because 
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water is required for the excretion of urea, dehydration can 
result when excess protein is provided (Gault et al., 1968). 
Protein intake in excess of 1.5 g/kg body weight per day is 
more likely to result in azotemia for older adults rather than 
younger adults (Frankenfield, Cooney, Mith, & Rowe, 2000; 
Clevenger et al., 1992). A rising blood urea nitrogen (BUN) 
that is not proportional to changes in creatinine levels and/or 
a rising ammonia level with worsening encephalopathy indi-
cate a need to reduce protein intake (Cerra et al., 1997). 
Although the recommended dietary allowance (RDA) 
for protein in healthy adults is 0.8 g/kg body weight per day 
(Otten et al., 2006d), protein needs can be almost twice this 
amount in critically ill patients. Studies have found that pro-
viding 1–1.2 g/kg of body weight per day was optimal in the 
first 2 weeks of critical illness (Ishibashi, Plank, Sando, & Hill, 
1998) and that 1.25 g protein/kg body weight/d was ideal in 
the 1st week post trauma (Larsson, Lennmarken, Martensson, 
Sandsedt, & Vinnars, 1990). The goal of providing nutrition sup-
port therapy, including an exogenous source of protein, during 
critical illness is to minimize nitrogen losses. Provision of more 
than 1.5 g/kg body weight per day does not further lead toward 
attaining this goal (Ishibashi et al., 1998; Hoffer, 2003; Larsson, 
Lennmarken, Martensson, Sandsedt, & Vinnars, 1990; Shaw, 
Wildbore, & Wolfe, 1987). Patients with open wounds (e.g., open 
abdomens or burn patients) and with significant gastrointesti-
nal losses (e.g., enterocutaneous fistulas) may be an exception. 
High-protein regimens (over 1.5 g/kg body weight per day) are 
recommended for patients with burn wounds until significant 
healing is achieved (A.S.P.E.N., 2002). Studies in patients with 
burns have shown that high protein regimens help attain nitro-
gen balance (Kagan, Matsuda, Hanumadass, Castillo, & Jonas-
son, 1982; Matsuda, Kagan, Hanumadass, & Jonasson, 1983), 
increase the rate of restored body weight and muscle function 
(Demling & DeSanti, 1998), and improve immune function and 
survival in burned children (Alexander et al., 1980). 
Fluid. Daily fluid needs vary greatly in the critical care setting. 
In general, fluid administration is adjusted to maintain normal 
urine output, blood pressure, and organ perfusion. An easy esti-
mate for stable ICU patients is 30–40 ml fluid/kg body weight or 
1–1.5 ml/cal consumed, but this may require adjustments based 
on age, size, and organ function (Lucarelli, Pell, Shirk, & Mirtallo, 
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2005). Familiarity with electrolyte composition of body fluids 
and intravenous fluids is essential when ordering intravenous 
fluids for critically ill patients (Tables 10.2 and 10.3). 
Vitamins and Minerals. It is unknown whether the vitamin and 
mineral needs of critically ill patients differs from the needs of 
the healthy population. Patients should receive a minimum of 
the RDA for vitamins and mineralsand most enteral formula-
tions provide this amount once patients have reached their 
prescribed goal volumes. However, in some cases when these 
needs are not met, a multivitamin with minerals should be pre-
scribed (Lefton, Esper, & Kochevar, 2007). On the other hand, 
some enteral formulations provide supplemental amounts of 
vitamins and minerals beyond RDA amounts. For ICU patients 
requiring PN, standard amounts of vitamins and trace ele-
ments are added to the PN daily (Mirtallo et al., 2004). 
The potential benefit of antioxidant supplementation 
in critically ill patients has been of recent interest. Studies 
have shown that antioxidant supplementation can decrease 
the incidence of organ failure (Nathens et al., 2002; Porter, 
Ivatury, Azimuddin, & Swami, 1999), result in fewer infectious 
complications (Porter et al., 1999), and reduce 28-day mortal-
ity (Crimi et al., 2004). However, these studies have varied in 
terms of the ICU population studied, the antioxidant regi-
mens studied (including route of administration and dosage). 
Therefore, arriving at conclusions regarding widespread use 
would be premature at this time. 
Selenium has also been studied in the critically ill popula-
tion. Patients with low selenium levels at the time of admission 
had a threefold increase in ventilator association pneumo-
nia (VAP), organ dysfunction, and mortality (Forceville et al., 
1998). In another study, patients randomized to receive sele-
nium supplementation had a reduced incidence of renal failure 
(Angstwurm, Schottdorf, Schopohl, & Gaertner, 1999). Further 
research is needed to determine the clinical significance of low 
selenium levels and whether replacement improves outcomes. 
Electrolytes. Electrolyte needs must be individualized and 
vary tremendously among critically ill patients. Table 10.4 
shows general recommendations for electrolyte needs, but 
this may need to be adjusted depending on body size, organ 
function, and electrolyte losses. 
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Reprinted with permission from Shires III, G. T., Barber, A., & Shires, G. T. (1999). Fluid and electrolyte management of the surgical patient. 
In S. I. Schwartz (Ed.), Principles of surgery (7th ed., pp. 55–56). New York: McGraw–Hill.
10.2 Composition of Gastrointestinal Secretions
1
Volume 
(ml/24 hours)
Sodium
(mmol/L)
Potassium 
(mmol/L)
Chloride
(mmol/L)
Bicarbonate
(mmol/L)
Saliva 1500 (500–2000) 10 20 10 20
Stomach 1500 (100–4000) 60 10 130 0
Duodenum 100–2000 140 5 104 0
Ileum 3000 (100–9000) 140 (80–150) 5 (2–8) 104 (43–137) 30
Colon 60 30 40
Pancreas (100–800) 140 (113–185) 5 (3–7) 75 (54–95) 115
Bile (50–800) 145 (131–164) 5 (3–12) 100 (89–180) 35
10.3 Composition of Intravenous Fluids
1
Glucose
(g/dl)
Sodium
(mEq/L)
Potassium
(mEq/L)
Calcium
(mEq/L)
Chloride
(mEq/L)
Lactate
(mEq/L)
Osmolarity
(mOsm/L)
Lactated Ringers — 130 4 3 109 28 273
0.9% NaCl
(normal saline)
— 154 — — 154 — 308
0.45% NaCl (half 
normal saline)
— 77 — — 77 — 154
5% dextrose in 
water
5 — — — — — 253
5% dextrose in 
0.45% NaCl
5 77 — — 77 — 407
5% dextrose in 
0.9% NaCl
5 154 — — 154 — 560
3% sodium 
chloride
— 513 — — 513 — 1026
Reprinted with permission from Shires III, G. T., Barber, A., & Shires, G. T. (1999) Fluid and electrolyte management of the surgical patient. In S. I. Schwartz 
(Ed.), Principles of surgery (7th ed., pp. 55–56). New York: McGraw–Hill..
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 Nutrition Support 
Enteral nutrition (EN) continues to be the preferred route 
of nutritional support over parenteral nutrition (PN). The 
popular phrase “if the gut works, use it” is well known among 
clinicians. Historically, PN had been the preferred route of 
nutrition support in the 1970s and early 1980s. During the late 
1980s, studies in trauma patients began reporting reduced 
infectious complications with EN when compared with PN 
(Moore & Jones, 1986; Moore, Moore, & Jones, 1989; Kudsk 
et al., 1992; Moore, et al., 1992). More recent meta-analysis 
of the use of PN compared with EN have found no effect 
on mortality (Heyland, MacDonald, Keefe, & Drover, 1998) 
(Peter, Moran, & Phillips–Hughes, 2005). However, PN results 
in greater infectious complications, catheter related blood 
stream infections (CRBSI), and hospital length of stay (Peter, 
Electrolyte Enteral Parenteral
Sodium 500 mg (22 mEq) 1–2 mEq/kg body weight
Potassium 2 g (51 mEq) 1–2 mEq/kg body weight
Chloride 750 mg (21 mEq) As needed to maintain
 acid–base balance
Acetate — As needed to maintain
 acid–base balance
Calcium 1200 mg (60 mEq) 10–15 mEq
Magnesium 420 mg (35 mEq) 8–20 mEq
Phosphorus 700 mg (23 mmol) 20–40 mmol
10.4 Daily Electrolyte Requirements
Note: This table gives general ranges for safe administration of nutrients in generally healthy 
people. Nutrient prescriptions must be individualized for each patient and clinical situation.
Reprinted with permission from A.S.P.E.N. Board of Directors and Clinical Guidelines Task Force. 
(2002). Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. 
Journal of Parenteral and Enteral Nutrition, 26, pp. 1SA–138SA.
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Moran, & Phillips–Hughes, 2005). When EN is not possible, 
PN may be beneficial in patients with preexisting malnutri-
tion, but care must be taken to avoid overfeeding and prevent 
complications associated with refeeding syndrome (Heyland 
et al., 1998; Jeejeebhoy, 2001). EN is also cheaper compared 
with PN (American Dietetic Association [ADA], 2007). 
 Enteral Nutrition 
Enteral Access. Several options are available for enteral feed-
ing access in critically ill patients. Nasoenteric devices are 
used initially to meet the patients’ short-term needs. There is 
considerable debate over whether the tip of the feeding tube 
should be in the stomach or the small bowel. Several stud-
ies have found that patients fed via postpyloric feeding access 
receive more nutrition earlier (Kearns et al., 2000; Kortbeek, 
Haigh, & Doig, 1999; Minard, Kudsk, Melton, Patton, & Tolley, 
2000; Montecalvo et al., 1992; Taylor, Fettes, Jewkes, & Nel-
son, 1999). This improved nutrient delivery is likely a result 
of less frequent interruptions of the feedings, because gas-
tric feedings are frequently withheld for high gastric resid-
ual volumes (GRV), nursing care, and tests or procedures in 
which the patient must lay flat. Feeding into the jejunum is 
associated with lower GRV (ADA, 2007; Davies et al., 2002; 
Montejo et al., 2002). Feedings into the small bowel have not 
been shown to result in less aspiration (Kearns et al., 2000; 
Neumann & DeLegge, 2002) or a lower incidence of pneumo-
nia (Kearns et al., 2000; Kortbeek et al., 1999; Montecalvo et al., 
1992; Montejo et al., 2002), but these studies evaluated duode-
nal feedings. To prevent aspiration, the tip of the feeding tube 
should be placed in the jejunum beyond the ligament of Treitz. 
The ability to place small bowel feeding tubes into the jejunum 
varies among institutions and depends on the skill level of the 
personnel who will insert feeding tubes or the availability of 
portable fluoroscopy or endoscopy. Patients who require mul-
tiple abdominal surgeries should have a small-bowel feeding 
access placed during surgery. Small-bowel feeding access has 
been recommended when two or more risk factors for aspira-
tion are present. These risk factors include, but are not limited 
to, endotracheal intubation, decreased level of consciousness/
sedation, persistently high GRV/vomiting, need for supine 
position, and presence of nasoenteric tubes, all of which are 
common in critically ill patients (McClave et al., 2002). 
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Prior to initiation of enteral feedings, radiographic con-
firmation of feeding tube placement is recommended for any 
blindly placed feeding tubes (gastric or small bowel). It is 
also useful to mark the exit site of the feeding tube when the 
initial radiograph is done because any increase in the exter-
nal length would be a clue that the feeding tube is dislodged 
(Bankhead et al., 2008). 
Patients requiring long-term enteral feedings should 
have a more permanent feeding access placed such as a per-
cutaneous endoscopic gastrostomy (PEG) or a percutaneous 
endoscopic jejunostomy (PEJ). 
Enteral Formulations. Adult enteral formulations are consid-
ered “medical foods” by the U.S. government and are there-
fore not subject to the same regulatory standards as drugs 
or PN. Most critically ill patients can tolerate a standard 
intact formula. Very few patients with altered digestion and 
absorption may require a formula that is partially hydrolyzed 
or elemental. However, there is insufficient evidence to sug-
gest that elemental formulas result in better outcomes when 
compared with standard polymeric formulas in patients with 
maldigestion or malabsorption (Makola, 2005). 
Some products contain fiber. The recommended fiber 
intake for healthy individuals is 14 g/1,000 cal (Otten, Hell-
wig, & Meyers, 2006c); however, there is no recommendation 
for fiber intake in the critically ill population. Some studies 
have found that feeding formulas with added soluble fiber 
may help alleviate or prevent diarrhea, because it increases 
sodium and water absorption (Spapen et al., 2001; Rushdi, 
Pichard, & Khater, 2004). Insoluble fiber may reduce transit 
time (Malone, 2005). Patients who are receiving fiber-sup-
plemented formulas should be monitored closely for bowel 
function, because cases of small bowel obstruction have been 
reported in patients who were given fiber-supplemented 
feeding formulas (McIvor, Meguid, Curtas, & Kaplan, 1990; 
Scaife, Saffle, & Morris, 1999). 
Several disease-specific formulas (e.g., diabetic, renal, 
and hepatic formulas) are available, but the efficacy of their 
use should be evaluated in conjunction with their increased 
cost. There is very little evidence to support the routine use of 
many of these products in the critically ill population (Russell
& Charney, 2002). 
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The category of “immune-enhancing” formulas that 
contain supplemental amounts of arginine, nucleic acids, 
omega-3 fatty acids, or vitamins and minerals has received the 
most attention. Potential benefits include reduced infection 
rates (Beale, Bryg, & Bihari, 1999; Heyland et al., 2001; Heys, 
Walker, Smith, & Eremin, 1999), fewer ventilator days (Beale 
et al., 1999), and shorter length of hospital stay (Beale et al., 
1999; Heys et al., 1999). Evidence-based guidelines have not 
recommended the routine use of these products in all criti-
cally ill patients (ADA, 2007), but others have suggested their 
use in severely injured trauma patients (Jacobs et al., 2004; 
Kudsk et al., 2001) or in patients requiring GI surgery (Kudsk 
et al., 2001) There is difficulty arriving at a conclusion based 
on available research, because the studies enrolled differ-
ent patient populations, used different feeding formulations, 
compared study products with control products that were not 
isonitrogenous, used different feeding protocols, and studied 
different outcome variables. 
Initiation and Advancement of EN. Critically ill patients should 
be started on EN once they have been adequately resuscitat-
ed and are hemodynamically stable. Patients should be able 
to sustain a mean arterial pressure (MAP) of 70 mmHg or 
more before starting feedings (ADA, 2007). Patients with a 
cardiac index <2 L·min −1·m2, MAP <70 mmHg, and oxygen 
saturation <95% when requiring FiO 2 >60% and PEEP >5 cm 
are not likely to tolerate EN (Skipper, Peloquin, Gregoire, & 
Tangney, 2001). 
The goal is to start enteral feedings within 24–48 hours 
of injury or ICU admission (ADA, 2007; Heyland et al., 2003). 
Additional research suggests that enteral feedings should 
be started within 24 hours of injury or admission (Marik & 
Zaloga, 2001). Starting “early” enteral feedings compared 
with “late” feedings has been associated with reduced infec-
tious complications and may reduce LOS (ADA, 2007). The 
benefit of early enteral feedings is mostly seen in surgical, 
trauma, and burn population. One study found increased 
infectious complications and longer LOS in medical ICU 
patients started on early EN versus late EN (Ibrahim et al., 
2002). In surgical patients, the presence of flatus or a bowel 
movement is not needed prior to initiating EN (Bankhead 
et al., 2008). 
372 Critical Care
Enteral feedings should be initiated at full strength but 
often are initiated at a lower infusion rate that is advanced to 
a “goal rate” once tolerance to the enteral feeding has been 
established. Whether patients are started at 20 ml/hr or at 
50 ml/hr and how tolerance is defined, varies among institu-
tions. To keep the initial amount of tube feeding delivered in 
perspective, one must consider that 15 ml of formula is the 
equivalent of one tablespoon of formula. 
Enteral feedings are most often delivered at a continuous 
rate in the ICU setting as opposed to bolus or intermittent 
feeding regimens. The increasingly common use of insulin 
drips in the critical care setting combined with intermittent 
enteral feedings would make achievement of optimal glucose 
control challenging. 
Enteral Feeding Protocols. With an increasing emphasis on 
patient safety, many facilities have been developing protocols 
to improve the overall quality of care. These include protocols 
for initiating and advancing enteral feedings in ICU patients, 
which tend to focus on when feedings should be initiated and 
how much EN should be delivered. Studies of enteral feeding 
protocols have shown that more patients reach their “goal” 
volume within 72 hours of admission (Spain et al., 1999), 
required fewer ventilator days and had a lower risk of death 
(Barr, Hecht, Flavin, Khorana, & Gould, 2004), and received 
more EN and had shorter LOS (Martin, Doig, Heyland, 
Morrison, & Sibbald, 2004). An average intake of 60% to 70% 
of goal enteral feedings during the 1st week of critical illness 
has been associated with a decreased LOS, fewer days on the 
ventilator, and reduced infectious complications (ADA, 2007). 
Enteral feeding protocols can be developed into standard 
order forms that can help guide the clinician prescribe enteral 
nutrition to best meet each patients’ needs. Orders for EN 
should include but is not limited to the following: patient iden-
tifiers, enteral formulation, enteral access delivery site, and 
the administration method and rate (Bankhead et al., 2008) 
Complications Associated with EN. The most common com-
plications associated with EN in critically ill patients include 
diarrhea (Cataldi-Betcher, Seltzer, Slocum, & Jones, 1983; 
Smith, et al.,1990) and high GRV (Cataldi-Betcher et al., 
1983). These and other complications associated with EN are 
shown in Exhibit 10.1. 
Chapter 10: Nutrition, Fluids, and Electrolytes in the Critically Ill Patient 373
Exhibit
10.1 Troubleshooting ComplicationsAssociated with EN
 Complication Etiology Prevention Treatment 
 Aspiration  ■ Feeding access  ■ Monitor or confi rm  ■ Replace feeding
  dislodged or  proper feeding  access as
  migrated back  tube placement.  needed.
  into esophagus  
■ Emesis  
■ Gastroesopheal  ■ Refer to refl ux,  ■ Refer to refl ux, 
  refl ux or  elevated GRV  elevated GRV
  elevated GRV  below  below
  Clogged  ■ Insuffi cient  ■ 30 ml water  ■ Flush with 30 ml
 feeding  water fl ushes  fl ush any time  warm water.
 tube   that the feedings  ■ Avoid use of
■ Administering  are interrupted  juices and sodas
  medications via  ■ 30 ml water   for fl ushing
   feeding tube  fl ush before  feeding tubes.
   and after  ■ If not cleared
   residual check  with water, fl ush
   ■ 30 ml water  5 ml water
   fl ush before  mixed with
   and after each  viokase and
   medication  sodium
   administered  bicarbonate,
   ■ Use liquid form  or use
   of medications  commercially
   when feasible.  available
    declogging
    solution.
   ■ Replace 
    feeding access
    if unable to
    clear.
(continued)
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 Complication Etiology Prevention Treatment 
 Constipation  ■ Inadequate fi ber  ■ Use fi ber-  ■ Change to a
  intake  containing formula  fi ber-containing
   if appropriate  formula if
   and tolerated.  appropriate
   ■ Provide adequate  and tolerated.
   fl uid. ■ Provide
    adequate fl uid.
■ Dehydration  ■ Add appropriate  ■ Rehydrate
   water fl ushes to 
   meet fl uid need. 
  ■ Lack of activity ■ Encourage  ■ Encourage
   ambulation if  ambulation if
   possible.  possible.
 Diarrhea  ■ Concurrent   ■ Avoid enteral  ■ Discontinue 
  drug therapy  route of  causative agent
  (antibiotics,  administration  if possible.
  sorbitol-  for meds with   
  containing elixir  high sorbitol 
  medications,  content.  ■ Replace
  magnesium-  ■ Dilute medications  electrolyte
  containing   with high  losses by 
  antacids,  osmolarity in  IV route.
  phosphorus  water when 
  supplements)  given via 
   enteral route.
   ■ Avoid enteral
   magnesium and
   phosphorus
   supplementation; 
   opt for parenteral
   route.
Exhibit
10.1 Troubleshooting ComplicationsAssociated with EN (continued)
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 Complication Etiology Prevention Treatment 
  ■ Disease or  ■ Pancreatic  ■ Treat underlying
  condition  enzymes if  condition.
  associated with  indicated  ■ Pancreatic enzymes
  malabsorption   if indicated
   ■ Semi-elemental
    formula if indicated
■ Inadequate fi ber   ■  Change to fi ber-
  intake   containing enteral
    products.
  ■ Infectious source   ■ Check for C. diffi cile
  (e.g.,  C. diffi cile )   toxin and provide
    antiobiotics if
    positive.
  Elevated GRV  ■ Decreased   ■ Minimize  ■ Stool softeners as
  bowel motility,   use of  needed
  ileus, narcotics,  narcotics  
  electrolyte ■ Monitor  ■ Treat underlying
  disorder  electrolytes;  issue causing ileus.
   keep  ■ Reduce use
   magnesium   of narcotics.
   >2.0 and  ■ Replace potassium
   potassium  and magnesium
   >4.0.  levels if needed.
  ■ Delayed gastric   ■ Promotility agents
  emptying   if problem is
    persistent
■ Feeding tube   ■ Confi rm  ■ Replace feeding
  dislodged or  feeding  access if needed.
  migrated back  access by 
  into esophagus  x-ray.
Source: Lefton, J. (2002). Management of common gastrointestinal complications in tube-fed 
 patients. Support Line, 19–25.
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The etiology of diarrhea in critically ill tube-fed patients 
is typically multifactorial and most often is not related to the 
feeding formulation itself. The use of antibiotics and delivery 
of medications that may contain sorbitol or those that have 
a high osmolarity via the enteral route can lead to diarrhea. 
Laxatives, stool softeners, promotility agents, phosphorus 
supplements, and magnesium-containing antacids have been 
implicated as causing diarrhea. Careful review of the medi-
cation administration record in conjunction with tolerance 
to enteral feedings during daily rounds may help avoid diar-
rhea. The presence of enteric pathogens such as  Clostridium 
difficile should be ruled out prior to administering antidiar-
rheal agents (Lefton, 2002). 
High GRV or delayed gastric emptying is thought to 
increase the risk of reflux and aspiration of gastric contents. 
Possible causes of high GRV include ileus, sepsis, use of nar-
cotics, and obstruction. One single episode of a high GRV does 
not equate to feeding intolerance, and persistently low GRV 
does not mean that the patient is always tolerating the enteral 
feeding regimen (Lefton, 2002). One issue of much debate is 
the GRV threshold at which feedings should be temporarily 
discontinued. Recent guidelines have suggested that feedings 
should be held after GRV are 250 ml in two consecutive mea-
surements (ADA, 2007). Others have suggested that feedings 
should not be held unless GRV are >500 ml (McClave, et al., 
2002). For patients with persistently high GRV, promotility 
agents should be added and consideration should be given to 
small-bowel feeding access (ADA, 2007). However, if increas-
ing gastric output is accompanied by worsening abdominal 
pain and distension, feedings should be held, and a workup to 
determine the etiology of feeding intolerance is warranted. 
Additional complications may include hyperglycemia, 
refeeding syndrome, and electrolyte abnormalities although 
these tend to be more dramatic with PN. Changing to an enteral 
formulation marketed for use in hyperglycemic patients has not 
been adequately studied in the critically ill population (Lampert 
& Lefton, 2008); therefore, standard enteral formulations, avoid-
ing overfeeding, and exogenous insulin when needed is the 
preferred management for hyperglycemic critically ill patients 
who are receiving EN. Refeeding syndrome can be avoided by 
initiating EN at a lower rate and advancing the feedings slowly 
while monitoring electrolyte levels. These complications and 
electrolyte abnormalities are shown in Exhibit 10.2. 
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Exhibit
 Complication Etiology Prevention Treatment 
 Azotemia  ■ Catabolism 
  ■ GI bleed 
  ■ Excess protein   ■ Keep protein  ■ Reduce protein  
  administration  administration   in EN or PN if
   to <2 g·kg·day   indicated.
   and <1.5 g·kg·  ■ Increase fl uid
   day for older  intake. 
   adults.
 Elevated liver  ■ Overfeeding  ■ Avoid  ■ Reduce total 
 enzymes  (dextrose  overfeeding.  calories delivered
  >4–5 mg·kg −1 ·   to provide no more
  min −1 or lipids   than 25 cals·kg·  
  >1 gm·kg·day)   day.
   ■ Reduce dextrose
    and/or lipid 
    content of PN. 
  ■ Long-term   ■ Cycle PN if patient
  PN use   is stable on PN
    (glucose well
    controlled without  
    use of insulin). 
  ■ Lack of GI   ■ Provide some 
  stimulation in   nutrition via the
  patients unable    enteral route
  to eat orally   if possible.
 Hyperglycemia  ■ Stress response   ■ Provide exogenous 
  or infection   insulin if needed.
  ■ Steroid therapy 
  ■ Preexisting  ■ Initiate PN with  ■ Provide  exogenous 
  history of  2.5 mg·kg −1 ·  insulin if needed. 
  diabetes  min−1 dextrose 
  mellitus  and follow 
   glucose levels.
10.2  Troubleshooting Metabolic Complications Associated with EN and PN
(continued)
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 Complication Etiology Prevention Treatment 
  ■ Excessive   ■ Avoid  ■ Reduce EN
  glucose  overfeeding.  feeding rate if
  administration  ■ Keep dextrose  indicated (keep to 
   administration  <25–30
   in PN to 1 <4  kcals·kg· day)
   mg·kg −1 ·min −1 .  ■ Reduce dextrose
   ■ Assess dextrose  in PN if indicated.
   administration  ■ Remove dextrose 
   from other  from other
   sources (e.g.,  sources (e.g., IVF) 
   IVFs and meds)  if indicated.
    ■ Provide exogenous  
    insulin if needed.
  ■ Results falsely   ■ Recheck
  elevated because   laboratories
  of blood drawn
  from PN line 
 Hypoglycemia ■ EN interrupted,   ■ Close   ■ Adjust insulin
  but insulin  monitoring of  dose.
  infusion   glucose levels
  continues. 
  ■ Excess insulin  ■ Cautiously add  ■ Discontinue PN
  in TPN  insulin to TPN   until new bag is
   if indicated—  available with less
   add 2/3 of  insulin; provide
   previous day’s  source of dextrose
   insulin  (usually D 10 W at
   requirements.  same rate as PN or
    per hospital policy). 
    per hospital policy).
Exhibit
10.2 Troubleshooting Metabolic Complications Associated with EN and PN (continued)
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 Complication Etiology Prevention Treatment 
 Hypernatremia  ■ Fluid imbalance  ■ Add H 2 O   ■ Assess fl uid needs
  —excess water   fl ushes for  
  loss  patients on EN;   ■ Calculate H 2 O
■ Inadequate free  enteral  defi cit** (L) =
  water  formulation is  ([serum Na + /140] −
   not intended to  1) × wt (kg) × 0.6
   meet fl uid  ■ Adjust IVF
   needs.  composition
    and/or rate 
  ■ Excess sodium   ■ Reduce sodium
  intake   in PN and/or IVF
   if indicated 
 Hyponatremia  ■ Fluid overload  ■ Usual dose of   ■ Restrict fl uid 
  ■ Adrenal  Na + in PN is as needed
  insuffi ciency  100–150 m 
  ■ CHF  Eq/day 
  ■ SIADH 
  ■ Cirrhosis/Ascites 
  ■ Renal failure 
  ■ Pseudohypo-
  natremia (for
  every 100 mg/dl
  glucose above
  normal, serum
  Na+ will drop by
  1.6–2.0 mEq/L) 
  ■ GI losses  ■ Anticipate   ■ Increase sodium
■ Inadequate Na+  increased  in PN if indicated
  in PN  sodium losses  (hypovolemic, 
   with ileostomies/  hyponatremic with
   jejunostomies  low osmolality) 
     ■ Sodium defi cit
    **(mEq) = (140 −
    serum Na + ) × wt
    (kg) × 0.6 
 Hyperkalemia  ■ Renal failure  ■ Anticipate  ■ Use K+ binders if
   reduced K+  needed
   need for renal
   failure patients 
(continued)
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 Complication Etiology Prevention Treatment 
  ■ Metabolic  ■ Correct acidosis
  acidosis   ■ Change to a lower 
  ■ Excess K+ in   K+ content enteral
  EN/PN   formulation if high
    K+ levels persist 
    ■ Reduce or eliminate
    K+ in PN 
  ■ Hemolyzed blood  ■ Recheck K+ result
  sample  
  ■ Catabolism 
 Hypokalemia  ■ Refeeding  ■ Usual dose of  ■ Correct acute
  syndrome  K+ in PN is  hypokalemia with
■ Increased GI  60–120 mEq/d  IV K+ source
  losses  (for patients  separate from PN
■ Increased K+  with normal  (generally 20 mEq
  excretion from   K+ levels and  K+ will increase
  certain meds   good renal  serum K+ level by
  (e.g.,   function)  0.2 mEq/L)
  Amphotericin  ■ Anticipate  ■ Increase K+ in
  B, Furosemide)  higher K+   PN for chronic
■ Inadequate K+   needs when  hypokalemia or for
  in PN  initiating PN in  those with
   malnourished  increased
   patients or  requirements
   patients with
   higher than
   normal K+ 
   losses 
  ■ Hyperglycemia  ■ Control glucose  ■ Provide insulin if 
   levels  needed
  ■ Metabolic   ■ Correct alkalosis
  alkalosis   
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 Complication Etiology Prevention Treatment 
 Hyperchloremia  ■ Excessive   ■ For TPN, give  ■ Change IVF to
  administration  Na+ and Cl− in  give less Cl−
  of Cl− or Cl−  a 1:1 ratio and  ■ Reduce Cl− in TPN
  containing IVF  other anions in 
  (e.g., normal  acetate form 
  saline) 
  ■ Increased loss   ■ Anticipate  ■ Calculate HCO 3 −
  of HC0 3 −  higher  defi cit** = 0.5 ×
   bicarbonate  wt (kg) (desired
   needs with high  HCO3 − minus
   GI losses  measured HCO 3 −)
 Hypochloremia  ■ High gastric   ■ Usual dose of  ■ Provide more
  losses (NG  Cl− in PN is  chloride w/ IVF if
  suctioning,   100–150  additional fl uid is
  vomiting)  mEq/day  needed. 
  ■ Chronic diarrhea   ■ Increase Cl− in
■ Inadequate Cl−   TPN. 
  in PN   ■ Calculate Cl−
    defi cit**(mEq) =
    0.5 × wt (kg) × (103
    − measured Cl−) 
  ■ Metabolic   ■ Volume and K+
  alkalosis   repletion 
 Hyperphos-  ■ Renal failure  ■ Anticipate  ■ Reduce or
 phatemia   reduced PO 4  eliminate PO 4
   needs for renal  administration.
   failure patients. 
  ■ Excess PO 4   ■ Change to a  
  administration   lower PO 4 content
    enteral formula-
    tion if high PO4
    levels persist.
    ■ Reduce or elimi-
    nate PO 4 adminis-
    tration in PN. 
    ■ PO 4 binders if
    indicated (for
    enterally fed
    patients) 
(continued)
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 Complication Etiology Prevention Treatment 
 Hypophos-  ■ Refeeding  ■ Usual dose of  ■ Correct acute
 phatemia  syndrome  PO 4 in PN is  hypophosphate-
■ Inadequate PO 4  15–30 mmol/  mia with IV PO 4
  in TPN  day  source separate
   ■ Anticipate  from TPN
   higher PO 4  (0.16–0.64 mmol
   needs when  PO 4 /kg wt depen-
   initiating PN in  ding on severity
   malnourished  of hypophospha-
   patients.  temia)* 
    ■ Increase PO 4 in 
    PN for chronic 
    hypophosphate-
    mia or those with 
    increased
    requirements 
  ■ Hyperglycemia  ■ Control glucose   ■ Provide exogenous
■ Patients  levels   insulin as needed 
  requiring CRRT 
  ■ Alcoholism 
  ■ Hyperpara-
  thyroidism 
  ■ Hyperglycemia 
 Hypermagna-  ■ Renal failure  ■ Anticipate  ■ Reduce Mg in PN
 semia  ■ Excess Mg in TPN  reduced Mg  if indicated.
■ Adrenal  needs in renal 
  insuffi ciency  failure patients 
■ Hypothyroidism  (exception is 
   patients on 
   CRRT). 
  ■ Severe acidosis   ■ Correct acidosis. 
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 Complication Etiology Prevention Treatment 
 Hypomagna-  ■ Inadequate Mg  ■ Usual dose of  ■ Correct acute
 semia  in PN  Mg in PN is 8–  hyopmagnesemia
■ Refeeding  24 mEq/day   with IV Mg source
  syndrome  ■ Anticipate  separate from PN
■ High GI losses   higher needs  ■ Increase Mg in 
■ Increased losses  when initiating   PN for chronic
  from meds  PN in malnour-  hypomagnesemia, 
  (Amphotericin B)  ished patients  patients at risk of
   or those with  refeeding syn-
   higher than  drome, and those
   normal Mg  with high losses
   losses.  
  ■ Alcoholism   ■ Supplement Mg. 
 Hypercalcemia  ■ Excess Ca+ in PN   ■ Reduce Ca+ in
    PN if indicated. 
  ■ Prolonged   ■ Encourage  ac-
  immobilization  tivity if feasible.
  ■ Cancer with
  bone metastisis 
  ■ Renal failure 
  ■ Hyperpara-
  thyroidism 
  ■ Excessive
  Vitamin D 
 Hypocalcemia  ■ Inadequate Ca+  ■ Usual dose of  ■ Correct acute
  in PN  Ca+ in PN is   hypocalcemia
■ Ca+ wasting  9–22 mEq/day  separate from PN
  drugs   ■ Increase Ca+ in
    PN if indicated 
  ■ Hypoalbumi-   ■ Correct Ca+ level  
  nemia   for low albumin 
    = (4.0 g/dl −
    albumin level) ×
    0.8 + measured
    calcium
    ■ Check ionized
    calcium to confi rm
    low Ca+ level
(continued)
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 Complication Etiology Prevention Treatment 
  ■ Reduced   ■ Supplement
  vitamin D intake   vitamin D
    (although not in PN) 
 Parenteral Nutrition 
Parenteral nutrition (PN) is a complex admixture that may 
contain more than 40 different components. It ranks second 
behind anti-infective agents as a class of medications with 
errors in preparation or administration. Serious harm and 
even death has been reported from improperly prepared or 
administered PN solutions. A.S.P.E.N. has published “Safe 
Practices for Parenteral Nutrition” to help avoid some of 
the potential complications that can occur with PN (Mirtallo 
et al., 2004). 
Parenteral nutrition in critically ill patients is reserved 
for those who are unable to be fed enterally. This may include 
patients with malabsorption, short bowel syndrome, com-
plete bowel obstruction, severe necrotizing pancreatitis, 
high-output gastrointestinal fistulas, hemodynamic instabil-
ity, and intolerance to enteral feedings. When considering PN, 
it should be anticipated that patients will require the therapy 
for at least 5 days. (Mirtallo, 2007). 
Parenteral Access. Parenteral nutrition can be administered 
through a peripheral or a central line. The ability to meet 
 * 1 mEq potassium phosphate = 0.68 mmol phosphate; 1 mEq sodium phosphate = 0.75 mmol 
phosphate
 Abbreviations: EN = enteral nutrition; PN = parenteral nutrition; IVF = intravenous fl uid; GI = gas-
trointestinal; wt = weight; kg = kilograms; Na+ = sodium; K+ = potassium; CHF = congestive heart 
failure; SIADH = syndrome of inappropriate ADH secretion; Cl− = chloride; HCO 3 − = bicarbonate; 
IV = intravenous; NG = nasogastric; PO 4 = phosphorus; mEq = milliequivalent; mmol = millimoles; 
Mg = magnesium; Ca+ = calcium; CRRT = continuous renal replacement therapy. 
Sources:  Klein, Stanek, & Wiles, (1998), Kraft, Btaiche, Sacks, & Kudsk, (2005), Clark, Sacks, 
Dickerson, Kudsk, & Brown, (1995), Piazza–Barnett & Matarese, (1999), Schmidt, (2000), Klein, 
et al., (2002), Hamilton & Austin, (2006). 
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patients’ nutrient needs with peripheral PN (PPN) is limited 
because of restraints in osmolarity of the solution. Patients 
must have good peripheral venous access and be able to tol-
erate large volumes of fluid (Mirtallo, 2007). PPN is not an 
appropriate choice for patients requiring fluid restrictions 
(e.g., renal, cardiac, or liver failure) and patients with meta-
bolic stress or malnutrition. The use of PPN is also consid-
ered to be a short-term therapy, and patients should be given 
total PN (TPN) if they continue to require PN for more than 
2 weeks. Typically, no >10% dextrose solution (100 g dextrose/
liter) can be given via a peripheral IV site, but amino acids, 
vitamins, minerals, and electrolytes in the PPN will also con-
tribute to the osmolarity of the solution. 
More concentrated PN solutions with higher osmolari-
ties can be administered through a central line with the 
tip of the catheter placed in the superior vena cava. Most 
critically ill patients have central lines in place for admin-
istration of other medications and/or fluids. One major 
complication associated with central lines and TPN is the 
development of catheter-related blood stream infections 
(CRBSI). Prevention and treatment of CRBSI are discussed 
in Chapter 11. 
Parenteral Formulations. Parenteral formulations contain 
dextrose, lipids, and amino acids to make up the macronu-
trient content of the formula. Dextrose and fat are energy 
sources providing 3.4 and 9 cal/g, respectively. Amino acids 
provide 4 cal/g if used for energy. Patients with critical ill-
ness, requiring large amounts of propofol (delivered in a fat 
emulsion that provides 1.1 cal/ml) for sedation, may not need 
additional fat with their PN formula. Formulas may be pro-
vided as a 2-in-1 solution in which the lipids are provided 
separately or as a 3-in-1 solution where the lipids are mixed 
in with the dextrose and amino acids. 
Institutions may require prescription of PN macronutrients 
as percent stock solution, percent final concentration, grams 
per day, grams per kilogram of body weight per day, or calories 
per day. This can lead to a great deal of confusion when patients 
transfer from one facility to another, and significant errors can 
occur. Therefore, A.S.P.E.N. has suggested PN macronutrients 
be prescribed in grams per day or grams per kilogram of body 
weight per day. The use of percent concentration to prescribe 
PN should be avoided (Mirtallo, et al., 2004). Sample TPN mac-
ronutrient calculations are shown in Exhibit 10.3. 
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The following electrolytes may be added to PN solutions: 
sodium, potassium, calcium, phosphorus, and magnesium. 
Sodium and potassium may be added as chloride, acetate, 
or phosphate salt. Bicarbonate is not stable in PN solutions, 
and acetate is used for base needs. The amount of chloride 
and acetate added to the PN formulation depends on the 
acid–base balance of the patient. For example, patients with 
high gastric losses will most likely need chloride, whereas 
renal failure patients may benefit from some acetate in the 
solution. Electrolytes should be prescribed as a total amount 
per day rather than per liter (Mirtallo, et al., 2004). 
There is no single measure of nutritional status or adequacy of nutrient intake.
Patient JD is critically ill and has been assessed to need approximately 2,000 ml 
fl uid, 1,800 cal, and 80 g of protein daily. The following steps will help determine 
the macronutrient content of the PN solution that would provide the estimated 
calorie and protein needs.
1. Determine calories to be provided as protein.
 80 g protein × 4 cal/g = 320 cal
2. Determine calories remaining to be provided as fat and dextrose.
 1,800 total calories − 320 protein calories = 1,480 calories
3. Determine the amount of calories to be provided as fat
 (an easy estimate is 30% calories as fat and 70% calories as dextrose).
 1,480 × 0.30 = 444 calories as fat
 Determine grams of fat to be added to PN solution.
 444 cal as fat ÷ 9 cal/g = 49.3 g or ~50 g fat/day
4. Determine calories left to be provided as dextrose.
 1,800 − (320 protein cal + 444 fat cal) = 1,036 dextrose cal
5. Determine grams of dextrose to be added to the PN solution.
 1,036 cal as dextrose ÷ 3.4 cal/g = 304 grams or ~300 g dextrose/day
The PN prescription would then be for 2,000 ml (or 2 L) containing 80 g amino 
acids/day, 50 g fat/day, and 300 g of dextrose/day. The amount of dextrose 
should be initiated as 150 g/day and eventually increased to 300 g/day if glucose 
levels are well controlled and electrolytes stable.
Exhibit
10.3
Sample Calculations to Determine 
Macronutrient Content of PN 
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There are limitations in regard to the total amount of 
phosphorus and calcium that can safely be added to the PN 
formulation. Excess calcium and phosphorus could result 
in patients’ harm or death, because calcium phosphate 
precipitates leading to diffuse microvascular pulmonary 
emboli (Mirtallo et al., 2004). Institution policy regard-
ing PN compounding and compatibility issues should be 
followed. 
A multiple vitamin infusion (MVI) and a multiple trace 
element (MTE) solution should be added daily to the PN 
prescription (Mirtallo et al., 2004). Tables 10.5 and 10.6 show 
daily vitamin and mineral requirements for adults requiring 
PN. Patients with significant GI losses through ostomies or 
fistulas or other malabsorptive states requiring long-term PN 
may need additional zinc, copper and chromium supplemen-
tation. Long-term PN patients with cholestasis or bile duct 
obstruction should have copper and manganese monitored, 
and supplementation may need to be adjusted or eliminated 
from the PN solution (Misra & Kirby, 2000). 
Vitamin Requirement
Thiamin (B1) 6 mg
Ribofl avin (B2) 3.6 mg
Niacin (B3) 40 mg
Folic acid 600 mcg
Pantothenic acid 15 mg
Pyridoxine (B6) 6 mg
Cyanocobalamin (B12) 5 mcg
Biotin 60 mcg
Ascorbic Acid (C) 200 mg
Vitamin A 3300 IU
Vitamin D 200 IU
Vitamin E 10 IU
Vitamin K 150 mcg
10.5 Daily Requirements for Adult Parenteral Vitamins
Source: Food and Drug Administration.
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Little is known about the compatibility of drugs in PN solu-
tions. H2 blockers and insulin are the only medications that 
are added to PN solutions. When insulin is added to the PN 
regimen, regular insulin should be used. There are several sug-
gested methods for calculating insulin needs to be added to the 
PN. One easy method is to add two thirds of what the patient 
required from the previous day’s sliding scale insulin regimen. 
However, some ICUs may prefer not to add insulin to the PN 
solution and continue with unit specific insulin drip protocols. 
Initiation and Advancement of PN. Baseline laboratory val-
ues including electrolytes, BUN, creatinine, glucose, hepatic 
function, and triglyceride levels should be obtained prior 
to initiating PN. Any acute electrolyte abnormalities (e.g., 
low K+, PO4, and magnesium levels) or hyperglycemia 
should be corrected prior to initiation of PN. When glucose 
levels are >300 mg/dl, BUN is >100 mg/dl, sodium level is 
>150 mEq/L, chloride level is >115 mEq/L, or phosphorus lev-
els are <2.0 mg/dl, it would be prudent to delay initiation of 
PN until these levels are corrected (Mirtallo J. et al., 2007). 
Amino acids and IV fat emulsions can be initiated at 
“goal” amounts, whereas dextrose is typically initiated at half 
the goal amount. Large amounts of dextrose provided too 
quickly to patients who may be at risk of refeeding syndrome 
or those with hyperglycemia will exacerbate these complica-
tions. By providing half the dextrose in the initial PN formula, 
Trace Element Standard Intake
Chromium 10–15 mcg
Copper 0.3–0.5 mg
Iron Not routinely added
Manganese 60–100 mcg
Selenium 20–60 mcg
Zinc 2.5–5 mg
10.6 Daily Trace Element Supplementation to Adult PN Formulations
Source: Mirtallo, J., Canada, T., Johnson, D., Kumpf, V., Peterson, C., Sacks, G., et al., (2004). Safe 
practices for parenteral nutrition. Journal of Parenteral and Enteral  Nutrition, S39–S70.
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clinicians can monitor tolerance and incrementally increase 
the amount of dextrose over a few days if glucose levels are 
maintained <150 mg/dl and phosphorus levels >2.0 mg/dl. 
Complications Associated with PN. There are several compli-
cations associated with PN including mechanical complica-
tions because of central line insertion and CRBSI. However, 
this section will focus on the metabolic complications that 
may occur and are largely avoidable when PN prescriptions 
are developed by clinicians who are knowledgeable in PN 
support therapy. 
Hyperglycemia is probably the most common complica-
tion associated with PN use. Providing a mixed fuel substrate 
solution and keeping the dextrose to <4 mg·kg −1·min−1 will 
help avoid hyperglycemia associated with overfeeding (Kha-
odhiar & Bistrian, 1999; Jacobs et al., 2004). However, many 
critically ill patients experience hyperglycemia as part of 
their metabolic response and will require exogenous sources 
of insulin regardless of the amount of dextrose prescribed 
in the PN. Additional sources of dextrose such as those in 
additional IVFs should be limited. 
Patients who have exhibited poor nutritional intake pri-
or to initiation of PN or that have been assessed to have a 
poor nutritional status are at risk for developing refeeding 
syndrome with initiation of PN. When refeeding syndrome 
develops, potassium, phosphorus, and magnesium will shift 
intracellularly, and serum levels will drop requiring replace-
ment. Even a starvation period as short as 48 hours has been 
reported to predispose critically ill patients to refeeding 
hypophosphatemia (Marik & Bedigian, 1996). Sodium reten-
tion and fluid overload can also occur as a result of refeeding 
syndrome. An additional 50–100 mg IV or 100 mg oral thia-
mine over 5–7 days has also been suggested for patients at 
risk of refeeding syndrome (Kraft, Btaiche, & Sacks, 2005). 
Electrolyte abnormalities can also occur in patients 
requiring PN (see Exhibit 10.2, pages 377 through 384). Care-
ful monitoring of daily electrolyte levels and adjustments 
in the PN prescription can help to avoid these complica-
tions. Further details about electrolyte disorders have been 
addressed in great detail elsewhere (Kraft et al., 2005). 
Most metabolic complications associated with use of PN 
are related to overfeeding the patient or providing too much 
nutrition too soon. When starting patients on PN, consultation 
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with the nutrition support clinician will offer a thorough evalu-
ation of nutrition status, nutrient needs, and suggestions for 
initiation and advancement of the regimen to help avoid these 
complications. 
 Monitoring Nutrition Support Therapy 
There is no single measure that is indicative of patients’ 
nutritional status nor the adequacy of nutrients provided. 
Albumin is a transport protein with a long half life (about 
21 days) that has often been used in nutrition assessment. 
However, its application in the assessment of critically ill 
patients is inappropriate because serum levels will fall with 
fluid resuscitation, capillary leakage, blood loss, and the acute 
phase response (APR). During the APR, such as that which 
occurs with SIRS, sepsis, trauma, burn, and other sources of 
inflammation, protein synthesis is altered. The liver will syn-
thesize more positive acute phase reactants (e.g., C-reactive 
protein) and less negative acute phase reactants (e.g., albu-
min) (Gabay & Kushner, 1999). 
Transthyretin (or prealbumin) has a much shorter half-
life (about 3 days), but similar to albumin is a negative acute 
phase reactant (Gabay & Kushner, 1999). Prealbumin levels 
will be low during periods of inflammation, regardless of 
adequate nutrition support provision. Studies of albumin and 
prealbumin levels in critically ill patients have found that 
they are better indicators of the severity of injury and prog-
nosis rather than nutritional status (Boosalis et al., 1989). 
Another monitoring tool used in nutrition assessment is 
nitrogen balance. Nitrogen balance is simply the difference 
between nitrogen input and output. The equation is as follows: 
N2 balance = (grams protein intake/6.25) − (urine urea 
nitrogen + 4) 
An additional 4 g of nitrogen losses is added to account for 
nonurine urea losses (feces and sweat). A nitrogen balance 
result that is +2−4 is theoretically indicative of anabolic 
metabolism; however, nitrogen balance really reflects the dif-
ference between protein intake and renal excretion of nitro-
gen-containing compounds. Additional protein to achieve a 
positive nitrogen balance may not always mean that patients 
will become anabolic (Russell & Mueller, 2007). Extremely cat-
abolic patients may not reach a point of anabolism until they 
have recovered from their initial insult or injury. The test also 
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requires an accurate record of protein intake, accurate urine 
collection, and good renal function (Russell & Mueller, 2007). 
Because there is no single indicator of a patients’ nutri-
tional status or the adequacy of nutrient intake, clinicians 
must consider the whole picture of how patients are pro-
gressing. Outcomes suggesting adequate nutritional intake 
in the critical care setting include: 
 ■ Tolerance of enteral feedings without complications 
or frequent interruptions 
 ■ Healing of wounds 
 ■ Resolution of infections 
 ■ Weaning from mechanical ventilation 
 ■ Trend toward improvement in acute phase proteins 
(prealbumin)
 Conclusion 
Critically ill patients experience a myriad of metabolic chang-
es and require nutrition support therapy to avoid excessive 
losses of protein and lean tissue. Both enteral and paren-
teral nutrition support therapies are employed in the critical 
care setting although EN remains the preferred route. Both 
therapies require skilled and knowledgeable clinicians to 
prescribe, administer, and monitor therapy to avoid possible 
complications. Nutritional needs, current nutritional support, 
and tolerance should be reviewed by the ICU team (including 
the nutrition support clinician) daily during team rounds. 
 Evidence-Based Practice Guidelines 
 Initiate nutritional support within 24–48 hours of ICU admission. 
 Enteral route is preferable to parenteral. 
 Start enteral feeds only when patient is hemodynamically 
stable (MAP ≥ 70). 
 Administer enteral nutrition via a postpyloric nasoenteric 
tube when feasible. 
 Initiate nutritional support at half (or less) of goal rate to mini-
mize complications. 
 Do not administer nutritional support greater than calcu-
lated needs in response to low nutritional laboratory values. 
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 Online Resources 
American Society for Parenteral and Enteral Nutrition 
(A.S.P.E.N.) (http://www.nutritioncare.org) Enteral Nutrition 
Practice Recommendations Guidelines for the Use of Paren-
teral and Enteral Nutrition in Adult and Pediatric Patients 
Safe Practices for Parenteral Nutrition 
American Dietetic Association (ADA) (http://www.adaevidence
library.com) Critical Illness Guidelines 
Canadian Clinical Practice Guidelines (http://www.criticalcare
nutrition.com)
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 Introduction 
Electrolyte and metabolic disturbances are common in criti-
cally ill and injured patients. These disturbances alter physi-
ologic function and contribute to morbidity and mortality. 
Although these disturbances are commonly encountered, the 
insidious failure of the hormonal balancing act in critical ill-
ness may precipitate a life-threatening crisis. The metabolic 
effects related to acute endocrine dysfunction have gained 
a considerable amount of interest in the last decade. The 
most common life threatening hormonal and electrolyte dis-
turbances in critically ill patients present as glucose/insulin 
deregulation, cortisol deficiencies, and vasopressin deregu-
lation. The ensuing metabolic disturbances that accompany 
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many systemic disease processes or result from altered 
endocrine function are complex and threatening, but the 
most concerning of these is the presence of lactic acidosis 
and refractory hypotension. With early recognition and treat-
ment of these abnormalities, life-threatening complications, 
such as multiple organ dysfunction related to hypoperfusion 
might be avoided and outcomes may improve. These abnor-
malities will be discussed in this chapter.  
 Pathophysiology 
The physiologic stress response is controlled largely by the 
hypothalamic–pituitary–adrenal (HPA) axis and the sympatho-
adrenal system (SAS), which includes the sympathetic nervous 
system and the adrenal medulla (Marik, 2006). The HPA axis 
and the SAS are functionally related. Activation of the HPA and 
SAS systems provides a survival foundation for the host. The 
ability to compensate in hypermetabolic states depends on the 
balancing act and integrated response of the two systems. 
These two systems are activated by cellular triggers, 
which communicate primarily to the hypothalamus initiat-
ing a range of releasing, limiting, or stimulating responses. 
This response controls the internal milieu, that is, increased 
sympathetic activity, increased circulating catecholamines, 
increased glucagon and cortisol, which all contribute to 
increased gluconeogenesis, metabolic alterations, and 
exhaustion of the HPA. The mechanisms leading to dysfunc-
tion of the HPA axis during critical illness are complex and 
poorly understood and likely include increased or decreased 
production of releasing, regulating, stimulating hormones 
(hypothalamic and pituitary), as well as an altered response 
of the target organs and distal receptor sites. The appropri-
ate responses ultimately answer the triggering cellular call, 
which, in return, creates a negative feedback loop (Figure 
11.1). Understanding these essential stimulation-inhibition 
mechanisms provides the basis for bedside and laboratory 
evaluation. With early recognition and treatment of these 
abnormalities, life-threatening complications such as mul-
tiple organ dysfunction might be avoided and patient out-
comes may improve. 
The primary hormonal disturbances in critically ill 
patients to be discussed here include altered glucose regu-
lation and insulin reactivity; relative (situational) adrenal 
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insufficiency; relative pituitary or receptor dysfunction 
(vasopressin) and alterations in thyroid response. 
 Critical Illness Hyperglycemia 
Hyperglycemia with or without diabetes is associated with 
increased mortality and morbidity. It is rare for patients to be 
admitted to the hospital for primary management of diabe-
tes, but relatively common for elevated blood sugar to com-
plicate the initial diagnosis. A recent study by Umpierrez and 
Kitabchi (2004) showed 1,886 patients admitted to a commu-
nity hospital met criteria for the diagnosis of hyperglycemia 
(defined as an admission or in-hospital fasting glucose levels 
exceeding 126 mg/dl [7 mmol/L]). According to Umpierrez 
and Kitabchi, 38% of patients presented with hyperglycemia, 
26% of the total with known diabetes, and the remaining 12% 
with no prior history of diabetes. Stress or new hyperglyce-
mia was associated with a higher in-hospital mortality rate 
(16%) as compared with those patients with a prior history 
of diabetes and therefore managed (3%) and the remaining 
1,177 patients with normoglycemia (1.7%). Even after risk 
adjustment for confounding variables and factors, patients 
with new hyperglycemia had an 18.3-fold increase in mor-
tality rate compared with a 2.7-fold increase in the known 
diabetes group. Providers often perceive hyperglycemia as 
a compensatory consequence of stress and acute illness and 
therefore do not recognize the significance. This misunder-
standing will often delay treatment until blood glucose (BG) 
exceeds 200–250 mg/dl. 
 Glucose Regulation 
Glucose transport into cells occurs as facilitated diffusion 
using one of the five different glucose transporter (GLUT) 
channel proteins. GLUT-1–mediated insulin-independent 
transport occurs in most tissues and accounts for basal glu-
cose uptake, whereas the membrane presence of GLUT-4 is 
specifically and reversibly up regulated by insulin. The role 
of insulin at this level is essential to the maintenance of cel-
lular levels of glucose. Insulin is produced by the beta cells 
of the islets of Langerhans of the pancreas under the influ-
ence of the BG level. At the cellular level, insulin interacts 
with a protein on the cell surface. The ultimate reaction is the 
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production of the glucose transporter (GLUT-4) in muscle 
cells, which passes or migrates to the surface and facilitates 
the entrance of larger molecular nutrients such as glucose. At 
this level, insulin binds to the insulin receptor sites, requir-
ing them to be responsive. Insulin bound to the sites create a 
second messenger response molecules which then mobilizes 
other responses. (1 and 2 insulin receptor substrate (IRS). 
IRS-1 activates other systems required to mobilize stored 
GLUT-4 transporter molecules to the cell membrane). During 
moderate hyperglycemia, cells usually shift and hold GLUT 
transport molecules (intracellularly) decreasing the cellular 
uptake of glucose and therefore protecting themselves from 
glucose overload. 
Glucose uptake related to the glucose transporters 
GLUT-1, GLUT-2, or GLUT-3 is profoundly effected in 
stress and illness. Cytokines, angiotensin II, endothelin-
1, vascular endothelial growth factor, transforming growth 
factor, and hypoxia, have all been proven to significantly 
affect and upregulate the expression and availability of 
GLUT-1 and GLUT-3 in different cell types, which often 
over rides the normal hyperglycemic protection mecha-
nisms. GLUT-2 and GLUT-3 allow glucose to enter cells 
directly proportional to the extracellular glucose level 
which may be significantly higher in critical illness states 
(Clerici & Mathay, 2000;  Sánchez–Alvarez, Tabernero, & 
Medina, 2004). 
Hyperglycemia in septic patients is partially related 
to the presence of proinflammatory cytokines, counterre-
gulatory hormones, and excessive glucose availability 
(hyperglycemia). Hepatic insulin resistance and increased 
gluconeogenesis are major contributors to hyperglycemia. 
Total body glucose uptake is typically increased in critical 
illness due to alterations in the cellular protection process 
which normally limit uptake in the non-insulin dependent 
cells such as the central nervous system or blood cells (see 
Table 11.1 on page 404).  
The physiologic response to injury, trauma, sepsis, or 
with major operations is heralded by hypermetabolism and 
catabolism, both leading to peripheral protein waste, com-
promise of the immune system and the skin, and eventu-
ally, multiorgan dysfunction. The liver plays a crucial role in 
this process. During normal physiologic conditions, the liver 
synthesizes mainly constitutive-hepatic proteins, such as 
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albumin, prealbumin, or transferrin. After profound stress 
(surgery, trauma, sepsis), the liver shifts to a hepatic acute-
phase response, now synthesizing many different proteins, 
such as C-reactive protein (CRP). The goal of this response 
is to restore homeostasis; however, a prolonged, exaggerated 
output promotes increased and continuous hypermetabo-
lism and catabolism. Mediators of the acute-phase response 
are proinflammatory cytokines, such as interleukin-1 (IL-1 
beta), interleukin-6 (IL-6), interleukin-8 (IL-8), tumor-
necrosis factor (TNF), and/or the anti-inflammatory cyto-
kine interleukin-10 (IL-10) (Moshage, 1997; Livingston, 
Mosenthal, & Deitch, 1995; Selzman et al., 1998; De Maio, 
Mooney, Matesic, Paidas, & Reeves, 1998; Pruitt, Copeland, 
& Moldawer, 1995; & Williams & Giroir, 1995). The presence 
of these communicators ensures that the patient’s normal 
protein stores will be low when measured. 
The presence of hyperglycemia in a patient with  any
critical illness should always be considered to indicate 
inflammation and compensation that may rapidly become 
maladaptive. Serious metabolic complications of uncon-
trolled hyperglycemia resulting from the inflammatory 
mediated loss of cellular protection mechanisms (GLUT-4) 
coupled with increased production of counter regulatory 
Cause Response Effect
pro-HPA and ↑ hepatic glucose ↑ glycogenolysis and
 sympathetic activation:  production  gluconeogenesis
 catecholamines and  
 glucagon↑↑
↓ Glut-4 (cell protection) Impaired peripheral  hyperglycemia and
  glucose uptake  insulin resistance
↑glucose uptake in  Brain and blood cells ↓ immunocompetence
 non–insulin-   most prominently ↑ red cell lysis
 dependent tissues  affected ↓ neurologic function
11.1 Some Proposed Causes of Critical Illness Induced Hyperglycemia
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hormones such as glucagon, catecholamines (epinephrine), 
cortisol, and others, affects multiple systems and sends out 
a signal that must not be ignored. Van den Berghe (2001), 
and the Leuven 1 group, hypothesized that even moderate 
sustained hyperglycemia, was directly or indirectly harm-
ful to vital organs and systems and contributed to adverse 
outcomes (Table 11.2). 
The Leuven 1 group actively studied the benefit of tighter 
glycemic controls (TGC) in critically ill patients with hyper-
glycemia and those without diabetes. The Leuven protocol 
demonstrated that a BG target of 80–110 mg/dl in the inten-
sive insulin group yielded benefits in morbidity, including 
decreased blood transfusion requirements, decreased need 
for dialysis, increased immunocompetence, and decreased 
length of stay, as well as a 30% reduction in mortality when 
compared with a more traditional approach to hypergly-
cemia (see Table 11.3 on page 406). Although the trial was 
introduced in a mixed medical–surgical unit, 71% of patients 
were predominantly cardiothoracic patients and all required 
mechanical ventilation. The Leuven I study reported an 
increase in the number of patients with severe hypoglycemia 
from 0.8% to 5.1%; however, there were no associated adverse 
consequences reported. 
Endothelial Protection Response
↓ nitric oxide production ↑ vascular tone
↑ response to fl uids/vasopressors
↓ oxyradicals endothelial protection
Other effects Response
↓ C-reactive protein ↑ anti-infl ammation
↓ mannose-binding lectin ↓ proinfl ammation
↓ TNF-α
↓ superoxide radicals
↓ cellular energy metabolism ↑ Glut-4 uptake
11.2 The Proposed Effects of Insulin on the Endothelium
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Hyperglycemia in the critically ill patient, whether in a 
known diabetic or stress-induced, has long been known to 
increase morbidity and  mortality (Sung, Bochicchio, Joshi, 
et al., 2005).  Negative effects include longer lengths of stay, 
increased incidence of  infection, and in-hospital death (Whit-
comb,  Pradhan, Pittas, et al., 2005). Observational studies and 
early randomized trials have suggested that lowering glu-
cose levels can improve outcomes, especially in critical care 
patients treated with intravenous insulin to a range of 80–110 
mg/dl (Capes, Hunt, & Malmberg, et al., 2001; Kingsley et al., 
1999; McCowen, Malhotra, Bistrian, et al., 2001). In 2001, a 
large scale trial of ICU patients reported that reducing blood 
glucose concentrations to 4.4–6.1 mmol/L lessened in-patient 
mortality (Van der Berghe, Wouters, Weekers, 2001).  More 
recent studies in the critical care population were unable to 
replicate earlier studies, and identified severe hypoglycemia as 
a significant risk of intensive glucose control (van der Berghe, 
Wilmer, Hermans, et al., 2006; Arabi, Dabbagh, Tanmin, et al., 
2008; Brunkhorst, Engel, Donado, Restrepo, et al., 2008; Devos, 
Preiser, Melot, 2007). Wiener, Wiener, & Larson (2008) con-
cluded in a meta-analysis that such therapy was not a factor in 
reduction of mortality among critically ill hospitalized patients. 
Severe hypoglycemia was evident and resulted in the termina-
tion of large scale study in Germany (Brunkhorst, F., Engel, C., 
Protocol target  Appropriate to skills, experience, and tools available 
 to the ICU
 Concern for nurse work burden
80–150 mgm/dl  Successful implementation drives a decreasing 
 level of glycemic control
Data monitoring tools  Essential for collection of effi ciency and time 
 required to achieve goals
 Record hypoglycemia
 Collection of clinical outcomes
11.3 Safe Effective Glucose Control
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Bloos, F., et al., 2008) and Europe (Devos, P., Preiser, J., Melot, 
C., 2007).  The American Diabetes Association (2008) and the 
American Association of Clinical Endocrinologists (2007) have 
recommended intensive insulin therapy even in the presence 
of conflicting data. The Normoglycemia in Intensive Care Eval-
uation-Survival Using Glucose Algorithim Regulation (NICE-
SUGAR) study was a large scale international study includ-
ing 6104 hospitalized critically ill patients (Finfer et al., 2009). 
They reported 1580 deaths. 
Following the NICE-SUGAR findings, Griesdale et al. 
(2009) conducted a meta-analysis of existing randomized tri-
als of intensive insulin regimes in critically ill patients. They 
explored the effects of this therapy in relation to hypoglycemia 
and death. The researchers reviewed 26 international studies 
involving more than 13,500 patients. Their findings supported 
that there is no mortality benefit related to intensive insulin 
regimes except in surgical ICU patients. 
While both hyperglycemia and hypoglycemia are cor-
related to poor outcomes in critically ill patients, intensive 
insulin therapy is not ideal for every patient. Griesdale et al. 
(2009) emphasized that trials of intensive insulin therapy were 
distinctly different and the demographics of patients, units, 
and treatment protocols varied. The method of blood glucose 
measurement included central lines, arterial lines, and capil-
lary measurement. Administration of insulin varied dramati-
cally from subcutaneous to peripheral and central line IV dos-
ing.  Finally the researchers cited extremes in achieving target 
goals based on health care teams and thus the term “intensive 
insulin therapy” were not consistent. The authors emphasize 
that differences in outcomes may be secondary to existing 
hyperglycemia prior to therapy and accuracy in glucose mea-
surement and intervention.  Suggestions for future research 
include identification of optimal targets for blood sugar in dis-
tinct patient populations.
The ADA and the AACE issued a statement regarding the 
findings of the NICE-SUGAR study and urge that practitioners 
should not abandon the concept of good glucose management 
in the hospital setting. (ADA/AACE, 2009). The two organiza-
tions maintain that strategies must be identified to help hospi-
tals establish structured protocols for safe and effective man-
agement of blood glucose in both intensive care units and other 
hospital settings. A task force representing the ADA/AACE is 
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currently attempting to identify “reasonable, achievable, and 
safe glucose targets, and to describe the protocols, procedures, 
and system improvements to achieve optimal glucose control 
efficiently and safely.” (Korytkowski, 2009). Current recom-
mendations suggest reasonable attempts to treat critical care 
patients in a less intensive yet “good” range similar to the con-
ventional arm of the NICE-SUGAR trial.” (ADA/AACE, 2009). 
This equates to a blood sugar of  8-10mmol/L.  Krinsley (2006) 
and Devos et al., (2008) recommend a method of glucose 
control that promotes a stepwise approach system appropri-
ately coined :  Safe,  Effective,  Glucose Control ( SEGC). This 
methodology targets an intermediate BG level to protect the 
patient from the negative effects of both hyper and hypogly-
cemia and meets the current post NICE-SUGAR guidelines. 
Application of tight control methodologies is not recom-
mended (Table 11.4). 
Whatever lower range is chosen, the risk of hypoglyce-
mia is increased if the insulin dosing scheme is not properly 
constructed and vigilant, accurate evaluation is not performed 
Pathology Type 1 Type 2
↓Insulin Production from 
Islet β-type cells
Auto-immune destruction Not generally present 
in the early disease, 
occurs as disease 
progresses
Insulin defi ciency Yes Not generally in early 
disease
Glucose intolerance Yes Yes
Insulin resistance* 5%–30% of adult patients, 
not the common cause
Yes
Central obesity* Not generally/causative Yes
Dyslipedemia* Not generally/causative Yes
Hypertension* Not generally/causative Yes
11.4 Proposed Differences in Pathophysiology of Diabetic Mellitus
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(Krinsley, 2006). Sliding scale subcutaneous and regular insulin 
regimens are not useful in the critical care setting in achieving 
goal control, because the insulin dose is determined  after the 
blood sugar has already increased, not in a predictive, prophy-
lactic method. 
Targets can be achieved with frequent analysis of blood 
from an arterial catheter or finger-stick BG determinations 
and an when the insulin infusion rate is dictated by a dosing 
algorithm. There is complexity involved in controlling the BG 
to any target ranges and teamwork is absolutely essential. 
Patient safety concerns dictate that bedside providers should 
follow a single protocol based on frequent BG determina-
tions and properly adjust the therapy accordingly. One of the 
most important methods for evaluation may include using 
arterial blood (both point of care [POC] as well as in patient 
laboratory analysis) whenever possible (Kanji et al., 2005). 
 Managing Diabetics in Acute States 
 Insulin Basics 
Insulin is necessary for the transport of glucose into the cells 
for use as fuel and also to provide mechanisms for exces-
sive fuel storage I. The ability to utilize and breakdown these 
stored units (glycogenolysis) is an insulin dependent process. 
This breakdown of storage substances is normal and vital to 
the metabolic process. The liver also promotes the catabolism 
of protein and to a lesser extent, the glycerol produced in fat 
breakdown to support gluconeogenesis. Glucose production 
by the liver is one of the most important contributors to the 
hyperglycemia of diabetes and is profoundly affected by the 
presence or absence of insulin. 
Type 1 Diabetes Mellitus. Type 1 insulin-dependent diabetes 
(T1DM) occurs when there is a primary damage/death of the 
beta cells resulting in an absolute insulin deficiency. Abso-
lute insulin deficiency results in a primary failure of the glu-
cose to be utilized or even stored by the cell. Fat breakdown 
results in the release of free fatty acids (FFAs). FFAs travel to 
the liver and are converted into acetone, acetoacetic acid, and 
betahydroxybuteric acid or ketone bodies. The presence of 
excess acids will affect the homeostatic, neutral blood envi-
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ronment (blood pH). Historically, T1DM was diagnosed at an 
early age and was referred to as juvenile or thin diabetes. 
When the condition is a birth defect or genetic deficit trig-
gered by an autoimmune response, this may still be the case; 
however, over the last 50 years, the evolution of the seden-
tary, supersize mentality in western cultures has promoted a 
greater increase in causative factors for the T1DM. 
Type 2 Diabetes Mellitus. Type 2 insulin-dependent diabetes 
(T2DM) is more difficult to understand and describe. T2DM 
combines both insulin resistance and insulin deficiency and 
is frequently diagnosed on a continuum. This evolutional pro-
cess is both genetic and environmental and continues to be 
the subject of significant discussion and ongoing research. 
 Genetic Issues in T2DM 
Genes control several chemical steps in beta cell action, 
including the secretion, action, and transportation of insulin. 
Genetic defects can prevent enzyme production and block 
the action of insulin. The insulin block then affects glucose 
uptake, gluconeogensis, and increases the breakdown of the 
triglycerides. 
 Insulin Resistance 
Insulin resistance (the first defect) occurs in the peripheral 
cells (primarily muscle and fat) of the muscles and the liver. 
Genetic factors affect this resistance; but the roles of envi-
ronmental factors are what unveil and elevate the condition. 
Environmental factors include aging, sedentary lifestyle, 
obesity, and particularly central obesity. As insulin resistance 
develops, decreasing the transport of glucose to the cell, the 
beta cells respond to the cellular “starvation” by increas-
ing insulin production. Insulin resistance that persists or 
increases over time causes the beta cells to fail secondary 
to genetic defects, glucose and/or fat toxicity, and/or exhaus-
tion. Frequently a complete or absolute deficiency that was 
not diagnosed at an early age is related to a combination 
of all these factors. When insulin resistance persists over 
time, the insulin secretion may begin to decrease and BG 
levels begin to rise, clinical signs and symptoms will begin 
to proliferate. 
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People who suffer from obesity already have a degree of 
insulin resistance and compensatory hyperinsulinemia. The 
presence of central obesity places patients at risk because of their 
abdominal adipose tissue that becomes increasingly resistant to 
insulin as it accumulates. However, only those individuals with 
central obesity plus genetic deficits go on to develop diabetes. 
This condition is commonly referred to as  metabolic syndrome.
 Insulin Deficiency 
The insulin deficiency in T2DM is frequently due to beta cell 
exhaustion from the constant hypersecretion of insulin, and 
glucose/lipid toxicity. The toxicity of high levels of glucose is 
profoundly expressed in nervous system, vascular and beta 
cells. Bardsley, and Want (2004) showed that 50% of beta-
cell insulin production is lost by the time that the diagnosis 
of T2DM is made. For most T2DMs, insulin therapy will be 
needed within 3–5 years after diagnosis (Bardsley & Want). 
Diabetic ketoacidosis (DKA) and hyperglycemic hyperosmo-
lar syndrome (HHS) are the most serious acute complica-
tions of diabetes mellitus. Although these disorders are not 
absolutely related to the type of diabetes, most commonly, 
diabetic ketoacidosis (DKA) occurs in the T1DM and HHS in 
the T2DM. Both are characterized by insulinopenia and are 
differentiated primarily, although not always, via the sever-
ity of hyperglycemia, acidosis, and dehydration. In critical 
illness states, the high concentrations of catecholamines, 
cortisol, and growth hormone may cause a relative insulin 
deficiency (↑hormones/ ↑↑glucose/insulin) and thus fur-
ther worsen hyperglycemia. When administering any or all 
of these agents exogenously, the provider must be aware of 
these effects and adjust insulin therapy accordingly. 
As the glucose concentration and osmolality of extracellu-
lar fluid increases (5.6 mOsm/kg for every 100 mg/dl increase 
in plasma glucose), an osmolar gradient is created that draws 
water out of the cells. The diuresis of the hyperosmolar glu-
cose molecule initially increases glomerular filtration and 
limits the profound accumulation of serum glucose. Through 
the renal filtration process, glucose, water, and most elec-
trolytes will be wasted in the urine. Careful analysis of the 
patient’s laboratory results is required to prevent errors. The 
fluid flux and acidosis will significantly impact the serum 
concentration of sodium as well as the intracellular presence 
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of potassium. When evaluating dehydration, the common for-
mula for calculating the serum osmolality must be performed 
and corrected. The measure of sodium content (135–145 mEq/
dl) may return from the laboratory as normal, low, or elevated. 
However, the sodium concentration is profoundly affected by 
the renal glomerular filtration rate (GFR). When the patient 
persists in an osmotic diuresis the serum sodium is being lost 
at an alarming rate and the measured content without regard 
to corrected concentrations may under predict how dehydrat-
ed the patient actually is. 
A measured and calculated sodium concentration 
(2[Na+] + [serum glucose/18] + BUN/2.8 = serum osmolality. 
Normal 275–295 mOsm/L) is frequently performed to 
evaluate dehydration and the concentration gradient for 
electrophysiological conduction. Blood urea nitrogen (BUN) 
is not always included in the formula because it is freely 
permeable through the intracellular wall and therefore 
does not exert pressure in the osmolar gradient. 
To determine the  true concentration and, therefore, not 
underestimate the volume loss that has occurred, a correc-
tion of the serum sodium and the concentration gradient is 
absolutely necessary in hyperglycemic patients. For every 
100 mg/dl BG measured above the normal of 100 mg/dl, add 
1.6 mEq back to the measured sodium. This correction is 
used to determine dehydration, not true sodium. 
Example: 
1. Patient A has a blood glucose of 500 mgm/dl. 
2. Patient A has a serum sodium of 138 mEq/dl. 
In order to determine true dehydration: 
3. Glucose of 500 = 500 − 100 = 400 (four 100s above the 
normal glucose) 
4. 4(1.6 mEq) = 6.4 mEq to be added to correct the sodium 
5. Corrected sodium= 2(138 + 6.4) = 144.4 
The corrected sodium is then utilized in the osmolar 
calculation
2(144) + (500/18) is 288 + 27.7 = 315 corrected osmolality 
reflecting dehydration. 
In addition, serum potassium concentration is generally 
elevated in relationship to cellular potassium due to the extra-
cellular shift of potassium caused by insulin deficiency, acide-
mia, and hypertonicity. When the patient has metabolic acidosis 
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(from ketosis as well as lactic acidosis), the H+ (metabolic acid) 
moves across the cellular wall and shifts the intracellular ion 
K+ out of the cell into the serum. The measured serum K+ may 
then over predict the patient’s true ionic state. 
While the patient is in a hyperglycemic osmotic diuresis 
state, K+ moves from cell to serum to urine in a profound K+
dumping mode. Volume and insulin are given to manage both 
ketosis and hypovolemia. The H+ will exchange (to serum) 
with the K+ (to cell) and if the provider has not been cau-
tious, profound serum hypokalemia may occur. Potassium 
is required for electrical and mechanical response of cells, 
muscles, heart, and nervous system cells. Great care must be 
applied in managing a hyperglycemic crisis in a low–normal 
or low serum potassium state. 
The serum phosphate level in patients with DKA, like 
serum potassium, does not truly reflect the actual body deficit. 
Diabetic Ketoacidosis. Diabetic ketoacidosis (DKA) is an acute 
complication of diabetes mellitus that can be life threatening. 
The basic underlying mechanism for diabetic ketoacidosis is 
an absolute insulin deficiency coupled with elevated levels 
of counter regulatory hormones, such as glucagon, cortisol, 
catecholamines, growth hormone, proinflammatory cytokines. 
These hormones are frequently over stimulated by an infec-
tious processes. Elevated cortisol levels stimulate protein 
catabolism increasing circulating levels of amino acids that 
become the fuel for gluconeogenesis in the liver. The hyper-
secretion and concentration of catecholamines, cortisol, and 
growth hormone, both endogenous and exogenous, combined 
with the resulting ketosis and acidosis impair cellular glucose 
uptake as well as insulin action and secretion, thus the vicious 
cycle of hyperglycemia persists and worsens (Umpierrez & 
Kitabchi, 2004). The serum glucose continues to elevate as 
cellular inability to process and transport glucose continues 
and glycogenolysis and gluconeogenesis begins. 
DKA is expressed by marked hyperglycemia, ketosis, aci-
dosis, and dehydration. The renal transport rate of the hyper-
osmolar glucose molecule is significant, causing the profound 
initial diuresis and loses of a significant amounts  of fluids 
and electrolytes. These are both effected by the rate of glucose 
wasting in the urine (see Table 11.5 on page 414). DKA can 
cause significant abdominal pain that resolves with appropri-
ate measures of treatment; however, caution should be taken, 
as the pain could be a result or indication of the precipitating 
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cause of DKA. Further evaluation is needed if abdominal pain 
does not resolve with resolution of dehydration and metabolic 
acidosis (Umpierrez, Khajavi, & Kitabchi, 1996). 
Hyperglycemic Hyperosmolar Syndrome (HHS). Although the 
hallmark of HHS is life-threatening dehydration and severe 
hyperglycemia, the pathophysiology is poorly understood. 
Currently, science points to the higher levels of endogenous 
insulin reserve in HHS than one might see in T1DM. Often 
Signs Symptoms Analysis
Dehydration Polyuria/polydypsia/
 polyphagia
History most important
Dry mucus membranes Weight loss Serum glucose >250 
 mg/dl (in the absence 
 of insulin administration)
Decreased skin turgor Vomiting Serum and urine ketones 
 >3 mmol
Tachycardia Abdominal pain Blood pH <7.30 (beware 
 of the compensation 
 of rapid respiratory rate)
Kussmauls respirations Weakness Anion gap >20 (in the 
 presence of normal 
 chloride and albumin)
Hypotension Drowsiness Uncomplicated acidosis: 
 for every 1 mmol ↑ in 
 gap, there should be 
 1 mmol ↓ in bicarbonate
Alteration in mental 
 status
Sleepy to comatose Δ anion - Δ bicarbonate
 Normal with acidosis
 −6 to + 6
11.5 Signs and Symptoms of DKA
Note: Typically DKA is more commonly seen in T1DM, however, this is not a requirement for 
diagnosis.
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there is adequate insulin concentration to prevent lipolysis 
(and therefore ketosis), but not enough insulin to inhibit 
hepatic glucose production and/or stimulate glucose use 
(Umpierrez & Kitabchi, 2004; Bardsley & Want, 2004). 
There appears to be no limit on the level of BG that can be 
achieved during crisis. The rising level of blood glucose reflects 
that, glucose is produced but not used, and there appears to 
be enough insulin to store some glucose as glycogen which is 
then rapidly lysed (hence the very high levels) and also enough 
to at least initially limit the breakdown of nonglucose products 
(lipolysis). However, there is not enough to respond to the starv-
ing cell (transport) or limit liver production (Table 11.6). 
Signs Symptoms Analysis
Dehydration Profound Serum osmolality >320 mOsm/L
   Serum sodium may be normal, 
 low or high
 If measured (not corrected) sodium
 is elevated above normal, patient
 is in danger of terminal
 dehydration
Dry mucus membranes Profound  Serum glucose >600 mg/dl (in the
 absence of insulin administration)
Decreased skin turgor Profound  Serum and urine ketones usually
 negative, may have mild 
 ketonemia
Tachycardia Abdominal Blood pH >7.30 (except if in 
  pain  hypovolemic shock)
Kussmaul’s respirations Not present  Anion gap <20 (except in 
 hypovolemic shock)
Hypotension Present
Shock/coma Present Evaluate serum osmolality
   If <320 consider other causes 
 for coma 
11.6 Signs and Symptoms of HHS
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Typically when glucose production is profoundly high, 
the GFR (osmotic diuresis) is abnormally active initially 
producing polyuria, and the patient may quite literally uri-
nate themselves into a coma and subsequent death. The 
concomitant dehydration may significantly impact the pres-
ence of acids (H+ as well as Ketones), which explains the 
decreased diagnostic emphasis on presence or absence of 
metabolic acidosis. 
The comparative analysis aside, both forms of hypergly-
cemic crisis are life threatening and appropriate treatment 
is emergent and critical. The treatment is focused on fluids, 
electrolytes, source control, and insulin replacement. Current 
 DKA HHS
Serum glucose Usually <800 May be >1000
Serum and urine ++++ May not be present
 ketones
Serum K+  Serum levels over predict Normal in the absence
 cellular, may be low   of acidosis
 (profound cellular
 hypokalemia)
Serum Na+ Normal Variable
Serum Osmolarity elevated Profoundly elevated
pH  Metabolic acidosis (presence  Normal Metabolic acidosis
 of ketones [lipolysis] and   primarily as an effect
 lactic acid [glycogenolysis]   from lactic acidosis in
 and tissue hypoxia with   severe dehydration and 
 dehydration)  hypovolemic shock 
  syndromes
Anion gap wide  Normal or wide in the 
 presence of lactic 
 acidosis
11.7 Comparing the Two Conditions
Chapter 11: Endocrine Emergencies 417
recommendations for the treatment of patients with moder-
ate or severe diabetic ketoacidosis and those with HHS are 
listed in Table 11.7. 
Insulin therapy may need to be delayed in a few primary 
conditions, arterial hypotension and severe hyperglycemia, 
as well as significant hypokalemia states associated with 
dehydration and hyperglycemia (Umpierrez & Kitabchi, 
2004). In hypotensive patients with severe hyperglycemia, 
if insulin is administered, this may generate vascular col-
lapse and a significant fluid shift causing life-threatening 
hypotension. In addition, patients with low serum potassium 
(<2.5–3.0 mEq/L) are typically profoundly depleted at the 
intracellular level and must receive potassium replacement 
before insulin therapy commences (Exhibit 11.1). 
Thyroid Dysfunction. Thyrotropin-releasing hormone (TRH), 
secreted by the hypothalamus, stimulates the pituitary to 
produce Thyrotropin, which then regulates the synthesis and 
secretion of thyroid hormones in the thyroid gland. 
■  initial intravenous bolus of regular insulin at a dose of 0.1 units/kg body 
weight, followed by
■  continuous infusion of regular insulin at a dose of 0.1 units/kg until blood 
glucose levels reach 250 mg/dl
■  once glucose is <250 add dextrose to the intravenous fl uids and reduce 
insulin infusion to 0.05 units · kg−1 · hour−1
■ In HHS, convert to a standard glucose regulation strategy
■  In DKA, continuous intravenous therapy until ketoacidosis is controlled. Two 
of the following normalized acid base requirements must be met:
■ serum bicarbonate ≥ 18 mEq/L
■ venous pH ≥ 7.3
■ anion gap ≤ 14 mEq/L
■  capillary blood glucose is determined every 1–2 hours at the bedside using a 
glucose oxidase reagent strip,
■  blood is drawn every 4 hours to determine serum electrolytes, glucose, 
blood urea nitrogen, creatinine, magnesium, phosphate, and venous pH
11.1 Recommended Treatment for Elevated Blood Glucose in Crisis 
Exhibit
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The thyroid hormones thyroxin (T4) and triiodothyro-
nine (T3) are the active hormones produced by the thyroid 
gland (Table 11.8). The active circulating hormones control 
basal metabolism, glucose uptake and lipolysis, oxygen 
consumption and heat production. The normal levels of 
these hormones also increase protein synthesis in muscle, 
bone and brain and therefore affect growth. The thyroid 
hormones act in a synergistic manner with the circulating 
catecholamines, together creating a rise in heart rate and 
vascular tone, therefore the blood pressure. The ratio is 20% 
T3 to 80% T4, and T3, while more metabolically active, has 
a shorter effective response time. T3 and T4 must be trans-
ported by proteins (Thyroglobulin binding protein: TGBs) 
and the compound must be presented to the liver or skeletal 
muscle for cleavage to occur. The hormone secretion is con-
trolled by Thyrotropin or the thyroid-stimulating hormone 
(TSH) released from the adeno-hypophysis of the pituitary. 
The pituitary response is controlled by hypothalamic Thy-
rotropin-releasing hormone (TRH) that in turn responds to 
cellular signals (Figure 11.2). 
Thyroid disorders affect about 2% of the population and, 
along with diabetes, are the most common type of endocrine 
disorder. Signs and symptoms can be very generalized and 
may be confused with other medical disorders, not limited 
to the endocrine system. The signs and symptoms occur in 
concert with an increased hormone (tachycardia, atrial fibril-
lation, rapid metabolic and digestive rates) whereas hypo-
thyroidism causes a marked reduction in the same clinical 
Measure Normal Target with Therapy
TSH standard: 0.4 and 4.5 mIU/L TSH to 0.4 to 2.5 mIU/L in 
 consider: 0.4 and 2.5 mIU/L. T4-treated hypothyroid patients
free T4 60–170 nmol/l standard with levothyroxine
T3 0.8–2.7 nmol/l controversial
11.8 Thyroid Measures
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measures. In severe illness of any cause, down-regulation of 
the thyroid hormone system may occur. 
The endocrine adaptations to critical illness are variable 
and much less than predictable. Illness in patients with pre-
existing hypothyroidism or hyperthyroidism may precipitate 
extremes of the primary disorder such as Myxedema coma 
or thyroid storm. These conditions, although presenting with 
exaggerated nonspecific signs and symptoms, are in the end 
much more obvious than the simple diagnosis of hypothy-
roidism or pre-hypothyroidism, which often is based on the 
relative suspicion that should be considered when patients 
present with refractory, exaggerated clinical states. 
Abnormal laboratory analysis of thyroid function provides 
a relatively definitive diagnosis. Initial serum measurements 
should include a free T4 and TSH, but concerns regarding 
11.2
Vasopressor
dependent
Shock
spot
cortisol
<25 μg/dL
spot
cortisol
>25 μg/dL
< 9 μg/dL
stimulate
with
corticotropin
> 9 μg/dL
< 9 μg/dL
TREAT Serial
Evaluation
TREAT
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thyroidal dysfunction should be referred to a endocrinology 
specialist for a more thorough diagnostic panel. 
Hypothyroidism. Primary hypothyroidism, the most common 
presenting form of thyroidal disorders, t is caused by thy-
roid suppressionfor any direct reason (i.e., cancer, radiation, 
autoimmune dysfunction).  Secondary hypothyroidism is gen-
erated from deficiencies outside of the thyroid, and is related 
to the pitutitary gland.  Tertiary hypothyroidism is related to 
hypothalamic deficiency related to the release of thyrotro-
pin-releasing hormone (TRH). L less obvious may be the 
hypothyroidism which is diagnosed by the elevated of thy-
roid autoantibodies or caused by iodine containing agents. 
In the setting of primary hypothyroidism, a decline in 
serum free T4 and a raised concentration of serum TSH sup-
port the definitive diagnosis. This negative feedback relation-
ship between cells, hypothalamus, pituitary and thyroid is so 
responsive, that even slight shifts downward in free T4 associ-
ate dynamically with TSH (Figure 11.2 on page 419). This hyper 
vigilant, super sensitive response has led to the long and rich 
history of evaluating TSH levels in conjunction with free T4 to 
support diagnosis of both hypo and hyperthyroid states. 
NOTE: The pituitary hormone should always reflect the 
presence or absence of free T4, i.e., when free T4 is elevated, 
TSH should be almost absent. Conversely, when free T4 is 
low, TSH should be elevated. 
When the TSH of individuals in the U.S older than 12 
were measured and evaluated, 86% had a serum TSH between 
0.4 and 2.5 mIU/L (Hollowell, Staehling, & Flanders, et al., 
2002). Therefore, the recommended methodology for appro-
priate treatment is to adjust T4 dosage to bring the TSH to 
optimal levels. Hollowell, et al., found that in tertiary care cen-
ters only 50% of patients received appropriate treatment, and 
nationwide, patients continue to be over or under treated. 
In 2003, the American Association of Clinical Endocri-
nologists stated that treating patients with levothyroxine 
should be considered when the TSH >3.0 mIU/L (Wartofsky 
& Dickey, 2005). Other experts maintain that testing capa-
bility is not as precise as it must be to lower the limits from 
4.5 mIU/L (Surks, Goswami & Daniels, 2005). 
There are many reasons for a transient increase in serum 
TSH that requires serial testing to be measured at initial 
evaluation, at 1 month and again at 3 months. Those patients 
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who have clinical symptomatology as well as a persistent 
TSH between 2.5 mIU/L and 4.5 mIU/L should be considered 
at risk, and an in depth family history, a specialist consult, 
and a more intensive and expensive measurement profile 
which includes anti-TPO antibodies. This profile allows for 
identification of patients at risk or those who are progressing 
slowly to a more overt form of hypothyroidism. 
Hypothyroidism is eight times more common in women 
than men and often presents in the later decades of life. The 
patient often complains of non-specific clinical signs such as 
depression, lethargy, weight gain, swelling, constipation and 
some mental acuity delays, among others (see Table 11.9 on 
page 422). Because hypothyroidism presents with a depression 
of clinical signs (respiratory rate, heart rate, blood pressure, 
temperature, metabolic rate among others) the symptoms 
are frequently misdiagnosed. As metabolic effects decrease, 
blood glucose goes down along with most other important 
byproducts of metabolism. In fact, all measures of cardiovas-
cular and metabolism decrease. The only frequently elevated 
metabolic measures that do not perform in this manner are 
cholesterol and triglycerides, which are often elevated. 
Occasionally, elderly patients might present after a bout 
of pneumonia, severe sepsis, after a stroke or in relationship 
to aspiration. In acutely ill patients care must be taken to a.) 
evaluate situational hypothyroidism and b.) rule out euthy-
roid sick syndrome. 
Individuals who are acutely or critically ill may suffer an 
extreme disruption of the normal thyroid axis, particularly relat-
ed to the nocturnal surge that is normally seen with Thyrotro-
pin. However, these patients will suffer a low T3 level even after 
the TSH is restored to normal (Langouche & Van den  Berghe, 
2006), and are commonly referred to as presenting with low T3 
syndrome. Patients with poor heart function or more intense 
inflammatory reaction showed more pronounced down-
regulation of the thyroid system. During sepsis, the pituitary 
gland is activated via blood-borne pro-inflammatory cytokines 
and through a complex interaction between the autonomic ner-
vous system and the immune cells. Sepsis elicits a very repro-
ducible pattern of pituitary hormone function causing a rapid 
inhibition of secretion of thyroid-stimulatory hormone. 
The euthyroid sick syndrome (ESS) may manifest as a 
low T3, low T4, low TSH, or all three. ESS results from inac-
tivation of 5′-Deiodinase, resulting in conversion of FT 4 to 
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Sings and Symptoms of 
Hypothyroidism Physical Examination
Less active than usual with loss of  Delayed relaxation time of deep tendon
 interest in things previously enjoyed.  refl ex
Lethargy, Fatigue and decreased  Sluggish appearing slow responses
 mobility
Dry skin
Apathy and psychomotor retardation Mental status change
Weakness, arthralgia, myalgia  Carotenemia: An orange or yellow 
 tint without scleral icterus
Coarsening of the voice Brittle nails and hair
Constipation
Cold intolerance Low body temperature
Edema, weight gain  Facial features that are puffy and coarse
Cardiovascular  Sinus bradycardia and a prolonged 
 PR and QT intervals, fl at T waves
 Low voltage
  Systolic hypotension with diastolic 
 hypertension
  Pleural. Pericardial and peritoneal 
 effusions
Respiratory and metabolic  C02 retention, hypoglycemia, 
 hyponatremia
 Elevated cholesterol and triglycerides
11.9 Clinical Signs of Hypothyroidism
rT3 (a reverse form of T3 which is not metabolically active). 
ESS may occur in critically ill patients, but is also coexis-
tent with DM, malnutrition, iodine loads, or medications 
(including Amiodarone, PTU, and glucocorticoids). 
ESS should be considered when TSH and or T4 are normal, 
T3 is low and the patient presents with symptoms that  suggest 
hypothyroidism (Docter, Krenning, de Jong & Henneman 
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(1993). Although there is some disagreement on management, 
currently practitioners are advised to terminate the causative 
agent and to allow resumption of normal thyroid function. 
Myxedema Coma This exaggeration of the hypothyroid 
response may occur in undiagnosed hypothyroid patients or 
when an individual has not been optimally treated, or not treat-
ed appropriately during stressful situations (Exhibit 11. 2). 
Clinically, hypoxemia, hypotension, hypoglycemia, hypo-
natremia, and confusion confound and delay the diagnosis of 
extreme hypothyroidism. The general signs and symptoms 
of profound hypothyroidsim are exacerbated, to the point of 
myxedema megacolon as well as myxedema madness. 
Because myxedema coma is a life threatening event, rapid 
therapy must be considered. Outcome predictors that should 
facilitate prompt and aggressive treatment include advanced 
age, body temperature <93°F, hypothermic condition persist-
ing more than three days, bradycardia <44 beats/minute pro-
found hypotension and /or myocardial infarction. 
Common Factors that Precipitate or Exacerbate Myxedema
Hypothermia (exposed to cold)
Cerebrovascular accidents
Congestive heart failure
Infections
Medications Amiodarone (oral and over time)
 Lithium carbonate
 Sedatives, narcotics, anesthesia
Metabolism Hypoglycemia
 Hyponatremia
 Acidosis
 Hypocalcemia
Respiratory Hypercapnea, hypoxemia
11.2 Factors that Infl uence Myxedema Coma
Exhibit
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The goal of immediate therapy is to support the thyroid 
hormone levels as well as intervene in the organ systems 
involved. Initial therapy must include immediate intravenous 
thyroid replacement (L-thyroxine (T4), 300 to 500 μg IV ini-
tially, then 1.7 mcg/kg/day intravenously until bowel func-
tion is normal, consider administration of T3 as 20 mcg IV 
bolus (loading dose 10–25 mcg), then 10 mcg Q8-12H until 
the patient can take oral therapy). Other primary interven-
tions include, securing the airway and assuring ventilation, 
vigilant cardiac and respiratory monitoring, steroidst, passive 
rewarming, appropriate hydration and diuresis (with hypona-
tremia at the center of focus). Hydrocortisone 100 mg intrave-
nously every 8 hours, is an adjunctive therapy that may also 
be essential. As soon as possible, oral therapy should be initi-
ated. Care must be taken to assure that patients take medica-
tion on an empty stomach and at the same time each day. 
Hyperthyroidism 
Thyrotoxic Crisis (Thyroid Storm). The effects of hyperthyroid-
ism are related to the continuous tissue exposure to excessive 
circulating thyroid hormone, which then produces a very hyper-
metabolic state. The most common cause of this syndrome is 
Graves’ disease, followed by toxic multinodular goiter, and soli-
tary hyperfunctioning nodules. Autoimmune postpartum and 
subacute thyroiditis, tumurs that secrete thyrotropin, and drug-
induced thyroid dysfunction are also important causes. Hyper-
thyroid symptoms such as those expressed in Exhibit 11.3 are 
often positioned with opthalmic signs, at the more acute diag-
nostic point. Other indicators of hyperthyroidism may include 
osteoporosis, hypercalcemia, congestive heart failure, prema-
ture atrial contractions or atrial fibrillation, shortness of breath, 
muscle weakness, anxiety, or amenorrhea (Cooper, 2003). About 
15% of elderly individuals with new onset atrial fibrillation have 
thyrotoxicosis. And Shimzu, et.al, (2002) found AF resistant to 
pharmacologic or electrical therapies until the thyroid condition 
was treated. 40% of the patients will present with ophthalmop-
athy, in particular exophthalmus. When thyrotoxicosis,  goiter 
and ocular signs present in a triad, the diagnosis of Graves’ dis-
ease is self evident. 50% of patients with Graves’ disease may 
not have clinically detectable ophthalmopathy at presentation, 
which creates some concern for diagnosticians. The presence of 
profound hypothyroid states may create adrenal insufficiency 
and hypoglycemia as well. 
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Heat intolerance, sweating Warm smooth moist skin
Purpura, pruritis Palmar erythema
Dyspnea on exertion Thin hair
Weight loss with hyperphagia Lid retraction and lag
Abdominal pain or secretary diarrhea, Myxedema of the pretibial areas
 hyper defecation
Tremulousness, tremor, weakness Wide pulse pressure
Urinary frequency, nocturia, thirst Increased systolic blood pressure
Cardiac Angina pectoris
 Short PR
 Tachycardia and atrial fi brillation
 ST segment changes
Anxiety, emotional liability  Dementia, severe psychomotor 
 dysfunction
11.3 Signs and Symptoms of HyperthyroidismSymptoms Signs
Thyroid storm is a rare but potentially life-threatening 
complication of Graves disease. An acute decrease in  thyroxine-
binding globulin facilitates high levels of free and metabolically 
active hormone. The active thyroid hormone increases the den-
sity of beta-adrenergic receptors and alters the system respon-
siveness to catecholamines. The symptoms of hyperthyroidism 
are exaggerated and may include significant tachycardia, hyper-
pyrexia, congestive heart failure, neurological compromise, and 
gastroenterological or hepatic dysfunction. This profoundly 
exacerbated thyroid state presents as a  medical emergency.
Although primarily a clinical assessment, laboratory diag-
nostic testing may reveal suppressed TSH levels and increased 
serum free T4, a significant increase in RAIU (radioactive iodide 
uptake), a markedly elevated erythrocyte sedimentation rate as 
well as other less obvious indicators. If the TSH is low and the 
free T4 is normal, evaluation of free T3 should be undertaken. 
The emergent therapeutic goal will be to immediately suppress 
Exhibit
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 Name of Dosing frequency
Therapies Medication and Route IV or (PO/NG)
β-blockers: Antagonizes Propranolol 1mg/min IV up to 10 mg
 effects of increased   (as required and titrated
 adrenergic   over time) and 60–80 mg
Tone, blocks T4-to-T3 Esmolol  every 4 h po or by NG tube
 conversion Propylthiouracil  800 to 1200 mg orally initially,
 then begin 200–250 mg q4h
 for total daily dose of 
 1200–1500 mg
 Methimazole  30 mg po immediately, then
 30 mg every 6 h
Iodinated contrast  Iopanoic acid or  0.5–1.0 g/d po or by NG tube
 agents:  ipodate
Blocks T4-to-T3 conver- Lugol’s solution 10 drops tid po or by NG tube
 sion, blocks thyroid Potassium Iodide 5 drops every 6 h po or by
Hormone release (via  SSKI  NG tube
 iodine release) Sodium iodine 0.5–1.0 g intravenously every
 Hydrocortisone  12 hours
 Dexmethasone 
Cool patient Cooling blankets  Acetaminephine only Salicy-
 late converts T4 to T3
Hydrate as needed Isotonic solutions
11.10 Interventions for Thyrotoxicosis (Thyroid Storm)
the thyroid hormones and their Beta enhancing effects, as well 
as providing overall system support. Of vital concern is the 
administration of beta antagonists,  generally Propranolol 1.0 to 
10 mg VERY SLOWLY titrated intravenously over 30 minutes, or 
40 to 120 mg orally every 6 hours. One may also consider intra-
venous Esmolol (0.25–0.5 mcg/kg loading, infusion of 0.05–0.1 
mcg/kg/min. All therapies can be reviewed in Table 11.10. Once 
crises is over, the definitive treatment of Graves disease requires 
the historical triad that previous generations of clinicians have 
used; surgery, radioiodine, and antithyroid medications. 
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 Acute Adrenal Insufficiency 
The ability to mount a compensatory, life-saving stress response 
is based on the complex interactions between the sympathetic 
nervous system and the pituitary expression of critical stress hor-
mones, which stimulate the target organs. As stress increases, so 
does the expression of the hormonal cascade. Central to the stress 
response is the release of cortisol (see Figure 11.1 on page 401). 
Cortisol has several important physiologic actions on 
metabolism, cardiovascular function and the immune system. 
The metabolic effects of cortisol include an increase in BG 
concentrations through the activation of key enzymes involved 
in hepatic gluconeogenesis and inhibition of glucose uptake in 
peripheral tissue. In addition, cortisol activates lipolysis in adi-
pose tissue, which affects the release of free fatty acids into the 
circulation. Cortisol also has a permissive effect on other hor-
mones including catecholamines and glucagon and may result 
in the development of a relative insulin resistance and hyper-
glycemia, at the expense of protein and lipid catabolism. The 
synergistic effects of cortisol on local catecholamine uptake 
essentially maintains vascular tone. Another possible cortisol 
effect is an inhibition of the nuclear factor-κB (NF-kappa B), 
which profoundly affects systemic inflammation through vari-
ous mechanisms (Riad M et al., 2002). Steroids are typically 
released in a pulsatile, diurnal pattern, meant to support the 
daily rhythms of human physiologic states (not pathologic). 
However, the role of cortisol in sustaining metabolic and vas-
cular function through various critical illness states is widely 
underappreciated. During a critical illness, particularly severe 
sepsis and multiple organ dysfunction syndrome, it is not 
uncommon for patients to experience a disturbance of cortisol 
release, resistance, and/or pituitary dysfunction. This disorder, 
which is often situational, is termed  relative adrenal insuffi-
ciency and is related to the primary stress condition. Previous 
observational and controlled studies regarding adrenal insuf-
ficiency have yielded more controversy and group discussions 
rather than actual data. Lack of specific signs and symptoms 
makes early recognition of acute adrenal insufficiency diffi-
cult, although the concept of relative adrenal insufficiency has 
been at the center of many scientific sessions and research 
in the last 10 years. Debate continues about what represents 
relative adrenal insufficiency; however, the single most impor-
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tant clinical clue in critically patients is failure to respond to 
fluid boluses and/or vasopressor dependency.
Adrenal insufficiency may be the result of failure of the adre-
nal glands caused by autoimmune disease, glaucomatous disease, 
human immunodeficiency virus (HIV) infection, adrenal hemor-
rhage, meningococcemia or failure of the hypothalamic/pituitary 
axis, which may occur secondary to withdrawal from glucocor-
ticoid therapy. In critically ill patients, the most studied cause is 
severe sepsis. Relative adrenal insufficiency may be exacerbated 
via a chain of events (Table 11.11). 
 Measurement Issues 
Relative or functional adrenal insufficiency occurs in patients 
with severe illness when the corticosteroid response is 
reduced in proportion to the severity of illness. This condition 
usually reverses with recovery from the illness, but can con-
found the issues of responsiveness as well as interfere with 
catecholamine—both endogenous and exogenous—effects 
on vascular tone. The diagnostic criteria for relative adrenal 
insufficiency continues to be debated, especially as it relates 
to patients with septic shock or those requiring vasopres-
sors. Unfortunately, the measurement of total cortisol reflects 
both cortisol bound to protein, cortisol- binding globulin and 
Decreased 
Production/Transport Decreased Response
1. The hypothalamic–pituitary– adrenal 1. Decreased number of
 axis is already profoundly stimulated.  receptor availability
2. Pituitary glucocorticoid feedback  2. Decreased availability of 
 might be altered.  receptor sites
3. The adrenal glands are already  3. Diminished binding sites
 stimulated by the increased secretion  4. Increased clearance
 of peptides with corticotropin releasing 
 hormone—like activity.
4. Adrenal hemorrhage
11.11 Reasons for HPA Dysfunction
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albumin, and free cortisol,(physiologically active form). Low 
serum albumin levels may actually create false alterations in 
the measured serum cortisol levels, and low serum albumin 
states are very common in critical illness (Marik & Zaloga, 
2003). Clinicians have used low random cortisol concentra-
tions, measuring total rather than free, as well as a decreased 
response to a short adrenocorticotropic hormone (ACTH) 
stimulation test (standard one time dose of 250 μg or physi-
ologic 1 μg dose of cosyntropin) to diagnose adrenal insuf-
ficiency in critical illness. Issues that surround this method 
of measurement include the following: (a) diurnal or circa-
dian variations are lost in critical illness; (b) 250 μg of ACTH 
may be a supraphysiologic stimulation, therefore, yielding an 
adrenal response when the patient may not have a normal 
physiologic response: and finally, (c) the method, timing, and 
delay associated with the evaluation may limit introduction of a 
life-saving corticosteroid replacement therapy. 
Opposing researchers have disagreed on both the method-
ology of evaluation criteria for adrenal insufficiency as well as 
the laboratory criteria (Marik & Zaloga, 2003; Annane et al., 2004; 
Hamrahaim, Osenis, & Arafah, 2004). The disagreement focuses 
on the basic measures of serum cortisol and the components that 
generate metabolic activity at the cellular levels. Changes in bind-
ing proteins can alter total cortisol levels with or without changes 
in free cortisol concentrations. Most institutions do not measure 
the free cortisol. Circulating free cortisol measures evaluate cor-
tisol availability as well as cellular uptake. 
In this case, therapeutic intervention may be the most 
important clinical clue. Prompt improvement in the hemody-
namic status (particularly blood pressure) of the patient when 
100 μg hydrocortisone intravenous (IV) bolus is given may be 
the most important physiologic indicator of a relative or pro-
portional insufficiency. 
In critically ill patients with possible situational or relative 
adrenal insufficiency, suggestive laboratory findings include 
hyponatremia, hyperkalemia, persistent acidosis, relative hypo-
glycemia, in addition to refractory hypotension (pressure not 
responsive to fluid resuscitation and  vasopressor administration). 
Generally, patients will also present with persistent  tachycardia, 
which may be a clinical differential for acute hypothyroidism. 
The additional findings that should arouse suspicion of relative 
adrenal insufficiency in a critically ill patient include fever with-
out an apparent source, or fever that is unresponsive to antibiot-
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ics, as well as discrepancy between the expected disease severity 
and the actual clinical status of the patient. 
Emergent treatment may be indicated in these patients, 
even if the diagnosis is not established. Sprung and colleagues 
(1984) randomized patients with septic shock in three groups 
including (a) methylprednisolone 30 mg/kg for one to two dos-
es, (b) dexamethasone 6 mg for one to two doses, or (c) placebo. 
The overall mortality rate for the entire study period was not 
different among the groups; however, the mortality rate at 133–
150 hours after treatment was significantly lower in the steroid 
(40%) versus placebo (69%) groups. In addition, shock reversal 
within 24 hours of randomization was significantly improved 
in the steroid-treated group. Most recently, the  CORTICUS trial 
(Lipiner–Friedman et al., 2007), the  largest to date study on the 
role of relative adrenal insufficiency in severe sepsis provided 
the following three confirmations as well as one unexpected 
result: (a) the defined value of baseline and ACTH stimulated 
cortisol levels in relation to mortality from severe sepsis or 
septic shock, (b) delta cortisol, (change occurring when ACTH-
stimulated cortisol minus baseline cortisol) should be 9 mg or 
more. This delta event was more predictive of clinical outcomes 
than the basal cortisol level, (c) physicians should be aware that 
etomidate influences ACTH test results and clinical outcome. 
Importantly, in this large trial, In addition, no survival benefits 
were evident. 
The SCCM guidelines support the intuitive and assump-
tive use of hydrocortisone in patients with sepsis and/or acute 
respiratory distress syndrome who present with hypotension 
that remains refractory to appropriate volume resuscitation 
and vasopressor management. Other suggestions for manage-
ment are based on the data from a wide variety of studies.  
When Dexmethasone is used initially for emergent ste-
roid replacement, a short ACTH stimulation test can be per-
formed for diagnosis after resuscitative therapy is instituted 
as Dexmethasone does not interfere with the serum cortisol 
assay and therefore response. 
 Vasopressin Abnormalities 
Vasopressin is produced in the hypothalamus and released direct-
ly from the pituitary gland. The effects of vasopressin depend on 
the receptor site affinity as well as site activity. Activation of V1 
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receptor, which reside on vascular smooth muscle is responsible 
for vasoconstriction. Activation of V2 receptors on renal tubules 
is responsible for water reabsorption, reflecting vasopressin’s 
antidiuretic effect (Exhibit 11.4). V3 pituitary receptors have more 
central effects, such as  increasing adrenocorticotrophic hormone 
production in response to o the V3 receptor sites (Holmes, Landry, 
& Granton, 2003, 2004). Vasopressin increases the passive water 
permeability of the cell membrane of the nephron-collecting 
ducts. It is a potent vasoconstrictor as well as a  neurotransmitter, 
regulating the secretion of ACTH and effects the cardiovascu-
lar system, temperature, and other visceral functions. In addi-
tion, vasopressin promotes hemostasis as well as stimulating the 
release of endothelial coagulation factors therefore increasing 
platelet aggregation. 
 Loss of Vascular Tone 
From the time of Landry’s sentinel publication in 1997, sev-
eral studies have shown that in patients with advanced shock 
and refractory hypotension there is evidence for low serum 
concentrations of vasopressin, also known as antidiuretic hor-
mone (ADH). In recent studies, plasma vasopressin  levels were 
almost always increased at the initial phase of septic shock and 
Vasopressin Receptors
Two principal types of receptors, V1 and V2.
V1 receptors have been sub classifi ed further as V1a and V1b.
Typical G-protein coupled.
■  V1a receptor found in vascular smooth muscle, myometrium, the bladder, 
platelets, renal medullary interstitial cells, vasa recta in the renal micro-
circulation, epithelial cells in the renal cortical collecting duct, spleen, 
testis, and in many CNS structures.
■ V1b receptors only in the anterior pituitary
■  V2 receptors are predominantly located in principal cells of the renal 
 collecting duct system.
11.4 The Vasopressor Receptors and Their Purpose
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decreased during the later stages. In fact, Vasopressin deficiency 
was evaluated in one third of patients with late septic shock 
(Malay, Ashton, Landry, & Townsend, 1999; Patel, Chittock, Rus-
sel, & Walley, 2002). Unfortunately, the appropriate circulating 
levels of vasopressin in critical illness have not been confirmed; 
however, measured vasopressin deficiency can be considered as 
relative at <30 mcg/ml or absolute when <10 mcg/ml.  
When patients require catecholamine vasopressors to 
maintain their systolic blood pressure >90 mmHg, there should 
always be suspicion of vasopressin deficiency. In this case, vaso-
pressin replacement at a continuous fixed dose (0.01–0.04 units/
min IV) can be used to supplement catecholamine infusions. 
Patients with acute myocardial infarction, acute bowel infarc-
tion, or ischemic gangrene of the distal extremities may have 
worsening ischemia if vasopressin therapy is applied. 
Multiple studies have shown that infusion of low-dose vaso-
pressin decreases the norepinephrine dose, maintains blood 
pressure and cardiac output, decreases pulmonary vascular 
resistance, and increases urine output in this patient  population 
(Malay et al., 1999; Patel et al., 2002). The introduction of vaso-
pressin must be cautiously approached as vasopressin is linked 
to vasospasm of both the coronary arteries and the gastric vas-
culature. When critically ill patients, particularly those in severe 
sepsis, present with refractory hypotension and require increas-
ing vasopressors support, consider cortisol 100 mg IV bolus, fol-
lowed by 50–75 mg every 6 hours for 7–10 days and/or initiation 
of a vasopressin drip at 0.1–0.4 units/min. 
 Inability to Regulate Vasopressin (ADH) Hormone 
The renal regulation of sodium is partially controlled by 
the expression of ADH or vasopressin, which then affects 
water conservation or loss. The essential body water, both 
intracellular and extracellular, must be stable to allow nor-
mal cellular functions (dependent on ionic concentration 
gradients) to take place. Small changes in blood solute con-
centration (plasma osmolality) regulate vasopressin release. 
When vasopressin is released in response to the osmolar 
signal, this directly affects (in physiologic states) the distal 
tubules of the kidney. The release of vasopressin is primarily 
related to the serum osmolality and to the volume load, and 
at very low levels, vasopressin may also decrease portal pres-
sures (Oliver et al., 2007). Together with the renal counter-
current regulation mechanism, the effect is to keep sodium 
Chapter 11: Endocrine Emergencies 433
in a content range of 138–142 mmol/L, which then, of course, 
reflects serum osmolarity. Alterations in sodium and water 
regulation potentiate a series of life-threatening events. 
SIADH: Syndrome of Inappropriate Antidiuretic Hormone. 
SIADH is a rare but well-recognized disorder, and the clinical 
diagnosis is based on features first proposed by Bartter and 
Schwartz in 1967. The syndrome of inappropriate  antidiuretic 
hormone (SIADH) secretion presents with an inappropriately 
elevated serum ADH level relative to serum osmolality and 
hypervolemia. Despite a low serum sodium concentration, the 
patient is not effectively diuresing water to bring concentrations 
back to a normal range. This disorder can be considered as a fail-
ure to excrete excessive water appropriately. Urine output may 
be adequate, but the amount of water to sodium waste is out of 
proportion. 
Causes of SIADH are many and can be generated by a 
single problem or combination of events (Table 11.12). 
Once suspected, SIADH requires careful management 
with water restriction and occasionally (in severe hypona-
tremic/hypervolemic states) aggressive salt retaining and 
diuresis must be applied. When evaluating sodium concen-
tration and content states, attention must be paid to other 
variables that affect cellular hydration or dehydration.) 
Hyperglycemia accounts for 15% of hyponatremia in inpa-
tients. Serum Na + falls by 1.6 mmol/L for every 100 mg/dl (5.6 
mmol/L) increase in plasma glucose (Kumar, 1998). 
Disease States Pharmacologic States
Acute and chronic pulmonary disease Phenothiazines
Central nervous system disorders Vincristine
Acute psychosis Thiazides
Surgical stress Morphine
Malignancies Carbamazepine
Genetic Vasopressin
HIV–AIDS Antipsychotic agents
11.12 Causes of SIADH
434 Critical Care
When evaluating patients for hyponatremia, all possible 
causes must be considered (Table 11.13). The first component 
of evaluation includes the following four essentials for defini-
tive diagnosis: (a) the effective serum osmolality must be 
below 270 mOsm/kg water; (b) the urine concentration (>100 
mOsm/kg) is inappropriately high related to the dilute serum; 
(c) the urine sodium is >20 mEq/L in a none salt-wasting state 
(no diuretic administration, no abnormal salt intake); and (d) 
adrenal, thyroid, pituitary disease, renal insufficiency cannot 
be present. 
In general, patients with SIADH cannot excrete a  solute-free 
urine, and do not regulate the water-sodium in proportion, giving 
rise to moderate nonedematous volume  expansion and dilutional 
hyponatraemia. Symptoms depend on the level of hyponatremia 
and the rate at which it develops. Above 125 mmol/L, symptoms 
are rare; in the range of 125–130 mmol/L, the predominant symp-
toms are gastrointestinal. When the serum sodium falls below 
125 mmol/L, the patient may present with severe  neurological 
symptoms and this calls for immediate treatment. Signs and 
symptoms associated with significant hyponatraemia are nausea 
and vomiting, muscular weakness, headache, lethargy, reversible 
ataxia, and psychosis and, in severe cerebral edema, respiratory 
depression, increased intracerebral pressure, seizures, coma, and 
even tentorial herniation. The presence of symptoms and the 
duration of the hyponatremic state are key factors which will 
guide the treatment decisions, as  noted in Table 11.14. Hyponatre-
Types Total Sodium Total Water Cause
Hyponatremic  ↓↓↓ total body ↓ total body Diuresis (loop)
Hypovolemia  sodium  water  Mineralcorticoid
 defi ciency  cerebral 
 salt  wasting
Hyponatremic  normal or ↑ total ↑↑↑ total body Heart, liver, renal
Hypervolemia   body sodium  water  failures
Hyponatremic  Normal total  Total body water SIADH
Hypervolemia  body sodium
11.13 Differentiating Low Sodium Disturbances
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mia developing rapidly over 48 hours or less carries a greater risk 
of permanent neurological disorders related to cerebral edema 
unless the serum sodium is corrected. However, patients with 
chronic hyponatremia are at greater risk of osmotic demyelination 
if the correction is excessive or too rapid. In addition to sodium 
replacement, the patient must be fluid restricted. 
The use of common pharmacologic agents, such as the 
selective serotonin re-uptake inhibitors is associated with dis-
ruption of antidiuretic hormone action. SIADH is more likely 
in some populations, including people who are elderly or 
who take diuretics. Serum sodium levels should be monitored 
closely in those at higher risk (Rottmann, 2007). 
Diabetes Insipidus. The role of the kidney is to maintain a 
perfectly balanced serum as it relates to Na+ and water. The 
essential evaluation of this property requires the comparative 
 Acute SIADH  Chronic SIADH
 <48 hours  >48 hours 
 duration duration
Risk of cerebral edema High Low
Risk of central pontine Low High
 myelinolysis
Neurologic symptoms Present Present
Rate of Na+ increase  ■ 2 mmol/hr until ■ Immediate: 10% 
 sodium measurement  symptoms resolve  replacement
   ■ May then discon-  (10 mmol/L)
  tinue or return to ■ Continuous:
  normal levels   1.0–1.5 mmol/hr
fl uid administration rate  1–2 ml · kg−1 · hr−1 0.5–1.0 ml · kg−1 · hr−1
 of 3% sodium chloride
fl uid administration rate of 4–6 ml · kg−1 · hr−1 NA
 3% sodium chloride if
 symptoms include 
 seizures, obtunded, coma
11.14 Therapies for Acute or Chronic SIADH
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analysis of the serum sodium (135–145 mmol/dl) to urine sodium 
(<20 mEq/dl) and the serum osmolality (275–295 mOsm/L) to 
urine osmolality (50–1000 mOsm/L). When the serum is con-
centrated, urine should be concentrated; when serum is dilute, 
urine should be more dilute. The renal mechanisms provide a 
first line of defense to hypo and hypervolemia as well as hypo 
and hyperosmolarity. An increase in plasma osmolality,  usually 
indicating a loss of extracellular water, normally stimulates vaso-
pressin secretion (antidiuresis) which promotes fluid conserva-
tion and a decreased urine output, and conversely, a decrease in 
plasma osmolality inhibits vasopressin release into the systemic 
circulation and promotes more fluid wasting (increased urine 
output). When vasopressin is released, its primary action will 
be to stimulate the V2 receptors found in the renal collecting 
duct (Robertson et al., 1976). The serum osmolality signal, the 
pituitary release of vasopressin, and the renal response should 
facilitate urine concentrations that are in the same direction as 
the serum concentration (if serum is concentrated, urine should 
be concentrated and sparse, if serum is dilute, urine should be 
dilute and proportionately plentiful). Finally, the thirst stimu-
lant, which is as important as vasopressin release, is the third 
regulator of serum osmolality. Polyuric disorders can be caused 
by any alteration in the three mechanisms (Table 11.15). 
The renal losses of water that lead to euvolemic hyperna-
tremia (inability to conserve water) are a consequence of either 
a defect in vasopressin production and/or release (central dia-
betes insipidus) or failure of the collecting duct to respond to 
the hormone (nephrogenic). Common features of both types of 
diabetes insipidus include polyuria, polydipsia, hypernatremia, 
and elevated serum osmolality. The diagnostics should be firmly 
based on the patient’s serum sodium/urine sodium  levels and 
even more importantly the serum concentration/urine concen-
tration relationships. 
Glucose is a hyperosmolar molecule and, in the insulino-
penic state, does not cross the cell wall. By its presence in the 
extracellular fluid (ECF), the concentration gradient pulls water 
from the cell (intracellular) to the extracellular space, leading to 
cellular dehydration, which is one of the reasons hypotonic solu-
tion may be needed for  cellular fluid resuscitation. The lower-
ing of measured serum (Na +) in this situation is not related to 
the actual sodium content, but to the  concentration of sodium in 
the translocation of fluid from the intracellular to the extracel-
lular compartment. Na+ measures in a hyperglycemic state may 
underpredict the patient’s volume status and fluid loss. There-
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fore, total body water has not increased, simply shifted because 
of the concentration gradient. 
The patient with DI has an inability to conserve water The 
symptoms associated with either central or nephrogenic dia-
betes insipidus are primarily neurologic. Hypovolemic signs 
and symptoms as well as altered mental status, lethargy, sei-
zures, hyperreflexia, irritability, and restlessness are common 
presentations for both types. 
The administration of a water deprivation period (2 hours) 
followed by the administration of aqueous vasopressin dif-
ferentiates the type of diabetes insipidus (Table 11.14 on page 
435). Once definitive diagnosis has been made, therapy will be 
designed for the problem. Central DI, is treated with fluid resus-
citation and the exogenous desmopressin (vasopressin) will be 
  Urine  Serum 
  Output/ Sodium/
Causes of   Urine  Serum
Polyuria Symptoms Osmolality Osmolality
Defi ciency of  Polyuria, polydipsia ↑↑↑ increase ↑↑↑ increase
 osmoregulated  nocturia, signs of ↑↑↑ increase ↑↑↑ increase
 vasopressin  severe hypovolemia  RESPONDS to
Central     vasopressin
DI/Neurogenic    administration 
    (11.14)
Reduced renal  Polyuria, polydipsia, ↑↑↑ increase ↑↑↑ increase
 response to   nocturia, signs of ↑↑↑ increase ↑↑↑ increase
 adequate   severe hypovolemia,  DOES NOT
 vasopressin  often hyperglycemic   RESPOND to
Nephrogenic DI     vasopressin 
    administration 
    (11.14)
Excessive   Variable ↑↑ increase
 persistent   Serum K+ ↑↑ increase
 fl uid intake   is low
11.15 Causes of Polyuria
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titrated to achieve normal serum–urine relationships. Dosing 
(0.1–1.1 μg intravenously) will depend on what is required to 
reverse the osmolalities. Administration of exogenous vasopres-
sin replaces what the pituitary has limited. Unless the problem 
is congenital, the probability is that the patient will eventually 
restore normal regulation relationships without the additional 
vasopressin. Nephrogenic DI must be evaluated first for cause 
whether it is metabolic or pharmacologic. Following that, salt 
restriction and salt-wasting diuretics will be administered to 
increase the urine output and decrease the serum osmolality. 
Potassium-sparing diuretics may be added to the mix as well. 
 Summary 
Endocrinopathy during critical illness can manifest as hyper-
glycemia and insulin resistance or as insufficient production 
of either adrenal corticosteroids or vasopressin. The founda-
tion of normal endocrine response may crumble in critical 
illness, particularly in hyperinflammatory shock. When the 
foundation begins to dissemble, the vigilant critical care pro-
vider may thwart the destruction with rapid and aggressive 
therapeutic interventions. There are many conditions associ-
ated with endocrine dysfunction and a wide variety of organ 
alterations. Those discussed here are the most commonly 
known dysfunctions in the critically ill, adult patient. 
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 Introduction 
The diagnosis and management of infection in the intensive 
care unit (ICU) affects more than just the individual patient. 
Whether or not a course of antibiotic therapy is success-
ful for one patient, the bacterial ecology of the unit will be 
affected in ways that can affect other patients indefinitely. 
Wise choices can minimize the emergence of resistance, 
whereas unwise choices and practices can jeopardize the 
health of many. In this chapter, we will try to explain why 
patients in the critical care environment are at increased 
risk for infection, how infection affects patients, and how to 
diagnose hospital-acquired infections (HAIs) in the critically 
ill patients. We will then discuss treatment options for infec-
tions commonly found in critically ill patients .
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 Epidemiology 
The most common infections in the critical care environ-
ment are sinusitis, pneumonia, urinary tract infection (UTI), 
and catheter-related bloodstream infection (CR-BSI). Most 
nosocomial infections are subsequent to instrumentation of 
their respective organ systems. Data from the National Noso-
comial Infection Surveillance system (NNIS) demonstrate 
that 97% of UTI, 83% of nosocomial pneumonia episodes, and 
87% of bloodstream infections were associated with indwell-
ing instrumentation of the affected body system (Richards, 
Edwards, Culver, & Gaynes, 2000). The average added costs 
for each patient with a health care-associated infection (HAI) 
were found to be in excess of $8,000 in one recent study 
(Murphy, Whiting, & Hollenbeak, 2007). Infection-associated 
mortality rates vary widely across studies and in different 
patient populations, as well as within these populations due to 
age, comorbidities, and severity of illness. In the ICU, approxi-
mately 30% of patients are affected by HAIs during their stay, 
with trauma and burn patients having the greatest risk for the 
development of infection (Vincent, 2003). 
 Pathophysiology 
Treatment in the ICU includes invasion and violation of the 
most basic bodily defenses against infection. In addition to 
the breakdown of defenses, the patient care environment 
is often heavily colonized with the most antibiotic-resistant 
human pathogens. Other critically ill persons reside close 
to each other, and many ICUs still retain the design flaw of 
shared bays, which may contain multiple patients. Patients 
may be cared for by multiple health care providers who are 
concurrently caring for other patients with heavy bacterial 
colonization or active infection. 
In critically ill persons, the natural drainage of the sinuses 
is compromised in patients who are recumbent 24 hours a day. 
In addition, sedated patients cannot take the normal steps 
of personal hygiene to keep the upper airways and sinuses 
clear of secretions. Nasogastric tubes incite inflammation 
in the nasopharynx and mechanically obstruct their ostia, 
interfering with drainage. The accumulation of secretions in 
the sinuses can, and frequently does, become infected. The 
diagnosis of sinusitis is difficult to make with certainty, and 
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treatment is complicated by the difficulty of draining these 
bony cavities and the lack of penetration of antibiotics into 
these virtual abscesses (Stein & Caplan, 2005). 
The respiratory system is normally protected by several 
mechanisms, many of which are routinely compromised in the 
ICU. Endotracheal intubation bypasses the normal defense of 
the closed glottis and introduces a foreign body into the trachea. 
The endotracheal tube incites an inflammatory response, 
impairs the mucociliary elevator, and provides a surface for 
the formation of a biofilm. A biofilm is a slippery coating of 
bacteria that forms quickly and easily on wet environmental 
surfaces. The biofilm is thought to contain a large proportion 
of the environmental bacterial biomass and has been linked 
strongly to the presence of resistant bacteria and recurrent 
patient infections. These biofilms are inherently resistant to 
antimicrobial agents through multiple mechanisms; therefore, 
they provide an ideal nidus for infection in the critically ill 
patients (Costerton, Stewart, & Greenberg, 1999). 
The balloon cuff of the endotracheal tube, contrary 
to common misconception, does not prevent aspiration of 
secretions. The cuff also locally injures the epithelial lining 
of the trachea, allowing for direct invasion of the trachea by 
bacteria. The lumen of the tube also quickly develops a bio-
film, accumulates secretions, and is a direct conduit from the 
outside world into the lungs. Sedation or paralysis impairs 
coughing, which is needed to expectorate mucus. Positive 
pressure ventilation, while lifesaving, does not ventilate all 
areas of the lung evenly. Portions of the lung can become 
collapsed, consolidated, and infected if special care is not 
taken to provide lung recruitment maneuvers with the ven-
tilator (Leong & Huang, 2006) In addition, alkalinization of 
the stomach from gastric ulcer prophylaxis allows bacterial 
overgrowth, with potential reflux of this bacteria-laden fluid 
up an esophagus compromised by a nasogastric tube. 
Within the genitourinary system, the urethra serves as 
the conduit for UTI. Indwelling urinary catheters traverse an 
orifice normally used only for the release of urine. The urinary 
catheter locally inflames the urethral epithelium,  provides 
a direct conduit into the bladder from the urine collection 
bag and provides a nidus for the accumulation of biofilm. 
Anatomically, the catheter exits the body at a site near the 
perineum and its attendant frequent soilage, predisposing 
to ascending infection. Finally, the urinary drainage system 
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may be violated for sampling of urine for laboratory analysis, 
for pressure measurements, or for routine emptying of the 
collection bag. Nephrostomy tubes and suprapubic catheters 
share similar risks to patients (Bagshaw & Laupland, 2006). 
Urinary tract infections are the most common nosocomial 
infections in hospitalized patients, likely secondary to the 
high prevalence of urinary catheters in hospital inpatients 
(Saint et al., 2008; Vincent, 2003). 
Vascular catheters violate the normally closed circula-
tory system, allow access for bacteria from the skin to the 
bloodstream, and allow for the formation of biofilm on the 
catheter. In addition, the catheters are routinely accessed for 
administration of therapeutic agents, blood sampling, and 
pressure monitoring. Each time the system is accessed, the 
opportunity for entry of bacteria exists. The prevention of 
CR-BSI has spawned an entire industry and science related 
to its prevention, with anti-infective coated catheters, anti-
infective dressings, and protocols for the management of 
central vascular catheters. (Jones, 2006; Timsit, 2007) 
Clinical Manifestations. The manifestations of systemic inflam-
mation and infection mimic each other, as described above. 
Essentially, all physiologic derangements can be related to either 
infectious or noninfectious causes. Therefore, localized signs of 
infection such as purulent sputum or nasal drainage infiltrate 
on chest radiograph, erythema around a catheter site, or cloudy, 
foul-smelling urine are of significance when combined with 
culture data in the critically ill patient. Clinical vigilance and 
the inclusion of “infection” in the differential diagnosis of each 
derangement will lead to the prompt and accurate diagnosis of 
infection (Sprung et al., 2006). 
 Diagnosis 
Diagnosis of infection depends on recognition of clinical 
signs of infection, appropriate radiologic imaging when indi-
cated, and directed microbiologic sampling. Clinical signs of 
infection may be difficult to recognize in the ICU. Infection 
closely mimics the systemic inflammatory response syn-
drome (SIRS) that can normally be expected in a large per-
centage of critically ill patients. Fever, tachycardia, tachypnea, 
and leukocytosis can all be present without an infection, and 
distinguishing SIRS from sepsis is not always possible. There 
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are no validated criteria by which to differentiate patients with 
SIRS from those who have an infection, which makes it dif-
ficult to determine when to begin antibiotics in patients who 
are suspected of harboring an infection. Unfortunately, it has 
been shown that delay of appropriate antibiotic therapy in 
ICU-related pneumonia and bloodstream infection increases 
mortality (Iregui, Ward, Sherman, Fraser, & Kollef, 2002; 
Ibrahim, Sherman, Ward, Fraser, & Kollef, 2000). On the other 
hand, overuse of antibiotics can lead to resistance, increased 
cost, and risk of adverse effects. Clinical judgment must be 
used in each case to decide if an infection is present and if 
empiric antibiotics should be started. 
Sinusitis. The diagnosis of sinusitis can be difficult. The 
intubated and sedated patient usually cannot complain of 
sinus pain, or pain is masked by the administration of anal-
gesics for other causes. Culture of the sinuses depends on 
either trans-skeletal aspiration of accessible sinus cavities 
(not all are accessible) or endoscopic culture, both of which 
are generally performed only by a trained otolaryngologists 
or maxillofacial surgeons. Imaging is complicated by the fact 
that mucosal thickening and accumulation of fluid does not 
necessarily mean infection is present; both of these findings 
are possible in the forced recumbency of the critical care 
environment. The attribution of clinical sepsis to sinusitis is 
often a diagnosis of exclusion in the absence of direct sam-
pling of the sinus contents. 
Pneumonia. The diagnosis of pneumonia in the ICU is 
complicated by the presence of opacified areas on chest 
radiograph because of noninfectious entities such as pul-
monary contusions, atelectasis, fluid overload, transfusion-
related acute lung injury (TRALI), and acute lung injury 
(ALI) or adult respiratory distress syndrome (ARDS). The 
Centers for Disease Control (CDC) criteria for the diagnosis 
Differentiation between infection and SIRS is diffi cult in patients 
with critical illness. Correlation of clinical symptomatology, cul-
ture results, and clinician judgement is imperative in the diag-
nosis of infection.
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of ventilator pneumonia (new or progressing infiltrate on 
chest x-ray, fever, leukocytosis, and purulent tracheobron-
chial secretions) are unfortunately nonspecific and can be 
present in other various conditions. Quantitative clinical 
assessment tools such as the Clinical Pulmonary Infection 
Score (CPIS) can aid in the diagnosis through the iden-
tification of symptomatic patients who are at higher risk 
for ventilator-associated pneumonia (VAP) (Luyt, Chastre, 
& Fagon, 2004; Minei et al., 2006). Microbiologic diagnosis 
is labor- and resource-intensive and requires a sophisti-
cated microbiology laboratory. Bronchoalveolar lavage, 
either bronchoscopic or nonbronchoscopic, requires train-
ing, sterile technique, and considerable time and expense. 
Protected specimen brush technique, wherein a protected 
brush is inserted deep into the airways to collect a speci-
men, is likewise challenging. Quantitative techniques for 
culture also demand a high level of resource commitment 
on the part of an institution. Even with quantitative tech-
niques, there is debate regarding the proper diagnostic 
cutoff to signify pneumonia and both 10^4 and 10^5 have 
been commonly used. Nonquantitative techniques do not 
adequately distinguish between colonization and infection 
(Rea-Neto et al., 2008). 
Urinary Tract Infection. Like all other ICU-associated infec-
tions, the diagnosis is complicated by the fact that patients 
may be sedated or intubated, and may not be able to com-
plain of pain or other symptoms. Only in advanced cases will 
there be obvious findings such as purulence from the ure-
thral meatus. Cloudiness of the urine is a nonspecific finding, 
and only urinalysis and culture of the urine when infection 
is suspected will lead to accurate diagnosis. These infections 
are more likely in men than in women and are uncommon 
early in the ICU stay (Golob et al., 2008). 
Catheter-Related Bloodstream Infection. The diagnosis of 
catheter-related bloodstream infection (CR-BSI) requires 
the presence of a bloodstream infection and a culture positive 
segment of a vascular catheter. Many techniques of diagnosis 
have been discussed, but the most commonly accepted is the 
Maki roll plate technique. Recognizing that the intracutaneous 
segment most often represents the conduit by which the 
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bacteria reached the bloodstream, Maki described rolling 
the ICS on sheep’s blood agar and submitting this to the 
laboratory for semiquantitative culture. Greater than 15 
colony- forming units of bacteria signify an infected line 
and the need to remove the line from the infected site. 
(Maki, Weise, & Serafin, 1977). CR-BSI is more specific 
and is differentiated from catheter-associated bloodstream 
infection (CA-BSI), in which the diagnosis requires only a 
bloodstream infection and the presence of an indwelling 
vascular catheter. Although any type of bloodstream infec-
tion requires antimicrobial therapy, the cause (infected 
intravascular catheter) and effect (bloodstream infection) 
is more closely linked in CR-BSI versus CA-BSI because of 
the addition of an infected catheter segment that contains 
the same bacteria found in the bloodstream. CA-BSI is more 
likely than CR-BSI to reflect a bloodstream infection whose 
primary source lies elsewhere. 
 Treatment 
Effective treatment of infections depends on the follow-
ing three factors: source control, physiologic support, and 
appropriate antimicrobial therapy. All three are essential 
whenever possible; however, source control is not possible 
in many ICU infections, where the source is often the pul-
monary system. 
Effective treatment of infection in patients with critical illness in-
cludes the following steps:
1.  Identifi cation and removal (if possible) of nidus of infection 
(abscess, catheter or other indwelling device)
2.  Culture of affected site/fl uid and identifi cation of causative 
organism
3.  Empiric antimicrobial therapy that is highly likely to cover 
subsequently identifi ed organism
4.  Choosing the narrowest spectrum antimicrobial agent that 
targets the identifi ed organism and effectively achieves 
therapeutic levels in the target fl uid/organ system
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Source control is defined as removing the cause of the 
infection and any infected material. This is clearly under-
stood in intra-abdominal infection—an appendectomy is a 
source control for appendicitis. It is also clear that in CR-
BSI, the infected catheter must be removed and resited in 
addition to the use of appropriate antimicrobial therapy. In 
other clinical infections, there are few data with which to 
define source control. 
Physiologic support can be optimized in the ICU patient 
where most parameters can be controlled to a high degree 
through medical or nursing interventions. Respiratory fail-
ure secondary to infection may require mechanical ven-
tilation, or increased support settings for those patients 
already receiving mechanical ventilation. Circulatory failure 
(distributive shock) because of sepsis usually requires inter-
vention with intravenous fluid boluses and not infrequent 
vasopressor support. 
Finally, antibiotic stewardship is critical. There are 
two phases of the antibiotic treatment. The first is the 
empiric phase, during which time patients have met clini-
cal criteria for pneumonia, but culture results are not yet 
available. It is crucial that appropriate empiric antibiotic 
therapy is started early. Delay in initiation of appropriate 
empiric antibiotics has been shown to be an independent 
predictor of mortality in pneumonia (Iregui et al., 2002). 
Ideally, the antibiotics should be chosen on the basis of an 
ICU-specific antibiogram. The antibiogram varies between 
units in a single hospital, and what may be appropriate 
empiric therapy in one ICU may be entirely inappropri-
ate in another (Namias et al., 2000). Based on the known 
pathogens in an ICU, appropriately broad empiric therapy 
should be started. However, this does not imply that the 
broad spectrum coverage should be continued indefi-
nitely. One approach has been to administer broad spec-
trum therapy for 72 hours or until final culture results are 
available, whichever comes first, and then to narrow the 
empiric coverage down to the least expensive, narrowest 
spectrum agent with activity against the recovered organ-
ism. In this way, patients can benefit from appropriate cov-
erage and the bacterial ecology of the ICU does not have to 
suffer, because the broad spectrum antibiotics are limited 
in duration (Namias et al., 2008). 
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Choice of antibiotics depends entirely on the suspected 
organism. Published choices for community acquired pneu-
monia focus on Streptococcus pneumoniae, whereas recom-
mendations for hospital-acquired or ventilator-associated 
pneumonia emphasize coverage for  Pseudomonas aerugino-
sa. In addition, methicillin resistant  Staphylococcus aureus
(MRSA) has become so prevalent in ICU that consideration 
must be given to empiric coverage of MRSA with vanco-
mycin or linezolid. There are controversial data to show 
the superiority of one agent over another, but it is true that 
linezolid achieves higher tissue concentrations in the lung 
than vancomycin at standard doses. Some have suggested 
that it may be necessary to achieve trough levels of 20 μg/
ml of vancomycin to effectively treat MRSA pneumonia 
(Lam & Wunderink, 2006). Extended-spectrum β-lactamase 
(ESBL)- producing organisms have made it necessary to 
use carbapenems more frequently, because these agents are 
less susceptible to hy drolysis by ESBLs than other agents. 
However, the next generation of resistant organisms, the 
Klebsiella pneumoniae carbapenemase-producing organ-
isms, are threatening the utility of the carbapenems in North 
America at this time. These organisms can be resistant to all 
antibiotics at our disposal (Pitout & Laupland, 2008).  Aci-
netobacter baumannii represents another vexing challenge 
in the treatment of pneumonia. This organism has become 
highly resistant to most, if not all, common antimicrobials in 
many inpatient settings (Trottier, Namias, et al., 2007; Trot-
tier, Segura, et al., 2007). A newer agent with activity against 
Acinetobacter is tigecycline. Unfortunately, standard suscep-
tibility breakpoints for tigecycline against Acinetobacter do 
not exist yet, so there is uncertainty in the use of this agent 
for Acinetobacter pneumonia at this time (Karageorgopoulos, 
Kelesidis, Kelesidis, & Falagas, 2008). Another agent that has 
been resurrected for Acinetobacter is colistimethate, a poly-
mixin analog. This agent is highly nephrotoxic but retains 
activity against Acinetobacter and other Gram-negative 
organisms such as Pseudomonas species. 
Treatment of Sinusitis. Treatment of sinusitis is compli-
cated by the difficulty of diagnosis and source control, as 
mentioned earlier. The health care provider is usually left 
to make the diagnosis using clinical criteria, as culture 
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techniques that are invasive (endoscopy or trans-skeletal 
tap) may be deemed of more risk than benefit, and radio-
logic imaging is nonspecific for infection. Initial man-
agement should be directed toward improving drainage 
by removing any indwelling tubes that block the ostia of 
the sinuses. Antibiotic therapy is limited by the fact that 
undrained sinus cavities will be poorly perfused, and anti-
biotics are therefore unlikely to penetrate the collection. 
Sinusitis in the ICU should not be treated like sinusitis in 
the community; appropriate antibiotic choices include cef-
tazidime, cefepime, piperacillin plus an aminoglycoside, or 
imipenem (Gilbert, Moellering, Eliopoulos, Sadle, & Cham-
bers, 2008). In severe refractory cases, surgical debride-
ment of the sinuses by an otolaryngologist may become 
necessary. 
Treatment of Ventilator-Associated Pneumonia. Pneumonia 
is particularly a difficult problem in critically ill patients. 
A combination of pain, inflammation, recumbency, and 
sedation all conspire to keep patients from taking maximal 
inspirations or clearing the airways with an effective cough, 
and these factors may lead to aspiration of food or oro-
pharyngeal fluids. Once the diagnosis is made, treatment 
choices must be made. The treatment of pneumonia is with 
antibiotics specific to the causative organism. The atten-
dant physiologic support is discussed in further details in 
other chapters. 
Colistimethate (colistin) fell out of clinical favor as 
a result of a high incidence of associated nephrotoxicity 
with intravenous use; therefore, to avoid systemic toxic-
ity, the nebulized drug has been used in some centers to 
treat VAP caused by antibiotic-resistant bacteria such 
as Acinetobacter. There are published series of the use 
of nebulized colistimethate being used to treat VAP with 
good outcomes. Nebulized tobramycin has also been used 
for the treatment of Acinetobacter and  Pseudomonas pneu-
monia, drawing on the extensive experience with the use 
of nebulized tobramycin in cystic fibrosis patients (Trot-
tier, Namias, et al., 2007; Trottier, Segura, et al., 2007). The 
primary advantage of nebulized antibiotic use is that the 
delivery is local (intrapulmonary) and the drug is not sys-
temically absorbed. Therefore, the attendant side effects 
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of intravenous use of the drugs are not experienced by 
patients. Unfortunately, some patients experience local 
adverse effects such as bronchospasm with nebulized 
administration, but these side effects are usually manage-
able with bronchodilator use. 
Duration of therapy for VAP is one of the few cases 
of antibiotic management where prospective randomized 
data exist. Chastre et al., (2003) showed that 8 days of 
therapy yields outcomes equivalent to 15 days of therapy, 
with the caveat that for certain pneumonias, particularly 
Pseudomonas species, longer courses of therapy may be 
needed. 
Treatment of Urinary Tract Infection. Urosepsis can result 
from infected calculi or obstruction of urinary outflow, 
and ultrasound to rule out calculi or hydronephrosis are 
appropriate in the evaluation of serious UTI. If either of 
these are found, urologic consultation is mandatory. The 
critical care practitioner should obtain urine for urinaly-
sis and culture, and immediately begin empiric antibiotics 
directed at suspected pathogens. Whenever possible, the 
unit experience with causative organisms for UTI should 
direct antimicrobial therapy. In the absence of such infor-
mation,  Escherichia coli, Proteus species,  Enterobacter spe-
cies, and  Klebsiella species are the usual organisms.  Pseu-
domonas species should be considered in the ICU setting. 
Susceptibility reports may be less important in UTI than 
in other areas, because most of the antibiotics are renally 
excreted, and are therefore present in concentrations in 
the urine that can exceed minimum inhibitory concentra-
tions by hundreds of times. Removal of biofilm-bearing 
catheters is important, because the MIC of organisms in 
the biofilm may be elevated several hundred fold (Wagen-
lehner, Weidner, & Naber, 2007). By the time culture results 
are available, it is likely that the empiric regimen chosen at 
the outset based on the unit-specific antibiogram will have 
treated the infection. If symptoms persist and antibiotics 
are to be continued, they should be narrowed in focus to 
the identified organism. 
Treatment of Catheter-Related Bloodstream Infection. The 
mainstay of treatment of CR-BSI is removal of the infected 
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catheter. It is the rare exception where the importance of 
the infected line is so high that it is worth the risk of death 
to leave it in place with attempts at antibiotic sterilization 
rather than removing the line. There are no prospective 
randomized data to direct the duration of treatment of CR-
BSI. Certainly, antibiotics should be continued until clinical 
symptoms have resolved and blood cultures have cleared. 
Short courses (< 10 days) of antibiotics for  S. aureus infec-
tions have been associated with recurrent septicemia (Raad 
& Sabbagh, 1992). 
 Prognosis and Outcomes 
Outcomes from infection in the ICU are confounded by the 
underlying morbidity of patients. It is frequently asked 
whether a patient died of an infection or  with an infec-
tion. Mortality estimates exist for each of the infections 
discussed herein, which are highly variable according 
to the patient population and individual patient sever-
ity of illness. These estimates are aggregates and do not 
contribute to the clinical management of patients with 
these infections. Regardless, mortality rates from HAIs 
are unacceptably high, and these infections will there-
fore likely receive increasing scrutiny from payors, the 
public, and the health care community (Kollef et al., 2006; 
Vincent, 2003). 
 Preventive Measures 
Excessive costs, decreasing reimbursement, and wide rec-
ognition of the significant morbidity and mortality resulting 
from nosocomial infection has prompted interest in man-
agement strategies and products that may decrease rates 
of HAIs. Many strategies that have been shown to decrease 
rates of infection are nearly cost-free, but require provider 
effort and frequently behavioral change for those who have 
less than admirable adherence rates to practice recommen-
dations. The most obvious example of this kind is handwash-
ing, which is almost cost-free, simple, and has been dem-
onstrated to provide dramatic results in decreasing rates of 
infection and antimicrobial resistance rates in health care 
settings (see Exhibit 12.1). 
Exhibit
Recommendations to Decrease Hospital-Acquired Infections
Prevention of sinusitis
■  Remove any indwelling tubes from nares; use orogastric tube, oral 
endotracheal intubation instead.
■  Maintain elevation of head of bed at least 30 degrees to 45 degrees unless 
contraindicated.
■  If sinusitis is suspected, initiate medication to improve drainage such as 
pseudoephedrine or anti-infl ammatory nasal sprays (as tolerated by patient 
condition).
Prevention of UTI
■ Remove indwelling urinary catheters as soon as clinically feasible.
■  Consider the use of indwelling urinary catheters with antimicrobial impregnation.
■ Assure adequate hydration and dependent gravitational urinary fl ow.
Prevention of VAP
■  Minimize chemical paralysis and sedation use; employ a daily “sedation 
vacation” as tolerated by the patient’s condition.
■  Consider endotracheal tubes with subglottic suction port to decrease pooling 
of secretions on endotracheal tube cuff and subsequent aspiration.
■  Oral hygiene and pharyngeal suctioning at least every 4 hours in the 
intubated patient; consider the use of chlorhexidine oral rinse.
■ Do not routinely instill normal saline with endotracheal suctioning.
■  Use respiratory care practitioner-driven weaning protocols and facilitate 
prompt extubation of patients.
Prevention of CR-BSI
■  Minimize the use of central venous catheters (CVC); subclavian site 
preferred if needed CVC.
■ Assess need for CVC daily and remove promptly when no longer needed.
■ Use antimicrobial-impregnated intravenous catheters.
■  Choose the catheter with the fewest number of lumens necessary for 
patient care.
■  Employ chlorhexidine-impregnated disks (Biopatch®) to encircle CVC 
insertion site
■  Assure that an occlusive dressing is covering the insertion site at all times; 
change when loose or visibly soiled.
12.1 Evidence-Based Practice Guidelines
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 Summary 
Infection presents a serious problem in the ICU. The diagnosis 
of infection in critically ill patients is confounded by the pres-
ence of SIRS. When uncertainty exists, empiric antibiotics 
should be judiciously employed while awaiting culture and 
susceptibility results. ICU-specific antibiograms should 
be used to direct empiric therapy if they are available, and 
therapy should be narrowed to the appropriate spectrum 
when culture results are available. Antibiotic stewardship is 
critical to mitigate the problem of antimicrobial resistance. 
The ACNP is uniquely positioned to coordinate the care of 
critically ill patients in the ICU and to provide longitudinal 
consistency. 
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 Introduction 
Technology development and increased knowledge have 
dramatically improved outcomes in critically ill patients dur-
ing the past 2 decades. The appropriate and ethical use of 
expensive resources required to achieve this improved out-
come have sparked frequent and sometimes dramatic debate 
around the world (Bloche, 2005; Ditto, 2006). Fortunately, it 
is evident that there is increasing interest among critical 
care clinicians in improving end-of-life and palliative care. 
With that interest has come the realization that such care 
requires as much knowledge, skill, and dedication as the 
intensive preservation of life and restoration of health in 
critically ill persons (Truog et al., 2008). Research in the 
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area of end-of-life care has matured significantly during 
the past 2 decades and is gradually progressing from descrip-
tive, observational studies to more advanced trials of clinical 
interventions to improve the quality of dying and palliative 
care (Levy & McBride, 2006). Providing comprehensive end-
of-life and palliative care requires the dedication of significant 
resources and the efforts of a multidisciplinary team which 
includes (at minimum) nursing, medicine, social work, and 
pastoral care participants. The acute care nurse practitioner 
(ACNP) can take a leading role in the multidisciplinary team 
providing palliative and end-of-life care services in various 
clinical settings. Advanced practice nurses have developed 
and pioneered models of care suitable for various types of 
institutions and patient populations, providing benefit to 
the patient, family, and the primary health care team. These 
services have often demonstrated a financial benefit to the 
institutions as well (Emnett, Byock, & Twohig, 2002). 
 Epidemiology of Death and Dying 
Death is an inevitable finale to the life cycle, with more 
than 70% of deaths occurring in persons older than the age 
of 65 years. Approximately 2.5 million Americans died in 
2006, with the majority of deaths resulting from heart dis-
ease, cancer, and stroke (National Center for Health Statis-
tics). Although it is clearly documented in multiple studies 
that most Americans would prefer to die in the comfort of 
their home environment, the available data demonstrate 
that just over half of deaths occur in an acute care envi-
ronment, with the remaining half fairly evenly divided 
between home and nursing home deaths (Field & Cassel, 
1997; Gruneir et al., 2007). Geographic location and num-
ber of available acute care beds are factors that influence 
the place of death, with urban and developed areas hav-
ing a higher percentage of in-hospital deaths (Beccaro 
et al., 2006; Gruneir et al.; Yun, Lim, Choi, & Rhee, 2006). 
More than 20% of deaths in the United States occur in the 
intensive care unit, although the number of acute care 
deaths has decreased during the past 2 decades. This fact 
is likely a result of increased public awareness and more 
frequent planning of end-of-life care, as well as patient 
preferences (Angus et al., 2004). 
Chapter 13: End-of-Life Palliative Care 461
 Ethical and Legal Issues 
Medical ethics is a continually evolving area of study. However, 
certain broad principles are well established in health care and 
should be applied to all situations when addressing decision 
making at the end of life. These principles are the following: 
 ■ Autonomy—the principle that individuals should be 
self-determining and that providers have a duty to 
respect the choices of patients. 
 ■ Nonmaleficence—first do no harm; i.e., medical 
treatment should help patients and not hurt them. 
 ■ Beneficence—taking positive steps to actively help 
patients. 
 ■  Justice—fair and equitable treatment, even distribution 
of resources and opportunities (Beauchamp & Childress, 
2001; Thompson, 2007). 
At face value, these concepts are easy to understand and 
appear almost common sense; however, the interpretation 
of these concepts and their application to clinical situations 
involving human emotion and unclear patient outcomes is 
often complex. Providers, families, and patients may become 
personally invested in specific outcomes for reasons other than 
the above mentioned. When this is suspected or apparent, the 
input of an institutional ethics committee to provide a thought-
ful and more impartial view of the situation may be helpful and 
may prevent conflicts. Proactive (anticipatory) ethics consul-
tations were found to be helpful, informative, supportive, fair, 
and respectful of personal values by both health care providers 
and family members in a recent study (Cohn, Goodman-Crews, 
Rudman, Schneiderman, & Waldman, 2007). 
Who Makes Decisions at the End of Life? The ethical right of 
patients to make autonomous decisions and the obligation 
of health care providers to respect these decisions is well 
affirmed by medical ethicists (Beauchamp & Childress, 2001). 
Advance directives are legally recognized by both statutory 
and common law precedents in 48 states and the District 
of Columbia, and all states recognize the  validity of surro-
gate decision makers for incompetent patients (Emanuel, 
Hauser, & Emanuel, 2008). In addition, health care facilities
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are mandated to inquire about and provide opportunity 
for persons admitted to the facility to complete an advance 
directive, as mandated in the United States by the  Patient Self-
Determination Act (1990). Although as many as 80% of Ameri-
cans endorse and support the idea of advance directives, only 
approximately 20% of the population has prepared such a doc-
ument (Hampson & Emanuel, 2005). Multiple factors including 
culture, geographic location, and level of education have been 
described as influencing the completion of advance directives. 
In addition, in one study, the existence of these documents led 
to a greater percentage of do-not- resuscitate (DNR) orders and 
decreased use of cardiopulmonary resuscitation (CPR), but did 
not affect the use of invasive technologies such as mechanical 
ventilation (Houghton, 2009). 
Because most patients have not completed clear advance 
directives and many are unable to communicate their wishes in 
a situation, the use of a durable power of attorney for health 
care has become common and accepted in the medical com-
munity (Arnold & Kellum, 2003; Thompson, 2007; Tonelli, 2005; 
White et al., 2007). These surrogates may also be known as a 
health care “proxy,” and the process of choosing and appoint-
ing this individual may follow specific guidelines according 
to state law. The ability of these persons to make complex 
decisions that mirror the patient’s actual wishes is a matter of 
some debate because multiple factors may be involved in the 
decision-making process that may influence surrogate deci-
sions (Ditto, 2006; Kressel & Chapman, 2007; Limerick, 2007; 
Lewis et al., 2006; Shalowitz, Garrett–Mayer, & Wendler, 2006; 
Nelson & Lindemann, 2007). Nonetheless, legal authority to 
make end-of-life decisions commonly rests with these indi-
viduals. The responsibility of the health care provider is to 
ascertain that these decisions are informed and freely made 
without undue influences and reflect, to the extent possible, 
the known or potential wishes of the patient. 
In cases where there is no available surrogate for an inca-
pacitated patient, the question of “who decides?” is a matter 
of debate (White, Curtis, Lo, & Luce, 2006). One recent study 
found that 1 in 20 ICU deaths occurred in patients without 
a surrogate or advance directive. In this study, most of these 
decisions were made by health care providers without judi-
ciary or ethics committee review and were in conflict with the 
recommendations of both the American College of Physicians 
and the American Medical Association (White et al., 2007). 
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 Dimensions of End-of-Life Care 
End-of-life care can be conceptualized and implemented 
within five broad dimensions. These dimensions of care 
consist of communication and conflict resolution; alleviation 
of distressing symptoms (palliation); withdrawal, limiting, 
or withholding of therapy; emotional/psychological care of 
the patient and family; and caregiver organizational support 
(Houghton, 2009). These represent a fluid conceptual frame-
work for providing care, and clinical situations will vary 
widely in what is required within each dimension. 
 Communication and Conflict Resolution 
Perhaps the most difficult conversations occurring between 
health care providers, patients, and families involve the dis-
cussion of when it is appropriate to transition from a curative 
goal to a more supportive “comfort” approach. The  primary
purpose of critical care units is to save lives and restore health, 
and this focus is integrated in the culture of critical care pro-
viders. Multiple factors have been demonstrated to influ-
ence the continued provision of aggressive care in the face 
of a poor or futile prognosis (Nelson et al., 2006; Robichaux & 
Clark, 2006; Sibbald, Downar, & Hawryluck, 2007). The lack of 
availability of accurate tools to predict treatment failure and/
or death often makes the recognition of futile care unclear 
and subjective, further complicating the decision-making 
process (Bernat, 2005; Lamont, 2005). In addition, discussing 
the fact that a given person has failed to respond to a trial of 
aggressive medical intervention is often difficult for provid-
ers and may represent personal failure or defeat to the clini-
cian (Dracup & Bryan-Brown, 2006; Kaufman, 2005). Defin-
ing medical futility for a specific treatment in an individual 
patient is problematic, but a widely recognized definition is 
care that, in the experience of the provider(s) or on the basis 
of research evidence, has failed to provide benefit for the last 
100 similar patients (Emanuel, Hauser, & Emanuel, 2008). Dis-
cussing a poor prognosis with a patient and/or family should 
be done in a private, unhurried fashion and requires empa-
thy, skill, and listening on the part of the provider. Differences 
of opinion and conflicting feelings or beliefs about what is 
best for the patient will often arise. Fortunately, most conflicts 
involving end-of-life decisions among patients, families, and 
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providers can be resolved through frequent and open com-
munication on both sides, with the input of an ethics con-
sult if “impartial” input is desired (Bloche, 2005; Cohn et al., 
2007; Lautrette et al., 2007; Lautrette, Ciroldi, Ksibi, & Azoulay, 
2006). Discussions in which the patient’s terminal status is 
clearly presented more often result in decisions to alter the 
course of care toward a less aggressive mode (Aldridge & 
Barton, 2007). Therefore, if the patient is clearly in the dying 
process, this needs to be communicated and may need to be 
repeated to the family and the patient (when appropriate). 
Although most end-of-life decisions are made by consensus, a 
small minority of cases proceed to become public and highly 
sensationalized (Bloche, 2005). These unfortunate and often 
tragic cases have lead to significant public debate and have 
prompted legal action and even court intervention in the 
decision-making process. Fear of being embroiled in a similar 
situation may drive health care providers to offer alternatives 
and provide care they otherwise might view to be futile or not 
in the patient’s best interest. 
The communication process in critical care should be 
dynamic and ongoing, because clear and honest communi-
cation between members of the health care team and the 
patient and/or family has been identified as a key factor in 
quality care at the end of life (Truog et al., 2008). The message 
from the health care team to the family should be consistent 
and presented in nonmedical terms. Family members need 
to be given ample time to express themselves and ask ques-
tions, as this has been demonstrated to increase satisfaction 
with care and decrease dysfunctional bereavement patterns 
after the patient’s death. The plan of care should be based on 
the known or perceived preferences of the patient whenever 
possible, and it is important to convey to the family that nei-
ther they nor the patient will receive less care if the decision 
is reached to withhold, limit, or withdraw therapy (Lautrette 
et al., 2007; McDonagh et al., 2004; Weissman, 2004; West, 
Engelberg, Wenrich, & Curtis, 2005; White & Curtis, 2006). 
 Palliative Care within the Critical Care 
Environment 
Palliation is the provision of care with the intent of relieving 
distressing symptoms of an illness or injury that may negatively 
influence the quality of life of the patient or family (Medina 
& Puntillo, 2006; Mosenthal & Murphy, 2006). Palliative care 
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should be an integral part of the health care of all patients 
today in any setting, because it is well documented that per-
sons with chronic or acute illness/injury may experience 
and suffer with a wide range of disease-related symptoms. 
However, the focus on palliation in the critical care unit is 
recent and not well integrated into the culture of most units. 
Palliative care is often overlooked by many critical care clini-
cians and may be viewed by providers, patients, and fami-
lies as “giving up” on any hope of cure. Such care need not 
be in opposition with lifesaving, curative care and should 
be viewed as a necessary part of humane, patient-focused 
health care (Mularski et al., 2006). 
Some of the most commonly experienced symptoms by 
critically ill or injured persons include pain, nausea, vomiting, 
hunger and thirst, diarrhea, confusion, agitation and delirium, 
anxiety, depression, and sleep disturbance. All of these symp-
toms are amenable to amelioration with medical and nursing 
interventions. Palliative care consults have been demonstrated 
to decrease hospital lengths of stay and resource utilization 
while improving multiple patient and family-centered outcomes 
(Campbell, 2006; Curtis, 2005; Medina & Puntillo, 2006; Treece et 
al., 2006; Twaddle et al., 2007). A multidisciplinary approach to 
treatment that includes both pharmacological and nonpharma-
cological interventions is recommended (Qaseem et al., 2008). 
Assessment of distressing symptoms of illness/injury or 
hospitalization must be ongoing, so that the effectiveness of 
treatments implemented may be objectively measured and 
treatment tailored to patient response. Clinical tools to assess 
the severity of patient symptoms should be utilized whenever 
possible, although in the critical care environment, the patient 
condition often obviates the use of patient symptom self-
reporting tools. When patient condition permits, it is prefer-
able that these assessment tools be completed by the patient 
or family member rather than by the health care provider. 
Multiple symptom assessment tools can be found online and 
can be downloaded free of charge (see Online Resources). 
Recommendations for pharmacological and nonpharmaco-
logical interventions for symptoms commonly distressing to 
terminally ill patients are provided in Table 13.1 on page 466. 
Pain is the symptom experienced by most patients, and 
the assessment of pain is familiar to most clinicians in all spe-
cialty areas. The use of a 0–10 scale for the assessment of pain 
is commonly practiced, is easy to understand, and is familiar 
to many patients. Pain rating should be assessed regularly, 
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 Pharmacological Nonpharmacological 
Symptom Treatment Treatment
Anxiety Benzodiazepines 
 (alprazolam, lorazepam, 
midazolam, clonazepam)
Patient reorientation, reassurance, 
 explanation of medical/nursing care, 
quiet environment, guided imagery, 
music therapy, family presence
Depression Serotonin reuptake 
 inhibitors (SSRI) (slow 
onset of action, only 
available by mouth)
Clear communication of plan of care, 
psychotherapy, social support 
systems, pastoral care/spiritual 
support
Delirium Antipsychotic agents 
(haloperidol, olanzapine, 
risperidone)
Explain to family that delirium is 
common at the end of life; reduce 
stimulation; assure patient safety
Dyspnea Opiates,  anxiolytics, 
 diuretics if fl uid 
 overload is a concern, 
bronchodilators if 
wheezing is present
Optimal positioning, oxygen, 
minimize activity and physiologic 
demands (i.e., fever), titration of 
ventilator
Diarrhea Loperamide, bismuth 
 subsalicylate (Pepto 
Bismol),  attapulgite 
 (Kaopectate, 
 diphenoxylate & 
atropine  (Lomotil), 
tincture of opium; treat 
infectious causes
Identify causative infectious agents 
or medications, maintain hydration 
(if deemed benefi cial to patient), 
Fecal Management System (FMS), 
or other incontinence (if deemed 
benefi cial to patient); management 
system to minimize patient distress, 
skin breakdown, and discomfort
Nausea/
 vomiting
Metoclopramide
(prokinetic) ondansetron, 
promethazine (anticho-
linergic)
Quiet environment, head of bed 
 elevated, nasogastric  suctioning, 
review of medications, 
aromatherapy
Pain Nonsteroidals (NSAIDS), 
opioids, tricyclic antide-
pressants, gabapentin, 
pregabalin,  anesthetics 
(local/topical or 
 injected), nerve block-
ade (see Chapter 14)
Assessment and identifi cation of 
precipitating factors, positioning, 
distraction, cognitive/behavioral 
therapy, palliative surgery, others
13.1 Interventions for Common Distressing Symptoms
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because some patients are unable or unwilling to communi-
cate their pain to health care providers. When medication or 
comfort measures such as positioning are implemented, the 
pain rating should be reassessed within a short time to eval-
uate effectiveness. Under-treatment of pain is unacceptable, 
and medication dosages must be titrated upward as necessary 
to provide the patient with adequate relief; generally, a pain 
rating of < 2 should be achieved. Chronic pain is not easily 
relieved with routine analgesics, a more in-depth assessment 
of the pain can be achieved through the use of the McGill 
Pain Questionnaire or another standardized instrument 
(Institute for Clinical Systems Improvement, 2008). Identify-
ing and eliminating the source of the pain (when possible) 
is vital to effective treatment. Additional means of assessing 
the source of pain and treating common types of pain identi-
fied in clinical settings is provided in Table 13.2 on page 468. 
 Withdrawing or Withholding Life-Sustaining 
Interventions 
The vast majority of deaths in the critical care unit are pre-
ceded by some type of withholding, limiting, or withdrawal of 
medical therapy, although the public and many health care 
providers do not seem to be aware of this fact (Sprung et al., 
2008; White, Engelberg, Wenrich, Lo, & Curtis, 2007). Empha-
sis should be noted that actual legal statutes governing the 
withholding or withdrawal care are rare (with the excep-
tion of euthanasia). Therefore, the clinician’s actions must 
be based on the highest ethical principles, institutional or 
professional guidelines, and most importantly, the perceived 
or stated wishes of the patient. Most decisions to limit, with-
hold, or withdraw care are the result of consensus and do not 
prompt legal intervention or dramatic publicity. As described 
previously, a surrogate decision maker is common in critical 
care situations, as the illness of the person usually preempts 
their active participation in care decisions. 
The overriding ethical and legal principle guiding with-
drawal or limitation of therapy is the concept of whether 
or not a treatment or medication is of benefit to the patient 
(Foster & Carpenter, 2007; Gavrin, 2007; Wainwright & 
Gallagher, 2007). If there is no foreseen benefit to the patient, 
then the therapy is futile and can ethically be withdrawn (see 
Exhibit 13.1 on page 469).  Commonly withheld or withdrawn 
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Source: Institute for Clinical Systems Improvement (ICSI).
Type of Pain
   Neuropathic
 Somatic Pain Visceral Pain Pain
Location Localized Generalized Radiating or 
 specifi c
Patient 
 Description
Pinprick, stabbing, 
or sharp
Ache, pressure, 
or sharp
Burning, prickling, 
tingling, electric 
shock like, or 
lancinating
Mechanism
of Pain
A-delta fi ber  activity, 
located in the 
periphery
C-fi ber  activity, 
 involved  deeper 
 innervation
Dermatomal 
(peripheral) or 
nondermatomal 
(central)
Clinical
 Examples
■  Superfi cial 
 laceration
■  Superfi cial burns
■  Intramuscular 
injections, venous 
access
■  Otitis media
■  Stomatitis
■  Extensive 
 abrasion
■  Periosteum, 
joints, 
muscles
■  Colic and 
muscle
spasm pain
■  Sickle cell
■  Appendicitis
■  Kidney 
stone
■  Trigeminal
■  Avulsion 
neuralgia
■  Posttraumatic 
neuralgia
■  Peripheral 
neuropathy 
(diabetes, HIV)
■  Limb 
 amputation
■  Herpetic
Most
Responsive 
Treatments
■  Acetaminophen
■  Cold packs
■  Corticosteroids
■  Local anesthetic 
either topically or 
by infi ltration
■  Nonsteroidal anti-
infl ammatory 
drugs (NSAIDs)
■  Opioids
■  Tactile stimulation
■  Corticoste-
roids
■  Intraspinal 
local anes-
thetic agents
■  NSAIDs
■  Opioid via 
any route
■  Anticon-
vulsants
■  Corticosteroids
■  Neural 
 blockade
■  NSAIDs
■  Opioids via 
any route
■  Tricyclic anti-
depressants
13.2 Assistive Tool for DeterminingType of Pain
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therapies include mechanical ventilation, dialysis, vasopres-
sors, antibiotics, and nutritional support. Many institutions 
will have specific protocols for withdrawal of ventilator or 
other medical therapies. Clinical protocols for withdrawal 
of ventilator support (often called  terminal weaning ) are 
available from professional societies such as the American 
Association of Critical Care Nurses (AACN) and many large 
health care institutions (see Online Resources). The pro-
cess of withdrawal or reduction of ventilator support can 
be emotionally distressing for both providers and families. 
Clear communication about the terminal weaning process 
should be provided to the family, and the clinician should 
remain immediately available to order medications or other 
therapies to avoid respiratory distress or patient discomfort. 
1.  Death occurs as a consequence of the underlying disease. The goals of care 
are to relieve suffering and not to hasten death.
2.  Withholding life-sustaining treatment is morally and legally equivalent to 
withdrawing treatment. Both actions require the same degree of active 
 physician/nurse participation as any other procedure.
3.  Any treatment can be withdrawn or withheld, including nutrition, fl uids, 
antibiotics, or blood products.
4.  Any dose of analgesic or anxiolytic medication may reasonably be used to 
relieve suffering, even if the medication has the potential to hasten death. 
Signs of suffering may include dyspnea, tachypnea, diaphoresis, grimacing, 
accessory muscle use, nasal fl aring, and restlessness.
5.  Life-sustaining treatment should not be withdrawn while a patient is 
 receiving paralytic agents. After discontinuation of such drugs, the  patient 
must demonstrate suffi cient motor activity to allow thorough clinical 
 assessment before withdrawal of support.
6.  Cultural and religious views infl uence the perspectives of patients and  family 
members regarding life-sustaining treatment. These issues should be 
openly discussed and an effort made to accommodate various perspectives. 
Pastoral or spiritual care providers may assist in this process.
Adapted from University of Washington/Harborview Medical Center physician orders. Retrieved 
June 19, 2008, from http://depts.washington.edu/eolcare/instruments/wls-orders2.pdf
Exhibit
13.1 Ethical Principles for Withholding and Withdrawing Life-Sustaining Therapy
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The practice of  terminal weaning is widely variable and 
could consist of anything from complete extubation to simply 
decreasing levels of positive end-expiratory pressure (PEEP) 
or the fraction of inspired oxygen (FiO2) (Kirchhoff, Palzkill, 
Kowalkowski, Mork, &  Gretarsdottir, 2008; Medina &  Puntillo, 
2006;  Reynolds,  Cooper, & McKneally, 2007). Exhibit 13.2 
describes common steps in the ventilator removal process. 
Preparation
Meet and discuss options with the family and the patient (when appropriate). 
Consider:
Does the family want to be present?
Does the family want to spend time with the patient after death?
Is organ donation an option?
When will the process take place?
What method of discontinuation shall be utilized? Options include  stepwise 
 reduction of ventilator settings or immediate cessation of  ventilatory 
 support. The endotracheal tube may be left in place or removed if 
 ventilation is  completely discontinued.
All conversations must be documented in the patient’s medical record.
Procedure
 Create the most peaceful environment possible within the area surrounding 
the patient. Monitors and unnecessary devices should be discontinued, alarms 
turned off, restraints removed. Provide family visitation access and include 
chairs, tissues, and privacy.
 Educate the family and patient (if appropriate) about the process that will 
 occur and what they may likely experience or witness.
 Provide support staff, such as spiritual care providers and social work, and 
assure adequate nurse availability.
 Assure the patient and/or family that all providers will strive to make the 
patient comfortable during the ventilator withdrawal process, premedicate 
when appropriate. Ascertain that any neuromuscular blockade effects are gone 
to avoid the risk of masking patient discomfort.
Adapted from Massachusetts General Hospital Policy and Procedures (n.d.). Limitation of life-
 sustaining treatment policy: Ventilator withdrawal guidelines.
Exhibit
13.2 Ventilator Removal/Terminal Weaning
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Making ethical distinctions are important when deter-
mining the need for and desired effects of administering 
medications for pain, anxiety, or respiratory distress symp-
toms during any withdrawal of care, as euthanasia is ille-
gal in most countries. Because such ethical distinctions are 
often unclear and context-dependent, clinicians’ perception 
of the situation may vary widely (Rubenfeld & Elliott, 2005; 
Sprung et al., 2008; Szalados, 2007). Dosages of anxiolytics 
or opioids are required to assure patient’s comfort during 
the dying process and may far exceed what is commonly 
administered in clinical practice. Providers are encouraged 
to administer as much as necessary, keeping in mind the 
intent is to assure patient comfort and not to hasten the 
dying process. Specific medications and actions are further 
discussed in Chapter 14. 
 Emotional and Psychological Care 
of the Patient/Family 
A recent study demonstrated that severe psychiatric mor-
bidity (major depressive disorder, generalized anxiety 
disorder, panic disorder, or complicated grief disorder) 
occurred during the first year after the patient’s death in 
34% of family members who had served as a surrogate for 
a relative dying in the intensive care unit (Siegel, Hayes, 
Venderwerker, Loseth, & Prigerson, 2008). Providing non-
judgmental, emotional, and psychological care to dying 
patients and their family is probably the most challenging 
aspect of end-of-life care. Often it requires a great deal of 
personal strength and ongoing self-care on the part of the 
clinician to remain emotionally present and authentic in 
what is likely a difficult situation for the patient’s family 
members (Rushton, Roshi, & Dossey, 2007). 
Family-centered care, which emphasizes the impor-
tance of the family structure that the patient is a part of, 
has been identified as the ideal framework for provision of 
end-of-life care (Truog et al., 2008). With that in mind, it is 
vital to remember that the patient’s family is whomever the 
patient or family identifies with as being family. This may 
include nontraditional family structures such as unmar-
ried long-term heterosexual couples, same-sex partners, or 
other biologically unrelated persons. Emotional and psy-
chological needs of patient and family groups vary widely, 
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and it should never be assumed that all situations call for 
certain interventions during the dying process. For some 
families, spiritual support and the presence of a spiritual 
or religious representative is essential, whereas for other 
families, the support they require involves good com-
munication and reassurance that can be provided by the 
clinicians caring for the patient (Cook, Rocker, Giacomini, 
Sinuff, & Heyland, 2006; Wall, Engelberg, Gries, Glavan, & 
Curtis, 2007). Some larger institutions now have access to 
a bereavement team that has expertise in guiding families 
and professional staff through the withdrawal and dying 
process. 
Maintaining the dignity, privacy, and comfort of the 
patient and the family during the dying process is essen-
tial and often requires more time listening than actually 
“doing” something. Although the critical care unit is rarely 
an environment that is conducive to privacy and quiet, 
every effort needs to be made to allow for family presence 
and support. 
 Caregiver Organizational Support 
Clinicians caring for dying patients may experience  moral 
distress or “burnout,” especially when the dying process 
involves the withdrawal or withholding of a medical thera-
py (Badger, 2005; Elpern, Covert, & Kleinpell, 2005; Meltzer 
& Huckabay, 2004; Rushton, 2006). Experience and educa-
tion with care of the dying and the  withdrawal process may 
minimize this distress, and both nurses and physicians have 
strongly identified a need for further and continuing educa-
tion in care at the end of life (Nelson et al., 2006; Beckstrand, 
Callister, & Kirchhoff, 2006; Wlody, 2007). Many excellent 
resources for meeting these educational needs now exist 
(see Online Resources), but this requires institutional sup-
port and provision of adequate time for busy clinicians to 
attend or complete educational programs. The American 
Association of College Nursing first made recommenda-
tions in 1998 about the inclusion of end-of-life care in nurs-
ing curricula, leading to the development of the End-of-Life 
Nursing Education Consortium (ELNEC). This project, which 
began in 2000, has since developed six different training 
programs, one of which focuses specifically on end-of-life 
Chapter 13: End-of-Life Palliative Care 473
care in the critical care environment (http://www.aacn.nche
.edu/ELNEC/factsheet.htm). 
Providing care to dying patients and their families can 
be extremely time-intensive, and minimal staffing patterns 
may not adequately support this important aspect of patient 
care (Beckstrand et al., 2006; Beckstrand & Kirchhoff, 2005; 
Nelson, 2006). In addition to supporting nurses and physi-
cians through sufficient staffing resources, other helpful 
institutional behaviors include debriefing/support sessions 
after the death of a patient, an environment of support 
among colleagues, and the availability of persons for discus-
sion of organ donation possibilities (Badger, 2005; Hamric & 
Blackhall, 2007; Nelson, 2006; Truog et al., 2008). 
 Providing Culturally Competent
End-of-Life Care 
Physicians and nurses frequently believe that they lack 
the skills and education to handle difficult end-of-life 
issues with critically ill patients and their families (Boyle, 
Miller, & Forbes-Thompson, 2005; Nelson et al., 2006). 
This discomfort may be magnified when the patient is 
from a culture or ethnic background that is different from 
that of the provider (Kwak & Haley, 2005;  Siriwardena 
& Clark, 2004; Valente, 2004). In the United States, this 
phenomenon is becoming more and more common as the 
nation has become increasingly culturally diverse (U.S. 
Census Bureau, 2008). Therefore, it is important to under-
stand how cultural and ethnic differences may influence 
the manner in which patients and/or families prefer to 
communicate, make decisions, and which care options they 
may choose. Acknowledging and embracing these cultural 
preferences may improve the quality of the end-of-life 
experience for patients, families, and providers (Doolen 
& York, 2007; Shrank et al., 2005). Religious beliefs may 
also have a profound influence on the patients and their 
families’ choices for end-of-life care as well as affecting 
how providers view these choices. Significant differences 
exist  between and  within many major religious groups, and 
it is important to clarify the beliefs of the patient and fam-
ily during conversations and family conferences. Insight 
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on the part of the health care provider into the influence 
of their own beliefs on end-of-life choices is important in 
identifying any preexisting value judgments (Dorff, 2005; 
Johnson, Elbert-Avila, & Tulsky, 2005; Keown, 2005; Mark-
well, 2005; Sachedina, 2005). 
 Summary 
Providing quality end-of-life care requires significant 
expertise. Family members will likely remember the man-
ner in which a dying person is treated at the time of death 
for many years, which may explain why some providers 
find end-of-life care a very rewarding element of their 
practice. This is increasingly evident from a growing body 
of research that specialized in continuing education in this 
area that is vital for health care providers working in the 
critical care environment. End-of-life care may be concep-
tualized and implemented within five domains that include 
(a) communication and conflict resolution; (b) palliation; 
(c) withdrawal, limiting, or withholding medical therapy; 
(d) emotional and psychological care of the patient and 
family; and (e) caregiver organizational support. Compo-
nents of important end-of-life interventions are listed in 
Exhibit 13.3. 
Assess patient and family members’ understanding of the condition 
and prognosis and address any educational needs.
Assure family members that the patient will not suffer or be abandoned 
and that care will continue even if medical therapy is withdrawn.
Provide for emotional support and/or spiritual care resources.
Facilitate health care team communication with the family, while respecting 
cultural preferences for communication and decision making.
Assure that any distressing symptoms shown by the patient are promptly 
 addressed.
Provide for visitation/presence of family and extended family.
Protect patient’s privacy and dignity in an environment as peaceful as possible.
Exhibit
13.3 Important Provider Actions for Quality End-of-Life Care
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 Evidence-Based Practice: Palliative Care 
 Twaddle et al. (2007) reviewed 1,596 health records from 35 aca-
demic hospitals across the United States for compliance with 
11 key performance measures (KPM) of palliative care. Their 
objective was to benchmark the quality of palliative care in aca-
demic hospitals. The KPM included palliative care activities such 
as assessment and treatment of pain and dyspnea, psychoso-
cial assessment, communication with patient and/or family, and 
documentation of prognosis. Compliance with assessment of 
pain (96.1%) and dyspnea (90.2%) were high, but relief of these 
problems was lower (73.3% and 77.2%). The overall mortality rate 
(in hospital) for the sample was 16.8%, demonstrating that the 
sample was comprised of severely ill patients. Findings dem-
onstrated that compliance with the 11 KPM was associated with 
improved quality of care, decreased costs, and decreased length 
of stay. 
 These fi ndings demonstrate that palliative care is not only 
humane and in the patient’s best interest, but that it makes fi -
nancial sense as well to integrate comprehensive palliative care 
into the care of all persons with chronic or acute illness. 
 Online Resources 
http://www.massgeneral.org/palliativecare/WithdrawalProtocol.pdf 
http://depts.washington.edu/eolcare/aboutus/index.html (University 
of Washington/Harborview Medical Center) 
http://www.aacn.nche.edu/elnec (American Association of 
Colleges of Nursing) 
http://www.aacn.org/AACN/PalCare.nsf/vwdoc/RWJ (American 
Assoc. of Critical Care Nurses) 
http://www.apa.org/pi/eol/homepage.html (American Psychological 
Association) 
http://www.nlm.nih.gov/medlineplus/endoflifeissues.html 
(National Library of Medicine) 
http://www.eperc.mcw.edu (Medical College of Wisconsin) 
http://www.dyingwell.org (Dr. Ira Byock) 
http://www.endoflife.northwestern.edu (Northwestern University) 
http://www.nationalconsensusproject.org/Guideline.pdf 
http://www.promotingexcellence.org (assessment tools) 
http://www.guideline.gov (assessment/treatment guidelines for 
disease processes/symptoms)
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 Introduction 
Invasive procedures are the mainstay of survival in critical 
care. Considerations include that these lifesaving interven-
tions are associated with risk and may be as deadly as their 
potential to resuscitate. How the procedure is performed 
and how the protective measures are utilized to decrease 
secondary sequelae may determine the ultimate survival of 
patients and the success of the procedure. Therefore, educa-
tion and competency are paramount. 
According to the World Health Organization (WHO), 48% 
of intensive care unit (ICU) patients have central venous 
catheters and 28,000 ICU patients in the United States of 
America die each year of central line infections (Berenholtz 
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et al., 2004; WHO, 2007). Therefore, prior to the decision to 
initiate any invasive procedure, a significant thought process 
needs to be discussed to determine if the benefit to patients 
outweighs the potential risks. Patients’ physiologic condition 
and level of stability further needs to be evaluated to deter-
mine the likelihood of patient survival should a complication 
occur. 
 Preemptive Planning 
Preemptive planning may prevent subsequent sequelae. 
Hemorrhage is a potential risk of most invasive procedures. 
Therefore, being prepared by knowing the results of recent 
coagulation profiles, correcting coagulopathies, or consider-
ing aborting the procedure based on results may avert a sec-
ondary complication. Patients with a prolonged prothrombin 
time would benefit from a careful thought process regard-
ing whether the intervention would be lifesaving. If there 
is an alternative intervention, and if the procedure remains 
the only feasible intervention, then correction of the coagu-
lapathy with fresh frozen plasma should be instituted and 
ultrasound technology for placement should be considered 
(Kirkpatrick et al., 2008). Site location for central venous 
access must be carefully weighed, balancing the risk of infec-
tion and venous thrombosis with the potential risk of bleed-
ing. Internal jugular or femoral vein catheterization carry a 
higher risk of infection, but a lower incidence of hemorrhagic 
complications upon insertion. The subclavian vein carries a 
higher risk of hemorrhage from inadvertent subclavian artery 
puncture, therefore coagulopathy is a relative contraindica-
tion to catheterization of this vessel. Health care providers 
who are capable of intervening in the event of a complication 
need to be available to intercede if necessary. 
 Pain Management 
Patients’ pain and comfort are a priority, and adequate pain 
control or sedation is crucial to patient and provider safety 
during invasive procedures. Local anesthesia is essential 
and may minimize the need for additional medication for 
analgesia or sedation. Caution should be taken with seda-
tion, particularly in critically ill patients who may have a 
tenuous respiratory status, inability to protect their airway, 
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or hypotension. The procedural sterile drape should have 
adequate clear covering so the nurse and ACNP completing 
the intervention have a clear view of the patient’s face, air-
way, and ventilator apparatus when the patient is artificially 
ventilated. 
 Safety 
Critically ill patients should be monitored with a cardiorespi-
ratory and oxygen saturation monitoring system. Supplemen-
tal oxygen should be provided as indicated while performing 
the procedure. When the procedure is considered either life-
saving or unavoidable to facilitate recovery and if the patient 
has tenuous respiratory status, preemptive intubation may 
be a consideration. As an example, if a central line needs to 
be placed and the patient would not tolerate Trendelenburg 
positioning, or if a patient needs a bronchoscopic evaluation 
and has tenuous respiratory status or respiratory compro-
mise, intubation should be considered as part of the preemp-
tive planning and patient safety. 
Observing universal precautions is mandated to protect 
the patient from serious infectious complications, to inhibit 
the spread of infectious agents, and also to protect health 
care providers from exposure to blood and body fluids. 
Hand washing is the first line of defense to prevent infec-
tion. Wash hands for a minimum of 15 seconds with soap 
and water prior to a procedure and after all patient contact. 
An alcohol-based product may be utilized appropriately 
(Boyce and Pittet, 2002). 
Skin preparation should be completed with chlorhexi-
dine 2% solution or a combination product with 70% isopropyl 
alcohol (Chloraprep®). Using sterile gloves, cleansing should 
be done with a back and forth scrubbing motion around the 
insertion site, . The area must be allowed to fully dry prior to 
proceeding (CDC, 2008). Cap, mask with eye protection, gown, 
and gloves are applied by the inserter and assistants; utili-
zation of strict sterile technique and full body drapes are to 
be employed for all invasive procedures (Institute of Health 
Improvement [IHI], 2008). Observers and the patients’ bed-
side nurse should also wear a cap, mask with eye protection, 
and patient care gown. When the procedure is complete, a 
Biopatch® (chlorhexidine impregnated dressing), and a ster-
ile, occlusive, transparent dressing or antibiotic-enhanced 
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dressing is placed prior to breaking the sterile field. Bedside 
procedures are high risk for injury from sharp objects, there-
fore safety consciousness by monitoring and disposing of all 
sharps appropriately will prevent secondary injury to the 
health care providers participating in the care of the patient. 
 Ultrasound Technology 
Ultrasound technology has advanced significantly in the last 
decade and devices have grown from small 3×3-inch displays 
to portable machines with large displays and sophisticated 
capabilities. The use of ultrasound for placing vascular access 
devices (VADs) and other invasive procedures has become a 
standard of care and is recommended by the Society of Criti-
cal Care Medicine (SCCM). Previously, central lines were 
placed using landmarks only. With the addition of ultrasound 
the vessels are able to be visualized, resulting in a higher 
success rates with fewer attempts and complications. If the 
arterial system is inadvertently punctured during the place-
ment of a VAD, a hematoma, vascular compromise, compro-
mise of the airway (depending on the site used), blood vessel 
or other structural damage, and subsequent mortality and 
morbidity may result. Ultrasound technology minimizes the 
risks and allows the clinician to use real-time visualization of 
the needle entering the vessel (Kirkpatrick et al., 2008). The 
ability to visualize the vessel allows for the appropriate place-
ment of the needle. This should increase patient satisfaction, 
decrease the number of attempts, and decrease the risk of 
complications. Evaluation of the vessels depends on the type 
of procedure that is planned. Education and experience with 
performing ultrasound are recommended prior to using it for 
placement of vascular access (Kirkpatrick et al., 2008). 
Central venous catheters (CVCs) are typically placed in the 
internal jugular, femoral, or subclavian veins; ultrasound allows 
for direct visualization of the vessel. The subclavian vein can 
be difficult to visualize depending on the size of the patient. 
The internal jugular, femoral vein, and other venous sites such 
as the basilic vein for peripherally inserted central venous 
catheter (PICC) placement are typically easy to visualize using 
ultrasound, and their large size allows for rapid access. 
Utilization of ultrasound guidance for PICC line place-
ment can have multiple benefits. Ultrasound technology 
facilitates clinicians’ ability to evaluate the track of the vein 
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into the axillary and subclavian vein and may also assess 
malposition of the catheter during the insertion process. 
After placing the PICC in one of the arm vessels, the inter-
nal jugular may be visualized prior to the chest radiograph 
allowing the clinician to see if the catheter has been inad-
vertently malpositioned; that is, entering the internal jugular 
vein instead of the superior vena cava. 
There are many different types of ultrasound machines 
and probes available. The typical requirements for vascular 
access probe include a length from 25–35 mm and frequency 
range from 9–14 MHz. The higher probe frequency will pro-
vide clearer images but would limit the penetration depth. 
The lower probe frequency will provide an increased pen-
etration depth but would limit image clarity. Currently, there 
is no probe that would provide both clarity and good depth 
penetration; therefore, a machine that can accommodate 
multiple probes is generally beneficial. This further facili-
tates the ability to have abdominal and cardiac probes, mak-
ing the ultrasound multifaceted. 
Probe placement during the procedure can be done 
using two different approaches. The longitudinal approach 
consists of probe placement parallel to the vessel, facilitat-
ing visualization but making vessel access more difficult. The 
transverse approach provides easy visualization of the vessel 
and surrounding structures and allows for visualization of 
the needle puncturing the vessel. The limiting factor can be 
the ability to follow the needle tip. Once the tip of the needle 
is past the image area of the probe, it can result in the inap-
propriate interpretation of the image. 
 Vascular Access 
 Central Venous Access 
Central venous access indications include invasive moni-
toring, right atrial/central venous pressure, access for pul-
monary artery catheter placement, central venous oxygen 
saturation, temporary transvenous pacing, administration of 
resuscitation fluids, and inability to attain peripheral access. 
Central venous access may be indicated to deliver intrave-
nous fluids, nutrition, or as long-term access. In addition, 
central catheters are indicated for vasoactive medications, 
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caustic or sclerosing medications, chemotherapy, hyperos-
molar solutions, and total parenteral nutrition (TPN), which 
requires a large, high-flow vein for delivery (Braner, Lai, 
Erman, Tegtmeyer, 2007). Central venous access may also 
be used for other procedures such as hemodialysis and 
plasmaphoresis. 
 General Technique 
The procedure should be explained to the patient or to their 
health care proxy, including the rationale and potential com-
plications and benefits of the procedure. Written informed 
consent should be obtained except in the event of a lifesaving 
emergent intervention, in which case two physicians’ consent
is obtained. Maintain sterile technique as described previ-
ously under the subheading of safety. Place the patient in an 
approximately 15-degree Trendelenburg position, or flat with 
lower extremities slightly elevated if Trendelenburg is not 
tolerated. A shoulder roll may be placed vertically between 
the patient’s scapulae for subclavian vein access, specifically 
in obese or kyphotic patients. Body positioning will enhance 
the potential for success. 
Identify anatomical landmarks based on site choice and 
anesthetize the skin at the insertion site with 1% lidocaine. To 
access the vein, advance the needle bevel up while applying 
gentle negative pressure on the syringe (see specific section 
for more details). Once in the vein, the position of the bevel 
can help direct wire position, for example, inferiorly into the 
superior vena cava (SVC) for subclavian vein access. Secure 
the needle with the nondominant hand to prevent needle 
displacement or vein injury. Evaluate for potential accidental 
arterial cannulation by observing the color of the blood (least 
reliable), blood gas analysis (time consuming), and pulsatility 
of blood return (unreliable in hypotensive patients or patients 
with right venous pressures). Alternatively, a catheter may be 
attached to sterile IV tubing and the height of the resulting 
column of blood may be indicative of relative pressure or 
pulsatility; the tubing may also be connected to the monitor 
through a pressure transducer and the waveform observed. 
Ultrasound may also be employed to visualize the needle, 
wire, or catheter in vein, except generally in subclavian vein 
placement. Maintain the open end of the needle completely 
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covered to prevent air emboli especially in hypovolemic or 
spontaneously breathing patients. 
If the vein is not accessed on first attempt, withdraw the 
needle slowly because the needle may have compressed and 
subsequently completely penetrated the vein on insertion, 
particularly in dehydrated patients. Maintain gentle nega-
tive pressure on the barrel of the syringe by pulling back on 
the plunger and the vein may be accessed on withdrawal. 
Withdraw the needle to skin level before altering the angle; 
altering the angle with the needle partially inserted may 
lacerate the vein or accompanying artery. Note that repeated 
passes of the needle increases the risk of mechanical com-
plications. Remove the needle immediately if the artery is 
punctured, and compress the vessel for at least 5 minutes if 
there is no coagulation disorder. 
After successful venous catheterization, the J-tipped end 
of the guidewire is inserted through the needle or wire-guid-
ed syringe. Once in place, maintain constant manual control 
of the guidewire to prevent wire embolization. Monitor con-
tinuously for arrhythmias by listening to the heart rate tones 
on the monitor. As the guidewire is advanced, arrhythmias or 
ectopy may develop; withdraw wire until the heart resumes 
previous normal rhythm. The wire should only be inserted to 
approximately 20 cm depth in most instances to minimize the 
occurrence of dysrhythmia. Using a scalpel, insert the back 
of the scalpel along the wire into the skin to make an inci-
sion large enough to accommodate the dilator and catheter, 
approximately 1–2 mm. Insert the dilator just the depth that 
is required to access the vein. Further advancement of the 
stiff dilator may cause injury to the wall of the vein and sub-
sequently penetrate the artery. Remove the dilator carefully 
to avoid displacement of the guidewire. Apply pressure to the 
skin entry site to control blood loss and prevent air entry in 
vein. Place the central line catheter over the guidewire while 
maintaining a portion of the guidewire in hand. The central 
line catheter must not enter the skin until the guidewire has 
exited the hub of the catheter, therefore never having the 
wire out of hand or sight. In general, the right internal jugu-
lar (IJ) is placed to approximately 14 cm, right subclavian to 
16 cm, left IJ and left subclavian to 18 cm, and femoral to 
20 cm. These predetermined lengths will vary based on the 
size and height of the patient. 
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Once the catheter is in place, remove the guidewire while 
keeping all ports of the catheter clamped, covered, or secured 
with positive or neutral displacement valves. Attain blood 
return in all ports to the hub of the catheter to prevent air from 
entering the system, and then flush through the positive dis-
placement valves, confirming that all ports have blood return 
and flush easily. Suture the catheter to the skin to secure it 
in position. Clean the skin area around the catheter with 2% 
chlorhexidine or sterile saline, allow the area to dry, apply skin 
prep to area around the site, apply antibiotic impregnated 
transparent dressing or Biopatch® with transparent dressing 
occlusively to the insertion site (Maki, et al., 2000). 
Remove drapes and dispose of sharps and biohazard 
wastes appropriately. The inserter should clean the area 
and the tray to avoid injury to others. Obtain a chest x-ray 
to confirm catheter placement and to evaluate for mechani-
cal complications. The catheter tip should be at the level of 
the SVC or approximately at the level of the right main stem 
bronchus on radiograph. Femoral lines do not require radio-
graph for confirmation of position (see Exhibit 14.1). 
Subclavian. The subclavian vein lies under the medial third 
of the clavicle, superior to the first rib, where it is anterior 
and inferior to the subclavian artery. The anterior scalene 
muscle lies between the vein and artery. The vein joins with 
the internal jugular to become the brachiocephalic vein as 
it enters the thoracic cavity at the head of the clavicle. Anteri-
orly, the cupula of the pleura projects the level of the clavicle 
(Agur & Lee, 1999). 
With the subclavian approach, there is an increased risk 
of pneumothorax as a mechanical complication, particularly 
in inexperienced practitioners. Other complications include, 
but are not limited to, hemothorax, air embolism, arterial 
puncture, tracheal puncture, and aortic perforation (Braner 
et al., 2007). Bullous emphysema is a relative contraindica-
tion for the subclavian approach, as this increases the risk 
of pneumothorax and spontaneous death. The subclavian 
artery and vein are difficult to compress; therefore, this 
approach is also relatively contraindicated in coagulopathic 
patients. However, the subclavian vein has the lowest risk of 
infectious complications, possibly because of the ease of site 
care (IHI, 2008). 
Exhibit
 Preparation for Initial Insertion Skin 
 Indications: Central TPN, vancomycin, and poor peripheral access. Minimize 
use of femoral lines if possible. 
 Supplies needed at bedside: 
  3 packages 4×4 gauze 
  1 sterile half sheet 
  1 sterile gown, Chlorhexidine solution or Chloraprep® applicator 
  2 pairs sterile gloves 
  central line kit, mask, and hat 
 Procedure: 
 1.  Obtain informed consent from the patient or health care proxy. An 
experienced practitioner must be present at the bedside to observe or 
perform line insertion. 
 2. Put on mask and hat. 
 3. Don sterile gloves. 
 4.  Prep the catheter insertion site and surrounding skin (approximately 
10 inches in diameter) with Chlorhexidine soaked 4×4 gauzes or 
Chloraprep® applicator. Scrub for 30 seconds minimum in multiple 
directions. Let Chlorhexidine dry completely. 
 5.  While the Chlorhexidine is drying, remove gloves used during preparation, 
put on sterile gown and new set of sterile gloves. 
 6.  Proceed with insertion of central venous catheter of the desired type. 
 7.  In cases when the continuous infusion (drip) must be administered through 
the line just placed, attach a sterile IV extension tubing to the drip, fi ll the 
tubing, and attach the sterile end of the extension tubing to the 
appropriate port of the catheter that will maintain sterility during the 
remainder of the procedure. This would be the sidearm of the introducer or 
one of the lumens in the triple-lumen catheter. 
 8.  Suture the introducer in place or, if using a triple-lumen catheter, attach the 
snap clip. 
 9.  Cover with sterile 4×4 gauze. In the case of a triple-lumen catheter, make 
sure that the triangle joining the 3 separate lumens is covered by the 
gauze so that there will be no adhesive adhering to the area that must be 
cleansed and prepped prior to a guidewire change. 
 10.  Apply Biopatch® and assist the nurse in completing a sterile, occlusive 
dressing including the time and date of insertion. 
 11. Document the procedure in the medical record. 
14.1 Initial Line Insertion Procedure
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The insertion site is approximately one fingerbreadth 
lateral and one fingerbreadth inferior to the curve of the 
clavicle in the deltopectoral groove. Insertion occurs at 
approximately 2 cm lateral and 2 cm caudal to the middle 
third of the clavicle, advancing the needle into the skin 
under the clavicle (Braner, et al., 2007). Anesthetize the 
skin; insert the needle just through the skin and into the 
subcutaneous tissue. Place the index finger of the nondom-
inant hand at the sternal notch to mark the landmark and 
help direct the insertion. Use the thumb of the nondomi-
nant hand to compress the subcutaneous tissue and needle, 
to guide the needle under the clavicle while directing the 
needle toward the sternal notch. Maintain a shallow inser-
tion angle, as close and as parallel to the patient as pos-
sible, to avoid causing a pneumothorax. The costoclavicular 
ligament or head of the first rib or clavicle may be encoun-
tered preventing access of the vein. Redirect the angle of 
the needle if the vein is not accessed by withdrawing the 
needle and by redirecting the angle slightly cephalad; if 
still not successful, again withdraw the needle and redirect 
the angle slightly caudad. 
Internal Jugular. The internal jugular vein lies deep to the 
sternocleidomastoid muscle (SCM), lateral to the carotid 
artery and continues between the heads of the sterno-
cleidomastoid. The internal jugular vein joins with the sub-
clavian to form the brachiocephalic vein at the head of the 
clavicle (Agur & Lee, 1999). There is some variability in the 
position of the internal jugular, making the use of ultra-
sound beneficial. 
Complications include carotid artery puncture, which 
is potentially avoidable with the use of ultrasound. Should 
this occur, the needle should be removed immediately and 
pressure be held. Remember that the pleural cupola extends 
above the level of the clavicle, making pneumothorax a poten-
tial complication. The risk for pneumothorax is lower when 
a high insertion point is chosen. Infectious complications are 
higher than the subclavian position, because of the difficulty 
in maintaining the site and potential for contamination with 
oral and tracheal secretions. 
There are three techniques for cannulation of the inter-
nal jugular vein, the anterior, central, and posterior approach 
as detailed below. For all techniques, turn the patient’s head 
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away from the side of insertion. Palpate the carotid artery 
to obtain landmarks, prior to needle advancement. Palpa-
tion of the artery during needle advancement may occlude 
the lumen of the vein; therefore, use light palpation to avoid 
occlusion. The vein should be accessed at a 10- to 20-degree 
angle above the skin to avoid pneumothorax and injury to 
deep structures in the neck. 
Anterior Approach. With the nondominant hand, push the 
sternal head of the SCM laterally. At the level of the apex 
of the heads of the SCM, enter the skin medial to the SCM 
and lateral to the carotid pulse. Direct the needle under 
the SCM toward the ipsilateral nipple while advancing 
the needle. Withdraw and redirect the needle medially if 
the vein is not accessed, but never more medial than the 
carotid pulse. 
Central Approach. At the apex of the heads of the clavicular 
and sternal heads of the SCM, lateral to the carotid pulse, 
enter the skin. Direct the needle at an angle of 20 degrees 
above the coronal plane toward the ipsilateral nipple while 
advancing the needle (Graham, Ozment, Tegtmeyer, Lai, & 
Braner, 2007). Withdraw and redirect the needle medially if 
the vein is not accessed. However, the needle should never 
be directed more medial than a line parallel with the spinal 
axis to avoid carotid puncture. 
Posterior Approach. At the level of the apex of the heads of 
the SCM, enter the skin posterior to the dorsal border of the 
SCM. Direct the needle under the SCM toward the contra-
lateral nipple. Withdraw and redirect laterally if the vein is 
not accessed. This approach has an increased risk of carotid 
puncture. 
Femoral. The femoral vein lies within the femoral sheath, 
just medial to the femoral artery. The vein is approximately 
midway between the anterior superior iliac spine and the 
pubic tubercle, inferior to the inguinal ligament (Tsui et al., 
2008). Femoral access is often obtained as emergency access; 
it can be placed while chest compressions and intubation are 
being performed. However, the risk of infectious complica-
tions is highest in this position. This is likely because of the 
frequent emergent placement and also because of the moist 
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groin environment and relative difficulty of site care. There 
is also a higher risk of thrombosis at the femoral site. The use 
of ultrasound is recommended to decrease the risk of arterial 
puncture and potential pseudoaneurysm. 
Palpate the femoral artery pulse; if not palpable, the course 
of the artery may be marked by Doppler signal, but ultrasound 
should be used if feasible. When placing the catheter under 
emergent conditions, use the landmarks as described above. 
Using the location of the femoral artery, enter the skin just medi-
al to the artery. Insert the needle at a 45-degree angle and direct 
the needle parallel with the course of the artery. Access the vein 
inferior to the inguinal ligament. Superior to the inguinal liga-
ment, the vessels are not compressible if bleeding should arise 
or upon removal of the catheter. Redirect the needle if unsuc-
cessful on maintaining palpation of the artery while advancing 
the needle laterally, closer to the femoral pulse. To guidewire a 
central venous catheter, see Exhibit 14.2. 
Pulmonary Artery Catheter. Indications for pulmonary artery 
catheter (PAC) placement are controversial, mainly because 
of the general lack of expertise in interpretation of the data 
obtained, which may cause more harm than benefit. The 
insertion of a PAC has not conclusively been shown to affect 
survivability and other sources may be used to attain similar 
information. Generally, use is indicated when volume and 
hemodynamic status cannot accurately be determined by 
exam and less invasive monitoring (Lefor & Gomella, 2001). 
Qualified personnel must be available to interpret the data. 
Complications occur with insertion, use, and interpreta-
tion of data. The incidence of complication varies between 
0.05% and 0.2%, but if the complication occurs, the mortality 
rate is 30% to 50%. With insertion, in addition to complica-
tions associated with central venous catheter insertion, com-
plications include dysrhythmias, right bundle branch block, 
catheter knotting, and pulmonary artery injury or rupture. 
During use, complications include pulmonary infarction, 
endocardium or valve injury, cardiac perforation, and cath-
eter balloon rupture (Lefor & Gomella, 2001). Misinterpreta-
tion of data may lead to inappropriate interventions, or lack 
of intervention, and worsening organ system dysfunction. 
Placement may be difficult in patients with low cardiac out-
put, pulmonary artery hypertension, dilated right ventricle or 
atrium, or tricuspid regurgitation. Placement site preference, in 
terms of ease of placement, is right internal jugular equal to left 
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 Supplies needed at bedside: 
  3 packages of 4×4 gauze mask and hat 1 sterile drape 
  1 sterile gown 2 pairs sterile gloves 
  1 suture removal kit 1 scalpe l
  1 Agar plate or sterile container 1 catheter insertion kit 
  Chlorhexidine solution or Chloraprep® applicator 
 1.  An experienced practitioner must be present at the bedside to observe or 
perform the line change. 
 2. Put on mask and hat. Don gloves. 
 3.  Remove occlusive dressing. Have the 3 lumens capped for ease in 
preparation. Don sterile gloves. Using chlorhexidine-soaked 4×4 gauze 
or a Chloraprep® applicator, scrub for 30 seconds minimum in multiple 
directions. Prep the insertion site surrounding 10-inch area of skin, the 
external portion of the triple-lumen catheter including the triangle, and the 
3 lumens and their corresponding hubs and caps. Place a sterile drape 
under the catheter and hubs. Let the Chlorhexidine dry completely. 
 4. Remove the gloves, put on sterile gown and new sterile gloves. 
 5.  With a sterile scalpel, remove the suture holding the catheter; note the 
centimeter marking at the skin. 
 6.  Insert guidewire through the distal lumen. Optional— using the sterile scalpel, 
cut the distal lumen near the catheter hub, then thread guidewire. 
 7. Remove existing catheter over the guidewire; place on sterile tray. 
 8. Insert the new central venous catheter over the guidewire. 
 9.  Aspirate blood from all ports with sterile syringe, fl ush with 2–3 cc normal 
saline. Reposition the catheter as necessary to enable easy aspiration of blood. 
 10.  With sterile forceps, pick up the intra-cutaneous (ICS) segment and cut with 
sterile scissors both proximally and distally. 
 11.  Exerting downward pressure, roll the ICS back and forth at least four times 
across the surface of the agar. Gently press the ICS into the agar without 
breaking its surface. Repeat the process with the catheter tip, placing it on 
the same agar plate. Alternatively, the catheter ICS and tip may be sent to 
the laboratory in a sterile specimen cup. 
 12.  Place the clip around the triple-lumen catheter and suture the catheter in place. 
 13.  Assist the nurse in completing a sterile, occlusive dressing including the 
time and date of insertion. 
 14. Document the procedure in the medical record. 
14.2 Procedure for Guidewiring an Existing Central Venous Catheter
Exhibit
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subclavian, followed by right subclavian, left internal jugular, 
and lastly, femoral veins, right being easier than left in general. 
After placement of an introducer sheath (see central 
venous catheter placement), sterility is maintained. Sterile 
gloves are changed and an additional sterile field is applied. 
The PAC is inspected for bends, kinks, and integrity of the bal-
loon and thermister. The assistant attaches pressure tubing 
and calibrates the transducer and all lumens are flushed with 
saline. The pulmonary artery port remains open, and the cath-
eter is moved up and down to show tracing on the monitor. 
Place the transducer through a sterile sleeve and lock the 
proximal end without opening the sleeve. With the balloon 
deflated, advance the catheter through the introducer sheath 
to about 20 cm or just through the end of the introducer. Main-
tain the coil in the catheter in the orientation facilitating that it 
will “float” through the heart. Inflate the balloon with 1.5 ml of 
air and slowly advance the catheter while continuously moni-
toring the pressure tracing and EKG. 
Always inflate the balloon when advancing, and deflate 
the balloon when withdrawing the catheter. Never continue 
advancing catheter if resistance is met. A central venous pres-
sure tracing will occur until entrance into the right ventricle, 
which should occur at approximately 35–40 cm from the IJ 
or 30–40 cm from the subclavian position. A typical ventricle 
pressure curve will occur with high systolic pressure and low, 
near zero, diastolic pressure. Quickly advance through the 
right ventricle to prevent ectopy and catheter coiling. 
Entrance into the pulmonary artery is noted by a step 
up of the diastolic pressure. This should occur within 10 cm 
after reaching the right ventricle, and if it does not, then the 
catheter is likely coiling. With the balloon deflated, pull the 
catheter back, then inflate the balloon and attempt again. 
When malignant dysrhythmias occur, deflate the balloon 
and pull the catheter back. After entrance into the pulmo-
nary artery, slowly continue to advance the catheter until a 
wedged tracing is obtained, and then deflate the balloon and 
a pulmonary artery pressure should result. 
Sometimes the wedge tracing persists and this indicates 
that the catheter is too deep and should be withdrawn. Rein-
flate the balloon and if the wedge occurs with less than 1.25 ml, 
the catheter is too deep and should be repositioned. The pres-
ence of mitral regurgitation may make interpretation of wedge 
tracing difficult, resulting in the placement being wedged in the 
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pulmonary artery. Once the catheter is in appropriate position, 
then deflate the balloon. The balloon should be left deflated, 
except when actively checking a wedge pressure for 20 seconds 
or less to prevent pulmonary infarction and erosion of the pul-
monary artery. A pulmonary artery tracing should be continu-
ously observed unless the balloon is inflated. Advance the sleeve 
to cover the external portion of the catheter and secure with the 
locking mechanism. Obtain a chest x-ray to confirm placement 
in proximal branches of the pulmonary arteries, never more 
than 5 cm from midline. When changing a pulmonary artery 
catheter to a triple-lumen catheter, follow the central lines 
guidelines in Exhibit 14.3. For more information on pulmonary 
 Central access will be changed based on following criteria: 
 Inclusion: Dialysis catheters, triple- and quad-lumen catheters, axilla and 
femoral arterial lines 
 Routine guidewire of catheters has not shown a decrease in infection. 
 Catheter change should occur with symptomatology :
 1. Temperature > 38.4 or < 36 
  a. Temperature previously stable 
  b. Present catheter > 6 days old
 c.  Patients on renal replacement therapy with signifi cant change in 
temperature OR diffi culty with blood fl ow of current catheter .
 2.  Follow white blood cell count (WBC) and consider all parameters. 
Isolated increase in WBC has not been correlated with line sepsis. 
  a. Consider continuing increase in WBC, if previously stable WBC. 
  b. Signifi cant increase in WBC and clinical suspicion of line infection. 
 3. Patient being transferred out of uni t
  a. Consider discontinuation of central access. 
  b. Consider change to PICC line if central access still indicated. 
  c. Consider need to guidewire catheter if > 14 days old. 
 Goal :
 Discontinue all invasive therapies as soon as feasible. 
14.3 Central Line Guidelines
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artery catheter waveform interpretation and troubleshooting, 
visit the pulmonary artery catheter education project Website 
(http://www.pacep.org/; Lefor & Gomella, 2001). 
Peripherally Inserted Central Line. The indications for a 
peripherally inserted central venous catheter (PICC) are 
similar to those for a central line, except a PICC is not an 
emergency catheter and is not used for rapid resuscitation. 
A PICC is generally indicated for long-term intravenous 
needs usually greater than 5–7 days. As technology has 
advanced, catheter materials have improved, resulting in a 
wider range of capabilities from long-term antibiotics use 
to patients requiring critical care. PICC lines now have a 
range from single lumen to triple lumen and can tolerate 
the pressure requirement for CT angiography. An alterna-
tive to a centrally placed PICC line is a midline catheter, 
which does not enter the central circulation and may be 
placed for short-term peripheral therapy. The insertion 
procedure for the PICC line and midline is the same. A 
midline is indicated when noncentral therapy is neces-
sary. Total parenteral nutrition (TPN) for example, may be 
administered through a central PICC, whereas short-term 
antibiotics could be administered through a midline. Local 
site hematoma and venous thrombosis are more common 
than with other central lines, although the risk of either is 
generally low. Complication rates related to insertion with 
PICC lines are lower when compared with other catheters. 
Because the catheter is generally inserted in the basilic 
vein, the risk of pneumothorax or hemothorax is negligi-
ble. A central PICC may be left in place for an indefinite 
amount of time in the absence of complications. Evaluat-
ing a patient for PICC placement requires consideration 
of the underlying condition. Ultrasound technology should 
be used to evaluate venous status and availability. Patients 
who have renal failure may require dialysis access and may 
not be candidates for upper extremity PICC line placement. 
Veins above the level of the antecubital fossa should be 
used, including (in order of preference) the basilic, median 
cubital, and cephalic veins. The basilic vein is the largest, 
with the highest flow rate and the most direct course to the 
superior vena cava. Caution should be used when choosing 
the cephalic vein, because it will have an increased risk of 
Chapter 14: Procedures in Critical Care 497
thrombosis and malposition. Measurement for a PICC line 
would start from the planned insertion site to the axillary 
region proceeding to the right clavicular head then down 
to the third intercostal space. This should place the tip of 
the catheter in lower superior vena cava (SVC) near the 
entrance of the right atrium. 
The patient should be placed supine with the arm 
abducted perpendicular to the trunk and the patient’s chin 
turned toward the side of insertion; if this is not possible, 
then a position of comfort should be selected. Maximum 
sterile barrier precautions are used for all PICC line place-
ments and may require placing a cap and mask on extubated 
patients. Prepare the skin by cleaning the area for 30 seconds 
and then apply sterile barriers as indicated under the sub-
heading of safety. Once the skin cleansing has dried, place 
the tourniquet, and while using ultrasound guidance with a 
sterile cover on the ultrasound probe, place a small amount 
of injectable anesthetic at the proposed insertion site. Once 
the anesthetic has taken effect, use an appropriate-sized 
angiocatheter or echogenic needle, based on the wire size 
contained within the kit in the chosen peripheral vessel. 
When venous access has been obtained, generally with blood 
return in the catheter hub, place the guidewire through the 
intravenous angiocatheter, then remove the angiocatheter 
and release the tourniquet. The guidewire should slide in 
smoothly and never be forced. 
Using a No. 11 blade scalpel, make a small incision near 
the guidewire while maintaining control of the guidewire. 
Prior to making the incision, additional injectable anesthetic 
may be required at the insertion site. Gently enter the vein 
with a two-part peel-away dilator, taking care to not rupture 
the vein or bend the guidewire. Using a sterile measuring 
tape, verify the catheter length measurement once a defini-
tive insertion site has been obtained and cut the catheter 
again if indicated. Sterile gloves should be changed at this 
point if the catheter length needs to be adjusted or addi-
tional handling of the catheter is indicated. This should 
facilitate prevention of site infection and phlebitis. Remove 
the guidewire and the inner portion of the dilator leaving 
the peel-away sheath in place. Guide the PICC catheter 
through the peel-away sheath noting that most catheters 
have a stylet inside the catheter. Resistance may occur, but 
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do not force the catheter. Reposition or rotate the patient’s 
arm and reattempt passage of the catheter. Once the cath-
eter has advanced past the shoulder into the subclavian 
vein, remove and take apart the peel-away sheath advanc-
ing the catheter completely. While maintaining sterile tech-
nique, use the ultrasound sound probe to review and study 
the internal jugular to evaluate for malposition, because 
this will be readily visible with the stylet in place. This can 
decrease the need for repeated radiographs for malposi-
tion. Once the catheter is in place, remove the stylet from 
within the catheter. Check each port for blood return and 
easy flushing. Securing of the catheter can be done using 
sutures (not recommended) or an adhesive securing device 
and place a sterile dressing as indicated in the safety sub-
heading. Obtain a single-view chest radiograph to confirm 
placement in the superior vena cava. A midline catheter may 
be placed using the same technique, but with the catheter 
trimmed such that the final position will rest in the axillary 
vein, a noncentral location. A chest radiograph is not indi-
cated for a midline catheter. 
 Complications of Central Venous Catheters 
In general, the complications of inserting a central venous 
catheter are mechanical and infectious. Mechanical com-
plications include pneumothorax, hemothorax, injury to 
the vein or accompanying artery, thoracic duct injury, wire, 
catheter or air embolus, venous thrombosis, thrombophlebi-
tis, catheter malposition, and dysrhythmias. Infectious com-
plications include superficial site infection, catheter colo-
nization, and catheter-related or catheter-associated blood 
stream infections. Infectious complications are reduced with 
the use of antibiotic impregnated catheters, proper site care, 
minimizing line access/use, and consideration of site pref-
erence with femoral site infection generally greater than 
internal jugular site infection, which is higher than subcla-
vian site infection (IHI, 2008). In addition, future infection is 
greatly influenced by maintenance of sterile technique dur-
ing placement, care, and maintenance of the catheter, dress-
ing, and insertion ports. All catheters should only be opened 
using strict sterile technique and ports should be entered 
only after a 15-second scrub of the hub to be accessed with 
Chapter 14: Procedures in Critical Care 499
chlorhexidine or alcohol and after allowing the hub to dry 
(CDC, 2008; IHI, 2008). See Exhibit 14.4 for central catheter 
guidelines regarding evaluation of infection. All emergently 
placed catheters should be replaced when the patient sta-
bilizes. All central lines should be removed promptly when 
they are no longer absolutely needed to minimize infectious 
complications. This discussion of catheter needs should be 
addressed daily in rounds and during the evaluation of the 
patient (IHI, 2008). See Exhibit 14.4 for discontinuation of 
central venous catheters. 
 Arterial Line 
There are several indications for arterial line placement. 
Patients with respiratory failure and severe hypoxemia may 
require frequent blood gases and therefore need access to 
the arterial system. There are patients who also require beat-
to-beat monitoring of blood pressure because of hemody-
namic instability that requires titration of vasoactive agents, 
 1.  There is no need to routinely culture line segment if it is being discontinued, 
unless it is desired for confi rmation of a diagnosis of line-related bacteremia. 
 2.  If culture is to be formed, don sterile gloves, mask, and hat. Place a small 
sterile drape. 
 3.  Place patient in Trendelenburg position if line is subclavian or jugular. 
Remove sutures, securing catheter with sterile scissors or scalpel. With a 
smooth, swift motion, remove catheter and apply pressure with sterile 4×4s.
Place catheter on sterile drape if performing culture. 
 4.  After ensuring hemostasis, apply an occlusive pressure dressing to site. 
 5.  For culture, grasp intracutaneous segment with sterile forceps. Cut a 2–3cm 
segment and place on agar plate. Roll several times to ensure appropriate 
inoculation of plate. Only sterile instruments should come in contact with 
catheter ICS. Repeat the process with the catheter tip placing it on the same 
agar plate or send in sterile specimen cup. 
14.4 Procedure for Discontinuing a Central Venous Catheter
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either for hypotension or hypertension. In addition, patients 
who will not tolerate variation in blood pressure, for example 
those with aortic dissection or stroke, are candidates for con-
tinuous arterial pressure monitoring. 
Contraindications include areas that have compromised 
circulation such as sites with known deficiencies. Examples 
include Raynaud syndrome and thromboangitis, including 
sites with infection or traumatic injury proximal to the area 
of insertion (Tegtmeyer, Brady, Lai, Hodo, & Braner, 2006). 
Complications include thrombosis or emboli, which leads to 
impaired perfusion and potentially limb-threatening isch-
emia. This risk is minimized with the use of a continuous 
flush system versus an intermittent flush system. Pseudoa-
neurysm and hematoma may also occur; this is minimized 
with adequate compression of the artery upon removal of 
the catheter. Local site infection or systemic infection occurs 
similar to central venous catheter; this risk is increased in 
the axillary or femoral position. 
The radial artery is the preferred site followed by the 
axillary artery. The dorsalis pedis artery should be avoided in 
diabetic patients or those with peripheral vascular disease. 
The femoral site is preferred in emergency situations because 
of the speed and facility of placement, particularly when com-
pressions are being performed. A femoral line should always 
be placed below the inguinal ligament; where it is compress-
ible should complications arise and upon discontinuation. The 
brachial artery should be avoided and it is not considered an 
acceptable site because of the potential embolic and ischemic 
complications that may occur to the hand. 
Radial. The radial artery is located 1–2 cm from the wrist 
between the bony head of the distal radius and the flexor 
carpi radialis tendon (Tegtmeyer et al., 2006). Before access-
ing the radial artery, perform the modified Allen test to con-
firm collateral flow to the hand from the ulnar artery. Should 
radial cannulation become complicated, request the patient 
to make a fist and compress the radial and ulnar arteries. 
Have the patient release the fist and at this point, release the 
pressure on the ulnar artery while maintaining pressure on 
the radial artery. The hand should flush red within 6 seconds 
if the ulnar artery and palmar arch are patent. The Allen test 
should determine if the palmer arch is apparently not intact 
and an alternative location should be considered. Ultrasound 
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may also be used to verify patency, or to guide placement. 
Place a roll under the patient’s wrist to dorsiflex the hand 
and place the arm on a firm surface, while remembering that 
excessive dorsiflexion can also cause constriction or occlusion 
of arterial flow. Consider applying tape to the hand to main-
tain position. Maintain sterile technique as described under 
the subheading of safety. Infiltrate a tiny wheal of lidocaine 
at the insertion site. At approximately 30 to 45-degree angle, 
insert a 20-gauge 1.5–2-inch angiocatheter or needle toward 
the pulse until pulsatile blood returns. When using an angio-
catheter, flatten the angle to approximately 10 to 15 degrees, 
and advance the catheter over the needle while holding the 
needle steady. When using a self-contained over-the-wire 
catheter, once the artery is accessed, advance the wire fol-
lowed by placing the catheter over the wire. For the Seldinger 
technique, once the artery is accessed, thread a guidewire 
through the needle then remove the needle and then thread a 
catheter over the wire and remove the wire. For arterial lines 
placed in the axilla or femoral site, generally a 12 cm cath-
eter is used to lessen the risk of mechanical failure. Flush any 
entrained air from the system and attach the pressure tubing. 
Ensure that arterial pressure waveform is obtained. Suture 
the catheter to the skin and apply a sterile dressing. 
For children or smaller patients, a through-and-through 
technique may be employed. Once the artery is accessed, 
the catheter and needle are intentionally advanced through 
the posterior wall of the artery until there is no longer blood 
return. Slowly withdraw the needle and catheter until a flash 
of blood occurs, then advance the catheter while removing 
the needle. 
Generally, if the artery is unable to be cannulated, this 
may be secondary to arterial spasm or the angle of the nee-
dle is too acute to access the vessel. Blood return should 
readily be seen in the hub of the catheter; if this does not 
occur, the tip of the needle may not be completely in the 
artery (Tegtmeyer et al., 2006). 
Dorsalis Pedis. Use the same technique as for radial artery 
catheter placement. 
Axillary. In preparing the patient as described for all arte-
rial access, abduct and externally rotate the arm. When 
attempting to access the vessel, enter the axilla as high into 
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the axillary vein as feasible at a downward position while 
palpating the axillary pulse in the biceps groove. Insert a 20-
gauge needle into the axillary artery while using ultrasound 
guidance if feasible. Place a guidewire through the needle 
when stabilizing the needle. Remove the needle and insert 
a 16-cm catheter over the guidewire. Remove the guidewire. 
Flush the catheter and attach the pressure tubing. Ensure 
appropriate pressure tracing and then secure the catheter to 
the skin with suture and apply a sterile dressing. 
Femoral. The path of the femoral artery may be marked by 
Doppler signal or ultrasound may be used for guidance. At 
least 2 cm below the inguinal ligament, insert a 20-gauge 
needle at about a 45-degree angle. The skin insertion site 
should be far enough below the inguinal ligament that the 
actual arterial puncture occurs below the ligament. Once 
pulsatile blood return is established, place the guidewire 
through the needle. Remove the needle and thread a 16-cm 
catheter over the wire. Remove the wire. Flush and attach 
pressure tubing. Ensure appropriate pressure tracing. 
Secure the catheter with suture and place sterile dressing. 
 Thoracentesis 
A thoracentesis may be performed to diagnose the etiology 
of a pleural effusion, for therapeutic removal of fluid, or for 
installation of a sclerosing compound for pleurodesis. Analy-
sis of pleural fluid facilitates diagnostic information deter-
mining whether the fluid is transudate, which is a product of 
unbalanced hydrostatic forces, or exudate, which is a product 
of increased capillary permeability or lymphatic obstruc-
tion (Thomsen, DeLaPena, & Setnik, 2006). Some common 
causes of transudate include congestive heart failure, cirrho-
sis, nephrotic syndrome, and pulmonary embolism. Common 
causes of exudate include cancer, pneumonia, trauma, pul-
monary embolism, rheumatoid arthritis, and systemic lupus 
erythematosus (SLE) (Thomsen et al., 2006). Complications 
of the procedure include pneumothorax, injury to intercostal 
vessels, hemothorax, visceral puncture, intrabdominal organ 
injury, air embolism, and bleeding in patients who are anti-
coagulated secondary to a hypercoagulable state. Vigilance 
when completing a thoracentesis in ventilated patients should 
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be employed because positive pressure may alter the lungs’ 
anatomy increasing the risk of pneumothorax. Caution must 
be employed and the approach must be altered with conditions 
that might elevate the hemidiaphragm including previous lung 
resection, presence of ascites, or morbid obesity. 
Radiographs should be reviewed to evaluate for anatomic 
variations and size of effusion. When possible, the patient 
should be seated with legs draped over the edge of the bed, 
leaning forward, and resting the arms on a bedside table, thus 
moving the scapulae anterolaterally. When the seated posi-
tion is not possible, place the patient supine with the arm 
raised over the head to open the intercostal spaces. Prepro-
cedure imaging and the use of ultrasound technology may 
guide patient placement and catheter placement location. The 
level of effusion should also be evaluated by auscultation of 
diminished or absent breath sounds, dullness to percussion, 
and decreased or absence of fremitus (Thomsen, DeLaPena, 
& Setnik, 2006). When the patient is able to sit upright, the 
parietal pleura is at the level of the 10th vertebra, posteriorly. 
Staying above the 8th intercostal space should prevent injury 
to the abdominal viscera. Typically, the 7th intercostal space 
is used. This is found at the tip of the scapulae in the upright 
position. This is a sterile procedure, and the patient should be 
prepared and draped for any invasive procedure. 
Initially, use a small 25-gauge needle and 1% lidocaine to 
anesthetize the skin. Then use a larger needle approximately 
22 gauge to anesthetize the subcutaneous tissues and pari-
etal pleura along the superior edge of the ribs. While slowly 
advancing the needle and injecting the anesthetic, aspirate 
on the plunger of the syringe to assure that the placement 
of the needle is not intravascular and to avoid injury to the 
nerves and vessels. As soon as fluid or air is aspirated, with-
draw needle ∼2 mm and inject lidocaine. This will inject the 
lidocaine under the sensitive parietal pleura. Injecting just 
above the superior edge of the inferior rib will avoid injury 
to the intercostal neurovascular bundle. 
Mark the point on the needle where the depth of fluid 
or air is aspirated; this is how deep the thoracentesis needle 
will subsequently need to be inserted. A 20-gauge or larger 
angiocatheter, with a three-way stopcock attached to a syringe 
and IV tubing with collection bag is used to enter the pleural 
space. While aspirating, advance the needle slowly to the pre-
viously marked depth. Advance perpendicular to the chest 
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wall to avoid injury to the intercostal neurovascular bundle. 
When fluid or air is encountered, advance the catheter over the 
needle into the pleural space and remove the needle. Attain a 
specimen of fluid (approximately 50 ml) to send for analysis, 
and then open the stopcock to the collection bag allowing the 
effusion to drain by gravity. Allowing the effusion to drain by 
gravity, as opposed to suction, is less painful and has lower 
risk of reexpansion pulmonary edema. Limiting the drainage 
to 1,500 ml or less on initial drainage will also diminish the 
risk of reexpansion injury (Thomsen, DeLaPena, & Setnik, 
2006). When drainage is complete, remove the catheter and 
place an occlusive dressing. Obtain an upright chest radio-
graph to evaluate for adequacy of drainage and for presence 
of pneumothorax. Although pneumothorax is rare, if it occurs, 
the drainage system may be connected to an underwater seal 
pleurovac to resolve the issue. Send the recovered fluid for 
laboratory and microbiologic evaluation as indicated. 
 Chest Tube Thoracostomy 
A chest tube thoracostomy may be used to drain traumatic 
or nontraumatic effusions. Traumatic effusions include pneu-
mothorax, hemothorax, hemopneumothorax, or chylothorax. 
Nontraumatic effusions include spontaneous pneumothorax, 
reactive effusion, malignant effusion, empyema, and chy-
lothorax. A chest tube should also be considered in a clini-
cally unstable patient who is unable to be ventilated. Caution 
should be used in patients with previous thoracic surgery, and 
potential for complete adherence of the lung to the chest wall, 
clotting disorders, bullous emphysema, massive hemothorax, 
and hepatomegaly (Dev, Nascimiento, Simone, & Chien, 2007). 
Complications include inadequate drainage of the pleural 
space, bleeding, hemothorax, intercostal artery perforation, 
perforation of the visceral organs and major vascular struc-
tures, subcutaneous emphysema, introduction of bacteria 
leading to development of empyema, and significant pain if 
appropriate local anesthesia is not used (Dev et al., 2007). 
Select a tube size based on the indication and patient’s 
size. For a nontraumatic pneumothorax, use 18–24 French 
tube; for a simple effusion, use a 28–32 French tube. For an 
empyema, chylothorax, hemothorax, or traumatic pneumo-
thorax, a large tube such as 32–40 French tube should be used 
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because of the necessary coexistence of a hemothorax. The 
use of chest tubes with internal trocars should be avoided to 
prevent injury to the lungs, mediastinal structures, diaphragm, 
and abdominal viscera. 
Position the patient supine at the edge of the bed, with 
the ipsilateral arm raised above the head if possible or with 
the shoulder abducted to expand the intercostal spaces. Use 
2% Chlorhexidine solution and sterile gauze to vigorously 
cleanse the area. Then widely prep and drape the patient 
such that the anatomic landmarks remain within the ster-
ile field. Most commonly, a chest tube is placed between the 
fourth and sixth intercostals space in the mid or anterior axil-
lary line when draining a pneumothorax, and in the poste-
rior axillary line for an effusion in a recumbent (bed-bound) 
patient. The anterior axillary line is marked by the lateral 
border of the pectoralis muscle. In men, the nipple overlies 
the fourth intercostal space; in women, the inframammary 
fold lies at the fifth intercostal space. At the anterior axillary 
line, the parietal pleural reflection is at the level of the eighth 
vertebra. A line above the horizontal level of the nipple is 
often referred to as the “triangle of safety,” which is located at 
the anterior border of the latissimus dorsi, the lateral border 
of the pectoralis major muscle, and the apex just below the 
axilla (Dev et al., 2007). Staying above the sixth intercostal 
space should be low risk for injury to the spleen, liver, or 
diaphragm. Anesthetize the skin, subcutaneous tissue, and 
parietal pleura as described. Remember that the intercostal 
nerves travel from posterior, around the thorax to anterior; 
therefore, directing the local anesthetic somewhat laterally 
will provide excellent local anesthesia. 
When preparing the thoracotomy tray, set up the chest tube 
by placing a Kelly clamp on the distal tip of the tube and the 
proximal end of the tube. Initially use a small 25-gauge needle 
and 1% lidocaine to anesthetize the skin. Then use a larger 
needle approximately 21–22 gauge, approximately 10–20 ml of 
1% to 2% lidocaine solution to anesthetize the subcutaneous tis-
sues, parietal pleura, and intercostal muscles along the superior 
edge of the ribs (Dev et al., 2007). While slowly advancing the 
needle and injecting the anesthetic, aspirate on the plunger of 
the syringe to assure that the placement of the needle is not 
intravascular and to avoid injury to the nerves and vessels. After 
anesthetizing, make a skin incision large enough to admit the 
index finger over the fifth or sixth rib approximately 1.5–2.0 cm 
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in length parallel to the rib. Use a Kelly clamp to develop a tract 
that tunnels to the parietal pleura one rib space superior to the 
incision (Dev et al.). This minimizes air sucking into the chest 
cavity or pleural fluid leaking out and allows for the subcutane-
ous tissue to collapse over the hole in the pleura when the chest 
tube is removed. 
Spread the chest wall muscles with a hemostat until the 
pleura is reached, dissecting through the subcutaneous tis-
sue. With a closed hemostat and your index finger, explore the 
tract and puncture the pleura in a controlled motion at the 
superior edge of the rib to prevent injury to the neurovascu-
lar bundle. Digitally explore the tract to ensure that there is 
no lung adhesion to prevent injury, taking caution to prevent 
personal injury if the patient has rib fractures. Enlarge the 
hole by opening the hemostat to spread the muscle. A rush of 
air or fluid should occur. Using the distal tip of the chest tube 
with the Kelly clamp and the proximal clamp intact, guide 
the tube through the tract. Once the distal tip has passed 
through the incision and into the tract, unclamp the Kelly, 
remove, and then position the tube within the thoracic cav-
ity. To drain an effusion, turn the hemostat posteriorly and 
toward the mediastinum or diaphragm to guide for posterior 
placement. The tube may be directed anteriorly and toward 
the lung apex for a spontaneous pneumothorax. Rotating 
the tube laterally while advancing the tube will help prevent 
ineffective placement within the fissure. 
Secure the tube and close the incision around the tube 
with a zero silk suture using a mattress or uninterrupted 
sutures on both sides of the incision. Use the loose ends of 
the sutures to wrap around the tube so that when removing 
the tube, the wound may be closed preventing subsequent 
pneumothorax and approximating the skin (Dev et al., 2007). 
Attach the tube to an underwater seal closed drainage system 
at approximately 20 cm of water. The chest tube should not 
be reclamped to prevent reaccumulation of pneumothorax. 
Place an occlusive, absorptive dressing. Obtain an upright 
chest x-ray to verify tube placement and adequate treatment 
of the effusion or pneumothorax. 
 Chest Tube Removal 
The removal of the chest tube should occur upon resolution 
of the reason for initial chest tube placement. A chest tube 
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placed to resolve a pneumothorax should have a chest radio-
graph to verify that the pneumothorax is resolved. The chest 
tube should be placed to an underwater seal to assure the 
lung remains expanded without continuous suction. A repeat 
chest radiograph should indicate that the lung has remained 
expanded for approximately 12–24 hours postremoval of 
suction. A chest tube placed to drain pleural fluid may be 
removed after resolution of effusion and once drainage is less 
than 100–200 ml in a 24-hour period. The general expectation 
would also be that the patient’s clinical status has improved. 
Instruct the patient to breathe in to total lung capacity 
after a full expiration of air, or if mechanically ventilated, 
time the removal to end expiration and quickly remove the 
tube, pulling the end strings of the sutures together to tie and 
occlude the site with Vaseline gauze. Using tape and gauze, 
secure the dressing and evaluate the chest radiograph to 
ensure that a residual pneumothorax has not occurred. 
 Paracentesis 
A paracentesis is performed to treat symptomatic ascites or to 
obtain diagnostic fluid. Patients with new onset ascites, should 
have a sample of the fluid obtained to aid in diagnosis of the 
etiology. Patients with known ascites, presenting with fever, 
abdominal pain, hypotension, or encephalopathy should 
have a sample of fluid evaluated to determine the etiology. A 
nasogastric tube should be inserted prior to paracentesis for 
suspected bowel obstruction and a foley should be inserted 
in the patient with urinary retention, or if feasible, the patient 
may urinate (Thomsen, Shaffer, et al., 2006). Paracentesis is 
relatively contraindicated in uncooperative patients and in 
those with uncorrected coagulopathy, acute surgical abdomen, 
intra-abdominal adhesions, distended bowel, infections at the 
puncture site, and in pregnancy. Complications include peri-
tonitis, perforated viscus, hemorrhage, and persistent ascites 
leak. Oliguria, hypotension, electrolyte abnormalities, and 
precipitation of hepatic encephalopathy may occur as a result 
of fluid shifts. The use of ultrasound will enhance the success 
of the procedure and minimize secondary complications. 
Place the patient supine and examine the abdomen to 
choose a site. Avoid surgical scars and other areas of possible 
adhesion formation to avoid potential bowel injury. Ultra-
sound or computed tomography (CT) may be beneficial in 
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selecting a safe window. In the absence of previous abdominal 
incisions, the preferred site is midway between the umbilicus 
and anterior superior iliac spine, lateral to the rectus muscle. 
The needle insertion site is approximately 2 cm below the 
umbilicus in the midline or in the right or left lower quad-
rant, 2–4 cm medial and cephalad to the anterior superior iliac 
spine (Thomsen, Shaffer, White, & Setnik, 2006). Prep and 
drape the patient in sterile fashion as with any invasive pro-
cedure. Anesthetize the skin and subcutaneous tissue down 
to the level of the peritoneum with 1% lidocaine. Advance a 
16–20 gauge angiocatheter while aspirating perpendicular 
to the abdominal wall then angled to create a “z” track. This 
helps to prevent persistent ascites leak. Some resistance may 
be met at the level of the fascia, and a “pop” may be felt when 
the fascia is traversed. When fluid is encountered, advance 
the catheter and remove the needle. Attach a stopcock and 
extension tubing to a closed collection system. Drain the 
desired amount of fluid while monitoring for hypotension; 
if a large volume is to be removed, send fluid for analysis. 
Remove the catheter and place a sterile dressing. 
 Intubation 
In general, indications for endotracheal intubation are air-
way control and respiratory failure. Intubation may provide 
patency to an obstructed airway and allow for pulmonary 
toilet when the patient is unable to clear secretions. In the 
presence of poor mental status (i.e., Glasgow coma score 
less than 9) or absent gag or swallow reflex, intubation pro-
vides for airway control. Respiratory failure may be a result 
of hypoxia or inadequate ventilation. Patients may require 
intubation for acute hypoxia with an arterial partial pres-
sure of oxygen (PaO2) less than 60 with a fraction-inspired 
oxygen (FiO2) more than 0.5, or an alveolar to arterial oxy-
gen gradient greater than 300. Inadequate alveolar ventila-
tion may occur as a result of medications or decreased level 
of consciousness. It may also result from increased work of 
breathing or minute ventilation during the bronchoscopy 
by adjusting mechanical ventilation. Maintaining control of 
the airway is the lifeline of the patient and decisions regard-
ing the airway should be made with expertise and careful 
consideration. When in doubt, err on the side of intubation 
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versus loss of an airway and potential patient complications 
such as cardiorespiratory arrest. 
Endotracheal intubation is not a benign procedure, 
and complications may arise during placement of the tube 
and from actual endotracheal presence of the tube. During 
intubation, injury to the lips, teeth, vocal cords, larynx, and 
cervical spine may occur. Airway bleeding may make intu-
bation difficult. Esophageal intubation, aspiration, arrhyth-
mias, hypotension or hypertension, and laryngospasm are 
additional risks. Loss of an airway will result in anoxic brain 
injury. Post intubation, the patient is at risk for tube occlusion, 
tube migration, ventilator-associated pneumonia, sinusitis, 
tracheomalacia, and subglottic stenosis. 
Experience with airway management should occur in a 
controlled setting with an individual with experience prior to 
attempting intubation in emergency conditions. In an emer-
gency, the most experienced person should perform the intu-
bation and always call for backup or additional assistance or 
a laryngeal mask airway (LMA) placed to maintain the air-
way. Stay calm and remember to be gentle. Most patients can 
be bag-mask ventilated until more experienced help arrives 
if an airway is difficult or unable to be attained. The goal is 
to avoid emergent intubation by intervening prior to respira-
tory collapse. 
Intubation requires additional personnel to facilitate 
the procedure by preparing the patient and equipment. 
Prepare all the equipment necessary, assuring suction and 
oxygen are readily available. Pre oxygenate the patient 
using bag, valve, mask (BVM) ventilation. Insert the stylet 
into the endotracheal tube (ETT) and keep the endotra-
cheal tube sterile until insertion. Pre medicate the patient 
with appropriate sedative, anxiolytic, narcotic, and/or para-
lytic medications. Rapid sequence intubation (RSI) may be 
indicated in cases of potential aspiration, difficult airway, 
and potential for anoxia. Avoid the use of paralytics unless 
an experienced provider is available, because the use of 
paralytics will eliminate the patient’s ability to breathe 
spontaneously. This may be life threatening in the event of 
a difficult intubation. 
Lift the patient’s chin and lower jaw and, where able, extend 
the neck to form a straight path from the mouth to the trachea. 
Use jaw thrust in a patient with potential cervical spine injury 
or severe degenerate disease of the spine. Using a curved 
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laryngoscope Macintosh blade, insert the blade on the right 
side of the mouth, sweeping the tongue to the left as the blade 
is brought to the midline. As the epiglottis is brought into view, 
advance the blade into the vallecula. Keep the wrist straight 
and lift forward and upward because this position prevents 
the use of the teeth as a fulcrum for leverage. This maneuver 
stretches the epiglottis upward and exposes the cords. When 
using a straight Miller blade, advance the blade posterior to 
the epiglottis and lift upward and forward to expose to cords. 
Advance the ETT 2–3 cm through the cords, then remove the 
stylet, and inflate the cuff. Confirm placement with a carbon 
dioxide detector, observation of chest wall excursion, ausculta-
tion over bilateral lung fields and epigastrium, and evaluation 
of tidal volume return. Obtain a chest x-ray to evaluate correct 
placement 2–3 cm above the carina. 
Common causes of failed intubation include inadequate 
neck extension, inadequate sedation or muscle relaxation, 
obscuration of the glottis by the tongue, lack of familiarity 
with the anatomy, and misplacement of the laryngoscope 
blade particularly by inserting the laryngoscope too deep 
resulting in the lifting of the entire larynx such that only the 
esophagus is visible and accessible. When an attempt at intu-
bation fails, provide BVM to return the patient’s oxygen satu-
ration to normal. Attempt again or seek more experienced 
assistance if available. 
 Cricothyroidotomy 
Cricothyroidotomy is an emergency procedure to secure the 
airway and is performed when other options are not feasi-
ble, secondary to severe oromaxillary facial trauma, or when 
other options have failed, such as orotracheal or nasotra-
cheal intubation. Even with this invasive approach, failure to 
secure the airway may still occur. Any bleeding may obscure 
vision and make completion of the cricothyroidotomy diffi-
cult. Injury to the airway, including cords, larynx and trachea, 
or esophagus may occur. Pneumomediastinum and pneumo-
thorax are additional potential complications and long-term 
subglottic stenosis may result. 
Patients that are able to be ventilated using a BVM should 
continue to receive oxygen with this intervention throughout 
the procedure. Unless contraindicated secondary to trauma, 
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hyperextend the patient’s neck. Even though a cricothyroid-
otomy is considered an emergency procedure, prep the skin 
with chlorhexidine 2% and drape the neck in sterile fashion 
if feasible. Locate the thyroid cartilage as the most promi-
nent structure in the neck. Moving inferiorly, the cricothy-
roid membrane will be felt as a space between the thyroid 
cartilage and the cricoid cartilage. Anesthetize the skin if the 
patient is conscious and time permits. 
Stabilize the trachea with the nondominant hand using 
the left thumb and middle finger and using the index finger 
to palpate the thyroid cartilage. Move the index finger down 
until the cricoid cartilage is palpated and then make a midline, 
longitudinal 2.5 cm skin incision centered over the cricothy-
roid membrane; carry the incision through the subcutaneous 
tissue. An initial transverse incision may incur more bleed-
ing, obscuring visualization and potential injury to the laryn-
geal nerves (Hsiao & Pacheco-Fowler, 2008). Next, identify 
the cricothyroid membrane and make a transverse incision 
in the membrane approximately 1.3 cm in depth to minimize 
the risk of esophageal perforation (Hsiao & Pacheco-Fowler, 
2008). Using a clamp or the scalpel handle, spread the mem-
brane longitudinally to hold the airway open. 
Insert an appropriately sized endotracheal tube or tra-
cheostomy tube, usually a 4.0–6.0 mm in an adult, into the 
trachea while directing the tube caudally. Never let go of the 
tube until it is secured to prevent accidental dislodgement 
of the tube and loss of the airway. Inflate the cuff and then 
connect the bag valve to the endotracheal tube and ventilate 
with 100% oxygen. Auscultate breath sounds, observe chest 
rise, and utilize the carbon dioxide detector to confirm place-
ment. Secure tube with suture and tracheostomy ties or tape 
and place a gauze dressing around the tube. Obtain a chest 
x-ray to confirm placement. Because of the risk of subglottic 
stenosis, a cricothyroidotomy will need to be revised to a for-
mal tracheostomy when the patient is stable, usually within 
24–72 hours (Hsiao & Pacheco-Fowler, 2008). 
In patients under 12 years of age, needle cricothyroidotomy 
should be the only form of cricothyroidotomy to be performed 
because of the relatively high risk of subglottic stenosis. Sta-
bilize the trachea with the nondominant hand. Insert a 12- or 
14-gauge angiocatheter with syringe attached through the cri-
cothyroid membrane perpendicular to the trachea. When air is 
aspirated, advance the catheter, direct it caudally and remove 
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the needle. Attach an oxygen source via extension tubing or 
the bag valve unit. This is a temporary procedure (about 45 
min), allowing the patient to be oxygenated until he or she is 
stable to be transported to a higher level of care. 
 Bronchoscopy 
Bronchoscopy is most commonly used for therapeutic or 
diagnostic aspiration of the tracheobronchial tree. Bron-
choscopy is used to obtain specimens for evaluation and cul-
ture in cases of suspected lower respiratory tract infection, 
to treat major atelectasis resulting from bronchial plugging, 
and to evaluate and possibly treat hemoptysis. Specifically, 
trained practitioners may use bronchoscopy for endobron-
chial or transbronchial biopsies, retrieval of foreign bodies, 
and to guide intubation for difficult airways. Complications 
include hypoxia, hypercapnea, barotrauma, hypertension, 
hypotension, dysrhythmias, aspiration, introduction of infec-
tion, hemorrhage, laryngospasm, and elevated intracranial 
pressure. Contraindications to bronchoscopy in intubated 
patients include cardiovascular instability despite pharma-
cologic intervention, hypoxemia despite fraction of inspired 
oxygen of 100% and severe acid/base or electrolyte abnor-
malities. Even experienced providers should not perform 
bronchoscopy in an extubated patient with respiratory dis-
tress and hypoxemia, because despite supplemental oxygen 
by mask, this precludes cooperation or the ability to protect 
the airway. These patients should be intubated prior to pro-
ceeding with bronchoscopy. 
While preparing for the procedure, increase the supple-
mental oxygen to 100%. Hypoxia occurs during bronchoscopy 
even in healthy patients. Select a bronchoscope size based 
on size of the endotracheal tube, which will allow for venti-
lation, typically the inner diameter of the ETT tube must be 
2.5 mm larger than the bronchoscope. A pediatric broncho-
scope (4 mm) may be used for smaller endotracheal tubes; 
however, the suctioning ability is limited. A 5 mm scope can 
be used through an 8 mm or 9 mm endotracheal tube. The 
patient should be provided with equivalent minute ventilation 
during the bronchoscopy by adjusting mechanical ventilation. 
Decrease the flow rate to minimize peak pressures; increase 
the respiratory rate and tidal volume to compensate for air 
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leak. An assistant should be available to monitor the minute 
ventilation, pulse oximetry, and vital signs. Provide appro-
priate analgesia and sedation. Paralytics may be used in intu-
bated patients to protect the patient and the bronchoscope. 
Make sure to increase the ventilator settings to maximize 
ventilation until the paralytic agent has reversed. In extubated 
patients, 1% lidocaine may be applied topically to the airway 
and used alternatively to control cough. 
Place a sterile drape on the patient’s chest and wear 
sterile gloves, hat, and mask with eye protection, to minimize 
introduction of organisms into the patient’s bronchial tree and 
to protect the provider from the spray of secretions. Place a 
three-way adapter between the endotracheal tube and venti-
lator. The port through which the bronchoscope is passed has 
a rubber diaphragm to minimize air leakage. Have an assistant 
hold the endotracheal tube to prevent displacement. Lubri-
cate the bronchoscope with water soluble lubricant. Place the 
bronchoscope through the adaptor and continue through the 
endotracheal tube. Aspirate upper airway secretions, keeping 
the suction port off the mucosa. Use the carina and membra-
nous portion of the trachea for orientation. Systematically 
evaluate the right middle, right lower, right upper, left lower, 
left upper lobes, and lingula down to the level of the subseg-
mental bronchi. Make sure not to push the bronchoscope 
against the mucosa to avoid injury. Aspirate mucus plugs and 
have the assistant place a collection trap in line with the suc-
tion port. Gently wedge the bronchoscope into segmental or 
subsegmental bronchus in the area of infiltrate seen on chest 
x-ray. When diffuse infiltrates are seen on radiograph, use a 
nondependent area like the lingula or right middle lobe to 
obtain washings. Have the assistant instill 20 ml aliquots of 
sterile saline to a total of 100 ml. Aspirate each aliquot before 
installation of the next. Aliquots can be collected and pooled 
as one specimen. At least 40% of the lavage fluid must be 
recovered for the sample to be considered adequate. Send the 
specimen for cell counts, special stains, and cultures (bacte-
rial, mycobacterial, fungal, viral) as indicated. 
In cases of major atelectasis with physiologic compro-
mise, bronchoscopy is therapeutic only if the atelectasis is 
the result of bronchial obstruction. Evaluate the chest radio-
graph to confirm proper placement of the endotracheal tube. 
Auscultate breath sounds, and if breath sounds are present 
over the affected area, the atelectasis is unlikely to be post 
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obstructive and the bronchoscopy will not be therapeutic. 
In this instance or if physiologic compromise is not present, 
chest physiotherapy or increasing positive end expiratory 
pressure (PEEP) are preferred treatments. 
Hemoptysis in intubated patients is usually the result of 
airway trauma from the end of the endotracheal or trache-
ostomy tube or from suctioning. Hemoptysis resulting from 
endobronchial lesions, such as tumors, may be treated topically. 
Occasionally, pulmonary embolus results in hemoptysis, but 
lesions will not be seen on bronchoscopy. Pneumonia may pro-
duce hemoptysis, especially in coagulopathic patients. Rarely, a 
tracheostomy may erode into the innominate artery resulting 
in massive hemoptysis, although this may be preceded by a less 
dramatic, herald bleed. Bleeding from a tracheoinnominate fis-
tula is a surgical emergency, and bronchoscopy is not indicated. 
The source of a herald bleed is unlikely to be seen by bronchos-
copy. Bronchoscopic treatment of hemoptysis includes instal-
lation of epinephrine (3–5 ml of 1:10,000 solution) and topical 
application of thrombin. When bleeding is not controlled with 
topical measures, a more experienced practitioner may place a 
balloon-tipped catheter to tamponade the bleeding. In addition, 
arteriography with embolization or surgical intervention may 
be indicated. 
 Percutaneous Tracheostomy 
Patients who are anticipated to require long-term airway 
control are generally considered for tracheostomy. The per-
cutaneous option is available when the surface anatomy is 
readily identifiable and normal. This is not an emergency 
airway option. In addition, a percutaneous tracheostomy is 
not safe in patients who are unable to tolerate bronchoscopy 
or who require high levels of ventilator support, especially 
high positive end-expiratory pressure (PEEP). Complica-
tions include inadvertent loss of the airway, injury to the 
trachea, injury to the esophagus, malposition of the trache-
ostomy tube (i.e., pretracheal space). Long-term complica-
tions include tracheoesophageal fistula, tracheoinnominate 
fistula, tracheal stenosis, and tracheal malacia. 
This procedure requires two operators: one to perform 
the bronchoscopy and one to perform the tracheostomy. 
Place the patient supine and extend the neck if possible. 
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Provide the patient with adequate analgesia, sedation, and 
paralytic. Adjust the ventilator settings to allow adequate 
oxygenation and ventilation during the procedure. Per-
form bronchoscopy to identify anatomic landmarks and 
the anterior portion of the trachea. With the bronchoscope 
positioned at the end of the endotracheal tube, withdraw 
the endotracheal tube to the level of the cricothyroid mem-
brane. Take extreme caution not to extubate the patient, 
and maintain the bronchoscope at the end of the endotra-
cheal tube to allow visualization of the entire trachea. This 
enables the bronchoscopist to monitor tracheal dilation and 
subsequent tracheal dilation. 
Prep the neck and widely drape as for any invasive proce-
dure. Confirm that the cuff of the tracheostomy tube is functional 
prior to the start of the procedure. Anesthetize the skin with 1% 
lidocaine because inadvertent injection into the thyroid leads 
to rapid absorption of the lidocaine and epinephrine and can 
lead to hypertension and tachycardia. Identify the larynx and 
cricoid cartilage, moving caudally, count the tracheal rings. The 
tracheostomy should be placed between the first and  second or 
second and third tracheal rings. Make a midline, vertical skin 
incision centered over the second and third tracheal rings just 
large enough to accommodate the tracheostomy tube. The mid-
line is avascular and less bleeding should be encountered than 
with a horizontal incision, although a small horizontal incision 
may be used and is generally more aesthetic. 
Use the nondominant hand to stabilize the trachea. 
Slowly advance the angiocatheter perpendicular to the tra-
chea while aspirating until air returns indicating the position 
within the airway. Avoid puncture of the posterior, membra-
nous portion of the trachea to avoid injury to the esophagus. 
The bronchoscopist should confirm if placement is midline 
and at the correct tracheal ring level also to monitor for 
potential injury to the membranous portion of the trachea. 
Advance the angiocatheter caudally and remove the needle. 
Insert the guidewire through the catheter and remove the 
catheter. Inserting the wire too deep can cause injury to 
the lung. From this point, the guidewire is the only thing 
securing the path to the trachea. Do not remove the wire 
until final tracheostomy placement is confirmed within the 
airway. Dilate the subcutaneous tissue and trachea with the 
smallest dilator placed over the wire, utilizing the Seldinger 
technique. 
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Depending on the brand of the kit used, use sequential 
dilators or tapered dilator to enlarge the tract and hole in the 
trachea to the size of the tracheostomy tube. While advancing 
the dilator, maintain its position perpendicular to the trachea 
following the curve of the dilator. Use only moderate force to 
prevent injury to the trachea, and if the dilator does not pass 
easily, return to a smaller dilator. The skin incision may need to 
be enlarged if the skin creates resistance. Load the tracheosto-
my tube on the appropriate sized dilator and insert the trache-
ostomy over the guidewire and into the trachea. Remove the 
dilator and the wire, never releasing the tracheostomy until it 
is secured to prevent accidental dislodgement of the tube and 
resultant loss of the airway. Place the bronchoscope through 
the tracheostomy to visualize the carina, confirming proper 
position within the airway. Remove the bronchoscope, inflate 
the cuff, insert the inner cannula, and attach the ventilator. 
Confirm placement with carbon dioxide detector, observa-
tion of chest rise, auscultation of breath sounds, and return of 
appropriate tidal volume via the ventilator. Secure the trache-
ostomy with sutures and tracheostomy ties. Now it is accept-
able to remove the endotracheal tube. Obtain a chest x-ray to 
confirm placement and evaluate for complications. 
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 Introduction 
In critically ill patients, adequate sedation and analgesia 
increase patient comfort, reduce the stress response as related 
to inflammation and trauma, facilitate diagnostic and thera-
peutic procedures, and enable patients to interact with the 
environment while being able to endure medical and nursing 
interventions. Achieving an appropriate level may have a ben-
eficial impact in decreasing morbidity by reducing pulmonary 
complications and preventing agitation. Although there is no 
clear consensus on the best evaluation and management of 
sedation and analgesia in critically ill patients, numerous tools 
have been devised to help guide clinicians. Regular evalua-
tions of patient sedation and pain requirements are important 
when setting individual patient-specific goals. This may be 
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guided by standardized protocols to facilitate a balanced seda-
tion and analgesia plan while reducing duration of mechanical 
ventilation, length of time in the intensive care unit (ICU) set-
ting, and subsequent cost. In this chapter, we address issues 
pertinent to sedation and analgesia for the ACNP. 
 Sedation in the ICU 
 Introduction 
Providing adequate sedation for the critically ill patient can 
be challenging because it is necessary to provide a sufficient 
level of patient comfort while avoiding the risk of overseda-
tion and its associated complications. Sedation reduces the 
stress response, provides anxiolysis, controls agitation, aids in 
mechanical ventilation, provides amnesia during neuromuscu-
lar blockade, and helps to facilitate nursing care (Ostermann, 
Keenan, Seiferling, & Sibbald, 2000; Weissman, 2005). The opti-
mal level of sedation provides relief of anxiety and agitation 
based on specific goals while still allowing for the patient to 
comfortably interact with the environment. The sedation goal 
is patient specific to achieve defined targets, for example, man-
agement of a difficult airway or improvement in mechanical 
ventilation. However, the common principle is to target seda-
tion to a level appropriate for that individual patient and to 
avoid the excessive use of sedation medications. Because of the 
lack of analgesic properties of most sedatives, it is necessary 
to treat pain separately while achieving an adequate level of 
sedation. 
 Sedation Therapy 
The indications for the use of sedative agents are generally 
multifactorial and are not well defined. The causes of anxi-
ety in critically ill patients may be caused by the inability to 
communicate in an environment with continuous noise sec-
ondary to monitoring alarms, personnel, continuous ambient 
lighting, and excessive stimulation from frequent vital signs, 
motion, and inadequate analgesia (Jacobi et al., 2002).  Anxiety, 
agitation, and delirium are commonly seen in up to 85% of 
critically ill patients when using validated sedation scales 
(Ely et al., 2001). Assurance, communication, and information 
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may facilitate calming a patient as an initial intervention, but 
pharmacological agents are more frequently needed to relieve 
anxiety in the ICU setting. 
Benzodiazepines. The most common intravenous ben-
zodiazepines used in the ICU setting include midazolam, 
lorazepam, and diazepam, which are an accepted stan-
dard of care because of their relative safety, anterograde 
amnesia, and relative opioid-sparing effects. Medications 
in this category are lipid-soluble to some degree and are 
hepatically metabolized and renally excreted. Benzodiaz-
epines generally do not cause respiratory depression in 
healthy individuals, although an exaggerated response is 
seen in patients with respiratory, cardiac, or hepatic insuf-
ficiency or in the elderly caused by decreased metabolism 
of benzodiazepines (Barr, Zomorodi, Bertaccini, Shafer, & 
Geller, 2001). Benzodiazepines differ in their potency, onset 
of action (generally 2–5 minutes), and duration of action 
caused by half-life, uptake, distribution, and metabolism. 
Patient- specific factors such as age, comorbidities, prior 
alcohol, and drug use affect intensity and duration of action 
and require individual titration of benzodiazepines. 
Midazolam is the benzodiazepine of choice for short-term 
sedation because of its fast onset, short duration of action, and 
high lipid solubility. Midazolam is usually administered as a 
continuous infusion and may generate prolonged sedation 
because of drug and active metabolite  (hydroxymidazolam) 
accumulation (Fragen, 1997). Lorazepam has the slowest onset 
of action of the intravenous benzodiazepines, but also has the 
less potential for drug interactions because of its metabo-
lism via glucuronidation. Although this makes lorazepam a 
poor drug for initial treatment of agitation, the long half-life 
is ideal for the continuation of sedation via either intermit-
tent bolus or continuous infusion (Watling, Johnson, & Yanos, 
1996). Because of the long elimination timeframe and half-life 
of 12–15 hours, lorazepam is not a recommended drug when 
rapid awakening is desired but is more appropriate for long-
term ventilated patients. 
Diazepam provides rapid onset of sedation and awaken-
ing after single dose but produces prolonged sedation after 
repeated doses because of the accumulation of active metabo-
lites. Although this had been acceptable for providing long-
term sedation, diazepam is the least favorable  benzodiazepine 
522 Critical Care
in the ICU. Also, preparations of lorazepam and diazepam 
contain the solvents polyethylene glycol and propylene glycol, 
which have been implicated in reversible acute tubular necro-
sis and lactic acidosis when used in high doses. 
Propofol.  Propofol is a unique, rapid-acting sedative- hypnotic 
drug that is used for induction and maintenance of general 
anesthesia and for short-term sedation for mechanically ven-
tilated patients in the ICU. Propofol is an extremely lipophilic 
drug and has rapid onset of action while producing similar 
degrees of amnesia as benzodiazepines without the analgesic 
properties. Propofol is redistributed and metabolized by the 
hepatic conjugation and allows for awakening shortly after 
discontinuation of the infusion. Propofol is  ideal for use dur-
ing invasive procedures and for sedation <72 hours, although 
recent evidence suggests that it may also be useful and cost-
effective for longer time periods in selected patients (Carson 
et al., 2006). Propofol is also appropriate for patients with 
neurological injury, as it will allow for frequent and accu-
rate neurological examinations. Because of the potential for 
significant respiratory depression, propofol should only be 
used in mechanically ventilated patients and in controlled 
airway situations for short procedures. Propofol has a poten-
tial to cause profound hypotension, which is more common 
in patients with hypovolemia, heart failure, and the elderly 
and is relatively contraindicated in severe hypovolemia or 
hemorrhagic shock (McKeage & Perry, 2003). Because propo-
fol is suspended in a lipid emulsion and contains 1.1 kcal/ml, 
these calories should be counted toward the patient’s daily 
nutrition and fat intake. This formulation is also known to 
cause a transient elevation in triglyceride levels in up to 10% 
of patients and must be frequently monitored during pro-
longed infusions. Anaphylactoid reactions to propofol are 
infrequent but can be severe (Riker & Fraser, 2005). Strict 
sterile technique must be adhered to as the lipid emulsion 
promotes bacterial growth and improper technique has been 
previously attributed to postsurgical infection complications 
(Bennett, et al., 1995). Propofol infusion syndrome is rare 
but lethal event that may be seen with high-dose,  prolonged
infusions characterized by acute onset heart failure, brady-
cardia, lactic acidosis, hyperlipidemia, and rhabdomyolysis 
(Kang, 2002). 
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Dexmedetomidine. Dexmedetomidine is a relatively new, 
highly selective, centrally acting alpha 2-adrenergic ago-
nist that produces sedation, anxiolysis, mild analgesia, and 
sympatholysis. The sedation produced with dexmedetomi-
dine allows for patients to be quickly awakened and has 
minimal effect on respiratory depression. Patients receiving 
dexmedetomidine infusions are easily aroused, appear calm 
and comfortable, and will often return to a hypnotic state if 
not stimulated. Because of the short half-life, dexmedeto-
midine is usually given by continuous infusion and may be 
used in nonmechanically ventilated patients or noninvasive 
positive-pressure ventilation. The unique properties of this 
drug make it especially useful in patients who are at risk for 
respiratory depression, such as patients with sleep apnea, 
patients with chronic obstructive lung disease, and patients 
with severe alcohol withdrawal. Common adverse reactions 
to this drug include hypotension and bradycardia, which 
is usually seen in the elderly and in those with advanced 
heart block. Currently, dexmedetomidine is approved for 
<24 hours; however, new data suggests that it may be con-
tinued for 5 days and may decrease delirium in critically ill 
patients (Pandharipande et al., 2007). 
 Assessment of Sedation 
Approximately 80% of all patients in the ICU receive some 
method of pharmacological sedation (Walder, Frick, Gueg-
ueniat, Diby, & Romand, 2002). With the majority of patients 
receiving sedation, it is surprising that just over half of 
patients are continually monitored with sedation scales and 
in even fewer facilities that protocols exist to reach sedation 
goals to predetermined endpoints. An ideal sedation scale 
should be easy to use, should quantify behavior, should pro-
vide an accurate description of sedation or agitation within 
a defined category, should aid to guide sedation therapy, and 
should be validated in an ICU population. 
There are more than 20 different scales published, but 
there is not a single scale that exists that has been  accepted
as a golden standard (De Jonghe et al., 2000). The Riker 
Sedation–Agitation Scale categorizes a patient’s behavior 
into seven predetermined groups and was the first scale to 
be proven effective and validated in critically ill patients 
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(Riker, Picard, & Fraser, 1999). Today, the most common tools 
used in the ICU to quantify sedation are the Ramsay Scale, 
which describes three levels of awake states and three levels 
of asleep states, and the Richmond Agitation–Sedation Scale 
(RASS), which defines a numerical score from varying levels 
of sedation and agitation on a 10-level scale. The RASS has 
been the most validated scale and arguably, may be the scale 
of choice to use (Ely et al., 2003). 
However, the specific scale chosen appears less impor-
tant than having a system in place to monitor sedation. 
An institution-accepted sedation scale will place focus on 
patient safety and comfort, provide better communication 
among caregivers, and improve the consistency of medication 
administration and quality of sedation. Sedation scales facili-
tate and evaluate trends in patient behavior that may reveal 
a change in the underlying condition, which allows more 
precise medication titration. Sedation scales also decrease 
overall sedative and analgesic drugs while decreasing length 
of time on mechanical ventilation or need for vasopressor 
support (Sessler & Varney, 2008). 
The value of implementing a sedation and pain scale 
alone to guide management has also been shown not only 
to decrease agitation and pain events, but also to dramati-
cally reduce both duration of mechanical ventilation and 
the rate of nosocomial infection (Chanques et al., 2006). An 
inherent problem with any scale is the issue of subjectivity 
of the scoring systems, interindividual rating variability, and 
lack of continuity of measurements. New objective methods 
including tracking of heart rate variability, lower esopha-
geal contractility, auditory, and somatosensory have evoked 
potentials and processed electroencephalography have been 
suggested, but none have been validated in the ICU. 
 Sedative Selection 
An ideal sedative agent would have rapid onset of action, 
would be effective at providing adequate sedation, would 
allow rapid recovery after discontinuation, would be easy to 
administer, would lack drug accumulation, would have few 
adverse effects, would interact minimally with other drugs, 
and would be inexpensive. There is much controversy and 
conflicting data that exists in the recent literature about the 
most appropriate selection of sedating agents. The algorithm 
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suggested by the Society of Critical Care Medicine in the last 
published clinical practice guidelines is a good starting point 
for the selection of pharmacological agents (Jacobi et al., 
2002). The guidelines recommend using sedation scales, set 
defined treatment goals, and suggest pharmacological agents 
for use after pain and delirium have been addressed. Mid-
azolam is the preferred drug agent for agitation because of its 
rapid onset of action. For ongoing sedation, either lorazepam 
or propofol is suggested as initial therapy. However, except 
for neurosurgery patients, it is recommended that propofol 
be converted to lorazepam after 72 hours. Although this is 
a rational approach to the utilization of sedatives, new data 
on propofol and dexmedetomidine challenge this view when 
clinical outcomes are studied. 
The effectiveness of both midazolam and propofol are 
very similar, and a quantitative systemic review of 27 trials 
failed to show superiority of either drug (Walder, Elia, Henzi, 
Romand, & Tramèr, 2001). When propofol was compared with 
intermittent lorazepam for sedation, patients who receive 
propofol had fewer mechanically ventilated days; however, 
there was no difference in mortality between groups  (Carson
et al., 2006). A combination of midazolam–propofol also had 
no improvement in length of time to wean patients following 
cardiac surgery (Walder, Borgeat, Suter, & Romand, 2002). In 
the decision-making process, although the use of dexmedeto-
midine for sedation in the ICU has been limited to 24 hours 
previously, recent research has shown efficacy and safety 
data that extends the use of dexmedetomidine for 5 days and 
a decreased incidence of delirium when compared to loraz-
epam, especially in an elderly population (Pandharipande 
et al., 2007). 
 Analgesia in the ICU 
 Introduction 
In addition to providing adequate sedation for patients in ICU, 
it is also imperative to recognize pain as an individual param-
eter, assess, evaluate, and intervene appropriately to resolve 
pain. Although the potential of providing excessive amounts 
of analgesics is always possible, if adequately assessed, the 
risk of this can be minimized. Most patients receive some 
526 Critical Care
form of parenteral analgesic while in the ICU, and over half 
of patients discharged from the ICU recall pain as their worst 
experience (Dasta, Fuhrman, & McCandles, 1994). 
Analgesics may also have some sedating properties in 
moderate to high doses, whereas some sedatives will have 
opioid-sparing effects. However, sedation and analgesia 
should be seen as two parallel concepts in the ICU and appro-
priate pharmacologic agents should be chosen to treat each 
process. Additionally, the appropriate dose of opioid must 
be administered and titrated to patient response but not to 
a specific dose or limit. The effective management of pain 
in the ICU also depends on detecting and quantifying the 
intensity of pain, optimizing nonpharmacologic measures, 
and reassessing the daily goals of analgesia. 
 Treatment of Pain 
Although the pain experienced by patients in the ICU origi-
nates from many sources, the treatment modalities are in 
general fairly similar. The first step in the assessment and 
treatment of pain involves ruling out potentially reversible 
or treatable etiologies of pain (i.e., surgical intervention) and 
then targeting the irreversible etiologies of pain. Regional 
anesthetic techniques (neuraxial or peripheral nerve blocks) 
should be considered in appropriate patients and can ade-
quately treat pain with local anesthetic and/or opioids while 
limiting the systemic effects of these agents. These techniques 
usually achieve patient analgesia goals, some may also benefit 
by limiting parenteral opioids and allowing for a more rapid 
postoperative recovery. This idea can be exemplified by the 
placement and use of a thoracic epidural catheter in a patient 
after thoracotomy, which allows for excellent pain relief while 
minimizing splinting and pulmonary complications. However, 
the large majority of ICU patients will require parenteral 
opioids as the necessary means of achieving analgesia. 
 Opiates 
Opiates are synthetic substances that produce their effects by 
stimulating discreet receptors in the central nervous  system. 
Opiates relieve pain and the sensibility to noxious stimuli 
while also producing sedation and euphoria. Opiates may 
produce a change in sensorium, especially the more soluble 
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forms such as morphine and hydromorphone (Pasternak, 
1993). However, it is important to remember that opioids do 
not produce amnesia. The risks of opiates include respira-
tory depression, pruritis, ileus, urinary retention, histamine 
release, and the potential for accumulation of active or neu-
rotoxic metabolites. Patients may be given parenteral opiates 
either as pro re nata (prn) boluses, intermittent scheduled 
boluses, continuous infusion, or via patient-controlled anal-
gesia (PCA) through infusion pump. PCA administration of 
opioids has been associated with improved satisfaction, more 
effective analgesia, and decreased side effects when com-
pared to intermittent administration of opioids in an appro-
priate patient population (Liu, Carpenter, & Neal, 1995). 
Morphine. Morphine is the most common opioid used in 
both postoperative and critically ill patients. Typical onset of 
action is 10–20 minutes, duration is between 2–4 hours, and 
is hepatically metabolized and renally excreted. Although the 
relatively long duration of action can be advantageous to limit 
dosing intervals, morphine has several active metabolites that 
can potentially accumulate, especially in higher doses and in 
patients with renal insufficiency. Morphine-6-glucuronide is 
a more potent active drug, and morphine-3-glucuronide can 
produce central nervous system excitation with seizures and 
myoclonus (Smith, 2000). Morphine also causes histamine 
release and may lead to vasodilatation and hypotension after 
its administration. 
Fentanyl. Fentanyl is a synthetic opioid that has a much 
shorter onset of 1–2 minutes and duration of 30–60 minutes. 
Because of these properties, the administration of fentanyl is 
appropriate for continuous infusion, easily titratable because 
of its rapid onset of action, and is indicated in mechanically 
ventilated patients requiring a continuous level of analgesia. 
Fentanyl is significantly more lipid soluble than morphine 
and does not cause histamine release, resulting in stable 
hemodynamic properties. Although fentanyl has no biologi-
cally active metabolites, continuous infusions may result in 
prolonged sedation because the context-sensitive half-life is 
increased while the drug is deposited into fatty tissue. When 
appropriately titrated to patient response and comfort level, 
fentanyl also has a rapid offset to allow for relative ease in 
evaluating neurological function and daily wake up tests. 
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Hydromorphone. Hydromorphone is an opioid with an onset 
of action from 5–15 minutes and duration of 2–3 hours. Hydro-
morphone is approximately five times as potent as morphine, 
is frequently used when pain is not well controlled by mor-
phine, and may be given by intermittent bolus, continuous 
infusion, or PCA. The advantage is a decreased side effect 
profile without histamine release or hypotension and is an 
alternative when morphine is not well tolerated. Although it 
has active metabolites, dosing adjustment is not indicated for 
renal impairment. 
Nonopioid Analgesics. Kertorolac is currently the only par-
enterally administered nonsteroidal anti-inflammatory 
drug. This nonspecific cyclooxygenase inhibitor has moder-
ate analgesic and anti-inflammatory activity. The analgesic 
properties of ketorlac can be seen within 30 minutes and last 
up to approximately 6 hours after administration. Ketorlac is 
usually administered with an opioid and used for its opioid-
sparing effects. Although ketorlac is partially metabolized in 
liver and renally excreted, it should not be administered for 
>5 days because of the increased risk of gastrointestinal and 
operative site bleeding. There is also a risk of renal function 
impairment because it inhibits renal prostaglandin synthesis, 
but this effect is minimal if the drug is not used for >5 days 
and should not be initiated in preexisting renal impairment. 
 Assessment of Pain 
Although pain is nearly ubiquitous in an ICU setting, the 
actual assessment of pain is more difficult to discern. Several 
scales have been well validated in addressing sedation in 
ICU patients; however, no single method for evaluating pain 
has been adequately validated for the ICU. Monitoring pain 
in an awake and interactive patient is best accomplished by 
directly asking the patient about the intensity, quality, nature, 
and duration of the pain. The Visual Analogue Scale, Verbal 
Descriptor Scale, and Numeric Rating Scale are all subjective 
scales that have been used with varying degrees of success 
to quantify pain. More objective markers of pain, such as 
evaluation of vital signs and behavioral responses can also 
be used to evaluate pain, especially in a patient who is unable 
to communicate. The Critical Care Pain Observation Tool is 
a relatively new scale that attempts to objectively  quantify 
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pain in critically ill patients. This scale evaluates facial 
expression, body movement, muscle tension, and ventilator 
compliance, and assigns a value of 0–2 for each parameter 
(Gélinas & Johnston, 2007). The benefit of this type of scale 
is that it allows a reproducible objective measure of pain that 
can be followed, even if the patient cannot identify a specific 
level of discomfort. This tool facilitates objective communi-
cation among health care providers regarding levels of pain 
and can assist with assessments evaluating that the goals of 
analgesia are achieved. Although there is no ideal scale for 
the quantification of pain, it is imperative that pain be evalu-
ated frequently by a consistent measure, which can then help 
guide the treatment of pain in ICU patients. 
 Summary 
The understanding, assessment, and treatment of anxiety, 
pain, and agitation in the ICU is essential to providing care to 
critically ill patients. Although nearly all patients will experi-
ence anxiety and pain in the ICU, the actual detection and 
quantification of these constructs are challenging. The use 
of adequate scales and scoring systems can assist clinicians 
to consistently document the level of sedation or pain, which 
will help to guide specific patient therapy. Although numerous 
pharmacological agents are currently in our armamentarium 
to provide analgesia and sedation to patients, it is often not 
clear which agent is the best in a specific patient scenario, 
especially with new emerging studies and drugs challenging 
older paradigms of sedation. The crucial event is to integrate 
specific sedation and analgesia assessment scales and proto-
cols into daily ICU practice to provide the best care possible 
and ultimately improve patient outcomes. 
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 While walking to get his morning coffee, Julio, a 69-year-old 
Hispanic man, was struck by a motor vehicle. He was critically 
injured and entered the health care system. Unconscious and 
badly injured, he was not carrying any license or identifi cation. 
He was evacuated to the nearest trauma center. Hours later, the 
police located Julio’s family and they drove 2 hours to reach him, 
unaware of just what they would fi nd. . . 
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This scenario is too familiar to critical care professionals. An 
injured patient typically requiring an entire team to provide 
immediate life-saving measures “hits the door.” The adrena-
line of the team is palpable as the art and science of nursing
and medicine merge to address the complex needs of the 
victim. Trauma, resuscitation, and intensive care are cutting 
edge and highly specialized services, and the experienced 
health care professional views the process as orchestral, 
whereas the novice views it as fast paced and overwhelming. 
The goals of the team are to prevent the loss of life and maxi-
mize quality of life. The central focus is clear: the patient. 
Patients typically have minimal recall of the most acute 
aspects of their hospitalization following illness, injury, or 
surgical intervention. They surrender control (voluntarily 
or involuntarily) to highly trained and competent providers. 
They designate their loved ones to advocate on their behalf. 
Most are unaware of the enormity of the task of being a  family
member of a critical care patient. The emotional effects can 
seem insurmountable. 
The needs and expectations of the family of critically ill 
patients are replete in the literature. Family members typi-
cally want health professionals to supply clear information 
about their loved one, provide pertinent education, and offer 
realistic guidance and support during the process. However, 
these are typically secondary to the need to be near their 
loved one. Most families articulate the importance of trust and 
sensitive interactions among the health care team. The value 
of compassion and effective communication are essential to 
family adjustment regardless of patient outcome. Research 
underscores the value of family and friends in the critical 
care experience. However, many facilities are  unwilling or 
unable to bridge the gap between traditional critical care 
paradigms and the needs of patients and families. 
 Julio’s wife, adult daughter, brother, and sister-in-law arrive to 
the critical care unit. What will they encounter? How will those 
providing care to the family members integrate them into the 
plan of care? Will they be met with a traditional and exclusively 
patient-dominated culture? Will the team be open to accept the 
family as part of the critical care process? 
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Dodek et al., (2004) reiterated two decades of data to sup-
port that improvement of the quality of care in intensive care 
units (ICUs) requires the measurement and utilization of fam-
ily satisfaction data in a manner that reflects active translation 
into unit-based quality improvement initiatives. They further 
added that acutely ill, hospitalized individuals require holis-
tic care that includes family-centeredness as a dimension of 
health care quality. Hanson, Danis, and Garrett (1997) and 
Malacrida et al., (1998) offered initial studies on measuring 
family satisfaction in the critical care setting and provided 
evidence suggesting that several key factors related to com-
munication, ICU staff courtesy, and compassion were critical 
factors. Heyland et al., (2003) added the importance of fam-
ily respect and an emphasis on information provided to loved 
ones as central to family-centered care. Azoulay et al., (2004) 
cited the level of health care received by patients as significant 
predictors of overall family satisfaction. The Joint Commission 
on Accreditation of Healthcare Organizations (JACHO) and 
the U.S. Institute of Medicine identify family centeredness as 
one of the key dimensions of health care quality and being 
safe and secure in the hospital environment. 
Empirical data on family satisfaction in intensive care has 
shed some light on the importance of effective communication 
with family and support systems. Families need compassion 
and empathy, polite professional encounters, comprehensive 
educational information, and high-quality care targeted to the 
patient as well as the individuals supporting the patient. Dodek 
and colleagues (2004) iterated that excellence in critical care 
necessitates the measurement and utilization of family satis-
faction data in quality initiatives. This is only possible when 
direct and ongoing communication is evident. 
The satisfaction of the family is no longer a secondary 
gain or an optional nursing intervention. To meet the stan-
dards of optimal care to critically ill patients, there must be 
data that can be translated into a measure of family- centered
care. Even though the patient is at the core of any care model, 
it is essential that effective contemporary models of acute 
care include the family as a direct extension of the patient. 
The JACHO holds institutions accountable in fostering a 
family-centered approach to care. Evidentiary support to 
illustrate each facility’s perspective is reviewed on a regular 
interval. The day-to-day challenges remain at the hands of 
the direct care nursing team. 
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Family-centered care must carry more than a theoreti-
cal connotation. This is an organized and intentional way of 
providing critical care governing standards of care across the 
country and requires a team approach. There is no single ele-
ment that transcends a unit to “family-centered care.” Fam-
ily-centered care requires a philosophical commitment and a 
genuine desire to negate traditional approaches. 
 The Philosophy of Family-Centered Care 
A family-centered care concept views a patient’s family as a 
unit to be cared for and organizes care delivery around the 
patient’s family, as opposed to the more traditional patient 
centered model (see Table 16.1). The philosophy should 
lend itself easily to the mission and vision of the institution 
while maintaining harmony with the theory that guides nurs-
ing practice.  Family centered care demands a collaborative 
approach to care in which all members of the team identify 
the significance of this philosophy and regard family as an 
essential part of the practice of critical care. There is an inher-
ent duty to ensure that the family needs are met when the 
loved one is critically ill. 
Hennemen and Cardin (2002) noted that the common-
alities of organizations providing family-centered care typi-
cally include strong evidence of leadership, caring nursing 
personnel, and the support of a committed multidisciplinary 
team. This painstaking process and typically those hesitant to 
recreating a family-centered paradigm have strong personal 
beliefs and attitudes supporting their reality. Proponents of 
quality critical care advocate for a holistic approach to the 
patient and are readily able to embrace the family as part of 
the whole picture. 
Barriers to family-centered care have included nurse’s 
perceptions that patients suffer physiologic stressors sec-
ondary to visitors; nurses may have identified a desire to 
limit caregiver stress and exhaustion as rationale to maintain 
antiquated policies and procedures. Some team members 
perceive that meeting family needs will detract from the time 
with the patient. As health care is more consumer-driven and 
judged by aspects of patient and family satisfaction, the evo-
lution of family-centered care becomes more of an expecta-
tion than an exception. Family members are more likely to 
be involved in determining where and how the patient’s care 
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  Traditional Patient- Family-Centered
 Centered Model Unit Model 
 Entry  Families seek  permission to 
enter. 
 Uncertainty of the abil-
ity to see their loved one 
is common. 
 An individual who is aware 
of the general status 
of the family member 
greets and welcomes 
the family. 
 Access  Visiting hours are clearly 
defi ned. 
 If it is not a “visiting time,” 
an  exception may be 
made this time to  appease 
 family (two at a time). 
 No furniture is near the bed-
side or a chair must be 
obtained from outside 
the patient’s bedside 
 perimeter. 
 The family is escorted 
to the bedside and 
 introduced to the 
nurse and team 
as available. 
 A chair is available for 
the family to sit close 
to their loved one. 
 There is “time” to acclimate 
to the surroundings. 
 Immediate 
Information 
 Initial information by a 
 designated team  member/
unit clerk 
 Phone numbers to unit and/
or physician 
 Visiting hours 
 Information from direct 
care provider  regarding 
 environment, patient 
status, and current 
level of care 
 Education  Episodic and  prospective 
approach 
 Referred predominantly 
to medical provider 
 Proactive team approach 
 Information regarding 
daily family rounds 
 Invitation to attend daily 
rounds 
 Evaluation  Patient focused  Patient and family 
provide input. 
16.1
 Comparison of Traditional
Patient-Centered Model versus
Family-Cente r ed Critical Care Model 
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will progress. The practicality of keeping the family within 
the confines of a waiting room is outdated and unacceptable. 
Partnership with family serves to promote a holistic approach 
to the care of patients with critical illness. 
 Synergy Model for Patient Care 
The American Association of Critical Care Nurses reconcep-
tualized the synergy model to form their AACN Synergy Model 
for Patient Care to address the needs of critically ill patients 
(Hardin & Kaplow, 2005). The model centers on the concept 
that the needs or characteristics of patients and families 
influence and drive the characteristics or competencies of 
nurses. Synergy results when the needs and characteristics 
of a patient and clinical unit or system are matched with a 
nurse’s competencies. 
The continuum of health to illness necessitates a wide 
range of needs for patients. Individuals who are acutely ill 
have more severe or complex requirements. The dimensions of 
nursing practice are driven by the needs of patients and their 
family. Therefore, nurses must be capable of providing care in 
multiple dimensions along the continuum. The fundamental 
tenet of synergy is that when the nurse’s competencies arise 
from patient needs, then characteristics of the nurse and the 
patient synergize, and optimal patient outcomes can result. 
The synergy model is reflective of the ideal that each 
patient and family and clinical unit and system is unique, with 
a varying capacity for health and vulnerability to illness. Each 
one brings a set of unique characteristics to the care situa-
tion. These characteristics span the health–illness continuum. 
Some of the key components are delineated in Table 16.2. 
The synergy model emphasizes that nursing care is reflective 
of the integration of knowledge, skills, experience, and attitudes 
needed to meet the needs of patients and families. Specific areas 
of competence are defined in Table 16.3, on page 540. Just as the 
continuum of patient care is dynamic, the continuum of nurs-
ing characteristics are derived from patient needs. The levels of 
expertise ranging from competent to expert are further explored 
in the model, which may be viewed at the AACN Website. 
The AACN synergy model assumes that the needs of 
the patient and the competencies of the nurse are viewed in 
context. The patient is seen as a part of both family and com-
munity, and the nurse must be cognizant of this relation-
ship in enacting a plan of care. To guide the model, there are 
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five assumptions regarding patients, nurses, and families. 
These are the following: 
 ■ Patients are biological, psychological, social, and spiri-
tual entities who present at a particular developmental 
stage. The whole patient (body, mind, and spirit) must 
be considered. 
 ■ The patient, family, and community all contribute to 
providing a context for the nurse–patient relationship. 
 ■ Patients can be described by several characteristics. All 
characteristics are connected and contribute to each 
other. Characteristics cannot be looked at in isolation. 
 ■ Similarly, nurses can be described on several dimen-
sions. The interrelated dimensions paint a profile of 
the nurse. 
 ■ A goal of nursing is to restore a patient to an optimal 
level of wellness as defined by the patient. Death can 
be an acceptable outcome, in which the goal of nurs-
ing care is to move a patient toward a peaceful death. 
Resiliency  The capacity to return to a restorative level of 
functioning, using compensatory mechanisms; 
the ability to bounce back quickly after an insult 
Vulnerability  Susceptibility to actual or potential stressors that 
may adversely affect patient outcomes 
Stability  The ability to maintain a steady-state equilibrium 
Complexity  The intricate entanglement of two or more systems 
(i.e., family, therapies) 
Resource availability  Extent of resources (technical, fi scal, personnel) 
Participation in care  Extent to which patient/family engages in aspects 
of care 
Participation in
  decision making
 Extent to which patient/family engage in decision 
making
Predictability  A characteristic that allows one to expect a certain 
course of events or illness 
16.2
 Characteristics of Patients, Clinical 
Units and Systems of Concern to 
Nurses
Adapted from the AACN Synergy Model for Patient Care (http://www.aacn.org/WD/Certifi cations/
Content/synmodel.pcms?mid=2869&menu=#Patient)
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Clinical
 Judgment
Clinical reasoning, which includes clinical decision  making, 
critical thinking, and a global grasp of the situation, 
coupled with nursing skills acquired through a process 
of integrating formal and informal experiential knowledge 
and evidence-based guidelines
Advocacy
and Moral 
Agency
Concerns of the patient/family and nursing staff; serving as a 
moral agent in identifying and helping to resolve ethical and 
clinical concerns within and outside the clinical setting
Caring
 Practices
Nursing activities that create a compassionate, supportive, 
and therapeutic environment for patients and staff, with 
the aim of promoting comfort and healing and preventing 
unnecessary suffering
Includes, but is not limited to, vigilance, engagement, and 
responsiveness of caregivers, including family and health 
care personnel
Collaboration Working with others (e.g., patients, families, health care providers) 
in a way that promotes/encourages each person’s contributions 
towards achieving optimal/realistic patient/family goals
Involves intradisciplinary and interdisciplinary work with 
 colleagues and community
Systems
Thinking
Body of knowledge and tools that allow the nurse to manage 
whatever environmental and system resources exist for 
the patient/family and staff, within or across health care 
and non-health care systems
Response
to Diversity
The sensitivity to recognize, appreciate, and incorporate 
 differences into the provision of care
Differences may include, but are not limited to, cultural 
 differences, spiritual beliefs, gender, race, ethnicity, 
 lifestyle, socioeconomic status, age, and values.
Facilitation of 
Learning
The ability to facilitate learning for patients/families, nursing 
staff, other members of the health care team, and community
Includes both formal and informal facilitation of learning
Clinical
Inquiry
(Innovator/
Evaluator)
The ongoing process of questioning and evaluating practice 
and providing informed practice
Creating practice changes through research utilization 
and experiential learning
16.3 Nurse Competencies of Concern to Patients, Clinical Units and Systems 
Adapted from the AACN Synergy Model for Patient Care (http://www.aacn.org/WD/Certifi cations/
Content/synmodel.pcms?mid=2869&menu=#Nurse)
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 Implementation toward a Family-Centered 
Approach 
Family-Centered Care. Implicit in the synergy model, fam-
ily-centered care is not easily defined. There is no universal 
meaning of family-centered care. A generalized concept of 
policy, belief, and action by a team is necessary to develop a 
family-centered model. This is not an isolated activity and 
should not be confused with open visitation. Adding a chair 
to the bedside is only a minor adaptation. Instead, family-
centered care is best understood as a philosophical commit-
ment to acknowledge the needs of the patients’ family as well 
as the vital role that family brings to the health and well-being 
of patients. 
Some patients may require the presence of a supportive 
loved one to achieve stability. However, enabling a spouse to 
remain at the bedside 24 hours a day should not be translated 
into effectively meeting the needs of the family. Just as the care 
of the patient is driven by the uniqueness of circumstance, so 
should the care of the family. Effective communication strate-
gies enhance the ability of patient and family to determine 
the level of family inclusion in the critical care process. 
Misconceptions exist regarding how family-centered 
care may impact the ability of nurses to provide optimal care. 
Clarification of the goals and purpose of family-centered 
care will enable the team to explore, discuss, and allay fears 
regarding this philosophy. Ultimately, the family-centered 
care approach supports a patient’s right to a safe and sup-
portive critical care experience. Whenever possible, patients 
should be allowed to direct the quantity of inclusion or exclu-
sion of family participation with respect for care and the 
extent of information that they wish to be provided to their 
family. The needs of patients are always held paramount 
even in a family-centered care approach. 
Policies, procedures, and educational materials that provide 
for the care and safety of patients and family in critical care are 
typically viewed as positive and essential to navigate the system 
(AACN, 2007). They can help staff to streamline key issues while 
promoting a positive first impression. An orientation to the unit 
and preprinted information should focus on open and effective 
relationships with the patients and their family. Unit-specific 
information may offer the family insight into the philosophy 
of caring within the ICU setting (AACN, 2007). This is an ideal 
moment for staff to convey key procedures necessary in provid-
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ing structure consistent with the patient needs while still find-
ing consistency in family-centered critical care practices. 
 What would Julio’s family see and hear when they enter the 
 critical care area? Will they perceive a welcoming presence? 
Will there be any doubt that they are part of their loved one’s 
plan of care? 
 Understanding Family Needs 
Families of critically ill patients need to be assured that 
they will receive current and accurate information about 
their loved one, afforded comfort and support, guided in 
appropriate decision making, and given the opportunity to 
remain close to the patient. Although this may appear to be 
a simple strategy, it is evident through research that this is 
not consistently offered to families. There are existing tools 
and guides to enable adequate assessment of family needs 
(AACN, 2007). 
Nurses are viewed as primary resources for  relaying 
information about the patients’ current condition and updates 
on critical elements of care. Nurses have traditionally func-
tioned as liaisons between the medical team and families. 
Nurses are very effective in conveying changes in condition, 
and families have relayed confidence and satisfaction with 
nurses’ ability to keep them informed. 
Nurses, families, and other members of the health care 
team may interpret issues from alternative view points. Cultural 
determinants, familial roles, and existing family dynamics may 
enhance or aggravate the health and well-being of the patient. 
Realistic expectations are necessary to identify that the desires 
of the patient in family-centered care may necessitate restric-
tions for some family members. Because of individual circum-
stances, the critical illness or injury of a loved one may neces-
sitate a referral for intensive counseling or spiritual support. 
The ability of the nurse to provide for the needs of the 
patients and their family is evident in the ongoing care, 
communication, and support provided at the bedside. Strat-
egies that target the needs of the family include promoting
a caring perspective in all interactions, engaging with the 
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patient and family, and offering practical, realistic, and truth-
ful support while providing encouragement. These strategies 
are incorporated into a family center concept and the estab-
lishment of flexible visiting schedules. Nurses are inescapably 
linked to the caring perspective of healing in critical care. 
 Discussion Questions 
Establishing a family-centered approach must start with the 
fundamental question:  Who is the patient’s family? Once the 
health care team is aware who the patient considers family, 
then the additional dialogue is necessary to extend an opti-
mal level of nursing care, which is the hallmark of advanced 
practice in critical care. 
The following is a series of questions that place in per-
spective the currency of family-centered care in an institu-
tion. Taken in the context of the discussion presented in this 
chapter, responding to these questions can help in defining 
how to proceed in securing and enhancing procedures in 
terms of such care.
 ■ What practices currently exist that may be viewed as 
family friendly? 
 ■ What practices may display a sense that family is 
unwelcomed or unwanted in the critical care area? 
 ■ How effective is your team in keeping the family cur-
rent on information? 
 ■ What strategies are employed to offer consistent com-
fort and support? 
 ■ Are there resources that may be included beyond the 
critical care unit? 
 ■ How does the team guide the patient and family in 
appropriate decision making? 
 ■ What do you and your teams do specifically to ensure 
that the family can remain close to the patient? 
 ■ Does a family educational guide exist to facilitate 
understanding of the concepts of the ICU? 
 How will the needs of Julio and his family be addressed by the 
health care team? What strategies can be employed to orient 
them to the situation, establish an open and working relationship, 
and maintain communication? 
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 Adapting Existing Policy 
Once the multidisciplinary team defines the concept of fam-
ily-centered care, the process of transition can begin. The 
team needs to determine the presence or absence of policies 
and procedures that support the proactive beliefs of family 
centeredness. Multidisciplinary presence will be critical to 
the creation of effective  practices. The team may include rep-
resentatives from nursing, medicine, administration, ancillary 
services, security, social work, volunteer services, education, 
and former patient and family representatives (most facilities 
have committees with former patient and family advocates 
volunteering ideas). 
Typically, visitation is one area that needs to be adapt-
ed to enable effective family-centered care. There are dual 
reasons that presence at the bedside enhances the needs of 
patients and their loved ones. Successful visitation protocols 
offer the family the opportunity to see firsthand the high-
quality critical care that a unit offers to the critically ill. Staff 
may need to be reoriented to the perspective that the family 
seeing them in action may allay fears that their loved one is 
in good hands when they are not present. A family- centered
care approach should be visible in all areas of the unit. Upon 
entry, the family should be able to sense a welcoming per-
spective. This may be achieved by colorful signs or  posters
identifying the connection between patient, family, and 
staff. Patient and family educational aids should support the 
philosophical approach. Staff areas should foster a positive 
reminder of the importance of an open approach to family 
communications. 
Orientation for new employees should foster the con-
cept of family-centered care and delineate the unit practices 
that are essential to enact it. Quality improvement measures 
should include aspects of family satisfaction, and continuous 
recognition of effective team members will underscore the 
value of the family-centered approach. During transitioning 
or improving family-centered protocols, the role of education 
cannot be minimized. Unit conferences and staff development 
offerings should include clear and concise interventions that 
demonstrate family-centered ideals. Spiritual support per-
sonnel, social workers, and counselors may provide reassur-
ance and support especially in times when nursing personnel 
may be engaged in direct care with the patient. 
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An ongoing and proactive approach to the family ensures 
attention to patient care and may prevent conflict or crisis 
during periods of high family stress. The family should feel 
appreciated and welcomed into the critical care environment. 
Maintaining an effective unit structure, attention to detail, and 
education regarding the specific unit protocol promotes safety 
and security. As an example, each visitor must present photo 
identification and receive a badge according to hospital policy. 
Some units request family to remain at the bedside or in the 
waiting area during change of shift to protect patients’ privacy. 
 Discussion Questions 
The following discussion questions will also help in clarify-
ing the status of family-centered care in an institution. 
 ■ Who is currently involved in patient and family care? 
 ■ Who should be included in employing, improving, and 
maintaining family-centered care strategies? 
 ■ What policies and procedures embrace the family-
centered philosophy? 
 ■ Which practices negate the concept of family-centered 
care?
 How will Julio’s wishes, condition, and family presence be incor-
porated in his plan of care while maintaining a safe and effective 
unit operation? 
 The Dynamics of Ongoing Quality 
Family-Centered Critical Care 
The commitment to family-centered care is complex and 
requires consistency. Families must be assured that they have 
access to information and the ability to see their loved one reg-
ularly. Inconsistency creates a sense of frustration, lack of trust, 
and a loss of control in families who are already distraught. 
This may trigger thoughts of how patient care practices may 
be applied among varied providers. Overt variations to poli-
cy can also create a sense of partiality and negativity among 
team members. No one wishes to be perceived as a non caring 
546 Critical Care
provider by asking the family to limit visiting time when in 
actuality, they are upholding existing guidelines. Establishing 
guidelines to partner with families influences the ability of the 
caregiver to consistently achieve mutual goals. 
The road to family-centered care will contain many 
twists and turns. With a commitment to success, a desire to 
optimize care, and provision of a supportive environment, no 
goal is insurmountable. Open communication among staff, 
administration, and advocacy teams will allow for review of 
ongoing improvement. The learning curve must be recog-
nized and staff will require mentorship, positive reinforce-
ment, and feedback to change philosophy and engage in reg-
ular family-centered care practices. The extreme situations 
in  which difficult family dynamics or problem family mem-
bers will not dissipate with family centered care. However, it 
is reasonable to believe that they will be the exceptions to 
the rule and staff may be more able to preempt aggressive 
or ineffective interactions by identifying red flags early in 
family assessment. 
Ensuring that a family oriented critical care philosophy 
and standards of care are upheld by the governing bodies of 
the unit and health care facility is essential to patient, fam-
ily, and team satisfaction. Growth and success of the staff, in 
accordance with the creation of a positive and effective culture 
centered on quality outcomes, is paramount. Implementing a 
family-centered approach to care is only the beginning of an 
ongoing institutional commitment (Table 16.4). 
Family-centered care is a reality in today’s health care 
climate. Patients and their families have basic needs that 
must be met if health care institutions are to be successful in 
addressing clients’ needs and providing holistic care. 
 Discussion Questions 
Additional discussion questions include: 
 ■ How can the ICU implement proactive strategies to 
maintain a family-centered approach? 
 ■ How do patients, families, and health care providers 
define successful family-centered care? 
 ■ How do health professionals define successful family-
centered care? 
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 Patient-Specifi c Consideration Unit-Specifi c Aspects 
 Who does the patient defi ne as family?
Does the patient wish to limit family 
visitation?
How does the patient prefer information 
to be communicated to the family?
 Is there  a primary contact person? 
 How do we identify a patient’s family?
Where is the information documented? 
 How does the patient wish to include 
family in their plan of care?
 Will family presence facilitate healing?
 Will family presence offer  reassurance? 
 How do we approach the patient about 
family-centered care practices?
How do we approach the family about 
unit practices to support the patient? 
 What is important for staff to know in 
caring for the patient and his/her 
family while the patient is in the 
 critical care area? 
 Are there any specifi c needs or issues 
that must be addressed to provide 
optimal care? 
 Will the family be able to see the 
patient?
 Does the unit refl ect an openness to 
encourage family presence? 
 How will the family know that the 
 patients is okay? What if something 
bad happens to the patient? 
 How will communication be 
 maintained when family presence 
is not possible?
How will the staff maintain continuity 
of FCCC practices despite varied 
attitudes and beliefs?
Who should be included in the  planning, 
implementation, and evaluation of 
the process? 
16.4  Considerations in Adopting a Family-Centered Critical Care Approach 
 ■ How do we establish quality measures for improvement 
and benchmarking? 
 What will Julio’s family tell you about their experience? Would they 
want to return to your unit if circumstanced required critical care? 
Are they interested in being ambassadors for future families? 
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 Advancing Practices in Family-Centered Care 
Family Presence during Resuscitation. Duran et al., (2007) defined 
family presence as the attendance of patients’ family members 
during resuscitation and/or invasive procedures that have a 
place in the context of family-centered care. The goals of fam-
ily-centered care do not become negated during the most critical 
moments of care. The health care team must make every effort to 
meet the needs of patients’ families,  including their requests for 
information, support, and the ability to remain close to the patient 
even during resuscitation. Research (Duran, 2007) supports that 
the patients’ families have certain needs during a health- related 
crisis. They may be met through observation of clinical staff and 
support of team efforts during a code scenario. Protocols should 
designate an individual to maintain honest, consistent, and thor-
ough communication with the family. This team member should 
remain in close proximity of the codes and emotionally con-
nected to the patient. Families can then witness providers caring 
for the patient and have access to see for themselves the status 
of their loved one. Family presence during resuscitation and/or 
invasive procedures may enable the family to gain perspective 
that is otherwise impossible to achieve. 
Traditional obstacles to family presence have centered 
on professional and litigious perceptions. There is little data 
to support an increase in litigation. Most anecdotal discus-
sion centers on nurses and physicians fear of upsetting or 
offending family. There is concern that families are incapable 
of handling the stress of the situation, others offered con-
cerns for staff pressure and most related concerns that fam-
ily may distract or impede efforts aimed at the patient. 
The Emergency Nurses Association (ENA, 2001) offered 
the first research studies to explore family presence during 
resuscitation. Findings supported that families viewed this 
as positive in addressing their needs (ENA, 2001).  Providers 
described increases in locus of control, understanding of the 
reality of their family member’s situation, and improved edu-
cation. Subsequent studies by the American Association for 
the Surgery of Trauma (AAST) and the ENA to determine 
the members’ opinions on family presence during trauma 
resuscitation revealed nurses more open to family presence 
than trauma physicians. More recent data supports this trend 
(Moreland, 2005, Sachetti, Paston, & Carraccio, 2005). 
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The American Nurses Association (ANA) Code of Ethics 
(ANA, 2000) addresses nurses’ primary responsibility to rec-
ognize the “patient’s place in the family or networks of rela-
tionship” reference. Protocols for family presence are includ-
ed in many specialty organizations including AACN and ENA. 
The National Association of Emergency Medical Technicians, 
the National Association of Social Workers, and The Ameri-
can Heart Association endorse family presence policies. 
Studies addressing patients and family member’s per-
ceptions during resuscitation largely support the option of 
allowing family to be present (reference). Most family cited 
that being near the patient enabled them to comprehend the 
reality of the situation, process grief responses, and demon-
strate beyond a doubt that everything had been done to resus-
citate their loved one. To date, no study  has found that keeping 
family away from the bedside during treatment or CPR ben-
efits anyone (Mason, 2004). In fact, families may suffer emo-
tional turmoil including anxiety, depression, helplessness, and 
guilt if excluded from resuscitation efforts (Marrone & Fogg, 
2005). As family presence becomes a more accepted practice, 
health care providers will need to accommodate families at 
the bedside and address unit and system specific barriers. 
 Discussion Questions 
 ■ Is our unit presently promoting family presence? 
 ■ What would be needed to facilitate this action? 
 ■ How would the patient and family perception of health 
care be impacted by the promotion of family presence 
policies and procedures? 
 Online Resources  
American Association of Critical care Nurses 
http://www.aacn.org/ 
American Hospital Association 
http://www.aha.org/aha/issues/Quality-and-Patient-Safety
/strategies-patientcentered.html
Institute for Family Centered Care 
http://www.familycenteredcare.org/advance/orglm-links.html 
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Institute for Healthcare Improvement 
http://www.ihi.org/ihi 
Institute of Medicine 
http://www.iom.edu/ 
Joint Commission Accreditation 
http://www.jointcommission.org/ 
References
American Nurses Association. (ANA). (2000).  Code of Ethics for Nurses 
With Interpretive Statements . Silver Spring, MD.
Azoulay, E., Sprung CL. (2004). Family-physician interactions in the 
intensive care unit.  Critical Care Medicine, 32 (11), 2323–2328.
Dodek, P. M., Heyland, D. K., Rocker, G. M., & Cook, D. J. (2004). Translat-
ing family satisfaction data into quality improvement.  Critical Care 
Medicine, 32, 1922–1927. 
Duran, C. R., Oman, K. S., Abel, J. J., Koziel, V. M., & Szymanski, D. (2007). 
Attitudes toward and beliefs about family presence: A survey of 
healthcare providers, patients’ families, and patients.  American 
Journal of Critical Care , 16(3), 270–279. 
Emergency Nurses Association. (2001).  Presenting the option for family 
presence. (2nd ed.). Bedford Park, IL. 
Hanson L. C., Danis, M., & Garrett, J. (1997). What is wrong with end-
of-life care? Opinions of bereaved family members.  Journal of the 
American Geriatric Society , 45, 1339–1344. 
Hardin, S. R., & Kaplow, R. (2005)  Synergy for Clinical Excellence: The 
AACN Synergy Model for Patient Care . Boston: Jones & Bartlett. 
Henneman, E. A., & Cardin, S. (2002). Family-centered critical care: A prac-
tical approach to making it happen.  Critical Care Nurse , 22, 12–19. 
Heyland D. K., Rocker, G. M., O’Callaghan, C. J., Dodek, P. M., & Cook, D. J. 
(2003) Dying in the ICU: Perspectives of family members.  Chest, 124,
392–397. 
Malacrida, R., Bettelini, C. M., Degrate, A., Martinez, M., Badia, F., Piazza, J., 
et al. (1998) Reasons for dissatisfaction: A survey of relatives of inten-
sive care unit patients who died.  Critical Care Medicine , 26, 1187–1193. 
Marrone, L., & Fogg, C. (2005). Family presence during resuscitation: Are pol-
icies allowing family into the trauma room humane and necessary—or 
just asking for trouble? Nursing 35(8) ED Insider Suppl., 21–22.  
Mason, D. (2004). Family presence.  NSO Risk Advisor – Fall 2004. Retrieved 
May 1, 2009 from http://www.nso.com/newsletters/advisor/2004_fall/ 
Moreland, P. (2005). Family presence during invasive procedures and 
resuscitation in the emergency department: A review of the litera-
ture.  Journal of Emergency Nursing, 31 (1), 58–72. 
Piazza, J. et al. (1998) Reasons for dissatisfaction: A survey of relatives 
of intensive care patients who died. Critical Care Medicine, 26, 
1187–1193.
Sacchetti, A., Paston, C., & Carraccio, C. (2005). Family members do not 
disrupt care when present during invasive procedures.  Academic 
Emergency Medicine, 12, 477–479. 
A
AACE.  See American Association of 
Clinical Endocrinologists 
AACN.  See American Association of 
Critical Care Nurses 
AAST.  See American Association for the 
Surgery of Trauma 
ABCDE mnemonic (airway, breathing, 
circulation, disability, exposure), 
272–273
Abdominal trauma and assessment, 
285–289
ABIOMED® AB5000 Ventricle, 132 
Absence seizure, 213 
A/C.  See Assist/control ventilation 
ACC.  See American College of 
Cardiology
Accelerated acute rejection in 
transplants, 266 
ACE.  See American College of 
Endocrinology
ACE inhibitors, 115–116, 123 
Acid base balance, 262–263 
Acinetobacter baumannii, 451 
ACLS.  See Advanced cardiac life support 
ACNPs.  See Acute care nurse 
practitioners
ACTH.  See Adrenocorticotropic 
hormone
Acute adrenal insufficiency, 427–430 
Acute care nurse practitioners (ACNPs) 
challenges to practice, 12–14 
first certification for, 3 
Model Nursing Practice Act and, 
24–25
number of, 2 
origins and history of, 2–3, 4–5 
regulation of, 9, 11 
role expansion opportunities, 11–12 
roles of, 3 
scope and standards of practice for, 3, 
6, 10–11, 21–25 
settings and specialty practices, 3, 6–9 
strategies for ensuring clinical 
competency, 13 
Acute care surgical intensive care unit 
(SICU) protocols, 30–32 
Acute catabolic phase in metabolism of 
critical illness, 358, 390 
Acute Motor and Sensory neuropathy, 
227
Acute Motor Axonal neuropathy, 227 
Acute rejection 
in kidney-pancreas transplants, 266 
in liver transplants, 254–255 
Acute respiratory distress syndrome 
(ARDS) management, 50, 70–73 
Acute severe asthma (ASA) 
management, 74–76 
Acute spinal cord injury (ASCI).  See
Neurological critical care 
Adaptive support ventilation (ASV), 
68–69
Adrenal insufficiency, 427–430 
Adrenocorticotropic hormone (ACTH), 
429–430
Advanced cardiac life support (ACLS), 
107–108
Advanced directives, 42–47 
Advanced Trauma Life Support (ATLS), 
297
AHA.  See American Heart Association 
AIDS, as contraindication for kidney-
pancreas transplant, 258 
Airway, breathing, circulation, disability, 
exposure (ABCDE mnemonic), 
272–273
Airway pressure release ventilation 
(APRV), 66–67 
Alaska, scope of practice, 21, 23–24 
Alcoholism, 248 
Altered mental status terminology, 148 
American Academy of Neurology, 237 
American Association for the Surgery of 
Trauma (AAST), 548 
 551
INDEX
American Association of Clinical 
Endocrinologists (AACE), 407,
408, 420 
American Association of Colleges of 
Nursing, 2, 14 
American Association of Critical Care 
Nurses (AACN), 2, 469 
Synergy Model for Patient Care,
538–540
Web site for, 539 
American College of Cardiology (ACC), 
and American Heart Association 
(AHA) Guidelines Task Force, 
90–91
American College of Chest Physicians/
Society of Critical Care Medicine 
Consensus Conference, 
identification of high-risk 
patients, 320–323 
American College of Endocrinology 
(ACE), 408 
American College of Physicians, 462 
American College of Surgeons 
Committee on Trauma, 279 
American Diabetes Association (ADA), 
407
American Dietetic Association’s Critical 
Illness Guidelines, 359 
American Heart Association (AHA) 
and American College of Cardiology 
(ACC) Guidelines Task Force, 
90–91
death rate reduction goal, 89–90 
family-centered care and, 549 
“Get with the Guidelines”, 90 
American Medical Association, 462 
American Nurses Association, 2 
code of ethics, 548–549 
American Society for Parenteral and 
Enteral Nutrition (A.S.P.E.N.), 
357, 361 
Anabolic phase in metabolism of critical 
illness, 358  
Analgesia, 525–528 
nonopioids, 528 
opiates, 526–527 
fentanyl, 527 
hydromorphone, 528 
morphine, 527 
pain assessment, 528–529 
pain treatment, 526 
Anemia, postburn, 302 
Aneurysmal subarachnoid hemorrhage 
(SAH).  See Neurological critical 
care
Aneurysms, 124–126 
Angina, 117–118 
Anion gap, 346–348 
Anterior-posterior chest and pelvic film, 
276
Antiarrhythmic drugs, 95 
Antibiotic prophylaxis, 191–192 
Antibiotics, 449–456 
for catheter-related bloodstream 
infections, 453–454 
for sinusitis, 452 
for urinary tract infections, 453 
for ventilator-associated pneumonia, 
452–453
Antibiotic stewardship, 450 
Antioxidant supplementation, 365 
Anti-T cell antibodies, 266 
Aortic surgery, 124–126 
Apoptosis, 324–325, 327 
APRV.  See Airway pressure release 
ventilation 
ARBs, 115–116 
ARDS.  See Acute respiratory distress 
syndrome
Arizona, scope of practice, 21 
Arrhythmias, 96–105 
atrial, 99, 101–103 
supraventricular, 103–105 
ventricular, 96–99, 100 
Arterial line placement, 499–502 
Arterial pressure wave, 340–341 
Arterial pumpers, 274 
ASA.  See Acute severe asthma (ASA) 
management
A.S.P.E.N.  See American society 
for Parenteral and Enteral 
Nutrition 
Aspiration, in enteral nutrition, 369–370, 
376
Aspirin, heart attacks and, 91, 122 
Assist/control ventilation (A/C), 63–64 
Asthma, 51 
See also Acute severe asthma (ASA) 
management
ASV.  See Adaptive support ventilation 
ATC.  See Automatic tube compensation 
Atelectasis, 50 
ATLS.  See Advanced Trauma Life 
Support
Atonic seizure, 214 
Atrial arrhythmias, 99, 101–103 
Atrial tachycardia, 103–105 
Atrioventricular block, 105–107 
Auditing, 20 
Auscultation, 273–274 
Autoimmune hepatitis, 249 
Automatic tube compensation (ATC), 69 
552 Index
Index 553
Auto-PEEP, 51, 71, 74–76 
See also Positive end-expiratory 
pressure (PEEP) 
B
Beck’s triad, 285 
Benzodiazepines, 521–522 
Beta-blockers, 116, 122 
Bioethicists, 40 
Bioimpedance cardiography, 135 
Bioimpedence, 339 
Biphasic ventilation, 66–67 
Blood flow and tissue oxygenation, 
328–329
Blood glucose levels, 257 
Blood glucose management, 263–264 
in kidney-pancreas transplants, 
263–264
in liver transplants, 252 
Blood urea nitrogen (BUN), 364 
Boards of Nursing (BONs), 2, 9, 11, 
18–20
disciplinary action and, 34, 36–37 
BONs.  See Boards of Nursing 
BOOP.  See Bronchiolitis obliterans 
organizing pneumonia 
Brain anatomy review, 140 
Brain death, 235–238 
Brainstem, 140 
Breathing, establishing, 272 
Bronchiolitis obliterans organizing 
pneumonia (BOOP), 50 
Bronchoscopy, 512–514 
Bronchospasm, 51 
Bud-Chiari syndrome, 249 
BUN.  See Blood urea nitrogen 
Burn management, 297–317 
background and statistics, 297–299 
cardiovascular symptoms, 306–307 
compartment syndrome, 301–302 
first, second, and third-degree burns, 
298–299
fluid management, 307–309 
infection control, 309 
inhalation injury, 302–304 
layers of the skin, 298–299 
metabolic response, 302 
neurological symptoms, 304–305 
nutrition, 313–314 
pathophysiology, 299–301 
postburn anemia, 302 
prognosis and outcome, 314–315 
pulmonary symptoms, 305–306 
renal considerations, 309 
temperature regulation, 310 
wound management, 310–313 
Burns Wean Assessment Program 
(BWAP), 78–80 
C
CABG.  See Coronary artery bypass 
grafting
Calcium channel blockers, 117 
Caloric needs.  See Energy requirements 
Campylobacter jejuni, 228 
Carbohydrates, 361–362 
Cardiac arrest, 107–108 
Cardiac concepts, 89–137 
aneurysms, 124–126 
antiarrhythmic drugs, 95 
aortic surgery, 124–126 
atrial arrhythmias, 99, 101–103 
atrial tachycardia, 103–105 
atrioventricular block, 105–107 
background, statistics, guidelines, 89–92 
cardiac arrest, 107–108 
chest pain, 117–118 
coronary artery bypass, 126–127 
Crawford classification, 124 
dissection, 124–126 
electrical conduction system, 92–93 
electrocardiograms (ECGs), 93–96, 100 
electrophysiology, 92 
extracorporeal membrane 
oxygenation (ECMO), 134 
heart failure, 108–113 
heart transplant, 127–130 
intraaortic balloon counterpulsation 
(IABP), 134 
myocardial infarction, 118–124 
pharmacotherapy in heart failure and 
myocardial infarction, 113–117, 
121–124
postcardiac surgery monitoring, 
134–136
supraventricular arrhythmias, 
103–105
treatment considerations in heart 
failure, 114 
ventricular arrhythmias, 96–99, 100 
ventricular assist devices (VADs), 
129–134
Cardiac output, 332–333 
Cardiac output/index, 331 
Cardiac output measurement, 339–343 
Cardiac tamponade, 284–285 
554 Index
Cardiovascular system, burns and, 
306–307
Caregiver organizational support, 472–473 
Case studies 
advanced directives, 47 
license renewal, 20 
medical malpractice, 38–39 
protocols and, 37 
terminating life support, 40 
Catheterization, 275–276 
See also Procedures 
Catheter-related bloodstream infections 
(CRBSI), 448–449, 453–454 
in parenteral nutrition, 368, 385 
CBC.  See Complete blood count 
CBF.  See Cerebral blood flow 
Cellular perfusion, 327–328 
Centers for Disease Control (CDC), 
injury statistics, 271 
Central line infections, 481 
Central venous catheters (CVCs), 484–499 
See also Procedures 
Cerebellum, 140 
Cerebral autoregulation, 153 
Cerebral blood flow (CBF), 153 
Cerebral contusions, 169 
Cerebral cortex, 140 
Cerebral edema, 151–152, 210 
See also Neurological critical care 
Cerebral perfusion pressure (CPP), 
152–153
Cerebral vascular accidents (CVAs) 
risk factors for in the presence of 
atrial fibrillation, 103 
thrombolysis and, 91 
See also Neurological critical care; 
Stroke
Cerebrospinal fluid (CSF), 152, 231–233 
Certification, 3, 9 
Cervical spine injury, 291–292 
Chest pain, 117–118 
Chest radiography (CT scan), 119 
Chest tube removal, 506–507 
Chest tube thoracostomy, 504–506 
Cholestatic liver disease, 248 
Chronic bronchitis, 51 
Chronic end-stage renal disease, 256 
Chronic hepatitis, 248–249 
Chronic obstructive pulmonary disease 
(COPD), 51 
Chronic rejection, in liver transplants, 
255–256
Chronic rejection in kidney-pancreas 
transplants, 266 
Circulation, establishing, 273 
Cirrhosis, 248 
Clonic seizure, 213–214 
CMV.  See Control mandatory ventilation 
Collaborative practice agreements 
(CPAs), 25–29 
Collaborative practice models, 11–12, 21 
Coma, pharmacological, 162–163 
Compartment syndrome, 301–302 
Compensatory mechanisms, 336–338 
Competencies, 3, 6–8, 13 
Complete blood count (CBC), 276 
Complex partial seizure, 213 
Complications
in enteral nutrition, 372–376 
in parenteral nutrition, 377–384, 
389–390
Computerized axial tomography (CT), 
146, 147, 289, 291 
Concussions, 166–167 
Conferences, 2 
Conflict resolution, end-of-life and, 
463–464
Consciousness assessment, 140–141, 142 
Continuing education, 12, 19–20 
disciplinary action and, 32 
Contraindications
for kidney-pancreas transplants, 258 
for kidney transplants, 258 
for liver transplants, 248, 250 
Controlled substances, prescribing, 21, 29 
Control mandatory ventilation (CMV), 63 
Coordination assessment, 144 
COPD.  See Chronic obstructive 
pulmonary disease 
Coronary artery bypass grafting 
(CABG), 122, 126–127 
Coronary heart disease 
statistics on, 89–90 
See also Cardiac concepts 
Corticosteroid therapy, 267 
CPAs.  See Collaborative practice 
agreements
CPP.  See Cerebral perfusion pressure 
Cranial nerves, 140, 144, 145 
Crawford classification, 124 
Credentialing, 9, 11, 12 
See also Regulation 
Cricothyroidotomy, 510–512 
Critical injuries, 271–295 
abdominal assessment, 287–289 
abdominal trauma, 285–287 
background and statistics, 271–272 
cardiac tamponade, 284–285 
initial assessment of, 272–276 
ABCDE mnemonic (airway, 
breathing, circulation, disability, 
exposure), 272–273 
aspiration and, 276 
catheterization, 275–276 
ECG monitoring, 275 
lab tests for, 276 
Index 555
neurological examination, 274 
radiological imaging for, 276 
removal of patient’s clothing, 274 
ventilation, 273–274 
musculoskeletal injuries, 289–293 
assessment, 290 
cervical spine, 291–292 
fracture management principles, 
290–291
pelvic fractures, 292–293 
rib fractures, flail chest, and 
pulmonary contusion, 280–282 
shock and, 276–280 
simple pneumothorax or hemothorax, 
282–284
Cruzan, by her parents and co-guardians 
v. Missouri Department of Health,
41–42
Cruzan, Nancy, 41–42 
CSF.  See Cerebrospinal fluid 
CT scan.  See Chest radiography; 
Computerized axial tomography 
CVAs.  See Cerebral vascular accidents 
Cytomegalovirus, 228 
Cytotoxic edema, 151–152 
D
Death and dying.  See End-of-life and 
palliative care 
Deep tendon reflexes (DTRs), 144, 146 
Defensive medicine, 37–38 
Dehydration, 363 
Department of Health, 18–19 
Dermatomes, 143 
Dermis, 298–299 
Dexmedetomidine, 523 
Diabetes insipidus (DI), 435–438 
Diabetes mellitus, 256–257, 258 
type 1 (T1DM), 409–410 
type 2 (T2DM), 410–413 
See also Endocrine emergencies 
Diabetic ketoacidosis (DKA), 413–414 
Diagnostic peritoneal lavage (DPL), 289 
Dialysis, 256, 257 
Diazepam, 521–522 
Diffuse axonal injury, 167 
Digital rectal examination, 288 
Digoxin, 117 
Disability, assessing for injuries, 273 
Discharge management, in liver 
transplants, 252 
Disciplinary process, 20, 29, 32, 34, 36–37 
Dissection, 124–126 
Diuretics, 114–115 
DKA.  See Diabetic ketoacidosis 
DNP.  See Doctorate of Nursing Practice 
Doctorate of Nursing Practice (DNP), 14 
Doppler imaging, 120–121, 135, 136 
DPL.  See Diagnostic peritoneal lavage 
Drugs
antiarrhythmic, 95 
antiepileptic, 216–217 
for cerebral edema, 161–162 
for heart failure and myocardial 
infarction, 113–117, 121–124 
postoperative neurosurgery, 189–190 
status epilepticus, 220–224 
See also Analgesia; Antibiotics; Sedation 
DTRs.  See Deep tendon reflexes 
Dye-dilution techniques, 135 
Dying.  See End-of-life and palliative care 
Dynamic hyperinflation (auto-PEEP), 51 
E
Early treatment, in multisystem organ 
failure, 324 
ECF.  See Extracellular fluid 
ECGs.  See Electrocardiograms 
ECMO.  See Extracorporeal membrane 
oxygenation 
EEG.  See Electroencephalogram 
Elective neurosurgical surgery.  See
Neurological critical care 
Electrical conduction system, 92–93 
Electrocardiograms (ECGs), 93–96 
critically injured patients and, 276 
ventricular arrhythmia classifications, 
100
Electroencephalogram (EEG), 146 
Electrolyte levels 
in enteral nutrition, 376–384 
in parenteral nutrition, 389 
Electrolyte management, 263 
Electrolyte requirements, 365, 368 
Electromyography (EMG), 146 
Electrophysiology, 92 
ELNEC.  See End-of-Life Nursing 
Education Consortium 
Emergency Nurses Association, 548–549 
EMG.  See Electromyography 
Emphysema, 51 
EN.  See Enteral nutrition 
Encephalitis.  See Neurological critical care 
Endocrine emergencies, 399–442 
acute adrenal insufficiency, 427–430 
diabetic ketoacidosis (DKA), 413–414 
glucose regulation, 402–409 
hyperglycemia, 402, 406 
hyperglycemic hyperomolar 
syndrome (HHS), 414–417 
556 Index
hyperthyroidism, 424–426 
hypothyroidism, 420–423 
insulin basics, 409 
myxedema coma, 423–424 
organs in, 401 
pathophysiology, 400–402 
thyroid dysfunction, 417–420 
type 1 diabetes mellitus (T1DM), 
409–410
type 2 diabetes mellitus (T2DM), 
410–413
vasopressin abnormalities, 430–438 
diabetes insipidus, 435–438 
polyuric disorders, 436–437 
syndrome of inappropriate 
anitdiuretic hormone (SIADH), 
433–435
End-of-life and palliative care, 39–47, 
459–480
caregiver organizational support, 
472–473
communication and conflict 
resolution, 463–464 
cultural competency and, 473–474 
decisions about, 461–462 
dimensions of, 463 
emotional and psychological care of 
the patient/family, 471–472 
epidemiology of death and dying, 460 
ethical and legal issues, 461–462 
evidence-based palliative care, 475 
health care proxy (health care power 
of attorney), 43, 45–47 
interventions for common distressing 
symptoms, 466 
living wills, 43–44 
online resources, 475 
pain and, 465, 467, 468 
palliative care within the critical care 
environment, 464–467 
provider actions, 475 
ventilator removal/terminal weaning, 
470
withdrawing or withholding life-
sustaining interventions, 40–42, 
467, 469 
End-of-Life Nursing Education 
Consortium (ELNEC), 472–473 
Endothelial cascade, 326 
Endothelial dysfunction, 324 
End-stage renal failure (ESRF), 257 
Energy requirements, 359–361 
Enteral nutrition (EN), 368–384 
complications associated with, 372–376 
diarrhea, 372, 376 
electrolyte levels, 376–384 
high gastric residual volumes 
(GRV), 369, 372, 376 
hyperglycemia, 376 
troubleshooting, 373–374, 377–384 
enteral access, 369–370 
aspiration, 369–370, 376 
fluoroscopy or endoscopy, 369 
nasoenteric devices, 369 
percutaneous endoscopic 
gastrostomy (PEG), 370 
percutaneous endoscopic 
jejunostomy (PEJ), 370 
feeding protocols, 372 
formulations, 370–371 
fiber, 370 
immune-enhancing formulas, 371 
initiation and advancement of, 
371–372
versus parenteral nutrition (PN), 368 
See also Nutrient requirements; 
Nutrition; Nutrition support 
Epidermis, 298 
Epidural hematoma, 168 
Epilepsy.  See Neurological critical care 
Epstein-Barr virus, 228 
Eschar, 299 
ESRF.  See End-stage renal failure 
Esophageal Doppler probes, 340 
Ethics, 17 
collaborative practice agreements 
and, 25–26 
dying and, 461–462 
Evidence-based practice, 14 
for cardiovascular disease, 90–91 
to decrease hospital-acquired 
infections, 455 
for nutrition, 391–392 
palliative care, 475 
Exposure, 273 
Extracellular fluid (ECF), 437 
Extracorporeal membrane oxygenation 
(ECMO), 134 
F
Family-centered care, 533–550 
adapting existing policy, 544–545 
barriers to, 536, 537 
considerations of, 547 
dynamics of ongoing quality family-
centered critical care, 545–546 
family presence during resuscitation, 
548–549
implementation of, 541–542 
online resources for, 549 
Endocrine emergencies (Continued)
Index 557
philosophy of, 536–538 
synergy model for patient care, 538–540 
traditional patient-centered model 
vs. family-centered critical care 
model, 536–538 
understanding family needs, 542–543 
FAST.  See Focused assessment with 
sonography for trauma 
Feeding protocols, in enteral nutrition, 372 
Femoral artery, 492, 502 
Femoral vein, 491–492 
Fentanyl, 527 
FHF.  See Fulmanant hepatic failure 
Fiber, in enteral nutrition, 370 
Fick principle, 135 
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chronic end-stage renal disease, 256 
contraindications for, 258 
diabetes, 256, 257 
dialysis, 256, 257 
early postoperative management, 260 
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